assay_id,assay_organism,variant_id,assay_type,description,assay_strain,chembl_id,assay_tax_id,confidence_score,src_id,relationship_type,tid,curated_by,src_assay_id,cell_id,bao_format,tissue_id
1,,,B,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,CHEMBL615117,,8,1,H,12052,Autocuration,,,BAO_0000019,
2,,,F,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,CHEMBL615118,,0,1,U,22226,Autocuration,,,BAO_0000219,
3,,,B,,,CHEMBL615119,,0,1,U,22226,Autocuration,,,BAO_0000019,
4,Bos taurus,,B,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,CHEMBL615120,9913.0,4,1,H,104729,Autocuration,,,BAO_0000249,
5,Homo sapiens,,F,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,CHEMBL615121,9606.0,1,1,N,80001,Intermediate,,163.0,BAO_0000219,
6,Homo sapiens,,F,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,CHEMBL615122,9606.0,1,1,N,80001,Intermediate,,163.0,BAO_0000219,
7,Mus musculus,,F,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,CHEMBL615123,10090.0,1,1,N,80001,Intermediate,,163.0,BAO_0000219,
8,Homo sapiens,,F,In vitro cell cytotoxicity was determined against 143B cell line,,CHEMBL615124,9606.0,1,1,N,80001,Expert,,163.0,BAO_0000219,
9,Homo sapiens,,F,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,CHEMBL615125,9606.0,1,1,N,80001,Intermediate,,163.0,BAO_0000219,
10,Homo sapiens,,F,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,CHEMBL615126,9606.0,1,1,N,80001,Intermediate,,163.0,BAO_0000219,
11,Homo sapiens,,F,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,CHEMBL615127,9606.0,1,1,N,80001,Intermediate,,163.0,BAO_0000219,
12,Homo sapiens,,F,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,CHEMBL615128,9606.0,1,1,N,80001,Expert,,163.0,BAO_0000219,
13,Staphylococcus aureus,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL857900,1280.0,1,1,N,50185,Intermediate,,,BAO_0000218,
14,Staphylococcus aureus,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615129,1280.0,1,1,N,50185,Intermediate,,,BAO_0000218,
15,Staphylococcus aureus,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615130,1280.0,1,1,N,50185,Intermediate,,,BAO_0000218,
16,Staphylococcus aureus,,F,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615131,1280.0,1,1,N,50185,Intermediate,,,BAO_0000218,
17,Rattus norvegicus,,A,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,CHEMBL884521,10116.0,9,1,D,100122,Expert,,,BAO_0000357,
18,,,B,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615132,,8,1,H,12054,Autocuration,,,BAO_0000357,
19,,,B,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,CHEMBL615133,,8,1,H,12054,Autocuration,,,BAO_0000019,
20,,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615134,,8,1,H,12054,Autocuration,,,BAO_0000357,
21,,,B,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615135,,8,1,H,12054,Autocuration,,,BAO_0000357,
22,,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615136,,8,1,H,12054,Autocuration,,,BAO_0000357,
23,,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,CHEMBL615137,,8,1,H,12054,Autocuration,,,BAO_0000357,
24,,,B,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,CHEMBL615138,,8,1,H,12054,Autocuration,,,BAO_0000357,
25,,,B,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,CHEMBL836324,,0,1,U,22226,Autocuration,,,BAO_0000219,
26,Oryctolagus cuniculus,,B,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,CHEMBL615139,9986.0,8,1,H,12054,Autocuration,,,BAO_0000357,
27,Oryctolagus cuniculus,,B,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,CHEMBL615140,9986.0,8,1,H,12054,Autocuration,,,BAO_0000357,
28,,,B,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,CHEMBL615141,,8,1,H,12426,Autocuration,,,BAO_0000219,
29,soya bean,,B,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,CHEMBL615142,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
30,Glycine max,,B,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,CHEMBL615143,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
31,Glycine max,,B,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,CHEMBL615144,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
32,Glycine max,,B,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,CHEMBL872867,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
33,Glycine max,,B,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,CHEMBL615145,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
34,Glycine max,,B,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,CHEMBL615146,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
35,Glycine max,,B,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,CHEMBL615147,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
36,Rattus norvegicus,,A,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,CHEMBL615148,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
37,Escherichia coli,,B,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,CHEMBL615149,562.0,0,1,U,22226,Autocuration,,,BAO_0000019,
38,,,B,Dissociation constant with dimeric 16S rRNA RNA construct B,,CHEMBL615150,,0,1,U,22226,Autocuration,,,BAO_0000019,
39,,,B,Dissociation constant towards 16S rRNA construct A,,CHEMBL615151,,3,1,M,22222,Intermediate,,,BAO_0000225,
40,,,B,Dissociation constant towards 16S rRNA construct B,,CHEMBL615152,,3,1,M,22222,Intermediate,,,BAO_0000225,
41,Escherichia coli,,B,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,CHEMBL615153,562.0,3,1,M,100263,Expert,,,BAO_0000225,
42,Escherichia coli,,B,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,CHEMBL615154,562.0,3,1,M,100263,Expert,,,BAO_0000225,
43,,,B,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL615155,,8,1,H,13053,Autocuration,,,BAO_0000019,
44,,,B,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL615156,,8,1,H,13053,Autocuration,,,BAO_0000019,
45,Homo sapiens,,B,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,CHEMBL615157,9606.0,8,1,H,20001,Autocuration,,,BAO_0000019,
46,Homo sapiens,,B,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,CHEMBL615158,9606.0,8,1,H,20001,Autocuration,,,BAO_0000019,
47,Rattus norvegicus,,B,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,CHEMBL615159,10116.0,9,1,D,12971,Expert,,,BAO_0000019,
48,Rattus norvegicus,,B,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,CHEMBL615172,10116.0,9,1,D,12971,Expert,,,BAO_0000019,
49,Rattus norvegicus,,B,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,CHEMBL615173,10116.0,9,1,D,12971,Expert,,,BAO_0000019,
50,Rattus norvegicus,,B,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,CHEMBL615174,10116.0,9,1,D,12971,Expert,,,BAO_0000019,
51,,,B,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL884518,,8,1,H,13053,Autocuration,,,BAO_0000019,
52,,,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,CHEMBL615175,,8,1,H,11512,Autocuration,,,BAO_0000357,
53,,,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,CHEMBL615176,,8,1,H,11512,Autocuration,,,BAO_0000357,
54,,,B,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,CHEMBL615177,,8,1,H,11512,Autocuration,,,BAO_0000357,
55,Rattus norvegicus,,B,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,CHEMBL615178,10116.0,5,1,D,104740,Autocuration,,,BAO_0000249,
56,Homo sapiens,,F,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,CHEMBL615179,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
57,Rattus norvegicus,,F,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,CHEMBL615180,10116.0,7,1,D,104835,Autocuration,,,BAO_0000219,
58,Rattus norvegicus,,F,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,CHEMBL615181,10116.0,7,1,D,104821,Autocuration,,,BAO_0000219,
59,Rattus norvegicus,,F,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,CHEMBL615182,10116.0,7,1,D,104848,Autocuration,,,BAO_0000219,
60,Homo sapiens,,F,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,CHEMBL615183,9606.0,1,1,N,80002,Expert,,506.0,BAO_0000219,
61,Homo sapiens,,F,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,CHEMBL615184,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
62,Homo sapiens,,F,Cytotoxic activity against human ovarian cancer (1A9) cell line,,CHEMBL615185,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
63,Homo sapiens,,F,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,CHEMBL615186,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
64,Homo sapiens,,F,Effective dose of compound against replication of 1A9 cell line was evaluated,,CHEMBL615187,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
65,Homo sapiens,,F,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,CHEMBL885343,9606.0,1,1,N,80002,Expert,,506.0,BAO_0000219,
66,Homo sapiens,,F,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,CHEMBL615188,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
67,Homo sapiens,,F,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,CHEMBL615189,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
68,Homo sapiens,,F,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,CHEMBL615190,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
69,Homo sapiens,,F,Inhibitory activity against Taxol resistant 1A9 cell lines,,CHEMBL615191,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
70,Homo sapiens,,F,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,CHEMBL615192,9606.0,1,1,N,80002,Expert,,506.0,BAO_0000219,
71,Homo sapiens,,F,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,CHEMBL827083,9606.0,1,1,N,80002,Expert,,506.0,BAO_0000219,
72,Homo sapiens,,F,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,CHEMBL615193,9606.0,1,1,N,80002,Expert,,506.0,BAO_0000219,
73,Homo sapiens,,F,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,CHEMBL615194,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
74,Homo sapiens,,F,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,CHEMBL615195,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
75,Homo sapiens,,F,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,CHEMBL615196,9606.0,1,1,N,80002,Intermediate,,506.0,BAO_0000219,
76,Homo sapiens,,F,Inhibitory concentration against Jurkat cells,,CHEMBL615197,9606.0,1,1,N,81072,Intermediate,,503.0,BAO_0000219,
77,,,F,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,CHEMBL615198,,0,1,U,22226,Intermediate,,,BAO_0000019,
78,Rattus norvegicus,,A,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,CHEMBL615199,10116.0,9,1,D,100121,Expert,,,BAO_0000357,
79,,,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,CHEMBL615200,,8,1,H,11231,Expert,,,BAO_0000357,
80,,,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,CHEMBL615201,,8,1,H,11231,Expert,,,BAO_0000357,
81,,,B,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,CHEMBL615202,,8,1,H,11231,Expert,,,BAO_0000357,
82,Candida albicans,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,CHEMBL615203,5476.0,8,1,H,11231,Autocuration,,,BAO_0000251,
83,Candida albicans,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,CHEMBL615204,5476.0,8,1,H,11231,Autocuration,,,BAO_0000251,
84,Saccharomyces cerevisiae,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,CHEMBL615205,4932.0,8,1,H,11231,Autocuration,,,BAO_0000251,
85,Saccharomyces cerevisiae,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,CHEMBL615206,4932.0,8,1,H,11231,Autocuration,,,BAO_0000251,
86,Sus scrofa,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,CHEMBL615207,9823.0,8,1,H,12083,Autocuration,,,BAO_0000251,2107.0
87,Rattus norvegicus,,B,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,CHEMBL827084,10116.0,8,1,H,11231,Autocuration,,,BAO_0000019,
88,Rattus norvegicus,,B,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,CHEMBL615208,10116.0,8,1,H,11231,Autocuration,,,BAO_0000019,
89,Rattus norvegicus,,B,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,CHEMBL615209,10116.0,8,1,H,11231,Autocuration,,,BAO_0000019,
90,Rattus norvegicus,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,CHEMBL615210,10116.0,9,1,D,12083,Autocuration,,,BAO_0000251,2107.0
91,Rattus norvegicus,,B,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,CHEMBL615211,10116.0,9,1,D,12083,Autocuration,,,BAO_0000251,2107.0
92,Rattus norvegicus,,B,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,CHEMBL615212,10116.0,9,1,D,12083,Autocuration,,,BAO_0000251,2107.0
93,,,B,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,CHEMBL615213,,8,1,H,11377,Expert,,,BAO_0000357,
94,,,B,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,CHEMBL615273,,8,1,H,11377,Expert,,,BAO_0000357,
95,Homo sapiens,,F,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,CHEMBL615274,9606.0,1,1,N,81020,Expert,,726.0,BAO_0000219,
96,Homo sapiens,,F,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,CHEMBL615275,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
97,Homo sapiens,,F,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,CHEMBL615276,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
98,Homo sapiens,,F,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,CHEMBL615277,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
99,Homo sapiens,,F,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,CHEMBL615326,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
100,Hepatitis B virus,,F,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,CHEMBL883130,10407.0,1,1,N,50606,Expert,,,BAO_0000218,
101,Homo sapiens,,F,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,CHEMBL884519,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
102,Homo sapiens,,F,Concentration required to inhibit 50% of 2.2.15 cell line,,CHEMBL615327,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
103,Homo sapiens,,A,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,CHEMBL615328,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
104,Homo sapiens,,F,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,CHEMBL615329,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
105,Homo sapiens,,F,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,CHEMBL615330,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
106,Hepatitis B virus,,F,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,CHEMBL615331,10407.0,1,1,N,50606,Expert,,,BAO_0000218,
107,Homo sapiens,,F,In vitro anti-HBV activity in 2.2.15 cells,,CHEMBL615332,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
108,Homo sapiens,,F,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,CHEMBL615333,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
109,Homo sapiens,,F,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,CHEMBL615334,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
110,Homo sapiens,,F,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,CHEMBL615335,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
111,Homo sapiens,,F,Cytotoxicity in 2.2.15 cells,,CHEMBL615336,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
112,Homo sapiens,,F,Cytotoxicity in 2.2.15 cells; Not determined,,CHEMBL615337,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
113,Homo sapiens,,F,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,CHEMBL615338,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
114,Homo sapiens,,F,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,CHEMBL615339,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
115,Homo sapiens,,F,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,CHEMBL615340,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
116,Homo sapiens,,F,Antiviral activity against HBV was determined in 2.215 cell line,,CHEMBL615341,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
117,Homo sapiens,,B,Inhibition of 20-HETE synthesis in human renal microsomes,,CHEMBL615342,9606.0,0,1,U,22226,Autocuration,,,BAO_0000251,
118,,,B,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,CHEMBL615343,,0,1,U,22226,Autocuration,,,BAO_0000019,
119,Homo sapiens,,F,Inhibitory concentration against 2008 (ovarian) cells,,CHEMBL615344,9606.0,1,1,N,80612,Intermediate,,388.0,BAO_0000219,
120,Homo sapiens,,F,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,CHEMBL615345,9606.0,1,1,N,80612,Intermediate,,388.0,BAO_0000219,
121,Homo sapiens,,F,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,CHEMBL615346,9606.0,1,1,N,80612,Intermediate,,388.0,BAO_0000219,
122,Homo sapiens,,F,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,CHEMBL615347,9606.0,1,1,N,80612,Intermediate,,388.0,BAO_0000219,
123,Homo sapiens,,F,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,CHEMBL615348,9606.0,1,1,N,80612,Intermediate,,388.0,BAO_0000219,
124,Homo sapiens,,F,In vitro inhibition of 2008/R ovarian cancer cell line,,CHEMBL827085,9606.0,1,1,N,80613,Intermediate,,561.0,BAO_0000219,
125,Homo sapiens,,F,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,CHEMBL615349,9606.0,1,1,N,80613,Intermediate,,561.0,BAO_0000219,
126,Homo sapiens,,F,In vitro inhibition of 2008/S ovarian cancer cell line,,CHEMBL615350,9606.0,1,1,N,80614,Intermediate,,389.0,BAO_0000219,
127,Homo sapiens,,F,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,CHEMBL615351,9606.0,1,1,N,80614,Intermediate,,389.0,BAO_0000219,
128,Homo sapiens,,B,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,CHEMBL615352,9606.0,2,1,S,100256,Expert,,,BAO_0000220,
129,Homo sapiens,,B,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,CHEMBL615353,9606.0,2,1,S,100256,Intermediate,,,BAO_0000220,
130,,,B,Inhibition of chymotrypsin-like activity of 20S proteasome,,CHEMBL615354,,2,1,S,100256,Expert,,,BAO_0000220,
131,,,B,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,CHEMBL615355,,2,1,S,100256,Expert,,,BAO_0000220,
132,,,B,Inhibitory activity against 20S proteosome,,CHEMBL615356,,2,1,S,100256,Intermediate,,,BAO_0000220,
133,Homo sapiens,,B,Compound was tested for inhibitory activity against tryptase,,CHEMBL615357,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
134,Homo sapiens,,F,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,CHEMBL615358,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
135,Homo sapiens,,F,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,CHEMBL827086,9606.0,1,1,N,81020,Intermediate,,726.0,BAO_0000219,
136,,,B,Compound was tested for the inhibition of Alpha-glucosidase,,CHEMBL615359,,0,1,U,22226,Autocuration,,,BAO_0000019,
137,,,B,Inhibitory concentration against human neutrophil elastase (HNE),,CHEMBL615360,,8,1,H,235,Autocuration,,,BAO_0000357,
138,Rattus norvegicus,,F,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,CHEMBL615361,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,948.0
139,,,F,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615362,,8,1,H,19640,Autocuration,,,BAO_0000019,
140,,,F,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615363,,8,1,H,19640,Expert,,,BAO_0000019,
141,,,B,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615364,,8,1,H,19640,Autocuration,,,BAO_0000357,
142,,,F,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615365,,8,1,H,19640,Expert,,,BAO_0000019,
143,Mus musculus,,F,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,CHEMBL615366,10090.0,1,1,N,80360,Intermediate,,524.0,BAO_0000219,
144,Mus musculus,,F,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,CHEMBL615367,10090.0,1,1,N,80360,Intermediate,,524.0,BAO_0000219,
145,Homo sapiens,,F,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,CHEMBL615368,9606.0,1,1,N,80384,Intermediate,,554.0,BAO_0000219,
146,Ovis aries,,F,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,CHEMBL615369,9940.0,0,1,U,22226,Autocuration,,,BAO_0000019,
147,Ovis aries,,F,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,CHEMBL615370,9940.0,0,1,U,22226,Autocuration,,,BAO_0000019,
148,,,B,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,CHEMBL615673,,8,1,H,191,Autocuration,,,BAO_0000357,
149,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,CHEMBL615674,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
150,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,CHEMBL615675,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
151,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,CHEMBL615676,9606.0,0,1,U,22226,Autocuration,,635.0,BAO_0000219,
152,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,CHEMBL615677,9606.0,0,1,U,22226,Autocuration,,635.0,BAO_0000219,
153,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,CHEMBL615678,9606.0,0,1,U,22226,Autocuration,,635.0,BAO_0000219,
154,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,CHEMBL615679,9606.0,0,1,U,22226,Autocuration,,635.0,BAO_0000219,
155,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,CHEMBL615680,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
156,Homo sapiens,,F,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,CHEMBL615681,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
157,,,B,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,CHEMBL857972,,6,1,H,104290,Autocuration,,,BAO_0000249,
158,Streptococcus pyogenes,,F,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,CHEMBL857899,1314.0,1,1,N,50264,Intermediate,,,BAO_0000218,
159,Human herpesvirus 3,,F,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,CHEMBL615371,10335.0,1,1,N,50527,Intermediate,,,BAO_0000218,
160,vericilla zoster virus,,F,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,CHEMBL615372,10335.0,1,1,N,50527,Expert,,468.0,BAO_0000218,
161,vericilla zoster virus,,F,Antiviral activity against 07/1 strain of VZV; ND: No data,,CHEMBL615373,10335.0,1,1,N,50527,Intermediate,,,BAO_0000218,
162,vericilla zoster virus,,F,Antiviral activity against 07/1 strain of VZV; ND=No data,,CHEMBL615374,10335.0,1,1,N,50527,Intermediate,,,BAO_0000218,
163,escherichia cloac,,F,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,CHEMBL615375,561.0,1,1,N,50145,Intermediate,,,BAO_0000218,
164,,,B,Ratio of Ki at A2 to Ki at A1 receptors,,CHEMBL615376,,0,1,U,22226,Autocuration,,,BAO_0000019,
165,Candida albicans,,B,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,CHEMBL615377,5476.0,8,1,H,11143,Expert,,,BAO_0000249,
166,Candida glabrata CBS 138,,B,"Inhibition of 1,3-beta-glucan synthase",,CHEMBL615378,284593.0,8,1,H,18077,Expert,,,BAO_0000357,
167,Homo sapiens,,F,Inhibition of growth of 1-87 human tumor cell line,,CHEMBL615379,9606.0,1,1,N,80609,Intermediate,,832.0,BAO_0000219,
168,Rattus norvegicus,,B,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,CHEMBL615380,10116.0,9,1,D,12166,Expert,,,BAO_0000219,
169,Glycine max,,B,Inhibitory activity against soybean 1-lipoxygenase (SLO),,CHEMBL615381,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
170,Glycine max,,B,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,CHEMBL615382,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
171,Glycine max,,B,% inhibition against soybean 1-lipoxygenase (SLO),,CHEMBL615383,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
172,Glycine max,,B,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,CHEMBL615384,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
173,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,CHEMBL615385,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
174,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,CHEMBL615386,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
175,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,CHEMBL615387,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
176,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,CHEMBL615388,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
177,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,CHEMBL615214,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
178,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,CHEMBL827087,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
179,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,CHEMBL615215,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
180,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,CHEMBL615216,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
181,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,CHEMBL615217,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
182,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,CHEMBL615218,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
183,Glycine max,,B,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,CHEMBL615219,3847.0,9,1,D,100171,Autocuration,,,BAO_0000357,
184,Mus musculus,,B,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,CHEMBL615220,10090.0,0,1,U,22226,Autocuration,,,BAO_0000019,
185,Mus musculus,,F,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,CHEMBL615221,10090.0,1,1,N,80049,Intermediate,,294.0,BAO_0000219,
186,,,F,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,CHEMBL615222,,0,1,U,22226,Intermediate,,,BAO_0000019,
187,,,B,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,CHEMBL615223,,8,1,H,11489,Autocuration,,,BAO_0000357,
188,,,B,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,CHEMBL615224,,8,1,H,11862,Autocuration,,,BAO_0000357,
189,,,B,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,CHEMBL615225,,8,1,H,11862,Autocuration,,,BAO_0000357,
190,,,B,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,CHEMBL615226,,8,1,H,11489,Autocuration,,,BAO_0000357,
191,,,B,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,CHEMBL615227,,8,1,H,11862,Autocuration,,,BAO_0000357,
192,Bos taurus,,F,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,CHEMBL615228,9913.0,9,1,D,12347,Expert,,,BAO_0000019,
193,Rattus norvegicus,,B,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,CHEMBL615229,10116.0,9,1,D,100120,Expert,,,BAO_0000357,
194,Rattus norvegicus,,B,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,CHEMBL615230,10116.0,9,1,D,100120,Expert,,,BAO_0000357,2369.0
195,Rattus norvegicus,,B,Inhibition of rat adrenal 11-beta-hydroxylase,,CHEMBL615231,10116.0,9,1,D,100120,Expert,,,BAO_0000357,
196,Rattus norvegicus,,B,Inhibition of rat adrenal 11-beta-hydroxylase,,CHEMBL884520,10116.0,9,1,D,100120,Expert,,,BAO_0000357,
197,Rattus norvegicus,,B,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,CHEMBL615232,10116.0,9,1,D,100120,Expert,,,BAO_0000357,
198,,,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,CHEMBL615233,,8,1,H,10328,Autocuration,,,BAO_0000019,
199,,,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,CHEMBL827088,,8,1,H,11490,Autocuration,,,BAO_0000357,
200,,,B,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,CHEMBL615234,,8,1,H,11490,Autocuration,,,BAO_0000357,
201,,,F,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,CHEMBL615235,,8,1,H,11134,Autocuration,,,BAO_0000019,
202,,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615236,,8,1,H,12052,Autocuration,,,BAO_0000019,
203,,,B,Compound was tested in vitro for inhibition of 12-LO human platelet,,CHEMBL615237,,8,1,H,11134,Autocuration,,,BAO_0000019,
204,,,F,Inhibitory concentration against human platelet 12-lipoxygenase,,CHEMBL615238,,8,1,H,11134,Autocuration,,,BAO_0000019,
205,,,B,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,CHEMBL615239,,8,1,H,11134,Autocuration,,,BAO_0000019,
206,Homo sapiens,,F,Inhibitory concentration against human platelet 12-lipoxygenase,,CHEMBL615240,9606.0,9,1,D,11134,Autocuration,,,BAO_0000019,
207,,,B,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,CHEMBL615241,,8,1,H,11835,Expert,,,BAO_0000019,
208,,,B,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,CHEMBL615242,,8,1,H,11601,Expert,,,BAO_0000357,
209,,,B,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,CHEMBL615243,,8,1,H,11134,Autocuration,,,BAO_0000019,
210,,,B,Inhibitory activity against human platelet 12-lipoxygenase,,CHEMBL615244,,8,1,H,11134,Autocuration,,,BAO_0000019,
211,,,B,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,CHEMBL615245,,8,1,H,11134,Autocuration,,,BAO_0000019,
212,,,B,% inhibition against human platelet 12-lipoxygenase (12-HLO),,CHEMBL615246,,8,1,H,11134,Autocuration,,,BAO_0000019,
213,,,B,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,CHEMBL615247,,8,1,H,11134,Autocuration,,,BAO_0000019,
214,,,B,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,CHEMBL615248,,8,1,H,11134,Autocuration,,,BAO_0000019,
215,,,B,Inhibitory activity towards porcine 12-lipoxygenase,,CHEMBL615249,,8,1,H,11601,Autocuration,,,BAO_0000357,
216,,,B,Tested for inhibition against porcine 12-LO,,CHEMBL615250,,8,1,H,11601,Autocuration,,,BAO_0000357,
217,,,B,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,CHEMBL615251,,8,1,H,12052,Autocuration,,,BAO_0000019,
218,,,B,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,CHEMBL615252,,8,1,H,12052,Autocuration,,,BAO_0000019,
219,,,B,In vitro inhibition of rat platelet 12-lipoxygenase,,CHEMBL828340,,8,1,H,12052,Expert,,,BAO_0000019,
220,,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615253,,8,1,H,12052,Autocuration,,,BAO_0000019,
221,,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,CHEMBL615254,,8,1,H,12052,Autocuration,,,BAO_0000019,
222,,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,CHEMBL615255,,8,1,H,12052,Autocuration,,,BAO_0000019,
223,,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615256,,8,1,H,12052,Autocuration,,,BAO_0000019,
224,,,B,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,CHEMBL615257,,8,1,H,12052,Autocuration,,,BAO_0000019,
225,,,B,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,CHEMBL615258,,8,1,H,12052,Autocuration,,,BAO_0000019,
226,Homo sapiens,,F,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,CHEMBL615259,9606.0,1,1,N,80007,Intermediate,,621.0,BAO_0000219,
227,Homo sapiens,,F,In vitro antitumor activity against 41M cell line.,,CHEMBL615260,9606.0,1,1,N,80007,Expert,,621.0,BAO_0000219,
228,Homo sapiens,,F,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,CHEMBL615261,9606.0,1,1,N,80007,Intermediate,,621.0,BAO_0000219,
229,Homo sapiens,,F,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,CHEMBL615262,9606.0,1,1,N,80007,Intermediate,,621.0,BAO_0000219,
230,Homo sapiens,,F,In vitro antitumor activity against 41McisR cell line.,,CHEMBL615263,9606.0,1,1,N,80007,Expert,,621.0,BAO_0000219,
231,Homo sapiens,,F,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,CHEMBL838393,9606.0,1,1,N,80007,Expert,,621.0,BAO_0000219,
232,Homo sapiens,,F,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,CHEMBL615264,9606.0,1,1,N,80007,Intermediate,,621.0,BAO_0000219,
233,Homo sapiens,,B,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,CHEMBL615265,9606.0,9,1,D,84,Expert,,,BAO_0000357,
234,Homo sapiens,,B,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,CHEMBL615266,9606.0,9,1,D,68,Expert,,,BAO_0000357,
235,,,B,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,CHEMBL615267,,8,1,H,68,Expert,,,BAO_0000357,
236,,,B,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,CHEMBL615268,,8,1,H,10201,Expert,,,BAO_0000357,
237,,,B,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,CHEMBL615269,,8,1,H,10201,Expert,,,BAO_0000357,
238,,,B,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,CHEMBL615270,,8,1,H,10201,Expert,,,BAO_0000357,
239,,,B,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,CHEMBL615271,,8,1,H,12220,Autocuration,,,BAO_0000357,
240,Escherichia coli,,B,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,CHEMBL615272,562.0,8,1,H,11303,Autocuration,,,BAO_0000357,
241,Escherichia coli,,B,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,CHEMBL615103,562.0,8,1,H,11303,Autocuration,,,BAO_0000357,
242,Escherichia coli,,B,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,CHEMBL615104,562.0,8,1,H,11303,Autocuration,,,BAO_0000357,
243,,,B,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,CHEMBL615105,,8,1,H,12220,Autocuration,,,BAO_0000357,
244,,,B,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,CHEMBL872866,,8,1,H,12220,Autocuration,,,BAO_0000357,
245,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615106,9823.0,8,1,H,11303,Autocuration,,,BAO_0000357,
246,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,CHEMBL615107,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
247,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615108,9823.0,8,1,H,11303,Autocuration,,,BAO_0000357,
248,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,CHEMBL615109,9823.0,8,1,H,11303,Autocuration,,,BAO_0000357,
249,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615110,9823.0,8,1,H,11303,Autocuration,,,BAO_0000357,
250,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,CHEMBL840105,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
251,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,CHEMBL615111,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
252,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615112,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
253,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,CHEMBL615113,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
254,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,CHEMBL615114,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
255,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615115,9823.0,8,1,H,11303,Autocuration,,,BAO_0000357,
256,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615116,9823.0,8,1,H,11303,Autocuration,,,BAO_0000019,
257,,,B,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,CHEMBL615698,,8,1,H,11303,Autocuration,,,BAO_0000357,
258,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615699,9823.0,0,1,U,22226,Autocuration,,,BAO_0000019,
259,Sus scrofa,,B,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,CHEMBL615700,9823.0,0,1,U,22226,Autocuration,,,BAO_0000019,
260,Saccharomyces cerevisiae,,B,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,CHEMBL615701,4932.0,8,1,H,100249,Expert,,,BAO_0000357,
261,Rattus norvegicus,,B,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,CHEMBL615702,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
262,Rattus norvegicus,,B,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,CHEMBL615703,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
263,Rattus norvegicus,,B,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,CHEMBL615704,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
264,,,F,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,CHEMBL615705,,6,1,H,104698,Autocuration,,,BAO_0000019,
265,,,F,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,CHEMBL615706,,6,1,H,104698,Autocuration,,,BAO_0000019,
266,Cavia porcellus,,F,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,CHEMBL615707,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
267,,,F,Stimulatory activity of intragastric pressure was tested in the rat,,CHEMBL615708,,8,1,H,10623,Expert,,,BAO_0000019,
268,,,B,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,CHEMBL615709,,8,1,H,121,Autocuration,,,BAO_0000357,
269,Rattus norvegicus,,F,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,CHEMBL615710,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
270,,,F,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,CHEMBL615711,,8,1,H,12688,Autocuration,,,BAO_0000019,
271,Homo sapiens,,B,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,CHEMBL615712,9606.0,9,1,D,121,Expert,,,BAO_0000357,
272,Homo sapiens,,B,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,CHEMBL836325,9606.0,9,1,D,121,Expert,,,BAO_0000357,
273,,,F,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,CHEMBL615713,,8,1,H,12198,Autocuration,,,BAO_0000019,
274,,,B,Inhibition constant of high-affinity 5-HT uptake,,CHEMBL615714,,8,1,H,12198,Autocuration,,,BAO_0000357,
275,,,F,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,CHEMBL615715,,8,1,H,12198,Autocuration,,,BAO_0000019,
276,,,F,Maximum rate was determined for high affinity transport of 5-HT,,CHEMBL615716,,8,1,H,12198,Autocuration,,,BAO_0000019,
277,,,F,Compound was tested for agonistic activity against 5-HT uptake,,CHEMBL615717,,4,1,H,104714,Autocuration,,,BAO_0000019,
278,,,B,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,CHEMBL881818,,8,1,H,10577,Expert,,,BAO_0000019,
279,Bos taurus,,B,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,CHEMBL884540,9913.0,8,1,H,105,Expert,,,BAO_0000357,
280,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,CHEMBL615718,10116.0,5,1,D,104744,Autocuration,,,BAO_0000224,
281,,,B,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,CHEMBL615719,,4,1,H,104744,Autocuration,,,BAO_0000224,
282,,,B,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,CHEMBL615720,,4,1,H,104744,Autocuration,,,BAO_0000249,
283,,,B,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,CHEMBL615721,,4,1,H,104744,Autocuration,,,BAO_0000249,
284,,,B,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615722,,4,1,H,104744,Autocuration,,,BAO_0000019,
285,,,F,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,CHEMBL615723,,8,1,H,51,Autocuration,,,BAO_0000019,
286,,,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615724,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
287,,,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615725,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
288,,,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615726,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
289,,,F,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,CHEMBL615727,,8,1,H,10576,Autocuration,,,BAO_0000218,
290,Cavia porcellus,,F,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,CHEMBL615728,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
291,,,B,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL857971,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
292,,,B,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,CHEMBL615729,,8,1,H,107,Autocuration,,,BAO_0000357,
293,Rattus norvegicus,,F,Efficacy against 5-hydroxytryptamine 2A receptor,,CHEMBL615730,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
294,,,F,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,CHEMBL615731,,8,1,H,12687,Expert,,,BAO_0000019,
295,,,F,Relative potency towards 5-HT2A receptor of rat tail artery,,CHEMBL615732,,8,1,H,12687,Expert,,,BAO_0000019,
296,,,F,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,CHEMBL615733,,8,1,H,12687,Expert,,,BAO_0000019,
297,,,F,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,CHEMBL615734,,8,1,H,12687,Expert,,,BAO_0000019,
298,,,F,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,CHEMBL615735,,8,1,H,12687,Autocuration,,,BAO_0000019,
299,,,F,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,CHEMBL615736,,8,1,H,12687,Expert,,,BAO_0000019,
300,Cavia porcellus,,F,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL615737,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
301,Cavia porcellus,,F,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,CHEMBL615738,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
302,Cavia porcellus,,F,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL615739,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
303,,,B,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,CHEMBL615278,,8,1,H,10623,Autocuration,,,BAO_0000357,
304,Rattus norvegicus,,F,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,CHEMBL615279,10116.0,9,1,D,10623,Expert,,,BAO_0000019,
305,,,B,Binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL615280,,8,1,H,168,Expert,,,BAO_0000357,
306,Gallus gallus,,B,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,CHEMBL615281,9031.0,0,1,U,22226,Autocuration,,,BAO_0000019,
307,Homo sapiens,,F,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,CHEMBL615282,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
308,Homo sapiens,,F,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,CHEMBL615283,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
309,Homo sapiens,,B,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,CHEMBL615284,9606.0,1,1,N,80156,Autocuration,,649.0,BAO_0000219,
310,Homo sapiens,,B,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,CHEMBL615285,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
311,Homo sapiens,,B,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,CHEMBL615286,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
312,Homo sapiens,,B,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,CHEMBL615287,9606.0,7,1,D,104703,Autocuration,,,BAO_0000219,
313,,,F,Chymotryptic inhibitory activity against 26S proteasome,,CHEMBL615288,,2,1,S,100256,Intermediate,,,BAO_0000220,
314,,,B,Inhibitory activity against 26S proteasome degradation of IkB,,CHEMBL615289,,2,1,S,100256,Intermediate,,,BAO_0000220,
315,Homo sapiens,,F,In vitro inhibition of 2780/DOX ovarian cancer cell line,,CHEMBL615290,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
316,Homo sapiens,,F,In vitro inhibition of 2780/S ovarian cancer cell line,,CHEMBL884522,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
317,Homo sapiens,,F,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,CHEMBL615291,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
318,,,B,Association constant for binding to AATT 28-mer AATT hairpin,,CHEMBL615292,,3,1,M,22222,Intermediate,,,BAO_0000225,
319,,,B,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,CHEMBL615293,,3,1,M,22222,Intermediate,,,BAO_0000225,
320,,,B,Reaction Rate Parameter for 28-mer AATT hairpin,,CHEMBL615294,,3,1,M,22222,Intermediate,,,BAO_0000225,
321,,,B,Reaction Rate Parameter for 28-mer AATT hairpin,,CHEMBL615295,,3,1,M,22222,Intermediate,,,BAO_0000225,
322,Homo sapiens,,F,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,CHEMBL825021,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
323,Homo sapiens,,F,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,CHEMBL615296,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
324,Homo sapiens,,F,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,CHEMBL615297,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
325,Cricetulus griseus,,F,Cytotoxicity against cell line 2SC/20 determined by MTT test,,CHEMBL615298,10029.0,0,1,U,22226,Autocuration,,,BAO_0000019,
326,Cricetulus griseus,,F,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,CHEMBL615299,10029.0,0,1,U,22226,Autocuration,,,BAO_0000019,
327,Cricetulus griseus,,F,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,CHEMBL615300,10029.0,0,1,U,22226,Autocuration,,,BAO_0000019,
328,,,B,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,CHEMBL615301,,8,1,H,241,Autocuration,,,BAO_0000357,
329,Homo sapiens,,B,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,CHEMBL615302,9606.0,9,1,D,241,Expert,,,BAO_0000357,
330,Rattus norvegicus,,B,Selectivity ratio of ID50 in liver and heart,,CHEMBL615303,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
331,,,B,"Selectivity, ratio of relative ID50 in liver and heart",,CHEMBL615304,,8,1,H,12132,Autocuration,,,BAO_0000019,
332,,,B,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,CHEMBL615305,,8,1,H,12132,Autocuration,,,BAO_0000019,
333,,,B,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615306,,8,1,H,12132,Autocuration,,,BAO_0000218,
334,,,B,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615307,,8,1,H,12132,Autocuration,,,BAO_0000218,
335,,,B,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615308,,8,1,H,12132,Autocuration,,,BAO_0000218,
336,,,F,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615309,,8,1,H,12132,Autocuration,,,BAO_0000218,
337,,,B,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,CHEMBL615310,,0,1,U,22226,Autocuration,,,BAO_0000019,
338,,,B,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,CHEMBL615311,,8,1,H,12132,Autocuration,,,BAO_0000019,
339,Homo sapiens,,B,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,CHEMBL615312,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
340,,,B,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,CHEMBL615313,,8,1,H,12132,Autocuration,,,BAO_0000019,
341,,,F,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,CHEMBL615314,,8,1,H,12132,Autocuration,,,BAO_0000019,
342,,,B,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,CHEMBL615315,,8,1,H,12132,Autocuration,,,BAO_0000019,
343,Rattus norvegicus,,B,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,CHEMBL615316,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
344,,,B,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,CHEMBL615317,,8,1,H,12132,Autocuration,,,BAO_0000218,
345,,,B,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615318,,8,1,H,12132,Autocuration,,,BAO_0000218,
346,Rattus norvegicus,,B,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,CHEMBL615319,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
347,,,B,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,CHEMBL615320,,8,1,H,12132,Autocuration,,,BAO_0000019,
348,,,F,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,CHEMBL615321,,8,1,H,12132,Autocuration,,,BAO_0000019,
349,Rattus norvegicus,,B,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,CHEMBL615322,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
350,Escherichia coli,,B,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,CHEMBL615323,562.0,8,1,H,19690,Autocuration,,,BAO_0000357,
351,Escherichia coli,,B,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,CHEMBL615407,562.0,8,1,H,19690,Autocuration,,,BAO_0000357,
352,Escherichia coli,,B,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,CHEMBL857267,562.0,8,1,H,19690,Autocuration,,,BAO_0000357,
353,Escherichia coli,,B,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,CHEMBL615408,562.0,8,1,H,19690,Autocuration,,,BAO_0000357,
354,,,B,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,CHEMBL615409,,8,1,H,19690,Autocuration,,,BAO_0000357,
355,,,B,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,CHEMBL615410,,8,1,H,19690,Autocuration,,,BAO_0000357,
356,,,B,Inhibition constant against 3-dehydroquinate synthase,,CHEMBL615411,,8,1,H,19690,Autocuration,,,BAO_0000357,
357,,,B,Association rate constant against 3-dehydroquinate synthase,,CHEMBL615412,,8,1,H,19690,Autocuration,,,BAO_0000357,
358,,,B,Rate constant against 3-dehydroquinate synthase,,CHEMBL615413,,8,1,H,19690,Autocuration,,,BAO_0000357,
359,,,B,Inhibitory activity against fuc-TVII,,CHEMBL615414,,0,1,U,22226,Autocuration,,,BAO_0000019,
360,Rattus norvegicus,,B,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615415,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
361,Rattus norvegicus,,B,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615416,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
362,Rattus norvegicus,,B,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615417,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
363,Rattus norvegicus,,B,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615418,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
364,Rattus norvegicus,,B,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615419,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
365,Rattus norvegicus,,B,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,CHEMBL615420,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
366,Rattus norvegicus,,B,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,CHEMBL615421,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
367,Rattus norvegicus,,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,CHEMBL615422,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
368,Rattus norvegicus,,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,CHEMBL615423,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
369,Rattus norvegicus,,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,CHEMBL872868,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
370,Rattus norvegicus,,B,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,CHEMBL615424,10116.0,9,1,D,12236,Autocuration,,,BAO_0000251,2107.0
371,,,B,Inhibitory activity against 3-phosphoglycerate kinase.,,CHEMBL825022,,4,1,H,104832,Autocuration,,,BAO_0000224,
372,,,B,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,CHEMBL615425,,4,1,H,104832,Autocuration,,,BAO_0000224,
373,,,B,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,CHEMBL615426,,4,1,H,104832,Autocuration,,,BAO_0000224,
374,Homo sapiens,,B,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,CHEMBL615427,9606.0,9,1,D,10612,Expert,,,BAO_0000357,
375,Homo sapiens,,F,Cytotoxicity on 3677 melanoma cells,,CHEMBL615428,9606.0,1,1,N,80616,Intermediate,,844.0,BAO_0000219,
376,Homo sapiens,,F,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,CHEMBL615429,9606.0,1,1,N,80616,Intermediate,,844.0,BAO_0000219,
377,Mus musculus,,F,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,CHEMBL615430,10090.0,1,1,N,80617,Intermediate,,700.0,BAO_0000219,
378,Homo sapiens,,F,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,CHEMBL615431,9606.0,0,1,U,22226,Intermediate,,,BAO_0000019,
379,,,F,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,CHEMBL615432,,0,1,U,22226,Autocuration,,798.0,BAO_0000218,
380,,,F,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,CHEMBL615433,,0,1,U,22226,Autocuration,,798.0,BAO_0000218,
381,Human rhinovirus 14,,F,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,CHEMBL615434,12131.0,9,1,D,12464,Expert,,,BAO_0000019,
382,Human rhinovirus sp.,,F,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,CHEMBL615435,169066.0,1,1,N,50085,Intermediate,,,BAO_0000218,
383,human rhinovirus type 14,,F,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,CHEMBL615436,169066.0,1,1,N,50679,Intermediate,,,BAO_0000218,
384,human rhinovirus type 14,,F,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,CHEMBL615437,169066.0,1,1,N,50679,Intermediate,,,BAO_0000218,
385,Human rhinovirus 14,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615438,12131.0,9,1,D,12464,Expert,,,BAO_0000019,
386,Human rhinovirus 14,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615439,12131.0,9,1,D,12464,Expert,,,BAO_0000019,
387,Human rhinovirus 14,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615440,12131.0,9,1,D,12464,Expert,,,BAO_0000019,
388,Human rhinovirus 14,,F,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,CHEMBL615441,12131.0,9,1,D,12464,Expert,,,BAO_0000019,
389,Enterovirus,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,CHEMBL615641,12059.0,1,1,N,50665,Intermediate,,,BAO_0000218,
390,Enterovirus,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,CHEMBL872065,12059.0,1,1,N,50665,Intermediate,,,BAO_0000218,
391,Enterovirus,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,CHEMBL825023,12059.0,1,1,N,50665,Intermediate,,,BAO_0000218,
392,Enterovirus,,F,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,CHEMBL615642,12059.0,1,1,N,50665,Intermediate,,,BAO_0000218,
393,Human rhinovirus B,,B,Inhibition of human rhinovirus 3C protease,,CHEMBL615643,147712.0,8,1,H,12464,Expert,,,BAO_0000357,
394,Homo sapiens,,B,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,CHEMBL615644,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
395,Mus musculus,,F,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,CHEMBL615645,10090.0,1,1,N,80619,Intermediate,,833.0,BAO_0000218,
396,Mus musculus,,F,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,CHEMBL615646,10090.0,1,1,N,80619,Intermediate,,833.0,BAO_0000218,
397,Mus musculus,,F,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,CHEMBL615647,10090.0,1,1,N,80619,Intermediate,,833.0,BAO_0000218,
398,Mus musculus,,F,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,CHEMBL615648,10090.0,1,1,N,80619,Intermediate,,833.0,BAO_0000218,
399,Mus musculus,,F,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,CHEMBL615649,10090.0,1,1,N,80619,Intermediate,,833.0,BAO_0000218,
400,Mus musculus,,F,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,CHEMBL615650,10090.0,1,1,N,80619,Intermediate,,833.0,BAO_0000218,
401,Mus musculus,,F,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,CHEMBL615651,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000218,
402,Mus musculus,,F,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,CHEMBL615652,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000218,
403,Mus musculus,,F,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,CHEMBL615653,10090.0,1,1,N,80620,Expert,,847.0,BAO_0000218,
404,Mus musculus,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,CHEMBL615654,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
405,Mus musculus,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,CHEMBL615655,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
406,Mus musculus,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,CHEMBL825024,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
407,Mus musculus,,F,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,CHEMBL615656,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
408,Mus musculus,,F,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,CHEMBL615657,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
409,Mus musculus,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,CHEMBL615658,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
410,Mus musculus,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,CHEMBL615659,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
411,Mus musculus,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,CHEMBL615660,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
412,Mus musculus,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,CHEMBL615661,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
413,Mus musculus,,F,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,CHEMBL615662,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
414,Mus musculus,,F,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,CHEMBL615663,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
415,Mus musculus,,F,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,CHEMBL615664,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
416,Mus musculus,,F,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,CHEMBL615665,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
417,Mus musculus,,F,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,CHEMBL615666,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
418,Mus musculus,,F,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL615667,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
419,Mus musculus,,F,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615668,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
420,Mus musculus,,F,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615669,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
421,Mus musculus,,F,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615670,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
422,Mus musculus,,F,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL836739,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
423,Mus musculus,,F,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615671,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
424,Mus musculus,,F,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615672,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
425,Mus musculus,,F,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615791,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
426,Mus musculus,,F,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL615792,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
427,Mus musculus,,F,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615793,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
428,Mus musculus,,F,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615794,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
429,Mus musculus,,F,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615795,10090.0,1,1,N,80620,Intermediate,,847.0,BAO_0000219,
430,Homo sapiens,,F,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,CHEMBL615590,9606.0,1,1,N,80621,Intermediate,,971.0,BAO_0000219,
431,,,F,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,CHEMBL615591,,0,1,U,22226,Autocuration,,,BAO_0000218,
432,,,F,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,CHEMBL615592,,0,1,U,22226,Autocuration,,,BAO_0000218,
433,,,F,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,CHEMBL615593,,0,1,U,22226,Autocuration,,,BAO_0000218,
434,,,F,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,CHEMBL615594,,0,1,U,22226,Autocuration,,,BAO_0000218,
435,Mus musculus,,F,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,CHEMBL615595,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
436,Mus musculus,,F,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,CHEMBL615596,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
437,,,F,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,CHEMBL615597,,8,1,H,11169,Expert,,723.0,BAO_0000219,
438,Mus musculus,,F,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,CHEMBL615598,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
439,Mus musculus,,F,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,CHEMBL615599,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
440,Mus musculus,,F,Effective dose against murine 3T3 fibroblasts cells,,CHEMBL615600,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
441,Mus musculus,,F,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,CHEMBL615601,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
442,Mus musculus,,F,Cytotoxic effect on 3T3 cells,,CHEMBL615602,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
443,Mus musculus,,F,Cytotoxic effect on 3T3 cells,,CHEMBL615603,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
444,Mus musculus,,F,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,CHEMBL615604,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
445,Mus musculus,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,CHEMBL615605,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
446,Mus musculus,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,CHEMBL615606,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
447,Mus musculus,,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,CHEMBL884526,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
448,Mus musculus,,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,CHEMBL615607,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
449,Mus musculus,,F,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,CHEMBL615608,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
450,Mus musculus,,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,CHEMBL615609,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
451,Mus musculus,,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,CHEMBL615682,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
452,Mus musculus,,F,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,CHEMBL615683,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
453,Mus musculus,,F,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,CHEMBL615684,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000218,
454,Mus musculus,,F,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,CHEMBL615685,10090.0,7,1,D,104860,Autocuration,,,BAO_0000219,
455,Mus musculus,,F,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,CHEMBL615686,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
456,Mus musculus,,F,Inhibitory activity against 3T3 cell line,,CHEMBL615687,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
457,Mus musculus,,F,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,CHEMBL884523,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
458,,,F,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,CHEMBL615688,,8,1,H,11169,Expert,,,BAO_0000019,
459,Mus musculus,,F,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,CHEMBL615689,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
460,Mus musculus,,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,CHEMBL615690,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
461,,,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,CHEMBL615691,,8,1,H,11169,Expert,,,BAO_0000019,
462,,,F,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,CHEMBL615692,,8,1,H,11169,Expert,,,BAO_0000019,
463,Mus musculus,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,CHEMBL615693,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
464,Mus musculus,,F,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,CHEMBL615324,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
465,Homo sapiens,,F,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,CHEMBL615325,9606.0,9,1,D,9,Expert,,723.0,BAO_0000219,
466,Homo sapiens,,F,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,CHEMBL615490,9606.0,9,1,D,9,Expert,,723.0,BAO_0000219,
467,Homo sapiens,,F,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,CHEMBL615491,9606.0,9,1,D,188,Expert,,723.0,BAO_0000219,
468,Homo sapiens,,F,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,CHEMBL615492,9606.0,9,1,D,188,Expert,,723.0,BAO_0000219,
469,Mus musculus,,F,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,CHEMBL615493,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
470,Mus musculus,,F,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,CHEMBL615494,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
471,Mus musculus,,F,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,CHEMBL615495,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
472,Mus musculus,,F,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,CHEMBL615496,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
473,Mus musculus,,F,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,CHEMBL615497,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
474,Mus musculus,,F,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,CHEMBL615498,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
475,Mus musculus,,A,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,CHEMBL615499,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
476,Mus musculus,,F,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,CHEMBL835522,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
477,Mus musculus,,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,CHEMBL615500,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
478,Mus musculus,,F,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615501,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
479,Mus musculus,,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615502,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
480,Mus musculus,,F,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615503,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
481,Mus musculus,,F,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615504,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
482,Mus musculus,,F,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615505,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
483,Mus musculus,,F,Inhibition of swiss 3T3 mouse fibroblast proliferation,,CHEMBL615506,10090.0,1,1,N,80951,Expert,,723.0,BAO_0000219,
484,Mus musculus,,F,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,CHEMBL615507,10090.0,1,1,N,80951,Intermediate,,723.0,BAO_0000219,
485,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615508,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
486,Mus musculus,,F,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,CHEMBL615509,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
487,Mus musculus,,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,CHEMBL615510,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
488,Mus musculus,,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,CHEMBL615511,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
489,Mus musculus,,F,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,CHEMBL615512,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
490,Mus musculus,,F,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,CHEMBL615513,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
491,Mus musculus,,F,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,CHEMBL615514,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
492,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,CHEMBL615515,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
493,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,CHEMBL615516,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
494,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615517,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
495,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,CHEMBL615518,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
496,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615519,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
497,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,CHEMBL615520,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
498,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,CHEMBL615521,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
499,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,CHEMBL615522,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
500,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615523,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
501,,,F,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,CHEMBL615524,,1,1,N,80006,Expert,,620.0,BAO_0000218,
502,,,F,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615525,,1,1,N,80006,Expert,,620.0,BAO_0000218,
503,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,CHEMBL615526,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
504,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615527,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
505,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,CHEMBL615528,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
506,,,F,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615529,,1,1,N,80006,Expert,,620.0,BAO_0000218,
507,,,F,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615530,,1,1,N,80006,Expert,,620.0,BAO_0000218,
508,,,F,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,CHEMBL615531,,1,1,N,80006,Expert,,620.0,BAO_0000218,
509,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,CHEMBL615532,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
510,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615533,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
511,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,CHEMBL615534,,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
512,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,CHEMBL615535,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
513,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615536,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
514,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615537,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
515,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615538,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
516,,,F,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,CHEMBL836166,,1,1,N,80006,Intermediate,,620.0,BAO_0000218,
517,,,F,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,CHEMBL615539,,8,1,H,11214,Expert,,620.0,BAO_0000219,
518,Mus musculus,,F,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,CHEMBL615540,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
519,,,F,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,CHEMBL615541,,8,1,H,11214,Expert,,620.0,BAO_0000219,
520,Mus musculus,,F,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,CHEMBL615542,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
521,Mus musculus,,F,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,CHEMBL615543,10090.0,1,1,N,80006,Intermediate,,620.0,BAO_0000219,
522,Mus musculus,,F,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,CHEMBL615544,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
523,Mus musculus,,F,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,CHEMBL615545,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
524,Mus musculus,,F,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,CHEMBL615546,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
525,Mus musculus,,F,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,CHEMBL615547,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
526,Mus musculus,,F,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,CHEMBL615548,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
527,Mus musculus,,F,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,CHEMBL615549,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
528,Mus musculus,,F,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,CHEMBL615550,10090.0,1,1,N,80006,Expert,,620.0,BAO_0000219,
529,Rattus norvegicus,,F,Inhibitory activity against rat fibroblast (3Y1) cell line,,CHEMBL615551,10116.0,1,1,N,80622,Intermediate,,1118.0,BAO_0000219,
530,Rattus norvegicus,,F,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,CHEMBL615552,10116.0,1,1,N,80622,Expert,,1118.0,BAO_0000219,
531,Rattus norvegicus,,F,Cytotoxicity in 3Y1 cells.,,CHEMBL615553,10116.0,1,1,N,80622,Expert,,1118.0,BAO_0000219,
532,Rattus norvegicus,,F,Cytostatic effect in 3Y1 cells.,,CHEMBL615554,10116.0,1,1,N,80622,Expert,,1118.0,BAO_0000219,
533,Rattus norvegicus,,F,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,CHEMBL615555,10116.0,1,1,N,80622,Intermediate,,1118.0,BAO_0000219,
534,Rattus norvegicus,,F,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,CHEMBL615556,10116.0,1,1,N,80622,Expert,,1118.0,BAO_0000219,
535,,,B,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,CHEMBL615557,,0,1,U,22226,Autocuration,,,BAO_0000019,
536,,,B,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,CHEMBL615558,,0,1,U,22226,Autocuration,,,BAO_0000019,
537,,,B,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,CHEMBL872066,,0,1,U,22226,Autocuration,,,BAO_0000019,
538,Sus scrofa,,B,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,CHEMBL615559,9823.0,9,1,D,11607,Expert,,,BAO_0000019,
539,,,B,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,CHEMBL615560,,8,1,H,11607,Autocuration,,,BAO_0000019,
540,,,B,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,CHEMBL615561,,8,1,H,11607,Autocuration,,,BAO_0000019,
541,,,B,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,CHEMBL857062,,8,1,H,11607,Expert,,,BAO_0000019,
542,,,B,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,CHEMBL615562,,8,1,H,11607,Expert,,,BAO_0000019,
543,,,B,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,CHEMBL615563,,8,1,H,11607,Autocuration,,,BAO_0000019,
544,,,B,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,CHEMBL615564,,8,1,H,11607,Autocuration,,,BAO_0000357,
545,,,B,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,CHEMBL615565,,8,1,H,11607,Autocuration,,,BAO_0000019,
546,,,B,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,CHEMBL615566,,8,1,H,11607,Autocuration,,,BAO_0000019,
547,Sus scrofa,,B,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,CHEMBL615567,9823.0,9,1,D,11607,Expert,,,BAO_0000019,
548,,,B,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,CHEMBL615568,,8,1,H,11607,Autocuration,,,BAO_0000019,
549,,,B,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,CHEMBL615569,,8,1,H,11607,Autocuration,,,BAO_0000357,
550,,,B,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,CHEMBL615570,,8,1,H,11607,Autocuration,,,BAO_0000019,
551,,,B,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,CHEMBL615571,,8,1,H,11607,Autocuration,,,BAO_0000019,
552,,,B,Binding affinity against melatonin (MT1) receptor (pC1),,CHEMBL615572,,4,1,H,104733,Autocuration,,,BAO_0000224,
553,,,B,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,CHEMBL615573,,0,1,U,22226,Autocuration,,,BAO_0000019,
554,,,B,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,CHEMBL615574,,0,1,U,22226,Autocuration,,,BAO_0000019,
555,,,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,CHEMBL615575,,0,1,U,22226,Autocuration,,,BAO_0000019,
556,,,B,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,CHEMBL615576,,8,1,H,10619,Autocuration,,,BAO_0000357,
557,,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,CHEMBL615577,,8,1,H,10619,Autocuration,,,BAO_0000357,
558,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,CHEMBL615578,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
559,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,CHEMBL615579,,8,1,H,51,Expert,,,BAO_0000357,
560,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL615580,,8,1,H,51,Expert,,,BAO_0000357,
561,,,B,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,CHEMBL615581,,8,1,H,51,Expert,,,BAO_0000019,
562,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615582,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
563,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615583,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
564,,,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615584,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
565,,,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL833691,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
566,,,B,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615585,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
567,,,B,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615586,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
568,,,B,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL884524,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
569,,,B,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615587,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
570,,,B,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,CHEMBL615588,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
571,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,CHEMBL615589,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
572,Bos taurus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,CHEMBL615442,9913.0,8,1,H,51,Expert,,,BAO_0000221,10000000.0
573,,,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,CHEMBL615443,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
574,,,B,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,CHEMBL615444,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
575,,,B,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,CHEMBL615445,,8,1,H,51,Expert,,,BAO_0000221,10000000.0
576,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,CHEMBL615446,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
577,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,CHEMBL615447,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
578,,,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615448,,8,1,H,51,Expert,,,BAO_0000221,10000000.0
579,,,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615449,,8,1,H,51,Expert,,,BAO_0000221,10000000.0
580,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL615450,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
581,,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,CHEMBL615451,,8,1,H,51,Expert,,,BAO_0000221,10000000.0
582,,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,CHEMBL615452,,8,1,H,51,Autocuration,,,BAO_0000357,
583,,,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615453,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
584,,,B,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615454,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
585,,,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615455,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
586,,,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615456,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
587,,,B,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615457,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
588,,,B,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,CHEMBL615458,,8,1,H,51,Expert,,,BAO_0000218,10000000.0
589,,,B,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615459,,8,1,H,51,Expert,,,BAO_0000221,10000000.0
590,Homo sapiens,,B,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,CHEMBL615460,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
591,Cavia porcellus,,F,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,CHEMBL615461,10141.0,8,1,H,51,Autocuration,,,BAO_0000019,
592,Cavia porcellus,,F,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,CHEMBL615462,10141.0,8,1,H,51,Autocuration,,,BAO_0000019,
593,Cavia porcellus,,F,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,CHEMBL615463,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
594,Cavia porcellus,,B,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,CHEMBL615464,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,2116.0
595,Cavia porcellus,,B,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615465,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,2116.0
596,Cavia porcellus,,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,CHEMBL615466,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,2116.0
597,Cavia porcellus,,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615467,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,2116.0
598,Cavia porcellus,,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615468,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,2116.0
599,Cavia porcellus,,B,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,CHEMBL615469,10141.0,8,1,H,51,Autocuration,,,BAO_0000221,2116.0
600,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615470,10141.0,8,1,H,51,Autocuration,,,BAO_0000357,
601,Cavia porcellus,,B,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615471,10141.0,8,1,H,51,Autocuration,,,BAO_0000357,
602,Cavia porcellus,,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,CHEMBL615472,10141.0,8,1,H,51,Autocuration,,,BAO_0000357,
603,Cavia porcellus,,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,CHEMBL883242,10141.0,8,1,H,106,Autocuration,,,BAO_0000221,10000000.0
604,Cavia porcellus,,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,CHEMBL615473,10141.0,8,1,H,106,Autocuration,,,BAO_0000221,10000000.0
605,Cricetulus griseus,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHEMBL615474,10029.0,8,1,H,11863,Autocuration,,449.0,BAO_0000218,
606,,,B,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,CHEMBL615475,,8,1,H,51,Autocuration,,,BAO_0000357,
607,,,F,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,CHEMBL615476,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
608,,,F,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,CHEMBL615477,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
609,,,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,CHEMBL615478,,8,1,H,51,Autocuration,,,BAO_0000019,
610,,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL615160,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
611,,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL615161,,8,1,H,51,Expert,,449.0,BAO_0000219,
612,,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,CHEMBL615162,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
613,,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,CHEMBL615163,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
614,,,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615164,,8,1,H,51,Expert,,449.0,BAO_0000219,
615,,,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615165,,8,1,H,51,Expert,,449.0,BAO_0000219,
616,,,B,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,CHEMBL615166,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
617,,,F,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,CHEMBL615167,,8,1,H,51,Autocuration,,,BAO_0000219,
618,Homo sapiens,,B,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,CHEMBL615168,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
619,Homo sapiens,,B,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,CHEMBL615169,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
620,Homo sapiens,,B,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL615170,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
621,Homo sapiens,,B,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHEMBL615171,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
622,,,F,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,CHEMBL615694,,8,1,H,51,Autocuration,,,BAO_0000019,
623,,,F,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,CHEMBL615695,,8,1,H,51,Autocuration,,,BAO_0000019,
624,,,F,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL615696,,8,1,H,51,Autocuration,,,BAO_0000019,
625,,,F,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL615697,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
626,Homo sapiens,,F,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHEMBL859410,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
627,,,F,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHEMBL615841,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
628,Homo sapiens,,F,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHEMBL615842,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
629,,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL835003,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
630,,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,CHEMBL615843,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
631,Homo sapiens,,F,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHEMBL615979,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
632,,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHEMBL615980,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
633,Homo sapiens,,F,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHEMBL615981,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
634,Homo sapiens,,F,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,CHEMBL615982,9606.0,9,1,D,51,Expert,,,BAO_0000019,
635,Homo sapiens,,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL615983,9606.0,9,1,D,51,Expert,,,BAO_0000019,
636,Homo sapiens,,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL615984,9606.0,9,1,D,51,Expert,,,BAO_0000019,
637,Homo sapiens,,F,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL615985,9606.0,9,1,D,51,Expert,,,BAO_0000019,
638,,,F,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615986,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
639,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615987,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
640,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHEMBL615988,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
641,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615989,,8,1,H,51,Expert,,449.0,BAO_0000219,
642,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHEMBL615990,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
643,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,CHEMBL615991,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
644,,,F,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615992,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
645,,,F,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHEMBL615993,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
646,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615994,,8,1,H,51,Expert,,449.0,BAO_0000219,
647,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,CHEMBL615995,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
648,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615996,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
649,,,F,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHEMBL615997,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
650,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615998,,8,1,H,51,Autocuration,,,BAO_0000019,
651,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615999,,8,1,H,51,Autocuration,,,BAO_0000019,
652,,,F,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,CHEMBL616000,,8,1,H,51,Autocuration,,,BAO_0000019,
653,,,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616001,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
654,Homo sapiens,,F,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,CHEMBL616002,9606.0,9,1,D,51,Expert,,,BAO_0000019,
655,,,F,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,CHEMBL616003,,8,1,H,51,Expert,,,BAO_0000019,
656,Homo sapiens,,F,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,CHEMBL616004,9606.0,9,1,D,51,Expert,,,BAO_0000019,
657,Homo sapiens,,F,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,CHEMBL616005,9606.0,9,1,D,51,Expert,,,BAO_0000019,
658,,,F,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616006,,8,1,H,51,Autocuration,,,BAO_0000019,
659,,,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,CHEMBL616007,,8,1,H,51,Expert,,,BAO_0000019,
660,,,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616008,,8,1,H,51,Autocuration,,,BAO_0000019,
661,,,F,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616009,,8,1,H,51,Autocuration,,,BAO_0000019,
662,,,F,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,CHEMBL616010,,8,1,H,51,Expert,,,BAO_0000019,
663,Homo sapiens,,F,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,CHEMBL616011,9606.0,9,1,D,51,Expert,,,BAO_0000019,
664,Homo sapiens,,F,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,CHEMBL615740,9606.0,9,1,D,51,Expert,,,BAO_0000019,
665,,,F,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,CHEMBL615741,,8,1,H,51,Autocuration,,,BAO_0000019,
666,,,F,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,CHEMBL615742,,8,1,H,51,Expert,,,BAO_0000019,
667,,,F,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,CHEMBL615743,,8,1,H,51,Autocuration,,,BAO_0000019,
668,,,F,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,CHEMBL615744,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
669,,,F,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,CHEMBL615745,,8,1,H,51,Expert,,449.0,BAO_0000219,
670,,,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL615746,,8,1,H,51,Autocuration,,,BAO_0000357,
671,,,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL615747,,8,1,H,51,Autocuration,,,BAO_0000357,
672,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615748,,8,1,H,51,Autocuration,,,BAO_0000019,
673,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,CHEMBL615749,,8,1,H,51,Autocuration,,,BAO_0000019,
674,,,F,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,CHEMBL615750,,8,1,H,51,Autocuration,,,BAO_0000019,
675,Homo sapiens,,F,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,CHEMBL616259,9606.0,9,1,D,51,Expert,,,BAO_0000019,
676,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL616260,,8,1,H,51,Autocuration,,,BAO_0000019,
677,Homo sapiens,,F,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,CHEMBL616261,9606.0,9,1,D,51,Expert,,,BAO_0000019,
678,Homo sapiens,,F,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL616262,9606.0,9,1,D,51,Expert,,,BAO_0000019,
679,Homo sapiens,,F,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL616263,9606.0,9,1,D,51,Expert,,,BAO_0000019,
680,Homo sapiens,,F,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,CHEMBL616264,9606.0,9,1,D,51,Expert,,,BAO_0000019,
681,Homo sapiens,,F,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,CHEMBL616265,9606.0,9,1,D,51,Expert,,,BAO_0000019,
682,Homo sapiens,,F,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL616266,9606.0,9,1,D,51,Expert,,,BAO_0000019,
683,Homo sapiens,,F,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL616267,9606.0,9,1,D,51,Expert,,,BAO_0000019,
684,Homo sapiens,,F,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,CHEMBL616268,9606.0,9,1,D,51,Expert,,,BAO_0000019,
685,Homo sapiens,,B,Inhibition of human 5-hydroxytryptamine 1A receptor,,CHEMBL616269,9606.0,9,1,D,51,Expert,,,BAO_0000357,
686,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL884528,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
687,,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,CHEMBL616270,,9,1,D,105,Expert,,722.0,BAO_0000219,
688,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,CHEMBL616271,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
689,,,F,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL616272,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
690,,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,CHEMBL616273,,8,1,H,51,Expert,,,BAO_0000357,
691,Homo sapiens,,B,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616274,9606.0,9,1,D,51,Expert,,,BAO_0000357,
692,,,B,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL616275,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
693,,,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL616276,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
694,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,CHEMBL616277,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
695,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,CHEMBL616278,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
696,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,CHEMBL616279,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
697,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,CHEMBL616280,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
698,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,CHEMBL616281,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
699,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,CHEMBL616282,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
700,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,CHEMBL616283,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
701,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,CHEMBL616284,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
702,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,CHEMBL616285,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
703,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,CHEMBL616286,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
704,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,CHEMBL616287,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
705,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,CHEMBL616288,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
706,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,CHEMBL616289,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
707,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,CHEMBL615610,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
708,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,CHEMBL615611,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
709,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,CHEMBL615612,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
710,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,CHEMBL615613,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
711,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,CHEMBL615614,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
712,Rattus norvegicus,,F,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,CHEMBL615615,10116.0,0,1,U,22226,Autocuration,,,BAO_0000218,
713,,,B,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,CHEMBL615616,,4,1,H,105093,Autocuration,,,BAO_0000019,
714,,,B,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,CHEMBL615617,,8,1,H,11923,Autocuration,,,BAO_0000249,1898.0
715,,,B,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,CHEMBL615618,,8,1,H,10577,Autocuration,,,BAO_0000019,
716,,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,CHEMBL615619,,8,1,H,10577,Autocuration,,,BAO_0000019,
717,,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,CHEMBL615620,,8,1,H,10577,Expert,,,BAO_0000019,
718,,,B,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,CHEMBL615621,,8,1,H,55,Autocuration,,,BAO_0000357,
719,,,B,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,CHEMBL615622,,8,1,H,55,Autocuration,,,BAO_0000357,
720,,,F,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,CHEMBL615623,,8,1,H,12166,Autocuration,,,BAO_0000019,
721,,,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL615624,,8,1,H,12166,Autocuration,,,BAO_0000019,
722,,,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL615625,,8,1,H,12166,Autocuration,,,BAO_0000019,
723,,,F,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL767045,,8,1,H,12166,Autocuration,,,BAO_0000019,
724,Cavia porcellus,,F,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,CHEMBL615626,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
725,Cavia porcellus,,F,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,CHEMBL615627,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
726,Cavia porcellus,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,CHEMBL615628,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
727,Cavia porcellus,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,CHEMBL615629,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
728,Homo sapiens,,B,Inhibitory concentration against 5-lipoxygenase from human whole blood,,CHEMBL615630,9606.0,9,1,D,55,Expert,,,BAO_0000357,
729,,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,CHEMBL615631,,8,1,H,55,Autocuration,,,BAO_0000219,
730,,,F,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,CHEMBL615632,,8,1,H,17087,Autocuration,,,BAO_0000218,
731,,,B,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,CHEMBL615633,,8,1,H,17087,Autocuration,,,BAO_0000357,
732,,,F,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,CHEMBL615634,,8,1,H,17087,Autocuration,,,BAO_0000218,
733,Sus scrofa,,B,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,CHEMBL615635,9823.0,8,1,H,55,Expert,,,BAO_0000019,
734,,,B,In vitro inhibition of rat 5-Lipoxygenase,,CHEMBL615636,,8,1,H,12166,Expert,,,BAO_0000357,
735,Rattus norvegicus,,B,Inhibitory activity against 5-Lipoxygenase,,CHEMBL615637,10116.0,9,1,D,12166,Expert,,,BAO_0000357,
736,,,B,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,CHEMBL615638,,8,1,H,12166,Expert,,702.0,BAO_0000219,
737,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL615639,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
738,,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,CHEMBL615640,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
739,,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,CHEMBL615796,,8,1,H,12166,Autocuration,,,BAO_0000019,
740,,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,CHEMBL615845,,8,1,H,12166,Autocuration,,,BAO_0000219,
741,,,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,CHEMBL615846,,8,1,H,12166,Autocuration,,,BAO_0000357,
742,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,CHEMBL615847,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
743,,,B,The compound was tested for inhibition of isolated 5-Lipoxygenase,,CHEMBL615848,,8,1,H,12166,Autocuration,,,BAO_0000357,
744,Rattus norvegicus,,B,Ratio of IC50 against 5-LO and COX,,CHEMBL615849,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
745,,,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,CHEMBL615850,,8,1,H,12166,Autocuration,,,BAO_0000357,
746,,,B,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,CHEMBL615851,,8,1,H,12166,Autocuration,,,BAO_0000357,
747,,,B,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,CHEMBL615852,,8,1,H,12166,Autocuration,,,BAO_0000219,
748,,,F,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,CHEMBL615853,,8,1,H,12166,Autocuration,,,BAO_0000019,
749,,,B,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,CHEMBL884527,,8,1,H,120,Autocuration,,,BAO_0000357,2367.0
750,Columba livia,,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,CHEMBL872871,8932.0,0,1,U,22226,Autocuration,,,BAO_0000019,
751,Columba livia,,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,CHEMBL615854,8932.0,0,1,U,22226,Autocuration,,,BAO_0000019,
752,Columba livia,,B,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,CHEMBL767046,8932.0,0,1,U,22226,Autocuration,,,BAO_0000019,
753,,,B,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,CHEMBL615855,,8,1,H,10732,Autocuration,,,BAO_0000357,
754,Rattus norvegicus,,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,CHEMBL615856,10116.0,9,1,D,12198,Expert,,,BAO_0000019,
755,Rattus norvegicus,,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,CHEMBL615857,10116.0,9,1,D,12198,Expert,,,BAO_0000019,
756,Rattus norvegicus,,F,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,CHEMBL615858,10116.0,9,1,D,12198,Expert,,,BAO_0000019,
757,,,B,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,CHEMBL615859,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
758,,,B,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,CHEMBL615860,,8,1,H,51,Autocuration,,,BAO_0000357,
759,Oryctolagus cuniculus,,B,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL615861,9986.0,0,1,U,22226,Autocuration,,,BAO_0000019,
760,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL615862,9986.0,0,1,U,22226,Autocuration,,,BAO_0000019,
761,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,CHEMBL615863,9986.0,0,1,U,22226,Autocuration,,,BAO_0000019,
762,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,CHEMBL615864,9986.0,0,1,U,22226,Autocuration,,,BAO_0000019,
763,,,B,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615865,,4,1,H,104744,Autocuration,,,BAO_0000221,10000000.0
764,,,B,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615866,,4,1,H,104744,Autocuration,,,BAO_0000221,10000000.0
765,,,B,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615867,,4,1,H,104744,Autocuration,,,BAO_0000221,10000000.0
766,,,B,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,CHEMBL615868,,4,1,H,104744,Autocuration,,,BAO_0000249,
767,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,CHEMBL615869,10116.0,5,1,D,104744,Autocuration,,,BAO_0000249,
768,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,CHEMBL615870,10116.0,5,1,D,104744,Autocuration,,,BAO_0000019,
769,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,CHEMBL615871,10116.0,5,1,D,104744,Autocuration,,,BAO_0000019,
770,,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,CHEMBL615872,,4,1,H,104744,Autocuration,,,BAO_0000224,
771,,,B,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,CHEMBL833492,,4,1,H,104744,Autocuration,,,BAO_0000221,10000000.0
772,,,B,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,CHEMBL615873,,4,1,H,104744,Autocuration,,,BAO_0000221,10000000.0
773,,,B,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,CHEMBL615479,,4,1,H,104744,Autocuration,,,BAO_0000224,
774,,,B,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,CHEMBL615480,,4,1,H,104744,Autocuration,,,BAO_0000019,
775,Rattus norvegicus,,B,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,CHEMBL615481,10116.0,5,1,D,104744,Autocuration,,,BAO_0000249,
776,,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL872869,,4,1,H,104744,Autocuration,,,BAO_0000019,
777,,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615482,,4,1,H,104744,Autocuration,,,BAO_0000019,
778,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615483,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
779,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615484,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
780,,,B,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,CHEMBL615485,,4,1,H,104744,Autocuration,,,BAO_0000019,
781,Rattus norvegicus,,B,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,CHEMBL615486,10116.0,5,1,D,104744,Autocuration,,,BAO_0000224,
782,,,B,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,CHEMBL615487,,4,1,H,104744,Autocuration,,,BAO_0000224,
783,,,B,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615488,,4,1,H,104744,Autocuration,,,BAO_0000224,
784,,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615489,,4,1,H,104744,Autocuration,,,BAO_0000224,
785,,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615389,,4,1,H,104744,Autocuration,,,BAO_0000224,
786,,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,CHEMBL615390,,4,1,H,104744,Autocuration,,,BAO_0000019,
787,,,B,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,CHEMBL615391,,4,1,H,104744,Autocuration,,,BAO_0000019,
788,,,B,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,CHEMBL615392,,4,1,H,104744,Autocuration,,,BAO_0000224,
789,Rattus norvegicus,,B,Affinity for 5-hydroxytryptamine 1 receptor,,CHEMBL615393,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
790,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,CHEMBL615394,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
791,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615395,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
792,,,B,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,CHEMBL615396,,4,1,H,104744,Autocuration,,,BAO_0000224,
793,,,B,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,CHEMBL615397,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
794,,,B,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615398,,4,1,H,104744,Autocuration,,,BAO_0000019,
795,Rattus norvegicus,,B,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,CHEMBL615399,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
796,,,B,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,CHEMBL615400,,4,1,H,104744,Autocuration,,,BAO_0000019,
797,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,CHEMBL615401,10116.0,5,1,D,104744,Autocuration,,,BAO_0000019,
798,Rattus norvegicus,,B,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,CHEMBL615402,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
799,,,B,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,CHEMBL615403,,4,1,H,104744,Autocuration,,,BAO_0000019,
800,,,B,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,CHEMBL615404,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
801,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,CHEMBL615781,,4,1,H,104744,Autocuration,,,BAO_0000019,
802,,,B,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,CHEMBL615782,,4,1,H,104744,Autocuration,,,BAO_0000220,955.0
803,,,B,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,CHEMBL615783,,4,1,H,104744,Autocuration,,,BAO_0000221,955.0
804,,,B,Compound was tested for binding affinity against 5-HT1 receptor,,CHEMBL873481,,0,1,U,22226,Autocuration,,,BAO_0000019,
805,,,B,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,CHEMBL615784,,0,1,U,22226,Autocuration,,,BAO_0000019,
806,,,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,CHEMBL615785,,8,1,H,10576,Expert,,,BAO_0000357,
807,,,F,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,CHEMBL615786,,8,1,H,10576,Autocuration,,,BAO_0000249,
808,,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,CHEMBL615787,,8,1,H,10576,Autocuration,,,BAO_0000218,
809,,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,CHEMBL615788,,8,1,H,10576,Autocuration,,,BAO_0000218,
810,,,F,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,CHEMBL767044,,8,1,H,10576,Autocuration,,,BAO_0000019,
811,,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,CHEMBL615789,,8,1,H,10576,Autocuration,,,BAO_0000218,
812,,,F,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,CHEMBL615790,,8,1,H,10576,Autocuration,,,BAO_0000218,
813,,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,CHEMBL615813,,8,1,H,10576,Autocuration,,,BAO_0000019,
814,,,F,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,CHEMBL615814,,8,1,H,10576,Autocuration,,,BAO_0000219,
815,,,F,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,CHEMBL615815,,8,1,H,51,Expert,,,BAO_0000219,
816,,,F,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,CHEMBL615816,,8,1,H,10576,Autocuration,,,BAO_0000219,
817,,,B,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,CHEMBL615817,,8,1,H,10576,Expert,,,BAO_0000249,
818,,,B,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,CHEMBL615818,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
819,,,B,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,CHEMBL615819,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
820,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,CHEMBL615820,,8,1,H,10576,Expert,,,BAO_0000249,
821,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,CHEMBL615821,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
822,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,CHEMBL615822,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
823,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,CHEMBL615823,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
824,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,CHEMBL615824,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
825,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,CHEMBL615825,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
826,,,B,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,CHEMBL615826,,8,1,H,10576,Expert,,,BAO_0000357,
827,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL615827,,8,1,H,10576,Expert,,,BAO_0000249,
828,,,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,CHEMBL615828,,8,1,H,10576,Expert,,,BAO_0000249,10000000.0
829,,,B,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615829,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
830,,,B,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,CHEMBL615830,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
831,,,B,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,CHEMBL615831,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
832,,,B,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,CHEMBL615832,,8,1,H,10576,Autocuration,,,BAO_0000357,
833,,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,CHEMBL615833,,8,1,H,10576,Autocuration,,,BAO_0000019,
834,,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,CHEMBL615834,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
835,,,B,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,CHEMBL615835,,8,1,H,10576,Intermediate,,,BAO_0000249,
836,,,B,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,CHEMBL615836,,8,1,H,10576,Autocuration,,,BAO_0000249,10000000.0
837,Rattus norvegicus,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,CHEMBL615837,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
838,Rattus norvegicus,,B,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,CHEMBL615838,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
839,,,B,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,CHEMBL615839,,8,1,H,10576,Expert,,,BAO_0000249,
840,,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,CHEMBL884525,,8,1,H,10576,Autocuration,,,BAO_0000019,
841,,,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,CHEMBL615840,,8,1,H,10576,Autocuration,,,BAO_0000249,
842,,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615405,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
843,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL615406,,8,1,H,10576,Expert,,,BAO_0000019,
844,,,B,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,CHEMBL615900,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
845,,,B,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,CHEMBL615901,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
846,,,B,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,CHEMBL615902,,8,1,H,10576,Expert,,,BAO_0000357,
847,,,B,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,CHEMBL615903,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
848,,,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,CHEMBL615904,,8,1,H,10576,Autocuration,,,BAO_0000357,
849,,,B,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,CHEMBL615905,,8,1,H,10576,Expert,,,BAO_0000357,
850,,,B,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL615906,,8,1,H,10576,Autocuration,,,BAO_0000019,
851,,,F,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL615907,,8,1,H,10576,Autocuration,,,BAO_0000019,
852,,,B,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL615908,,8,1,H,10576,Expert,,,BAO_0000019,
853,,,B,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,CHEMBL615909,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
854,,,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,CHEMBL615910,,8,1,H,10576,Autocuration,,,BAO_0000019,
855,,,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,CHEMBL615911,,8,1,H,10576,Autocuration,,,BAO_0000019,
856,,,B,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,CHEMBL615912,,8,1,H,10576,Autocuration,,,BAO_0000019,
857,,,B,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL615913,,8,1,H,10576,Expert,,,BAO_0000019,
858,,,B,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL615914,,8,1,H,10576,Expert,,,BAO_0000357,
859,,,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,CHEMBL615915,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
860,,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,CHEMBL615916,,8,1,H,10576,Autocuration,,,BAO_0000357,
861,,,B,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,CHEMBL615917,,8,1,H,10576,Expert,,,BAO_0000357,
862,,,B,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL615918,,8,1,H,10576,Expert,,,BAO_0000357,
863,,,B,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,CHEMBL615919,,8,1,H,10576,Expert,,,BAO_0000249,10000000.0
864,Rattus norvegicus,,B,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL615920,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
865,,,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,CHEMBL615921,,8,1,H,10576,Autocuration,,,BAO_0000357,
866,,,B,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,CHEMBL615922,,8,1,H,10576,Expert,,,BAO_0000357,
867,Rattus norvegicus,,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,CHEMBL881290,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
868,,,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,CHEMBL615923,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
869,,,F,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615924,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
870,,,F,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615925,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
871,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,CHEMBL615926,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
872,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,CHEMBL615927,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
873,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL615928,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
874,Rattus norvegicus,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,CHEMBL615929,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
875,,,B,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,CHEMBL615930,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
876,,,B,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615931,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
877,,,F,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL615932,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
878,,,F,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL615933,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
879,,,B,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL615934,,8,1,H,51,Autocuration,,,BAO_0000357,
880,,,B,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,CHEMBL615935,,8,1,H,51,Autocuration,,,BAO_0000357,
881,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615936,,8,1,H,51,Autocuration,,,BAO_0000019,
882,,,B,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,CHEMBL615937,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
883,,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,CHEMBL615938,,8,1,H,51,Autocuration,,,BAO_0000357,
884,,,B,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,CHEMBL615797,,8,1,H,51,Autocuration,,,BAO_0000357,
885,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615798,,8,1,H,51,Autocuration,,,BAO_0000357,
886,,,B,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,CHEMBL872870,,8,1,H,51,Autocuration,,,BAO_0000357,
887,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,CHEMBL615799,,8,1,H,51,Autocuration,,,BAO_0000357,
888,,,B,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615800,,8,1,H,51,Autocuration,,,BAO_0000357,
889,,,F,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL615801,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
890,,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,CHEMBL615802,,8,1,H,51,Autocuration,,,BAO_0000019,
891,,,B,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,CHEMBL615803,,8,1,H,51,Autocuration,,,BAO_0000357,
892,,,F,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,CHEMBL835002,,8,1,H,51,Expert,,,BAO_0000019,
893,,,F,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,CHEMBL615804,,8,1,H,51,Autocuration,,,BAO_0000019,
894,,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,CHEMBL615805,,8,1,H,51,Expert,,308.0,BAO_0000219,
895,,,B,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,CHEMBL615806,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
896,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,CHEMBL615807,9606.0,9,1,D,51,Expert,,,BAO_0000357,
897,,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,CHEMBL615808,,8,1,H,51,Autocuration,,,BAO_0000357,
898,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615809,9606.0,9,1,D,51,Expert,,,BAO_0000357,
899,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,CHEMBL615810,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
900,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615811,,8,1,H,51,Autocuration,,,BAO_0000357,
901,,,B,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,CHEMBL615812,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
902,,,B,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL615751,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
903,,,B,Binding affinity against human 5-hydroxytryptamine 1A receptor,,CHEMBL615752,,8,1,H,51,Autocuration,,,BAO_0000357,
904,,,B,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,CHEMBL615753,,8,1,H,51,Expert,,449.0,BAO_0000219,
905,,,B,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,CHEMBL615754,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
906,,,B,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,CHEMBL615755,,8,1,H,51,Autocuration,,,BAO_0000357,
907,Homo sapiens,,B,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL615756,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
908,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,CHEMBL615757,,8,1,H,51,Autocuration,,,BAO_0000019,
909,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,CHEMBL615758,,8,1,H,51,Autocuration,,,BAO_0000357,
910,,,B,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,CHEMBL615759,,8,1,H,51,Expert,,,BAO_0000357,
911,,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,CHEMBL615760,,8,1,H,51,Autocuration,,,BAO_0000357,
912,,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,CHEMBL615761,,8,1,H,51,Expert,,308.0,BAO_0000219,
913,,,B,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,CHEMBL872104,,8,1,H,51,Autocuration,,,BAO_0000357,
914,,,B,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615762,,8,1,H,51,Autocuration,,,BAO_0000357,
915,,,B,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615763,,8,1,H,51,Autocuration,,,BAO_0000357,
916,,,B,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,CHEMBL615764,,8,1,H,51,Autocuration,,,BAO_0000357,
917,,,B,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,CHEMBL615765,,8,1,H,51,Autocuration,,1167.0,BAO_0000219,
918,,,B,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,CHEMBL615766,,8,1,H,51,Autocuration,,,BAO_0000019,
919,,,B,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615767,,8,1,H,51,Autocuration,,,BAO_0000357,
920,,,B,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615768,,8,1,H,51,Expert,,,BAO_0000357,
921,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615769,,8,1,H,51,Autocuration,,,BAO_0000357,
922,,,B,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,CHEMBL615770,,8,1,H,51,Expert,,,BAO_0000357,
923,,,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615771,,8,1,H,51,Autocuration,,,BAO_0000357,
924,,,B,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,CHEMBL615772,,8,1,H,51,Expert,,,BAO_0000357,
925,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL615773,,8,1,H,51,Autocuration,,,BAO_0000357,
926,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,CHEMBL615774,,8,1,H,51,Expert,,,BAO_0000357,
927,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615775,,8,1,H,51,Autocuration,,,BAO_0000357,
928,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,CHEMBL615776,,8,1,H,51,Autocuration,,,BAO_0000357,
929,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615777,,8,1,H,51,Expert,,,BAO_0000357,
930,,,B,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,CHEMBL615778,,8,1,H,51,Autocuration,,,BAO_0000219,
931,Homo sapiens,,B,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL615779,9606.0,9,1,D,51,Expert,,,BAO_0000357,
932,,,B,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL615780,,8,1,H,51,Autocuration,,,BAO_0000357,
933,,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,CHEMBL616298,,8,1,H,51,Autocuration,,,BAO_0000357,
934,,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,CHEMBL616299,,8,1,H,51,Autocuration,,,BAO_0000357,
935,,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,CHEMBL616300,,8,1,H,51,Autocuration,,485.0,BAO_0000219,
936,,,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,CHEMBL616301,,8,1,H,51,Expert,,485.0,BAO_0000219,
937,,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,CHEMBL616302,,8,1,H,51,Autocuration,,,BAO_0000019,
938,,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,CHEMBL616117,,8,1,H,51,Autocuration,,,BAO_0000019,
939,,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,CHEMBL616118,,8,1,H,51,Autocuration,,,BAO_0000019,
940,,,B,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,CHEMBL616119,,8,1,H,51,Autocuration,,,BAO_0000019,
941,Homo sapiens,,B,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,CHEMBL616120,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
942,,,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,CHEMBL616121,,8,1,H,51,Autocuration,,,BAO_0000357,
943,,,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,CHEMBL616122,,8,1,H,51,Autocuration,,,BAO_0000357,
944,,,B,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,CHEMBL616123,,8,1,H,51,Autocuration,,,BAO_0000357,
945,Homo sapiens,,B,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,CHEMBL616124,9606.0,9,1,D,51,Expert,,,BAO_0000357,
946,,,B,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,CHEMBL616125,,8,1,H,51,Expert,,,BAO_0000357,
947,Rattus norvegicus,,B,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,CHEMBL616126,10116.0,8,1,H,51,Expert,,,BAO_0000357,
948,,,B,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,CHEMBL616127,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
949,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL616128,,8,1,H,51,Expert,,,BAO_0000019,
950,,,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,CHEMBL616129,,8,1,H,51,Autocuration,,,BAO_0000357,
951,,,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616130,,8,1,H,51,Expert,,,BAO_0000357,
952,,,B,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,CHEMBL616131,,8,1,H,51,Autocuration,,,BAO_0000357,
953,,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,CHEMBL616132,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
954,Homo sapiens,,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,CHEMBL616133,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
955,,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616134,,8,1,H,51,Autocuration,,,BAO_0000357,
956,,,B,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,CHEMBL616135,,8,1,H,51,Autocuration,,,BAO_0000357,
957,Homo sapiens,,B,Affinity for 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616136,9606.0,9,1,D,51,Expert,,,BAO_0000357,
958,,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,CHEMBL616137,,8,1,H,51,Autocuration,,,BAO_0000019,
959,,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,CHEMBL872105,,8,1,H,51,Autocuration,,,BAO_0000019,
960,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,CHEMBL616138,,8,1,H,51,Autocuration,,,BAO_0000357,
961,Homo sapiens,,B,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616139,9606.0,9,1,D,51,Expert,,,BAO_0000357,
962,,,F,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,CHEMBL616140,,8,1,H,51,Autocuration,,,BAO_0000019,
963,,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,CHEMBL616141,,8,1,H,51,Expert,,,BAO_0000019,
964,,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616142,,8,1,H,51,Autocuration,,,BAO_0000357,
965,,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,CHEMBL616143,,8,1,H,51,Autocuration,,,BAO_0000357,
966,,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616144,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
967,,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,CHEMBL616145,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
968,,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616012,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
969,,,B,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616013,,8,1,H,51,Autocuration,,308.0,BAO_0000219,
970,,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616014,,8,1,H,51,Autocuration,,,BAO_0000019,
971,,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616015,,8,1,H,51,Autocuration,,,BAO_0000019,
972,,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616016,,8,1,H,51,Autocuration,,,BAO_0000019,
973,,,F,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,CHEMBL616017,,8,1,H,51,Autocuration,,,BAO_0000218,
974,,,B,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,CHEMBL616018,,8,1,H,51,Autocuration,,,BAO_0000019,
975,,,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,CHEMBL616019,,8,1,H,51,Autocuration,,,BAO_0000019,
976,,,F,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,CHEMBL616020,,8,1,H,51,Autocuration,,,BAO_0000019,
977,,,B,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,CHEMBL858018,,8,1,H,51,Autocuration,,,BAO_0000357,
978,,,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616021,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
979,,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,CHEMBL616022,,8,1,H,51,Expert,,,BAO_0000019,
980,,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,CHEMBL616023,,8,1,H,51,Autocuration,,,BAO_0000019,
981,,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,CHEMBL616024,,8,1,H,51,Autocuration,,,BAO_0000019,
982,,,F,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,CHEMBL616025,,8,1,H,51,Autocuration,,,BAO_0000019,
983,,,F,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL616026,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
984,,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,CHEMBL616027,,8,1,H,51,Autocuration,,,BAO_0000019,
985,Homo sapiens,,F,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,CHEMBL616028,9606.0,9,1,D,51,Expert,,,BAO_0000019,
986,Homo sapiens,,F,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,CHEMBL616029,9606.0,9,1,D,51,Expert,,,BAO_0000019,
987,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,CHEMBL616030,,8,1,H,51,Expert,,449.0,BAO_0000219,
988,,,B,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,CHEMBL616031,,8,1,H,51,Expert,,,BAO_0000019,
989,Homo sapiens,,F,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616032,9606.0,9,1,D,51,Expert,,,BAO_0000019,
990,Homo sapiens,,F,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616033,9606.0,9,1,D,51,Expert,,,BAO_0000019,
991,,,F,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616034,,8,1,H,51,Autocuration,,,BAO_0000019,
992,,,F,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616035,,8,1,H,51,Autocuration,,,BAO_0000019,
993,,,F,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616036,,8,1,H,51,Autocuration,,,BAO_0000019,
994,,,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616037,,8,1,H,51,Autocuration,,,BAO_0000019,
995,,,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616038,,8,1,H,51,Autocuration,,,BAO_0000019,
996,,,F,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616039,,8,1,H,51,Autocuration,,,BAO_0000019,
997,,,F,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616040,,8,1,H,51,Autocuration,,,BAO_0000019,
998,Homo sapiens,,F,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616041,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
999,Homo sapiens,,F,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616042,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
1000,Homo sapiens,,F,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616043,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
1001,,,F,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,CHEMBL616044,,8,1,H,51,Autocuration,,,BAO_0000019,
1002,,,F,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL616045,,8,1,H,51,Autocuration,,,BAO_0000019,
1003,,,F,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616046,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1004,,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHEMBL616047,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
1005,,,F,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL616048,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
1006,Homo sapiens,,F,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,CHEMBL616049,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
1007,,,F,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHEMBL616050,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
1008,,,F,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,CHEMBL616051,,8,1,H,51,Expert,,,BAO_0000219,
1009,,,F,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,CHEMBL616212,,8,1,H,51,Autocuration,,,BAO_0000219,
1010,,,F,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL616213,,8,1,H,51,Autocuration,,,BAO_0000019,
1011,,,B,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,CHEMBL616214,,8,1,H,51,Expert,,,BAO_0000219,
1012,,,B,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,CHEMBL616215,,8,1,H,51,Expert,,,BAO_0000219,
1013,,,B,Binding activity radioligand.,,CHEMBL616216,,8,1,H,51,Autocuration,,,BAO_0000357,
1014,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL616217,,8,1,H,51,Autocuration,,,BAO_0000019,
1015,,,B,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,CHEMBL616218,,8,1,H,51,Autocuration,,,BAO_0000357,
1016,,,B,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,CHEMBL616219,,8,1,H,51,Autocuration,,,BAO_0000357,
1017,,,B,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL616220,,8,1,H,51,Autocuration,,,BAO_0000357,
1018,Homo sapiens,,B,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,CHEMBL833493,9606.0,9,1,D,51,Expert,,,BAO_0000357,
1019,,,B,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,CHEMBL616221,,8,1,H,51,Autocuration,,,BAO_0000357,
1020,Homo sapiens,,B,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHEMBL616222,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
1021,,,F,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616223,,8,1,H,51,Autocuration,,,BAO_0000019,
1022,,,F,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHEMBL616224,,8,1,H,51,Autocuration,,,BAO_0000019,
1023,,,B,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,CHEMBL616225,,8,1,H,51,Expert,,,BAO_0000019,
1024,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,CHEMBL616226,9606.0,9,1,D,51,Expert,,722.0,BAO_0000219,
1025,,,B,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,CHEMBL616227,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1026,,,B,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,CHEMBL616228,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1027,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,CHEMBL616229,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1028,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,CHEMBL616230,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1029,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,CHEMBL616231,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1030,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,CHEMBL616232,,8,1,H,51,Autocuration,,,BAO_0000357,
1031,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,CHEMBL616233,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1032,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,CHEMBL857973,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1033,,,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,CHEMBL616234,,8,1,H,51,Autocuration,,,BAO_0000219,
1034,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,CHEMBL616235,,8,1,H,51,Autocuration,,,BAO_0000357,
1035,,,B,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,CHEMBL616236,,8,1,H,51,Expert,,308.0,BAO_0000219,
1036,,,B,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,CHEMBL616237,,8,1,H,51,Expert,,,BAO_0000019,
1037,,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,CHEMBL616238,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1038,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,CHEMBL616239,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1039,,,B,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,CHEMBL616240,,8,1,H,51,Autocuration,,,BAO_0000219,
1040,Homo sapiens,,B,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,CHEMBL616241,9606.0,9,1,D,51,Expert,,308.0,BAO_0000219,
1041,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,CHEMBL616242,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1042,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,CHEMBL616243,,8,1,H,51,Autocuration,,722.0,BAO_0000219,
1043,,,B,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616244,,9,1,D,51,Expert,,,BAO_0000357,
1044,Homo sapiens,,B,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616245,9606.0,9,1,D,51,Autocuration,,,BAO_0000357,
1045,,,B,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,CHEMBL616246,,8,1,H,106,Autocuration,,,BAO_0000357,
1046,,,B,Binding affinity against 5-HT1D receptor,,CHEMBL616247,,8,1,H,105,Autocuration,,,BAO_0000357,
1047,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616248,,8,1,H,105,Autocuration,,,BAO_0000357,
1048,,,B,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL616249,,8,1,H,107,Autocuration,,,BAO_0000357,
1049,Homo sapiens,,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,CHEMBL616250,9606.0,8,1,H,10576,Autocuration,,,BAO_0000357,
1050,,,B,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL616251,,8,1,H,51,Autocuration,,,BAO_0000357,
1051,,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,CHEMBL616252,,8,1,H,11863,Autocuration,,,BAO_0000218,
1052,,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,CHEMBL616253,,8,1,H,11863,Autocuration,,,BAO_0000218,
1053,,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,CHEMBL616254,,8,1,H,11863,Autocuration,,,BAO_0000218,
1054,Mus musculus,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,CHEMBL616255,10090.0,9,1,D,11863,Expert,,,BAO_0000218,
1055,Mus musculus,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,CHEMBL832872,10090.0,9,1,D,11863,Expert,,,BAO_0000218,
1056,Mus musculus,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,CHEMBL616256,10090.0,9,1,D,11863,Expert,,,BAO_0000218,
1057,Mus musculus,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,CHEMBL616257,10090.0,9,1,D,11863,Expert,,,BAO_0000218,
1058,Mus musculus,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,CHEMBL616258,10090.0,9,1,D,11863,Expert,,,BAO_0000218,
1059,Mus musculus,,F,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,CHEMBL616384,10090.0,9,1,D,11863,Expert,,,BAO_0000218,
1060,,,B,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,CHEMBL616385,,8,1,H,11863,Autocuration,,,BAO_0000221,10000000.0
1061,,,B,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,CHEMBL616386,,8,1,H,11863,Expert,,,BAO_0000357,
1062,Mus musculus,,B,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,CHEMBL616387,10090.0,9,1,D,11863,Expert,,,BAO_0000221,10000000.0
1063,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,CHEMBL616388,,8,1,H,11863,Autocuration,,,BAO_0000221,10000000.0
1064,Mus musculus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,CHEMBL616389,10090.0,9,1,D,11863,Expert,,,BAO_0000221,10000000.0
1065,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,CHEMBL616390,,8,1,H,11863,Autocuration,,,BAO_0000221,10000000.0
1066,,,B,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,CHEMBL616391,,8,1,H,11863,Autocuration,,,BAO_0000357,
1067,Mus musculus,,B,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,CHEMBL616392,10090.0,9,1,D,11863,Expert,,,BAO_0000221,10000000.0
1068,Sus scrofa,,B,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,CHEMBL616393,9823.0,8,1,H,51,Autocuration,,,BAO_0000357,
1069,Sus scrofa,,B,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,CHEMBL616394,9823.0,8,1,H,51,Autocuration,,,BAO_0000357,
1070,Sus scrofa,,B,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,CHEMBL616395,9823.0,8,1,H,51,Autocuration,,,BAO_0000019,
1071,Sus scrofa,,B,Compound was evaluated for the binding affinity at 5- HT1A receptor,,CHEMBL616396,9823.0,8,1,H,51,Autocuration,,,BAO_0000357,
1072,Sus scrofa,,B,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,CHEMBL872907,9823.0,8,1,H,51,Autocuration,,,BAO_0000019,
1073,Sus scrofa,,B,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,CHEMBL616397,9823.0,8,1,H,51,Autocuration,,,BAO_0000019,
1074,Sus scrofa,,B,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,CHEMBL616398,9823.0,8,1,H,51,Autocuration,,,BAO_0000019,
1075,Sus scrofa,,B,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,CHEMBL616399,9823.0,8,1,H,51,Expert,,,BAO_0000357,
1076,Sus scrofa,,B,Binding activity radioligand.,,CHEMBL857065,9823.0,8,1,H,51,Autocuration,,,BAO_0000357,
1077,Sus scrofa,,B,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL616400,9823.0,8,1,H,51,Expert,,,BAO_0000019,
1078,Sus scrofa,,B,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL616401,9823.0,8,1,H,51,Autocuration,,,BAO_0000019,
1079,,,B,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,CHEMBL616402,,8,1,H,10624,Expert,,,BAO_0000019,
1080,Sus scrofa,,B,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,CHEMBL616403,9823.0,8,1,H,51,Expert,,,BAO_0000019,
1081,Sus scrofa,,B,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,CHEMBL616404,9823.0,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
1082,Sus scrofa,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,CHEMBL616405,9823.0,8,1,H,51,Autocuration,,,BAO_0000249,
1083,Sus scrofa,,B,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,CHEMBL616406,9823.0,8,1,H,51,Autocuration,,,BAO_0000019,
1084,Sus scrofa,,F,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,CHEMBL616407,9823.0,8,1,H,51,Expert,,,BAO_0000019,
1085,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,CHEMBL616408,9986.0,8,1,H,51,Autocuration,,,BAO_0000019,
1086,Rattus norvegicus,,B,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,CHEMBL616409,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1087,Rattus norvegicus,,B,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,CHEMBL616410,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1088,,,B,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,CHEMBL616411,,8,1,H,10576,Autocuration,,,BAO_0000357,
1089,Rattus norvegicus,,F,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,CHEMBL616412,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1090,Rattus norvegicus,,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,CHEMBL616413,10116.0,9,1,D,10576,Expert,,,BAO_0000249,10000000.0
1091,,,B,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616414,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1092,Rattus norvegicus,,B,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,CHEMBL616415,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1093,,,B,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,CHEMBL616416,,8,1,H,10576,Autocuration,,,BAO_0000019,
1094,,,B,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616417,,8,1,H,10576,Expert,,,BAO_0000357,
1095,,,B,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,CHEMBL616418,,8,1,H,10576,Autocuration,,,BAO_0000357,
1096,,,B,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL616419,,8,1,H,10576,Autocuration,,,BAO_0000219,
1097,,,B,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,CHEMBL616420,,8,1,H,10576,Autocuration,,,BAO_0000357,
1098,,,B,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,CHEMBL616421,,8,1,H,10576,Autocuration,,,BAO_0000249,
1099,,,B,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,CHEMBL616422,,8,1,H,10576,Autocuration,,,BAO_0000249,
1100,,,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,CHEMBL616423,,8,1,H,10576,Expert,,,BAO_0000249,
1101,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,CHEMBL616424,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1102,,,B,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,CHEMBL616425,,8,1,H,10576,Expert,,,BAO_0000357,
1103,,,B,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,CHEMBL616426,,8,1,H,10576,Expert,,,BAO_0000357,
1104,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,CHEMBL616427,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1105,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,CHEMBL616428,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1106,,,B,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616290,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1107,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,CHEMBL616052,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1108,,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,CHEMBL616053,,8,1,H,10576,Autocuration,,,BAO_0000357,
1109,,,B,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL616054,,8,1,H,10576,Autocuration,,,BAO_0000249,
1110,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616055,,8,1,H,10576,Autocuration,,,BAO_0000357,
1111,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,CHEMBL616056,,8,1,H,10576,Autocuration,,,BAO_0000357,
1112,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,CHEMBL616057,,8,1,H,10576,Expert,,,BAO_0000019,
1113,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL616058,10116.0,9,1,D,10576,Expert,,,BAO_0000221,955.0
1114,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL616059,,8,1,H,10576,Autocuration,,,BAO_0000221,955.0
1115,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,CHEMBL616060,,8,1,H,10576,Autocuration,,,BAO_0000249,
1116,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,CHEMBL616061,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1117,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,CHEMBL616062,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1118,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL616063,,8,1,H,10576,Autocuration,,,BAO_0000249,
1119,,,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,CHEMBL616064,,8,1,H,10576,Autocuration,,,BAO_0000249,2435.0
1120,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,CHEMBL616065,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1121,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,CHEMBL616066,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1122,,,B,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616067,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1123,,,B,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,CHEMBL616068,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1124,,,B,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616069,,8,1,H,10576,Intermediate,,,BAO_0000221,10000000.0
1125,,,B,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL616070,,8,1,H,10576,Expert,,,BAO_0000249,
1126,,,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616071,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1127,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,CHEMBL616072,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1128,,,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,CHEMBL616073,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1129,,,B,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,CHEMBL616074,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1130,,,B,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,CHEMBL616075,,8,1,H,10576,Expert,,,BAO_0000019,
1131,,,B,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,CHEMBL616076,,8,1,H,10576,Autocuration,,,BAO_0000357,
1132,Rattus norvegicus,,B,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,CHEMBL616077,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1133,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,CHEMBL616078,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1134,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,CHEMBL616079,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1135,Rattus norvegicus,,B,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHEMBL616080,10116.0,9,1,D,10576,Expert,,485.0,BAO_0000219,
1136,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616081,,8,1,H,10576,Autocuration,,,BAO_0000357,
1137,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,CHEMBL616082,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1138,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,CHEMBL616083,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1139,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL616084,,8,1,H,10576,Autocuration,,,BAO_0000019,
1140,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,CHEMBL616085,,8,1,H,10576,Expert,,,BAO_0000019,
1141,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,CHEMBL616086,,8,1,H,10576,Autocuration,,,BAO_0000019,
1142,,,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,CHEMBL616087,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1143,,,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,CHEMBL616088,,8,1,H,10576,Expert,,,BAO_0000357,
1144,,,B,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616089,,8,1,H,10576,Autocuration,,,BAO_0000019,
1145,Rattus norvegicus,,B,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,CHEMBL616090,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1146,,,B,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL616091,,8,1,H,10576,Autocuration,,,BAO_0000357,
1147,,,B,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,CHEMBL616092,,8,1,H,10576,Autocuration,,,BAO_0000249,2435.0
1148,,,B,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,CHEMBL616093,,8,1,H,10576,Autocuration,,,BAO_0000357,
1149,,,B,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,CHEMBL616094,,8,1,H,10576,Autocuration,,,BAO_0000218,
1150,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,CHEMBL616095,,8,1,H,10576,Autocuration,,,BAO_0000221,955.0
1151,Rattus norvegicus,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL616096,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1152,,,B,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,CHEMBL616097,,8,1,H,10576,Expert,,,BAO_0000249,
1153,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,CHEMBL616098,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1154,,,B,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616099,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1155,,,B,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616100,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1156,,,B,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,CHEMBL616101,,8,1,H,10576,Expert,,,BAO_0000357,
1157,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,CHEMBL616102,,8,1,H,10576,Expert,,,BAO_0000249,
1158,,,B,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,CHEMBL616103,,8,1,H,10576,Autocuration,,,BAO_0000357,
1159,,,B,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,CHEMBL616104,,8,1,H,10576,Expert,,,BAO_0000019,
1160,,,B,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,CHEMBL616105,,8,1,H,10576,Expert,,,BAO_0000019,
1161,Rattus norvegicus,,B,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,CHEMBL616106,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1162,,,B,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,CHEMBL616107,,8,1,H,10576,Autocuration,,,BAO_0000019,
1163,,,B,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,CHEMBL616108,,8,1,H,10576,Expert,,,BAO_0000357,
1164,,,B,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616109,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1165,,,B,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,CHEMBL616110,,8,1,H,10576,Autocuration,,,BAO_0000357,
1166,,,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,CHEMBL616111,,8,1,H,10576,Expert,,449.0,BAO_0000219,
1167,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,CHEMBL616112,,8,1,H,10576,Expert,,,BAO_0000019,
1168,,,B,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,CHEMBL616113,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1169,,,B,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616114,,8,1,H,10576,Autocuration,,,BAO_0000019,
1170,,,B,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616115,,8,1,H,10576,Autocuration,,,BAO_0000019,
1171,,,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616116,,8,1,H,10576,Autocuration,,,BAO_0000357,
1172,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,CHEMBL615844,,8,1,H,10576,Expert,,,BAO_0000221,955.0
1173,,,B,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL615939,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1174,,,B,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,CHEMBL615940,,8,1,H,10576,Expert,,,BAO_0000019,
1175,,,B,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,CHEMBL615941,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1176,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,CHEMBL615942,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1177,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL615943,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1178,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,CHEMBL615944,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1179,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,CHEMBL615945,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1180,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,CHEMBL615946,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1181,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,CHEMBL615947,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1182,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,CHEMBL615948,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1183,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,CHEMBL615949,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1184,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,CHEMBL615950,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1185,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,CHEMBL615951,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1186,,,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,CHEMBL615952,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1187,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,CHEMBL615953,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1188,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,CHEMBL615954,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1189,Rattus norvegicus,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL615955,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1190,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,CHEMBL615956,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1191,,,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,CHEMBL615957,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1192,,,B,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,CHEMBL615958,,8,1,H,10576,Expert,,,BAO_0000019,
1193,,,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,CHEMBL615959,,8,1,H,10576,Expert,,,BAO_0000019,
1194,,,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,CHEMBL615960,,8,1,H,10576,Autocuration,,,BAO_0000019,
1195,,,B,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,CHEMBL615961,,8,1,H,10576,Autocuration,,,BAO_0000019,
1196,,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL615962,,8,1,H,10576,Expert,,,BAO_0000221,955.0
1197,,,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,CHEMBL615963,,8,1,H,10576,Expert,,,BAO_0000019,
1198,,,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,CHEMBL615964,,8,1,H,10576,Autocuration,,,BAO_0000019,
1199,,,B,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,CHEMBL615965,,8,1,H,10576,Autocuration,,,BAO_0000019,
1200,,,B,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,CHEMBL615966,,8,1,H,10576,Expert,,449.0,BAO_0000219,
1201,,,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,CHEMBL615967,,8,1,H,10576,Expert,,,BAO_0000249,
1202,,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,CHEMBL615968,,8,1,H,10576,Expert,,,BAO_0000019,
1203,,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHEMBL615969,,8,1,H,10576,Autocuration,,449.0,BAO_0000218,
1204,,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,CHEMBL615970,,8,1,H,10576,Autocuration,,,BAO_0000218,
1205,Rattus norvegicus,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,CHEMBL615971,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1206,,,B,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL615972,,8,1,H,10576,Expert,,,BAO_0000249,
1207,,,B,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,CHEMBL615973,,8,1,H,10576,Autocuration,,,BAO_0000249,
1208,,,B,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,CHEMBL615974,,8,1,H,10576,Autocuration,,,BAO_0000249,
1209,Homo sapiens,,B,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL615975,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
1210,,,B,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,CHEMBL615976,,8,1,H,10576,Expert,,,BAO_0000249,
1211,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL872106,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1212,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615977,,8,1,H,10576,Autocuration,,,BAO_0000357,
1213,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,CHEMBL615978,,8,1,H,10576,Autocuration,,,BAO_0000357,
1214,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,CHEMBL616166,,8,1,H,10576,Autocuration,,,BAO_0000357,
1215,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,CHEMBL616167,,8,1,H,10576,Autocuration,,,BAO_0000357,
1216,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,CHEMBL616168,,8,1,H,10576,Autocuration,,,BAO_0000357,
1217,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,CHEMBL616169,,8,1,H,10576,Autocuration,,,BAO_0000357,
1218,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,CHEMBL616170,,8,1,H,10576,Autocuration,,,BAO_0000357,
1219,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,CHEMBL616171,,8,1,H,10576,Autocuration,,,BAO_0000357,
1220,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,CHEMBL616172,,8,1,H,10576,Autocuration,,,BAO_0000357,
1221,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,CHEMBL616173,,8,1,H,10576,Autocuration,,,BAO_0000357,
1222,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,CHEMBL616174,,8,1,H,10576,Autocuration,,,BAO_0000357,
1223,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,CHEMBL616175,,8,1,H,10576,Autocuration,,,BAO_0000357,
1224,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,CHEMBL616176,,8,1,H,10576,Autocuration,,,BAO_0000357,
1225,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,CHEMBL616177,,8,1,H,10576,Autocuration,,,BAO_0000357,
1226,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,CHEMBL616178,,8,1,H,10576,Autocuration,,,BAO_0000357,
1227,,,B,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL616179,,8,1,H,10576,Autocuration,,,BAO_0000019,
1228,,,B,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,CHEMBL616180,,8,1,H,10576,Autocuration,,,BAO_0000357,
1229,,,B,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,CHEMBL616181,,8,1,H,10576,Autocuration,,,BAO_0000357,
1230,,,B,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,CHEMBL616182,,8,1,H,10576,Autocuration,,,BAO_0000019,
1231,,,B,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616183,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1232,,,B,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,CHEMBL615874,,8,1,H,10576,Expert,,,BAO_0000019,
1233,Rattus norvegicus,,B,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHEMBL615875,10116.0,9,1,D,10576,Expert,,485.0,BAO_0000219,
1234,,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,CHEMBL615876,,8,1,H,10576,Autocuration,,,BAO_0000019,
1235,,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,CHEMBL615877,,8,1,H,10576,Autocuration,,,BAO_0000019,
1236,,,B,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,CHEMBL615878,,8,1,H,10576,Autocuration,,,BAO_0000357,
1237,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,CHEMBL615879,,8,1,H,10576,Expert,,,BAO_0000357,
1238,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,CHEMBL615880,,8,1,H,10576,Expert,,,BAO_0000357,
1239,,,B,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,CHEMBL615881,,8,1,H,10576,Autocuration,,,BAO_0000019,
1240,Rattus norvegicus,,B,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,CHEMBL615882,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1241,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,CHEMBL615883,,8,1,H,10576,Autocuration,,,BAO_0000218,
1242,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,CHEMBL615884,,8,1,H,10576,Autocuration,,,BAO_0000218,
1243,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,CHEMBL615885,,8,1,H,10576,Autocuration,,,BAO_0000218,
1244,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,CHEMBL615886,,8,1,H,10576,Autocuration,,,BAO_0000218,
1245,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,CHEMBL615887,,8,1,H,10576,Autocuration,,,BAO_0000218,
1246,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,CHEMBL615888,,8,1,H,10576,Autocuration,,,BAO_0000218,
1247,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,CHEMBL615889,,8,1,H,10576,Autocuration,,,BAO_0000218,
1248,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,CHEMBL615890,,8,1,H,10576,Autocuration,,,BAO_0000218,
1249,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,CHEMBL615891,,8,1,H,10576,Autocuration,,,BAO_0000218,
1250,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,CHEMBL615892,,8,1,H,10576,Autocuration,,,BAO_0000218,
1251,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,CHEMBL615893,,8,1,H,10576,Autocuration,,,BAO_0000218,
1252,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,CHEMBL615894,,8,1,H,10576,Autocuration,,,BAO_0000218,
1253,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,CHEMBL615895,,8,1,H,10576,Autocuration,,,BAO_0000218,
1254,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,CHEMBL615896,,8,1,H,10576,Autocuration,,,BAO_0000218,
1255,,,F,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,CHEMBL615897,,8,1,H,10576,Autocuration,,,BAO_0000218,
1256,Rattus norvegicus,,F,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,CHEMBL615898,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1257,,,B,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,CHEMBL615899,,8,1,H,10576,Autocuration,,,BAO_0000019,
1258,,,B,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,CHEMBL616291,,8,1,H,10576,Autocuration,,,BAO_0000019,
1259,,,B,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,CHEMBL616292,,8,1,H,10576,Autocuration,,,BAO_0000357,
1260,,,F,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,CHEMBL616293,,8,1,H,10576,Autocuration,,,BAO_0000249,
1261,,,B,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616294,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1262,,,B,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,CHEMBL616295,,8,1,H,10576,Autocuration,,,BAO_0000249,10000000.0
1263,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,CHEMBL616296,,8,1,H,10576,Autocuration,,,BAO_0000221,955.0
1264,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,CHEMBL616297,,8,1,H,10576,Autocuration,,,BAO_0000019,
1265,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,CHEMBL616605,,8,1,H,10576,Autocuration,,,BAO_0000019,
1266,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,CHEMBL616606,,8,1,H,10576,Autocuration,,,BAO_0000019,
1267,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,CHEMBL616607,,8,1,H,10576,Autocuration,,,BAO_0000019,
1268,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,CHEMBL616608,,8,1,H,10576,Expert,,,BAO_0000019,
1269,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,CHEMBL616609,,8,1,H,10576,Autocuration,,,BAO_0000019,
1270,Rattus norvegicus,,F,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,CHEMBL616610,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1271,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,CHEMBL616611,,8,1,H,10576,Autocuration,,,BAO_0000019,
1272,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,CHEMBL616612,,8,1,H,10576,Expert,,,BAO_0000019,
1273,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,CHEMBL616613,,8,1,H,10576,Autocuration,,,BAO_0000019,
1274,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,CHEMBL616614,,8,1,H,10576,Expert,,,BAO_0000019,
1275,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,CHEMBL616615,,8,1,H,10576,Autocuration,,,BAO_0000019,
1276,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,CHEMBL616616,,8,1,H,10576,Expert,,,BAO_0000019,
1277,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,CHEMBL616617,,8,1,H,10576,Autocuration,,,BAO_0000019,
1278,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,CHEMBL616618,,8,1,H,10576,Autocuration,,,BAO_0000019,
1279,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,CHEMBL616619,,8,1,H,10576,Autocuration,,,BAO_0000019,
1280,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,CHEMBL616620,,8,1,H,10576,Expert,,,BAO_0000019,
1281,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,CHEMBL616621,,8,1,H,10576,Expert,,,BAO_0000019,
1282,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,CHEMBL616622,,8,1,H,10576,Autocuration,,,BAO_0000019,
1283,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,CHEMBL616146,,8,1,H,10576,Expert,,,BAO_0000019,
1284,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,CHEMBL832873,,8,1,H,10576,Autocuration,,,BAO_0000019,
1285,,,F,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,CHEMBL616147,,8,1,H,10576,Autocuration,,,BAO_0000019,
1286,,,F,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,CHEMBL872872,,8,1,H,10576,Autocuration,,,BAO_0000019,
1287,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,CHEMBL616148,,8,1,H,10576,Autocuration,,,BAO_0000019,
1288,,,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,CHEMBL616149,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1289,,,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,CHEMBL616150,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1290,Rattus norvegicus,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,CHEMBL616151,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1291,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,CHEMBL872873,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1292,,,B,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,CHEMBL616670,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1293,,,B,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,CHEMBL616671,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1294,Rattus norvegicus,,F,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,CHEMBL884861,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1295,,,B,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,CHEMBL616672,,8,1,H,10576,Autocuration,,,BAO_0000357,
1296,,,B,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,CHEMBL616673,,8,1,H,10576,Autocuration,,,BAO_0000019,
1297,,,F,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,CHEMBL616674,,8,1,H,10576,Expert,,,BAO_0000019,
1298,,,B,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,CHEMBL616675,,8,1,H,10576,Autocuration,,,BAO_0000357,
1299,,,B,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,CHEMBL616676,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1300,,,B,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616677,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1301,,,B,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616678,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1302,Rattus norvegicus,,B,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616679,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1303,,,B,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,CHEMBL616680,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1304,,,B,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616681,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1305,,,B,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616682,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1306,,,B,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616683,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1307,,,B,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,CHEMBL616684,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1308,,,B,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,CHEMBL616685,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1309,,,B,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,CHEMBL616686,,8,1,H,10576,Autocuration,,,BAO_0000221,955.0
1310,,,B,Affinity for 5-hydroxytryptamine 1A receptor site,,CHEMBL616687,,8,1,H,10576,Autocuration,,,BAO_0000357,
1311,,,B,Affinity for 5-hydroxytryptamine 1A receptor site,,CHEMBL616688,,8,1,H,10576,Autocuration,,,BAO_0000357,
1312,,,B,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,CHEMBL616689,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1313,,,B,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,CHEMBL616690,,8,1,H,10576,Autocuration,,,BAO_0000357,
1314,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,CHEMBL616691,,8,1,H,10576,Expert,,,BAO_0000357,
1315,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,CHEMBL616692,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1316,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,CHEMBL616693,,8,1,H,10576,Expert,,,BAO_0000249,
1317,Rattus norvegicus,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,CHEMBL616694,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1318,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,CHEMBL616695,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1319,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,CHEMBL616696,,8,1,H,10576,Autocuration,,,BAO_0000357,
1320,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,CHEMBL616697,,8,1,H,10576,Autocuration,,,BAO_0000357,
1321,,,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,CHEMBL616698,,8,1,H,10576,Autocuration,,,BAO_0000357,
1322,Rattus norvegicus,,B,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616949,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1323,,,B,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,CHEMBL616950,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1324,,,B,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,CHEMBL832875,,8,1,H,10576,Autocuration,,,BAO_0000357,
1325,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616951,,8,1,H,10576,Expert,,,BAO_0000221,955.0
1326,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616952,,8,1,H,10576,Expert,,,BAO_0000221,955.0
1327,,,B,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,CHEMBL616953,,8,1,H,10576,Expert,,,BAO_0000357,
1328,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,CHEMBL616954,,8,1,H,10576,Autocuration,,,BAO_0000357,
1329,,,B,GTPgammaS radioligand binding assay,,CHEMBL616955,,8,1,H,106,Autocuration,,,BAO_0000357,
1330,,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,CHEMBL616956,,8,1,H,106,Autocuration,,,BAO_0000357,
1331,,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,CHEMBL616957,,8,1,H,106,Autocuration,,,BAO_0000019,
1332,,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,CHEMBL616958,,8,1,H,106,Autocuration,,,BAO_0000019,
1333,,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,CHEMBL616959,,8,1,H,106,Autocuration,,,BAO_0000357,
1334,,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,CHEMBL616960,,8,1,H,106,Autocuration,,,BAO_0000357,
1335,,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,CHEMBL616961,,8,1,H,106,Autocuration,,,BAO_0000019,
1336,,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,CHEMBL616962,,8,1,H,106,Expert,,308.0,BAO_0000219,
1337,,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,CHEMBL616963,,8,1,H,106,Autocuration,,308.0,BAO_0000219,
1338,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,CHEMBL616524,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1339,,,B,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616525,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1340,,,B,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,CHEMBL872908,,8,1,H,106,Autocuration,,,BAO_0000019,
1341,,,B,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,CHEMBL616526,,8,1,H,106,Autocuration,,,BAO_0000019,
1342,Homo sapiens,,B,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616527,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1343,,,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,CHEMBL616528,,8,1,H,106,Expert,,,BAO_0000219,
1344,,,B,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616529,,8,1,H,106,Autocuration,,,BAO_0000357,
1345,,,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,CHEMBL616530,,8,1,H,106,Autocuration,,,BAO_0000357,
1346,,,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616531,,8,1,H,106,Expert,,,BAO_0000357,
1347,,,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616532,,8,1,H,106,Autocuration,,,BAO_0000357,
1348,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616533,,8,1,H,106,Autocuration,,,BAO_0000357,
1349,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616534,,8,1,H,106,Expert,,,BAO_0000357,
1350,,,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,CHEMBL616535,,8,1,H,106,Expert,,,BAO_0000357,
1351,,,B,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,CHEMBL616536,,8,1,H,106,Autocuration,,,BAO_0000357,
1352,,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616537,,8,1,H,106,Autocuration,,,BAO_0000357,
1353,,,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,CHEMBL616538,,8,1,H,106,Expert,,485.0,BAO_0000219,
1354,,,F,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,CHEMBL616539,,8,1,H,106,Expert,,,BAO_0000019,
1355,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,CHEMBL616540,,8,1,H,106,Expert,,,BAO_0000019,
1356,,,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,CHEMBL616429,,8,1,H,106,Autocuration,,,BAO_0000357,
1357,,,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616430,,8,1,H,106,Expert,,,BAO_0000357,
1358,Homo sapiens,,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,CHEMBL616431,9606.0,9,1,D,106,Expert,,,BAO_0000219,
1359,Homo sapiens,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616432,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1360,Homo sapiens,,B,Affinity for 5-hydroxytryptamine 1B receptor subtype,,CHEMBL616433,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1361,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616434,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1362,,,B,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,CHEMBL616435,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1363,,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,CHEMBL616436,,8,1,H,106,Expert,,,BAO_0000019,
1364,,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,CHEMBL616437,,8,1,H,106,Autocuration,,308.0,BAO_0000219,
1365,,,B,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,CHEMBL616438,,8,1,H,106,Autocuration,,308.0,BAO_0000219,
1366,,,B,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,CHEMBL616439,,8,1,H,106,Autocuration,,308.0,BAO_0000219,
1367,Homo sapiens,,B,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,CHEMBL616440,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1368,,,B,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,CHEMBL616441,,8,1,H,106,Autocuration,,485.0,BAO_0000219,
1369,,,B,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,CHEMBL616442,,8,1,H,106,Expert,,,BAO_0000357,
1370,,,B,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,CHEMBL616443,,8,1,H,106,Autocuration,,,BAO_0000357,
1371,,,B,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,CHEMBL616444,,8,1,H,106,Expert,,485.0,BAO_0000219,
1372,Homo sapiens,,B,Binding activity against human 5-hydroxytryptamine 1B receptor,,CHEMBL616445,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1373,Homo sapiens,,B,Binding activity against human 5-hydroxytryptamine 1B receptor,,CHEMBL616446,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1374,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616447,9606.0,9,1,D,106,Expert,,449.0,BAO_0000219,
1375,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616448,,8,1,H,106,Autocuration,,,BAO_0000357,
1376,,,B,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,CHEMBL616449,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1377,,,B,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,CHEMBL616450,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1378,,,B,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,CHEMBL857974,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1379,,,B,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL616451,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1380,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL616452,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1381,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHEMBL616453,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1382,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616454,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1383,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616455,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1384,,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHEMBL616456,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1385,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616457,,8,1,H,106,Autocuration,,,BAO_0000357,
1386,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHEMBL616458,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1387,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616459,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1388,,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,CHEMBL616460,,8,1,H,106,Expert,,,BAO_0000019,
1389,,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,CHEMBL616461,,8,1,H,106,Expert,,,BAO_0000019,
1390,,,F,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHEMBL616462,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1391,,,F,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHEMBL616463,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1392,,,F,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,CHEMBL616464,,8,1,H,105,Autocuration,,,BAO_0000019,
1393,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,CHEMBL616465,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1394,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL832874,,8,1,H,17105,Autocuration,,,BAO_0000357,
1395,Oryctolagus cuniculus,,F,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,CHEMBL616184,9986.0,8,1,H,106,Autocuration,,,BAO_0000019,
1396,Oryctolagus cuniculus,,B,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,CHEMBL616185,9986.0,8,1,H,106,Autocuration,,,BAO_0000019,
1397,Oryctolagus cuniculus,,B,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,CHEMBL616186,9986.0,8,1,H,106,Intermediate,,,BAO_0000019,
1398,Oryctolagus cuniculus,,B,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,CHEMBL616187,9986.0,8,1,H,106,Autocuration,,,BAO_0000019,
1399,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,CHEMBL616188,,8,1,H,10577,Expert,,,BAO_0000357,
1400,,,B,Binding affinity for 5-hydroxytryptamine 1B receptor,,CHEMBL873475,,9,1,D,10577,Intermediate,,,BAO_0000357,
1401,Rattus norvegicus,,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,CHEMBL616189,10116.0,9,1,D,10577,Expert,,,BAO_0000019,2435.0
1402,,,B,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,CHEMBL616190,,8,1,H,10577,Expert,,,BAO_0000357,
1403,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,CHEMBL616191,,8,1,H,10576,Autocuration,,,BAO_0000357,
1404,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,CHEMBL616192,,8,1,H,10576,Autocuration,,,BAO_0000357,
1405,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,CHEMBL616193,,8,1,H,10576,Autocuration,,,BAO_0000357,
1406,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,CHEMBL616194,,8,1,H,10576,Autocuration,,,BAO_0000357,
1407,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,CHEMBL616195,,8,1,H,10576,Autocuration,,,BAO_0000357,
1408,,,B,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,CHEMBL616196,,8,1,H,10576,Autocuration,,,BAO_0000357,
1409,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,CHEMBL616197,,8,1,H,10576,Autocuration,,,BAO_0000249,10000000.0
1410,,,B,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL616198,,8,1,H,10576,Intermediate,,,BAO_0000019,
1411,,,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,CHEMBL616199,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1412,,,B,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,CHEMBL616200,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1413,,,B,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616201,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1414,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,CHEMBL616202,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1415,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,CHEMBL616203,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1416,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,CHEMBL616204,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1417,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,CHEMBL616205,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1418,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,CHEMBL616206,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1419,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,CHEMBL616207,,8,1,H,10576,Expert,,,BAO_0000249,
1420,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,CHEMBL616208,,8,1,H,10576,Autocuration,,,BAO_0000249,
1421,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,CHEMBL616209,,8,1,H,10576,Autocuration,,,BAO_0000249,
1422,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,CHEMBL616210,,8,1,H,10576,Expert,,,BAO_0000357,
1423,,,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,CHEMBL616211,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1424,,,B,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,CHEMBL616504,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1425,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616505,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1426,,,F,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,CHEMBL616506,,8,1,H,10576,Autocuration,,,BAO_0000019,
1427,,,B,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL872107,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1428,Rattus norvegicus,,B,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,CHEMBL616507,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1429,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,CHEMBL616303,,8,1,H,10576,Autocuration,,,BAO_0000249,
1430,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,CHEMBL616304,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1431,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL616305,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1432,,,F,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,CHEMBL616306,,8,1,H,10576,Intermediate,,,BAO_0000221,10000000.0
1433,,,B,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,CHEMBL616307,,8,1,H,10576,Autocuration,,,BAO_0000357,
1434,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,CHEMBL881829,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1435,,,B,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,CHEMBL616308,,8,1,H,10576,Expert,,,BAO_0000357,
1436,,,B,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,CHEMBL616309,,8,1,H,10576,Autocuration,,,BAO_0000019,
1437,,,B,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,CHEMBL616310,,8,1,H,10576,Expert,,,BAO_0000019,
1438,,,B,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,CHEMBL616311,,8,1,H,10576,Autocuration,,449.0,BAO_0000219,
1439,,,B,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,CHEMBL616312,,8,1,H,10576,Expert,,,BAO_0000357,
1440,,,B,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,CHEMBL616313,,8,1,H,10576,Autocuration,,,BAO_0000357,
1441,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616314,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1442,,,B,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616315,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1443,,,B,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,CHEMBL616567,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1444,,,B,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,CHEMBL616568,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1445,,,B,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,CHEMBL616569,,8,1,H,10576,Intermediate,,,BAO_0000019,
1446,,,B,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,CHEMBL616570,,8,1,H,10576,Expert,,,BAO_0000357,
1447,,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,CHEMBL616571,,8,1,H,10576,Autocuration,,,BAO_0000357,
1448,,,B,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,CHEMBL616572,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1449,,,B,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,CHEMBL616573,,8,1,H,10576,Expert,,,BAO_0000249,
1450,Rattus norvegicus,,B,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,CHEMBL616574,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1451,,,B,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,CHEMBL616575,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1452,,,B,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,CHEMBL872108,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1453,,,B,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,CHEMBL616576,,8,1,H,10576,Autocuration,,,BAO_0000357,
1454,,,B,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,CHEMBL616577,,8,1,H,10576,Autocuration,,,BAO_0000249,
1455,,,B,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,CHEMBL616578,,8,1,H,10576,Autocuration,,,BAO_0000249,
1456,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,CHEMBL616579,,8,1,H,10576,Expert,,,BAO_0000357,
1457,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,CHEMBL616580,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1458,,,B,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,CHEMBL616581,,8,1,H,10576,Autocuration,,,BAO_0000019,
1459,,,B,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616582,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1460,,,B,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616583,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1461,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,CHEMBL616584,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1462,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616585,,8,1,H,10576,Expert,,,BAO_0000357,
1463,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,CHEMBL616586,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1464,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,CHEMBL616587,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1465,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,CHEMBL616588,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1466,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,CHEMBL616589,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1467,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616590,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1468,,,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,CHEMBL616591,,8,1,H,10576,Expert,,449.0,BAO_0000219,
1469,,,B,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616592,,8,1,H,10576,Expert,,,BAO_0000357,
1470,,,B,The inhibition activity of 5-HT1A at 1 uM,,CHEMBL616593,,8,1,H,10576,Autocuration,,,BAO_0000357,
1471,,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,CHEMBL616594,,8,1,H,10576,Expert,,485.0,BAO_0000219,
1472,,,B,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,CHEMBL616595,,8,1,H,10576,Expert,,,BAO_0000249,
1473,,,B,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,CHEMBL616596,,8,1,H,10576,Autocuration,,,BAO_0000357,
1474,,,B,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616597,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1475,,,B,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616598,,8,1,H,10576,Expert,,,BAO_0000221,10000000.0
1476,Rattus norvegicus,,F,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,CHEMBL616599,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1477,Rattus norvegicus,,F,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,CHEMBL616600,10116.0,9,1,D,10576,Expert,,,BAO_0000249,10000000.0
1478,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,CHEMBL616601,,8,1,H,10576,Autocuration,,,BAO_0000019,
1479,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,CHEMBL616602,,8,1,H,10576,Autocuration,,,BAO_0000019,
1480,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,CHEMBL616603,,8,1,H,10576,Autocuration,,,BAO_0000019,
1481,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,CHEMBL616604,,8,1,H,10576,Autocuration,,,BAO_0000019,
1482,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,CHEMBL616316,,8,1,H,10576,Autocuration,,,BAO_0000249,
1483,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,CHEMBL616317,,8,1,H,10576,Autocuration,,,BAO_0000249,
1484,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,CHEMBL616318,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1485,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,CHEMBL616319,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1486,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,CHEMBL616320,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1487,Rattus norvegicus,,B,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,CHEMBL616321,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1488,,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,CHEMBL616322,,8,1,H,10576,Autocuration,,,BAO_0000019,
1489,,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,CHEMBL616323,,8,1,H,10576,Autocuration,,,BAO_0000019,
1490,,,B,Ratio of binding affinity to 5-HT 1A and D2 receptor,,CHEMBL616324,,8,1,H,10576,Autocuration,,,BAO_0000357,
1491,,,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,CHEMBL616325,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1492,,,B,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,CHEMBL616326,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1493,,,B,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,CHEMBL616327,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1494,,,B,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,CHEMBL616328,,8,1,H,10576,Autocuration,,,BAO_0000357,
1495,,,B,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,CHEMBL858110,,8,1,H,10576,Autocuration,,,BAO_0000249,
1496,,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,CHEMBL616329,,8,1,H,10576,Autocuration,,,BAO_0000249,
1497,,,B,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,CHEMBL616330,,8,1,H,10576,Autocuration,,,BAO_0000249,
1498,,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,CHEMBL616331,,8,1,H,10576,Autocuration,,,BAO_0000249,
1499,,,F,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,CHEMBL616332,,8,1,H,10576,Autocuration,,,BAO_0000249,
1500,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL857063,,8,1,H,10576,Autocuration,,,BAO_0000249,955.0
1501,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,CHEMBL616333,,8,1,H,10576,Autocuration,,,BAO_0000019,
1502,,,F,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616334,,8,1,H,10576,Expert,,,BAO_0000019,
1503,,,B,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL616335,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1504,,,B,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,CHEMBL616336,,8,1,H,10576,Autocuration,,,BAO_0000019,
1505,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616337,,8,1,H,10576,Expert,,,BAO_0000249,
1506,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,CHEMBL616338,,8,1,H,10576,Autocuration,,,BAO_0000019,
1507,,,B,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,CHEMBL616339,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1508,,,B,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,CHEMBL616340,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1509,,,B,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616341,,8,1,H,10576,Autocuration,,,BAO_0000357,
1510,Rattus norvegicus,,B,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,CHEMBL616342,10116.0,9,1,D,10576,Expert,,,BAO_0000357,
1511,Rattus norvegicus,,B,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,CHEMBL616343,10116.0,9,1,D,10576,Expert,,,BAO_0000019,
1512,,,B,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,CHEMBL616344,,8,1,H,10576,Expert,,,BAO_0000019,
1513,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL616345,,8,1,H,10576,Expert,,,BAO_0000357,
1514,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,CHEMBL616346,,8,1,H,10576,Expert,,,BAO_0000019,
1515,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL616347,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1516,,,B,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,CHEMBL616348,,8,1,H,10576,Expert,,,BAO_0000019,
1517,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616349,,8,1,H,10576,Expert,,,BAO_0000357,
1518,Rattus norvegicus,,B,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,CHEMBL616152,10116.0,9,1,D,10576,Expert,,,BAO_0000249,
1519,,,B,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,CHEMBL616153,,8,1,H,10576,Autocuration,,,BAO_0000249,
1520,,,B,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,CHEMBL616154,,8,1,H,10576,Expert,,,BAO_0000019,
1521,,,B,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL616155,,8,1,H,10576,Autocuration,,,BAO_0000019,
1522,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,CHEMBL616156,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1523,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,CHEMBL616157,10116.0,9,1,D,10576,Expert,,,BAO_0000221,10000000.0
1524,,,B,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,CHEMBL616158,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
1525,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL616159,,8,1,H,10576,Autocuration,,,BAO_0000357,
1526,,,B,pKi value against rat 5-hydroxytryptamine 1A receptor.,,CHEMBL616160,,8,1,H,10576,Expert,,,BAO_0000357,
1527,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,CHEMBL616161,,8,1,H,10576,Autocuration,,,BAO_0000019,
1528,,,F,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,CHEMBL616162,,8,1,H,10576,Autocuration,,,BAO_0000019,
1529,Rattus norvegicus,,B,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,CHEMBL616163,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
1530,,,B,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL616164,,8,1,H,10626,Expert,,,BAO_0000249,
1531,,,B,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,CHEMBL616165,,8,1,H,10576,Autocuration,,,BAO_0000221,955.0
1532,Rattus norvegicus,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,CHEMBL616355,10116.0,8,1,H,51,Autocuration,,,BAO_0000019,
1533,,,F,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,CHEMBL616356,,8,1,H,10576,Autocuration,,,BAO_0000019,
1534,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616357,,8,1,H,10576,Autocuration,,,BAO_0000221,955.0
1535,,,B,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,CHEMBL616358,,8,1,H,10576,Autocuration,,,BAO_0000019,
1536,,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616359,,8,1,H,51,Autocuration,,,BAO_0000357,
1537,,,B,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,CHEMBL616360,,8,1,H,51,Expert,,,BAO_0000357,
1538,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616361,,8,1,H,51,Expert,,,BAO_0000357,
1539,,,B,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616362,,8,1,H,51,Autocuration,,,BAO_0000357,
1540,,,B,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,CHEMBL616363,,8,1,H,51,Autocuration,,,BAO_0000249,
1541,,,B,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,CHEMBL616364,,8,1,H,51,Autocuration,,,BAO_0000357,
1542,,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,CHEMBL616365,,8,1,H,51,Autocuration,,,BAO_0000357,
1543,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616366,,8,1,H,51,Expert,,,BAO_0000357,
1544,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL872906,,8,1,H,51,Expert,,,BAO_0000357,
1545,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,CHEMBL616367,,8,1,H,51,Autocuration,,,BAO_0000357,
1546,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616368,,8,1,H,51,Autocuration,,,BAO_0000357,
1547,,,B,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616369,,8,1,H,51,Autocuration,,,BAO_0000357,
1548,Homo sapiens,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,CHEMBL616370,9606.0,9,1,D,51,Expert,,,BAO_0000357,
1549,Homo sapiens,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,CHEMBL616371,9606.0,9,1,D,51,Expert,,,BAO_0000357,
1550,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616372,,8,1,H,51,Autocuration,,449.0,BAO_0000219,
1551,,,B,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,CHEMBL616373,,8,1,H,51,Expert,,,BAO_0000219,
1552,,,B,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616374,,8,1,H,51,Autocuration,,,BAO_0000218,
1553,,,B,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL616375,,8,1,H,51,Autocuration,,,BAO_0000221,10000000.0
1554,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616376,,8,1,H,51,Autocuration,,,BAO_0000357,
1555,,,B,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,CHEMBL857064,,8,1,H,51,Expert,,,BAO_0000357,
1556,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616377,,8,1,H,51,Autocuration,,,BAO_0000357,
1557,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616378,,8,1,H,51,Autocuration,,,BAO_0000357,
1558,,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,CHEMBL616379,,8,1,H,51,Autocuration,,,BAO_0000357,
1559,,,B,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616380,,8,1,H,11863,Autocuration,,,BAO_0000357,
1560,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,CHEMBL616381,,8,1,H,11863,Autocuration,,,BAO_0000357,
1561,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616382,,8,1,H,11863,Autocuration,,,BAO_0000357,
1562,,,B,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,CHEMBL616383,,8,1,H,11863,Autocuration,,,BAO_0000357,
1563,Mus musculus,,B,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,CHEMBL616350,10090.0,9,1,D,11863,Expert,,449.0,BAO_0000219,
1564,,,B,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL616351,,8,1,H,11863,Autocuration,,,BAO_0000357,
1565,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,CHEMBL616352,,8,1,H,11863,Autocuration,,,BAO_0000357,
1566,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616353,,8,1,H,11863,Autocuration,,,BAO_0000357,
1567,,,B,Binding affinity against serotonergic 5-HT1a receptor,,CHEMBL616354,,8,1,H,11863,Autocuration,,,BAO_0000357,
1568,,,B,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,CHEMBL616508,,8,1,H,11863,Autocuration,,,BAO_0000357,
1569,Mus musculus,,B,Binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616559,10090.0,9,1,D,11863,Expert,,,BAO_0000357,
1570,,,B,Binding affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616560,,8,1,H,11863,Autocuration,,,BAO_0000357,
1571,,,B,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,CHEMBL616561,,8,1,H,11863,Autocuration,,,BAO_0000357,
1572,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616562,,8,1,H,11863,Autocuration,,449.0,BAO_0000219,
1573,,,B,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616563,,8,1,H,11863,Autocuration,,449.0,BAO_0000219,
1574,,,B,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,CHEMBL616564,,8,1,H,11863,Autocuration,,,BAO_0000357,
1575,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,CHEMBL616565,,8,1,H,11863,Autocuration,,,BAO_0000357,
1576,,,B,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,CHEMBL616566,,8,1,H,11863,Autocuration,,,BAO_0000218,
1577,,,B,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,CHEMBL616989,,8,1,H,11863,Autocuration,,,BAO_0000357,
1578,,,B,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,CHEMBL857975,,8,1,H,11863,Autocuration,,,BAO_0000357,
1579,Mus musculus,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616990,10090.0,9,1,D,11863,Expert,,,BAO_0000357,
1580,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,CHEMBL616991,,8,1,H,11863,Autocuration,,,BAO_0000357,
1581,,,B,Tested against 5-hydroxytryptamine 1A receptor,,CHEMBL616992,,8,1,H,11863,Autocuration,,,BAO_0000357,
1582,,,B,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616993,,8,1,H,11863,Autocuration,,,BAO_0000357,
1583,Oryctolagus cuniculus,,B,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,CHEMBL616994,9986.0,8,1,H,106,Expert,,,BAO_0000019,
1584,Oryctolagus cuniculus,,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,CHEMBL616995,9986.0,8,1,H,106,Autocuration,,,BAO_0000019,
1585,Gorilla gorilla,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,CHEMBL616996,9593.0,9,1,D,105571,Intermediate,,722.0,BAO_0000219,
1586,Cavia porcellus,,F,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,CHEMBL616997,10141.0,8,1,H,106,Autocuration,,,BAO_0000218,
1587,Cavia porcellus,,F,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,CHEMBL616998,10141.0,8,1,H,106,Autocuration,,,BAO_0000218,
1588,Cavia porcellus,,F,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,CHEMBL616999,10141.0,8,1,H,106,Autocuration,,,BAO_0000019,
1589,Cavia porcellus,,F,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,CHEMBL617000,10141.0,8,1,H,106,Autocuration,,,BAO_0000019,
1590,Cavia porcellus,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,CHEMBL617001,10141.0,8,1,H,106,Autocuration,,,BAO_0000019,
1591,Cavia porcellus,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,CHEMBL858111,10141.0,8,1,H,106,Autocuration,,,BAO_0000019,
1592,,,F,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,CHEMBL617002,,8,1,H,106,Autocuration,,,BAO_0000019,
1593,,,F,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,CHEMBL617003,,8,1,H,106,Autocuration,,,BAO_0000019,
1594,,,F,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,CHEMBL617004,,8,1,H,106,Autocuration,,,BAO_0000019,
1595,Homo sapiens,,F,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,CHEMBL617005,9606.0,9,1,D,106,Expert,,,BAO_0000019,
1596,Homo sapiens,,F,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,CHEMBL616623,9606.0,9,1,D,106,Expert,,485.0,BAO_0000219,
1597,,,F,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,CHEMBL616624,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1598,,,B,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,CHEMBL883243,,8,1,H,106,Autocuration,,,BAO_0000357,
1599,,,F,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,CHEMBL616625,,8,1,H,106,Autocuration,,,BAO_0000019,
1600,,,F,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,CHEMBL616626,,8,1,H,106,Expert,,449.0,BAO_0000219,
1601,,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,CHEMBL616627,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1602,,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,CHEMBL616628,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1603,,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,CHEMBL616629,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1604,,,F,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,CHEMBL616630,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
1605,,,F,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL616631,,8,1,H,106,Expert,,,BAO_0000019,
1606,,,F,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL616632,,8,1,H,106,Autocuration,,,BAO_0000019,
1607,Homo sapiens,,B,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,CHEMBL616633,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1608,,,B,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,CHEMBL616634,,8,1,H,106,Expert,,449.0,BAO_0000219,
1609,,,B,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,CHEMBL616635,,8,1,H,106,Autocuration,,,BAO_0000357,
1610,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL885358,9606.0,9,1,D,106,Expert,,,BAO_0000357,
1611,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHEMBL616636,9606.0,9,1,D,106,Expert,,449.0,BAO_0000219,
1612,,,B,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,CHEMBL616637,,8,1,H,106,Expert,,449.0,BAO_0000219,
1613,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,CHEMBL616638,,8,1,H,106,Autocuration,,,BAO_0000357,
1614,,,B,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHEMBL616639,,8,1,H,106,Expert,,449.0,BAO_0000219,
1615,,,B,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHEMBL616640,,8,1,H,106,Expert,,449.0,BAO_0000219,
1616,,,B,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHEMBL616641,,8,1,H,106,Expert,,449.0,BAO_0000219,
1617,,,B,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,CHEMBL616642,,8,1,H,106,Expert,,449.0,BAO_0000219,
1618,,,B,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHEMBL616643,,8,1,H,106,Expert,,449.0,BAO_0000219,
1619,,,B,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,CHEMBL616644,,8,1,H,106,Autocuration,,,BAO_0000357,
1620,,,B,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,CHEMBL616645,,8,1,H,106,Autocuration,,,BAO_0000357,
1621,Oryctolagus cuniculus,,F,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616646,9986.0,8,1,H,105,Autocuration,,,BAO_0000019,
1622,Oryctolagus cuniculus,,F,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616647,9986.0,8,1,H,105,Expert,,,BAO_0000019,
1623,,,B,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,CHEMBL616509,,8,1,H,105,Autocuration,,,BAO_0000357,
1624,,,B,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,CHEMBL616510,,8,1,H,105,Autocuration,,,BAO_0000357,
1625,,,B,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,CHEMBL616511,,8,1,H,105,Autocuration,,,BAO_0000357,
1626,Bos taurus,,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,CHEMBL616512,9913.0,8,1,H,105,Expert,,,BAO_0000357,
1627,Bos taurus,,B,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,CHEMBL616513,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1628,Bos taurus,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,CHEMBL616514,9913.0,8,1,H,105,Autocuration,,,BAO_0000019,2435.0
1629,Bos taurus,,B,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,CHEMBL616515,9913.0,8,1,H,105,Expert,,,BAO_0000357,
1630,Bos taurus,,B,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,CHEMBL616516,9913.0,8,1,H,105,Autocuration,,,BAO_0000019,
1631,Bos taurus,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,CHEMBL616517,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1632,Bos taurus,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,CHEMBL616518,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1633,Bos taurus,,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,CHEMBL616519,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1634,Bos taurus,,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,CHEMBL616520,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1635,Bos taurus,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,CHEMBL616521,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1636,Bos taurus,,B,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,CHEMBL616522,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1637,Bos taurus,,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,CHEMBL884531,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1638,Bos taurus,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,CHEMBL616523,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1639,Bos taurus,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,CHEMBL616731,9913.0,8,1,H,105,Autocuration,,,BAO_0000019,2435.0
1640,Bos taurus,,B,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,CHEMBL616732,9913.0,8,1,H,105,Autocuration,,,BAO_0000019,
1641,Bos taurus,,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,CHEMBL616733,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1642,Bos taurus,,B,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,CHEMBL616734,9913.0,8,1,H,105,Autocuration,,,BAO_0000357,
1643,Bos taurus,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,CHEMBL616735,9913.0,8,1,H,105,Autocuration,,,BAO_0000249,
1644,Bos taurus,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,CHEMBL616736,9913.0,8,1,H,105,Autocuration,,,BAO_0000249,
1645,Bos taurus,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616737,9913.0,8,1,H,105,Expert,,,BAO_0000019,
1646,Bos taurus,,B,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,CHEMBL616738,9913.0,8,1,H,105,Autocuration,,,BAO_0000019,
1647,Bos taurus,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616739,9913.0,8,1,H,105,Expert,,,BAO_0000019,
1648,Bos taurus,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616740,9913.0,8,1,H,105,Expert,,,BAO_0000019,
1649,Bos taurus,,F,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616741,9913.0,8,1,H,105,Expert,,,BAO_0000019,
1650,Gorilla gorilla,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,CHEMBL616742,9593.0,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1651,Cavia porcellus,,B,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,CHEMBL616743,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1652,Cavia porcellus,,B,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,CHEMBL616744,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1653,Cavia porcellus,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,CHEMBL616745,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1654,Cavia porcellus,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616746,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1655,Cavia porcellus,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,CHEMBL616747,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1656,Cavia porcellus,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,CHEMBL616748,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1657,Cavia porcellus,,F,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,CHEMBL616648,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1658,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616649,10141.0,9,1,D,105570,Intermediate,,,BAO_0000357,
1659,Cavia porcellus,,B,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,CHEMBL616650,10141.0,9,1,D,105570,Intermediate,,,BAO_0000357,
1660,Cavia porcellus,,F,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616651,10141.0,9,1,D,105570,Intermediate,,,BAO_0000218,
1661,Cavia porcellus,,F,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616652,10141.0,9,1,D,105570,Intermediate,,,BAO_0000218,
1662,Cavia porcellus,,F,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616653,10141.0,9,1,D,105570,Intermediate,,,BAO_0000218,
1663,Cavia porcellus,,F,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,CHEMBL616654,10141.0,9,1,D,105570,Intermediate,,,BAO_0000218,
1664,Cavia porcellus,,B,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,CHEMBL616655,10141.0,9,1,D,105570,Intermediate,,,BAO_0000019,
1665,Cavia porcellus,,B,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,CHEMBL616656,10141.0,9,1,D,105570,Intermediate,,,BAO_0000357,
1666,Cavia porcellus,,B,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,CHEMBL616657,10141.0,8,1,H,105,Autocuration,,,BAO_0000019,
1667,Cavia porcellus,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,CHEMBL616658,10141.0,9,1,D,105570,Intermediate,,,BAO_0000357,2435.0
1668,Cavia porcellus,,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,CHEMBL616659,10141.0,9,1,D,105570,Intermediate,,,BAO_0000357,
1669,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616660,,8,1,H,51,Autocuration,,,BAO_0000357,
1670,,,B,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,CHEMBL616661,,8,1,H,106,Autocuration,,,BAO_0000357,
1671,,,F,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,CHEMBL616662,,8,1,H,105,Expert,,,BAO_0000019,
1672,,,F,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616663,,8,1,H,105,Autocuration,,,BAO_0000019,
1673,,,F,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616664,,8,1,H,105,Autocuration,,,BAO_0000019,
1674,Homo sapiens,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,CHEMBL881820,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1675,,,F,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,CHEMBL616665,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1676,,,B,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHEMBL616666,,8,1,H,105,Expert,,449.0,BAO_0000219,
1677,,,B,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,CHEMBL616667,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1678,,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHEMBL616668,,8,1,H,105,Expert,,449.0,BAO_0000219,
1679,Homo sapiens,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHEMBL616669,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1680,,,F,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,CHEMBL617040,,8,1,H,105,Expert,,449.0,BAO_0000219,
1681,,,F,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,CHEMBL617041,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1682,,,F,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,CHEMBL617042,,8,1,H,105,Expert,,449.0,BAO_0000219,
1683,,,F,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,CHEMBL617043,,8,1,H,105,Expert,,449.0,BAO_0000219,
1684,,,F,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,CHEMBL617044,,8,1,H,105,Autocuration,,,BAO_0000019,
1685,,,F,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHEMBL617045,,8,1,H,105,Expert,,449.0,BAO_0000219,
1686,Homo sapiens,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHEMBL617046,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1687,Homo sapiens,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHEMBL617047,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1688,,,F,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL617048,,8,1,H,105,Expert,,,BAO_0000019,
1689,,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,CHEMBL616897,,8,1,H,105,Autocuration,,,BAO_0000019,
1690,Homo sapiens,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,CHEMBL616898,9606.0,9,1,D,105,Expert,,,BAO_0000019,
1691,Homo sapiens,,F,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,CHEMBL858201,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1692,,,F,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,CHEMBL616899,,8,1,H,105,Autocuration,,,BAO_0000019,
1693,,,B,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,CHEMBL616900,,8,1,H,105,Autocuration,,,BAO_0000219,
1694,,,B,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,CHEMBL616901,,8,1,H,105,Expert,,449.0,BAO_0000219,
1695,,,B,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,CHEMBL616902,,8,1,H,105,Autocuration,,,BAO_0000357,
1696,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616903,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1697,,,B,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,CHEMBL616904,,8,1,H,105,Expert,,449.0,BAO_0000219,
1698,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,CHEMBL616905,,8,1,H,105,Autocuration,,,BAO_0000357,
1699,,,B,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHEMBL616906,,8,1,H,105,Expert,,449.0,BAO_0000219,
1700,,,B,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616907,,8,1,H,105,Expert,,449.0,BAO_0000219,
1701,,,B,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616908,,8,1,H,105,Expert,,449.0,BAO_0000219,
1702,Homo sapiens,,B,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616909,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1703,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616910,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1704,,,B,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616911,,8,1,H,105,Expert,,449.0,BAO_0000219,
1705,,,B,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616912,,8,1,H,105,Expert,,449.0,BAO_0000219,
1706,,,B,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,CHEMBL616913,,8,1,H,105,Autocuration,,,BAO_0000357,
1707,Homo sapiens,,B,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,CHEMBL616914,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1708,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616915,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1709,,,B,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,CHEMBL616916,,8,1,H,105,Autocuration,,,BAO_0000019,
1710,Homo sapiens,,B,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616917,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1711,,,B,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,CHEMBL616918,,8,1,H,105,Autocuration,,,BAO_0000357,
1712,,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,CHEMBL616919,,8,1,H,105,Expert,,,BAO_0000219,
1713,,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,CHEMBL616920,,8,1,H,105,Autocuration,,,BAO_0000357,
1714,,,B,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,CHEMBL872914,,8,1,H,105,Autocuration,,,BAO_0000357,
1715,,,B,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,CHEMBL616921,,8,1,H,105,Autocuration,,,BAO_0000357,
1716,,,B,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616922,,8,1,H,105,Expert,,,BAO_0000357,
1717,,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor,,CHEMBL616923,,8,1,H,105,Autocuration,,,BAO_0000357,
1718,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616924,,8,1,H,105,Expert,,,BAO_0000357,
1719,,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,CHEMBL875909,,8,1,H,105,Expert,,,BAO_0000357,
1720,,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,CHEMBL616925,,8,1,H,105,Autocuration,,,BAO_0000357,
1721,,,B,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,CHEMBL616926,,8,1,H,105,Autocuration,,,BAO_0000357,
1722,,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,CHEMBL616927,,8,1,H,105,Autocuration,,,BAO_0000357,
1723,,,F,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,CHEMBL616928,,8,1,H,105,Expert,,485.0,BAO_0000219,
1724,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,CHEMBL616929,9606.0,9,1,D,105,Expert,,,BAO_0000219,
1725,Homo sapiens,,B,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,CHEMBL616930,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1726,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616931,,8,1,H,105,Expert,,,BAO_0000019,
1727,,,B,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,CHEMBL616932,,8,1,H,105,Autocuration,,,BAO_0000357,
1728,,,B,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616933,,8,1,H,105,Expert,,,BAO_0000357,
1729,Homo sapiens,,B,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,CHEMBL616934,9606.0,9,1,D,105,Expert,,,BAO_0000219,
1730,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616935,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1731,,,B,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,CHEMBL616936,,8,1,H,105,Autocuration,,,BAO_0000357,
1732,Homo sapiens,,B,Affinity for 5-hydroxytryptamine 1D receptor subtype,,CHEMBL616937,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1733,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616938,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1734,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616939,,8,1,H,105,Autocuration,,,BAO_0000019,
1735,,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,CHEMBL616940,,8,1,H,105,Expert,,,BAO_0000019,
1736,Homo sapiens,,B,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,CHEMBL616941,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1737,,,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,CHEMBL616942,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
1738,,,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,CHEMBL616943,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
1739,,,B,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,CHEMBL616944,,4,1,H,104802,Autocuration,,449.0,BAO_0000219,
1740,,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,CHEMBL616945,,8,1,H,105,Autocuration,,,BAO_0000019,
1741,,,B,Binding activity radioligand.,,CHEMBL616946,,8,1,H,105,Autocuration,,,BAO_0000357,
1742,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL616947,,8,1,H,105,Autocuration,,,BAO_0000019,
1743,,,B,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,CHEMBL616948,,8,1,H,105,Expert,,485.0,BAO_0000219,
1744,,,B,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,CHEMBL616851,,8,1,H,105,Autocuration,,,BAO_0000357,
1745,,,B,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,CHEMBL616852,,8,1,H,105,Autocuration,,,BAO_0000357,
1746,,,B,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,CHEMBL616853,,8,1,H,105,Autocuration,,,BAO_0000357,
1747,Homo sapiens,,B,Binding activity against human 5-hydroxytryptamine 1D receptor,,CHEMBL616854,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1748,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616855,9606.0,9,1,D,105,Expert,,449.0,BAO_0000219,
1749,,,B,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,CHEMBL616856,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1750,,,B,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616857,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1751,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616858,,8,1,H,105,Autocuration,,,BAO_0000357,
1752,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616859,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1753,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,CHEMBL616860,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1754,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,CHEMBL616861,,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1755,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,CHEMBL616541,,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1756,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,CHEMBL616542,,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1757,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616543,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1758,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616544,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1759,,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,CHEMBL616545,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1760,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616546,,8,1,H,105,Autocuration,,,BAO_0000357,
1761,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,CHEMBL616547,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1762,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616548,,8,1,H,105,Autocuration,,449.0,BAO_0000219,
1763,,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,CHEMBL616549,,8,1,H,105,Expert,,,BAO_0000019,
1764,,,F,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,CHEMBL616550,,8,1,H,105,Expert,,,BAO_0000019,
1765,,,B,Binding affinity against 5-HT2C receptor,,CHEMBL857066,,8,1,H,108,Autocuration,,,BAO_0000357,
1766,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616551,,8,1,H,108,Autocuration,,,BAO_0000357,
1767,,,B,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,CHEMBL616552,,8,1,H,10577,Autocuration,,,BAO_0000357,
1768,,,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,CHEMBL832876,,8,1,H,10577,Autocuration,,,BAO_0000019,
1769,,,B,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,CHEMBL616553,,8,1,H,10577,Expert,,,BAO_0000019,
1770,,,B,Binding affinity towards 5-HT1B was determined,,CHEMBL616554,,8,1,H,10577,Autocuration,,,BAO_0000357,
1771,,,B,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,CHEMBL616555,,8,1,H,10577,Expert,,,BAO_0000019,
1772,,,B,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,CHEMBL616556,,8,1,H,10577,Expert,,,BAO_0000019,
1773,,,B,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,CHEMBL616557,,8,1,H,10577,Autocuration,,,BAO_0000019,
1774,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL616558,,8,1,H,10577,Expert,,,BAO_0000019,
1775,Rattus norvegicus,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,CHEMBL616749,10116.0,9,1,D,10577,Expert,,,BAO_0000019,
1776,,,B,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,CHEMBL616750,,8,1,H,10577,Autocuration,,,BAO_0000357,
1777,,,B,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,CHEMBL616751,,8,1,H,10577,Autocuration,,,BAO_0000357,
1778,,,B,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,CHEMBL616752,,8,1,H,10577,Autocuration,,,BAO_0000249,
1779,,,B,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,CHEMBL616753,,8,1,H,10577,Autocuration,,,BAO_0000019,2435.0
1780,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,CHEMBL616754,10116.0,9,1,D,10577,Expert,,,BAO_0000357,
1781,,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,CHEMBL616755,,8,1,H,10577,Autocuration,,,BAO_0000019,
1782,,,B,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,CHEMBL616756,,8,1,H,10577,Autocuration,,,BAO_0000019,2435.0
1783,,,B,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,CHEMBL616757,,8,1,H,10577,Autocuration,,,BAO_0000019,2435.0
1784,,,B,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,CHEMBL616758,,8,1,H,10577,Autocuration,,,BAO_0000357,2435.0
1785,,,B,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,CHEMBL616759,,8,1,H,10577,Autocuration,,,BAO_0000249,
1786,,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,CHEMBL616760,,8,1,H,10577,Autocuration,,,BAO_0000357,
1787,,,B,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,CHEMBL616761,,8,1,H,10577,Autocuration,,,BAO_0000019,2435.0
1788,,,B,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,CHEMBL616762,,8,1,H,10577,Autocuration,,,BAO_0000019,2435.0
1789,,,B,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,CHEMBL616763,,8,1,H,10577,Autocuration,,,BAO_0000019,
1790,,,B,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,CHEMBL872909,,8,1,H,10577,Expert,,,BAO_0000357,
1791,,,B,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,CHEMBL616764,,8,1,H,10577,Autocuration,,,BAO_0000357,
1792,Rattus norvegicus,,B,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,CHEMBL616765,10116.0,9,1,D,10577,Expert,,,BAO_0000357,
1793,,,B,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,CHEMBL616766,,8,1,H,10577,Autocuration,,,BAO_0000357,2435.0
1794,,,B,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,CHEMBL616767,,8,1,H,10577,Autocuration,,,BAO_0000357,2435.0
1795,,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,CHEMBL616768,,8,1,H,10577,Autocuration,,,BAO_0000357,
1796,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,CHEMBL616769,,8,1,H,10577,Autocuration,,,BAO_0000357,
1797,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,CHEMBL616770,,8,1,H,10577,Autocuration,,,BAO_0000019,
1798,,,B,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616771,,8,1,H,10577,Autocuration,,,BAO_0000019,
1799,,,B,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,CHEMBL616772,,8,1,H,10577,Autocuration,,,BAO_0000019,2435.0
1800,,,B,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,CHEMBL616773,,8,1,H,10577,Expert,,,BAO_0000019,
1801,,,B,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,CHEMBL616774,,8,1,H,10577,Autocuration,,,BAO_0000019,
1802,,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616775,,8,1,H,10577,Autocuration,,,BAO_0000357,
1803,,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,CHEMBL616776,,8,1,H,10577,Autocuration,,,BAO_0000249,
1804,,,B,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,CHEMBL616777,,8,1,H,10577,Autocuration,,,BAO_0000357,
1805,,,B,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,CHEMBL616778,,8,1,H,10577,Autocuration,,,BAO_0000357,
1806,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,CHEMBL616779,10116.0,9,1,D,10577,Expert,,,BAO_0000249,
1807,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616780,10116.0,9,1,D,10577,Expert,,,BAO_0000357,
1808,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,CHEMBL616781,,8,1,H,10577,Autocuration,,,BAO_0000019,
1809,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,CHEMBL616782,,8,1,H,10577,Autocuration,,,BAO_0000357,
1810,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,CHEMBL616783,,8,1,H,10577,Autocuration,,,BAO_0000357,
1811,,,B,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,CHEMBL616784,,8,1,H,10577,Expert,,,BAO_0000019,2435.0
1812,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,CHEMBL616785,,8,1,H,10577,Autocuration,,,BAO_0000357,
1813,,,B,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL857067,,8,1,H,10577,Autocuration,,,BAO_0000249,955.0
1814,,,B,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,CHEMBL616786,,8,1,H,10577,Autocuration,,,BAO_0000019,
1815,,,B,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL616787,,8,1,H,10577,Autocuration,,,BAO_0000249,955.0
1816,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,CHEMBL616788,,8,1,H,10577,Autocuration,,,BAO_0000357,
1817,,,B,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,CHEMBL616789,,8,1,H,10577,Autocuration,,,BAO_0000357,
1818,Rattus norvegicus,,B,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,CHEMBL616790,10116.0,9,1,D,10577,Expert,,,BAO_0000019,
1819,,,B,Binding affinity at 5-hydroxytryptamine 1B receptor,,CHEMBL616791,,8,1,H,10577,Expert,,,BAO_0000357,
1820,,,B,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,CHEMBL616792,,8,1,H,10577,Autocuration,,,BAO_0000019,
1821,Rattus norvegicus,,B,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,CHEMBL616793,10116.0,9,1,D,10577,Expert,,,BAO_0000249,
1822,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,CHEMBL616794,,8,1,H,10577,Autocuration,,,BAO_0000357,
1823,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616795,,8,1,H,10577,Autocuration,,,BAO_0000357,
1824,,,B,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,CHEMBL616796,,4,1,H,104686,Autocuration,,,BAO_0000019,
1825,,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL616797,,8,1,H,106,Autocuration,,,BAO_0000357,
1826,,,B,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,CHEMBL616798,,8,1,H,106,Autocuration,,,BAO_0000249,
1827,,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,CHEMBL616799,,8,1,H,106,Autocuration,,,BAO_0000357,
1828,,,B,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,CHEMBL616800,,8,1,H,106,Autocuration,,,BAO_0000357,
1829,,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,CHEMBL616801,,8,1,H,106,Autocuration,,,BAO_0000357,
1830,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,CHEMBL616802,,8,1,H,106,Autocuration,,,BAO_0000357,
1831,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616803,,8,1,H,106,Autocuration,,,BAO_0000357,
1832,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,CHEMBL857068,,8,1,H,106,Expert,,,BAO_0000357,
1833,,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,CHEMBL616804,,8,1,H,106,Autocuration,,,BAO_0000357,
1834,,,B,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616805,,8,1,H,106,Autocuration,,,BAO_0000357,
1835,,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,CHEMBL616806,,8,1,H,106,Autocuration,,,BAO_0000357,
1836,,,B,Binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL616807,,8,1,H,106,Autocuration,,,BAO_0000357,
1837,,,B,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,CHEMBL616808,,8,1,H,106,Autocuration,,,BAO_0000357,
1838,,,B,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616809,,8,1,H,106,Autocuration,,,BAO_0000357,
1839,,,B,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,CHEMBL616810,,8,1,H,106,Autocuration,,,BAO_0000357,
1840,,,B,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,CHEMBL616811,,4,1,H,104802,Autocuration,,,BAO_0000224,
1841,Bos taurus,,B,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,CHEMBL616812,9913.0,8,1,H,108,Autocuration,,,BAO_0000357,
1842,Sus scrofa,,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,CHEMBL616813,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1843,Sus scrofa,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,CHEMBL616814,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1844,Sus scrofa,,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,CHEMBL616815,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1845,Sus scrofa,,B,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,CHEMBL616816,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1846,Sus scrofa,,B,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,CHEMBL616817,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1847,Sus scrofa,,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,CHEMBL616818,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1848,Sus scrofa,,B,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,CHEMBL616819,9823.0,8,1,H,108,Expert,,,BAO_0000357,
1849,Sus scrofa,,B,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,CHEMBL616820,9823.0,8,1,H,108,Expert,,,BAO_0000357,
1850,Sus scrofa,,B,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,CHEMBL616821,9823.0,8,1,H,108,Expert,,,BAO_0000019,
1851,Sus scrofa,,B,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,CHEMBL616822,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
1852,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,CHEMBL616823,9986.0,8,1,H,108,Autocuration,,,BAO_0000019,
1853,Rattus norvegicus,,B,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,CHEMBL616824,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1854,Rattus norvegicus,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,CHEMBL616825,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1855,Rattus norvegicus,,B,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,CHEMBL616826,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1856,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,CHEMBL616827,10116.0,9,1,D,12689,Expert,,,BAO_0000019,
1857,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,CHEMBL616828,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1858,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,CHEMBL616829,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1859,Rattus norvegicus,,B,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616830,10116.0,9,1,D,12689,Autocuration,,,BAO_0000019,
1860,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616831,10116.0,9,1,D,12689,Expert,,,BAO_0000357,
1861,Rattus norvegicus,,B,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616832,10116.0,9,1,D,12689,Autocuration,,,BAO_0000019,
1862,Rattus norvegicus,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616833,10116.0,9,1,D,12689,Autocuration,,,BAO_0000019,
1863,Rattus norvegicus,,B,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616834,10116.0,9,1,D,12689,Expert,,,BAO_0000019,
1864,Rattus norvegicus,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL829595,10116.0,9,1,D,12689,Autocuration,,,BAO_0000019,
1865,Rattus norvegicus,,B,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,CHEMBL616835,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1866,Rattus norvegicus,,B,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,CHEMBL872910,10116.0,9,1,D,12689,Autocuration,,,BAO_0000249,
1867,,,B,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,CHEMBL616836,,8,1,H,12689,Expert,,,BAO_0000357,
1868,Rattus norvegicus,,B,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,CHEMBL616837,10116.0,9,1,D,12689,Autocuration,,,BAO_0000357,
1869,Rattus norvegicus,,B,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,CHEMBL616466,10116.0,9,1,D,12689,Autocuration,,,BAO_0000019,
1870,Rattus norvegicus,,B,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,CHEMBL616467,10116.0,9,1,D,12689,Autocuration,,722.0,BAO_0000219,
1871,,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,CHEMBL616468,,8,1,H,108,Autocuration,,,BAO_0000357,
1872,,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,CHEMBL616469,,8,1,H,108,Autocuration,,,BAO_0000357,
1873,,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,CHEMBL616470,,8,1,H,108,Autocuration,,,BAO_0000357,
1874,,,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616471,,8,1,H,12689,Autocuration,,,BAO_0000357,
1875,,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,CHEMBL616472,,8,1,H,12689,Autocuration,,,BAO_0000357,
1876,,,B,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616473,,8,1,H,12689,Autocuration,,,BAO_0000357,
1877,,,B,Binding affinity against serotonergic 5-HT1c receptor,,CHEMBL616474,,8,1,H,12689,Autocuration,,,BAO_0000357,
1878,,,B,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,CHEMBL616475,,8,1,H,12689,Autocuration,,,BAO_0000357,
1879,,,B,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,CHEMBL616476,,8,1,H,12689,Autocuration,,,BAO_0000357,
1880,Oryctolagus cuniculus,,B,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616477,9986.0,8,1,H,105,Autocuration,,,BAO_0000019,
1881,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,CHEMBL616478,,4,1,H,104686,Autocuration,,,BAO_0000224,
1882,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,CHEMBL616479,,4,1,H,104686,Autocuration,,,BAO_0000224,
1883,,,B,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,CHEMBL616480,,4,1,H,104686,Autocuration,,,BAO_0000019,
1884,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,CHEMBL616481,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
1885,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,CHEMBL616482,10116.0,5,1,D,104686,Autocuration,,,BAO_0000249,
1886,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,CHEMBL884713,10116.0,5,1,D,104686,Autocuration,,,BAO_0000221,955.0
1887,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,CHEMBL616483,,4,1,H,104686,Autocuration,,,BAO_0000224,
1888,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,CHEMBL616484,,4,1,H,104686,Autocuration,,,BAO_0000224,
1889,,,B,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,CHEMBL616485,,4,1,H,104686,Autocuration,,,BAO_0000019,
1890,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL616486,,4,1,H,104686,Autocuration,,,BAO_0000224,
1891,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,CHEMBL616487,,4,1,H,104686,Autocuration,,,BAO_0000224,
1892,,,B,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,CHEMBL616488,,4,1,H,104686,Autocuration,,,BAO_0000224,
1893,,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616489,,4,1,H,104686,Autocuration,,,BAO_0000019,
1894,,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616490,,4,1,H,104686,Autocuration,,,BAO_0000019,
1895,,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,CHEMBL616491,,4,1,H,104686,Autocuration,,,BAO_0000019,
1896,,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,CHEMBL616492,,4,1,H,104686,Autocuration,,,BAO_0000019,
1897,,,B,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616493,,4,1,H,104686,Autocuration,,,BAO_0000019,
1898,,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,CHEMBL616494,,4,1,H,104686,Autocuration,,,BAO_0000019,
1899,,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,CHEMBL616495,,4,1,H,104686,Autocuration,,,BAO_0000019,
1900,,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,CHEMBL616496,,4,1,H,104686,Autocuration,,,BAO_0000019,
1901,,,B,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616497,,4,1,H,104686,Autocuration,,,BAO_0000019,
1902,,,B,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616498,,4,1,H,104686,Autocuration,,,BAO_0000019,
1903,,,B,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,CHEMBL616499,,4,1,H,104686,Autocuration,,,BAO_0000019,
1904,,,B,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,CHEMBL616500,,4,1,H,104686,Autocuration,,,BAO_0000019,
1905,Rattus norvegicus,,B,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,CHEMBL616501,10116.0,5,1,D,104686,Autocuration,,,BAO_0000221,955.0
1906,,,B,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,CHEMBL616502,,4,1,H,104686,Autocuration,,,BAO_0000221,955.0
1907,,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,CHEMBL884529,,4,1,H,104686,Autocuration,,,BAO_0000249,
1908,,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,CHEMBL616503,,4,1,H,104686,Autocuration,,,BAO_0000249,
1909,,,B,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,CHEMBL616964,,4,1,H,104686,Autocuration,,,BAO_0000224,
1910,,,B,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,CHEMBL616965,,4,1,H,104686,Autocuration,,,BAO_0000249,
1911,,,B,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,CHEMBL616966,,4,1,H,104686,Autocuration,,,BAO_0000224,
1912,,,B,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL616967,,4,1,H,104686,Autocuration,,,BAO_0000224,
1913,Rattus norvegicus,,B,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,CHEMBL616968,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
1914,,,B,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL616969,,4,1,H,104686,Autocuration,,,BAO_0000224,
1915,,,B,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,CHEMBL884530,,4,1,H,104686,Autocuration,,,BAO_0000019,
1916,,,B,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,CHEMBL616970,,4,1,H,104686,Autocuration,,,BAO_0000224,
1917,,,B,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,CHEMBL616971,,4,1,H,104686,Autocuration,,,BAO_0000224,
1918,,,B,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,CHEMBL616972,,4,1,H,104686,Autocuration,,,BAO_0000224,
1919,,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,CHEMBL616973,,4,1,H,104686,Autocuration,,,BAO_0000224,
1920,,,B,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,CHEMBL616974,,4,1,H,104686,Autocuration,,,BAO_0000224,
1921,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,CHEMBL616975,,4,1,H,104686,Autocuration,,,BAO_0000019,
1922,,,B,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,CHEMBL616976,,4,1,H,104686,Autocuration,,,BAO_0000019,
1923,,,B,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,CHEMBL616977,,4,1,H,104686,Autocuration,,,BAO_0000224,
1924,,,B,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,CHEMBL616978,,4,1,H,104686,Autocuration,,,BAO_0000224,
1925,,,B,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,CHEMBL616979,,4,1,H,104686,Autocuration,,,BAO_0000224,
1926,,,B,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,CHEMBL616980,,4,1,H,104686,Autocuration,,,BAO_0000224,
1927,,,B,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,CHEMBL616981,,4,1,H,104686,Autocuration,,,BAO_0000249,
1928,,,B,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,CHEMBL616982,,4,1,H,104686,Autocuration,,,BAO_0000249,
1929,,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,CHEMBL616983,,4,1,H,104686,Autocuration,,,BAO_0000224,
1930,,,B,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,CHEMBL616984,,4,1,H,104686,Autocuration,,,BAO_0000019,
1931,Rattus norvegicus,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,CHEMBL616985,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
1932,,,B,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,CHEMBL616986,,4,1,H,104686,Autocuration,,,BAO_0000224,
1933,,,B,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,CHEMBL616987,,4,1,H,104686,Autocuration,,,BAO_0000224,
1934,,,B,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,CHEMBL616988,,4,1,H,104686,Autocuration,,,BAO_0000019,
1935,,,B,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617243,,4,1,H,104686,Autocuration,,,BAO_0000019,
1936,,,B,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,CHEMBL617244,,4,1,H,104686,Autocuration,,,BAO_0000019,
1937,Rattus norvegicus,,B,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617245,10116.0,5,1,D,104686,Autocuration,,485.0,BAO_0000219,
1938,,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,CHEMBL617246,,4,1,H,104686,Autocuration,,,BAO_0000249,
1939,,,B,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,CHEMBL617546,,4,1,H,104686,Autocuration,,,BAO_0000224,
1940,,,B,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,CHEMBL617547,,4,1,H,104686,Autocuration,,,BAO_0000249,
1941,,,B,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL617548,,4,1,H,104686,Autocuration,,,BAO_0000219,
1942,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617549,,4,1,H,104686,Autocuration,,,BAO_0000224,
1943,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,CHEMBL617550,,4,1,H,104686,Autocuration,,,BAO_0000224,
1944,,,B,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,CHEMBL617551,,4,1,H,104686,Autocuration,,,BAO_0000224,
1945,,,B,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,CHEMBL617552,,4,1,H,104686,Autocuration,,,BAO_0000249,
1946,,,B,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,CHEMBL617553,,4,1,H,104686,Autocuration,,,BAO_0000249,
1947,,,F,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,CHEMBL617554,,4,1,H,104686,Autocuration,,,BAO_0000019,1515.0
1948,,,B,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,CHEMBL617555,,4,1,H,104686,Autocuration,,,BAO_0000019,
1949,,,B,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,CHEMBL617556,,4,1,H,104686,Autocuration,,,BAO_0000224,
1950,,,B,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,CHEMBL617557,,8,1,H,10624,Autocuration,,,BAO_0000357,
1951,,,B,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,CHEMBL617558,,8,1,H,10624,Autocuration,,,BAO_0000357,
1952,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,CHEMBL617559,,8,1,H,17106,Expert,,,BAO_0000357,
1953,,,B,Binding affinity for 5-hydroxytryptamine 1D receptor,,CHEMBL617560,,9,1,D,17106,Expert,,,BAO_0000357,
1954,,,B,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617561,,8,1,H,17106,Autocuration,,,BAO_0000249,
1955,,,B,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617562,,8,1,H,17106,Autocuration,,,BAO_0000249,
1956,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,CHEMBL617563,,8,1,H,17106,Autocuration,,,BAO_0000357,2435.0
1957,,,F,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,CHEMBL617564,,8,1,H,17106,Autocuration,,,BAO_0000019,
1958,,,B,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,CHEMBL617565,,8,1,H,17106,Expert,,,BAO_0000019,
1959,,,B,Binding activity radioligand.,,CHEMBL856076,,8,1,H,17106,Autocuration,,,BAO_0000357,
1960,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617566,,8,1,H,17106,Autocuration,,,BAO_0000019,
1961,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL875911,,8,1,H,17106,Expert,,,BAO_0000019,
1962,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,CHEMBL617567,,8,1,H,17106,Autocuration,,,BAO_0000019,
1963,,,B,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617568,,8,1,H,17106,Autocuration,,,BAO_0000249,
1964,,,B,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,CHEMBL617569,,8,1,H,17106,Expert,,,BAO_0000019,
1965,,,B,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,CHEMBL617570,,8,1,H,17106,Expert,,,BAO_0000249,
1966,,,B,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,CHEMBL617571,,8,1,H,17106,Autocuration,,,BAO_0000357,
1967,Sus scrofa,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,CHEMBL617572,9823.0,8,1,H,105,Autocuration,,,BAO_0000357,
1968,Oryctolagus cuniculus,,B,The compound was tested for intrinsic activity against 5-HT1D receptor,,CHEMBL617573,9986.0,8,1,H,105,Expert,,,BAO_0000357,
1969,Oryctolagus cuniculus,,B,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL617574,9986.0,8,1,H,105,Autocuration,,,BAO_0000019,
1970,Oryctolagus cuniculus,,B,The compound was tested for binding affinity against 5-HT1D receptor,,CHEMBL617575,9986.0,8,1,H,105,Expert,,,BAO_0000357,
1971,,,B,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,CHEMBL617576,,8,1,H,10578,Autocuration,,,BAO_0000357,
1972,,,F,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,CHEMBL617577,,8,1,H,10578,Autocuration,,,BAO_0000019,
1973,,,F,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,CHEMBL617578,,8,1,H,10578,Autocuration,,,BAO_0000019,
1974,,,B,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,CHEMBL617579,,8,1,H,10578,Autocuration,,,BAO_0000357,
1975,,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL617580,,8,1,H,10578,Expert,,,BAO_0000019,
1976,,,B,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,CHEMBL617581,,8,1,H,10578,Autocuration,,,BAO_0000249,
1977,,,B,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,CHEMBL617582,,8,1,H,10578,Autocuration,,,BAO_0000357,
1978,,,B,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,CHEMBL617583,,8,1,H,10578,Expert,,,BAO_0000019,
1979,,,B,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,CHEMBL617584,,8,1,H,105,Autocuration,,,BAO_0000357,
1980,,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL617585,,8,1,H,105,Autocuration,,,BAO_0000357,
1981,,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,CHEMBL875912,,8,1,H,105,Autocuration,,,BAO_0000357,
1982,,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,CHEMBL617586,,8,1,H,105,Autocuration,,,BAO_0000357,
1983,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,CHEMBL617587,,8,1,H,105,Autocuration,,,BAO_0000357,
1984,,,B,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,CHEMBL617588,,8,1,H,105,Autocuration,,,BAO_0000357,
1985,,,B,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL857980,,8,1,H,105,Autocuration,,,BAO_0000357,
1986,,,B,Tested against 5-hydroxytryptamine 1D receptor,,CHEMBL617589,,8,1,H,105,Autocuration,,,BAO_0000357,
1987,,,B,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,CHEMBL617590,,8,1,H,105,Autocuration,,,BAO_0000357,
1988,,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,CHEMBL617591,,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1989,Homo sapiens,,B,Binding affinity against 5-Hydroxytryptamine 1D receptor,,CHEMBL617592,9606.0,9,1,D,105,Expert,,,BAO_0000357,
1990,,,B,,,CHEMBL617593,,8,1,H,105,Autocuration,,,BAO_0000357,
1991,,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617594,,8,1,H,106,Autocuration,,485.0,BAO_0000219,
1992,,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617595,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
1993,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,CHEMBL617596,,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1994,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,CHEMBL617597,,8,1,H,105,Autocuration,,722.0,BAO_0000219,
1995,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,CHEMBL617598,,8,1,H,105,Autocuration,,,BAO_0000019,
1996,,,B,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,CHEMBL872916,,8,1,H,105,Autocuration,,,BAO_0000357,
1997,,,B,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,CHEMBL617599,,8,1,H,105,Expert,,,BAO_0000357,
1998,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,CHEMBL617091,,8,1,H,105,Autocuration,,,BAO_0000357,
1999,,,B,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,CHEMBL617092,,8,1,H,105,Expert,,485.0,BAO_0000219,
2000,,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617093,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
2001,,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617094,,8,1,H,105,Autocuration,,,BAO_0000019,
2002,,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617095,,8,1,H,105,Autocuration,,,BAO_0000019,
2003,,,F,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617096,,8,1,H,105,Autocuration,,,BAO_0000019,
2004,,,F,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617097,,8,1,H,105,Autocuration,,,BAO_0000019,
2005,,,F,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617098,,8,1,H,105,Autocuration,,,BAO_0000019,
2006,,,B,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,CHEMBL617301,,8,1,H,105,Autocuration,,,BAO_0000357,
2007,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,CHEMBL617302,,8,1,H,105,Autocuration,,,BAO_0000357,
2008,,,B,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617303,,8,1,H,105,Autocuration,,,BAO_0000357,
2009,,,B,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617304,,8,1,H,105,Expert,,,BAO_0000357,
2010,,,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL617305,,8,1,H,105,Expert,,449.0,BAO_0000219,
2011,Homo sapiens,,B,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,CHEMBL617306,9606.0,9,1,D,105,Autocuration,,,BAO_0000219,
2012,,,B,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,CHEMBL617307,,8,1,H,17106,Autocuration,,,BAO_0000357,
2013,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,CHEMBL617308,9986.0,8,1,H,105,Autocuration,,,BAO_0000019,
2014,,,B,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617309,,8,1,H,105,Autocuration,,,BAO_0000357,
2015,,,B,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617310,,8,1,H,105,Autocuration,,,BAO_0000357,
2016,,,B,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617311,,8,1,H,105,Autocuration,,,BAO_0000357,
2017,,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,CHEMBL617312,,8,1,H,105,Autocuration,,,BAO_0000357,
2018,,,B,Affinity against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617313,,8,1,H,105,Autocuration,,,BAO_0000357,
2019,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617314,,8,1,H,105,Expert,,,BAO_0000357,
2020,,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617315,,8,1,H,106,Autocuration,,,BAO_0000019,
2021,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,CHEMBL617316,,8,1,H,106,Autocuration,,722.0,BAO_0000219,
2022,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,CHEMBL617317,,8,1,H,106,Autocuration,,722.0,BAO_0000219,
2023,,,B,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL617318,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
2024,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,CHEMBL617319,,8,1,H,106,Autocuration,,,BAO_0000019,
2025,,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617320,,9,1,D,106,Expert,,,BAO_0000357,
2026,,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617321,,9,1,D,106,Expert,,,BAO_0000357,
2027,,,B,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617322,,9,1,D,106,Expert,,,BAO_0000357,
2028,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616862,,8,1,H,106,Autocuration,,,BAO_0000357,
2029,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616863,,8,1,H,106,Autocuration,,,BAO_0000357,
2030,,,B,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,CHEMBL616864,,8,1,H,106,Autocuration,,449.0,BAO_0000219,
2031,,,B,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,CHEMBL616865,,8,1,H,106,Autocuration,,485.0,BAO_0000219,
2032,,,B,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,CHEMBL616866,,8,1,H,106,Autocuration,,485.0,BAO_0000219,
2033,,,F,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL616867,,8,1,H,106,Autocuration,,,BAO_0000019,
2034,,,B,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,CHEMBL616868,,8,1,H,106,Expert,,485.0,BAO_0000219,
2035,,,B,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,CHEMBL616869,,8,1,H,105,Expert,,,BAO_0000357,
2036,,,B,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL616870,,8,1,H,106,Expert,,449.0,BAO_0000219,
2037,,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,CHEMBL616871,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
2038,,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,CHEMBL616872,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
2039,,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,CHEMBL616873,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
2040,,,F,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,CHEMBL616838,,8,1,H,105,Autocuration,,485.0,BAO_0000219,
2041,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,CHEMBL616839,,8,1,H,105,Autocuration,,,BAO_0000357,
2042,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,CHEMBL616840,9986.0,8,1,H,106,Autocuration,,,BAO_0000019,
2043,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,CHEMBL616841,,8,1,H,105,Autocuration,,,BAO_0000357,
2044,,,B,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,CHEMBL616842,,8,1,H,105,Autocuration,,,BAO_0000357,
2045,,,B,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,CHEMBL857976,,8,1,H,105,Expert,,,BAO_0000357,
2046,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,CHEMBL616843,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2047,Homo sapiens,,B,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,CHEMBL616844,9606.0,9,1,D,10618,Expert,,,BAO_0000357,
2048,,,B,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,CHEMBL616845,,8,1,H,10618,Autocuration,,,BAO_0000357,
2049,Homo sapiens,,B,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,CHEMBL616846,9606.0,9,1,D,10618,Expert,,,BAO_0000357,
2050,,,B,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,CHEMBL616847,,8,1,H,10618,Autocuration,,,BAO_0000357,
2051,,,B,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,CHEMBL616848,,8,1,H,10618,Autocuration,,,BAO_0000019,
2052,,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,CHEMBL616849,,8,1,H,10618,Autocuration,,,BAO_0000357,
2053,,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,CHEMBL872911,,8,1,H,10618,Autocuration,,,BAO_0000357,
2054,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,CHEMBL616850,,8,1,H,10618,Autocuration,,,BAO_0000019,
2055,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,CHEMBL616699,9606.0,9,1,D,10618,Expert,,449.0,BAO_0000219,
2056,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616700,,8,1,H,10618,Autocuration,,,BAO_0000357,
2057,,,B,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616701,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2058,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616702,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2059,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHEMBL616703,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2060,,,B,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,CHEMBL616704,,8,1,H,10618,Autocuration,,,BAO_0000357,
2061,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616705,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2062,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,CHEMBL616706,,8,1,H,10618,Autocuration,,,BAO_0000357,
2063,,,B,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,CHEMBL616707,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2064,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616708,,8,1,H,10618,Autocuration,,,BAO_0000357,
2065,,,B,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,CHEMBL616709,,8,1,H,10618,Autocuration,,,BAO_0000357,
2066,,,B,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,CHEMBL616710,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2067,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,CHEMBL616711,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2068,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616712,,8,1,H,10618,Autocuration,,449.0,BAO_0000219,
2069,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616713,,8,1,H,10618,Autocuration,,,BAO_0000357,
2070,,,B,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616714,,8,1,H,10618,Autocuration,,,BAO_0000357,
2071,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,CHEMBL616715,,8,1,H,10618,Autocuration,,,BAO_0000357,
2072,,,B,Binding affinity towards 5-hydroxytryptamine 1E receptor,,CHEMBL616716,,8,1,H,10618,Autocuration,,,BAO_0000357,
2073,,,F,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,CHEMBL616717,,8,1,H,279,Autocuration,,,BAO_0000019,
2074,,,F,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,CHEMBL616718,,8,1,H,279,Expert,,,BAO_0000019,
2075,,,F,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,CHEMBL875905,,8,1,H,279,Autocuration,,,BAO_0000019,
2076,,,F,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,CHEMBL616719,,8,1,H,279,Autocuration,,,BAO_0000019,
2077,,,F,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,CHEMBL616720,,8,1,H,279,Expert,,,BAO_0000019,
2078,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,CHEMBL616721,,8,1,H,279,Autocuration,,,BAO_0000357,
2079,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,CHEMBL616722,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2080,,,B,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,CHEMBL616723,,8,1,H,279,Autocuration,,,BAO_0000357,
2081,,,B,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,CHEMBL616724,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2082,,,B,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,CHEMBL616725,,8,1,H,279,Autocuration,,,BAO_0000357,
2083,,,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,CHEMBL616726,,8,1,H,279,Autocuration,,,BAO_0000357,
2084,,,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,CHEMBL616727,,8,1,H,279,Autocuration,,,BAO_0000357,
2085,,,B,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,CHEMBL616728,,8,1,H,279,Autocuration,,,BAO_0000357,
2086,,,B,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,CHEMBL616729,,8,1,H,279,Autocuration,,,BAO_0000357,
2087,,,B,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,CHEMBL616730,,8,1,H,279,Expert,,,BAO_0000019,
2088,,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,CHEMBL617125,,8,1,H,279,Autocuration,,,BAO_0000357,
2089,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,CHEMBL857977,,8,1,H,279,Autocuration,,,BAO_0000357,
2090,,,B,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL617126,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2091,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,CHEMBL617127,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2092,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,CHEMBL617128,,8,1,H,279,Autocuration,,,BAO_0000357,
2093,,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,CHEMBL617129,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2094,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL617130,,8,1,H,279,Autocuration,,,BAO_0000357,
2095,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,CHEMBL617131,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2096,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL617132,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2097,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL617133,,8,1,H,279,Autocuration,,449.0,BAO_0000219,
2098,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,CHEMBL617134,,8,1,H,279,Autocuration,,,BAO_0000357,
2099,,,B,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,CHEMBL617135,,8,1,H,279,Autocuration,,,BAO_0000357,
2100,,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,CHEMBL617136,,8,1,H,279,Autocuration,,,BAO_0000357,
2101,,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,CHEMBL617137,,4,1,H,104686,Autocuration,,,BAO_0000019,
2102,,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,CHEMBL617138,,4,1,H,104686,Autocuration,,,BAO_0000019,
2103,,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617139,,4,1,H,104686,Autocuration,,,BAO_0000019,
2104,,,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,CHEMBL617140,,8,1,H,12687,Autocuration,,,BAO_0000019,
2105,,,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,CHEMBL617141,,4,1,H,104686,Autocuration,,,BAO_0000218,
2106,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL858112,,4,1,H,104686,Autocuration,,,BAO_0000019,
2107,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,CHEMBL617142,,8,1,H,17005,Intermediate,,,BAO_0000019,
2108,Bos taurus,,B,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,CHEMBL617143,9913.0,0,1,U,22226,Autocuration,,,BAO_0000019,
2109,Bos taurus,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,CHEMBL617144,9913.0,0,1,U,22226,Autocuration,,,BAO_0000019,
2110,Bos taurus,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,CHEMBL617145,9913.0,0,1,U,22226,Autocuration,,,BAO_0000019,
2111,,,B,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,CHEMBL617146,,0,1,U,22226,Autocuration,,,BAO_0000019,
2112,Cavia porcellus,,B,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,CHEMBL617147,10141.0,4,1,H,104784,Autocuration,,,BAO_0000019,
2113,Cavia porcellus,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,CHEMBL617148,10141.0,4,1,H,104784,Autocuration,,,BAO_0000019,
2114,Cavia porcellus,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,CHEMBL617149,10141.0,4,1,H,104784,Autocuration,,,BAO_0000019,
2115,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617150,,4,1,H,104784,Autocuration,,,BAO_0000224,
2116,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617151,,4,1,H,104784,Autocuration,,,BAO_0000224,
2117,,,B,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,CHEMBL617201,,4,1,H,104784,Autocuration,,,BAO_0000224,
2118,,,B,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,CHEMBL617202,,8,1,H,10209,Autocuration,,,BAO_0000357,
2119,,,B,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,CHEMBL617203,,4,1,H,104826,Autocuration,,,BAO_0000218,
2120,,,B,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,CHEMBL617204,,4,1,H,104826,Autocuration,,,BAO_0000019,
2121,,,B,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,CHEMBL617205,,4,1,H,104826,Autocuration,,,BAO_0000224,
2122,Mus musculus,,B,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,CHEMBL617206,10090.0,5,1,D,104826,Autocuration,,,BAO_0000019,
2123,,,B,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,CHEMBL617207,,4,1,H,104826,Autocuration,,,BAO_0000218,
2124,Mus musculus,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,CHEMBL617208,10090.0,5,1,D,104826,Autocuration,,,BAO_0000019,
2125,,,B,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617209,,4,1,H,104826,Autocuration,,,BAO_0000224,
2126,,,B,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,CHEMBL617210,,4,1,H,104826,Autocuration,,,BAO_0000224,
2127,,,B,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,CHEMBL617211,,4,1,H,104826,Autocuration,,,BAO_0000224,
2128,Mus musculus,,B,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,CHEMBL617212,10090.0,5,1,D,104826,Autocuration,,,BAO_0000019,
2129,Sus scrofa,,B,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,CHEMBL617213,9823.0,4,1,H,104784,Autocuration,,,BAO_0000224,
2130,Sus scrofa,,B,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,CHEMBL617214,9823.0,4,1,H,104784,Autocuration,,,BAO_0000224,
2131,,,B,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,CHEMBL617215,,0,1,U,22226,Autocuration,,,BAO_0000221,
2132,,,B,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,CHEMBL617216,,0,1,U,22226,Autocuration,,,BAO_0000221,
2133,Sus scrofa,,B,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,CHEMBL617217,9823.0,8,1,H,17005,Autocuration,,,BAO_0000357,
2134,,,B,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL617218,,4,1,H,104686,Autocuration,,,BAO_0000019,
2135,,,B,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL872913,,4,1,H,104686,Autocuration,,,BAO_0000019,
2136,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,CHEMBL617219,,4,1,H,104826,Autocuration,,,BAO_0000019,
2137,,,B,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,CHEMBL873482,,4,1,H,104686,Autocuration,,,BAO_0000224,
2138,Rattus norvegicus,,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,CHEMBL617220,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2139,,,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,CHEMBL617221,,4,1,H,104686,Autocuration,,,BAO_0000019,
2140,,,B,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,CHEMBL617222,,4,1,H,104686,Autocuration,,,BAO_0000019,
2141,,,F,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,CHEMBL875906,,4,1,H,104686,Autocuration,,,BAO_0000019,
2142,,,B,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,CHEMBL617223,,4,1,H,104686,Autocuration,,,BAO_0000019,
2143,,,B,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,CHEMBL617224,,4,1,H,104686,Autocuration,,,BAO_0000224,
2144,Rattus norvegicus,,B,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,CHEMBL617225,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2145,,,B,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,CHEMBL617226,,4,1,H,104686,Autocuration,,,BAO_0000224,
2146,,,B,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,CHEMBL617227,,4,1,H,104686,Autocuration,,,BAO_0000224,
2147,,,B,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,CHEMBL617228,,4,1,H,104686,Autocuration,,,BAO_0000224,
2148,,,B,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,CHEMBL617229,,4,1,H,104686,Autocuration,,,BAO_0000224,
2149,,,B,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,CHEMBL617230,,4,1,H,104686,Autocuration,,,BAO_0000224,
2150,,,B,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,CHEMBL617231,,4,1,H,104686,Autocuration,,,BAO_0000224,
2151,,,B,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,CHEMBL617232,,4,1,H,104686,Autocuration,,,BAO_0000224,
2152,,,B,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,CHEMBL617233,,4,1,H,104686,Autocuration,,,BAO_0000224,
2153,,,B,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL617234,,4,1,H,104686,Autocuration,,,BAO_0000224,
2154,,,F,Compound was tested for the inhibition of quipazine induced head twitches in rats,,CHEMBL617235,,4,1,H,104686,Autocuration,,,BAO_0000019,
2155,,,F,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,CHEMBL617236,,4,1,H,104686,Autocuration,,,BAO_0000019,
2156,,,B,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,CHEMBL617237,,4,1,H,104686,Autocuration,,,BAO_0000221,10000000.0
2157,,,B,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,CHEMBL617238,,4,1,H,104686,Autocuration,,,BAO_0000221,10000000.0
2158,Rattus norvegicus,,B,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,CHEMBL617239,10116.0,5,1,D,104686,Autocuration,,,BAO_0000221,955.0
2159,,,B,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617240,,4,1,H,104686,Autocuration,,,BAO_0000019,
2160,,,B,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,CHEMBL617241,,4,1,H,104686,Autocuration,,,BAO_0000249,
2161,,,B,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,CHEMBL875907,,4,1,H,104686,Autocuration,,,BAO_0000249,
2162,,,B,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,CHEMBL617242,,4,1,H,104686,Autocuration,,,BAO_0000019,
2163,,,F,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,CHEMBL617152,,4,1,H,104686,Autocuration,,,BAO_0000019,
2164,Rattus norvegicus,,B,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,CHEMBL617153,10116.0,5,1,D,104686,Autocuration,,,BAO_0000221,955.0
2165,Rattus norvegicus,,B,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,CHEMBL617154,10116.0,5,1,D,104686,Autocuration,,,BAO_0000249,
2166,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,CHEMBL617155,,4,1,H,104686,Autocuration,,,BAO_0000221,955.0
2167,,,F,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,CHEMBL617156,,4,1,H,104686,Autocuration,,,BAO_0000019,
2168,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,CHEMBL617157,,4,1,H,104686,Autocuration,,,BAO_0000019,
2169,,,F,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617158,,4,1,H,104686,Autocuration,,,BAO_0000019,
2170,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,CHEMBL617159,,4,1,H,104686,Autocuration,,,BAO_0000019,
2171,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,CHEMBL617160,,4,1,H,104686,Autocuration,,,BAO_0000019,
2172,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL858113,,4,1,H,104686,Autocuration,,,BAO_0000019,
2173,,,B,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,CHEMBL617247,,4,1,H,104686,Autocuration,,,BAO_0000220,955.0
2174,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617248,,4,1,H,104686,Autocuration,,,BAO_0000019,
2175,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL617249,,4,1,H,104686,Autocuration,,,BAO_0000249,955.0
2176,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,CHEMBL617250,,4,1,H,104686,Autocuration,,,BAO_0000019,
2177,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617251,,4,1,H,104686,Autocuration,,,BAO_0000019,
2178,Rattus norvegicus,,B,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,CHEMBL617252,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2179,,,B,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,CHEMBL617006,,4,1,H,104686,Autocuration,,,BAO_0000019,
2180,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,CHEMBL617007,,4,1,H,104686,Autocuration,,,BAO_0000019,
2181,,,F,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,CHEMBL617008,,4,1,H,104686,Autocuration,,,BAO_0000019,
2182,,,B,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,CHEMBL617009,,4,1,H,104686,Autocuration,,,BAO_0000019,
2183,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,CHEMBL617010,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2184,Rattus norvegicus,,B,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL857978,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2185,Rattus norvegicus,,B,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL617011,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2186,Rattus norvegicus,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,CHEMBL617012,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2187,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,CHEMBL617013,,4,1,H,104686,Autocuration,,,BAO_0000224,
2188,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,CHEMBL617014,,4,1,H,104686,Autocuration,,,BAO_0000249,
2189,,,B,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,CHEMBL617015,,4,1,H,104686,Autocuration,,,BAO_0000019,
2190,,,B,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,CHEMBL617016,,4,1,H,104686,Autocuration,,,BAO_0000019,
2191,,,B,pKi value for 5-hydroxytryptamine 2 receptor binding site,,CHEMBL617017,,4,1,H,104686,Autocuration,,,BAO_0000224,
2192,,,B,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,CHEMBL617018,,4,1,H,104686,Autocuration,,,BAO_0000221,955.0
2193,,,F,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,CHEMBL617019,,4,1,H,104686,Autocuration,,,BAO_0000019,
2194,,,B,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617020,,4,1,H,105075,Autocuration,,,BAO_0000019,
2195,,,B,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617021,,4,1,H,105075,Autocuration,,,BAO_0000019,
2196,,,B,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617022,,4,1,H,105075,Autocuration,,,BAO_0000019,
2197,,,B,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617023,,4,1,H,105075,Autocuration,,,BAO_0000019,
2198,,,B,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617024,,4,1,H,105075,Autocuration,,,BAO_0000019,
2199,,,B,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617025,,4,1,H,105075,Autocuration,,,BAO_0000019,
2200,,,B,Hill coefficient of compound was determined,,CHEMBL617026,,4,1,H,105075,Autocuration,,,BAO_0000224,
2201,,,B,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,CHEMBL617027,,0,1,U,22226,Autocuration,,,BAO_0000019,
2202,Rattus norvegicus,,B,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,CHEMBL617028,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2203,,,B,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,CHEMBL617029,,8,1,H,12687,Expert,,,BAO_0000019,
2204,,,B,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,CHEMBL875908,,8,1,H,12687,Expert,,,BAO_0000019,
2205,,,B,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,CHEMBL617030,,8,1,H,12687,Autocuration,,,BAO_0000357,
2206,,,B,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,CHEMBL617031,,8,1,H,12687,Autocuration,,,BAO_0000019,
2207,,,B,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,CHEMBL617032,,8,1,H,12687,Autocuration,,,BAO_0000019,
2208,Rattus norvegicus,,B,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,CHEMBL617033,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2209,,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,CHEMBL617034,,4,1,H,104686,Autocuration,,,BAO_0000224,
2210,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,CHEMBL617035,,4,1,H,104686,Autocuration,,,BAO_0000224,
2211,,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617036,,4,1,H,104686,Autocuration,,,BAO_0000019,
2212,,,B,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,CHEMBL617037,,4,1,H,104784,Autocuration,,,BAO_0000224,
2213,,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,CHEMBL617038,,0,1,U,22226,Autocuration,,,BAO_0000219,
2214,,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,CHEMBL617039,,4,1,H,104784,Autocuration,,,BAO_0000219,
2215,,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617161,,4,1,H,104784,Autocuration,,,BAO_0000224,
2216,,,B,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,CHEMBL617162,,4,1,H,104784,Autocuration,,,BAO_0000224,
2217,,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617163,,4,1,H,104784,Autocuration,,,BAO_0000224,
2218,,,B,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617164,,4,1,H,104784,Autocuration,,,BAO_0000224,
2219,,,B,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,CHEMBL617165,,4,1,H,104784,Autocuration,,,BAO_0000249,
2220,,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,CHEMBL617166,,4,1,H,104784,Autocuration,,,BAO_0000224,
2221,,,B,Binding affinity towards 5-HT2 receptor,,CHEMBL617167,,4,1,H,104784,Autocuration,,,BAO_0000224,
2222,,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL872912,,4,1,H,104784,Autocuration,,,BAO_0000224,
2223,,,B,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,CHEMBL617168,,4,1,H,104784,Autocuration,,,BAO_0000224,
2224,,,B,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,CHEMBL617169,,4,1,H,104686,Autocuration,,,BAO_0000224,
2225,,,B,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617170,,4,1,H,104784,Autocuration,,,BAO_0000224,
2226,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,CHEMBL617171,,4,1,H,104784,Autocuration,,,BAO_0000224,
2227,,,B,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617172,,4,1,H,104784,Autocuration,,,BAO_0000224,
2228,,,B,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617173,,4,1,H,104784,Autocuration,,,BAO_0000224,
2229,,,B,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617174,,0,1,U,22226,Autocuration,,,BAO_0000019,
2230,,,B,5-hydroxytryptamine 2 receptor binding affinity,,CHEMBL617175,,4,1,H,104784,Autocuration,,,BAO_0000224,
2231,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,CHEMBL617176,,8,1,H,17005,Autocuration,,,BAO_0000357,
2232,,,B,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,CHEMBL617177,,8,1,H,17005,Autocuration,,,BAO_0000357,
2233,,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,CHEMBL617178,,4,1,H,104784,Autocuration,,,BAO_0000224,
2234,,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,CHEMBL617179,,4,1,H,104784,Autocuration,,,BAO_0000224,
2235,,,B,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,CHEMBL617180,,4,1,H,104784,Autocuration,,,BAO_0000224,
2236,,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,CHEMBL617181,,8,1,H,17005,Autocuration,,,BAO_0000357,
2237,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617182,,8,1,H,17005,Autocuration,,,BAO_0000357,
2238,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617183,,8,1,H,17005,Autocuration,,,BAO_0000357,
2239,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,CHEMBL617184,,8,1,H,17005,Autocuration,,,BAO_0000357,
2240,,,B,Binding affinity against serotonergic 5-HT2 receptor,,CHEMBL617185,,8,1,H,17005,Autocuration,,,BAO_0000357,
2241,,,B,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,CHEMBL617186,,8,1,H,17005,Autocuration,,,BAO_0000357,
2242,,,B,Compound was evaluated for the binding affinity at 5- HT2 receptor,,CHEMBL617187,,8,1,H,17005,Autocuration,,,BAO_0000357,
2243,,,B,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,CHEMBL617188,,8,1,H,17005,Autocuration,,,BAO_0000357,
2244,,,B,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,CHEMBL617189,,8,1,H,17005,Autocuration,,,BAO_0000218,
2245,Homo sapiens,,B,Inhibitory activity against cloned human 5-HT2 receptor,,CHEMBL617190,9606.0,5,1,D,104784,Autocuration,,,BAO_0000224,
2246,Homo sapiens,,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,CHEMBL617191,9606.0,5,1,D,104784,Autocuration,,449.0,BAO_0000219,
2247,Homo sapiens,,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,CHEMBL617192,9606.0,5,1,D,104784,Autocuration,,449.0,BAO_0000219,
2248,Homo sapiens,,B,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,CHEMBL617193,9606.0,5,1,D,104784,Autocuration,,449.0,BAO_0000219,
2249,Homo sapiens,,B,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,CHEMBL617194,9606.0,5,1,D,104784,Autocuration,,449.0,BAO_0000219,
2250,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617195,,4,1,H,104784,Autocuration,,,BAO_0000224,
2251,,,B,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,CHEMBL881830,,4,1,H,104784,Autocuration,,,BAO_0000224,
2252,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617196,,8,1,H,17005,Autocuration,,,BAO_0000357,
2253,,,B,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,CHEMBL617197,,4,1,H,104686,Autocuration,,,BAO_0000224,
2254,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,CHEMBL617198,,8,1,H,17005,Expert,,,BAO_0000357,
2255,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL873476,,8,1,H,17005,Expert,,,BAO_0000357,
2256,,,B,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,CHEMBL617199,,8,1,H,17005,Expert,,,BAO_0000019,
2257,Cavia porcellus,,B,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,CHEMBL617200,10141.0,8,1,H,107,Autocuration,,,BAO_0000357,
2258,,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617484,,8,1,H,51,Autocuration,,,BAO_0000357,
2259,,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617485,,8,1,H,107,Autocuration,,,BAO_0000357,
2260,,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617486,,8,1,H,51,Autocuration,,,BAO_0000357,
2261,,,B,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,CHEMBL858022,,8,1,H,107,Autocuration,,,BAO_0000357,
2262,,,B,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHEMBL617049,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2263,Homo sapiens,,F,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617050,9606.0,9,1,D,107,Expert,,449.0,BAO_0000219,
2264,,,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,CHEMBL617051,,8,1,H,107,Autocuration,,,BAO_0000219,
2265,,,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,CHEMBL617052,,8,1,H,107,Autocuration,,,BAO_0000219,
2266,,,F,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,CHEMBL617053,,8,1,H,107,Autocuration,,,BAO_0000219,
2267,,,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,CHEMBL617054,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2268,,,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,CHEMBL617055,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2269,,,B,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,CHEMBL882924,,8,1,H,107,Autocuration,,,BAO_0000357,
2270,Homo sapiens,,B,Inhibition of human 5-hydroxytryptamine 2A receptor,,CHEMBL617056,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2271,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617057,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2272,,,B,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,CHEMBL617058,,8,1,H,107,Expert,,,BAO_0000219,
2273,,,B,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,CHEMBL617059,,8,1,H,107,Autocuration,,,BAO_0000357,
2274,,,B,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617060,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2275,,,B,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,CHEMBL617061,,8,1,H,107,Expert,,449.0,BAO_0000219,
2276,,,B,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,CHEMBL617062,,8,1,H,107,Expert,,307.0,BAO_0000219,
2277,,,B,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617063,,8,1,H,107,Expert,,449.0,BAO_0000219,
2278,,,F,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,CHEMBL617064,,8,1,H,107,Autocuration,,,BAO_0000019,
2279,,,F,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL617065,,8,1,H,107,Autocuration,,,BAO_0000019,
2280,,,B,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHEMBL617066,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2281,,,B,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,CHEMBL617067,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2282,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,CHEMBL617068,,8,1,H,107,Autocuration,,,BAO_0000019,
2283,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,CHEMBL617069,,8,1,H,107,Autocuration,,,BAO_0000019,
2284,,,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617070,,8,1,H,107,Autocuration,,,BAO_0000019,
2285,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,CHEMBL617071,,8,1,H,107,Autocuration,,,BAO_0000357,
2286,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL872915,,8,1,H,107,Autocuration,,,BAO_0000357,
2287,,,B,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,CHEMBL617072,,8,1,H,107,Autocuration,,,BAO_0000357,
2288,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,CHEMBL617073,,8,1,H,107,Autocuration,,,BAO_0000357,
2289,,,B,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,CHEMBL617074,,8,1,H,107,Autocuration,,,BAO_0000357,
2290,,,B,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617075,,8,1,H,107,Expert,,449.0,BAO_0000219,
2291,,,B,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,CHEMBL617076,,8,1,H,107,Autocuration,,,BAO_0000357,
2292,Homo sapiens,,B,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,CHEMBL617077,9606.0,9,1,D,107,Expert,,,BAO_0000019,
2293,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,CHEMBL617078,,8,1,H,107,Expert,,,BAO_0000357,
2294,Homo sapiens,,B,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,CHEMBL617079,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2295,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,CHEMBL617080,,8,1,H,107,Autocuration,,,BAO_0000357,
2296,,,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,CHEMBL617081,,8,1,H,107,Expert,,449.0,BAO_0000219,
2297,,,B,Binding affinity towards human 5-HT2A receptor in BEK cells,,CHEMBL617082,,8,1,H,107,Expert,,,BAO_0000219,
2298,,,B,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617083,,8,1,H,107,Autocuration,,,BAO_0000357,
2299,,,B,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,CHEMBL617084,,8,1,H,107,Autocuration,,,BAO_0000357,
2300,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 2A receptor,,CHEMBL617085,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2301,,,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL617086,,8,1,H,107,Autocuration,,,BAO_0000357,
2302,,,B,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,CHEMBL617087,,8,1,H,107,Autocuration,,,BAO_0000219,
2303,,,B,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,CHEMBL617088,,8,1,H,107,Autocuration,,,BAO_0000357,
2304,,,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,CHEMBL617089,,8,1,H,107,Autocuration,,,BAO_0000357,
2305,,,B,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,CHEMBL617090,,8,1,H,107,Expert,,,BAO_0000019,
2306,,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,CHEMBL617513,,8,1,H,107,Autocuration,,,BAO_0000357,
2307,,,B,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,CHEMBL617514,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2308,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,CHEMBL617515,,8,1,H,107,Autocuration,,,BAO_0000019,
2309,,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617516,,8,1,H,107,Autocuration,,,BAO_0000357,
2310,Homo sapiens,,B,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617517,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2311,Homo sapiens,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,CHEMBL617518,9606.0,9,1,D,107,Expert,,449.0,BAO_0000219,
2312,,,B,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617519,,8,1,H,107,Autocuration,,,BAO_0000357,
2313,Homo sapiens,,B,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,CHEMBL617520,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2314,,,B,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,CHEMBL617521,,8,1,H,107,Autocuration,,,BAO_0000357,
2315,Homo sapiens,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,CHEMBL617522,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2316,,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,CHEMBL617523,,8,1,H,107,Autocuration,,,BAO_0000357,
2317,,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL617524,,8,1,H,107,Autocuration,,,BAO_0000357,
2318,,,B,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,CHEMBL617525,,4,1,H,104686,Autocuration,,,BAO_0000019,
2319,Rattus norvegicus,,B,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,CHEMBL617526,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2320,,,B,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,CHEMBL617527,,4,1,H,104686,Autocuration,,,BAO_0000224,
2321,,,B,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,CHEMBL617528,,4,1,H,104686,Autocuration,,,BAO_0000019,
2322,,,B,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,CHEMBL617529,,4,1,H,104686,Autocuration,,,BAO_0000019,
2323,,,B,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,CHEMBL617530,,4,1,H,104686,Autocuration,,,BAO_0000224,
2324,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,CHEMBL617531,,4,1,H,104686,Autocuration,,,BAO_0000019,
2325,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,CHEMBL617532,,4,1,H,104686,Autocuration,,,BAO_0000019,
2326,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,CHEMBL617533,,4,1,H,104686,Autocuration,,,BAO_0000019,
2327,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,CHEMBL617534,,4,1,H,104686,Autocuration,,,BAO_0000019,
2328,,,B,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,CHEMBL617535,,4,1,H,104686,Autocuration,,,BAO_0000224,
2329,,,B,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,CHEMBL617536,,4,1,H,104686,Autocuration,,,BAO_0000224,
2330,,,B,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617537,,4,1,H,104686,Autocuration,,,BAO_0000224,
2331,,,B,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617538,,4,1,H,104686,Autocuration,,,BAO_0000224,
2332,,,B,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL617539,,4,1,H,104686,Autocuration,,,BAO_0000219,
2333,Rattus norvegicus,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617540,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2334,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,CHEMBL617541,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2335,,,B,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617542,,4,1,H,104686,Autocuration,,,BAO_0000224,
2336,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,CHEMBL617543,,4,1,H,104686,Autocuration,,,BAO_0000224,
2337,Rattus norvegicus,,B,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617544,10116.0,5,1,D,104686,Autocuration,,485.0,BAO_0000219,
2338,Rattus norvegicus,,B,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617545,10116.0,5,1,D,104686,Autocuration,,485.0,BAO_0000219,
2339,Rattus norvegicus,,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,CHEMBL617413,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2340,,,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,CHEMBL617414,,4,1,H,104686,Autocuration,,,BAO_0000019,
2341,Rattus norvegicus,,B,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,CHEMBL617415,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2342,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617416,,4,1,H,104686,Autocuration,,,BAO_0000224,
2343,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,CHEMBL617417,,4,1,H,104686,Autocuration,,,BAO_0000224,
2344,,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,CHEMBL617418,,4,1,H,104686,Autocuration,,,BAO_0000019,
2345,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,CHEMBL617419,,4,1,H,104686,Autocuration,,,BAO_0000019,
2346,,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617420,,4,1,H,104686,Autocuration,,,BAO_0000224,
2347,Rattus norvegicus,,B,Affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617421,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2348,,,B,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,CHEMBL617422,,4,1,H,104686,Autocuration,,,BAO_0000224,
2349,,,B,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,CHEMBL617423,,4,1,H,104686,Autocuration,,,BAO_0000019,
2350,,,B,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,CHEMBL617424,,4,1,H,104686,Autocuration,,,BAO_0000019,
2351,,,B,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,CHEMBL617425,,4,1,H,104686,Autocuration,,,BAO_0000019,
2352,,,B,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,CHEMBL617426,,4,1,H,104686,Autocuration,,,BAO_0000224,
2353,,,B,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,CHEMBL617427,,4,1,H,104686,Autocuration,,,BAO_0000218,
2354,,,B,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,CHEMBL617428,,4,1,H,104686,Autocuration,,,BAO_0000221,955.0
2355,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,CHEMBL617429,,4,1,H,104686,Autocuration,,,BAO_0000224,
2356,,,B,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,CHEMBL617430,,4,1,H,104686,Autocuration,,,BAO_0000019,
2357,,,B,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,CHEMBL617431,,4,1,H,104686,Autocuration,,,BAO_0000019,
2358,,,B,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,CHEMBL617432,,4,1,H,104686,Autocuration,,,BAO_0000019,1870.0
2359,,,B,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,CHEMBL617433,,4,1,H,104686,Autocuration,,,BAO_0000224,
2360,,,B,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,CHEMBL617434,,4,1,H,104686,Autocuration,,,BAO_0000224,
2361,Rattus norvegicus,,B,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,CHEMBL617435,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2362,,,B,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,CHEMBL617436,,4,1,H,104686,Autocuration,,,BAO_0000019,
2363,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,CHEMBL617437,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,2435.0
2364,,,B,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,CHEMBL617438,,4,1,H,104686,Autocuration,,,BAO_0000019,
2365,,,B,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617439,,4,1,H,104686,Autocuration,,,BAO_0000019,
2366,,,B,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617440,,4,1,H,104686,Autocuration,,,BAO_0000224,
2367,,,B,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,CHEMBL617441,,4,1,H,104686,Autocuration,,,BAO_0000224,
2368,Rattus norvegicus,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,CHEMBL872918,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2369,Rattus norvegicus,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,CHEMBL617442,10116.0,5,1,D,104686,Autocuration,,,BAO_0000019,
2370,,,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,CHEMBL617443,,4,1,H,104686,Autocuration,,,BAO_0000019,
2371,,,B,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,CHEMBL617444,,4,1,H,104686,Autocuration,,,BAO_0000019,
2372,,,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,CHEMBL617445,,4,1,H,104686,Autocuration,,,BAO_0000019,
2373,,,B,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,CHEMBL617446,,4,1,H,104686,Autocuration,,,BAO_0000019,
2374,,,B,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,CHEMBL617447,,4,1,H,104686,Autocuration,,,BAO_0000249,
2375,,,B,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,CHEMBL617448,,4,1,H,104686,Autocuration,,,BAO_0000019,
2376,,,B,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,CHEMBL617449,,4,1,H,104686,Autocuration,,,BAO_0000019,
2377,,,B,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,CHEMBL617450,,4,1,H,104686,Autocuration,,,BAO_0000019,
2378,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,CHEMBL617451,,4,1,H,104686,Autocuration,,,BAO_0000019,
2379,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,CHEMBL617452,,4,1,H,104686,Autocuration,,,BAO_0000019,
2380,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,CHEMBL617453,,4,1,H,104686,Autocuration,,,BAO_0000019,
2381,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,CHEMBL617660,,4,1,H,104686,Autocuration,,,BAO_0000019,
2382,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,CHEMBL617661,,4,1,H,104686,Autocuration,,,BAO_0000019,
2383,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,CHEMBL617662,,4,1,H,104686,Autocuration,,,BAO_0000019,
2384,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,CHEMBL872919,,4,1,H,104686,Autocuration,,,BAO_0000019,
2385,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,CHEMBL617663,,4,1,H,104686,Autocuration,,,BAO_0000019,
2386,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,CHEMBL617664,,4,1,H,104686,Autocuration,,,BAO_0000019,
2387,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,CHEMBL617665,,4,1,H,104686,Autocuration,,,BAO_0000019,
2388,,,B,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,CHEMBL617666,,4,1,H,104686,Autocuration,,,BAO_0000019,
2389,,,B,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,CHEMBL617667,,4,1,H,104686,Autocuration,,,BAO_0000019,
2390,,,B,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,CHEMBL617668,,4,1,H,104686,Autocuration,,,BAO_0000249,
2391,,,B,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,CHEMBL617669,,4,1,H,104686,Autocuration,,,BAO_0000249,
2392,,,B,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,CHEMBL617670,,4,1,H,104686,Autocuration,,,BAO_0000224,
2393,Rattus norvegicus,,B,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,CHEMBL617671,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2394,,,B,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617672,,4,1,H,104686,Autocuration,,,BAO_0000224,
2395,,,B,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,CHEMBL617673,,4,1,H,104686,Autocuration,,,BAO_0000019,
2396,,,B,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,CHEMBL617674,,4,1,H,104686,Autocuration,,,BAO_0000224,
2397,,,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617675,,4,1,H,104686,Autocuration,,,BAO_0000019,
2398,,,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,CHEMBL617676,,4,1,H,104686,Autocuration,,,BAO_0000019,
2399,,,B,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,CHEMBL617677,,4,1,H,104686,Autocuration,,,BAO_0000019,
2400,,,B,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,CHEMBL617678,,5,1,D,104686,Autocuration,,,BAO_0000019,
2401,,,B,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,CHEMBL617679,,4,1,H,104686,Autocuration,,,BAO_0000224,
2402,,,B,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,CHEMBL617680,,4,1,H,104686,Autocuration,,,BAO_0000224,
2403,,,B,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,CHEMBL617681,,4,1,H,104686,Autocuration,,,BAO_0000019,
2404,,,B,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,CHEMBL617682,,4,1,H,104686,Autocuration,,,BAO_0000221,955.0
2405,,,B,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,CHEMBL617683,,4,1,H,104686,Autocuration,,,BAO_0000224,
2406,,,B,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,CHEMBL617684,,4,1,H,104686,Autocuration,,,BAO_0000224,
2407,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617685,10116.0,5,1,D,104686,Autocuration,,,BAO_0000224,
2408,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,CHEMBL617686,,4,1,H,104686,Autocuration,,,BAO_0000019,
2409,,,B,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,CHEMBL617687,,4,1,H,104686,Autocuration,,,BAO_0000224,
2410,,,B,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617688,,4,1,H,104686,Autocuration,,,BAO_0000224,
2411,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617689,,4,1,H,104686,Autocuration,,,BAO_0000019,
2412,,,F,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617690,,4,1,H,104686,Autocuration,,,BAO_0000019,
2413,,,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,CHEMBL617691,,4,1,H,104686,Autocuration,,,BAO_0000218,
2414,,,F,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,CHEMBL617692,,4,1,H,104686,Autocuration,,,BAO_0000218,
2415,,,F,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,CHEMBL617693,,4,1,H,104686,Autocuration,,,BAO_0000218,
2416,,,F,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,CHEMBL617694,,4,1,H,104686,Autocuration,,,BAO_0000218,
2417,,,B,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,CHEMBL857985,,8,1,H,12687,Expert,,,BAO_0000221,955.0
2418,Rattus norvegicus,,B,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617695,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2419,,,B,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,CHEMBL617696,,8,1,H,12687,Autocuration,,,BAO_0000019,
2420,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617697,,8,1,H,12687,Autocuration,,,BAO_0000357,
2421,Rattus norvegicus,,B,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,CHEMBL617257,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2422,Rattus norvegicus,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,CHEMBL617258,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2423,,,B,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,CHEMBL617259,,8,1,H,12687,Expert,,,BAO_0000019,
2424,,,B,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,CHEMBL617260,,8,1,H,12687,Autocuration,,,BAO_0000357,
2425,Rattus norvegicus,,B,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617261,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2426,,,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,CHEMBL617262,,8,1,H,12687,Autocuration,,,BAO_0000019,
2427,,,B,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,CHEMBL617263,,8,1,H,12687,Expert,,,BAO_0000019,
2428,,,B,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,CHEMBL617264,,8,1,H,12687,Autocuration,,,BAO_0000019,
2429,Rattus norvegicus,,B,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,CHEMBL617265,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2430,,,B,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,CHEMBL617266,,8,1,H,12687,Autocuration,,,BAO_0000249,
2431,,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,CHEMBL617267,,8,1,H,12687,Autocuration,,,BAO_0000019,
2432,,,B,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,CHEMBL617268,,8,1,H,12687,Expert,,,BAO_0000019,
2433,,,B,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHEMBL617269,,8,1,H,12687,Autocuration,,449.0,BAO_0000219,
2434,,,B,Kinetic inhibition constant evaluated by measuring serotonergic activity,,CHEMBL617323,,8,1,H,12687,Expert,,,BAO_0000357,
2435,,,B,Serotonergic activity of the compound.,,CHEMBL617324,,8,1,H,12687,Autocuration,,,BAO_0000357,
2436,,,B,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,CHEMBL617325,,8,1,H,12687,Autocuration,,,BAO_0000249,
2437,Rattus norvegicus,,B,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,CHEMBL617326,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2438,,,B,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,CHEMBL617327,,8,1,H,12687,Expert,,,BAO_0000249,
2439,Rattus norvegicus,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617328,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2440,Rattus norvegicus,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617329,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2441,Rattus norvegicus,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617330,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2442,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617331,,8,1,H,12687,Autocuration,,,BAO_0000357,
2443,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,CHEMBL617332,,8,1,H,12687,Autocuration,,,BAO_0000357,
2444,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617333,,8,1,H,107,Expert,,,BAO_0000357,
2445,,,B,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,CHEMBL617334,,8,1,H,107,Autocuration,,,BAO_0000357,
2446,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,CHEMBL617335,,8,1,H,107,Autocuration,,,BAO_0000357,
2447,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,CHEMBL617336,,8,1,H,107,Autocuration,,,BAO_0000357,
2448,,,B,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,CHEMBL617337,,8,1,H,107,Autocuration,,,BAO_0000357,
2449,Homo sapiens,,B,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,CHEMBL617338,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2450,,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,CHEMBL617339,,8,1,H,107,Autocuration,,,BAO_0000357,
2451,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617340,,8,1,H,107,Expert,,,BAO_0000357,
2452,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,CHEMBL617341,,8,1,H,107,Autocuration,,,BAO_0000357,
2453,,,B,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617342,,8,1,H,107,Expert,,,BAO_0000357,
2454,,,B,Affinity for 5-hydroxytryptamine 2A receptor,,CHEMBL617343,,8,1,H,107,Expert,,,BAO_0000357,
2455,,,B,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,CHEMBL617344,,8,1,H,107,Expert,,723.0,BAO_0000219,
2456,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,CHEMBL617345,,8,1,H,107,Expert,,,BAO_0000357,
2457,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,CHEMBL617346,,8,1,H,107,Expert,,,BAO_0000357,
2458,,,B,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,CHEMBL617347,,8,1,H,107,Autocuration,,,BAO_0000357,
2459,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617348,,8,1,H,107,Autocuration,,,BAO_0000357,
2460,,,B,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617349,,8,1,H,107,Autocuration,,,BAO_0000357,
2461,,,F,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,CHEMBL617350,,8,1,H,107,Autocuration,,,BAO_0000019,
2462,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,CHEMBL872339,,8,1,H,107,Expert,,,BAO_0000357,
2463,,,B,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617351,,8,1,H,107,Autocuration,,,BAO_0000357,
2464,,,B,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617352,,8,1,H,107,Expert,,,BAO_0000357,
2465,,,B,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617353,,8,1,H,107,Autocuration,,,BAO_0000357,
2466,,,B,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,CHEMBL617354,,8,1,H,107,Autocuration,,,BAO_0000357,
2467,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,CHEMBL617355,,8,1,H,107,Autocuration,,,BAO_0000357,
2468,Mus musculus,,B,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,CHEMBL617356,10090.0,8,1,H,107,Expert,,449.0,BAO_0000219,
2469,,,B,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617357,,8,1,H,107,Autocuration,,,BAO_0000357,
2470,,,B,Binding affinity at 5-hydroxytryptamine 2A receptor,,CHEMBL617358,,8,1,H,107,Autocuration,,,BAO_0000357,
2471,,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617359,,8,1,H,107,Expert,,,BAO_0000357,
2472,,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617360,,8,1,H,107,Autocuration,,,BAO_0000357,
2473,,,B,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,CHEMBL875913,,8,1,H,107,Autocuration,,,BAO_0000357,
2474,,,B,Affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617361,,8,1,H,107,Autocuration,,,BAO_0000357,
2475,Homo sapiens,,B,Binding affinity against 5-Hydroxytryptamine 2A receptor,,CHEMBL617362,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2476,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,CHEMBL617363,,8,1,H,107,Autocuration,,,BAO_0000357,
2477,,,B,Tested against 5-hydroxytryptamine 2A receptor,,CHEMBL617364,,8,1,H,107,Autocuration,,,BAO_0000357,
2478,,,B,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,CHEMBL617365,,4,1,H,105075,Autocuration,,,BAO_0000224,
2479,,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,CHEMBL617366,,4,1,H,105075,Autocuration,,,BAO_0000224,
2480,,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,CHEMBL617367,,4,1,H,105075,Autocuration,,,BAO_0000224,
2481,,,B,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,CHEMBL617368,,4,1,H,105075,Autocuration,,,BAO_0000224,
2482,,,B,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,CHEMBL617369,,8,1,H,107,Autocuration,,,BAO_0000357,
2483,Homo sapiens,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,CHEMBL617370,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2484,Homo sapiens,,F,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617371,9606.0,9,1,D,227,Expert,,449.0,BAO_0000219,
2485,,,B,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,CHEMBL617372,,8,1,H,227,Autocuration,,,BAO_0000357,
2486,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,CHEMBL617373,9606.0,9,1,D,227,Expert,,,BAO_0000357,
2487,,,F,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,CHEMBL617374,,8,1,H,227,Autocuration,,,BAO_0000019,
2488,,,F,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,CHEMBL617375,,8,1,H,227,Autocuration,,,BAO_0000019,
2489,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,CHEMBL617376,,8,1,H,227,Autocuration,,,BAO_0000019,
2490,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,CHEMBL617377,,8,1,H,227,Autocuration,,,BAO_0000019,
2491,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,CHEMBL617378,,8,1,H,227,Autocuration,,,BAO_0000019,
2492,,,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,CHEMBL617379,,8,1,H,227,Autocuration,,,BAO_0000019,
2493,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,CHEMBL617380,,8,1,H,227,Autocuration,,,BAO_0000357,
2494,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,CHEMBL617381,,8,1,H,227,Autocuration,,,BAO_0000357,
2495,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,CHEMBL617382,,8,1,H,227,Autocuration,,,BAO_0000357,
2496,,,B,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617383,,8,1,H,107,Autocuration,,,BAO_0000357,
2497,,,B,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,CHEMBL617384,,8,1,H,107,Expert,,,BAO_0000357,
2498,,,B,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,CHEMBL617385,,8,1,H,107,Expert,,,BAO_0000357,
2499,,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,CHEMBL617386,,8,1,H,107,Autocuration,,,BAO_0000019,
2500,,,B,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,CHEMBL617387,,8,1,H,107,Autocuration,,,BAO_0000019,
2501,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL617388,,8,1,H,107,Autocuration,,723.0,BAO_0000219,
2502,,,F,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617389,,8,1,H,107,Autocuration,,449.0,BAO_0000219,
2503,Homo sapiens,,F,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617390,9606.0,9,1,D,107,Expert,,449.0,BAO_0000219,
2504,,,B,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,CHEMBL617391,,4,1,H,104817,Autocuration,,,BAO_0000224,
2505,,,B,Binding activity radioligand.,,CHEMBL617392,,8,1,H,107,Autocuration,,,BAO_0000357,
2506,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617393,,8,1,H,107,Autocuration,,,BAO_0000019,
2507,,,B,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,CHEMBL617394,,8,1,H,107,Autocuration,,307.0,BAO_0000219,
2508,,,B,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,CHEMBL617395,,8,1,H,107,Expert,,307.0,BAO_0000219,
2509,,,B,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,CHEMBL617396,,8,1,H,107,Expert,,307.0,BAO_0000219,
2510,,,B,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,CHEMBL617397,,8,1,H,107,Autocuration,,307.0,BAO_0000219,
2511,,,B,Binding affinity against 5-HT2A receptor,,CHEMBL617398,,8,1,H,107,Autocuration,,,BAO_0000357,
2512,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617399,,8,1,H,107,Autocuration,,,BAO_0000357,
2513,,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,CHEMBL617400,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2514,,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,CHEMBL617401,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2515,Homo sapiens,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,CHEMBL617402,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2516,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL617403,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2517,,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,CHEMBL617404,,8,1,H,107,Expert,,,BAO_0000357,
2518,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL857981,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2519,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL617405,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2520,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,CHEMBL617253,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2521,,,B,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,CHEMBL617254,,8,1,H,107,Expert,,,BAO_0000357,
2522,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL617255,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2523,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL617256,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2524,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL616874,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2525,Homo sapiens,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,CHEMBL616875,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2526,,,B,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL616876,,8,1,H,107,Expert,,722.0,BAO_0000219,
2527,,,B,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,CHEMBL616877,,8,1,H,107,Expert,,722.0,BAO_0000219,
2528,Homo sapiens,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,CHEMBL616878,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2529,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,CHEMBL616879,,8,1,H,107,Expert,,722.0,BAO_0000219,
2530,,,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,CHEMBL616880,,8,1,H,107,Expert,,722.0,BAO_0000219,
2531,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL616881,9606.0,9,1,D,107,Expert,,722.0,BAO_0000219,
2532,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,CHEMBL616882,,8,1,H,107,Autocuration,,723.0,BAO_0000219,
2533,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL616883,,8,1,H,107,Autocuration,,723.0,BAO_0000219,
2534,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL616884,,8,1,H,107,Autocuration,,723.0,BAO_0000219,
2535,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,CHEMBL616885,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2536,,,B,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,CHEMBL616886,,8,1,H,107,Autocuration,,485.0,BAO_0000219,
2537,,,B,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,CHEMBL616887,,8,1,H,107,Expert,,485.0,BAO_0000219,
2538,Homo sapiens,,B,Binding affinity for human 5-hydroxytryptamine 2A receptor,,CHEMBL616888,9606.0,9,1,D,107,Expert,,,BAO_0000357,
2539,,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,CHEMBL616889,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2540,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,CHEMBL616890,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2541,Homo sapiens,,B,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHEMBL616891,9606.0,9,1,D,107,Expert,,449.0,BAO_0000219,
2542,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,CHEMBL616892,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2543,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,CHEMBL616893,,8,1,H,107,Autocuration,,722.0,BAO_0000219,
2544,,,F,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,CHEMBL616894,,8,1,H,10620,Autocuration,,723.0,BAO_0000219,
2545,,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,CHEMBL616895,,8,1,H,107,Expert,,723.0,BAO_0000219,
2546,,,F,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,CHEMBL616896,,8,1,H,10620,Autocuration,,,BAO_0000019,
2547,,,B,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,CHEMBL617099,,8,1,H,10621,Autocuration,,,BAO_0000357,
2548,,,B,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,CHEMBL617100,,8,1,H,10621,Autocuration,,,BAO_0000357,
2549,Oryctolagus cuniculus,,B,Binding affinity against rabbit aorta 5-HT2A receptor,,CHEMBL884532,9986.0,8,1,H,107,Autocuration,,,BAO_0000357,
2550,Oryctolagus cuniculus,,B,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,CHEMBL617101,9986.0,8,1,H,107,Expert,,,BAO_0000357,
2551,Oryctolagus cuniculus,,B,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,CHEMBL617102,9986.0,8,1,H,107,Expert,,,BAO_0000357,
2552,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,CHEMBL617103,9986.0,8,1,H,107,Autocuration,,,BAO_0000019,
2553,Oryctolagus cuniculus,,B,The compound was tested for binding affinity against 5-HT2A receptor,,CHEMBL617104,9986.0,8,1,H,107,Expert,,,BAO_0000357,
2554,,,B,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,CHEMBL857979,,8,1,H,10576,Autocuration,,485.0,BAO_0000219,
2555,,,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,CHEMBL857502,,8,1,H,12687,Autocuration,,,BAO_0000019,
2556,,,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,CHEMBL617105,,8,1,H,12687,Autocuration,,,BAO_0000019,
2557,,,B,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,CHEMBL858021,,8,1,H,12687,Autocuration,,,BAO_0000019,945.0
2558,Rattus norvegicus,,B,Binding affinity for 5-HT 2A in rat stomach fundus,,CHEMBL875910,10116.0,9,1,D,12687,Expert,,,BAO_0000019,945.0
2559,,,B,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,CHEMBL617106,,8,1,H,12687,Autocuration,,,BAO_0000019,
2560,,,B,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,CHEMBL617107,,8,1,H,12687,Expert,,723.0,BAO_0000219,
2561,,,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,CHEMBL617108,,8,1,H,12687,Autocuration,,,BAO_0000019,
2562,,,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,CHEMBL617109,,8,1,H,12687,Autocuration,,,BAO_0000019,
2563,,,B,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,CHEMBL617110,,8,1,H,12687,Autocuration,,,BAO_0000357,
2564,,,B,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,CHEMBL617111,,8,1,H,12687,Autocuration,,,BAO_0000357,
2565,Rattus norvegicus,,F,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,CHEMBL617112,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2566,,,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617113,,8,1,H,12687,Autocuration,,,BAO_0000357,
2567,,,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617114,,8,1,H,12687,Autocuration,,,BAO_0000357,
2568,,,B,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617115,,8,1,H,12687,Autocuration,,,BAO_0000357,
2569,,,F,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617116,,8,1,H,12687,Autocuration,,,BAO_0000219,
2570,,,F,Efficacy at 5-hydroxytryptamine 2A receptor,,CHEMBL617117,,8,1,H,12687,Autocuration,,,BAO_0000019,
2571,,,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,CHEMBL617118,,8,1,H,12687,Autocuration,,,BAO_0000357,
2572,Rattus norvegicus,,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,CHEMBL617119,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2573,Rattus norvegicus,,B,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,CHEMBL617120,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2574,Rattus norvegicus,,F,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617121,10116.0,9,1,D,12687,Expert,,,BAO_0000219,
2575,,,F,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617122,,8,1,H,12687,Autocuration,,,BAO_0000219,
2576,,,B,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,CHEMBL617123,,8,1,H,12687,Autocuration,,,BAO_0000019,
2577,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,CHEMBL617124,,8,1,H,12687,Expert,,,BAO_0000019,
2578,,,B,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,CHEMBL617600,,8,1,H,12687,Expert,,,BAO_0000249,
2579,,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,CHEMBL617601,,8,1,H,12687,Expert,,,BAO_0000357,
2580,,,B,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,CHEMBL882923,,8,1,H,12687,Expert,,,BAO_0000019,
2581,,,B,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617602,,8,1,H,12687,Autocuration,,,BAO_0000357,
2582,,,B,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,CHEMBL617603,,8,1,H,12687,Autocuration,,,BAO_0000019,
2583,,,B,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617604,,8,1,H,12687,Autocuration,,,BAO_0000357,
2584,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617605,,8,1,H,12687,Expert,,,BAO_0000019,
2585,,,B,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,CHEMBL617606,,8,1,H,12687,Expert,,,BAO_0000019,
2586,Rattus norvegicus,,B,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,CHEMBL617607,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2587,,,B,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617455,,8,1,H,12687,Autocuration,,,BAO_0000249,
2588,Rattus norvegicus,,B,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,CHEMBL617456,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2589,,,B,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,CHEMBL617457,,8,1,H,12687,Expert,,,BAO_0000357,
2590,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617458,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2591,Rattus norvegicus,,B,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,CHEMBL617459,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2592,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,CHEMBL617460,,8,1,H,12687,Expert,,,BAO_0000357,
2593,,,B,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,CHEMBL617461,,8,1,H,12687,Expert,,,BAO_0000357,
2594,Rattus norvegicus,,B,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,CHEMBL617462,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2595,,,B,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,CHEMBL617463,,8,1,H,12687,Autocuration,,,BAO_0000357,
2596,,,B,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,CHEMBL617464,,8,1,H,12687,Autocuration,,,BAO_0000019,
2597,,,B,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,CHEMBL617465,,8,1,H,12687,Autocuration,,,BAO_0000019,
2598,,,B,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,CHEMBL617466,,8,1,H,12687,Expert,,,BAO_0000019,
2599,,,B,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,CHEMBL617467,,8,1,H,12687,Autocuration,,,BAO_0000019,
2600,,,B,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,CHEMBL617468,,8,1,H,12687,Expert,,,BAO_0000019,
2601,,,B,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,CHEMBL617469,,8,1,H,12687,Autocuration,,,BAO_0000019,
2602,,,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,CHEMBL617470,,8,1,H,12687,Autocuration,,,BAO_0000019,
2603,,,B,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,CHEMBL617471,,8,1,H,12687,Autocuration,,,BAO_0000019,
2604,,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,CHEMBL617472,,8,1,H,12687,Expert,,723.0,BAO_0000219,
2605,,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,CHEMBL617473,,8,1,H,12687,Expert,,,BAO_0000357,
2606,Rattus norvegicus,,B,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617474,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2607,Rattus norvegicus,,B,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617475,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2608,,,B,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,CHEMBL617476,,8,1,H,12687,Autocuration,,,BAO_0000221,955.0
2609,,,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617477,,8,1,H,12687,Expert,,,BAO_0000357,
2610,,,B,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617478,,8,1,H,12687,Expert,,723.0,BAO_0000219,
2611,,,F,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,CHEMBL617479,,8,1,H,12687,Autocuration,,,BAO_0000221,
2612,,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,CHEMBL617480,,8,1,H,12687,Autocuration,,,BAO_0000357,
2613,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617481,,8,1,H,12687,Expert,,,BAO_0000357,
2614,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,CHEMBL617482,,8,1,H,12687,Expert,,,BAO_0000019,
2615,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,CHEMBL617483,,8,1,H,12687,Autocuration,,,BAO_0000019,
2616,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL621528,,8,1,H,12687,Autocuration,,,BAO_0000357,
2617,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,CHEMBL621529,10116.0,9,1,D,12687,Expert,,723.0,BAO_0000219,
2618,,,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL621530,,8,1,H,12687,Expert,,,BAO_0000357,
2619,,,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL621531,,8,1,H,12687,Expert,,,BAO_0000357,
2620,Rattus norvegicus,,B,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,CHEMBL621532,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2621,,,B,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL621533,,8,1,H,12687,Expert,,,BAO_0000357,
2622,,,B,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL621534,,8,1,H,12687,Expert,,449.0,BAO_0000219,
2623,,,B,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,CHEMBL621535,,8,1,H,12687,Autocuration,,,BAO_0000019,
2624,,,B,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,CHEMBL621536,,8,1,H,12687,Autocuration,,,BAO_0000357,
2625,,,B,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,CHEMBL621537,,8,1,H,12687,Autocuration,,,BAO_0000357,
2626,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 2A receptor,,CHEMBL621538,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2627,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,CHEMBL621539,,8,1,H,12687,Autocuration,,,BAO_0000019,
2628,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,CHEMBL621540,,8,1,H,12687,Autocuration,,,BAO_0000019,
2629,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,CHEMBL621541,,8,1,H,12687,Autocuration,,,BAO_0000019,
2630,,,B,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,CHEMBL621542,,8,1,H,12687,Autocuration,,,BAO_0000019,
2631,,,B,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,CHEMBL621543,,8,1,H,12687,Expert,,,BAO_0000357,
2632,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,CHEMBL621544,,8,1,H,12687,Expert,,,BAO_0000357,
2633,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,CHEMBL621545,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2634,,,B,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL621546,,8,1,H,12687,Autocuration,,,BAO_0000357,
2635,,,B,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,CHEMBL621547,,8,1,H,12687,Autocuration,,,BAO_0000357,
2636,,,B,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,CHEMBL618692,,8,1,H,12687,Expert,,723.0,BAO_0000219,
2637,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL618693,,8,1,H,12687,Autocuration,,,BAO_0000357,
2638,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL872922,,8,1,H,12687,Autocuration,,,BAO_0000357,
2639,,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,CHEMBL618694,,8,1,H,12687,Autocuration,,,BAO_0000357,
2640,Rattus norvegicus,,B,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,CHEMBL618695,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2641,,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,CHEMBL618696,,8,1,H,12687,Autocuration,,,BAO_0000357,
2642,,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,CHEMBL618697,,8,1,H,12687,Expert,,,BAO_0000357,
2643,,,B,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,CHEMBL618892,,8,1,H,12687,Autocuration,,,BAO_0000357,
2644,,,B,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,CHEMBL618893,,8,1,H,12687,Autocuration,,,BAO_0000357,
2645,,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,CHEMBL618894,,8,1,H,12687,Autocuration,,,BAO_0000357,
2646,,,B,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,CHEMBL618895,,8,1,H,12687,Expert,,723.0,BAO_0000219,
2647,Rattus norvegicus,,B,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,CHEMBL618896,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2648,,,B,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,CHEMBL618897,,8,1,H,12687,Autocuration,,,BAO_0000019,5383.0
2649,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,CHEMBL618898,,8,1,H,12687,Autocuration,,,BAO_0000357,
2650,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,CHEMBL618899,,8,1,H,12687,Autocuration,,,BAO_0000357,
2651,,,B,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,CHEMBL618900,,8,1,H,12687,Autocuration,,,BAO_0000357,
2652,,,B,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,CHEMBL618901,,8,1,H,12687,Autocuration,,,BAO_0000019,
2653,,,B,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,CHEMBL618902,,8,1,H,12687,Autocuration,,,BAO_0000357,
2654,Rattus norvegicus,,B,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,CHEMBL618903,10116.0,9,1,D,12687,Expert,,,BAO_0000221,10000000.0
2655,,,B,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,CHEMBL618904,,8,1,H,12687,Autocuration,,,BAO_0000357,
2656,,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,CHEMBL618905,,8,1,H,12687,Autocuration,,,BAO_0000357,
2657,,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,CHEMBL618906,,8,1,H,12687,Autocuration,,,BAO_0000357,
2658,,,B,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,CHEMBL618907,,8,1,H,12687,Expert,,723.0,BAO_0000219,
2659,,,B,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,CHEMBL618908,,8,1,H,12687,Autocuration,,,BAO_0000019,
2660,,,B,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,CHEMBL617909,,8,1,H,12687,Autocuration,,,BAO_0000357,
2661,,,B,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,CHEMBL617910,,8,1,H,12687,Expert,,,BAO_0000019,
2662,,,B,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,CHEMBL617911,,8,1,H,12687,Autocuration,,,BAO_0000221,955.0
2663,,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL872923,,8,1,H,12687,Autocuration,,,BAO_0000249,
2664,,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617912,,8,1,H,12687,Autocuration,,,BAO_0000249,
2665,Rattus norvegicus,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,CHEMBL617913,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2666,,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617914,,8,1,H,12687,Expert,,,BAO_0000249,
2667,,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617915,,8,1,H,12687,Autocuration,,,BAO_0000249,
2668,,,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617916,,8,1,H,12687,Autocuration,,,BAO_0000249,
2669,Rattus norvegicus,,B,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,CHEMBL617917,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2670,,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,CHEMBL617918,,8,1,H,12687,Expert,,,BAO_0000019,
2671,,,B,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,CHEMBL617919,,8,1,H,12687,Autocuration,,,BAO_0000019,
2672,Rattus norvegicus,,B,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,CHEMBL617920,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2673,Rattus norvegicus,,B,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,CHEMBL617921,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2674,Rattus norvegicus,,B,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,CHEMBL617922,10116.0,5,1,D,105102,Expert,,,BAO_0000224,
2675,,,B,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL617923,,8,1,H,12687,Autocuration,,,BAO_0000357,
2676,,,B,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617924,,8,1,H,12687,Autocuration,,,BAO_0000357,
2677,,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,CHEMBL617925,,8,1,H,12687,Autocuration,,,BAO_0000357,
2678,Rattus norvegicus,,B,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,CHEMBL617926,10116.0,9,1,D,12687,Expert,,,BAO_0000357,
2679,,,B,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,CHEMBL617927,,8,1,H,12687,Autocuration,,,BAO_0000357,
2680,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617928,,8,1,H,12687,Autocuration,,,BAO_0000357,
2681,Rattus norvegicus,,B,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617929,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2682,,,B,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,CHEMBL617930,,8,1,H,12687,Expert,,,BAO_0000019,
2683,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,CHEMBL617931,,8,1,H,12687,Autocuration,,,BAO_0000019,
2684,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,CHEMBL617932,,8,1,H,12687,Autocuration,,,BAO_0000019,
2685,,,B,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,CHEMBL617933,,8,1,H,12687,Autocuration,,449.0,BAO_0000219,
2686,,,B,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,CHEMBL617934,,8,1,H,12687,Autocuration,,,BAO_0000019,
2687,,,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,CHEMBL617935,,8,1,H,12687,Autocuration,,,BAO_0000019,
2688,,,B,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,CHEMBL617936,,8,1,H,12687,Autocuration,,,BAO_0000357,
2689,,,B,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,CHEMBL617937,,8,1,H,12687,Autocuration,,,BAO_0000019,
2690,,,B,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,CHEMBL617938,,8,1,H,12687,Autocuration,,,BAO_0000019,
2691,,,B,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,CHEMBL617939,,8,1,H,12687,Autocuration,,,BAO_0000218,
2692,,,B,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,CHEMBL617940,,8,1,H,12687,Autocuration,,,BAO_0000218,
2693,,,B,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,CHEMBL617941,,8,1,H,12687,Autocuration,,,BAO_0000218,
2694,,,B,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,CHEMBL617942,,8,1,H,12687,Expert,,,BAO_0000357,
2695,,,B,Ratio of pKi of 5-HT2A to that of D2 receptor,,CHEMBL617943,,8,1,H,12687,Expert,,,BAO_0000357,
2696,,,B,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,CHEMBL617944,,4,1,H,105093,Expert,,,BAO_0000224,
2697,,,B,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,CHEMBL617945,,4,1,H,105093,Expert,,,BAO_0000224,
2698,,,B,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,CHEMBL617946,,4,1,H,105075,Expert,,,BAO_0000224,
2699,,,B,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,CHEMBL617947,,8,1,H,12687,Autocuration,,,BAO_0000357,
2700,,,B,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,CHEMBL617948,,8,1,H,12687,Expert,,,BAO_0000357,
2701,,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,CHEMBL858116,,8,1,H,12687,Autocuration,,,BAO_0000019,
2702,,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,CHEMBL617949,,8,1,H,12687,Autocuration,,,BAO_0000019,
2703,,,F,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,CHEMBL617950,,8,1,H,12687,Autocuration,,,BAO_0000019,
2704,,,F,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,CHEMBL617951,,8,1,H,12687,Expert,,,BAO_0000019,1515.0
2705,,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,CHEMBL617952,,8,1,H,12687,Expert,,,BAO_0000019,1515.0
2706,,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,CHEMBL617953,,8,1,H,12687,Autocuration,,,BAO_0000019,1515.0
2707,,,B,Binding activity radioligand.,,CHEMBL617954,,8,1,H,12687,Autocuration,,,BAO_0000357,
2708,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617955,,8,1,H,12687,Expert,,,BAO_0000019,
2709,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,CHEMBL857071,,8,1,H,12687,Autocuration,,,BAO_0000019,
2710,,,B,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,CHEMBL617270,,8,1,H,12687,Expert,,,BAO_0000019,
2711,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,CHEMBL617271,,8,1,H,12687,Autocuration,,339.0,BAO_0000219,
2712,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,CHEMBL617272,,8,1,H,12687,Autocuration,,339.0,BAO_0000219,
2713,,,B,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,CHEMBL617273,,8,1,H,12687,Autocuration,,,BAO_0000019,
2714,Rattus norvegicus,,F,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,CHEMBL617274,10116.0,9,1,D,12687,Expert,,,BAO_0000019,
2715,,,B,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL617275,,8,1,H,108,Autocuration,,,BAO_0000357,
2716,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617276,,8,1,H,108,Autocuration,,,BAO_0000357,
2717,,,B,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,CHEMBL617277,,8,1,H,108,Autocuration,,,BAO_0000357,
2718,,,B,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,CHEMBL617278,,8,1,H,108,Expert,,,BAO_0000019,
2719,,,B,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,CHEMBL617279,,8,1,H,108,Expert,,,BAO_0000019,
2720,,,B,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,CHEMBL617280,,8,1,H,108,Expert,,,BAO_0000019,
2721,,,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL617281,,8,1,H,108,Autocuration,,,BAO_0000357,
2722,,,B,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL617282,,8,1,H,108,Autocuration,,,BAO_0000357,
2723,,,B,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,CHEMBL617283,,8,1,H,108,Expert,,,BAO_0000019,
2724,,,B,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,CHEMBL617284,,8,1,H,108,Expert,,,BAO_0000019,
2725,,,B,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,CHEMBL617285,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2726,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,CHEMBL617286,,8,1,H,108,Autocuration,,,BAO_0000019,
2727,Homo sapiens,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,CHEMBL617287,9606.0,9,1,D,108,Expert,,,BAO_0000357,
2728,,,B,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,CHEMBL617288,,8,1,H,108,Expert,,,BAO_0000357,
2729,,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,CHEMBL617289,,8,1,H,108,Autocuration,,,BAO_0000357,
2730,,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL872917,,8,1,H,108,Autocuration,,,BAO_0000357,
2731,,,B,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,CHEMBL617290,,8,1,H,108,Autocuration,,,BAO_0000357,
2732,,,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL617291,,8,1,H,108,Autocuration,,449.0,BAO_0000219,
2733,,,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,CHEMBL617292,,8,1,H,108,Autocuration,,449.0,BAO_0000219,
2734,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL617293,,8,1,H,108,Autocuration,,723.0,BAO_0000219,
2735,Homo sapiens,,F,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617294,9606.0,9,1,D,108,Expert,,449.0,BAO_0000219,
2736,,,B,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,CHEMBL617295,,8,1,H,108,Expert,,,BAO_0000019,
2737,,,B,Binding activity radioligand.,,CHEMBL617296,,8,1,H,108,Autocuration,,,BAO_0000357,
2738,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617297,,8,1,H,108,Autocuration,,,BAO_0000019,
2739,,,B,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,CHEMBL617298,,8,1,H,108,Expert,,449.0,BAO_0000219,
2740,,,B,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,CHEMBL617299,,8,1,H,108,Expert,,449.0,BAO_0000219,
2741,,,B,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,CHEMBL617300,,8,1,H,108,Autocuration,,449.0,BAO_0000219,
2742,,,B,Binding affinity against 5-HT2C receptor,,CHEMBL617454,,8,1,H,108,Autocuration,,,BAO_0000357,
2743,,,B,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,CHEMBL617505,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2744,Homo sapiens,,B,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,CHEMBL617506,9606.0,9,1,D,108,Expert,,722.0,BAO_0000219,
2745,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,CHEMBL617507,9606.0,9,1,D,108,Expert,,722.0,BAO_0000219,
2746,,,B,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,CHEMBL617508,,8,1,H,108,Expert,,,BAO_0000357,
2747,Homo sapiens,,B,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,CHEMBL857982,9606.0,9,1,D,108,Expert,,722.0,BAO_0000219,
2748,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,CHEMBL617509,9606.0,9,1,D,108,Expert,,722.0,BAO_0000219,
2749,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,CHEMBL617510,9606.0,9,1,D,108,Expert,,722.0,BAO_0000219,
2750,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,CHEMBL617511,,8,1,H,108,Autocuration,,,BAO_0000357,
2751,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617512,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2752,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617749,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2753,,,B,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL617750,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2754,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL617751,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2755,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617752,,8,1,H,108,Expert,,722.0,BAO_0000219,
2756,,,B,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,CHEMBL617753,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2757,,,B,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,CHEMBL617754,,8,1,H,108,Expert,,722.0,BAO_0000219,
2758,Homo sapiens,,B,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,CHEMBL617755,9606.0,9,1,D,108,Expert,,722.0,BAO_0000219,
2759,,,B,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,CHEMBL617756,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2760,,,B,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,CHEMBL617757,,8,1,H,108,Expert,,722.0,BAO_0000219,
2761,,,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,CHEMBL617758,,8,1,H,108,Expert,,722.0,BAO_0000219,
2762,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,CHEMBL617759,,8,1,H,108,Autocuration,,723.0,BAO_0000219,
2763,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,CHEMBL617760,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2764,,,B,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,CHEMBL617761,,8,1,H,108,Expert,,485.0,BAO_0000219,
2765,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617762,9606.0,9,1,D,108,Expert,,,BAO_0000357,
2766,,,B,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,CHEMBL617763,,8,1,H,108,Autocuration,,,BAO_0000357,
2767,,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,CHEMBL857983,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2768,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,CHEMBL617764,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2769,,,B,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,CHEMBL617765,,8,1,H,108,Autocuration,,308.0,BAO_0000219,
2770,,,F,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,CHEMBL617766,,8,1,H,108,Autocuration,,,BAO_0000019,
2771,,,F,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,CHEMBL617767,,8,1,H,108,Autocuration,,,BAO_0000221,10000000.0
2772,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,CHEMBL617768,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2773,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,CHEMBL617769,,8,1,H,108,Autocuration,,722.0,BAO_0000219,
2774,,,B,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,CHEMBL858023,,8,1,H,11864,Autocuration,,,BAO_0000357,
2775,,,B,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,CHEMBL617770,,8,1,H,11864,Autocuration,,,BAO_0000019,945.0
2776,,,B,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,CHEMBL617771,,8,1,H,11864,Autocuration,,,BAO_0000019,945.0
2777,,,F,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,CHEMBL617772,,8,1,H,11864,Autocuration,,625.0,BAO_0000219,
2778,,,B,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,CHEMBL617773,,8,1,H,11864,Autocuration,,723.0,BAO_0000219,
2779,,,B,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,CHEMBL617850,,8,1,H,11864,Autocuration,,723.0,BAO_0000219,
2780,,,B,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,CHEMBL617851,,8,1,H,11864,Autocuration,,723.0,BAO_0000219,
2781,,,F,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,CHEMBL617852,,8,1,H,11864,Autocuration,,,BAO_0000019,
2782,Mus musculus,,B,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,CHEMBL858024,10090.0,8,1,H,12689,Autocuration,,,BAO_0000019,945.0
2783,Rattus norvegicus,,B,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,CHEMBL617853,10116.0,9,1,D,12689,Expert,,,BAO_0000019,945.0
2784,,,B,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,CHEMBL617854,,8,1,H,108,Expert,,,BAO_0000357,
2785,Sus scrofa,,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL873477,9823.0,8,1,H,108,Expert,,,BAO_0000357,
2786,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617855,,8,1,H,108,Expert,,,BAO_0000357,
2787,,,B,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,CHEMBL617856,,8,1,H,108,Expert,,,BAO_0000019,
2788,,,B,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,CHEMBL617857,,8,1,H,108,Autocuration,,,BAO_0000019,
2789,,,B,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,CHEMBL617858,,8,1,H,108,Autocuration,,,BAO_0000249,
2790,,,B,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,CHEMBL617859,,8,1,H,108,Autocuration,,,BAO_0000357,
2791,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617860,,8,1,H,108,Autocuration,,,BAO_0000357,
2792,,,B,Binding activity radioligand.,,CHEMBL617861,,8,1,H,108,Autocuration,,,BAO_0000357,
2793,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617862,,8,1,H,108,Expert,,,BAO_0000019,
2794,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,CHEMBL617863,,8,1,H,108,Autocuration,,,BAO_0000019,
2795,,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,CHEMBL617864,,8,1,H,108,Autocuration,,,BAO_0000249,
2796,,,B,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,CHEMBL617649,,8,1,H,108,Autocuration,,,BAO_0000249,
2797,Sus scrofa,,F,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,CHEMBL617650,9823.0,8,1,H,108,Expert,,,BAO_0000019,
2798,Sus scrofa,,F,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,CHEMBL617651,9823.0,8,1,H,108,Expert,,,BAO_0000019,
2799,Sus scrofa,,B,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,CHEMBL617652,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
2800,Sus scrofa,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,CHEMBL857072,9823.0,8,1,H,108,Autocuration,,,BAO_0000019,
2801,Sus scrofa,,B,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,CHEMBL617653,9823.0,8,1,H,108,Autocuration,,,BAO_0000357,
2802,,,B,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617654,,8,1,H,12687,Autocuration,,,BAO_0000019,
2803,,,F,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,CHEMBL617655,,8,1,H,12689,Autocuration,,,BAO_0000019,
2804,,,B,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,CHEMBL617656,,8,1,H,12689,Expert,,,BAO_0000357,
2805,,,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,CHEMBL617657,,8,1,H,12689,Autocuration,,,BAO_0000357,
2806,,,B,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,CHEMBL617658,,8,1,H,12689,Autocuration,,,BAO_0000357,
2807,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,CHEMBL617659,10116.0,9,1,D,12689,Expert,,,BAO_0000357,
2808,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,CHEMBL617838,10116.0,9,1,D,12689,Expert,,,BAO_0000357,
2809,Rattus norvegicus,,B,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,CHEMBL617839,10116.0,9,1,D,12689,Expert,,,BAO_0000249,
2810,,,B,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,CHEMBL617840,,8,1,H,12689,Autocuration,,,BAO_0000357,
2811,,,B,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,CHEMBL617841,,8,1,H,12689,Autocuration,,,BAO_0000019,
2812,,,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,CHEMBL875915,,8,1,H,12689,Autocuration,,,BAO_0000019,
2813,,,B,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,CHEMBL617842,,8,1,H,12689,Expert,,,BAO_0000219,
2814,,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,CHEMBL617843,,8,1,H,12689,Expert,,723.0,BAO_0000219,
2815,,,B,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,CHEMBL617844,,8,1,H,12689,Expert,,,BAO_0000357,
2816,,,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL617845,,8,1,H,12689,Expert,,,BAO_0000357,
2817,,,B,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,CHEMBL617846,,8,1,H,12689,Expert,,723.0,BAO_0000219,
2818,,,B,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,CHEMBL617847,,8,1,H,12689,Autocuration,,,BAO_0000357,
2819,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617848,,8,1,H,12689,Expert,,,BAO_0000357,
2820,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL617849,,8,1,H,12689,Autocuration,,,BAO_0000357,
2821,,,B,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL621507,,8,1,H,12689,Expert,,,BAO_0000357,
2822,,,B,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,CHEMBL621508,,8,1,H,12689,Expert,,,BAO_0000357,
2823,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,CHEMBL621509,,8,1,H,12689,Autocuration,,,BAO_0000019,
2824,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,CHEMBL621510,,8,1,H,12689,Autocuration,,,BAO_0000019,
2825,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,CHEMBL621511,,8,1,H,12689,Autocuration,,,BAO_0000019,
2826,,,B,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,CHEMBL621512,,8,1,H,12689,Expert,,625.0,BAO_0000219,
2827,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL621513,,8,1,H,12689,Autocuration,,,BAO_0000357,
2828,,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,CHEMBL621514,,8,1,H,12689,Expert,,,BAO_0000357,
2829,,,B,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,CHEMBL621515,,8,1,H,12689,Expert,,,BAO_0000219,
2830,,,B,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,CHEMBL621516,,8,1,H,12689,Autocuration,,,BAO_0000219,
2831,,,B,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,CHEMBL621517,,8,1,H,12689,Autocuration,,,BAO_0000019,5383.0
2832,,,B,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,CHEMBL621518,,8,1,H,12689,Autocuration,,,BAO_0000357,
2833,,,B,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,CHEMBL621519,,8,1,H,12689,Autocuration,,,BAO_0000019,
2834,,,B,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,CHEMBL621520,,8,1,H,12689,Autocuration,,,BAO_0000357,
2835,,,B,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,CHEMBL621521,,8,1,H,12689,Autocuration,,,BAO_0000357,
2836,,,B,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,CHEMBL621522,,8,1,H,12689,Autocuration,,,BAO_0000357,
2837,,,B,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,CHEMBL621523,,8,1,H,12689,Expert,,,BAO_0000219,
2838,,,B,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,CHEMBL621524,,8,1,H,12689,Autocuration,,,BAO_0000357,
2839,Rattus norvegicus,,B,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,CHEMBL621525,10116.0,9,1,D,12689,Expert,,,BAO_0000357,
2840,,,B,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,CHEMBL872921,,8,1,H,12689,Autocuration,,,BAO_0000357,
2841,,,B,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621526,,8,1,H,12689,Autocuration,,,BAO_0000357,
2842,,,B,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,CHEMBL621527,,8,1,H,12689,Expert,,,BAO_0000219,
2843,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,CHEMBL617865,10116.0,9,1,D,12689,Expert,,,BAO_0000019,
2844,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617866,,8,1,H,12689,Autocuration,,,BAO_0000357,
2845,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,CHEMBL617867,,8,1,H,12689,Autocuration,,,BAO_0000019,
2846,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,CHEMBL617487,,8,1,H,12689,Autocuration,,,BAO_0000357,
2847,,,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL617488,,8,1,H,12689,Expert,,,BAO_0000357,
2848,,,B,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,CHEMBL617489,,8,1,H,12689,Autocuration,,,BAO_0000357,
2849,,,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,CHEMBL617490,,8,1,H,12689,Autocuration,,,BAO_0000019,
2850,,,B,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,CHEMBL617491,,8,1,H,12689,Autocuration,,,BAO_0000019,
2851,,,B,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,CHEMBL617492,,8,1,H,12689,Autocuration,,,BAO_0000019,
2852,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,CHEMBL617493,,8,1,H,12689,Autocuration,,,BAO_0000019,
2853,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,CHEMBL617494,,8,1,H,12689,Autocuration,,,BAO_0000357,
2854,Rattus norvegicus,,B,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,CHEMBL617495,10116.0,9,1,D,12689,Expert,,,BAO_0000019,
2855,,,B,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,CHEMBL617496,,8,1,H,12689,Autocuration,,,BAO_0000357,
2856,,,B,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,CHEMBL617497,,8,1,H,12689,Autocuration,,485.0,BAO_0000219,
2857,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL617498,,8,1,H,12689,Autocuration,,,BAO_0000357,
2858,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,CHEMBL617499,,8,1,H,12689,Autocuration,,,BAO_0000357,
2859,,,F,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,CHEMBL617500,,8,1,H,12689,Autocuration,,,BAO_0000019,
2860,,,B,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617501,,8,1,H,108,Autocuration,,,BAO_0000357,
2861,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617502,,8,1,H,108,Expert,,,BAO_0000357,
2862,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,CHEMBL617503,,8,1,H,227,Autocuration,,,BAO_0000357,
2863,,,B,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,CHEMBL617504,,8,1,H,227,Autocuration,,,BAO_0000357,
2864,,,B,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,CHEMBL617406,,8,1,H,227,Autocuration,,,BAO_0000357,
2865,Homo sapiens,,B,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,CHEMBL617407,9606.0,9,1,D,227,Expert,,,BAO_0000019,
2866,,,B,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,CHEMBL617408,,8,1,H,227,Autocuration,,,BAO_0000357,
2867,,,B,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,CHEMBL617409,,8,1,H,227,Autocuration,,,BAO_0000357,
2868,,,B,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,CHEMBL617410,,8,1,H,227,Autocuration,,,BAO_0000357,
2869,,,B,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,CHEMBL617411,,8,1,H,227,Autocuration,,,BAO_0000357,
2870,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,CHEMBL617412,,8,1,H,227,Autocuration,,,BAO_0000019,
2871,Homo sapiens,,B,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,CHEMBL617774,9606.0,9,1,D,227,Expert,,,BAO_0000357,
2872,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,CHEMBL617775,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2873,Homo sapiens,,B,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,CHEMBL617776,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2874,Homo sapiens,,F,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617777,9606.0,9,1,D,227,Expert,,449.0,BAO_0000219,
2875,Homo sapiens,,F,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617778,9606.0,9,1,D,227,Expert,,449.0,BAO_0000219,
2876,,,B,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617779,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2877,,,B,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,CHEMBL617780,,8,1,H,227,Expert,,722.0,BAO_0000219,
2878,,,B,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,CHEMBL617781,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2879,Homo sapiens,,B,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,CHEMBL617782,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2880,Homo sapiens,,B,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,CHEMBL617783,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2881,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617784,,8,1,H,227,Autocuration,,,BAO_0000357,
2882,,,B,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,CHEMBL617785,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2883,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,CHEMBL857984,,8,1,H,227,Expert,,722.0,BAO_0000219,
2884,,,B,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,CHEMBL617786,,8,1,H,227,Expert,,722.0,BAO_0000219,
2885,,,B,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,CHEMBL617787,,8,1,H,227,Expert,,722.0,BAO_0000219,
2886,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,CHEMBL617788,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2887,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,CHEMBL617789,9606.0,9,1,D,227,Expert,,722.0,BAO_0000219,
2888,,,B,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,CHEMBL617790,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2889,,,B,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,CHEMBL617791,,8,1,H,227,Expert,,485.0,BAO_0000219,
2890,,,B,Binding affinity against 5-hydroxytryptamine 2B receptor,,CHEMBL617608,,8,1,H,227,Expert,,,BAO_0000357,
2891,,,B,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,CHEMBL617609,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2892,,,B,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,CHEMBL617610,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2893,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,CHEMBL617611,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2894,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617612,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2895,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617613,,8,1,H,227,Autocuration,,722.0,BAO_0000219,
2896,Oryctolagus cuniculus,,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,CHEMBL617614,9986.0,8,1,H,227,Autocuration,,,BAO_0000019,
2897,,,B,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,CHEMBL617615,,8,1,H,12688,Expert,,,BAO_0000019,945.0
2898,,,B,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,CHEMBL858114,,8,1,H,12688,Expert,,,BAO_0000357,945.0
2899,,,B,Affinity against serotonergic receptor in the isolated rat stomach fundus,,CHEMBL617616,,8,1,H,12688,Autocuration,,,BAO_0000357,945.0
2900,Rattus norvegicus,,F,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,CHEMBL617617,10116.0,9,1,D,12688,Expert,,,BAO_0000019,945.0
2901,Rattus norvegicus,,F,Antagonistic against 5-hydroxytryptamine 2B receptor,,CHEMBL875914,10116.0,9,1,D,12688,Expert,,,BAO_0000019,
2902,,,F,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,CHEMBL617618,,8,1,H,12688,Autocuration,,,BAO_0000019,945.0
2903,Rattus norvegicus,,B,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,CHEMBL617619,10116.0,9,1,D,12688,Expert,,,BAO_0000357,945.0
2904,,,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,CHEMBL617620,,8,1,H,12688,Autocuration,,,BAO_0000019,
2905,,,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,CHEMBL617621,,8,1,H,12688,Autocuration,,,BAO_0000019,
2906,,,F,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,CHEMBL617622,,8,1,H,12688,Autocuration,,,BAO_0000019,
2907,Rattus norvegicus,,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617623,10116.0,9,1,D,12688,Expert,,,BAO_0000357,945.0
2908,Rattus norvegicus,,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617624,10116.0,9,1,D,12688,Expert,,,BAO_0000357,945.0
2909,Rattus norvegicus,,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617625,10116.0,9,1,D,12688,Expert,,,BAO_0000357,945.0
2910,Rattus norvegicus,,B,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617626,10116.0,9,1,D,12688,Expert,,,BAO_0000357,945.0
2911,,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617627,,8,1,H,12688,Autocuration,,,BAO_0000019,945.0
2912,,,F,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617628,,8,1,H,12688,Expert,,,BAO_0000019,945.0
2913,,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,CHEMBL617629,,8,1,H,12688,Autocuration,,,BAO_0000019,945.0
2914,,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,CHEMBL858115,,8,1,H,12688,Autocuration,,,BAO_0000019,945.0
2915,Rattus norvegicus,,F,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,CHEMBL617630,10116.0,9,1,D,12688,Expert,,,BAO_0000019,945.0
2916,,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,CHEMBL617631,,8,1,H,12688,Autocuration,,,BAO_0000019,1515.0
2917,,,B,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617632,,8,1,H,12688,Autocuration,,,BAO_0000357,
2918,,,B,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,CHEMBL617633,,8,1,H,12688,Expert,,,BAO_0000357,
2919,,,B,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617634,,8,1,H,12688,Autocuration,,,BAO_0000357,
2920,,,B,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617635,,8,1,H,12688,Autocuration,,,BAO_0000357,
2922,Rattus norvegicus,,F,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617637,10116.0,9,1,D,12688,Autocuration,,,BAO_0000019,945.0
2923,,,B,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL617638,,8,1,H,227,Autocuration,,,BAO_0000357,
2924,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617639,,8,1,H,227,Autocuration,,,BAO_0000357,
2925,,,B,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617640,,8,1,H,227,Autocuration,,,BAO_0000357,
2926,,,B,Evaluated for the binding affinity to 5-HT 2B receptor,,CHEMBL617641,,8,1,H,227,Autocuration,,,BAO_0000357,
2927,,,B,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,CHEMBL617642,,8,1,H,227,Autocuration,,,BAO_0000357,
2928,,,B,Binding affinities against 5-hydroxytryptamine 2B receptor,,CHEMBL617643,,8,1,H,227,Autocuration,,,BAO_0000357,
2929,,,B,Binding affinities towards 5-hydroxytryptamine 2B receptor,,CHEMBL617644,,8,1,H,227,Autocuration,,,BAO_0000357,
2930,,,B,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,CHEMBL617645,,8,1,H,227,Autocuration,,,BAO_0000357,
2931,,,B,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,CHEMBL617646,,8,1,H,108,Expert,,,BAO_0000357,
2932,Bos taurus,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,CHEMBL617647,9913.0,8,1,H,108,Autocuration,,,BAO_0000357,
2933,Bos taurus,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,CHEMBL617648,9913.0,8,1,H,108,Autocuration,,,BAO_0000357,
2934,Bos taurus,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,CHEMBL617875,9913.0,8,1,H,108,Autocuration,,,BAO_0000357,
2935,Bos taurus,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,CHEMBL617876,9913.0,8,1,H,108,Autocuration,,,BAO_0000357,
2936,Bos taurus,,B,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,CHEMBL617877,9913.0,8,1,H,108,Expert,,,BAO_0000357,
2937,Bos taurus,,B,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,CHEMBL617878,9913.0,8,1,H,108,Expert,,,BAO_0000357,
2938,Bos taurus,,B,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,CHEMBL617879,9913.0,8,1,H,108,Autocuration,,,BAO_0000357,
2939,Cavia porcellus,,B,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,CHEMBL617880,10141.0,8,1,H,108,Autocuration,,,BAO_0000019,
2940,Cavia porcellus,,B,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,CHEMBL617881,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
2941,,,B,Binding affinity against 5-HT1A receptor,,CHEMBL857073,,8,1,H,51,Autocuration,,,BAO_0000357,
2942,,,F,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,CHEMBL617882,,8,1,H,108,Expert,,449.0,BAO_0000219,
2943,Homo sapiens,,F,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617883,9606.0,9,1,D,108,Expert,,449.0,BAO_0000219,
2944,,,F,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,CHEMBL617884,,8,1,H,108,Autocuration,,,BAO_0000219,
2945,,,B,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,CHEMBL617885,,8,1,H,108,Autocuration,,449.0,BAO_0000219,
2946,,,B,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,CHEMBL617886,,8,1,H,108,Autocuration,,449.0,BAO_0000219,
2947,Homo sapiens,,B,Inhibition of human 5-hydroxytryptamine 2C receptor,,CHEMBL617887,9606.0,9,1,D,108,Expert,,,BAO_0000357,
2948,,,B,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,CHEMBL617888,,8,1,H,108,Autocuration,,,BAO_0000357,
2949,,,B,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,CHEMBL617889,,8,1,H,108,Autocuration,,,BAO_0000019,
2950,,,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,CHEMBL617890,,8,1,H,108,Autocuration,,,BAO_0000357,
2951,,,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,CHEMBL617891,,8,1,H,108,Autocuration,,,BAO_0000357,
2952,,,B,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,CHEMBL617892,,8,1,H,108,Autocuration,,,BAO_0000357,
2953,,,B,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,CHEMBL617893,,8,1,H,108,Expert,,449.0,BAO_0000219,
2954,,,B,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,CHEMBL617894,,8,1,H,108,Expert,,449.0,BAO_0000219,
2955,,,B,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL617895,,8,1,H,108,Expert,,449.0,BAO_0000219,
2956,,,B,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,CHEMBL617896,,8,1,H,108,Autocuration,,449.0,BAO_0000219,
2957,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,CHEMBL617897,9606.0,9,1,D,108,Expert,,,BAO_0000357,
2958,,,F,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,CHEMBL617898,,8,1,H,108,Autocuration,,,BAO_0000019,
2959,,,F,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL617899,,8,1,H,108,Autocuration,,,BAO_0000019,
2960,Rattus norvegicus,,B,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,CHEMBL617900,10116.0,8,1,H,108,Expert,,449.0,BAO_0000219,
2961,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,CHEMBL617901,,8,1,H,108,Autocuration,,,BAO_0000019,
2962,,,F,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,CHEMBL617902,,8,1,H,108,Autocuration,,,BAO_0000019,
2963,,,F,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL617903,,8,1,H,108,Autocuration,,,BAO_0000019,
2964,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,CHEMBL617904,,8,1,H,108,Autocuration,,,BAO_0000357,
2965,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,CHEMBL617905,,8,1,H,108,Autocuration,,,BAO_0000357,
2966,,,B,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,CHEMBL617906,,8,1,H,108,Autocuration,,,BAO_0000357,
2967,,,B,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,CHEMBL617907,,8,1,H,108,Autocuration,,,BAO_0000357,
2968,,,B,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,CHEMBL617908,,8,1,H,108,Autocuration,,,BAO_0000357,
2969,,,B,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL620617,,8,1,H,108,Expert,,449.0,BAO_0000219,
2970,Homo sapiens,,B,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,CHEMBL620618,9606.0,9,1,D,108,Expert,,,BAO_0000019,
2971,,,B,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,CHEMBL620619,,8,1,H,108,Expert,,,BAO_0000357,
2972,Homo sapiens,,B,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL620620,9606.0,9,1,D,108,Expert,,,BAO_0000357,
2973,,,B,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,CHEMBL620621,,8,1,H,108,Autocuration,,,BAO_0000357,
2974,Rattus norvegicus,,B,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,CHEMBL872920,10116.0,7,1,D,104698,Autocuration,,,BAO_0000249,
2975,,,B,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,CHEMBL620622,,6,1,H,104698,Autocuration,,,BAO_0000223,
2976,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,CHEMBL620623,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
2977,,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,CHEMBL620624,,6,1,H,104698,Autocuration,,,BAO_0000019,
2978,,,B,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,CHEMBL620625,,6,1,H,104698,Autocuration,,,BAO_0000019,
2979,,,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,CHEMBL620626,,6,1,H,104698,Autocuration,,,BAO_0000219,
2980,,,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,CHEMBL621307,,6,1,H,104698,Autocuration,,,BAO_0000019,
2981,,,B,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,CHEMBL621308,,6,1,H,104698,Autocuration,,,BAO_0000019,
2982,,,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,CHEMBL621309,,6,1,H,104698,Autocuration,,,BAO_0000223,
2983,,,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,CHEMBL621310,,6,1,H,104698,Autocuration,,,BAO_0000223,
2984,,,B,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,CHEMBL621311,,6,1,H,104698,Autocuration,,,BAO_0000223,
2985,,,B,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,CHEMBL621502,,6,1,H,104698,Autocuration,,,BAO_0000249,
2986,,,B,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,CHEMBL621503,,6,1,H,104698,Autocuration,,,BAO_0000249,
2987,,,B,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,CHEMBL621504,,6,1,H,104698,Autocuration,,,BAO_0000249,
2988,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,CHEMBL621505,,6,1,H,104698,Autocuration,,,BAO_0000223,
2989,,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,CHEMBL621506,,6,1,H,104698,Autocuration,,,BAO_0000019,
2990,,,B,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,CHEMBL619781,,6,1,H,104698,Autocuration,,,BAO_0000223,
2991,,,B,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,CHEMBL619782,,6,1,H,104698,Autocuration,,,BAO_0000223,
2992,,,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,CHEMBL619783,,6,1,H,104698,Autocuration,,,BAO_0000019,
2993,Rattus norvegicus,,B,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,CHEMBL619784,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
2994,,,B,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL619785,,6,1,H,104698,Autocuration,,,BAO_0000249,
2995,,,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,CHEMBL619786,,6,1,H,104698,Autocuration,,,BAO_0000223,
2996,,,B,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,CHEMBL619787,,6,1,H,104698,Autocuration,,,BAO_0000019,
2997,,,B,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,CHEMBL872925,,6,1,H,104698,Autocuration,,,BAO_0000019,
2998,,,B,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,CHEMBL619788,,6,1,H,104698,Autocuration,,,BAO_0000019,
2999,,,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,CHEMBL619789,,6,1,H,104698,Autocuration,,,BAO_0000249,
3000,,,B,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,CHEMBL619790,,6,1,H,104698,Autocuration,,,BAO_0000249,
3001,,,B,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,CHEMBL619791,,6,1,H,104698,Autocuration,,,BAO_0000019,
3002,,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,CHEMBL619792,,6,1,H,104698,Autocuration,,,BAO_0000019,
3003,,,B,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,CHEMBL619793,,6,1,H,104698,Autocuration,,,BAO_0000249,
3004,Rattus norvegicus,,B,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL619794,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3005,,,B,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,CHEMBL619795,,6,1,H,104698,Autocuration,,,BAO_0000221,955.0
3006,,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,CHEMBL619796,,6,1,H,104698,Autocuration,,,BAO_0000019,
3007,,,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,CHEMBL620448,,6,1,H,104698,Autocuration,,,BAO_0000223,
3008,,,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,CHEMBL620449,,6,1,H,104698,Autocuration,,,BAO_0000223,
3009,,,B,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,CHEMBL620450,,6,1,H,104698,Autocuration,,,BAO_0000223,
3010,,,B,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,CHEMBL620451,,6,1,H,104698,Autocuration,,,BAO_0000223,
3011,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,CHEMBL620631,,6,1,H,104698,Autocuration,,,BAO_0000223,
3012,,,B,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,CHEMBL620632,,6,1,H,104698,Autocuration,,,BAO_0000019,
3013,,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,CHEMBL620633,,6,1,H,104698,Autocuration,,,BAO_0000019,
3014,,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,CHEMBL620634,,6,1,H,104698,Autocuration,,,BAO_0000223,
3015,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,CHEMBL620635,,6,1,H,104698,Autocuration,,,BAO_0000019,
3016,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620636,,6,1,H,104698,Autocuration,,,BAO_0000218,
3017,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620637,,6,1,H,104698,Autocuration,,,BAO_0000218,
3018,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620638,,6,1,H,104698,Autocuration,,,BAO_0000218,
3019,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620639,,6,1,H,104698,Autocuration,,,BAO_0000218,
3020,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620640,,6,1,H,104698,Autocuration,,,BAO_0000218,
3021,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620641,,6,1,H,104698,Autocuration,,,BAO_0000218,
3022,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,CHEMBL620642,,6,1,H,104698,Autocuration,,,BAO_0000218,
3023,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620643,,6,1,H,104698,Autocuration,,,BAO_0000218,
3024,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620644,,6,1,H,104698,Autocuration,,,BAO_0000218,
3025,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620645,,6,1,H,104698,Autocuration,,,BAO_0000218,
3026,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620646,,6,1,H,104698,Autocuration,,,BAO_0000218,
3027,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620647,,6,1,H,104698,Autocuration,,,BAO_0000218,
3028,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620648,,6,1,H,104698,Autocuration,,,BAO_0000218,
3029,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620649,,6,1,H,104698,Autocuration,,,BAO_0000218,
3030,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620650,,6,1,H,104698,Autocuration,,,BAO_0000218,
3031,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620651,,6,1,H,104698,Autocuration,,,BAO_0000218,
3032,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL872875,,6,1,H,104698,Autocuration,,,BAO_0000218,
3033,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620652,,6,1,H,104698,Autocuration,,,BAO_0000218,
3034,,,F,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,CHEMBL620653,,6,1,H,104698,Autocuration,,,BAO_0000019,
3035,,,B,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,CHEMBL857076,,6,1,H,104698,Autocuration,,,BAO_0000019,
3036,Rattus norvegicus,,B,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,CHEMBL620654,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3037,,,B,Binding activity radioligand.,,CHEMBL620655,,6,1,H,104698,Autocuration,,,BAO_0000223,
3038,,,B,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,CHEMBL620656,,6,1,H,104698,Autocuration,,,BAO_0000249,
3039,,,B,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,CHEMBL620657,,6,1,H,104698,Autocuration,,,BAO_0000249,
3040,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,CHEMBL620658,,8,1,H,108,Autocuration,,,BAO_0000357,
3041,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,CHEMBL620659,,8,1,H,108,Autocuration,,,BAO_0000357,
3042,,,B,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,CHEMBL620660,,8,1,H,108,Autocuration,,,BAO_0000357,
3043,,,B,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,CHEMBL620661,,8,1,H,108,Autocuration,,,BAO_0000357,
3044,,,B,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,CHEMBL620662,,8,1,H,108,Autocuration,,,BAO_0000357,
3045,,,B,Affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL620663,,8,1,H,108,Expert,,,BAO_0000357,
3046,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL620664,,8,1,H,108,Autocuration,,,BAO_0000357,
3047,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,CHEMBL620665,,8,1,H,108,Expert,,,BAO_0000357,
3048,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,CHEMBL620666,,8,1,H,108,Autocuration,,,BAO_0000357,
3049,,,B,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,CHEMBL620667,,8,1,H,108,Autocuration,,,BAO_0000357,
3050,,,B,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,CHEMBL620668,,8,1,H,108,Expert,,,BAO_0000357,
3051,,,B,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,CHEMBL620669,,8,1,H,108,Autocuration,,,BAO_0000357,
3052,,,B,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL620670,,8,1,H,108,Expert,,,BAO_0000357,
3053,,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,CHEMBL620671,,8,1,H,108,Autocuration,,,BAO_0000357,
3054,,,B,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,CHEMBL620672,,8,1,H,108,Autocuration,,,BAO_0000357,
3055,,,B,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,CHEMBL620673,,8,1,H,108,Autocuration,,,BAO_0000357,
3056,,,B,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,CHEMBL620674,,8,1,H,108,Autocuration,,,BAO_0000357,
3057,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,CHEMBL620675,,8,1,H,108,Autocuration,,,BAO_0000357,
3058,,,B,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,CHEMBL620676,,8,1,H,108,Autocuration,,,BAO_0000357,
3059,,,B,Affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621382,,8,1,H,108,Autocuration,,,BAO_0000357,
3060,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621383,9606.0,9,1,D,108,Expert,,,BAO_0000357,
3061,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,CHEMBL621384,,8,1,H,108,Autocuration,,,BAO_0000357,
3062,Bos taurus,,B,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,CHEMBL621385,9913.0,8,1,H,144,Autocuration,,,BAO_0000357,
3063,Bos taurus,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,CHEMBL617989,9913.0,8,1,H,144,Autocuration,,,BAO_0000357,
3064,Cavia porcellus,,F,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,CHEMBL617990,10141.0,4,1,H,104714,Expert,,,BAO_0000019,
3065,Cavia porcellus,,B,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,CHEMBL875085,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3066,Cavia porcellus,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,CHEMBL617991,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3067,Cavia porcellus,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,CHEMBL617992,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3068,Cavia porcellus,,B,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,CHEMBL617993,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3069,Cavia porcellus,,B,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,CHEMBL617994,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3070,Cavia porcellus,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,CHEMBL617995,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3071,Cavia porcellus,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,CHEMBL617996,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3072,Cavia porcellus,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,CHEMBL617997,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3073,Cavia porcellus,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,CHEMBL617998,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3074,Cavia porcellus,,F,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,CHEMBL617999,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3075,Cavia porcellus,,F,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,CHEMBL618000,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3076,Cavia porcellus,,F,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,CHEMBL617815,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3077,Cavia porcellus,,F,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,CHEMBL617816,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3078,Cavia porcellus,,F,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,CHEMBL617817,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3079,Cavia porcellus,,B,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,CHEMBL617818,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3080,Cavia porcellus,,B,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,CHEMBL617819,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3081,Cavia porcellus,,B,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,CHEMBL617820,10141.0,4,1,H,104714,Autocuration,,,BAO_0000223,
3082,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617821,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3083,Cavia porcellus,,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617822,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3084,Cavia porcellus,,F,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,CHEMBL617823,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3085,Cavia porcellus,,F,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,CHEMBL617824,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3086,Cavia porcellus,,F,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,CHEMBL617825,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3087,Cavia porcellus,,F,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,CHEMBL617826,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3088,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617827,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3089,Cavia porcellus,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617828,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3090,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617829,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3091,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,CHEMBL617830,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3092,Cavia porcellus,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,CHEMBL617831,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3093,Cavia porcellus,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,CHEMBL617832,10141.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3094,Cavia porcellus,,B,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,CHEMBL617833,10141.0,0,1,U,22226,Autocuration,,,BAO_0000019,
3095,,,B,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,CHEMBL617834,,8,1,H,51,Autocuration,,,BAO_0000357,
3096,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,CHEMBL617835,9606.0,5,1,D,104714,Expert,,,BAO_0000223,
3097,,,B,Binding affinity towards 5-HT3 receptor,,CHEMBL617836,,4,1,H,104714,Autocuration,,,BAO_0000223,
3098,,,B,Binding activity radioligand.,,CHEMBL617837,,4,1,H,104714,Autocuration,,,BAO_0000223,
3099,,,B,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL620392,,4,1,H,104714,Autocuration,,,BAO_0000019,
3100,,,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,CHEMBL620393,,4,1,H,104714,Autocuration,,,BAO_0000223,
3101,,,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,CHEMBL620394,,4,1,H,104714,Autocuration,,,BAO_0000223,
3102,,,B,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,CHEMBL620395,,4,1,H,104714,Autocuration,,,BAO_0000223,
3103,,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,CHEMBL620396,,0,1,U,22226,Autocuration,,,BAO_0000019,
3104,,,B,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,CHEMBL620582,,4,1,H,105030,Expert,,433.0,BAO_0000219,
3105,,,B,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,CHEMBL620583,,4,1,H,105030,Autocuration,,,BAO_0000218,
3106,,,B,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,CHEMBL620584,,4,1,H,105030,Autocuration,,,BAO_0000019,
3107,,,B,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,CHEMBL620585,,4,1,H,105030,Autocuration,,,BAO_0000224,
3108,,,B,Compound was evaluated for the binding affinity at 5- HT3 receptor,,CHEMBL620586,,4,1,H,105030,Autocuration,,,BAO_0000224,
3109,,,B,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,CHEMBL620587,,4,1,H,105030,Autocuration,,,BAO_0000019,
3110,,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,CHEMBL620588,,4,1,H,105030,Autocuration,,,BAO_0000019,
3111,,,F,5-hydroxytryptamine 3 receptor agonism in mouse,,CHEMBL620589,,4,1,H,105030,Autocuration,,,BAO_0000218,
3112,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,CHEMBL620590,,4,1,H,105030,Autocuration,,,BAO_0000219,
3113,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,CHEMBL617956,,4,1,H,105030,Autocuration,,,BAO_0000019,
3114,,,B,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,CHEMBL617957,,4,1,H,105030,Autocuration,,,BAO_0000019,
3115,,,B,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,CHEMBL617958,,4,1,H,105030,Autocuration,,,BAO_0000224,
3116,,,B,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,CHEMBL617959,,4,1,H,105030,Autocuration,,,BAO_0000219,
3117,,,B,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,CHEMBL617960,,4,1,H,105030,Autocuration,,,BAO_0000219,
3118,,,B,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,CHEMBL617961,,4,1,H,105030,Autocuration,,,BAO_0000224,
3119,,,B,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,CHEMBL617962,,4,1,H,105030,Autocuration,,,BAO_0000219,
3120,,,B,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,CHEMBL617963,,4,1,H,105030,Autocuration,,339.0,BAO_0000219,
3121,,,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,CHEMBL617964,,8,1,H,11765,Autocuration,,,BAO_0000019,
3122,,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,CHEMBL617965,,8,1,H,11765,Autocuration,,,BAO_0000219,
3123,Mus musculus,,B,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,CHEMBL617966,10090.0,9,1,D,10630,Autocuration,,,BAO_0000357,
3124,,,B,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL857074,,8,1,H,17106,Autocuration,,,BAO_0000019,
3125,Sus scrofa,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,CHEMBL617967,9823.0,8,1,H,144,Autocuration,,,BAO_0000357,
3126,Sus scrofa,,B,Binding activity radioligand.,,CHEMBL617968,9823.0,8,1,H,144,Autocuration,,,BAO_0000357,
3127,Oryctolagus cuniculus,,B,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,CHEMBL617969,9986.0,4,1,H,104714,Autocuration,,,BAO_0000223,
3128,Oryctolagus cuniculus,,B,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,CHEMBL617970,9986.0,4,1,H,104714,Autocuration,,,BAO_0000223,
3129,Oryctolagus cuniculus,,B,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,CHEMBL617971,9986.0,4,1,H,104714,Autocuration,,,BAO_0000223,
3130,Oryctolagus cuniculus,,B,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,CHEMBL617972,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3131,Oryctolagus cuniculus,,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617973,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3132,Oryctolagus cuniculus,,F,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617974,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3133,Oryctolagus cuniculus,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617975,9986.0,4,1,H,104714,Autocuration,,,BAO_0000221,2116.0
3134,Oryctolagus cuniculus,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617976,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3135,Oryctolagus cuniculus,,F,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617977,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3136,Oryctolagus cuniculus,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617978,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3137,Oryctolagus cuniculus,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617979,9986.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3138,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL617980,9986.0,4,1,H,104714,Autocuration,,449.0,BAO_0000219,
3139,Rattus norvegicus,,B,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,CHEMBL617981,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3140,,,B,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,CHEMBL617982,,8,1,H,12020,Autocuration,,,BAO_0000019,
3141,,,B,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,CHEMBL617983,,8,1,H,12020,Autocuration,,,BAO_0000357,
3142,Rattus norvegicus,,B,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,CHEMBL617984,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3143,,,B,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,CHEMBL617985,,6,1,H,104698,Autocuration,,,BAO_0000019,
3144,,,F,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,CHEMBL617986,,6,1,H,104698,Autocuration,,,BAO_0000218,948.0
3145,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,CHEMBL617987,,6,1,H,104698,Autocuration,,,BAO_0000019,948.0
3146,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,CHEMBL617988,,6,1,H,104698,Autocuration,,,BAO_0000019,948.0
3147,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,CHEMBL617792,,6,1,H,104698,Autocuration,,,BAO_0000019,948.0
3148,,,F,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,CHEMBL617793,,6,1,H,104698,Autocuration,,,BAO_0000019,948.0
3149,,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617794,,6,1,H,104698,Autocuration,,,BAO_0000019,
3150,,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617795,,6,1,H,104698,Autocuration,,,BAO_0000019,
3151,,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617796,,6,1,H,104698,Autocuration,,,BAO_0000019,
3152,,,F,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617797,,6,1,H,104698,Autocuration,,,BAO_0000019,
3153,Rattus norvegicus,,F,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,CHEMBL617798,10116.0,7,1,D,104698,Autocuration,,,BAO_0000218,
3154,,,F,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,CHEMBL617799,,6,1,H,104698,Autocuration,,,BAO_0000218,
3155,Rattus norvegicus,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617800,10116.0,7,1,D,104698,Autocuration,,,BAO_0000218,
3156,Rattus norvegicus,,F,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,CHEMBL617801,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3157,Rattus norvegicus,,F,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,CHEMBL617802,10116.0,7,1,D,104698,Autocuration,,,BAO_0000218,
3158,Rattus norvegicus,,F,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,CHEMBL617803,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3159,,,B,Binding affinity towards 5-HT3 receptor in rat was evaluated,,CHEMBL617804,,6,1,H,104698,Autocuration,,,BAO_0000019,
3160,Rattus norvegicus,,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,CHEMBL617805,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3161,,,B,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,CHEMBL617806,,6,1,H,104698,Autocuration,,,BAO_0000223,
3162,,,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,CHEMBL617807,,6,1,H,104698,Autocuration,,,BAO_0000019,
3163,,,B,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,CHEMBL617808,,6,1,H,104698,Autocuration,,,BAO_0000019,
3164,,,B,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,CHEMBL617809,,6,1,H,104698,Autocuration,,,BAO_0000249,
3165,,,B,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,CHEMBL617810,,6,1,H,104698,Autocuration,,,BAO_0000019,
3166,,,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,CHEMBL617811,,6,1,H,104698,Autocuration,,,BAO_0000249,955.0
3167,,,B,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,CHEMBL617812,,6,1,H,104698,Autocuration,,,BAO_0000221,955.0
3168,,,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL617813,,6,1,H,104698,Autocuration,,,BAO_0000249,
3169,,,B,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL617814,,6,1,H,104698,Autocuration,,,BAO_0000249,
3170,,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,CHEMBL617698,,6,1,H,104698,Autocuration,,,BAO_0000019,
3171,Rattus norvegicus,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,CHEMBL617699,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3172,Rattus norvegicus,,B,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,CHEMBL617700,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3173,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,CHEMBL617701,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3174,,,B,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,CHEMBL617702,,6,1,H,104698,Autocuration,,,BAO_0000019,
3175,,,B,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,CHEMBL617703,,6,1,H,104698,Autocuration,,,BAO_0000249,
3176,Rattus norvegicus,,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,CHEMBL617704,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3177,,,B,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,CHEMBL617705,,6,1,H,104698,Autocuration,,,BAO_0000223,
3178,Rattus norvegicus,,B,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,CHEMBL617706,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3179,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,CHEMBL617707,,6,1,H,104698,Autocuration,,433.0,BAO_0000219,
3180,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,CHEMBL617708,,6,1,H,104698,Autocuration,,433.0,BAO_0000219,
3181,,,B,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,CHEMBL617709,,6,1,H,104698,Autocuration,,,BAO_0000019,
3182,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,CHEMBL617710,,6,1,H,104698,Autocuration,,,BAO_0000019,
3183,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,CHEMBL882925,,6,1,H,104698,Autocuration,,,BAO_0000019,
3184,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,CHEMBL617711,,6,1,H,104698,Autocuration,,,BAO_0000019,
3185,,,F,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,CHEMBL617712,,6,1,H,104698,Autocuration,,,BAO_0000019,
3186,Rattus norvegicus,,F,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,CHEMBL617713,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3187,,,F,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,CHEMBL617714,,6,1,H,104698,Autocuration,,,BAO_0000019,
3188,,,F,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,CHEMBL617715,,6,1,H,104698,Autocuration,,,BAO_0000218,
3189,,,F,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,CHEMBL617716,,6,1,H,104698,Autocuration,,,BAO_0000218,
3190,,,F,Inhibition of 5-HT evoked reflex bradycardia in rat.,,CHEMBL617717,,6,1,H,104698,Autocuration,,,BAO_0000218,
3191,,,F,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617718,,6,1,H,104698,Autocuration,,,BAO_0000218,
3192,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,CHEMBL617719,,6,1,H,104698,Autocuration,,,BAO_0000218,
3193,,,F,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,CHEMBL617720,,6,1,H,104698,Autocuration,,,BAO_0000218,
3194,Rattus norvegicus,,F,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617721,10116.0,7,1,D,104698,Autocuration,,,BAO_0000218,
3195,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617722,,6,1,H,104698,Autocuration,,,BAO_0000218,
3196,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,CHEMBL617723,,6,1,H,104698,Autocuration,,,BAO_0000218,
3197,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617724,,6,1,H,104698,Autocuration,,,BAO_0000218,
3198,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617725,,6,1,H,104698,Autocuration,,,BAO_0000218,
3199,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617726,,6,1,H,104698,Autocuration,,,BAO_0000218,
3200,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617727,,6,1,H,104698,Autocuration,,,BAO_0000218,
3201,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617728,,6,1,H,104698,Autocuration,,,BAO_0000218,
3202,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,CHEMBL617729,,6,1,H,104698,Autocuration,,,BAO_0000218,
3203,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,CHEMBL617730,,6,1,H,104698,Autocuration,,,BAO_0000218,
3204,,,F,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617731,,6,1,H,104698,Autocuration,,,BAO_0000218,
3205,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617732,,6,1,H,104698,Autocuration,,,BAO_0000218,
3206,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,CHEMBL617733,,6,1,H,104698,Autocuration,,,BAO_0000218,
3207,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617734,,6,1,H,104698,Autocuration,,,BAO_0000218,
3208,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,CHEMBL872874,,6,1,H,104698,Autocuration,,,BAO_0000218,
3209,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,CHEMBL617735,,6,1,H,104698,Autocuration,,,BAO_0000218,
3210,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,CHEMBL617736,,6,1,H,104698,Autocuration,,,BAO_0000218,
3211,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,CHEMBL617737,,6,1,H,104698,Autocuration,,,BAO_0000218,
3212,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,CHEMBL617738,,6,1,H,104698,Autocuration,,,BAO_0000218,
3213,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617739,,6,1,H,104698,Autocuration,,,BAO_0000218,
3214,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617740,,6,1,H,104698,Autocuration,,,BAO_0000218,
3215,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617741,,6,1,H,104698,Autocuration,,,BAO_0000218,
3216,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617742,,6,1,H,104698,Autocuration,,,BAO_0000218,
3217,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617743,,6,1,H,104698,Autocuration,,,BAO_0000218,
3218,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617744,,6,1,H,104698,Autocuration,,,BAO_0000218,
3219,,,F,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,CHEMBL617745,,6,1,H,104698,Autocuration,,,BAO_0000218,
3220,,,F,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,CHEMBL617746,,6,1,H,104698,Autocuration,,,BAO_0000218,
3221,,,F,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,CHEMBL617747,,6,1,H,104698,Autocuration,,,BAO_0000218,
3222,,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,CHEMBL617748,,6,1,H,104698,Autocuration,,,BAO_0000218,
3223,,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,CHEMBL618909,,6,1,H,104698,Autocuration,,,BAO_0000218,
3224,,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,CHEMBL618910,,6,1,H,104698,Autocuration,,,BAO_0000218,
3225,,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,CHEMBL618911,,6,1,H,104698,Autocuration,,,BAO_0000218,
3226,,,F,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,CHEMBL618912,,6,1,H,104698,Autocuration,,,BAO_0000218,
3227,,,F,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,CHEMBL618913,,6,1,H,104698,Autocuration,,,BAO_0000218,
3228,,,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,CHEMBL618914,,6,1,H,104698,Autocuration,,,BAO_0000019,
3229,,,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,CHEMBL618915,,6,1,H,104698,Autocuration,,,BAO_0000019,
3230,Rattus norvegicus,,B,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,CHEMBL618916,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3231,,,F,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,CHEMBL618917,,6,1,H,104698,Autocuration,,,BAO_0000019,
3232,,,B,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,CHEMBL618918,,7,1,D,104698,Intermediate,,,BAO_0000221,10000000.0
3233,Rattus norvegicus,,B,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,CHEMBL618919,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3234,Rattus norvegicus,,B,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,CHEMBL618920,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3235,,,B,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,CHEMBL618921,,6,1,H,104698,Autocuration,,,BAO_0000223,
3236,,,B,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,CHEMBL618922,,6,1,H,104698,Autocuration,,,BAO_0000019,
3237,,,B,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,CHEMBL618923,,6,1,H,104698,Autocuration,,,BAO_0000019,
3238,,,B,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,CHEMBL618924,,6,1,H,104698,Autocuration,,,BAO_0000019,
3239,,,B,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,CHEMBL618925,,6,1,H,104698,Autocuration,,,BAO_0000019,
3240,,,B,Binding affinity towards 5-HT3 receptor in rat was evaluated,,CHEMBL618926,,6,1,H,104698,Autocuration,,,BAO_0000019,
3241,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,CHEMBL618927,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3242,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,CHEMBL618928,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3243,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,CHEMBL618929,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3244,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,CHEMBL618930,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3245,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,CHEMBL618931,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3246,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,CHEMBL619594,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3247,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,CHEMBL619595,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3248,Cavia porcellus,,F,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,CHEMBL619596,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3249,Cavia porcellus,,F,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,CHEMBL619755,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3250,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,CHEMBL619756,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3251,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,CHEMBL619757,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3252,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,CHEMBL619758,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3253,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,CHEMBL619759,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3254,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,CHEMBL619760,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3255,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,CHEMBL619761,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3256,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,CHEMBL619762,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3257,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,CHEMBL619763,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3258,Cavia porcellus,,F,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,CHEMBL617868,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3259,Cavia porcellus,,B,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,CHEMBL617869,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3260,Cavia porcellus,,B,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL882926,10141.0,9,1,D,20033,Intermediate,,,BAO_0000249,2435.0
3261,Cavia porcellus,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL617870,10141.0,9,1,D,20033,Intermediate,,,BAO_0000249,2435.0
3262,Cavia porcellus,,B,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,CHEMBL617871,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3263,Cavia porcellus,,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,CHEMBL617872,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3264,Cavia porcellus,,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,CHEMBL617873,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3265,Cavia porcellus,,B,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,CHEMBL617874,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3266,Cavia porcellus,,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,CHEMBL619067,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3267,Cavia porcellus,,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,CHEMBL619068,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3268,Cavia porcellus,,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,CHEMBL619069,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3269,Cavia porcellus,,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,CHEMBL619070,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3270,Cavia porcellus,,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,CHEMBL619071,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3271,Cavia porcellus,,F,Agonistic activity against 5-hydroxytryptamine 4 receptor,,CHEMBL619072,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3272,Cavia porcellus,,F,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,CHEMBL619073,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3273,Cavia porcellus,,F,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,CHEMBL619074,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3274,Cavia porcellus,,B,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,CHEMBL619075,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3275,Cavia porcellus,,B,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619076,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3276,Cavia porcellus,,B,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,CHEMBL619077,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3277,Cavia porcellus,,B,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL619078,10141.0,9,1,D,20033,Intermediate,,,BAO_0000249,2435.0
3278,Cavia porcellus,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL619079,10141.0,9,1,D,20033,Intermediate,,,BAO_0000249,2435.0
3279,Cavia porcellus,,B,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,CHEMBL619080,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3280,Cavia porcellus,,B,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,CHEMBL619081,10141.0,9,1,D,20033,Expert,,,BAO_0000357,
3281,Cavia porcellus,,B,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,CHEMBL619082,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3282,Cavia porcellus,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,CHEMBL619083,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3283,Cavia porcellus,,B,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,CHEMBL619084,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3284,Cavia porcellus,,F,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL859397,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3285,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,CHEMBL619085,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3286,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,CHEMBL619086,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3287,Cavia porcellus,,F,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,CHEMBL619087,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3288,Cavia porcellus,,F,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL619088,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3289,Cavia porcellus,,B,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,CHEMBL619089,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3290,Cavia porcellus,,B,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,CHEMBL619090,10141.0,8,1,H,168,Autocuration,,,BAO_0000357,
3291,Cavia porcellus,,F,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,CHEMBL619091,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3292,Cavia porcellus,,B,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619092,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3293,Cavia porcellus,,B,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,CHEMBL619093,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3294,Cavia porcellus,,B,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,CHEMBL619094,10141.0,8,1,H,168,Autocuration,,722.0,BAO_0000219,
3295,Cavia porcellus,,B,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,CHEMBL619095,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3296,Cavia porcellus,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,CHEMBL857988,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3297,Cavia porcellus,,B,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,CHEMBL619096,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3298,Cavia porcellus,,B,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,CHEMBL619097,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,2435.0
3299,Cavia porcellus,,B,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,CHEMBL619098,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,10000000.0
3300,Cavia porcellus,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,CHEMBL619751,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3301,Cavia porcellus,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,CHEMBL619752,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3302,Cavia porcellus,,F,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,CHEMBL875096,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3303,,,B,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,CHEMBL619004,,8,1,H,108,Autocuration,,,BAO_0000357,
3304,,,B,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,CHEMBL619005,,8,1,H,168,Autocuration,,,BAO_0000357,
3305,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,CHEMBL619006,,8,1,H,168,Autocuration,,,BAO_0000019,
3306,,,B,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,CHEMBL619007,,8,1,H,168,Autocuration,,308.0,BAO_0000219,
3307,,,B,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL619008,,8,1,H,168,Autocuration,,,BAO_0000357,
3308,,,B,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,CHEMBL619009,,8,1,H,168,Autocuration,,,BAO_0000357,
3309,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,CHEMBL619010,,8,1,H,168,Autocuration,,308.0,BAO_0000219,
3310,,,B,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,CHEMBL619011,,8,1,H,10622,Autocuration,,,BAO_0000357,
3311,,,B,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,CHEMBL619012,,8,1,H,10622,Autocuration,,,BAO_0000357,
3312,,,B,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,CHEMBL619013,,8,1,H,10622,Autocuration,,,BAO_0000219,
3313,,,B,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,CHEMBL619014,,8,1,H,10622,Autocuration,,,BAO_0000357,
3314,,,F,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,CHEMBL857503,,8,1,H,11249,Autocuration,,,BAO_0000019,2081.0
3315,,,F,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,CHEMBL619015,,8,1,H,11249,Autocuration,,,BAO_0000019,2081.0
3316,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL619016,,8,1,H,11249,Autocuration,,,BAO_0000357,
3317,,,B,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,CHEMBL619017,,8,1,H,11249,Autocuration,,,BAO_0000221,10000000.0
3318,Sus scrofa,,B,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,CHEMBL619018,9823.0,8,1,H,168,Autocuration,,,BAO_0000221,10000000.0
3319,Oryctolagus cuniculus,,B,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,CHEMBL619019,9986.0,8,1,H,168,Autocuration,,,BAO_0000019,
3320,Rattus norvegicus,,B,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619020,10116.0,9,1,D,10623,Expert,,,BAO_0000357,
3321,,,F,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,CHEMBL619021,,8,1,H,10623,Autocuration,,,BAO_0000019,
3322,,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,CHEMBL619022,,8,1,H,10623,Autocuration,,,BAO_0000357,
3323,,,B,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,CHEMBL619023,,8,1,H,10623,Autocuration,,,BAO_0000357,
3324,,,F,lntrinsic activity relative to 5-HT receptor,,CHEMBL619024,,8,1,H,10623,Autocuration,,,BAO_0000019,
3325,,,F,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,CHEMBL619025,,8,1,H,10623,Autocuration,,,BAO_0000019,
3326,,,F,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,CHEMBL619026,,8,1,H,10623,Expert,,,BAO_0000019,
3327,,,F,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,CHEMBL619027,,8,1,H,10623,Autocuration,,,BAO_0000019,
3328,,,F,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,CHEMBL619028,,8,1,H,10623,Autocuration,,,BAO_0000019,
3329,,,F,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,CHEMBL619029,,8,1,H,10623,Autocuration,,,BAO_0000019,
3330,,,F,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,CHEMBL619030,,8,1,H,10623,Autocuration,,,BAO_0000019,
3331,,,B,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,CHEMBL619031,,8,1,H,10623,Expert,,,BAO_0000357,
3332,,,F,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,CHEMBL619032,,8,1,H,10623,Autocuration,,,BAO_0000019,
3333,Rattus norvegicus,,B,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,CHEMBL619033,10116.0,9,1,D,10623,Expert,,,BAO_0000357,
3334,,,B,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,CHEMBL619034,,8,1,H,10623,Autocuration,,,BAO_0000357,
3335,,,B,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,CHEMBL619035,,8,1,H,10623,Autocuration,,,BAO_0000357,
3336,,,B,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,CHEMBL619036,,8,1,H,10623,Autocuration,,,BAO_0000357,
3337,Rattus norvegicus,,B,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,CHEMBL619037,10116.0,9,1,D,10623,Expert,,,BAO_0000019,
3338,,,B,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,CHEMBL619038,,8,1,H,10623,Autocuration,,,BAO_0000249,2435.0
3339,,,B,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,CHEMBL619039,,8,1,H,10623,Autocuration,,,BAO_0000249,
3340,,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,CHEMBL619040,,8,1,H,10623,Expert,,,BAO_0000249,
3341,Rattus norvegicus,,B,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,CHEMBL619041,10116.0,9,1,D,10623,Expert,,,BAO_0000019,2435.0
3342,,,B,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,CHEMBL619042,,8,1,H,10623,Autocuration,,,BAO_0000019,2435.0
3343,,,B,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,CHEMBL619043,,8,1,H,10623,Expert,,,BAO_0000249,2435.0
3344,,,B,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,CHEMBL619044,,8,1,H,10623,Expert,,,BAO_0000019,2435.0
3345,,,B,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,CHEMBL619045,,8,1,H,10623,Expert,,,BAO_0000249,2435.0
3346,,,B,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,CHEMBL619046,,8,1,H,10623,Expert,,,BAO_0000249,2435.0
3347,,,B,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,CHEMBL619047,,8,1,H,10623,Expert,,,BAO_0000249,
3348,,,F,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,CHEMBL619048,,8,1,H,10623,Autocuration,,,BAO_0000221,955.0
3349,,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,CHEMBL859398,,8,1,H,10623,Autocuration,,,BAO_0000019,
3350,,,F,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,CHEMBL619049,,8,1,H,10623,Autocuration,,,BAO_0000019,
3351,,,F,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,CHEMBL857886,,8,1,H,10623,Autocuration,,,BAO_0000019,
3352,,,F,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,CHEMBL619050,,8,1,H,10623,Autocuration,,,BAO_0000019,
3353,,,F,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,CHEMBL620591,,8,1,H,10623,Autocuration,,,BAO_0000019,
3354,Rattus norvegicus,,B,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,CHEMBL620592,10116.0,9,1,D,10623,Expert,,,BAO_0000357,
3355,,,B,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,CHEMBL620593,,8,1,H,10623,Expert,,,BAO_0000249,2435.0
3356,Rattus norvegicus,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,CHEMBL620594,10116.0,9,1,D,10623,Expert,,,BAO_0000019,
3357,,,F,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,CHEMBL875079,,8,1,H,10623,Expert,,,BAO_0000019,
3358,,,F,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,CHEMBL620595,,8,1,H,10623,Expert,,,BAO_0000019,
3359,Rattus norvegicus,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,CHEMBL620596,10116.0,9,1,D,10623,Expert,,,BAO_0000019,
3360,,,F,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,CHEMBL620597,,8,1,H,10623,Autocuration,,,BAO_0000019,
3361,,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,CHEMBL620598,,8,1,H,10623,Expert,,,BAO_0000019,
3362,,,F,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,CHEMBL620599,,8,1,H,10623,Expert,,,BAO_0000218,
3363,,,F,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,CHEMBL620600,,8,1,H,10623,Autocuration,,,BAO_0000019,
3364,Rattus norvegicus,,F,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,CHEMBL620601,10116.0,8,1,H,168,Autocuration,,,BAO_0000019,
3365,,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,CHEMBL620602,,8,1,H,168,Autocuration,,,BAO_0000019,
3366,,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620603,,8,1,H,168,Autocuration,,,BAO_0000357,
3367,,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,CHEMBL620604,,8,1,H,168,Autocuration,,,BAO_0000357,
3368,,,B,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,CHEMBL620605,,8,1,H,168,Autocuration,,,BAO_0000357,
3369,,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620606,,8,1,H,168,Autocuration,,,BAO_0000357,
3370,,,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL620607,,8,1,H,168,Autocuration,,,BAO_0000019,
3371,,,B,In vitro binding affinity towards 5-HT4 receptor was determined,,CHEMBL620608,,8,1,H,168,Autocuration,,,BAO_0000357,
3372,,,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL620609,,8,1,H,168,Autocuration,,,BAO_0000019,
3373,,,F,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,CHEMBL620610,,8,1,H,168,Autocuration,,,BAO_0000019,
3374,,,B,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,CHEMBL620611,,8,1,H,168,Autocuration,,,BAO_0000357,
3375,,,B,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,CHEMBL620612,,8,1,H,168,Autocuration,,,BAO_0000357,
3376,,,B,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,CHEMBL620613,,8,1,H,168,Autocuration,,,BAO_0000357,
3377,,,B,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,CHEMBL620614,,8,1,H,168,Autocuration,,,BAO_0000357,
3378,,,B,Binding affinity against 5-Hydroxytryptamine 4 receptor,,CHEMBL620615,,8,1,H,168,Expert,,,BAO_0000357,
3379,,,B,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,CHEMBL857075,,6,1,H,104698,Autocuration,,,BAO_0000249,
3380,,,B,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,CHEMBL620616,,6,1,H,104698,Autocuration,,,BAO_0000249,
3381,,,B,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,CHEMBL619411,,6,1,H,104698,Autocuration,,,BAO_0000249,
3382,,,B,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,CHEMBL619412,,6,1,H,104698,Autocuration,,,BAO_0000019,
3383,Rattus norvegicus,,B,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,CHEMBL619413,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3384,,,B,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,CHEMBL619414,,6,1,H,104698,Autocuration,,,BAO_0000221,10000000.0
3385,,,B,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,CHEMBL619415,,6,1,H,104698,Autocuration,,,BAO_0000019,
3386,,,B,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,CHEMBL619416,,6,1,H,104698,Autocuration,,,BAO_0000019,
3387,,,F,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,CHEMBL619417,,6,1,H,104698,Autocuration,,,BAO_0000019,
3388,Rattus norvegicus,,B,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,CHEMBL619418,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3389,Rattus norvegicus,,B,Binding affinity against 5-Hydroxytryptamine 3 receptor,,CHEMBL619419,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3390,,,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,CHEMBL619420,,6,1,H,104698,Autocuration,,,BAO_0000019,
3391,,,B,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,CHEMBL619421,,6,1,H,104698,Autocuration,,,BAO_0000249,
3392,Rattus norvegicus,,B,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,CHEMBL619422,10116.0,7,1,D,104698,Autocuration,,,BAO_0000019,
3393,,,B,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,CHEMBL619423,,6,1,H,104698,Autocuration,,,BAO_0000019,
3394,,,B,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,CHEMBL875080,,6,1,H,104698,Autocuration,,,BAO_0000019,
3395,,,B,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL619424,,6,1,H,104698,Autocuration,,,BAO_0000019,
3396,,,B,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,CHEMBL619425,,6,1,H,104698,Autocuration,,,BAO_0000249,
3397,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,CHEMBL619426,,6,1,H,104698,Autocuration,,,BAO_0000223,
3398,,,B,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,CHEMBL619427,,6,1,H,104698,Autocuration,,,BAO_0000223,
3399,Rattus norvegicus,,B,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL619645,10116.0,7,1,D,104698,Autocuration,,,BAO_0000223,
3400,,,B,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,CHEMBL619646,,9,1,D,10576,Expert,,,BAO_0000249,
3401,,,F,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,CHEMBL619647,,8,1,H,12020,Autocuration,,,BAO_0000221,955.0
3402,,,F,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,CHEMBL619648,,8,1,H,12020,Autocuration,,,BAO_0000019,
3403,,,F,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,CHEMBL619165,,8,1,H,12020,Autocuration,,,BAO_0000019,
3404,,,F,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620719,,8,1,H,12020,Autocuration,,,BAO_0000218,
3405,,,B,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,CHEMBL872924,,8,1,H,12020,Autocuration,,,BAO_0000019,
3406,,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620720,,8,1,H,12020,Autocuration,,,BAO_0000357,
3407,,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,CHEMBL620721,,8,1,H,12020,Autocuration,,,BAO_0000019,
3408,,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,CHEMBL620722,,8,1,H,12020,Autocuration,,,BAO_0000019,
3409,,,B,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,CHEMBL620723,,6,1,H,104698,Autocuration,,,BAO_0000019,
3410,,,B,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,CHEMBL620724,,8,1,H,12020,Autocuration,,,BAO_0000019,
3411,,,B,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,CHEMBL620725,,6,1,H,104698,Autocuration,,,BAO_0000249,
3412,Rattus norvegicus,,F,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,CHEMBL620726,10116.0,9,1,D,12020,Autocuration,,,BAO_0000019,
3413,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620727,,8,1,H,144,Expert,,,BAO_0000357,
3414,,,B,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,CHEMBL620728,,4,1,H,104714,Autocuration,,,BAO_0000223,
3415,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,CHEMBL620729,,0,1,U,22226,Autocuration,,,BAO_0000019,
3416,,,F,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,CHEMBL858288,,4,1,H,104714,Autocuration,,,BAO_0000019,
3417,,,B,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620730,,4,1,H,104714,Autocuration,,,BAO_0000223,
3418,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620731,,4,1,H,104714,Autocuration,,,BAO_0000223,
3419,Cavia porcellus,,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,CHEMBL620732,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3420,Cavia porcellus,,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,CHEMBL618042,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3421,Cavia porcellus,,F,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,CHEMBL618043,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3422,,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618044,,4,1,H,104714,Autocuration,,,BAO_0000223,
3423,,,F,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,CHEMBL618045,,4,1,H,104714,Autocuration,,,BAO_0000019,
3424,,,B,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,CHEMBL618046,,4,1,H,104714,Autocuration,,,BAO_0000223,
3425,,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,CHEMBL618047,,4,1,H,104714,Autocuration,,,BAO_0000019,
3426,,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,CHEMBL875084,,4,1,H,104714,Autocuration,,,BAO_0000019,
3427,,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,CHEMBL618048,,4,1,H,104714,Autocuration,,,BAO_0000019,
3428,,,B,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,CHEMBL618049,,4,1,H,104714,Autocuration,,,BAO_0000223,
3429,,,F,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,CHEMBL619764,,4,1,H,104714,Autocuration,,,BAO_0000019,
3430,,,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,CHEMBL619765,,4,1,H,104714,Autocuration,,,BAO_0000019,
3431,,,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,CHEMBL619766,,4,1,H,104714,Autocuration,,,BAO_0000019,
3432,,,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,CHEMBL619767,,4,1,H,104714,Autocuration,,,BAO_0000223,
3433,,,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,CHEMBL619768,,4,1,H,104714,Autocuration,,,BAO_0000223,
3434,,,F,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,CHEMBL619769,,4,1,H,104714,Autocuration,,,BAO_0000019,
3435,,,B,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,CHEMBL619770,,4,1,H,104714,Autocuration,,,BAO_0000223,
3436,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL619771,,4,1,H,104714,Autocuration,,,BAO_0000223,
3437,,,B,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,CHEMBL619772,,4,1,H,104714,Autocuration,,,BAO_0000219,
3438,,,B,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,CHEMBL619773,,4,1,H,104714,Autocuration,,,BAO_0000223,
3439,,,B,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,CHEMBL619774,,4,1,H,104714,Autocuration,,433.0,BAO_0000219,
3440,,,B,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,CHEMBL875083,,4,1,H,104714,Autocuration,,,BAO_0000019,
3441,,,B,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,CHEMBL620718,,4,1,H,104714,Autocuration,,433.0,BAO_0000219,
3442,,,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618127,,4,1,H,104714,Autocuration,,,BAO_0000223,
3443,,,B,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618128,,4,1,H,104714,Autocuration,,,BAO_0000223,
3444,,,B,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,CHEMBL618129,,4,1,H,104714,Autocuration,,,BAO_0000219,
3445,,,B,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,CHEMBL618130,,4,1,H,104714,Autocuration,,,BAO_0000223,
3446,,,F,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,CHEMBL618131,,4,1,H,104714,Autocuration,,,BAO_0000019,
3447,Cavia porcellus,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,CHEMBL618132,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3448,Cavia porcellus,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,CHEMBL618133,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3449,Cavia porcellus,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,CHEMBL618134,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3450,Cavia porcellus,,F,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,CHEMBL618135,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3451,,,B,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,CHEMBL618136,,4,1,H,104714,Autocuration,,,BAO_0000223,
3452,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618137,,4,1,H,104714,Autocuration,,,BAO_0000223,
3453,,,B,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,CHEMBL618138,,4,1,H,104714,Autocuration,,,BAO_0000223,
3454,,,B,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,CHEMBL618139,,4,1,H,104714,Autocuration,,,BAO_0000223,
3455,,,B,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,CHEMBL618140,,4,1,H,104714,Autocuration,,,BAO_0000223,
3456,,,B,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,CHEMBL618141,,4,1,H,104714,Autocuration,,,BAO_0000223,
3457,,,B,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL873478,,8,1,H,108,Expert,,,BAO_0000357,
3458,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618142,,6,1,H,104698,Autocuration,,,BAO_0000223,
3459,,,B,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,CHEMBL618143,,8,1,H,144,Autocuration,,,BAO_0000357,
3460,,,B,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618144,,8,1,H,144,Autocuration,,,BAO_0000357,
3461,,,B,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL618145,,8,1,H,144,Autocuration,,,BAO_0000357,
3462,,,B,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,CHEMBL618146,,4,1,H,104714,Autocuration,,,BAO_0000223,
3463,,,B,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,CHEMBL618147,,4,1,H,104714,Autocuration,,,BAO_0000223,
3464,,,B,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,CHEMBL618148,,4,1,H,104714,Autocuration,,,BAO_0000223,
3465,,,B,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,CHEMBL618149,,8,1,H,144,Autocuration,,,BAO_0000019,
3466,,,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL872927,,8,1,H,144,Autocuration,,,BAO_0000357,
3467,,,B,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618150,,8,1,H,144,Autocuration,,,BAO_0000357,
3468,,,B,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618151,,8,1,H,144,Autocuration,,,BAO_0000357,
3469,,,B,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,CHEMBL875094,,8,1,H,144,Autocuration,,,BAO_0000357,
3470,,,B,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,CHEMBL618152,,8,1,H,144,Autocuration,,,BAO_0000019,
3471,,,B,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,CHEMBL618153,,8,1,H,144,Autocuration,,,BAO_0000357,
3472,,,B,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,CHEMBL618888,,8,1,H,144,Autocuration,,,BAO_0000357,
3473,,,F,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,CHEMBL618889,,8,1,H,144,Autocuration,,,BAO_0000019,
3474,,,B,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,CHEMBL618890,,8,1,H,144,Autocuration,,,BAO_0000357,
3475,,,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,CHEMBL618891,,8,1,H,144,Autocuration,,,BAO_0000019,
3476,,,B,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,CHEMBL619054,,8,1,H,144,Autocuration,,,BAO_0000019,
3477,,,B,Binding affinity against the 5-hydroxytryptamine 3 receptor,,CHEMBL619055,,4,1,H,104714,Autocuration,,,BAO_0000223,
3478,,,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,,CHEMBL619056,,8,1,H,144,Autocuration,,,BAO_0000357,
3479,,,F,Percent efficacy against 5-hydroxytryptamine 3A receptor,,CHEMBL619057,,8,1,H,144,Autocuration,,,BAO_0000019,
3480,,,B,Binding affinity against human 5-hydroxytryptamine 3A receptor,,CHEMBL619058,,8,1,H,144,Autocuration,,,BAO_0000357,
3481,Rattus norvegicus,,F,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,CHEMBL619059,10116.0,9,1,D,12020,Expert,,,BAO_0000219,
3482,Rattus norvegicus,,F,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,CHEMBL619060,10116.0,9,1,D,12020,Expert,,,BAO_0000219,
3483,Rattus norvegicus,,F,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,CHEMBL875095,10116.0,9,1,D,12020,Expert,,,BAO_0000219,
3484,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,CHEMBL619061,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3485,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,CHEMBL619062,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3486,Cavia porcellus,,F,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,CHEMBL619063,10141.0,9,1,D,20033,Intermediate,,,BAO_0000019,
3487,Cavia porcellus,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,CHEMBL619064,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3488,Cavia porcellus,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,CHEMBL619065,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
3489,Cavia porcellus,,B,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,CHEMBL619066,10141.0,9,1,D,20033,Intermediate,,,BAO_0000221,2116.0
3490,,,B,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,CHEMBL619775,,8,1,H,10209,Autocuration,,,BAO_0000221,2116.0
3491,,,B,Affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL619776,,8,1,H,10209,Autocuration,,,BAO_0000357,
3492,Cavia porcellus,,B,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,CHEMBL619777,10141.0,4,1,H,104841,Autocuration,,,BAO_0000224,
3493,Cavia porcellus,,B,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,CHEMBL619778,10141.0,4,1,H,104841,Autocuration,,,BAO_0000224,
3494,Cavia porcellus,,B,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,CHEMBL619779,10141.0,4,1,H,104841,Autocuration,,,BAO_0000221,2116.0
3495,Cavia porcellus,,B,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,CHEMBL619780,10141.0,4,1,H,104841,Autocuration,,,BAO_0000224,
3496,Cavia porcellus,,B,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,CHEMBL619166,10141.0,4,1,H,104841,Autocuration,,,BAO_0000224,
3497,Cavia porcellus,,F,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,CHEMBL619167,10141.0,4,1,H,104841,Autocuration,,,BAO_0000019,
3498,Cavia porcellus,,F,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,CHEMBL619168,10141.0,4,1,H,104841,Autocuration,,,BAO_0000019,
3499,Homo sapiens,,B,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,CHEMBL619169,9606.0,9,1,D,168,Expert,,,BAO_0000219,2081.0
3500,Homo sapiens,,B,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,CHEMBL619170,9606.0,9,1,D,168,Expert,,,BAO_0000219,2081.0
3501,Homo sapiens,,F,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,CHEMBL619171,9606.0,5,1,D,104841,Autocuration,,,BAO_0000019,
3502,Homo sapiens,,F,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,CHEMBL619172,9606.0,9,1,D,168,Expert,,,BAO_0000219,2081.0
3503,Mus musculus,,B,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,CHEMBL619173,10090.0,0,1,U,22226,Autocuration,,,BAO_0000019,
3504,Mus musculus,,B,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,CHEMBL619174,10090.0,0,1,U,22226,Autocuration,,,BAO_0000019,
3505,,,B,5-hydroxytryptamine receptor binding affinity was determined in rats,,CHEMBL619175,,4,1,H,104705,Autocuration,,,BAO_0000019,
3506,,,B,Binding affinity at rat 5-hydroxytryptamine receptor.,,CHEMBL619176,,4,1,H,104705,Autocuration,,,BAO_0000224,
3507,,,B,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,CHEMBL619177,,4,1,H,104705,Autocuration,,,BAO_0000019,
3508,,,B,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,CHEMBL619178,,4,1,H,104705,Autocuration,,,BAO_0000224,
3509,,,B,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,CHEMBL619179,,4,1,H,104705,Autocuration,,,BAO_0000224,
3510,,,F,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,CHEMBL619180,,4,1,H,104705,Autocuration,,,BAO_0000019,945.0
3511,,,F,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,CHEMBL619181,,4,1,H,104705,Autocuration,,,BAO_0000019,945.0
3512,,,F,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,CHEMBL619182,,4,1,H,104705,Autocuration,,,BAO_0000019,
3513,,,B,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,CHEMBL619183,,4,1,H,104705,Autocuration,,,BAO_0000224,
3514,,,B,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,CHEMBL619184,,4,1,H,104705,Autocuration,,,BAO_0000224,
3515,,,B,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,CHEMBL619185,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
3516,,,B,Binding affinity for rat 5-hydroxytryptamine transporter.,,CHEMBL619186,,8,1,H,12198,Expert,,,BAO_0000357,
3517,,,B,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,CHEMBL619187,,4,1,H,104705,Autocuration,,,BAO_0000019,
3518,Rattus norvegicus,,B,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,CHEMBL619188,10116.0,5,1,D,104705,Autocuration,,,BAO_0000019,
3519,Rattus norvegicus,,B,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,CHEMBL619189,10116.0,5,1,D,104705,Autocuration,,,BAO_0000224,
3520,Rattus norvegicus,,F,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,CHEMBL619190,10116.0,9,1,D,12198,Expert,,,BAO_0000019,955.0
3521,Rattus norvegicus,,F,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,CHEMBL619191,10116.0,9,1,D,12198,Expert,,,BAO_0000221,2037.0
3522,Rattus norvegicus,,B,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,CHEMBL619192,10116.0,5,1,D,104705,Autocuration,,,BAO_0000019,
3523,Rattus norvegicus,,B,Percent binding affinity against 5-hydroxytryptamine receptor,,CHEMBL619193,10116.0,5,1,D,104705,Autocuration,,,BAO_0000224,
3524,,,B,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,CHEMBL619194,,0,1,U,22226,Autocuration,,,BAO_0000019,
3525,Rattus norvegicus,,B,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,CHEMBL619195,10116.0,5,1,D,104705,Autocuration,,,BAO_0000224,
3526,Rattus norvegicus,,B,Affinity against 5-hydroxytryptamine receptor was determined,,CHEMBL619196,10116.0,5,1,D,104705,Autocuration,,,BAO_0000224,
3527,Rattus norvegicus,,B,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,CHEMBL619197,10116.0,5,1,D,104705,Autocuration,,,BAO_0000019,945.0
3528,Homo sapiens,,B,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,CHEMBL619198,9606.0,9,1,D,121,Expert,,,BAO_0000219,
3529,Homo sapiens,,B,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,CHEMBL875081,9606.0,9,1,D,121,Expert,,,BAO_0000219,
3530,,,B,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,CHEMBL884712,,8,1,H,18065,Autocuration,,,BAO_0000357,
3531,,,B,Inhibition of 5-hydroxytryptamine reuptake,,CHEMBL884710,,8,1,H,121,Expert,,,BAO_0000357,
3532,,,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,CHEMBL619199,,8,1,H,18065,Autocuration,,,BAO_0000019,
3533,,,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,CHEMBL619200,,8,1,H,18065,Autocuration,,,BAO_0000019,
3534,,,F,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,CHEMBL619201,,8,1,H,18065,Autocuration,,,BAO_0000019,
3535,,,F,Tested for 5-hydroxytryptamine receptor uptake,,CHEMBL619202,,8,1,H,18065,Autocuration,,,BAO_0000019,
3536,Homo sapiens,,B,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHEMBL619203,9606.0,9,1,D,51,Expert,,449.0,BAO_0000219,
3537,Homo sapiens,,F,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,CHEMBL619204,9606.0,9,1,D,51,Expert,,,BAO_0000019,
3538,Homo sapiens,,B,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,CHEMBL619205,9606.0,8,1,H,10576,Autocuration,,,BAO_0000249,
3539,,,B,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,CHEMBL619206,,8,1,H,10576,Autocuration,,,BAO_0000357,
3540,,,B,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,CHEMBL619207,,8,1,H,10576,Expert,,,BAO_0000249,
3541,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,CHEMBL619208,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3542,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,CHEMBL619209,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3543,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,CHEMBL619210,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3544,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,CHEMBL619211,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3545,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,CHEMBL619212,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3546,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,CHEMBL620681,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3547,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,CHEMBL620682,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3548,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,CHEMBL620683,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3549,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,CHEMBL620684,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3550,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,CHEMBL620685,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3551,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,CHEMBL620686,,8,1,H,10825,Autocuration,,,BAO_0000019,2435.0
3552,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,CHEMBL620687,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3553,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,CHEMBL620688,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3554,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,CHEMBL620689,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3555,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,CHEMBL620690,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3556,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,CHEMBL620691,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3557,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,CHEMBL620692,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3558,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,CHEMBL620693,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3559,,,B,Binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL620694,,8,1,H,168,Expert,,,BAO_0000357,
3560,,,F,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL857986,,8,1,H,168,Autocuration,,,BAO_0000019,
3561,,,B,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,CHEMBL620695,,8,1,H,168,Autocuration,,,BAO_0000357,
3562,,,B,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,CHEMBL620696,,8,1,H,168,Expert,,,BAO_0000357,
3563,,,B,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,CHEMBL620697,,8,1,H,168,Autocuration,,,BAO_0000357,
3564,,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620698,,8,1,H,168,Autocuration,,,BAO_0000357,
3565,,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,CHEMBL620699,,8,1,H,168,Autocuration,,,BAO_0000357,
3566,,,B,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,CHEMBL620700,,8,1,H,168,Autocuration,,,BAO_0000357,
3567,,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,CHEMBL620701,,8,1,H,168,Autocuration,,643.0,BAO_0000219,
3568,,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,CHEMBL875082,,8,1,H,168,Autocuration,,643.0,BAO_0000219,
3569,,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,CHEMBL620702,,8,1,H,168,Autocuration,,643.0,BAO_0000219,
3570,,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,CHEMBL620703,,8,1,H,168,Autocuration,,643.0,BAO_0000219,
3571,,,B,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,CHEMBL620704,,8,1,H,168,Autocuration,,673.0,BAO_0000219,
3572,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,CHEMBL620705,,8,1,H,168,Expert,,673.0,BAO_0000219,
3573,,,B,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,CHEMBL620706,,8,1,H,168,Expert,,673.0,BAO_0000219,
3574,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,CHEMBL620707,,8,1,H,168,Expert,,673.0,BAO_0000219,
3575,,,B,Binding affinity towards 5-hydroxytryptamine 5 receptor,,CHEMBL620708,,8,1,H,10624,Expert,,,BAO_0000357,
3576,,,B,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,CHEMBL620709,,8,1,H,105,Autocuration,,,BAO_0000357,
3577,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 5A receptor,,CHEMBL620710,9606.0,9,1,D,10624,Expert,,,BAO_0000357,
3578,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,CHEMBL620711,,8,1,H,10624,Autocuration,,449.0,BAO_0000219,
3579,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,CHEMBL620712,9606.0,9,1,D,10624,Expert,,,BAO_0000357,
3580,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,CHEMBL620713,9606.0,9,1,D,10624,Expert,,,BAO_0000357,
3581,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,CHEMBL620714,9606.0,9,1,D,10624,Expert,,,BAO_0000357,
3582,Homo sapiens,,B,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,CHEMBL620715,9606.0,9,1,D,10624,Expert,,,BAO_0000357,
3583,,,B,Binding affinity towards 5-HT5A receptor,,CHEMBL620716,,8,1,H,10624,Autocuration,,,BAO_0000357,
3584,,,B,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,CHEMBL620717,,8,1,H,10624,Expert,,,BAO_0000357,
3585,,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,CHEMBL618072,,8,1,H,10624,Autocuration,,,BAO_0000357,
3586,,,B,Binding affinity towards cloned human 5-HT5A receptor was determined,,CHEMBL857987,,8,1,H,10624,Autocuration,,,BAO_0000357,
3587,,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL618073,,8,1,H,10624,Autocuration,,722.0,BAO_0000219,
3588,,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,CHEMBL618074,,8,1,H,10624,Autocuration,,722.0,BAO_0000219,
3589,,,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,CHEMBL618075,,8,1,H,10624,Autocuration,,722.0,BAO_0000219,
3590,Mus musculus,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,CHEMBL618076,10090.0,9,1,D,10625,Expert,,,BAO_0000357,
3591,Mus musculus,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,CHEMBL618077,10090.0,9,1,D,10625,Expert,,,BAO_0000357,
3592,Mus musculus,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,CHEMBL618078,10090.0,9,1,D,10625,Expert,,,BAO_0000357,
3593,Mus musculus,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,CHEMBL881821,10090.0,9,1,D,10625,Expert,,,BAO_0000357,
3594,Mus musculus,,B,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,CHEMBL618079,10090.0,9,1,D,10625,Expert,,,BAO_0000357,
3595,,,B,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,CHEMBL618080,,8,1,H,10625,Expert,,,BAO_0000357,
3596,,,B,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,CHEMBL618081,,8,1,H,10576,Autocuration,,722.0,BAO_0000219,
3597,,,B,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,CHEMBL618082,,8,1,H,10626,Autocuration,,722.0,BAO_0000219,
3598,,,B,Binding affinity towards 5-HT5a receptor,,CHEMBL618083,,8,1,H,10624,Expert,,,BAO_0000357,
3599,Homo sapiens,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor,,CHEMBL618084,9606.0,9,1,D,10624,Expert,,,BAO_0000357,
3600,,,B,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,CHEMBL618085,,8,1,H,10624,Expert,,,BAO_0000357,
3601,,,B,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,CHEMBL618086,,8,1,H,10624,Expert,,,BAO_0000357,
3602,,,B,Binding affinities against 5-hydroxytryptamine 5A receptor,,CHEMBL875092,,8,1,H,10624,Autocuration,,,BAO_0000357,
3603,,,B,Binding affinities towards 5-hydroxytryptamine 5A receptor,,CHEMBL618087,,8,1,H,10624,Autocuration,,,BAO_0000357,
3604,,,B,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,CHEMBL872926,,8,1,H,10624,Autocuration,,,BAO_0000357,
3605,Cavia porcellus,,F,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,CHEMBL618088,10141.0,4,1,H,104714,Autocuration,,,BAO_0000019,
3606,,,B,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,CHEMBL618089,,4,1,H,104714,Autocuration,,,BAO_0000223,
3607,Homo sapiens,,B,Inhibition of human 5-hydroxytryptamine 6 receptor,,CHEMBL618090,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3608,Homo sapiens,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,CHEMBL618091,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3609,,,B,Inhibition against human 5-hydroxytryptamine 6 receptor,,CHEMBL618092,,8,1,H,10627,Autocuration,,,BAO_0000357,
3610,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,CHEMBL618093,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3611,,,B,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,CHEMBL618094,,8,1,H,10627,Expert,,308.0,BAO_0000219,
3612,Homo sapiens,,B,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,CHEMBL618095,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3613,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL875093,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3614,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,CHEMBL618096,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3615,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,CHEMBL618118,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3616,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL618119,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3617,,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618120,,8,1,H,10627,Expert,,,BAO_0000357,
3618,,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618121,,8,1,H,10627,Autocuration,,,BAO_0000357,
3619,,,B,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,CHEMBL618122,,8,1,H,10627,Expert,,722.0,BAO_0000219,
3620,,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,CHEMBL618123,,8,1,H,10627,Autocuration,,,BAO_0000357,
3621,,,B,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,CHEMBL618124,,8,1,H,10627,Expert,,722.0,BAO_0000219,
3622,,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618125,,8,1,H,10627,Autocuration,,,BAO_0000357,
3623,Homo sapiens,,B,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,CHEMBL618126,9606.0,9,1,D,10627,Expert,,722.0,BAO_0000219,
3624,,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,CHEMBL618236,,8,1,H,10627,Expert,,,BAO_0000019,
3625,,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,CHEMBL618237,,8,1,H,10627,Expert,,,BAO_0000019,
3626,,,B,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,CHEMBL618238,,8,1,H,10627,Expert,,643.0,BAO_0000219,
3627,Homo sapiens,,B,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,CHEMBL618239,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3628,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,CHEMBL618240,,8,1,H,10627,Autocuration,,,BAO_0000019,
3629,,,B,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,CHEMBL618241,,8,1,H,10627,Autocuration,,,BAO_0000357,
3630,,,B,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,CHEMBL859399,,8,1,H,10627,Autocuration,,722.0,BAO_0000219,
3631,,,F,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,CHEMBL618242,,8,1,H,10627,Autocuration,,,BAO_0000019,
3632,,,B,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,CHEMBL857991,,8,1,H,10627,Autocuration,,,BAO_0000357,
3633,,,B,Binding affinity against human 5-hydroxytryptamine 6 receptor,,CHEMBL619951,,8,1,H,10627,Expert,,,BAO_0000357,
3634,Homo sapiens,,B,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,CHEMBL619952,9606.0,9,1,D,10627,Expert,,308.0,BAO_0000219,
3635,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,CHEMBL619953,9606.0,9,1,D,10627,Expert,,308.0,BAO_0000219,
3636,,,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,CHEMBL619954,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3637,,,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,CHEMBL619955,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3638,,,B,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,CHEMBL619956,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3639,,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL619957,,8,1,H,10627,Autocuration,,449.0,BAO_0000219,
3640,,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL619958,,8,1,H,10627,Autocuration,,722.0,BAO_0000219,
3641,,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,CHEMBL620627,,8,1,H,10627,Autocuration,,722.0,BAO_0000219,
3642,,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,CHEMBL620628,,8,1,H,10627,Autocuration,,722.0,BAO_0000219,
3643,,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,CHEMBL620629,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3644,,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620630,,8,1,H,10627,Autocuration,,,BAO_0000357,
3645,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,CHEMBL620782,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3646,,,B,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,CHEMBL620783,,8,1,H,10627,Autocuration,,,BAO_0000357,
3647,,,B,Binding affinity against human 5-hydroxytryptamine 6 receptor,,CHEMBL620784,,8,1,H,10627,Expert,,,BAO_0000357,
3648,,,B,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,CHEMBL620785,,8,1,H,10627,Expert,,308.0,BAO_0000219,
3649,,,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,CHEMBL857992,,8,1,H,10627,Autocuration,,,BAO_0000357,
3650,,,B,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,CHEMBL620786,,8,1,H,10627,Autocuration,,,BAO_0000219,
3651,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,CHEMBL620787,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3652,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,CHEMBL620788,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3653,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,CHEMBL620789,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3654,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,CHEMBL620790,,8,1,H,10627,Autocuration,,308.0,BAO_0000219,
3655,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,CHEMBL620791,,8,1,H,10628,Autocuration,,449.0,BAO_0000219,
3656,,,B,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,CHEMBL620792,,8,1,H,10628,Autocuration,,,BAO_0000019,
3657,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL620793,,8,1,H,10628,Autocuration,,,BAO_0000357,
3658,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620794,,8,1,H,10628,Autocuration,,,BAO_0000357,
3659,Homo sapiens,,B,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,CHEMBL620795,9606.0,9,1,D,10627,Autocuration,,308.0,BAO_0000219,
3660,,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620796,,8,1,H,10627,Expert,,,BAO_0000357,
3661,,,B,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,CHEMBL620797,,8,1,H,10627,Autocuration,,,BAO_0000357,
3662,Homo sapiens,,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,CHEMBL620798,9606.0,9,1,D,10627,Expert,,,BAO_0000019,
3663,,,B,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,CHEMBL620799,,8,1,H,10627,Autocuration,,,BAO_0000357,
3664,,,B,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620800,,8,1,H,10627,Expert,,,BAO_0000357,
3665,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,CHEMBL620801,,8,1,H,10627,Autocuration,,,BAO_0000357,
3666,,,B,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL875100,,8,1,H,10627,Autocuration,,,BAO_0000357,
3667,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620802,,8,1,H,10627,Autocuration,,,BAO_0000357,
3668,,,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620803,,8,1,H,10627,Expert,,,BAO_0000019,
3669,,,F,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,CHEMBL620804,,8,1,H,10627,Expert,,,BAO_0000019,
3670,,,B,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620805,,8,1,H,10627,Autocuration,,,BAO_0000357,
3671,,,B,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620806,,8,1,H,10627,Autocuration,,,BAO_0000357,
3672,,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,CHEMBL620807,,8,1,H,10627,Autocuration,,,BAO_0000357,
3673,,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,CHEMBL620808,,8,1,H,10627,Autocuration,,,BAO_0000357,
3674,,,B,Binding affinities against 5-hydroxytryptamine 6 receptor,,CHEMBL620809,,8,1,H,10627,Autocuration,,,BAO_0000357,
3675,,,B,Binding affinities towards 5-hydroxytryptamine 6 receptor,,CHEMBL620810,,8,1,H,10627,Autocuration,,,BAO_0000357,
3676,Homo sapiens,,B,Binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620811,9606.0,9,1,D,10627,Expert,,,BAO_0000357,
3677,,,B,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,CHEMBL620812,,8,1,H,10627,Autocuration,,,BAO_0000357,
3678,,,B,Affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL620813,,8,1,H,10627,Autocuration,,,BAO_0000357,
3679,,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,CHEMBL620814,,8,1,H,10627,Autocuration,,,BAO_0000357,
3680,Homo sapiens,,B,Inhibition of human 5-hydroxytryptamine 7 receptor,,CHEMBL620815,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3681,,,B,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,CHEMBL620816,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3682,,,B,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,CHEMBL620817,,8,1,H,10209,Autocuration,,,BAO_0000357,
3683,,,B,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,CHEMBL620818,,8,1,H,10209,Autocuration,,,BAO_0000357,
3684,,,B,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,CHEMBL620819,,8,1,H,10209,Expert,,722.0,BAO_0000219,
3685,Homo sapiens,,B,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,CHEMBL620820,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3686,,,B,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,CHEMBL620821,,8,1,H,10209,Autocuration,,449.0,BAO_0000219,
3687,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL620822,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3688,Homo sapiens,,B,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,CHEMBL620823,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3689,Homo sapiens,,B,Binding affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL620824,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3690,,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,CHEMBL620825,,8,1,H,10209,Expert,,449.0,BAO_0000219,
3691,,,B,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,CHEMBL872930,,8,1,H,10209,Autocuration,,,BAO_0000357,
3692,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL620826,,8,1,H,10209,Autocuration,,,BAO_0000357,
3693,,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,CHEMBL620827,,8,1,H,10209,Autocuration,,,BAO_0000357,
3694,,,B,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,CHEMBL620828,,8,1,H,10209,Autocuration,,,BAO_0000357,
3695,,,B,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL620829,,8,1,H,10209,Autocuration,,,BAO_0000357,
3696,,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,CHEMBL620830,,8,1,H,10209,Expert,,722.0,BAO_0000219,
3697,,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,CHEMBL620831,,8,1,H,10209,Expert,,,BAO_0000019,
3698,,,B,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,CHEMBL620832,,8,1,H,10209,Expert,,,BAO_0000019,
3699,Homo sapiens,,B,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,CHEMBL621548,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3700,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,CHEMBL621549,,8,1,H,10209,Autocuration,,,BAO_0000019,
3701,,,B,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,CHEMBL621550,,8,1,H,10209,Autocuration,,,BAO_0000357,
3702,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,CHEMBL621551,,8,1,H,10209,Autocuration,,449.0,BAO_0000219,
3703,,,B,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,CHEMBL621552,,8,1,H,10209,Autocuration,,,BAO_0000019,
3704,,,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,CHEMBL857077,,8,1,H,10209,Autocuration,,,BAO_0000357,
3705,,,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,CHEMBL618158,,8,1,H,10209,Autocuration,,,BAO_0000357,
3706,Homo sapiens,,B,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,CHEMBL618159,9606.0,9,1,D,10209,Expert,,643.0,BAO_0000219,
3707,,,B,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,CHEMBL875101,,8,1,H,10209,Autocuration,,643.0,BAO_0000219,
3708,Homo sapiens,,B,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,CHEMBL618160,9606.0,9,1,D,10209,Expert,,722.0,BAO_0000219,
3709,,,B,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,CHEMBL618161,,8,1,H,10209,Expert,,,BAO_0000357,
3710,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,CHEMBL618162,,8,1,H,10209,Expert,,722.0,BAO_0000219,
3711,,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,CHEMBL618163,,8,1,H,10209,Expert,,,BAO_0000357,
3712,,,B,Binding affinity against 5-hydroxytryptamine 7 human receptors,,CHEMBL618164,,8,1,H,10209,Autocuration,,,BAO_0000357,
3713,,,B,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,CHEMBL618165,,8,1,H,10209,Expert,,,BAO_0000219,
3714,,,B,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,CHEMBL618166,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3715,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL857989,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3716,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619888,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3717,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619889,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3718,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619890,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3719,,,B,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,CHEMBL619891,,8,1,H,10209,Autocuration,,449.0,BAO_0000219,
3720,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,CHEMBL619892,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3721,,,B,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,CHEMBL619893,,9,1,D,10209,Expert,,722.0,BAO_0000219,
3722,,,B,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,CHEMBL619894,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3723,,,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,CHEMBL619895,,9,1,D,10209,Intermediate,,722.0,BAO_0000219,
3724,,,B,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,CHEMBL619896,,9,1,D,10209,Intermediate,,,BAO_0000357,
3725,,,B,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,CHEMBL619897,,8,1,H,10209,Autocuration,,643.0,BAO_0000219,
3726,,,B,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,CHEMBL619898,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3727,,,B,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,CHEMBL619899,,8,1,H,10209,Expert,,722.0,BAO_0000219,
3728,,,B,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,CHEMBL619900,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3729,Homo sapiens,,B,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,CHEMBL619901,9606.0,9,1,D,10209,Expert,,722.0,BAO_0000219,
3730,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,CHEMBL620580,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3731,,,B,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,CHEMBL620581,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3732,,,B,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,CHEMBL620733,,8,1,H,10209,Autocuration,,722.0,BAO_0000219,
3733,Homo sapiens,,B,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,CHEMBL620734,9606.0,9,1,D,10209,Autocuration,,,BAO_0000357,
3734,Mus musculus,,B,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,CHEMBL620735,10090.0,9,1,D,10022,Expert,,,BAO_0000357,
3735,Oryctolagus cuniculus,,B,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,CHEMBL620736,9986.0,8,1,H,10209,Autocuration,,,BAO_0000019,
3736,,,B,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,CHEMBL620737,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3737,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,CHEMBL620738,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3738,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,CHEMBL620739,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3739,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,CHEMBL620740,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3740,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,CHEMBL620741,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3741,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,CHEMBL620742,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3742,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,CHEMBL620743,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3743,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,CHEMBL620744,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3744,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,CHEMBL620745,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3745,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,CHEMBL620746,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3746,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,CHEMBL620747,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3747,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,CHEMBL620748,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3748,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,CHEMBL620749,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3749,,,B,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,CHEMBL620750,,8,1,H,11923,Expert,,,BAO_0000357,
3750,Rattus norvegicus,,B,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,CHEMBL620751,10116.0,9,1,D,11923,Expert,,,BAO_0000357,
3751,,,B,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,CHEMBL620752,,8,1,H,11923,Expert,,,BAO_0000357,
3752,,,B,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,CHEMBL872929,,8,1,H,11923,Autocuration,,,BAO_0000019,
3753,Rattus norvegicus,,B,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,CHEMBL620753,10116.0,9,1,D,11923,Expert,,,BAO_0000357,
3754,Rattus norvegicus,,B,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,CHEMBL620754,10116.0,9,1,D,11923,Expert,,,BAO_0000357,
3755,Rattus norvegicus,,B,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,CHEMBL620755,10116.0,9,1,D,11923,Expert,,449.0,BAO_0000219,
3756,,,B,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,CHEMBL620756,,8,1,H,11923,Autocuration,,,BAO_0000357,
3757,,,B,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL620757,,8,1,H,11923,Autocuration,,,BAO_0000357,
3758,,,B,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,CHEMBL620758,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3759,,,B,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,CHEMBL620759,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3760,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,CHEMBL620760,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3761,,,B,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,CHEMBL620761,,8,1,H,11923,Autocuration,,449.0,BAO_0000219,
3762,,,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,CHEMBL620762,,8,1,H,11923,Autocuration,,,BAO_0000221,2116.0
3763,,,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,CHEMBL620763,,8,1,H,11923,Autocuration,,,BAO_0000221,2116.0
3764,,,F,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,CHEMBL620764,,8,1,H,11923,Autocuration,,,BAO_0000221,2116.0
3765,Rattus norvegicus,,B,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,CHEMBL857990,10116.0,9,1,D,11923,Expert,,,BAO_0000249,
3766,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,CHEMBL620765,,8,1,H,11923,Autocuration,,,BAO_0000357,
3767,,,B,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,CHEMBL620766,,8,1,H,11923,Expert,,,BAO_0000357,
3768,,,B,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,CHEMBL620767,,8,1,H,11923,Expert,,,BAO_0000019,1898.0
3769,,,B,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,CHEMBL620768,,8,1,H,11923,Autocuration,,,BAO_0000357,
3770,,,B,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,CHEMBL619051,,8,1,H,11923,Expert,,,BAO_0000249,1898.0
3771,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL619052,,8,1,H,11923,Expert,,,BAO_0000357,
3772,Rattus norvegicus,,F,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,CHEMBL619053,10116.0,9,1,D,11923,Expert,,722.0,BAO_0000219,
3773,Rattus norvegicus,,F,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,CHEMBL619703,10116.0,9,1,D,11923,Expert,,722.0,BAO_0000219,
3774,Rattus norvegicus,,F,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,CHEMBL619704,10116.0,9,1,D,11923,Autocuration,,722.0,BAO_0000219,
3775,,,B,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL619851,,8,1,H,10209,Expert,,,BAO_0000357,
3776,,,B,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,CHEMBL619852,,8,1,H,10209,Autocuration,,,BAO_0000357,
3777,,,B,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,CHEMBL619853,,8,1,H,10209,Autocuration,,,BAO_0000357,
3778,Homo sapiens,,B,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL619854,9606.0,9,1,D,10209,Expert,,,BAO_0000357,
3779,,,B,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,CHEMBL619855,,8,1,H,10209,Expert,,,BAO_0000357,
3780,,,B,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,CHEMBL619856,,8,1,H,10209,Autocuration,,,BAO_0000357,
3781,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,CHEMBL619857,,8,1,H,10209,Autocuration,,,BAO_0000357,
3782,,,F,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,CHEMBL619858,,8,1,H,10209,Expert,,,BAO_0000019,
3783,,,B,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,CHEMBL619859,,8,1,H,10209,Autocuration,,,BAO_0000357,
3784,,,B,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,CHEMBL619860,,8,1,H,10209,Autocuration,,,BAO_0000357,
3785,,,B,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,CHEMBL619861,,8,1,H,10209,Autocuration,,,BAO_0000357,
3786,,,B,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,CHEMBL619862,,8,1,H,10209,Expert,,,BAO_0000357,
3787,,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,CHEMBL619863,,8,1,H,10209,Autocuration,,,BAO_0000357,
3788,,,B,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,CHEMBL619864,,8,1,H,10209,Autocuration,,,BAO_0000357,
3789,,,B,Binding affinities against 5-hydroxytryptamine 7 receptor,,CHEMBL872928,,8,1,H,10209,Autocuration,,,BAO_0000357,
3790,,,B,Binding affinities towards 5-hydroxytryptamine 7 receptor,,CHEMBL619865,,8,1,H,10209,Autocuration,,,BAO_0000357,
3791,,,B,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,CHEMBL619866,,8,1,H,10209,Expert,,,BAO_0000357,
3792,,,B,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,CHEMBL619867,,8,1,H,10209,Autocuration,,,BAO_0000357,
3793,,,B,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,CHEMBL619868,,8,1,H,10209,Autocuration,,,BAO_0000221,2116.0
3794,,,F,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,CHEMBL619869,,8,1,H,55,Autocuration,,,BAO_0000019,
3795,Homo sapiens,,F,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,CHEMBL619870,9606.0,9,1,D,55,Expert,,,BAO_0000019,
3796,,,B,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,CHEMBL619871,,8,1,H,55,Autocuration,,,BAO_0000357,
3797,,,B,In vitro inhibition of human recombinant lipoxygenase enzyme,,CHEMBL619872,,8,1,H,55,Autocuration,,,BAO_0000357,
3798,,,B,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,CHEMBL619873,,8,1,H,55,Autocuration,,,BAO_0000357,
3799,,,B,Inhibition of 5-lipoxygenase in human whole blood.,,CHEMBL619874,,8,1,H,55,Expert,,,BAO_0000357,178.0
3800,,,B,Inhibition of 5-lipoxygenase in human whole blood.,,CHEMBL619875,,8,1,H,55,Expert,,,BAO_0000357,178.0
3801,,,B,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,CHEMBL619876,,8,1,H,55,Autocuration,,,BAO_0000357,
3802,,,B,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,CHEMBL619877,,8,1,H,55,Autocuration,,,BAO_0000357,
3803,,,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,CHEMBL619878,,8,1,H,55,Expert,,,BAO_0000219,
3804,,,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,CHEMBL619879,,8,1,H,55,Autocuration,,,BAO_0000019,178.0
3805,,,B,In vitro inhibition of 5-lipoxygenase from human polymorphs,,CHEMBL619880,,8,1,H,55,Autocuration,,,BAO_0000357,
3806,,,B,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,CHEMBL619881,,8,1,H,55,Autocuration,,,BAO_0000357,
3807,,,B,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,CHEMBL619882,,8,1,H,55,Expert,,,BAO_0000357,
3808,,,B,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,CHEMBL619883,,8,1,H,55,Autocuration,,,BAO_0000357,
3809,Homo sapiens,,B,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,CHEMBL619884,9606.0,9,1,D,55,Expert,,,BAO_0000357,178.0
3810,,,B,In vitro potency against human 5-Lipoxygenase,,CHEMBL619885,,8,1,H,55,Autocuration,,,BAO_0000357,
3811,Homo sapiens,,F,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,CHEMBL619886,9606.0,9,1,D,55,Expert,,,BAO_0000019,
3812,,,F,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,CHEMBL619887,,8,1,H,55,Autocuration,,,BAO_0000019,178.0
3813,,,F,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,CHEMBL875097,,8,1,H,55,Autocuration,,,BAO_0000019,
3814,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,CHEMBL618001,,8,1,H,55,Autocuration,,,BAO_0000219,
3815,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,CHEMBL618002,,8,1,H,55,Autocuration,,,BAO_0000219,
3816,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,CHEMBL618003,,8,1,H,55,Autocuration,,,BAO_0000219,
3817,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,CHEMBL618004,,8,1,H,55,Autocuration,,,BAO_0000219,
3818,,,B,Inhibition of human 5-lipoxygenase in human cells,,CHEMBL618005,,8,1,H,55,Autocuration,,,BAO_0000219,
3819,,,B,Inhibition of human neutrophil 5-lipoxygenase,,CHEMBL618006,,8,1,H,55,Expert,,,BAO_0000357,
3820,,,B,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,CHEMBL875086,,8,1,H,55,Autocuration,,,BAO_0000019,
3821,,,B,Inhibition of 5-lipoxygenase from human whole blood,,CHEMBL618007,,8,1,H,55,Expert,,,BAO_0000357,178.0
3822,,,B,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,CHEMBL618008,,8,1,H,55,Autocuration,,,BAO_0000357,
3823,,,B,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,CHEMBL618009,,8,1,H,55,Autocuration,,,BAO_0000219,
3824,,,B,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,CHEMBL618010,,8,1,H,55,Expert,,,BAO_0000357,
3825,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,CHEMBL618011,,8,1,H,55,Autocuration,,,BAO_0000357,
3826,,,B,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,CHEMBL618012,,8,1,H,55,Expert,,,BAO_0000357,
3827,,,B,Tested against 5-lipoxygenase,,CHEMBL882927,,8,1,H,55,Autocuration,,,BAO_0000357,
3828,,,B,Tested for activity against 5-Lipoxygenase (5-LO),,CHEMBL618013,,8,1,H,55,Autocuration,,,BAO_0000357,
3829,,,B,Tested for activity against 5-lipoxygenase,,CHEMBL618014,,8,1,H,55,Autocuration,,,BAO_0000357,
3830,,,B,Tested for inhibition of 5-HPETE production by human 5-LO,,CHEMBL618015,,8,1,H,55,Autocuration,,,BAO_0000357,
3831,,,F,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,CHEMBL618016,,8,1,H,55,Autocuration,,,BAO_0000019,
3832,,,B,Inhibition of Human 5-lipoxygenase,,CHEMBL618017,,8,1,H,55,Expert,,,BAO_0000357,
3833,,,B,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,CHEMBL618018,,8,1,H,55,Autocuration,,,BAO_0000019,
3834,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,CHEMBL875087,,8,1,H,55,Autocuration,,,BAO_0000219,
3835,,,B,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,CHEMBL618019,,8,1,H,55,Autocuration,,,BAO_0000219,
3836,,,B,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,CHEMBL618020,,8,1,H,55,Autocuration,,,BAO_0000019,
3837,,,B,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,CHEMBL618021,,8,1,H,55,Autocuration,,,BAO_0000019,
3838,,,B,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,CHEMBL618022,,8,1,H,55,Autocuration,,,BAO_0000357,178.0
3839,,,B,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,CHEMBL618023,,8,1,H,55,Autocuration,,,BAO_0000357,
3840,,,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,CHEMBL618024,,8,1,H,55,Autocuration,,,BAO_0000357,
3841,,,B,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,CHEMBL873950,,8,1,H,55,Expert,,,BAO_0000019,
3842,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,CHEMBL618025,,8,1,H,55,Autocuration,,,BAO_0000357,
3843,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,CHEMBL618026,,8,1,H,55,Autocuration,,,BAO_0000219,
3844,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,CHEMBL618027,,8,1,H,55,Autocuration,,,BAO_0000219,
3845,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,CHEMBL618028,,8,1,H,55,Autocuration,,,BAO_0000219,
3846,,,B,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,CHEMBL618029,,8,1,H,55,Autocuration,,,BAO_0000219,
3847,,,B,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,CHEMBL618030,,8,1,H,55,Expert,,,BAO_0000357,
3848,,,B,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,CHEMBL618031,,8,1,H,55,Expert,,,BAO_0000357,
3849,,,B,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,CHEMBL618032,,8,1,H,55,Autocuration,,,BAO_0000357,
3850,,,B,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,CHEMBL618033,,8,1,H,55,Autocuration,,,BAO_0000357,
3851,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,CHEMBL618034,,8,1,H,55,Autocuration,,,BAO_0000357,
3852,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,CHEMBL875088,,8,1,H,55,Autocuration,,,BAO_0000357,
3853,,,B,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,CHEMBL618035,,8,1,H,55,Autocuration,,,BAO_0000019,
3854,,,B,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,CHEMBL618036,,8,1,H,55,Autocuration,,,BAO_0000019,
3855,,,B,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,CHEMBL618037,,8,1,H,55,Expert,,,BAO_0000357,
3856,,,B,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,CHEMBL618038,,8,1,H,55,Expert,,,BAO_0000357,
3857,,,F,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,CHEMBL618761,,8,1,H,55,Autocuration,,,BAO_0000019,
3858,,,B,Inhibition of lipoxygenase at the concentration of 0.1 uM,,CHEMBL618762,,8,1,H,55,Expert,,,BAO_0000357,
3859,,,B,Inhibition of lipoxygenase at the concentration of 1 uM,,CHEMBL618763,,8,1,H,55,Expert,,,BAO_0000357,
3860,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,CHEMBL618764,,8,1,H,55,Autocuration,,,BAO_0000357,
3861,Homo sapiens,,B,Inhibition of 5-Lipoxygenase (5-LOX),,CHEMBL618765,9606.0,9,1,D,55,Expert,,,BAO_0000357,
3862,,,B,Inhibition of 5-lipoxygenase in mouse macrophages.,,CHEMBL618766,,8,1,H,17087,Expert,,,BAO_0000357,
3863,,,B,Inhibition of 5-lipoxygenase in mouse macrophages.,,CHEMBL618767,,8,1,H,17087,Expert,,,BAO_0000357,
3864,,,B,Inhibitory activity against lipoxygenase-2 in mice,,CHEMBL619380,,8,1,H,17087,Autocuration,,,BAO_0000357,
3865,,,B,Inhibitory activity against murine lipoxygenase-2.,,CHEMBL619381,,8,1,H,17087,Expert,,,BAO_0000357,
3866,Mus musculus,,B,Inhibition of 5-lipoxygenase from mouse macrophage,,CHEMBL619382,10090.0,9,1,D,17087,Expert,,,BAO_0000357,
3867,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,CHEMBL619383,,8,1,H,17087,Autocuration,,,BAO_0000357,
3868,Sus scrofa,,B,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,CHEMBL619384,9823.0,8,1,H,55,Autocuration,,,BAO_0000019,
3869,Sus scrofa,,B,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,CHEMBL619385,9823.0,8,1,H,55,Autocuration,,,BAO_0000019,
3870,Oryctolagus cuniculus,,B,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,CHEMBL882928,9986.0,8,1,H,55,Autocuration,,,BAO_0000019,
3871,Rattus norvegicus,,B,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,CHEMBL619386,10116.0,9,1,D,12166,Expert,,,BAO_0000019,
3872,,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,CHEMBL619387,,8,1,H,12166,Autocuration,,,BAO_0000019,
3873,,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,CHEMBL619388,,8,1,H,12166,Autocuration,,,BAO_0000019,
3874,,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,CHEMBL619389,,8,1,H,12166,Autocuration,,,BAO_0000019,
3875,,,B,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,CHEMBL619390,,8,1,H,12166,Expert,,,BAO_0000019,
3876,,,B,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,CHEMBL619391,,8,1,H,12166,Expert,,,BAO_0000019,
3877,,,B,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,CHEMBL619392,,8,1,H,12166,Autocuration,,,BAO_0000019,
3878,,,B,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,CHEMBL619393,,8,1,H,12166,Autocuration,,,BAO_0000019,
3879,,,B,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,CHEMBL619394,,8,1,H,12166,Autocuration,,,BAO_0000019,
3880,,,B,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,CHEMBL619395,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3881,,,B,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,CHEMBL619396,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3882,,,B,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,CHEMBL619397,,8,1,H,12166,Autocuration,,,BAO_0000357,
3883,,,B,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,CHEMBL619398,,8,1,H,12166,Autocuration,,,BAO_0000357,
3884,,,B,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,CHEMBL619399,,8,1,H,12166,Autocuration,,,BAO_0000357,
3885,,,B,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,CHEMBL619400,,8,1,H,12166,Autocuration,,,BAO_0000357,
3886,,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,CHEMBL619401,,8,1,H,12166,Autocuration,,,BAO_0000019,
3887,,,B,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,CHEMBL619402,,8,1,H,12166,Autocuration,,,BAO_0000019,
3888,Rattus norvegicus,,B,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,CHEMBL619403,10116.0,9,1,D,12166,Expert,,663.0,BAO_0000219,
3889,,,B,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,CHEMBL619404,,8,1,H,12166,Autocuration,,,BAO_0000357,
3890,,,B,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,CHEMBL619405,,8,1,H,12166,Autocuration,,,BAO_0000357,
3891,,,B,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,CHEMBL619406,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3892,Rattus norvegicus,,B,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,CHEMBL619407,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
3893,,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,CHEMBL619408,,8,1,H,12166,Autocuration,,,BAO_0000357,
3894,,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,CHEMBL619409,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3895,,,B,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,CHEMBL619410,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3896,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,CHEMBL619753,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3897,,,B,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,CHEMBL619754,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3898,,,B,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,CHEMBL619903,,8,1,H,12166,Expert,,,BAO_0000357,
3899,,,B,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,CHEMBL619904,,8,1,H,12166,Expert,,,BAO_0000357,
3900,,,B,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,CHEMBL619905,,8,1,H,12166,Expert,,,BAO_0000357,
3901,,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,CHEMBL619906,,8,1,H,12166,Autocuration,,,BAO_0000019,
3902,,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,CHEMBL619907,,8,1,H,12166,Autocuration,,,BAO_0000019,
3903,,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,CHEMBL619908,,8,1,H,12166,Autocuration,,,BAO_0000019,
3904,,,B,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,CHEMBL619909,,8,1,H,12166,Autocuration,,,BAO_0000019,
3905,,,F,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,CHEMBL619910,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3906,,,B,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,CHEMBL882929,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3907,,,B,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,CHEMBL619911,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3908,,,B,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,CHEMBL619912,,8,1,H,12166,Autocuration,,,BAO_0000019,
3909,Rattus norvegicus,,B,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,CHEMBL619913,10116.0,9,1,D,12166,Expert,,,BAO_0000357,
3910,,,B,In vitro inhibitory activity against RBL-1 5-LO,,CHEMBL619914,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3911,,,B,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,CHEMBL619915,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3912,,,B,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,CHEMBL619916,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3913,,,B,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,CHEMBL619917,,8,1,H,12166,Autocuration,,,BAO_0000218,
3914,,,B,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,CHEMBL619918,,8,1,H,12166,Autocuration,,,BAO_0000357,
3915,,,B,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,CHEMBL619919,,8,1,H,12166,Autocuration,,,BAO_0000218,
3916,,,B,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,CHEMBL883710,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3917,,,B,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,CHEMBL619920,,8,1,H,12166,Autocuration,,,BAO_0000019,178.0
3918,,,B,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,CHEMBL619921,,8,1,H,12166,Expert,,,BAO_0000357,
3919,,,F,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,CHEMBL619922,,8,1,H,12166,Autocuration,,,BAO_0000019,
3920,,,F,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,CHEMBL619923,,8,1,H,12166,Autocuration,,,BAO_0000219,
3921,,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,CHEMBL619924,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3922,,,B,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,CHEMBL619925,,8,1,H,12166,Expert,,,BAO_0000357,
3923,,,B,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,CHEMBL619926,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3924,,,B,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,CHEMBL619927,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3925,,,B,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,CHEMBL619928,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3926,,,B,In vitro inhibition of RBL-1 5-lipoxygenase,,CHEMBL619929,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3927,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,CHEMBL875089,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3928,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,CHEMBL619930,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3929,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,CHEMBL619931,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3930,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,CHEMBL619932,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3931,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,CHEMBL619933,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3932,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,CHEMBL619934,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3933,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,CHEMBL619935,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3934,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,CHEMBL619936,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3935,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,CHEMBL619937,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3936,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,CHEMBL619938,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3937,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,CHEMBL619939,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3938,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,CHEMBL619940,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3939,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,CHEMBL875090,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3940,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,CHEMBL619941,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3941,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,CHEMBL619942,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3942,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,CHEMBL883711,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3943,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,CHEMBL619943,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3944,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,CHEMBL619944,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3945,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,CHEMBL619945,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3946,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,CHEMBL619946,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3947,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,CHEMBL619947,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3948,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,CHEMBL619948,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3949,,,B,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,CHEMBL619949,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3950,,,B,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,CHEMBL619950,,8,1,H,12166,Expert,,,BAO_0000019,
3951,,,B,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,CHEMBL618050,,8,1,H,12166,Autocuration,,,BAO_0000019,
3952,,,F,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,CHEMBL875091,,8,1,H,12166,Expert,,663.0,BAO_0000219,
3953,,,F,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,CHEMBL618051,,8,1,H,12166,Expert,,663.0,BAO_0000219,
3954,Rattus norvegicus,,B,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,CHEMBL618052,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
3955,,,B,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,CHEMBL618053,,8,1,H,12166,Autocuration,,,BAO_0000019,
3956,,,B,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,CHEMBL618054,,8,1,H,12166,Expert,,,BAO_0000019,
3957,Rattus norvegicus,,B,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,CHEMBL618055,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
3958,,,B,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,CHEMBL618056,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3959,,,B,In vitro inhibitory activity against 5-lipoxygenase was determined,,CHEMBL618057,,8,1,H,12166,Autocuration,,,BAO_0000357,
3960,,,B,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,CHEMBL618058,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3961,,,B,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,CHEMBL618059,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3962,Rattus norvegicus,,F,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,CHEMBL618060,10116.0,9,1,D,12166,Expert,,,BAO_0000019,
3963,,,B,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,CHEMBL618061,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3964,,,B,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,CHEMBL618062,,8,1,H,12166,Autocuration,,,BAO_0000019,
3965,,,B,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,CHEMBL618063,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3966,,,B,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,CHEMBL618064,,8,1,H,12166,Autocuration,,,BAO_0000357,
3967,Rattus norvegicus,,B,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,CHEMBL618065,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
3968,Rattus norvegicus,,B,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,CHEMBL618066,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
3969,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL618067,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3970,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,CHEMBL618068,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
3971,Rattus norvegicus,,B,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,CHEMBL618069,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
3972,,,B,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL618070,,8,1,H,12166,Expert,,702.0,BAO_0000219,
3973,,,F,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,CHEMBL618071,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3974,,,F,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,CHEMBL619247,,8,1,H,10825,Autocuration,,,BAO_0000019,349.0
3975,,,F,Approximate dose levels for a half maximal reduction of 5-HTP levels,,CHEMBL619248,,8,1,H,10825,Autocuration,,,BAO_0000019,
3976,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL619249,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
3977,,,B,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL619250,,8,1,H,10576,Autocuration,,,BAO_0000221,10000000.0
3978,,,B,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,CHEMBL619251,,8,1,H,10577,Autocuration,,,BAO_0000019,
3979,Canis lupus familiaris,,F,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,CHEMBL619252,9615.0,8,1,H,55,Autocuration,,,BAO_0000019,178.0
3980,,,F,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,CHEMBL619253,,8,1,H,55,Autocuration,,,BAO_0000019,178.0
3981,,,B,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,CHEMBL619254,,8,1,H,12166,Autocuration,,,BAO_0000219,
3982,,,B,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,CHEMBL619255,,8,1,H,17140,Expert,,,BAO_0000219,
3983,,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,CHEMBL619256,,8,1,H,17140,Expert,,,BAO_0000219,
3984,,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,CHEMBL875418,,8,1,H,17140,Autocuration,,,BAO_0000219,
3985,,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,CHEMBL619257,,8,1,H,17140,Expert,,,BAO_0000219,
3986,,,B,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,CHEMBL619258,,8,1,H,17140,Autocuration,,,BAO_0000219,
3987,,,B,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,CHEMBL619259,,8,1,H,17140,Expert,,,BAO_0000357,
3988,,,B,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,CHEMBL619260,,8,1,H,17140,Expert,,,BAO_0000357,
3989,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619261,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3990,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619263,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3991,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619264,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3992,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619265,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3993,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619266,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3994,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619902,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3995,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620058,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3996,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620059,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3997,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620060,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3998,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620061,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
3999,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620062,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4000,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620063,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4001,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620064,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4002,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620065,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4003,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620066,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4004,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620067,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4005,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620068,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4006,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620069,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4007,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620070,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4008,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620071,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4009,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620072,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4010,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620036,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4011,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL857702,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4012,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620037,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4013,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620038,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4014,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620039,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4015,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620040,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4016,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620041,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4017,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620042,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4018,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620043,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4019,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620044,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4020,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620045,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4021,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620046,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4022,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620047,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4023,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620048,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4024,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL857703,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4025,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620049,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4026,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620050,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4027,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620051,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4028,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619213,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4029,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619214,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4030,Canis lupus familiaris,,F,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619804,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4031,Canis lupus familiaris,,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL619805,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4032,Canis lupus familiaris,,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619806,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4033,Canis lupus familiaris,,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619807,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4034,Canis lupus familiaris,,F,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619808,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4035,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,CHEMBL619809,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4036,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,CHEMBL619810,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4037,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,CHEMBL619811,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4038,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,CHEMBL620769,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4039,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,CHEMBL620770,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4040,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,CHEMBL620771,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4041,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,CHEMBL620772,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4042,Canis lupus familiaris,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,CHEMBL620773,9615.0,8,1,H,55,Autocuration,,,BAO_0000218,
4043,Cavia porcellus,,B,Ability to inhibit 5-lipoxygenase in guinea pig,,CHEMBL620774,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4044,Cavia porcellus,,B,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,CHEMBL620775,10141.0,8,1,H,55,Expert,,,BAO_0000357,
4045,Cavia porcellus,,B,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,CHEMBL620776,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4046,Cavia porcellus,,B,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620777,10141.0,8,1,H,55,Autocuration,,,BAO_0000218,178.0
4047,Cavia porcellus,,B,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,CHEMBL620778,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4048,Cavia porcellus,,B,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,CHEMBL620779,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4049,Cavia porcellus,,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,CHEMBL621500,10141.0,8,1,H,55,Expert,,,BAO_0000019,
4050,Cavia porcellus,,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,CHEMBL621501,10141.0,8,1,H,55,Expert,,,BAO_0000019,
4051,Cavia porcellus,,B,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,CHEMBL618098,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
4052,Cavia porcellus,,B,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,CHEMBL618099,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
4053,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase,,CHEMBL618100,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4054,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,CHEMBL618101,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4055,Cavia porcellus,,B,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,CHEMBL618102,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4056,Cavia porcellus,,B,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,CHEMBL618103,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4057,Cavia porcellus,,B,Inhibitory activity uM,,CHEMBL618104,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4058,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,CHEMBL883712,10141.0,8,1,H,55,Autocuration,,,BAO_0000219,
4059,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase at 10 uM,,CHEMBL618105,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4060,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,CHEMBL618106,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4061,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,CHEMBL618107,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4062,Cavia porcellus,,B,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,CHEMBL618108,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4063,Cavia porcellus,,B,Inhibitory activity uM,,CHEMBL618109,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4064,Cavia porcellus,,B,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,CHEMBL618110,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4065,Cavia porcellus,,B,Inhibitory activity uM,,CHEMBL618111,10141.0,8,1,H,55,Expert,,,BAO_0000357,
4066,Cavia porcellus,,F,Inhibitory activity uM,,CHEMBL618112,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
4067,Cavia porcellus,,B,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,CHEMBL618113,10141.0,8,1,H,55,Autocuration,,,BAO_0000019,
4068,Cavia porcellus,,B,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,CHEMBL618114,10141.0,8,1,H,55,Autocuration,,,BAO_0000357,
4069,Cavia porcellus,,F,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,CHEMBL620871,10141.0,8,1,H,55,Expert,,,BAO_0000221,2116.0
4070,,,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,CHEMBL620872,,8,1,H,55,Autocuration,,,BAO_0000357,
4071,,,B,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,CHEMBL620873,,8,1,H,55,Autocuration,,,BAO_0000357,
4072,,,B,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,CHEMBL620874,,8,1,H,55,Autocuration,,,BAO_0000357,
4073,,,B,In vitro inhibition of human 5-Lipoxygenase.,,CHEMBL620875,,8,1,H,55,Expert,,,BAO_0000357,
4074,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,CHEMBL620876,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4075,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,CHEMBL620877,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4076,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,CHEMBL857854,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4077,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,CHEMBL620878,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4078,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,CHEMBL620879,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4079,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,CHEMBL620880,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4080,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,CHEMBL620881,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4081,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,CHEMBL620882,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4082,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,CHEMBL620883,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4083,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,CHEMBL620884,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4084,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,CHEMBL620885,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4085,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,CHEMBL620886,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4086,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,CHEMBL620887,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4087,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,CHEMBL618039,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4088,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,CHEMBL618040,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4089,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,CHEMBL618041,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4090,Rattus norvegicus,,B,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,CHEMBL618216,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4091,Rattus norvegicus,,B,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,CHEMBL618217,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4092,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,CHEMBL618218,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4093,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,CHEMBL618219,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4094,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,CHEMBL618220,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4095,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,CHEMBL618221,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4096,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,CHEMBL618222,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4097,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,CHEMBL618223,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4098,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,CHEMBL618224,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4099,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,CHEMBL618225,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4100,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,CHEMBL618226,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4101,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,CHEMBL618227,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4102,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,CHEMBL618228,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4103,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,CHEMBL618229,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4104,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,CHEMBL618230,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4105,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,CHEMBL618231,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4106,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,CHEMBL618232,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4107,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,CHEMBL618233,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4108,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,CHEMBL618234,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4109,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,CHEMBL618235,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4110,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,CHEMBL618115,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4111,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,CHEMBL618116,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4112,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,CHEMBL618117,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4113,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,CHEMBL619968,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4114,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,CHEMBL619969,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4115,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,CHEMBL619970,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4116,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,CHEMBL619971,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4117,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,CHEMBL619972,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4118,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,CHEMBL619973,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4119,Rattus norvegicus,,B,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,CHEMBL619974,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4120,Rattus norvegicus,,B,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,CHEMBL619975,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4121,Rattus norvegicus,,B,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,CHEMBL619976,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,
4122,Rattus norvegicus,,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,CHEMBL619977,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4123,Rattus norvegicus,,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,CHEMBL619978,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4124,Rattus norvegicus,,B,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,CHEMBL619979,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4125,Rattus norvegicus,,B,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,CHEMBL619980,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4126,Rattus norvegicus,,B,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,CHEMBL619981,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4127,Homo sapiens,,F,In vitro inhibition of 7226/S myeloma cancer cell line,,CHEMBL619982,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
4128,Homo sapiens,,F,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,CHEMBL619983,9606.0,1,1,N,80698,Intermediate,,993.0,BAO_0000219,
4129,Homo sapiens,,F,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,CHEMBL620031,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4130,Homo sapiens,,F,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,CHEMBL620032,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4131,Cricetulus griseus,,F,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,CHEMBL620033,10029.0,1,1,N,81264,Expert,,505.0,BAO_0000219,
4132,Cricetulus griseus,,F,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,CHEMBL620034,10029.0,1,1,N,81264,Expert,,505.0,BAO_0000219,
4133,Rattus norvegicus,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,CHEMBL620035,10116.0,1,1,N,80635,Intermediate,,1119.0,BAO_0000219,
4134,Rattus norvegicus,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,CHEMBL618318,10116.0,1,1,N,80635,Intermediate,,1119.0,BAO_0000219,
4135,Rattus norvegicus,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,CHEMBL618319,10116.0,1,1,N,80635,Intermediate,,1119.0,BAO_0000219,
4136,Rattus norvegicus,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,CHEMBL618320,10116.0,1,1,N,80635,Intermediate,,1119.0,BAO_0000219,
4137,Rattus norvegicus,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,CHEMBL618321,10116.0,1,1,N,80635,Intermediate,,1119.0,BAO_0000219,
4138,Rattus norvegicus,,F,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,CHEMBL883118,10116.0,1,1,N,80635,Intermediate,,1119.0,BAO_0000219,
4139,Homo sapiens,,F,In vitro antitumor activity against renal 786-0 tumor cell lines,,CHEMBL883795,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4140,Homo sapiens,,F,Cytotoxic activity against 786-0 Renal cancer cell line,,CHEMBL618322,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4141,Homo sapiens,,F,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,CHEMBL618323,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4142,Homo sapiens,,F,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,CHEMBL618324,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4143,Homo sapiens,,F,In vitro antitumor activity against human renal 786-0 cell line,,CHEMBL618325,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4144,Homo sapiens,,F,Inhibition of Renal cancer in 786-0 cancer cell lines,,CHEMBL875416,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4145,Homo sapiens,,F,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,CHEMBL618326,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4146,Homo sapiens,,F,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,CHEMBL618327,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4147,Homo sapiens,,F,inhibition of the growth of renal cancer(786-0) cell line,,CHEMBL619215,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4148,Homo sapiens,,F,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,CHEMBL619216,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4149,Homo sapiens,,F,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,CHEMBL619217,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4150,Homo sapiens,,F,The IC50 value was measured on 786-0 cell line in ovarian tumor,,CHEMBL619218,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4151,Homo sapiens,,F,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,CHEMBL619219,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4152,Homo sapiens,,F,The IC50 value was measured on 786-0 cell line in renal tumor type.,,CHEMBL619220,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4153,Homo sapiens,,F,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,CHEMBL619221,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4154,Homo sapiens,,F,Tested for cytotoxic activity against renal cancer 786-0 cell line,,CHEMBL619222,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4155,Homo sapiens,,F,Compound was tested for growth inhibitory activity against 786-0 cell line,,CHEMBL857454,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
4156,,,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,CHEMBL619223,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4157,,,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,CHEMBL619224,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4158,,,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,CHEMBL619225,,8,1,H,12166,Autocuration,,,BAO_0000019,
4159,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL619226,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4160,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,CHEMBL619227,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4161,,,B,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,CHEMBL619228,,8,1,H,12166,Autocuration,,,BAO_0000357,
4162,,,B,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,CHEMBL619229,,8,1,H,12166,Autocuration,,,BAO_0000219,
4163,,,B,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,CHEMBL619230,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4164,,,B,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,CHEMBL619231,,8,1,H,12166,Autocuration,,,BAO_0000357,
4165,,,B,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,CHEMBL619232,,8,1,H,12166,Autocuration,,,BAO_0000357,
4166,,,B,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,CHEMBL619233,,8,1,H,12166,Expert,,,BAO_0000357,
4167,,,B,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,CHEMBL619234,,8,1,H,12166,Autocuration,,,BAO_0000357,
4168,,,B,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,CHEMBL619235,,8,1,H,12166,Autocuration,,,BAO_0000357,
4169,Rattus norvegicus,,B,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,CHEMBL619236,10116.0,9,1,D,12166,Expert,,,BAO_0000019,
4170,,,B,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,CHEMBL619237,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4171,,,B,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,CHEMBL619238,,8,1,H,12166,Autocuration,,,BAO_0000357,
4172,,,B,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,CHEMBL619239,,8,1,H,12166,Expert,,,BAO_0000357,
4173,,,B,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,CHEMBL619240,,8,1,H,12166,Autocuration,,,BAO_0000357,
4174,,,B,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,CHEMBL875417,,8,1,H,12166,Autocuration,,,BAO_0000019,
4175,,,B,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,CHEMBL619241,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4176,,,F,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,CHEMBL619242,,8,1,H,12166,Expert,,,BAO_0000019,
4177,,,B,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,CHEMBL883796,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4178,,,B,Tested for its inhibitory activity against 5-lipoxygenase,,CHEMBL619243,,8,1,H,12166,Autocuration,,,BAO_0000357,
4179,,,B,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,CHEMBL619244,,8,1,H,12166,Autocuration,,,BAO_0000357,
4180,,,B,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,CHEMBL619245,,8,1,H,12166,Expert,,,BAO_0000019,
4181,,,B,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,CHEMBL619246,,8,1,H,12166,Expert,,,BAO_0000019,
4182,,,B,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,CHEMBL619984,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4183,,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,CHEMBL619985,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4184,,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,CHEMBL619986,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4185,,,B,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,CHEMBL619987,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4186,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,CHEMBL619988,,8,1,H,12166,Autocuration,,,BAO_0000218,
4187,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,CHEMBL619989,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4188,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,CHEMBL619990,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4189,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,CHEMBL619991,,8,1,H,12166,Autocuration,,,BAO_0000219,
4190,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,CHEMBL619992,,8,1,H,12166,Autocuration,,,BAO_0000219,
4191,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,CHEMBL619993,,8,1,H,12166,Autocuration,,,BAO_0000218,
4192,,,F,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,CHEMBL619994,,8,1,H,12166,Autocuration,,663.0,BAO_0000219,
4193,,,F,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,CHEMBL619995,,8,1,H,12166,Autocuration,,663.0,BAO_0000219,
4194,,,B,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,CHEMBL619996,,8,1,H,12166,Autocuration,,,BAO_0000019,
4195,,,B,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,CHEMBL619997,,8,1,H,12166,Autocuration,,,BAO_0000019,
4196,,,B,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,CHEMBL619998,,8,1,H,12166,Expert,,,BAO_0000019,
4197,,,B,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,CHEMBL619999,,8,1,H,12166,Expert,,,BAO_0000019,
4198,,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,CHEMBL620000,,8,1,H,12166,Autocuration,,,BAO_0000019,
4199,,,B,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,CHEMBL620001,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4200,Rattus norvegicus,,B,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,CHEMBL620002,10116.0,9,1,D,12166,Expert,,,BAO_0000357,
4201,,,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,CHEMBL620003,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4202,,,F,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,CHEMBL620004,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4203,,,B,Compound was evaluated for the inhibition of 5-lipoxygenase,,CHEMBL874063,,8,1,H,12166,Autocuration,,,BAO_0000357,
4204,,,B,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,CHEMBL620005,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4205,,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,CHEMBL620006,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4206,,,B,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,CHEMBL620007,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4207,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,CHEMBL620008,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4208,Rattus norvegicus,,B,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,CHEMBL620009,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
4209,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,CHEMBL620010,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4210,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,CHEMBL620011,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4211,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,CHEMBL620677,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4212,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,CHEMBL620678,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4213,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,CHEMBL620679,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4214,,,B,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,CHEMBL620680,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4215,Rattus norvegicus,,B,Inhibitory activity against 5-lipoxygenase at 10 uM,,CHEMBL620838,10116.0,9,1,D,12166,Expert,,,BAO_0000357,
4216,,,B,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,CHEMBL620839,,8,1,H,12166,Autocuration,,,BAO_0000357,
4217,,,B,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,CHEMBL620840,,8,1,H,12166,Expert,,,BAO_0000357,
4218,,,B,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,CHEMBL620841,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4219,,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,CHEMBL620842,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4220,,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,CHEMBL620843,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4221,,,B,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,CHEMBL620844,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4222,,,B,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,CHEMBL620845,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4223,,,B,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,CHEMBL620846,,8,1,H,12166,Autocuration,,,BAO_0000019,
4224,,,B,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,CHEMBL873951,,8,1,H,12166,Autocuration,,,BAO_0000357,
4225,,,B,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,CHEMBL620847,,8,1,H,12166,Autocuration,,,BAO_0000357,
4226,,,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,CHEMBL620848,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4227,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,CHEMBL620849,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4228,,,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,CHEMBL620850,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4229,,,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,CHEMBL620851,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4230,,,B,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,CHEMBL620852,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4231,,,B,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL875098,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4232,Rattus norvegicus,,B,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,CHEMBL620853,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
4233,,,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,CHEMBL620854,,8,1,H,12166,Autocuration,,,BAO_0000019,
4234,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,CHEMBL620855,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4235,,,B,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,CHEMBL839884,,8,1,H,12166,Expert,,702.0,BAO_0000219,
4236,,,B,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL620856,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4237,,,B,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL620857,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4238,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,CHEMBL620858,,8,1,H,12166,Autocuration,,,BAO_0000019,
4239,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,CHEMBL620859,,8,1,H,12166,Autocuration,,,BAO_0000019,
4240,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,CHEMBL620860,,8,1,H,12166,Autocuration,,,BAO_0000019,
4241,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,CHEMBL620861,,8,1,H,12166,Autocuration,,,BAO_0000019,
4242,,,B,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,CHEMBL620862,,8,1,H,12166,Expert,,,BAO_0000357,
4243,,,B,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,CHEMBL620863,,8,1,H,12166,Autocuration,,,BAO_0000357,
4244,,,B,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,CHEMBL620864,,8,1,H,12166,Autocuration,,,BAO_0000019,
4245,,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,CHEMBL620865,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4246,,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,CHEMBL620866,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4247,,,B,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,CHEMBL620867,,8,1,H,12166,Autocuration,,663.0,BAO_0000219,
4248,,,B,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,CHEMBL620868,,8,1,H,12166,Autocuration,,663.0,BAO_0000219,
4249,,,F,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,CHEMBL620869,,8,1,H,12166,Autocuration,,663.0,BAO_0000219,
4250,,,F,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,CHEMBL873952,,8,1,H,12166,Autocuration,,,BAO_0000019,
4251,,,B,The compound was tested for inhibition of isolated 5-lipoxygenase,,CHEMBL875099,,8,1,H,12166,Autocuration,,,BAO_0000357,
4252,,,F,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,CHEMBL620870,,8,1,H,12166,Autocuration,,663.0,BAO_0000219,
4253,,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,CHEMBL618261,,8,1,H,12166,Autocuration,,,BAO_0000019,
4254,,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,CHEMBL618262,,8,1,H,12166,Autocuration,,,BAO_0000019,
4255,,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,CHEMBL619428,,8,1,H,12166,Autocuration,,,BAO_0000019,
4256,,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,CHEMBL619429,,8,1,H,12166,Autocuration,,,BAO_0000019,
4257,,,B,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,CHEMBL619430,,8,1,H,12166,Autocuration,,,BAO_0000019,
4258,,,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,CHEMBL620017,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4259,,,B,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,CHEMBL620018,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4260,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,CHEMBL620019,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4261,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,CHEMBL620020,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4262,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,CHEMBL620021,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4263,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,CHEMBL620022,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4264,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,CHEMBL620023,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4265,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,CHEMBL620024,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4266,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,CHEMBL620025,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4267,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,CHEMBL620026,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4268,,,F,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,CHEMBL620027,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4269,Rattus norvegicus,,F,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,CHEMBL620028,10116.0,9,1,D,12166,Expert,,,BAO_0000019,
4270,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,CHEMBL620029,,8,1,H,12166,Autocuration,,,BAO_0000357,
4271,,,B,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,CHEMBL620030,,8,1,H,12166,Autocuration,,,BAO_0000357,
4272,,,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,CHEMBL875415,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4273,,,B,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,CHEMBL618256,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4274,,,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,CHEMBL618257,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4275,,,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,CHEMBL618258,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4276,,,B,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,CHEMBL618259,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4277,,,B,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,CHEMBL618260,,8,1,H,12166,Autocuration,,,BAO_0000019,
4278,,,B,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,CHEMBL618215,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4279,,,B,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,CHEMBL618390,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4280,,,B,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,CHEMBL618391,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4281,,,B,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,CHEMBL618392,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4282,,,B,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,CHEMBL618393,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4283,,,B,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,CHEMBL618394,,8,1,H,12166,Autocuration,,,BAO_0000219,
4284,Homo sapiens,,B,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,CHEMBL618395,9606.0,8,1,H,12166,Expert,,702.0,BAO_0000219,
4285,Rattus norvegicus,,B,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,CHEMBL618396,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
4286,Rattus norvegicus,,B,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,CHEMBL858253,10116.0,9,1,D,12166,Expert,,702.0,BAO_0000219,
4287,Rattus norvegicus,,B,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,CHEMBL618397,10116.0,9,1,D,12166,Autocuration,,,BAO_0000019,
4288,Glycine max,,B,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,CHEMBL618398,3847.0,8,1,H,12054,Autocuration,,,BAO_0000357,
4289,,,B,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,CHEMBL618399,,0,1,U,22226,Autocuration,,,BAO_0000019,
4290,,,B,In vitro inhibition of 5-Lipoxygenase; Inactive.,,CHEMBL618400,,8,1,H,55,Expert,,,BAO_0000357,
4291,,,B,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,CHEMBL618401,,8,1,H,55,Autocuration,,,BAO_0000357,
4292,,,B,Inhibitory concentration against 5-lipoxygenase; No inhibition,,CHEMBL618402,,8,1,H,55,Autocuration,,,BAO_0000357,
4293,,,B,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,CHEMBL876400,,8,1,H,55,Autocuration,,702.0,BAO_0000219,
4294,,,B,Inhibitory activity against 5-lipoxygenase.,,CHEMBL618403,,8,1,H,55,Expert,,,BAO_0000357,
4295,,,B,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,CHEMBL618404,,8,1,H,55,Autocuration,,,BAO_0000357,
4296,,,B,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,CHEMBL618405,,8,1,H,55,Autocuration,,,BAO_0000357,
4297,,,B,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,CHEMBL618406,,8,1,H,55,Autocuration,,,BAO_0000357,
4298,,,F,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,CHEMBL618407,,8,1,H,55,Expert,,,BAO_0000019,
4299,,,B,Tested for the inhibitory activity against 5-lipoxygenase,,CHEMBL618408,,8,1,H,55,Autocuration,,,BAO_0000357,
4300,,,B,Compound was tested for its inhibitory activity against 5-lipoxygenase,,CHEMBL618409,,8,1,H,55,Autocuration,,,BAO_0000357,
4301,,,B,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,CHEMBL618410,,8,1,H,55,Autocuration,,,BAO_0000357,
4302,,,B,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,CHEMBL618411,,8,1,H,55,Autocuration,,,BAO_0000357,
4303,,,B,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,CHEMBL618412,,8,1,H,55,Autocuration,,,BAO_0000357,
4304,,,B,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,CHEMBL618413,,8,1,H,12166,Autocuration,,702.0,BAO_0000219,
4305,,,B,,,CHEMBL618414,,8,1,H,12166,Autocuration,,,BAO_0000357,
4306,,,B,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,CHEMBL618415,,8,1,H,10102,Autocuration,,,BAO_0000357,
4307,,,B,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,CHEMBL618416,,8,1,H,10102,Autocuration,,,BAO_0000019,
4308,,,B,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,CHEMBL876401,,8,1,H,10102,Autocuration,,,BAO_0000357,
4309,,,B,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,CHEMBL618417,,8,1,H,10102,Expert,,,BAO_0000357,
4310,,,B,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,CHEMBL618418,,8,1,H,10102,Autocuration,,,BAO_0000357,
4311,,,B,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,CHEMBL618419,,8,1,H,10102,Autocuration,,,BAO_0000357,
4312,,,B,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,CHEMBL618420,,8,1,H,10102,Autocuration,,,BAO_0000357,
4313,,,B,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,CHEMBL618421,,8,1,H,10102,Autocuration,,,BAO_0000357,
4314,,,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,CHEMBL618422,,8,1,H,11238,Autocuration,,,BAO_0000019,
4315,,,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,CHEMBL618423,,8,1,H,11238,Autocuration,,,BAO_0000019,
4316,,,B,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,CHEMBL618424,,8,1,H,11238,Autocuration,,,BAO_0000019,
4317,,,B,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,CHEMBL618425,,2,1,S,100284,Intermediate,,,BAO_0000220,
4318,Homo sapiens,,F,The dark toxicity against 543 human galactophore carcinoma cells,,CHEMBL618426,9606.0,0,1,U,22226,Autocuration,,,BAO_0000019,
4319,Homo sapiens,,F,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,CHEMBL618427,9606.0,1,1,N,80623,Expert,,390.0,BAO_0000219,
4320,Homo sapiens,,F,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,CHEMBL618428,9606.0,1,1,N,80008,Expert,,345.0,BAO_0000219,
4321,Homo sapiens,,F,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,CHEMBL618429,9606.0,1,1,N,80008,Intermediate,,345.0,BAO_0000219,
4322,Homo sapiens,,F,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,CHEMBL618430,9606.0,1,1,N,80008,Intermediate,,345.0,BAO_0000219,
4323,Homo sapiens,,F,Growth inhibition against human 5637 cell lines,,CHEMBL618431,9606.0,1,1,N,80008,Expert,,345.0,BAO_0000219,
4324,Homo sapiens,,F,Antitumor activity against human bladder carcinoma 5637 cells.,,CHEMBL883799,9606.0,1,1,N,80008,Expert,,345.0,BAO_0000219,
4325,Homo sapiens,,F,Antitumor activity against human bladder carcinoma 5637 cells,,CHEMBL618432,9606.0,1,1,N,80008,Intermediate,,345.0,BAO_0000219,
4326,Homo sapiens,,F,Antitumor activity against human bladder carcinoma 5637 cells,,CHEMBL618433,9606.0,1,1,N,80008,Intermediate,,345.0,BAO_0000219,
4327,Bos taurus,,B,In vitro inhibition of bovine trypsin(Trp).,,CHEMBL618434,9913.0,9,1,D,10443,Expert,,,BAO_0000357,
4328,Cercopithecidae,,B,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,CHEMBL618435,9527.0,8,1,H,240,Expert,,407.0,BAO_0000219,
4329,,,B,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,CHEMBL876402,,8,1,H,10577,Autocuration,,,BAO_0000357,
4330,,,F,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,CHEMBL618436,,6,1,H,104698,Autocuration,,,BAO_0000019,
4331,,,F,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,CHEMBL618437,,0,1,U,22226,Autocuration,,,BAO_0000218,
4332,Cavia porcellus,,B,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,CHEMBL618438,10141.0,9,1,D,20033,Intermediate,,,BAO_0000357,
4333,Rattus norvegicus,,A,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,CHEMBL883800,10116.0,8,1,H,17045,Expert,,,BAO_0000251,
4334,Rattus norvegicus,,A,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,CHEMBL618439,10116.0,8,1,H,17045,Expert,,,BAO_0000251,
4335,,,F,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,CHEMBL618440,,0,1,U,22226,Intermediate,,,BAO_0000019,
4336,,,F,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,CHEMBL618441,,0,1,U,22226,Intermediate,,,BAO_0000019,
4337,Trypanosoma brucei,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,CHEMBL618442,5691.0,8,1,H,11938,Expert,,,BAO_0000019,
4338,Trypanosoma brucei,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,CHEMBL618443,5691.0,8,1,H,11938,Autocuration,,,BAO_0000019,
4339,Ovis aries,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,CHEMBL619158,9940.0,8,1,H,11938,Expert,,,BAO_0000019,
4340,Ovis aries,,B,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,CHEMBL620974,9940.0,8,1,H,11938,Autocuration,,,BAO_0000019,
4341,,,B,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,CHEMBL620975,,8,1,H,11938,Autocuration,,,BAO_0000357,
4342,Homo sapiens,,F,Average inhibitory concentration against 60 human cell lines was reported,,CHEMBL620976,9606.0,0,1,U,22226,Intermediate,,,BAO_0000019,
4343,Homo sapiens,,F,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,CHEMBL620977,9606.0,0,1,U,22226,Expert,,,BAO_0000019,
4344,Homo sapiens,,F,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,CHEMBL620978,9606.0,1,1,N,80315,Intermediate,,542.0,BAO_0000219,
4345,Homo sapiens,,F,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,CHEMBL620979,9606.0,1,1,N,80315,Intermediate,,542.0,BAO_0000219,
4346,,,F,In vitro mean growth inhibitory activity against 60-cell panel,,CHEMBL620980,,1,1,N,80315,Expert,,542.0,BAO_0000219,
4347,,,F,In vitro mean growth lethal concentration against 60-cell panel,,CHEMBL620981,,1,1,N,80315,Expert,,542.0,BAO_0000219,
4348,,,F,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,CHEMBL620982,,1,1,N,80315,Expert,,542.0,BAO_0000219,
4349,,,F,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,CHEMBL620983,,1,1,N,80315,Expert,,542.0,BAO_0000219,
4350,,,F,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,CHEMBL620984,,4,1,H,104775,Autocuration,,,BAO_0000019,
4351,,,F,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,CHEMBL620985,,4,1,H,104775,Autocuration,,,BAO_0000019,
4352,,,B,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,CHEMBL620986,,8,1,H,275,Expert,,,BAO_0000357,
4353,Plasmodium falciparum,,F,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,CHEMBL620987,5833.0,1,1,N,50425,Expert,,,BAO_0000218,
4354,Plasmodium falciparum,,F,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,CHEMBL620988,5833.0,1,1,N,50425,Expert,,,BAO_0000218,
4355,Plasmodium falciparum,,F,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,CHEMBL620989,5833.0,1,1,N,50425,Expert,,,BAO_0000218,
4356,Plasmodium falciparum,,F,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,CHEMBL620990,5833.0,1,1,N,50425,Expert,,,BAO_0000218,
4357,Plasmodium falciparum,,F,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,CHEMBL620991,5833.0,1,1,N,50425,Intermediate,,,BAO_0000218,
4358,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,CHEMBL620992,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4359,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,CHEMBL620993,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4360,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,CHEMBL620994,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4361,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,CHEMBL620995,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4362,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,CHEMBL620996,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4363,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,CHEMBL875581,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4364,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,CHEMBL620997,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4365,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,CHEMBL620998,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4366,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,CHEMBL620999,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4367,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,CHEMBL621000,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4368,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,CHEMBL621001,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4369,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,CHEMBL621002,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4370,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,CHEMBL621003,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4371,Mus musculus,,F,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,CHEMBL621004,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4372,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,CHEMBL621005,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4373,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,CHEMBL621006,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4374,Mus musculus,,F,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,CHEMBL621007,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4375,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,CHEMBL621008,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4376,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,CHEMBL621009,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4377,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,CHEMBL857705,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4378,Mus musculus,,F,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,CHEMBL619828,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4379,Mus musculus,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,CHEMBL619829,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4380,Mus musculus,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,CHEMBL619830,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4381,Mus musculus,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,CHEMBL619831,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4382,Mus musculus,,F,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,CHEMBL619832,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4383,Mus musculus,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,CHEMBL619833,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4384,Mus musculus,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,CHEMBL619834,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4385,Mus musculus,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,CHEMBL619835,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4386,Mus musculus,,A,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,CHEMBL619836,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4387,Mus musculus,,F,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,CHEMBL619837,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4388,,,F,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,CHEMBL619838,,0,1,U,22224,Autocuration,,,BAO_0000218,
4389,Mus musculus,,A,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,CHEMBL619839,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4390,Mus musculus,,F,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,CHEMBL619840,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4391,Mus musculus,,F,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,CHEMBL619841,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4392,Mus musculus,,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,CHEMBL857704,10090.0,1,1,N,80628,Expert,,850.0,BAO_0000218,
4393,Mus musculus,,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,CHEMBL619842,10090.0,1,1,N,80628,Intermediate,,850.0,BAO_0000218,
4394,Mus musculus,,F,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,CHEMBL619843,10090.0,1,1,N,80628,Expert,,850.0,BAO_0000218,
4395,Staphylococcus aureus,,B,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,CHEMBL619844,1280.0,0,1,U,22226,Autocuration,,,BAO_0000019,
4396,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,CHEMBL857855,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4397,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,CHEMBL619845,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4398,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,CHEMBL619846,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4399,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,CHEMBL619847,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4400,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,CHEMBL619848,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4401,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,CHEMBL620893,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4402,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,CHEMBL620894,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4403,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,CHEMBL620895,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4404,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,CHEMBL620896,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4405,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,CHEMBL620897,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4406,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,CHEMBL620898,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4407,Rattus norvegicus,,B,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,CHEMBL620899,10116.0,0,1,U,22226,Autocuration,,,BAO_0000251,2107.0
4408,Cercopithecidae,,A,The apparent total plasma clearance in monkey,,CHEMBL620900,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4409,Cercopithecidae,,A,Compound was evaluated for Hepatic clearance in monkey,,CHEMBL620901,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4410,Cercopithecidae,,A,Lower clearance in monkey (i.v.) at 0.5 mpk,,CHEMBL620902,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4411,Cercopithecidae,,A,Plasma clearance in rhesus monkey,,CHEMBL620903,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4412,Cercopithecidae,,A,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL620904,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4413,Cercopithecidae,,A,Plasma clearance of compound was determined in monkey,,CHEMBL620905,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4414,Cercopithecidae,,A,Plasma clearance was calculated in rhesus monkey,,CHEMBL620906,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4415,Cercopithecidae,,A,Plasma clearance in rhesus monkey,,CHEMBL875420,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4416,Cercopithecidae,,A,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL620907,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4417,Cercopithecidae,,A,Plasma clearance was evaluated in rhesus,,CHEMBL620908,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4418,Cercopithecidae,,A,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,CHEMBL620909,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4419,Cercopithecidae,,A,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,CHEMBL620910,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4420,Cercopithecidae,,A,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL620911,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4421,Cercopithecidae,,A,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL620912,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4422,Cercopithecidae,,A,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,CHEMBL620913,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4423,Cercopithecidae,,A,Cmax in monkey after administration of 1 mg/kg iv,,CHEMBL620914,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4424,Cercopithecidae,,A,Cmax was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL620915,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4425,Cercopithecidae,,A,Cmax in cynomolgus monkey by iv administration,,CHEMBL620916,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4426,Cercopithecidae,,A,Cmax in cynomolgus monkey by po administration,,CHEMBL620917,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4427,Cercopithecidae,,A,Cmax value evaluated in monkey,,CHEMBL620918,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4428,Cercopithecidae,,A,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL620919,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4429,Cercopithecidae,,A,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,CHEMBL620920,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4430,Cercopithecidae,,A,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,CHEMBL620921,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4431,Cercopithecidae,,A,Maximal plasma concentration in squirrel monkeys,,CHEMBL620922,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4432,Cercopithecidae,,A,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL620923,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4433,Cercopithecidae,,A,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,CHEMBL620924,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4434,Cercopithecidae,,A,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620925,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4435,Cercopithecidae,,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL620926,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4436,Cercopithecidae,,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,CHEMBL620927,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4437,Cercopithecidae,,A,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,CHEMBL620928,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4438,Cercopithecidae,,A,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,CHEMBL620929,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4439,Cercopithecidae,,A,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,CHEMBL620930,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4440,Cercopithecidae,,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,CHEMBL620931,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4441,Cercopithecidae,,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,CHEMBL620932,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4442,monkey,,A,Absolute bioavailability was evaluated in monkey,,CHEMBL620933,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4443,monkey,,A,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL620934,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4444,monkey,,A,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,CHEMBL620935,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4445,Macaca mulatta,,A,Bioavailability of compound was determined in rhesus monkey,,CHEMBL620936,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4446,marmosets,,A,Bioavailability determined after oral administration in marmoset,,CHEMBL620937,38020.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4447,Macaca fascicularis,,A,Oral bioavailability in cynomolgus monkey,,CHEMBL620938,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4448,monkey,,A,Bioavailability in monkey (p.o.) at 2.0 mpk,,CHEMBL620939,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4449,monkey,,A,Bioavailability was evaluated after oral administration in monkey,,CHEMBL620940,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4450,Macaca fascicularis,,A,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL620941,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4451,Macaca mulatta,,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL620942,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4452,Macaca mulatta,,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL620943,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4453,monkey,,A,Bioavailability of the compound was determined in monkey,,CHEMBL620944,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4454,Saimiri sciureus,,A,Bioavailability in squirrel monkey (dose 5 mg/kg),,CHEMBL620945,9521.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4455,monkey,,A,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620946,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4456,monkey,,A,Oral bioavailability in monkey,,CHEMBL620947,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4457,Saimiri sciureus,,A,Compound was tested for bioavailability in squirrel monkey,,CHEMBL620948,9521.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4458,Macaca mulatta,,A,Oral bioavailability in Rhesus monkey,,CHEMBL620949,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4459,Macaca mulatta,,A,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,CHEMBL620950,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4460,Macaca fascicularis,,A,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,CHEMBL620951,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4461,Macaca fascicularis,,A,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,CHEMBL620952,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4462,monkey,,A,Oral bioavailability in monkey (dose 5 mg/kg),,CHEMBL875421,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4463,monkey,,A,Oral bioavailability of compound at 5 mg/kg in monkey,,CHEMBL620953,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4464,Canis lupus familiaris,,A,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,CHEMBL873491,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4465,Canis lupus familiaris,,A,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,CHEMBL620954,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4466,Canis lupus familiaris,,A,Plasma half life determined,,CHEMBL620955,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4467,Canis lupus familiaris,,A,Plasma half life in dog,,CHEMBL618097,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4468,Canis lupus familiaris,,A,Plasma half-life in Beagle dogs,,CHEMBL618268,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4469,Canis lupus familiaris,,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,CHEMBL618269,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4470,Canis lupus familiaris,,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,CHEMBL618270,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4471,Canis lupus familiaris,,A,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,CHEMBL618271,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4472,Canis lupus familiaris,,A,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,CHEMBL873493,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4473,Canis lupus familiaris,,A,Tested for the half life period in dog,,CHEMBL621031,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4474,Canis lupus familiaris,,A,Tested for the half life period in dog at dosage of 10 mpk,,CHEMBL621032,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4475,Canis lupus familiaris,,A,The compound was tested for half life in dog,,CHEMBL621033,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4476,Canis lupus familiaris,,A,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,CHEMBL621034,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4477,Canis lupus familiaris,,A,The half life was determined,,CHEMBL621035,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4478,Canis lupus familiaris,,A,The plasma half-life in dogs,,CHEMBL621036,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4479,Canis lupus familiaris,,A,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,CHEMBL621037,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
4480,Canis lupus familiaris,,A,Half life in dog,,CHEMBL619812,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4481,Canis lupus familiaris,,A,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,CHEMBL619813,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4482,Canis lupus familiaris,,A,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,CHEMBL873335,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4483,Canis lupus familiaris,,A,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL619814,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
4484,Mustela putorius furo,,A,Cmax in ferrets after 30 mg/kg oral dose,,CHEMBL619815,9669.0,1,1,N,50506,Expert,,,BAO_0000218,
4485,Mustela putorius furo,,F,Emesis in ferrets at 30 mg/kg oral dose,,CHEMBL619816,9669.0,1,1,N,50506,Expert,,,BAO_0000218,
4486,Macaca fascicularis,,A,Bioavailability in cynomolgus monkey,,CHEMBL619817,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4487,Macaca fascicularis,,A,Volume of distribution in cynomolgus,,CHEMBL619818,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
4488,Cavia porcellus,,A,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,CHEMBL619819,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4489,Cavia porcellus,,A,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,CHEMBL619820,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4490,Cavia porcellus,,A,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,CHEMBL875419,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4491,Cavia porcellus,,A,AUC in guinea pig after 3mg/kg oral dose,,CHEMBL619821,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4492,Cavia porcellus,,A,Bioavailability in guinea pig was tested,,CHEMBL619822,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4493,Cavia porcellus,,A,Tested for oral bioavailability in guinea pig at 5 mg/kg,,CHEMBL619823,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4494,Cavia porcellus,,A,Tested for the oral bioavailability of the compound,,CHEMBL619824,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4495,Cavia porcellus,,A,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,CHEMBL619825,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4496,Cavia porcellus,,A,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,CHEMBL619826,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4497,Cavia porcellus,,A,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,CHEMBL619827,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,2048.0
4498,Cavia porcellus,,A,Cmax in guinea pig after 3mg/kg oral dose,,CHEMBL618167,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4499,Cavia porcellus,,A,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618168,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
4500,Cavia porcellus,,A,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618169,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,955.0
4501,Cavia porcellus,,A,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618170,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4502,Cavia porcellus,,A,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618171,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,160.0
4503,Cavia porcellus,,A,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618172,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,2113.0
4504,Cavia porcellus,,A,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618173,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,2107.0
4505,Cavia porcellus,,A,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618174,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4506,Cavia porcellus,,A,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL875408,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
4507,Cavia porcellus,,A,Elimination T1/2 in Guinea pig (PO dose),,CHEMBL839827,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4508,Cavia porcellus,,A,Partition coefficient was measured as -log (counts per min ),,CHEMBL618175,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4509,Cavia porcellus,,A,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,CHEMBL618176,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4510,Cavia porcellus,,A,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,CHEMBL618177,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4511,Cavia porcellus,,A,Elimination T1/2 in Guinea pig (PO dose),,CHEMBL618178,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4512,Cavia porcellus,,A,"Tested for the half life period of the compound, intravenously",,CHEMBL618179,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4513,Cavia porcellus,,A,Half-life was measured,,CHEMBL873489,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4514,Cavia porcellus,,A,The time required for onset of inotropy after addition of a single dose of delta F75,,CHEMBL618180,10141.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4515,Cavia porcellus,,A,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,CHEMBL618181,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4516,Cavia porcellus,,A,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,CHEMBL618182,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4517,Cricetulus griseus,,A,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,CHEMBL618183,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4518,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL618184,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4519,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL618185,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4520,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL618186,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4521,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL618187,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4522,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,CHEMBL618188,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4523,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL875409,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4524,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL618189,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4525,Mus musculus,,A,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,CHEMBL618190,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4526,Mus musculus,,A,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,CHEMBL618191,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4527,Mus musculus,,A,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,CHEMBL618192,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4528,Mus musculus,,A,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,CHEMBL618193,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
4529,Mus musculus,,A,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,CHEMBL618194,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
4530,Mus musculus,,A,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,CHEMBL618195,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
4531,Mus musculus,,A,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,CHEMBL618196,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4532,Mus musculus,,A,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,CHEMBL618197,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4533,Mus musculus,,A,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,CHEMBL618198,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4534,Mus musculus,,A,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,CHEMBL618199,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
4535,Mus musculus,,A,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,CHEMBL618200,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
4536,Mus musculus,,A,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,CHEMBL618201,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
4537,Mus musculus,,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,CHEMBL618202,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
4538,Mus musculus,,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,CHEMBL618203,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
4539,Mus musculus,,A,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,CHEMBL618204,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
4540,Mus musculus,,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,CHEMBL618205,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4541,Mus musculus,,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,CHEMBL618206,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4542,Mus musculus,,A,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,CHEMBL618207,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4543,Mus musculus,,A,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,CHEMBL618208,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
4544,Mus musculus,,A,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,CHEMBL618932,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
4545,Mus musculus,,A,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,CHEMBL618933,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
4546,Mus musculus,,A,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,CHEMBL618934,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
4547,Mus musculus,,A,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,CHEMBL618935,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
4548,Mus musculus,,A,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,CHEMBL618936,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
4549,Mus musculus,,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,CHEMBL618937,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
4550,Mus musculus,,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,CHEMBL618938,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
4551,Mus musculus,,A,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,CHEMBL619104,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
4552,Mus musculus,,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,CHEMBL619105,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
4553,Mus musculus,,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,CHEMBL619106,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
4554,Mus musculus,,A,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,CHEMBL619107,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
4555,Mus musculus,,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,CHEMBL875410,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
4556,Mus musculus,,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,CHEMBL619108,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
4557,Mus musculus,,A,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,CHEMBL619109,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
4558,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,CHEMBL619110,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4559,Mus musculus,,F,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,CHEMBL619111,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4560,Mus musculus,,A,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL619112,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4561,Mus musculus,,A,MRT value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL619113,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4562,Mus musculus,,A,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,CHEMBL619114,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4563,Mus musculus,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,CHEMBL619115,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4564,Homo sapiens,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,CHEMBL619116,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4565,Homo sapiens,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,CHEMBL619117,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4566,Homo sapiens,,F,Compound was evaluated for cytotoxicity against A2780 cell lines.,,CHEMBL619118,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4567,Homo sapiens,,F,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,CHEMBL619119,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4568,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,CHEMBL619120,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4569,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,CHEMBL619121,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4570,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,CHEMBL619122,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4571,Homo sapiens,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,CHEMBL619123,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4572,Homo sapiens,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,CHEMBL619124,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4573,Homo sapiens,,F,Compound was evaluated for cytotoxicity against A2780 cell line,,CHEMBL619125,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4574,Homo sapiens,,F,In vitro inhibitory activity against human tumor cell line A2780,,CHEMBL875411,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4575,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,CHEMBL619126,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4576,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,CHEMBL619127,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4577,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,CHEMBL619128,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4578,Homo sapiens,,F,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,CHEMBL619129,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4579,Homo sapiens,,F,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,CHEMBL619130,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4580,Homo sapiens,,F,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,CHEMBL619131,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4581,Homo sapiens,,F,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,CHEMBL619132,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4582,Homo sapiens,,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,CHEMBL619133,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000218,
4583,Homo sapiens,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,CHEMBL619134,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4584,Homo sapiens,,F,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,CHEMBL619135,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4585,Homo sapiens,,F,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,CHEMBL619136,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4586,Homo sapiens,,F,Relative resistance factor in A2780 cisplatin-resistant line,,CHEMBL619137,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4587,Homo sapiens,,F,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,CHEMBL883713,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4588,Homo sapiens,,F,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,CHEMBL875412,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4589,Homo sapiens,,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,CHEMBL619138,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000218,
4590,Homo sapiens,,F,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,CHEMBL619262,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000218,
4591,Homo sapiens,,F,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,CHEMBL619139,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4592,Homo sapiens,,F,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,CHEMBL619140,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4593,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,CHEMBL619141,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4594,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,CHEMBL619142,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4595,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,CHEMBL619143,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4596,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,CHEMBL619144,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4597,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,CHEMBL619145,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4598,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,CHEMBL619146,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4599,Homo sapiens,,F,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,CHEMBL619147,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4600,Homo sapiens,,F,Antiproliferative effect of compound on A2780/DX cell line,,CHEMBL619148,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4601,Homo sapiens,,F,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,CHEMBL619149,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4602,Homo sapiens,,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,CHEMBL619150,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4603,Homo sapiens,,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,CHEMBL619151,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4604,Homo sapiens,,F,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,CHEMBL883794,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4605,Homo sapiens,,F,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,CHEMBL619152,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4606,Homo sapiens,,F,In vitro cytotoxicity against A2780ADR cell line,,CHEMBL619153,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4607,Homo sapiens,,F,In vitro cytotoxicity against A2780CIS cell line,,CHEMBL619154,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4608,Homo sapiens,,F,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,CHEMBL619155,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4609,Homo sapiens,,F,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,CHEMBL619156,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4610,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL619157,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4611,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL619797,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4612,Macaca mulatta,,A,Oral bioavailability of compound in rhesus macaques,,CHEMBL619798,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4613,monkey,,A,Oral bioavailability in monkey,,CHEMBL619799,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4614,monkey,,A,Oral bioavailability evaluated in monkey,,CHEMBL619800,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4615,monkey,,A,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,CHEMBL619801,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4616,Macaca mulatta,,A,Oral bioavailability in Rhesus monkey,,CHEMBL619802,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4617,Macaca mulatta,,A,Oral bioavailability was calculated in rhesus monkey,,CHEMBL619803,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4618,Macaca fascicularis,,A,Oral bioavailability in cynomolgus monkey,,CHEMBL619965,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4619,monkey,,A,Oral bioavailability in monkey,,CHEMBL619966,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4620,monkey,,A,Oral bioavailability in monkey,,CHEMBL619967,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4621,monkey,,A,Oral bioavailability in monkey (dose 1 mg/kg),,CHEMBL620073,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4622,monkey,,A,Oral bioavailability in monkey (dose 5 mg/kg),,CHEMBL620074,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4623,monkey,,A,Oral bioavailability in monkey,,CHEMBL620075,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4624,monkey,,A,Oral bioavailability in monkey,,CHEMBL620076,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4625,Macaca mulatta,,A,Oral bioavailability in rhesus monkey,,CHEMBL620077,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4626,Macaca mulatta,,A,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,CHEMBL620078,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4627,Saimiri sciureus,,A,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,CHEMBL620079,9521.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4628,monkey,,A,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL620080,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4629,Macaca mulatta,,A,Oral bioavailability in Rhesus monkey,,CHEMBL620081,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4630,Macaca mulatta,,A,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,CHEMBL620082,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4631,monkey,,A,Oral bioavailability in monkey at 10 mg/kg of the compound,,CHEMBL620083,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4632,Macaca mulatta,,A,Bioavailability in Rhesus monkey,,CHEMBL620084,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4633,Cercopithecidae,,A,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620085,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4634,Cercopithecidae,,A,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL874595,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4635,Cercopithecidae,,A,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,CHEMBL873352,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4636,Cercopithecidae,,A,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,CHEMBL620086,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4637,Cercopithecidae,,A,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,CHEMBL620087,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4638,Cercopithecidae,,A,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL620088,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4639,Cercopithecidae,,A,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,CHEMBL620089,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4640,Cercopithecidae,,A,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL620090,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4641,Cercopithecidae,,A,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620091,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4642,Cercopithecidae,,A,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL620092,9527.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4643,Cercopithecidae,,A,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,CHEMBL620093,9527.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4644,Cercopithecidae,,A,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,CHEMBL620094,9527.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4645,Cercopithecidae,,A,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,CHEMBL620095,9527.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4646,Cercopithecidae,,A,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620096,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4647,Cercopithecidae,,A,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620097,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4648,Cercopithecidae,,A,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,CHEMBL620098,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4649,Cercopithecidae,,A,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620099,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4650,Cercopithecidae,,A,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620100,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4651,Cercopithecidae,,A,Elimination Half-life of compound was determined in monkey,,CHEMBL620101,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4652,Cercopithecidae,,A,Half life of compound was determined in rhesus monkey,,CHEMBL620102,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4653,Cercopithecidae,,A,Half life in monkey plasma,,CHEMBL620103,9527.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
4654,Cercopithecidae,,A,Half life in monkey plasma; Not detected,,CHEMBL620104,9527.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
4655,Cercopithecidae,,A,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL874596,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4656,Cercopithecidae,,A,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,CHEMBL873490,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4657,Cercopithecidae,,A,Terminal half life of the compound.,,CHEMBL620105,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4658,Cercopithecidae,,A,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL620780,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4659,Cercopithecidae,,A,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620781,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4660,Cercopithecidae,,A,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,CHEMBL620956,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4661,Cercopithecidae,,A,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620957,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
4662,Cercopithecidae,,A,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620958,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
4663,Cercopithecidae,,A,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,CHEMBL620959,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4664,Cercopithecidae,,A,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL620960,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4665,Cercopithecidae,,A,Volume of distribution was evaluated in rhesus,,CHEMBL620961,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4666,Cricetulus griseus,,A,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,CHEMBL620962,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4667,Cricetulus griseus,,A,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,CHEMBL620963,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4668,Cricetulus griseus,,A,Bioavailability in hamster was determined,,CHEMBL620964,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4669,Cricetulus griseus,,A,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,CHEMBL620965,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4670,Cricetulus griseus,,A,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,CHEMBL620966,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4671,Cricetulus griseus,,A,Half life of compound was determined in hamster blood,,CHEMBL620967,10029.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
4672,Sus scrofa,,A,Michaelis-Menten constant of the compound.,,CHEMBL620968,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4673,Sus scrofa,,A,Vmax value was measured at 0 uM concentration of silyl ether.,,CHEMBL874597,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4674,Sus scrofa,,A,Vmax value was measured at 10 uM concentration of silyl ether.,,CHEMBL620969,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4675,Sus scrofa,,A,Vmax value was measured at 5 uM concentration of silyl ether.,,CHEMBL620970,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4676,Homo sapiens,,B,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,CHEMBL620971,9606.0,9,1,D,235,Expert,,,BAO_0000357,
4677,Homo sapiens,,A,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL620972,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4678,Homo sapiens,,A,Compound was evaluated for area under the curve expressed as (h*ug/ml),,CHEMBL620973,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4679,Homo sapiens,,A,Active metabolite of ifosfamide determined in humans; A-Active,,CHEMBL618243,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4680,Homo sapiens,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,CHEMBL618244,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4681,Homo sapiens,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,CHEMBL618245,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4682,Homo sapiens,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,CHEMBL618246,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4683,Homo sapiens,,A,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,CHEMBL618247,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4684,Homo sapiens,,A,Compound was evaluated for oral bioavailability in human,,CHEMBL618248,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4685,Homo sapiens,,A,Metabolite of ifosfamide determined in urine; NF-Not found,,CHEMBL618249,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4686,Homo sapiens,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,CHEMBL618250,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4687,Homo sapiens,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,CHEMBL874598,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4688,Homo sapiens,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,CHEMBL618251,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4689,Homo sapiens,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,CHEMBL618252,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4690,Homo sapiens,,A,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,CHEMBL618253,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4691,Homo sapiens,,A,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,CHEMBL618254,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4692,Homo sapiens,,A,Percent of compound in healthy individuals (Group D),,CHEMBL618255,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4693,Homo sapiens,,A,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,CHEMBL618983,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4694,Homo sapiens,,A,Binding towards human plasma protein at 10 uM,,CHEMBL618984,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4695,Homo sapiens,,A,Binding towards human plasma protein at 100 uM,,CHEMBL618985,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4696,Homo sapiens,,A,Human plasma protein binding activity was determined,,CHEMBL618986,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4697,Homo sapiens,,A,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,CHEMBL618987,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4698,Homo sapiens,,A,Percent binding of compound towards human plasma protein was determined,,CHEMBL618988,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4699,Homo sapiens,,A,Plasma clearance in human liver microsomes,,CHEMBL618989,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4700,Homo sapiens,,A,In vitro intrinsic clearance in human liver microsome,,CHEMBL618990,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4701,Homo sapiens,,A,In vitro intrinsic clearance in human liver microsome,,CHEMBL618991,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4702,Homo sapiens,,A,In vitro microsome metabolism clearance in human was determined,,CHEMBL876725,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4703,Homo sapiens,,A,In vitro microsome metabolism clearance in human was determined; High,,CHEMBL618992,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4704,Homo sapiens,,A,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,CHEMBL618993,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4705,Homo sapiens,,A,Pharmacokinetic property (clearance) in human liver microsome,,CHEMBL618994,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4706,Homo sapiens,,A,Plasma clearance in human liver microsomes,,CHEMBL618995,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4707,Homo sapiens,,A,In vitro clearance in human liver microsomes,,CHEMBL618996,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4708,Homo sapiens,,A,Intrinsic clearance in human liver microsomes was determined,,CHEMBL618997,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4709,Homo sapiens,,A,Intrinsic clearance in human liver microsomes was determined,,CHEMBL618998,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4710,Homo sapiens,,A,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,CHEMBL618999,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4711,Homo sapiens,,A,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL620223,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4712,Homo sapiens,,A,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,CHEMBL620224,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4713,Homo sapiens,,A,Stability in human plasma 2 hr after incubation expressed as percent concentration,,CHEMBL620225,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4714,Homo sapiens,,A,Stability in human plasma 4 hr after incubation expressed as percent concentration,,CHEMBL620226,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4715,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL620227,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4716,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL876726,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4717,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL620228,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4718,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL620229,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4719,Mus musculus,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL620230,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4720,Mus musculus,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,CHEMBL620231,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4721,Mus musculus,,F,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,CHEMBL620232,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4722,Mus musculus,,F,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,CHEMBL620233,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4723,Mus musculus,,A,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,CHEMBL620234,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4724,Mus musculus,,A,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL620235,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4725,Mus musculus,,A,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,CHEMBL620236,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4726,Mus musculus,,A,In vitro metabolic potential in mouse liver microsomes,,CHEMBL620237,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
4727,Mus musculus,,A,Ability of compound to bind to plasma protein was evaluated in HSA cells,,CHEMBL620238,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4728,Mus musculus,,A,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,CHEMBL620239,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2369.0
4729,Mus musculus,,A,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,CHEMBL620240,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4730,Mus musculus,,A,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,CHEMBL620241,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4731,Mus musculus,,A,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,CHEMBL876727,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4732,Mus musculus,,A,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,CHEMBL620242,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4733,Mus musculus,,A,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,CHEMBL620243,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4734,Mus musculus,,A,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,CHEMBL620244,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4735,Mus musculus,,A,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,CHEMBL620245,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1977.0
4736,Mus musculus,,A,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,CHEMBL620246,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1977.0
4737,Mus musculus,,A,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,CHEMBL620247,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1977.0
4738,Mus musculus,,A,Half life of compound was determined in plasma of mice at 24 mg/Kg,,CHEMBL620248,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
4739,Mus musculus,,A,Half life of compound was determined in plasma of mice at 40 mg/Kg,,CHEMBL873497,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
4740,Mus musculus,,A,Half life of compound was determined in plasma of mice at 5 mg/Kg,,CHEMBL620249,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
4741,Mus musculus,,F,Half life after intraperitoneal administration in mice at 18 uM/kg,,CHEMBL620250,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4742,Mus musculus,,F,Half life after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL620251,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4743,Mus musculus,,F,Half life after intraperitoneal administration in mice at 25 uM/kg,,CHEMBL620252,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4744,Mus musculus,,F,Half life after intraperitoneal administration in mice at 26 uM/kg,,CHEMBL620253,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4745,Mus musculus,,F,Half life after intravenous administration in mice at 23 uM/kg,,CHEMBL620254,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4746,Mus musculus,,A,Half life after intravenous administration in mice at 24 uM/kg,,CHEMBL620255,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4747,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,CHEMBL620256,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4748,Mus musculus,,A,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,CHEMBL876728,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4749,Mus musculus,,A,Maximum time required to reach Cp max was evaluated in mice after oral administration,,CHEMBL620257,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4750,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,CHEMBL620258,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4751,Mus musculus,,A,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,CHEMBL620259,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4752,Mus musculus,,A,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,CHEMBL620260,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4753,Mus musculus,,A,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,CHEMBL620261,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4754,Mus musculus,,A,Half life at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL620262,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4755,Mus musculus,,A,Half life at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL620263,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4756,Mus musculus,,A,Half life in ob/ob mice,,CHEMBL620264,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4757,Mus musculus,,A,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL620265,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4758,Mus musculus,,A,Half-life was measured in mouse,,CHEMBL620266,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4759,Mus musculus,,A,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL620267,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4760,Mus musculus,,A,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,CHEMBL619364,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4761,Mus musculus,,A,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,CHEMBL619365,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4762,Mus musculus,,A,T2 in brain of mice at the oral dose of 50 mg/kg,,CHEMBL619366,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4763,Mus musculus,,A,T2 in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL619367,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4764,Mus musculus,,A,T2 in liver of mice at the oral dose of 50 mg/kg,,CHEMBL619368,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
4765,Mus musculus,,A,T2 in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL619369,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
4766,Mus musculus,,A,T2 in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL876729,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
4767,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,CHEMBL619370,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4768,Mus musculus,,A,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,CHEMBL619371,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4769,Mus musculus,,A,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,CHEMBL619372,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4770,Mus musculus,,A,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,CHEMBL620012,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4771,Mus musculus,,A,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL620013,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4772,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL620014,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4773,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL620015,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4774,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621010,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4775,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621011,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4776,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621012,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4777,Homo sapiens,,F,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621013,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4778,Homo sapiens,,F,In vitro cytotoxicity against A2780TAX cell line,,CHEMBL621014,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4779,Homo sapiens,,F,In vitro inhibitory activity against human tumor cell line A2780cis,,CHEMBL618154,9606.0,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
4780,Homo sapiens,,F,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,CHEMBL618155,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
4781,Homo sapiens,,F,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,CHEMBL618156,9606.0,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
4782,Homo sapiens,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,CHEMBL618157,9606.0,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
4783,Homo sapiens,,F,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,CHEMBL618328,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4784,Homo sapiens,,F,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,CHEMBL618329,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4785,Homo sapiens,,F,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,CHEMBL618330,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4786,Homo sapiens,,F,In vitro antitumor activity against A2780cisR cell line.,,CHEMBL618331,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
4787,Homo sapiens,,F,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,CHEMBL618332,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
4788,Homo sapiens,,F,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,CHEMBL618333,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
4789,Homo sapiens,,F,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,CHEMBL618334,9606.0,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
4790,Homo sapiens,,F,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,CHEMBL618335,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
4791,Rattus norvegicus,,B,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,CHEMBL618336,10116.0,9,1,D,11736,Expert,,,BAO_0000019,
4792,,,F,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,CHEMBL618337,,8,1,H,11736,Expert,,,BAO_0000019,
4793,Rattus norvegicus,,F,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,CHEMBL618338,10116.0,9,1,D,11736,Expert,,,BAO_0000019,
4794,Homo sapiens,,F,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,CHEMBL618339,9606.0,9,1,D,278,Expert,,722.0,BAO_0000219,
4795,Homo sapiens,,F,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,CHEMBL618340,9606.0,9,1,D,278,Expert,,722.0,BAO_0000219,
4796,Mus musculus,,B,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,CHEMBL618341,10090.0,9,1,D,11831,Expert,,,BAO_0000019,
4797,,,F,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,CHEMBL618342,,8,1,H,11831,Expert,,,BAO_0000019,
4798,Mus musculus,,F,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,CHEMBL618343,10090.0,9,1,D,11831,Expert,,,BAO_0000019,
4799,,,B,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,CHEMBL621038,,8,1,H,280,Expert,,,BAO_0000357,
4800,Homo sapiens,,F,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,CHEMBL621039,9606.0,0,1,U,22226,Autocuration,,574.0,BAO_0000219,
4801,Homo sapiens,,F,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,CHEMBL621040,9606.0,0,1,U,22226,Autocuration,,574.0,BAO_0000219,
4802,Homo sapiens,,F,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,CHEMBL621041,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
4803,Homo sapiens,,F,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,CHEMBL621042,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
4804,Homo sapiens,,F,In vitro antitumor activity against A375cell line extracted form melanoma,,CHEMBL621043,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
4805,Homo sapiens,,F,Inhibition of cell growth in (A375) melan cell line,,CHEMBL621044,9606.0,1,1,N,80018,Expert,,455.0,BAO_0000219,
4806,Homo sapiens,,F,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,CHEMBL621045,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
4807,Homo sapiens,,F,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,CHEMBL621046,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
4808,Homo sapiens,,F,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,CHEMBL621047,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
4809,Homo sapiens,,F,Antiproliferative activity measured against A427 human lung carcinoma,,CHEMBL621048,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4810,Homo sapiens,,F,Antiproliferative activity measured against A427 human lung carcinoma,,CHEMBL883798,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4811,Homo sapiens,,F,Cytotoxicity against lung carcinoma A427 tumor cell lines,,CHEMBL621049,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4812,Homo sapiens,,F,Inhibition of large cell lung carcinoma (A427),,CHEMBL621050,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4813,Homo sapiens,,F,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,CHEMBL621051,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4814,Homo sapiens,,F,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,CHEMBL621052,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4815,Homo sapiens,,F,Inhibitory concentration in human lung carcinoma A427 cell line,,CHEMBL621053,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4816,Homo sapiens,,F,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,CHEMBL621054,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4817,Cercopithecidae,,A,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL621055,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4818,Cercopithecidae,,A,Tested for volume of distribution upon iv administration to african green monkey,,CHEMBL876398,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4819,Cercopithecidae,,A,Volume of distribution in monkey,,CHEMBL621056,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4820,Macaca mulatta,,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL621057,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4821,Macaca mulatta,,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,CHEMBL621058,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4822,Cercopithecidae,,A,Pharmacokinetic property(Vdss) in cynomolgus monkey,,CHEMBL621059,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4823,Cercopithecidae,,A,The distribution volume after intravenous administration in cynomolgus monkeys,,CHEMBL621060,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4824,Cercopithecidae,,A,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL621061,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4825,Cercopithecidae,,A,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,CHEMBL621062,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4826,Cercopithecidae,,A,Volume displacement was calculated in rhesus monkey,,CHEMBL621063,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4827,Cercopithecidae,,A,Volume of distribution in steady state was determined in rhesus monkey,,CHEMBL621064,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4828,Cercopithecidae,,A,Volume of distribution of compound was determined in monkey,,CHEMBL621065,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4829,Cercopithecidae,,A,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL621066,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4830,Cercopithecidae,,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL621067,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4831,Cercopithecidae,,A,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL621068,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4832,Cercopithecidae,,A,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL876399,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4833,Cercopithecidae,,A,Volume distribution in monkey after administration of 1 mg/kg iv,,CHEMBL621069,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4834,Cercopithecidae,,A,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL621070,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4835,Cercopithecidae,,A,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL621071,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4836,Cercopithecidae,,A,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL621072,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4837,Cercopithecidae,,A,Oral systemic bioavailability upon iv administration to african green monkey,,CHEMBL618209,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4838,Cercopithecidae,,A,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL618210,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4839,Cercopithecidae,,A,Baboon plasma free fraction. ,,CHEMBL618211,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4840,Cercopithecidae,,A,Area under the curve was calculated in rhesus monkey after iv administration,,CHEMBL618212,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4841,Cercopithecidae,,A,Area under the curve was calculated in rhesus monkey after peroral administration,,CHEMBL618213,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4842,Cercopithecidae,,A,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,CHEMBL618214,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4843,Cercopithecidae,,A,Half life period in monkey after 5 mg/kg dose,,CHEMBL873492,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4844,Cercopithecidae,,A,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,CHEMBL618272,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4845,Cercopithecidae,,A,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,CHEMBL618273,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4846,Cercopithecidae,,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,CHEMBL618274,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4847,Cercopithecidae,,A,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,CHEMBL618275,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4848,Cercopithecidae,,A,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL618276,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4849,Cercopithecidae,,A,Compound was evaluated for terminal half life in monkey,,CHEMBL618277,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4850,Cercopithecidae,,A,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,CHEMBL618278,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4851,Macaca mulatta,,A,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL618279,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4852,Cercopithecidae,,A,Half life of compound was determined in squirrel monkey,,CHEMBL618280,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4853,Macaca fascicularis,,A,Half life after iv administration in cynomolgus monkey,,CHEMBL618281,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4854,Cercopithecidae,,A,Half life in monkey plasma after administration of 1 mg/kg iv,,CHEMBL618282,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
4855,Cercopithecidae,,A,Half life was calculated in rhesus monkey,,CHEMBL618283,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4856,Cercopithecidae,,A,Half life in monkey,,CHEMBL618284,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4857,Cercopithecidae,,A,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL618285,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4858,Cercopithecidae,,A,Half life was evaluated in rhesus,,CHEMBL618286,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4859,Cercopithecidae,,A,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL618287,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4860,Cercopithecidae,,A,Half life period was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL618288,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4861,Cercopithecidae,,A,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL876393,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4862,Cercopithecidae,,A,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,CHEMBL618289,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4863,Cercopithecidae,,A,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,CHEMBL618290,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4864,Cercopithecidae,,A,Half-life was calculated in monkey,,CHEMBL618291,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4865,Cercopithecidae,,A,Half-life in Squirrel monkey,,CHEMBL618292,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4866,Cercopithecidae,,A,Half-life in rhesus monkey,,CHEMBL618293,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4867,Cercopithecidae,,A,Half-life was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL618294,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4868,Cercopithecidae,,A,Half-life period after intravenous administration in cynomolgus monkeys,,CHEMBL618295,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4869,Cercopithecidae,,A,Half-life period after oral administration in cynomolgus monkeys,,CHEMBL618296,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4870,Cercopithecidae,,A,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,CHEMBL618297,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4871,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618298,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4872,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618299,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4873,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618300,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4874,Homo sapiens,,A,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618301,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4875,Homo sapiens,,A,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,CHEMBL618302,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4876,Homo sapiens,,A,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,CHEMBL876394,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4877,Homo sapiens,,A,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,CHEMBL618303,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4878,Homo sapiens,,A,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,CHEMBL618304,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4879,Homo sapiens,,A,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,CHEMBL618305,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4880,Homo sapiens,,A,Oral bioavailability in human,,CHEMBL618306,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
4881,Homo sapiens,,A,Compound was tested for human plasma protein binding,,CHEMBL618307,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4882,Homo sapiens,,A,Compound was tested for human plasma protein binding; Not determined,,CHEMBL618308,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4883,Homo sapiens,,A,Protein binding activity of compound in human plasma; % Free,,CHEMBL618309,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4884,Homo sapiens,,A,Unbound fraction (plasma),,CHEMBL618310,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4885,Homo sapiens,,A,Half life for the hydrolysis of compound in human blood serum,,CHEMBL873353,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
4886,Homo sapiens,,A,Half life period in human plasma using phosphate buffer (0.08 M),,CHEMBL618311,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
4887,Homo sapiens,,A,Half life period in human plasma using phosphate buffer (0.1 M),,CHEMBL618312,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
4888,Homo sapiens,,A,Half-life in human plasma was determined,,CHEMBL618313,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
4889,Homo sapiens,,A,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,CHEMBL618314,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4890,Homo sapiens,,A,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,CHEMBL618315,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4891,Homo sapiens,,A,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,CHEMBL618316,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4892,Homo sapiens,,A,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,CHEMBL618317,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4893,Homo sapiens,,A,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,CHEMBL620138,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4894,Homo sapiens,,A,Partition coefficient (logP),,CHEMBL858280,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4895,Homo sapiens,,A,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,CHEMBL620139,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4896,Homo sapiens,,A,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,CHEMBL620140,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4897,Homo sapiens,,A,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,CHEMBL620141,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4898,Homo sapiens,,A,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,CHEMBL620142,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4899,Homo sapiens,,A,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,CHEMBL620143,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4900,Homo sapiens,,A,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,CHEMBL620144,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4901,Homo sapiens,,A,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,CHEMBL620145,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4902,Homo sapiens,,A,Metabolism of compound in human microsomes; Trace,,CHEMBL620146,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4903,Homo sapiens,,A,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,CHEMBL620147,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4904,Homo sapiens,,A,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,CHEMBL620148,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
4905,Homo sapiens,,A,In vitro metabolic potential in human liver microsomes,,CHEMBL620149,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
4906,Homo sapiens,,A,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,CHEMBL876412,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4907,Homo sapiens,,A,Tested for human plasma protein binding of the compound; Not tested,,CHEMBL619352,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4908,Homo sapiens,,A,Compound was tested for percent protein binding (PB) in human,,CHEMBL619353,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4909,Homo sapiens,,A,Protein binding in human plasma,,CHEMBL619354,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
4910,Homo sapiens,,A,Permeability coefficient (B to A) in Caco-2 cell,,CHEMBL619355,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4911,Homo sapiens,,A,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,CHEMBL619356,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4912,Homo sapiens,,A,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,CHEMBL619357,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4913,Homo sapiens,,A,In vitro rate of absorption observed as Caco-2 permeability in humans,,CHEMBL619358,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4914,Homo sapiens,,A,Cellular permeability of compound was determined in Caco-2 cells; High,,CHEMBL619359,9606.0,0,1,U,22224,Autocuration,,495.0,BAO_0000219,
4915,Homo sapiens,,A,Permeability in Caco-2 cells of compound,,CHEMBL619360,9606.0,0,1,U,22224,Autocuration,,495.0,BAO_0000219,
4916,Homo sapiens,,A,Permeability coefficient (A to B) in Caco-2 cell,,CHEMBL619361,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4917,Homo sapiens,,A,Permeability coefficient (B to A) in Caco-2 cell,,CHEMBL619362,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4918,Homo sapiens,,A,Permeability coefficient (Papp) (Caco-2 cell monolayer),,CHEMBL619363,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4919,Homo sapiens,,A,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,CHEMBL618942,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4920,Homo sapiens,,A,Compound was tested for protein binding in human plasma,,CHEMBL618943,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4921,Homo sapiens,,A,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,CHEMBL618944,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
4922,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,CHEMBL618945,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
4923,Mus musculus,,A,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL618946,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4924,Mus musculus,,A,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL876413,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4925,Mus musculus,,A,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,CHEMBL618947,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4926,Mus musculus,,A,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,CHEMBL618948,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
4927,Mus musculus,,A,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL618949,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
4928,Mus musculus,,F,Tmax after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL618950,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4929,Mus musculus,,A,Tmax after oral administration at 30 mg/kg in ICR mouse,,CHEMBL618951,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4930,Mus musculus,,A,Tmax after peroral administration in mice at 2.4 uM/kg,,CHEMBL618952,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4931,Mus musculus,,A,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL618953,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4932,Mus musculus,,A,Tmax in brain of mice at the oral dose of 50 mg/kg,,CHEMBL618954,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
4933,Mus musculus,,A,Tmax in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL618955,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4934,Mus musculus,,A,Tmax in liver of mice at the oral dose of 50 mg/kg,,CHEMBL618956,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
4935,Mus musculus,,A,Tmax in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL618957,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
4936,Mus musculus,,F,Tmax in mice at 18 uM/kg i.p. administration,,CHEMBL618958,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4937,Mus musculus,,F,Tmax in mice at 23 uM/kg i.v. administration,,CHEMBL618959,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4938,Mus musculus,,F,Tmax in mice at 25 uM/kg i.p. administration,,CHEMBL618960,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4939,Mus musculus,,F,Tmax in mice at 26 uM/kg i.p. administration,,CHEMBL876723,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4940,Mus musculus,,A,Tmax in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL618961,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
4941,Mus musculus,,A,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL618962,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4942,Mus musculus,,A,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL618963,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4943,Mus musculus,,A,Tmax value in IRC mice,,CHEMBL618964,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4944,Mus musculus,,A,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,CHEMBL618965,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4945,Mus musculus,,A,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,CHEMBL618966,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4946,Mus musculus,,A,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,CHEMBL618967,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
4947,Mus musculus,,A,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,CHEMBL618968,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
4948,Mus musculus,,A,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,CHEMBL618969,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
4949,Mus musculus,,A,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL618970,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4950,Mus musculus,,A,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL618971,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4951,Mus musculus,,A,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL618972,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4952,Mus musculus,,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL618973,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4953,Mus musculus,,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL618974,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4954,Mus musculus,,A,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,CHEMBL618975,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4955,Mus musculus,,A,Vd in mice,,CHEMBL618976,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4956,Mus musculus,,A,Volume of distribution in mouse,,CHEMBL618977,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4957,Mus musculus,,A,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL876724,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4958,Mus musculus,,A,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,CHEMBL618978,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4959,Mus musculus,,A,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,CHEMBL618979,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4960,Mus musculus,,A,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,CHEMBL618980,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4961,Mus musculus,,A,Pharmacokinetic property (vdss) was measured in mouse,,CHEMBL618981,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4962,Mus musculus,,A,Value distribution upon iv administration in mouse,,CHEMBL618982,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4963,Mus musculus,,A,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL620150,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4964,Mus musculus,,A,Volume of distribution was evaluated in mice after intravenous administration,,CHEMBL620151,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4965,Mus musculus,,A,Volume of distribution was evaluated in mice after oral administration,,CHEMBL620152,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4966,Mus musculus,,A,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,CHEMBL620153,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4967,Mus musculus,,A,Steady state volume of distribution was determined in mice,,CHEMBL876395,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4968,Mus musculus,,A,Volume distribution (steady state) of compound was determined in mouse,,CHEMBL620154,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4969,Mus musculus,,A,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,CHEMBL620155,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4970,Mus musculus,,A,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL620156,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4971,Mus musculus,,A,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL620157,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
4972,Mus musculus,,A,Biodistribution of compound (oxidized form) in in kidney tissue,,CHEMBL620158,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
4973,Mus musculus,,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,CHEMBL620159,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4974,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,CHEMBL620160,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4975,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL620161,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
4976,Homo sapiens,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,CHEMBL620162,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
4977,Homo sapiens,,F,Inhibition of A431 human squamous cell carcinoma cell proliferation,,CHEMBL620163,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4978,Homo sapiens,,F,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,CHEMBL620833,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4979,Homo sapiens,,F,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,CHEMBL876396,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4980,Homo sapiens,,F,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,CHEMBL620834,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4981,Homo sapiens,,F,Inhibition of A431 human carcinoma cell proliferation,,CHEMBL620835,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4982,Homo sapiens,,F,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,CHEMBL620836,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4983,Homo sapiens,,F,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,CHEMBL620837,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4984,Homo sapiens,,F,In vitro cytotoxicity against epidermoid carcinoma cell line,,CHEMBL621017,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4985,Homo sapiens,,F,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,CHEMBL621018,9606.0,9,1,D,9,Expert,,500.0,BAO_0000218,
4986,Homo sapiens,,F,Antiproliferative activity of compound was measured on human tumor cell line A431.,,CHEMBL621019,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4987,Homo sapiens,,F,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,CHEMBL621020,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4988,Homo sapiens,,F,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,CHEMBL621021,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4989,,,F,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,CHEMBL621022,,8,1,H,9,Expert,,500.0,BAO_0000219,
4990,Homo sapiens,,F,Tested for antiproliferative activity against human A431 cells,,CHEMBL621023,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4991,Homo sapiens,,F,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,CHEMBL621024,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
4992,Homo sapiens,,F,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,CHEMBL621025,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4993,Homo sapiens,,F,Inhibition of A431 cell proliferation,,CHEMBL621026,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4994,Homo sapiens,,F,Cytotoxic effect on A431 human epidermoid carcinoma cells,,CHEMBL621027,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4995,Homo sapiens,,F,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,CHEMBL876397,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
4996,Homo sapiens,,F,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,CHEMBL883797,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4997,Homo sapiens,,F,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,CHEMBL621028,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4998,Homo sapiens,,F,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,CHEMBL621029,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
4999,Homo sapiens,,F,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,CHEMBL621030,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5000,,,F,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,CHEMBL621147,,8,1,H,9,Expert,,500.0,BAO_0000219,
5001,Homo sapiens,,F,In vivo antiproliferative activity against A431 cell line,,CHEMBL621148,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000218,
5002,Homo sapiens,,F,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,CHEMBL621149,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5003,Homo sapiens,,F,Inhibition of A431 human epidermoid carcinoma cell proliferation,,CHEMBL621150,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
5004,Homo sapiens,,F,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,CHEMBL621151,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5005,Homo sapiens,,F,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,CHEMBL621152,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5006,Homo sapiens,,F,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,CHEMBL621153,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5007,Homo sapiens,,F,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,CHEMBL884000,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5008,Homo sapiens,,F,Inhibition of EGFR overexpressing A431 cell proliferation,,CHEMBL621154,9606.0,9,1,D,9,Expert,,,BAO_0000019,
5009,Homo sapiens,,F,Inhibition of A431 cell proliferation,,CHEMBL621155,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
5010,Homo sapiens,,F,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,CHEMBL621156,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5011,Homo sapiens,,F,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,CHEMBL621157,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5012,,,F,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,CHEMBL621158,,8,1,H,9,Expert,,500.0,BAO_0000219,
5013,Homo sapiens,,F,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,CHEMBL621159,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5014,Homo sapiens,,F,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,CHEMBL621160,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5015,Homo sapiens,,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,CHEMBL621161,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5016,Homo sapiens,,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,CHEMBL621162,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5017,Homo sapiens,,F,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,CHEMBL621163,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5018,Homo sapiens,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,CHEMBL621164,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5019,Homo sapiens,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,CHEMBL621165,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5020,Cercopithecidae,,A,Half-life period in cynomolgus monkey,,CHEMBL619159,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5021,Cercopithecidae,,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,CHEMBL619160,9527.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5022,Cercopithecidae,,A,Longer half-life in monkey (i.v.) at 0.5 mpk,,CHEMBL619161,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5023,Cercopithecidae,,A,Plasma half life in monkey,,CHEMBL619162,9527.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5024,Cercopithecidae,,A,Plasma half-life in rhesus monkey,,CHEMBL619163,9527.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5025,Cercopithecidae,,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL619164,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
5026,Cercopithecidae,,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL619320,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
5027,Cercopithecidae,,A,Tested for half life upon iv administration to african green monkey,,CHEMBL619321,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5028,Cercopithecidae,,A,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL873336,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5029,Cercopithecidae,,A,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL619322,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5030,Cercopithecidae,,A,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,CHEMBL619323,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5031,Cercopithecidae,,A,The time for peak concentration value after oral administration in cynomolgus monkeys,,CHEMBL619324,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5032,Cercopithecidae,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,CHEMBL619325,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5033,Cercopithecidae,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,CHEMBL876411,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5034,Cercopithecidae,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,CHEMBL619326,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5035,Cercopithecidae,,A,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,CHEMBL619327,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5036,Cercopithecidae,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,CHEMBL619328,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5037,Cercopithecidae,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,CHEMBL619329,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5038,Cercopithecidae,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,CHEMBL619330,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5039,Cercopithecidae,,A,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,CHEMBL619331,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5040,Cercopithecidae,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,CHEMBL619332,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5041,Cercopithecidae,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,CHEMBL619333,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5042,Cercopithecidae,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,CHEMBL619334,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5043,Cercopithecidae,,A,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,CHEMBL619335,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5044,Cercopithecidae,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,CHEMBL619336,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5045,Cercopithecidae,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,CHEMBL619337,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5046,Cercopithecidae,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,CHEMBL619338,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5047,Cercopithecidae,,A,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,CHEMBL619339,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5048,Rattus norvegicus,,A,Bioavailability in rat (cannulated) (dose 2 mg/kg),,CHEMBL619340,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
5049,Rattus norvegicus,,A,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL873496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
5050,Rattus norvegicus,,A,AUC value in rat after IV administration at a dose of 10 mg/kg,,CHEMBL619341,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
5051,Rattus norvegicus,,A,AUC value in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619342,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
5052,Rattus norvegicus,,A,Cmax value in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619343,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
5053,Rattus norvegicus,,A,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619344,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
5054,Rattus norvegicus,,A,Tmax value in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619345,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
5055,Rattus norvegicus,,A,Vc value in rat after IV administration at a dose of 10 mg/kg,,CHEMBL619346,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
5056,Rattus norvegicus,,A,Half life period in rat after IV administration at a dose of 10 mg/kg,,CHEMBL619347,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
5057,Papio hamadryas,,A,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,CHEMBL619348,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5058,Papio hamadryas,,A,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,CHEMBL619349,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5059,Papio hamadryas,,A,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,CHEMBL619350,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5060,Papio hamadryas,,A,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,CHEMBL619351,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5061,Papio hamadryas,,A,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,CHEMBL875953,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5062,Papio hamadryas,,A,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,CHEMBL621716,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5063,Papio hamadryas,,A,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,CHEMBL621717,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5064,Papio hamadryas,,A,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,CHEMBL621718,9557.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5065,beagle,,A,Area under curve after 1 mpk peroral administration to beagles,,CHEMBL621719,9615.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5066,beagle,,A,Area under curve after 2 mpk peroral administration to beagles,,CHEMBL621720,9615.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5067,beagle,,A,Cmax value after 1 mpk peroral administration to beagles,,CHEMBL621721,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5068,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,CHEMBL621722,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5069,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,CHEMBL621723,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5070,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,CHEMBL621724,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5071,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,CHEMBL623443,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5072,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,CHEMBL623444,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5073,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,CHEMBL623445,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5074,Homo sapiens,,A,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,CHEMBL623446,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
5075,Homo sapiens,,A,Metabolic stability observed at 30 min after administration in human liver microsomes,,CHEMBL623447,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5076,Homo sapiens,,A,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,CHEMBL623448,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5077,Homo sapiens,,A,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,CHEMBL623449,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5078,Homo sapiens,,A,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,CHEMBL623450,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5079,Homo sapiens,,A,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,CHEMBL623451,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5080,Homo sapiens,,A,Metabolic stability (% remaining at 30 mins) in human S9.,,CHEMBL623452,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5081,Homo sapiens,,A,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,CHEMBL623453,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5082,Homo sapiens,,A,Percent parent compound remaining after 20 min incubation with human liver microsomes,,CHEMBL623454,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5083,Homo sapiens,,A,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,CHEMBL623455,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5084,Homo sapiens,,A,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,CHEMBL624371,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5085,Homo sapiens,,A,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,CHEMBL624372,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5086,Homo sapiens,,A,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,CHEMBL624373,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5087,Homo sapiens,,A,Percent remaining in human plasma after incubation for 60 min at 37 C.,,CHEMBL624374,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5088,Homo sapiens,,A,The percent remaining in human plasma after 30 min was determined,,CHEMBL624556,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5089,Homo sapiens,,A,Conversion rate of the prodrug in human plasma,,CHEMBL624557,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5090,Homo sapiens,,A,Conversion rate of the prodrug in human plasma; ND means no data,,CHEMBL624558,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5091,Homo sapiens,,A,Half life of compound was determined in human blood,,CHEMBL624559,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
5092,Homo sapiens,,A,Half life of compound was determined in man with once daily dosing,,CHEMBL624560,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5093,Homo sapiens,,A,Half life in human microsomes,,CHEMBL624561,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
5094,Homo sapiens,,A,Half life in human plasma,,CHEMBL624562,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5095,Homo sapiens,,A,Half life in human plasma; Not detected,,CHEMBL624563,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5096,Homo sapiens,,A,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL624564,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5097,Homo sapiens,,A,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,CHEMBL624565,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5098,Homo sapiens,,A,Half-life in human plasma,,CHEMBL875152,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5099,Homo sapiens,,A,Half-life of the parent prodrug in plasma,,CHEMBL624566,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5100,Homo sapiens,,A,In vitro half life in human plasma was determined,,CHEMBL873805,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5101,Homo sapiens,,A,The compound was tested In Vitro for half life in human liver microsomes.,,CHEMBL624567,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5102,Homo sapiens,,A,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL624568,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5103,Homo sapiens,,A,Observed volume of distribution,,CHEMBL624569,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5104,Homo sapiens,,A,Oral bioavailability in human,,CHEMBL624570,9606.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5105,Homo sapiens,,A,Tested for human plasma protein binding of the compound,,CHEMBL624571,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5106,Homo sapiens,,A,"First order rate constant, k was determined in human plasma",,CHEMBL624572,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5107,Homo sapiens,,A,Observed rate constant in 80% human plasma at 37 degree Centigrade,,CHEMBL624573,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5108,Homo sapiens,,A,Observed rate constant in 80% human plasma at 37 degree Centigrade,,CHEMBL875153,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5109,Homo sapiens,,A,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,CHEMBL624574,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5110,Homo sapiens,,A,The compound was tested for the plasma binding in human,,CHEMBL624575,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5111,Homo sapiens,,A,Plasma protein binding (human),,CHEMBL624576,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5112,Homo sapiens,,A,Compound was evaluated for half-life in human liver microsomes,,CHEMBL624577,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5113,Homo sapiens,,A,Half life measured in vitro for its stability in human blood,,CHEMBL624578,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
5114,Homo sapiens,,A,Half life in human serum,,CHEMBL622796,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1977.0
5115,Homo sapiens,,A,Half life in human serum; ND=not determined,,CHEMBL622797,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1977.0
5116,Homo sapiens,,A,Half life were determined in CEM-SS cell extract in decomposition step 1,,CHEMBL622798,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5117,Homo sapiens,,A,Half life were determined in CEM-SS cell extract in decomposition step 2,,CHEMBL622799,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5118,Homo sapiens,,A,Half life of the in human plasma,,CHEMBL622800,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5119,Homo sapiens,,A,Half life period in human hepatic S9 fraction was determined,,CHEMBL622801,9606.0,0,1,U,22224,Autocuration,,,BAO_0000220,
5120,Homo sapiens,,A,Half life period in human liver microsome was determined,,CHEMBL622802,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5121,Homo sapiens,,A,Half life period was determined; 6-7,,CHEMBL622803,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5122,Homo sapiens,,A,Half life period was evaluated in human,,CHEMBL875154,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5123,Homo sapiens,,A,Half life time in human plasma,,CHEMBL622804,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5124,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622805,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5125,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622611,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5126,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622612,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5127,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL875160,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5128,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,CHEMBL622613,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5129,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622614,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5130,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622615,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5131,Mus musculus,,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,CHEMBL622616,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5132,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622617,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5133,Mus musculus,,A,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,CHEMBL622618,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
5134,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,CHEMBL622619,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
5135,Mus musculus,,A,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622620,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
5136,Mus musculus,,A,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622621,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5137,Mus musculus,,A,Biodistribution of compound (oxidized form) in blood tissue,,CHEMBL622622,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5138,Mus musculus,,A,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622623,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5139,Mus musculus,,A,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL622624,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5140,Mus musculus,,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622625,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5141,Mus musculus,,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622626,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5142,Mus musculus,,A,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL622627,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5143,Mus musculus,,A,Biodistribution of compound (oxidized form) in brain tissue of mice,,CHEMBL622628,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5144,Mus musculus,,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622629,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5145,Mus musculus,,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622630,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5146,Mus musculus,,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622631,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5147,Mus musculus,,A,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL622632,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5148,Mus musculus,,A,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL622633,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
5149,Mus musculus,,A,Biodistribution of compound (oxidized form) in heart tissue of mice,,CHEMBL622634,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5150,Mus musculus,,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622635,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5151,Mus musculus,,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL875161,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5152,Mus musculus,,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622636,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5153,Mus musculus,,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL623335,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5154,Mus musculus,,A,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL623336,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5155,Mus musculus,,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL623337,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5156,Mus musculus,,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL623338,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5157,Mus musculus,,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL623339,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5158,Mus musculus,,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL623524,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5159,Mus musculus,,A,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL623525,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5160,Mus musculus,,A,Biodistribution of compound (oxidized form) in liver tissue,,CHEMBL623526,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5161,Mus musculus,,A,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL623527,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5162,Mus musculus,,A,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL623528,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5163,Homo sapiens,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,CHEMBL624615,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5164,Homo sapiens,,F,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,CHEMBL621672,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5165,,,F,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,CHEMBL621673,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5166,,,F,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,CHEMBL621674,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5167,Homo sapiens,,F,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,CHEMBL884002,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5168,Homo sapiens,,F,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,CHEMBL621850,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5169,Homo sapiens,,F,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,CHEMBL621851,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5170,Homo sapiens,,F,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,CHEMBL621852,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5171,Homo sapiens,,F,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,CHEMBL621853,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5172,,,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,CHEMBL621854,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5173,,,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,CHEMBL621855,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5174,,,F,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,CHEMBL623724,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5175,,,F,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,CHEMBL623725,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5176,,,F,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,CHEMBL623726,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5177,Homo sapiens,,F,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,CHEMBL623727,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5178,,,F,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,CHEMBL623728,,8,1,H,9,Expert,,500.0,BAO_0000219,
5179,,,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,CHEMBL623729,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5180,,,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,CHEMBL623730,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5181,,,F,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,CHEMBL623731,,1,1,N,80852,Expert,,500.0,BAO_0000218,
5182,Mus musculus,,F,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623732,10090.0,1,1,N,80852,Expert,,500.0,BAO_0000218,
5183,Mus musculus,,F,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623733,10090.0,1,1,N,80852,Expert,,500.0,BAO_0000218,
5184,Mus musculus,,F,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623734,10090.0,1,1,N,80852,Expert,,500.0,BAO_0000218,
5185,Mus musculus,,F,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623735,10090.0,1,1,N,80852,Expert,,500.0,BAO_0000218,
5186,Homo sapiens,,F,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,CHEMBL623736,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
5187,Homo sapiens,,F,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,CHEMBL623737,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5188,Homo sapiens,,F,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,CHEMBL623738,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5189,Homo sapiens,,F,Dose giving a 50% decrease in the living cell number (A437 cells),,CHEMBL875168,9606.0,1,1,N,80852,Intermediate,,500.0,BAO_0000219,
5190,Homo sapiens,,F,In vitro inhibitory concentration against proliferation of A459 cell line.,,CHEMBL623739,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5191,Homo sapiens,,F,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,CHEMBL623740,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5192,Homo sapiens,,F,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,CHEMBL624424,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5193,Homo sapiens,,F,In vitro antitumor activity against renal A498 tumor cell lines,,CHEMBL624425,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5194,Homo sapiens,,F,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,CHEMBL624426,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5195,Homo sapiens,,F,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,CHEMBL624427,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5196,Homo sapiens,,F,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,CHEMBL624428,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5197,Homo sapiens,,F,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,CHEMBL624429,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5198,Homo sapiens,,F,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,CHEMBL624620,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5199,Homo sapiens,,F,Cytotoxicity on kidney carcinoma (A-498) cell line,,CHEMBL624621,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5200,Homo sapiens,,F,Compound was evaluated against Human cell line renal A498,,CHEMBL624622,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5201,Homo sapiens,,F,Compound was tested for inhibition of A498 human renal cancer cell line,,CHEMBL624623,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5202,Homo sapiens,,F,Growth inhibitory activity against A498 human cancer cell line,,CHEMBL874365,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5203,Homo sapiens,,F,In vitro antitumor activity against human renal A498 cell line,,CHEMBL624624,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5204,Homo sapiens,,F,In vitro cytotoxic activity against renal (A498) cell line,,CHEMBL624625,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5205,Homo sapiens,,F,In vitro cytotoxic activity against human renal cancer (A498) cell line,,CHEMBL624626,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5206,Homo sapiens,,F,Tested for cytostatic activity against renal A498 cell line,,CHEMBL624627,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5207,Homo sapiens,,F,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,CHEMBL883157,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5208,Homo sapiens,,F,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,CHEMBL624628,9606.0,1,1,N,80021,Expert,,624.0,BAO_0000219,
5209,beagle,,A,Cmax value after 2 mpk peroral administration to beagles,,CHEMBL624629,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5210,Canis lupus familiaris,,A,Bioavailability,beagle,CHEMBL623551,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5211,Canis lupus familiaris,,A,Bioavailability after 1 mpk peroral administration to beagles,beagle,CHEMBL623552,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5212,Canis lupus familiaris,,A,Bioavailability after 2 mpk peroral administration to beagles,beagle,CHEMBL623553,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5213,Bos taurus,,A,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,CHEMBL623554,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5214,Bos taurus,,A,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,CHEMBL623555,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5215,Bos taurus,,A,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,CHEMBL623556,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5216,Bos taurus,,A,Solubility against bovine alpha-chymotrypsin,,CHEMBL623557,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5217,Bos taurus,,A,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,CHEMBL623558,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5218,Bos taurus,,A,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,CHEMBL623559,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5219,Bos taurus,,A,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,CHEMBL623560,9913.0,0,1,U,22224,Autocuration,,,BAO_0000221,2106.0
5220,Bos taurus,,A,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,CHEMBL623561,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5221,Bos taurus,,A,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,CHEMBL623562,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5222,Bos taurus,,A,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,CHEMBL623563,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5223,Bos taurus,,A,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,CHEMBL623564,9913.0,0,1,U,22224,Autocuration,,,BAO_0000221,2106.0
5224,Bos taurus,,A,Half life in presence of 2 mg/mL BSA at pH 8.8,,CHEMBL873806,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5225,Bos taurus,,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,CHEMBL623565,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5226,Bos taurus,,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,CHEMBL623566,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5227,Bos taurus,,A,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,CHEMBL623567,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5228,Bos taurus,,A,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,CHEMBL623568,9913.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5229,Canis lupus familiaris,,A,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,CHEMBL623569,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5230,Canis lupus familiaris,,A,AUC after administration at 100 mg/kg/day in dogs,,CHEMBL623570,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5231,Canis lupus familiaris,,A,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,CHEMBL624254,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5232,Canis lupus familiaris,,A,AUC value after 15 mg/kg iv dose in Dogs,,CHEMBL624255,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5233,Canis lupus familiaris,,A,AUC value after 30 mg/kg po dose in Dogs,,CHEMBL624256,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5234,Canis lupus familiaris,,A,AUC value after administration of 4 mg/Kg oral dose in dog,,CHEMBL624257,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5235,Canis lupus familiaris,,A,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,CHEMBL624258,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5236,Canis lupus familiaris,,A,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,CHEMBL875277,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5237,Canis lupus familiaris,,A,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,CHEMBL622667,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5238,Canis lupus familiaris,,A,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,CHEMBL622668,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5239,Canis lupus familiaris,,A,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL622669,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5240,Canis lupus familiaris,,A,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,CHEMBL622670,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5241,Canis lupus familiaris,,A,Area under curve determined in dogs after oral administration of 10 mg/kg,,CHEMBL622671,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5242,Canis lupus familiaris,,A,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL622672,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5243,Canis lupus familiaris,,A,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL622673,9615.0,1,1,N,50588,Expert,,,BAO_0000218,
5244,Canis lupus familiaris,,A,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL622674,9615.0,1,1,N,50588,Expert,,,BAO_0000218,
5245,Canis lupus familiaris,,A,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL622675,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5246,Canis lupus familiaris,,A,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,CHEMBL622676,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5247,Canis lupus familiaris,,A,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL622677,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5248,Canis lupus familiaris,,A,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,CHEMBL622678,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5249,Canis lupus familiaris,,A,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,CHEMBL622679,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5250,Canis lupus familiaris,,A,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL622680,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5251,Canis lupus familiaris,,A,Area under curve was determine after peroral administration at 10 mpk in dog,,CHEMBL622681,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5252,Canis lupus familiaris,,A,Area under curve was determine after peroral administration at 5 mpk in dog,,CHEMBL875278,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5253,Canis lupus familiaris,,A,Area under curve was determined,,CHEMBL622682,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5254,Canis lupus familiaris,,A,Area under curve in dogs,,CHEMBL622683,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5255,Canis lupus familiaris,,A,Area under curve in dogs at 10 mg/kg dose fo oral administration,,CHEMBL622684,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5256,Canis lupus familiaris,,A,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,CHEMBL622685,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5257,Canis lupus familiaris,,A,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,CHEMBL622686,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5258,Canis lupus familiaris,,A,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL618344,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5259,Canis lupus familiaris,,A,Area under curve value in dog at a dose of 5 mg/kg,,CHEMBL875582,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5260,Canis lupus familiaris,,A,Area under curve was determined after 0.1 mg/kg iv administration in dog,,CHEMBL618345,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5261,Canis lupus familiaris,,A,Area under curve was determined after 0.3 mg/kg po administration in dog,,CHEMBL618346,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5262,Canis lupus familiaris,,A,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL618347,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5263,Canis lupus familiaris,,A,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,CHEMBL618348,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5264,Homo sapiens,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,CHEMBL618349,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5265,Homo sapiens,,A,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,CHEMBL618350,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5266,Homo sapiens,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,CHEMBL618351,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5267,Homo sapiens,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,CHEMBL618352,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5268,Homo sapiens,,A,Time taken to reduce 50% of the concentration of compound in blood plasma,,CHEMBL873494,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
5269,Homo sapiens,,A,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,CHEMBL618353,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5270,Homo sapiens,,A,Half life in human plasma,,CHEMBL618354,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5271,Homo sapiens,,A,Half life in human plasma was reported,,CHEMBL875583,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5272,Homo sapiens,,A,Half life in human serum,,CHEMBL618355,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,1977.0
5273,Homo sapiens,,A,Half life upon exposure to human plasma,,CHEMBL618356,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5274,Homo sapiens,,A,t1/2 in human microsomes,,CHEMBL618357,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,
5275,Homo sapiens,,A,Half life period in 80% human plasma at 37 degree Centigrade,,CHEMBL618358,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5276,Homo sapiens,,A,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,CHEMBL618359,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,14.0
5277,Homo sapiens,,A,Half-life measured in in vitro Cathepsin B assay in human plasma,,CHEMBL618360,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5278,Homo sapiens,,A,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,CHEMBL618361,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5279,Homo sapiens,,A,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,CHEMBL618362,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5280,Homo sapiens,,A,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,CHEMBL618363,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5281,Homo sapiens,,A,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,CHEMBL618364,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5282,Homo sapiens,,A,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,CHEMBL875584,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5283,Homo sapiens,,A,Half-life in the CEM cell extracts,,CHEMBL618365,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5284,Homo sapiens,,A,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,CHEMBL873495,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5285,Homo sapiens,,A,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,CHEMBL618366,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5286,Homo sapiens,,A,Half-life was determined,,CHEMBL618367,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5287,Homo sapiens,,A,Half-life (human blood stability),,CHEMBL618368,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
5288,Homo sapiens,,A,Half-life (human blood stability); no data,,CHEMBL618369,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
5289,Homo sapiens,,A,Half-life in human plasma,,CHEMBL618370,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5290,Homo sapiens,,A,CYP3A4 metabolism half-life (t1/2),,CHEMBL618371,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5291,Homo sapiens,,A,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,CHEMBL618372,9606.0,0,1,U,22224,Autocuration,,,BAO_0000221,178.0
5292,Homo sapiens,,A,In vitro half life in human plasma,,CHEMBL618373,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5293,Homo sapiens,,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,CHEMBL618374,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5294,Homo sapiens,,A,In vitro hydrolysis in human plasma,,CHEMBL618375,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5295,Homo sapiens,,A,In vitro hydrolysis in human plasma; no data,,CHEMBL618376,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5296,Homo sapiens,,A,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,CHEMBL618377,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5297,Homo sapiens,,A,Plasma half life in human,,CHEMBL618378,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5298,Homo sapiens,,A,Stability after incubation with human plasma (at 37 degree C),,CHEMBL618379,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5299,Homo sapiens,,A,T1/2 was evaluated in human plasma,,CHEMBL618380,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5300,Homo sapiens,,A,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,CHEMBL618381,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5301,Homo sapiens,,A,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,CHEMBL618382,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5302,Homo sapiens,,A,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,CHEMBL618383,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5303,Homo sapiens,,A,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,CHEMBL618384,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5304,Homo sapiens,,A,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,CHEMBL618385,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5305,Homo sapiens,,A,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,CHEMBL619099,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5306,Homo sapiens,,A,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,CHEMBL619100,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
5307,Homo sapiens,,A,Time taken for 50% to be consumed by serum PON1 was determined,,CHEMBL619101,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5308,Homo sapiens,,A,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,CHEMBL619102,9606.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5309,Homo sapiens,,A,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,CHEMBL619103,9606.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
5310,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL619268,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5311,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL619269,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5312,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL619270,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5313,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL619271,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5314,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL875585,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5315,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL619272,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5316,Homo sapiens,,F,Compound tested for growth inhibition of renal cancer cell line 786-0,,CHEMBL619273,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5317,Homo sapiens,,F,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,CHEMBL619274,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5318,Homo sapiens,,F,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,CHEMBL619275,9606.0,1,1,N,80640,Expert,,391.0,BAO_0000219,
5319,Homo sapiens,,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,CHEMBL619276,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5320,Homo sapiens,,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,CHEMBL619277,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5321,Homo sapiens,,F,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,CHEMBL619278,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5322,Homo sapiens,,F,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,CHEMBL619279,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5323,Homo sapiens,,F,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,CHEMBL858458,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5324,Homo sapiens,,F,Cytotoxic effect on renal cancer line 786-0,,CHEMBL619280,9606.0,1,1,N,80640,Expert,,391.0,BAO_0000219,
5325,Homo sapiens,,F,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,CHEMBL619281,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5326,Homo sapiens,,F,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,CHEMBL619282,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5327,Homo sapiens,,F,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,CHEMBL619283,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5328,Homo sapiens,,F,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,CHEMBL619284,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5329,Homo sapiens,,F,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,CHEMBL619285,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5330,Homo sapiens,,F,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,CHEMBL619286,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5331,Homo sapiens,,F,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,CHEMBL619287,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5332,Homo sapiens,,F,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,CHEMBL857455,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5333,Homo sapiens,,F,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,CHEMBL883801,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5334,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,CHEMBL619288,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5335,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,CHEMBL619289,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5336,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,CHEMBL619290,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5337,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,CHEMBL619291,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5338,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,CHEMBL619292,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5339,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,CHEMBL619293,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5340,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,CHEMBL619294,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5341,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,CHEMBL619295,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5342,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,CHEMBL619296,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5343,Homo sapiens,,F,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,CHEMBL619297,9606.0,1,1,N,80641,Intermediate,,972.0,BAO_0000219,
5344,Homo sapiens,,F,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,CHEMBL619298,9606.0,1,1,N,80640,Intermediate,,391.0,BAO_0000219,
5345,,,F,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,CHEMBL619299,,0,1,U,22226,Intermediate,,,BAO_0000019,
5346,Homo sapiens,,F,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,CHEMBL619300,9606.0,1,1,N,80433,Expert,,741.0,BAO_0000219,
5347,Homo sapiens,,F,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,CHEMBL619301,9606.0,1,1,N,80433,Expert,,741.0,BAO_0000219,
5348,Homo sapiens,,F,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,CHEMBL619302,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5349,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,CHEMBL619303,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5350,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,CHEMBL619304,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5351,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,CHEMBL857706,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5352,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,CHEMBL619305,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5353,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,CHEMBL619306,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5354,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL619307,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5355,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL619308,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5356,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,CHEMBL619309,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5357,Homo sapiens,,F,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,CHEMBL619310,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5358,Homo sapiens,,F,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,CHEMBL619311,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5359,Homo sapiens,,F,Compound was tested for the growth inhibition of A498 renal tumor cell line,,CHEMBL619312,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5360,Homo sapiens,,F,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,CHEMBL619313,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5361,Homo sapiens,,F,In vitro inhibitory concentration against renal cancer cell line A498,,CHEMBL619314,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5362,Homo sapiens,,F,Cytotoxicity against A 498 tumor cell line,,CHEMBL619959,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5363,Homo sapiens,,F,In vitro antitumor activity against A498 human cancer cell line,,CHEMBL619960,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5364,Homo sapiens,,F,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,CHEMBL619961,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5365,Homo sapiens,,F,Inhibitory dose required against A498 human tumor cell lines,,CHEMBL619962,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5366,Homo sapiens,,F,Anticancer activity against one renal cancer (A498 cell line),,CHEMBL875586,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5367,Homo sapiens,,F,In vitro cytotoxicity against melanoma A498 cell line,,CHEMBL619963,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5368,Homo sapiens,,F,Compound was tested for growth inhibitory activity against A498 cell line,,CHEMBL619964,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5369,Homo sapiens,,F,Compound tested for growth inhibition of renal cancer cell line A498,,CHEMBL620108,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5370,Homo sapiens,,F,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,CHEMBL620109,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5371,Homo sapiens,,F,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,CHEMBL620110,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5372,Homo sapiens,,F,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,CHEMBL620111,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5373,Homo sapiens,,F,Tested for cytotoxicity against A498 cell lines in renal cancer,,CHEMBL620112,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5374,Homo sapiens,,F,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,CHEMBL620113,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5375,Homo sapiens,,F,Cytotoxic effect on renal cancer lines A498,,CHEMBL620114,9606.0,1,1,N,80021,Expert,,624.0,BAO_0000219,
5376,Homo sapiens,,F,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,CHEMBL620115,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5377,Homo sapiens,,F,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,CHEMBL620116,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5378,Homo sapiens,,F,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,CHEMBL620117,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5379,Homo sapiens,,F,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,CHEMBL620118,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5380,Homo sapiens,,F,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,CHEMBL620119,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5381,Homo sapiens,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,CHEMBL620120,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5382,Homo sapiens,,F,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,CHEMBL620121,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5383,Homo sapiens,,F,Antitumor activity against A549 human lung carcinoma cell line,,CHEMBL620122,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5384,Homo sapiens,,F,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,CHEMBL620123,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5385,Homo sapiens,,F,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,CHEMBL620124,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5386,Homo sapiens,,F,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,CHEMBL620125,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5387,Homo sapiens,,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,CHEMBL620126,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5388,Homo sapiens,,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL883027,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5389,Homo sapiens,,F,In vitro cytotoxic activity against human lung A549 cell line,,CHEMBL620127,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5390,Homo sapiens,,F,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,CHEMBL620128,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5391,Homo sapiens,,F,In vitro cytotoxic activity against human lung A549 cell line),,CHEMBL620129,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5392,Homo sapiens,,F,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,CHEMBL620130,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5393,Homo sapiens,,F,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,CHEMBL620131,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5394,Homo sapiens,,F,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,CHEMBL620132,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5395,Homo sapiens,,F,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,CHEMBL620133,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5396,Homo sapiens,,F,Inhibition of A549 human lung carcinoma cell proliferation,,CHEMBL620134,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5397,Homo sapiens,,F,Inhibitory activity against A549 lung adenocarcinoma cell line,,CHEMBL620135,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5398,Homo sapiens,,F,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,CHEMBL620136,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5399,Homo sapiens,,F,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,CHEMBL620137,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5400,Homo sapiens,,F,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,CHEMBL620268,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5401,Homo sapiens,,F,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL620269,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5402,Homo sapiens,,F,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,CHEMBL620270,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5403,Homo sapiens,,F,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,CHEMBL620271,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5404,Homo sapiens,,F,Inhibition of A549 cancer cell proliferation,,CHEMBL620272,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5405,Homo sapiens,,F,Inhibition of A549 cancer cell proliferation (Not tested),,CHEMBL620273,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5406,Homo sapiens,,F,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,CHEMBL620274,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5407,Homo sapiens,,F,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,CHEMBL620275,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5408,Homo sapiens,,F,Antiproliferative potency determined as inhibitory concentration against A549 cells,,CHEMBL620276,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5409,Homo sapiens,,F,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,CHEMBL620277,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5410,Homo sapiens,,F,Cytotoxicity against Renal cell lines A549 was determined,,CHEMBL620278,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5411,Canis lupus familiaris,,A,Area under curve was determined in dog after a 3 mg/kg of oral dose,,CHEMBL620279,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5412,Canis lupus familiaris,,A,Area under curve was determined in dog after oral administration at 1 mg/kg,,CHEMBL620280,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5413,Canis lupus familiaris,,A,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL620281,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5414,Canis lupus familiaris,,A,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL620282,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5415,Canis lupus familiaris,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,CHEMBL621134,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5416,Canis lupus familiaris,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,CHEMBL621135,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5417,Canis lupus familiaris,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,CHEMBL621136,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5418,Canis lupus familiaris,,A,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,CHEMBL621137,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5419,Canis lupus familiaris,,A,Area under plasma concentration time curve in dog upon oral administration,,CHEMBL621138,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5420,Canis lupus familiaris,,A,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL875587,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5421,Canis lupus familiaris,,A,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,CHEMBL621139,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5422,Canis lupus familiaris,,A,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,CHEMBL621140,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5423,Canis lupus familiaris,,A,Area under the curve for the compound was obtained when tested in dog,,CHEMBL621141,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5424,Canis lupus familiaris,,A,Area under the curve at a dose of 1 mg/kg,,CHEMBL621142,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5425,Canis lupus familiaris,,A,Area under the curve at a dose of 1 mg/kg (oral),,CHEMBL621143,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5426,Canis lupus familiaris,,A,Area under the curve at i.v. dose of 0.2 mg/kg,,CHEMBL621144,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5427,Canis lupus familiaris,,A,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,CHEMBL621145,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5428,Canis lupus familiaris,,A,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,CHEMBL621146,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5429,Canis lupus familiaris,,A,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,CHEMBL622567,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5430,Canis lupus familiaris,,A,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,CHEMBL622568,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5431,Canis lupus familiaris,,A,Compound was evaluated for area under the curve in dog blood.,,CHEMBL622569,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5432,Canis lupus familiaris,,A,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,CHEMBL622570,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5433,Canis lupus familiaris,,A,AUC in dog after oral dose (1 mg/kg),,CHEMBL622571,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5434,Canis lupus familiaris,,A,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,CHEMBL622572,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5435,Canis lupus familiaris,,A,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,CHEMBL622573,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5436,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC after intravenous administration to dogs,,CHEMBL622574,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5437,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC after oral administration to dogs,,CHEMBL622575,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5438,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,CHEMBL622576,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5439,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,CHEMBL622577,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5440,Canis lupus familiaris,,A,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,CHEMBL622578,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5441,Canis lupus familiaris,,A,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,CHEMBL622579,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5442,Canis lupus familiaris,,A,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,CHEMBL622580,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5443,Canis lupus familiaris,,A,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,CHEMBL622581,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5444,Canis lupus familiaris,,A,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL622582,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5445,Canis lupus familiaris,,A,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL622583,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5446,Canis lupus familiaris,,A,Oral AUCN in dog (dosed at 0.5 mpk iv ),,CHEMBL622584,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5447,Canis lupus familiaris,,A,Oral AUCN in dog (dosed at 0.5 mpk iv ),,CHEMBL622585,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5448,Canis lupus familiaris,,A,Compound was evaluated for oral bioavailability in dog; 90-100,,CHEMBL622586,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5449,Canis lupus familiaris,,A,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,CHEMBL623281,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5450,Canis lupus familiaris,,A,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,CHEMBL623282,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5451,Canis lupus familiaris,,A,PAPP (membrane permeability) in dog kidney cell monolayer assay,,CHEMBL623283,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5452,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623284,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5453,Canis lupus familiaris,,A,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,CHEMBL623285,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5454,Canis lupus familiaris,,A,Plasma protein binding towards dog plasma at 10 uM,,CHEMBL623463,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5455,Canis lupus familiaris,,A,Plasma protein binding towards dog plasma at 100 uM,,CHEMBL875952,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5456,Canis lupus familiaris,,A,Bioavailability in dog (dose 4 mg/kg p.o.),,CHEMBL621705,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5457,Canis lupus familiaris,,A,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,CHEMBL621706,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5458,Canis lupus familiaris,,A,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL621707,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5459,Canis lupus familiaris,,A,Bioavailability in dogs,,CHEMBL621708,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5460,Canis lupus familiaris,,A,Bioavailability,,CHEMBL621709,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5461,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621710,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5462,Canis lupus familiaris,,A,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,CHEMBL621711,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5463,Canis lupus familiaris,,A,Bioavailability in dog (dose 10.0 mg/kg p.o.),,CHEMBL621712,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5464,Canis lupus familiaris,,A,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL621713,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5465,Canis lupus familiaris,,A,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,CHEMBL621714,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5466,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL621715,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5467,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL623717,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
5468,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL623718,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
5469,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL623719,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
5470,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL623720,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5471,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL623721,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5472,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL623722,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
5473,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL623723,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
5474,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL618543,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
5475,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL618544,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
5476,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL875155,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
5477,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL618545,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5478,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL618546,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5479,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL623529,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5480,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL623530,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5481,Mus sp.,,A,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL621764,10095.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5482,Cercopithecidae,,A,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,CHEMBL621765,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5483,Cercopithecidae,,A,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,CHEMBL621766,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,2037.0
5484,Cercopithecidae,,A,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,CHEMBL621767,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,1870.0
5485,Cercopithecidae,,A,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,CHEMBL621768,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5486,Cercopithecidae,,A,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,CHEMBL621769,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,2435.0
5487,Cercopithecidae,,A,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,CHEMBL621770,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5488,Cercopithecidae,,A,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,CHEMBL621771,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,2037.0
5489,Cercopithecidae,,A,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,CHEMBL621772,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,1870.0
5490,Cercopithecidae,,A,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,CHEMBL621773,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5491,Cercopithecidae,,A,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,CHEMBL621774,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,2435.0
5492,Cercopithecidae,,A,Compound was evaluated for oral bioavailability in rats,,CHEMBL621775,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5493,Cercopithecidae,,A,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,CHEMBL621776,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
5494,Cercopithecidae,,A,Half life period was evaluated in monkey,,CHEMBL621777,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
5495,Cercopithecidae,,A,Half-life in rhesus monkeys by intravenous administration of dose,,CHEMBL875162,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
5496,Mus musculus,,A,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,CHEMBL621778,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
5497,Mus musculus,,A,AUC after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL621779,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
5498,Mus musculus,,A,AUC value was determined after oral administration,,CHEMBL622479,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
5499,Mus musculus,,A,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,CHEMBL622480,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5500,Mus musculus,,A,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL622481,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5501,Mus musculus,,A,Area under curve by ioral administration in mouse,,CHEMBL622482,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5502,Mus musculus,,A,Area under curve by iv administration in mouse,,CHEMBL622483,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5503,Mus musculus,,A,Area under curve at 0-8 hr in IRC mice after peroral administration,,CHEMBL622484,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5504,Mus musculus,,A,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,CHEMBL622641,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5505,Mus musculus,,A,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,CHEMBL622642,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5506,Mus musculus,,A,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,CHEMBL622643,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5507,Mus musculus,,A,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,CHEMBL622644,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5508,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,CHEMBL622645,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5509,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,CHEMBL622646,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5510,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,CHEMBL621238,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5511,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,CHEMBL621239,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5512,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,CHEMBL621240,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5513,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL621241,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5514,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,CHEMBL621242,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5515,Homo sapiens,,F,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,CHEMBL620350,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5516,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,CHEMBL620351,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5517,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,CHEMBL620352,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5518,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,CHEMBL620353,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5519,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,CHEMBL620354,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5520,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,CHEMBL620355,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5521,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL620356,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5522,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,CHEMBL620357,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5523,Homo sapiens,,F,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,CHEMBL620358,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5524,Homo sapiens,,F,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,CHEMBL620359,9606.0,1,1,N,80433,Expert,,741.0,BAO_0000219,
5525,Homo sapiens,,F,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,CHEMBL620360,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5526,Homo sapiens,,F,Cytotoxicity of compound against 8226/DOX1V cells,,CHEMBL620361,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5527,Homo sapiens,,F,Cytotoxicity of compound against 8226/S cells,,CHEMBL620362,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5528,Homo sapiens,,F,Inhibitory concentration against 8226 myeloma cancer cell line,,CHEMBL620363,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5529,Homo sapiens,,F,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,CHEMBL620364,9606.0,1,1,N,80433,Intermediate,,741.0,BAO_0000219,
5530,Homo sapiens,,F,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,CHEMBL620365,9606.0,1,1,N,80647,Intermediate,,854.0,BAO_0000219,
5531,Homo sapiens,,F,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,CHEMBL620366,9606.0,1,1,N,80647,Intermediate,,854.0,BAO_0000219,
5532,Homo sapiens,,F,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,CHEMBL620367,9606.0,1,1,N,80647,Expert,,854.0,BAO_0000219,
5533,Homo sapiens,,F,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,CHEMBL620368,9606.0,1,1,N,80647,Intermediate,,854.0,BAO_0000219,
5534,,,B,Inhibitory activity against caspase-1,,CHEMBL620369,,0,1,U,22226,Autocuration,,,BAO_0000019,
5535,Enterococcus faecalis,,B,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,CHEMBL620370,1351.0,8,1,H,45,Autocuration,,,BAO_0000357,
5536,Homo sapiens,,F,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,CHEMBL620371,9606.0,1,1,N,80648,Intermediate,,705.0,BAO_0000219,
5537,Homo sapiens,,F,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,CHEMBL620372,9606.0,1,1,N,80648,Intermediate,,705.0,BAO_0000219,
5538,,,F,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,CHEMBL876492,,0,1,U,22226,Intermediate,,,BAO_0000019,
5539,,,F,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,CHEMBL620373,,0,1,U,22226,Intermediate,,,BAO_0000019,
5540,,,F,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,CHEMBL620374,,0,1,U,22226,Intermediate,,,BAO_0000019,
5541,,,B,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,CHEMBL620375,,0,1,U,22226,Autocuration,,,BAO_0000019,
5542,Streptococcus pyogenes,,F,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,CHEMBL857902,1314.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5543,Streptococcus pyogenes,,F,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,CHEMBL620376,1314.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5544,,,B,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,CHEMBL620377,,8,1,H,11922,Autocuration,,,BAO_0000357,
5545,Homo sapiens,,F,Tested for in vitro cytotoxic potency of compound in 9KB assay,,CHEMBL620378,9606.0,1,1,N,81115,Intermediate,,324.0,BAO_0000219,
5546,Homo sapiens,,A,Tested for in vitro cytotoxic potency of compound in 9KB assay,,CHEMBL620379,9606.0,1,1,N,81115,Intermediate,,324.0,BAO_0000219,
5547,Homo sapiens,,F,In vitro cytotoxicity of compound was tested against 9KB cells.,,CHEMBL620380,9606.0,0,1,U,22226,Autocuration,,,BAO_0000219,
5548,Rattus norvegicus,,F,Cytotoxic concentration against 9L cells was determined on day 3,,CHEMBL884006,10116.0,1,1,N,80653,Intermediate,,392.0,BAO_0000219,
5549,Rattus norvegicus,,F,Tested in vitro for anticancer activity against 9L cells,,CHEMBL620381,10116.0,1,1,N,80653,Expert,,392.0,BAO_0000219,
5550,Rattus norvegicus,,F,Tested in vitro for anticancer activity against 9L cells; Not determined,,CHEMBL620382,10116.0,1,1,N,80653,Expert,,392.0,BAO_0000219,
5551,Homo sapiens,,F,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,CHEMBL620383,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5552,Homo sapiens,,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,CHEMBL876493,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5553,Homo sapiens,,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,CHEMBL620384,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5554,Homo sapiens,,F,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,CHEMBL620385,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5555,Homo sapiens,,F,Cytotoxicity against human lung carcinoma A549 cell line,,CHEMBL620386,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5556,Homo sapiens,,F,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,CHEMBL620387,9606.0,9,1,D,25,Expert,,646.0,BAO_0000219,
5557,Homo sapiens,,F,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,CHEMBL621404,9606.0,9,1,D,25,Expert,,646.0,BAO_0000219,
5558,Homo sapiens,,F,"In vitro growth inhibition of A549, lung carcinoma",,CHEMBL621405,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5559,Homo sapiens,,F,"In vitro growth inhibition of A549, lung carcinoma.",,CHEMBL621406,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5560,Homo sapiens,,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,CHEMBL621407,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5561,Homo sapiens,,F,Cytotoxic activity against human lung cancer A549 cell line was determined,,CHEMBL621408,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5562,Homo sapiens,,F,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,CHEMBL885345,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5563,Homo sapiens,,F,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,CHEMBL621409,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5564,Homo sapiens,,F,Cytotoxicity in A549 (human carcinoma) cell line.,,CHEMBL876034,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5565,Homo sapiens,,F,Cytotoxicity on lung carcinoma (A-549) cell line,,CHEMBL621410,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5566,Homo sapiens,,F,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,CHEMBL621411,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5567,Homo sapiens,,F,Effective dose of compound against replication of A549 cell line was evaluated,,CHEMBL621412,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5568,Homo sapiens,,F,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,CHEMBL621413,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5569,Homo sapiens,,F,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,CHEMBL621414,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5570,Homo sapiens,,F,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,CHEMBL621415,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5571,Homo sapiens,,F,The compound was evaluated for antiproliferative activity against A549 cell line,,CHEMBL621416,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5572,Homo sapiens,,F,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,CHEMBL621417,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5573,Homo sapiens,,F,Concentration required for growth inhibition of human lung carcinoma cell line A549,,CHEMBL621418,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5574,Homo sapiens,,F,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,CHEMBL621419,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5575,Homo sapiens,,F,Growth inhibition against A549 cell line was evaluated,,CHEMBL621420,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5576,Homo sapiens,,F,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,CHEMBL875823,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5577,Homo sapiens,,F,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,CHEMBL621421,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5578,Homo sapiens,,F,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,CHEMBL621422,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5579,Homo sapiens,,F,Chemosensitivity against DT-diaphorase rich A549 cell lines,,CHEMBL884014,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5580,Homo sapiens,,F,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,CHEMBL621423,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5581,Homo sapiens,,F,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,CHEMBL621424,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5582,Homo sapiens,,F,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,CHEMBL621425,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5583,Homo sapiens,,F,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,CHEMBL621426,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5584,Homo sapiens,,F,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,CHEMBL621427,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5585,Homo sapiens,,F,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,CHEMBL621428,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5586,Homo sapiens,,F,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,CHEMBL621429,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5587,Homo sapiens,,F,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,CHEMBL621430,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5588,Homo sapiens,,F,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,CHEMBL621431,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5589,Homo sapiens,,F,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,CHEMBL621432,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5590,Homo sapiens,,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,CHEMBL621433,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5591,Homo sapiens,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,CHEMBL875824,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5592,Homo sapiens,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,CHEMBL621434,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5593,Homo sapiens,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,CHEMBL621435,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5594,Homo sapiens,,F,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,CHEMBL621436,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5595,Homo sapiens,,F,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,CHEMBL621437,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5596,Homo sapiens,,F,Compound was tested for the growth inhibition of A549 lung tumor cell line,,CHEMBL621438,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5597,Homo sapiens,,F,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,CHEMBL621439,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5598,Homo sapiens,,F,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,CHEMBL621440,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5599,Canis lupus familiaris,,A,Oral bioavailability in dog (conscious),,CHEMBL621441,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5600,Canis lupus familiaris,,A,Compound was evaluated for the oral bioavailability after oral administration in dog.,,CHEMBL621442,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5601,Canis lupus familiaris,,A,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,CHEMBL621443,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5602,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621444,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5603,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL625133,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5604,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL625134,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5605,Canis lupus familiaris,,A,Oral bioavailability in dog (fasted),,CHEMBL625135,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5606,Canis lupus familiaris,,A,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL625136,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5607,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL625137,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5608,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL625138,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5609,Canis lupus familiaris,,A,Percent bioavailability in dog,,CHEMBL625139,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5610,Canis lupus familiaris,,A,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,CHEMBL872264,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5611,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL625140,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5612,Canis lupus familiaris,,A,The compound was evaluated for bioavailability in dogs; 34-44,,CHEMBL624436,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5613,Canis lupus familiaris,,A,Bioavailability in dog (dose 4 mg/kg p.o.),,CHEMBL624437,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5614,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL872261,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5615,Canis lupus familiaris,,A,8 hour trough Blood level in dog was measured after administration of compound,,CHEMBL624438,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5616,Canis lupus familiaris,,A,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,CHEMBL624439,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5617,Canis lupus familiaris,,A,C24 after oral administration at 5 mg/kg,,CHEMBL624440,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5618,Canis lupus familiaris,,A,Clearance after oral and iv dosing in dogs,,CHEMBL624441,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5619,Canis lupus familiaris,,A,Clearance of the drug was measured in the plasma of dog,,CHEMBL624442,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5620,Canis lupus familiaris,,A,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,CHEMBL624443,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5621,Canis lupus familiaris,,A,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,CHEMBL624444,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5622,Canis lupus familiaris,,A,Clearance of compound was determined in dogs,,CHEMBL624445,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5623,Canis lupus familiaris,,A,Clearance on i.v. administration of 2 mg/kg was measured in dog,,CHEMBL624446,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5624,Canis lupus familiaris,,A,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL624447,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5625,Canis lupus familiaris,,A,Plasma clearance in dog was determined,,CHEMBL624448,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5626,Canis lupus familiaris,,A,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL624449,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5627,Canis lupus familiaris,,A,Plasma clearance in dog after administration of 0.25 mg/kg iv,,CHEMBL624450,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5628,Canis lupus familiaris,,A,Plasma clearance in dog after administration of 1 mg/kg iv,,CHEMBL875942,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5629,Canis lupus familiaris,,A,Plasma clearance in dogs,,CHEMBL624451,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5630,Canis lupus familiaris,,A,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,CHEMBL624452,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5631,Canis lupus familiaris,,A,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL624453,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5632,Canis lupus familiaris,,A,Plasma clearance after 15 mg/kg iv dose in Dogs,,CHEMBL624454,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5633,Canis lupus familiaris,,A,Plasma clearance after 30 mg/kg po dose in Dogs,,CHEMBL624455,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5634,Canis lupus familiaris,,A,Plasma administration to dogs,,CHEMBL624456,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5635,Canis lupus familiaris,,A,Plasma clearance was determined,,CHEMBL624457,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5636,Canis lupus familiaris,,A,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,CHEMBL624458,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5637,Canis lupus familiaris,,A,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,CHEMBL624459,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5638,Homo sapiens,,A,Intrinsic clearance in human liver microsomes,,CHEMBL624460,9606.0,2,1,S,102164,Intermediate,,,BAO_0000251,2107.0
5639,Homo sapiens,,A,Intrinsic clearance in human liver microsomes,,CHEMBL624461,9606.0,2,1,S,102164,Intermediate,,,BAO_0000251,2107.0
5640,Canis lupus familiaris,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL875943,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5641,Canis lupus familiaris,,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,CHEMBL624462,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5642,Canis lupus familiaris,,A,Clearance in dog (dose 1 mg/kg i.v.),,CHEMBL624463,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5643,Canis lupus familiaris,,A,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,CHEMBL624464,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5644,Canis lupus familiaris,,A,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL624465,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5645,Canis lupus familiaris,,A,Plasma clearance after peroral administration at 10 mpk in dog,,CHEMBL624466,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5646,Canis lupus familiaris,,A,Plasma clearance after peroral administration at 5 mpk in dog,,CHEMBL624467,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5647,Canis lupus familiaris,,A,Plasma clearance after peroral administration at 5 mg/kg in dog,,CHEMBL624468,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5648,Canis lupus familiaris,,A,Plasma clearance was measured in dog,,CHEMBL624469,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5649,Canis lupus familiaris,,A,Plasma clearance was measured in dog,,CHEMBL624470,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5650,Canis lupus familiaris,,A,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,CHEMBL624471,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5651,Canis lupus familiaris,,A,Total clearance was determined after 0.1 mg/kg iv administration in dog,,CHEMBL624472,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5652,Canis lupus familiaris,,A,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL622775,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5653,Canis lupus familiaris,,A,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,CHEMBL622776,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5654,Canis lupus familiaris,,A,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,CHEMBL622777,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5655,Canis lupus familiaris,,A,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,CHEMBL622778,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5656,Canis lupus familiaris,,A,Clearance by intravenous administration of 1.2 mg/kg in dog,,CHEMBL622779,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5657,Canis lupus familiaris,,A,Clearance by iv administration in dogs at a dose of 1 mg/kg,,CHEMBL622780,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5658,Canis lupus familiaris,,A,Clearance value was evaluated in dog plasma,,CHEMBL622781,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5659,Canis lupus familiaris,,A,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,CHEMBL622782,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5660,Canis lupus familiaris,,A,Compound was tested for plasma clearance in dog,,CHEMBL622783,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5661,Canis lupus familiaris,,A,Pharmacokinetic property (Plasma clearance) was measured in dog,,CHEMBL622784,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5662,Mus musculus,,A,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,CHEMBL622785,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5663,Mus musculus,,A,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,CHEMBL622786,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5664,Mus musculus,,A,Area under curve value in mouse at a dose of 10 mg/kg,,CHEMBL622787,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5665,Mus musculus,,A,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,CHEMBL875949,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5666,Mus musculus,,A,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,CHEMBL622788,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5667,Mus musculus,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,CHEMBL622789,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5668,Mus musculus,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL622790,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5669,Mus musculus,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,CHEMBL622791,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5670,Mus musculus,,F,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,CHEMBL622792,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5671,Mus musculus,,A,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,CHEMBL622793,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5672,Mus musculus,,A,Area under curve was determined for the compound at 24 mg/Kg,,CHEMBL622794,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5673,Mus musculus,,A,Area under curve was determined for the compound at 40 mg/Kg,,CHEMBL622795,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5674,Mus musculus,,A,Area under curve was determined for the compound at 5 mg/Kg,,CHEMBL621803,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5675,Mus musculus,,A,Area under the curve for the compound is obtained at dose 25 mg/kg,,CHEMBL621804,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5676,Mus musculus,,A,Area under the curve for the compound was obtained when tested in mouse,,CHEMBL621805,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5677,Mus musculus,,A,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,CHEMBL621806,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5678,Mus musculus,,A,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,CHEMBL621807,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5679,Mus musculus,,A,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL621808,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5680,Mus musculus,,A,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL621809,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5681,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,CHEMBL621810,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5682,Mus musculus,,A,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,CHEMBL875164,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5683,Mus musculus,,A,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,CHEMBL621811,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5684,Mus musculus,,A,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,CHEMBL621812,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5685,Mus musculus,,A,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,CHEMBL621813,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5686,Mus musculus,,A,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,CHEMBL621814,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5687,Mus musculus,,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL621815,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5688,Mus musculus,,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL621816,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5689,Mus musculus,,A,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,CHEMBL621817,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5690,Mus musculus,,A,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,CHEMBL621818,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5691,Mus musculus,,A,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,CHEMBL621819,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5692,Mus musculus,,A,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,CHEMBL621820,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5693,Mus musculus,,A,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,CHEMBL621821,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5694,Mus musculus,,A,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,CHEMBL621822,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5695,Mus musculus,,A,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,CHEMBL619474,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5696,Mus musculus,,A,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,CHEMBL619475,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5697,Mus musculus,,A,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,CHEMBL619476,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5698,Mus musculus,,A,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,CHEMBL619477,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5699,Mus musculus,,A,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,CHEMBL619478,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5700,Mus musculus,,A,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,CHEMBL619479,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5701,Mus musculus,,A,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,CHEMBL619480,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5702,Mus musculus,,A,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,CHEMBL619481,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5703,Mus musculus,,A,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,CHEMBL619482,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5704,Mus musculus,,A,Area under the curve was evaluated in mice after intravenous administration,,CHEMBL619483,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5705,Mus musculus,,A,Area under the curve was evaluated in mice after oral administration,,CHEMBL619484,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5706,Mus musculus,,A,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL619485,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
5707,Mus musculus,,A,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL619486,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
5708,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,CHEMBL619487,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5709,Mus musculus,,A,AUMC after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL619488,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5710,Mus musculus,,A,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,CHEMBL620106,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5711,,,F,The compound was tested in vitro for anticancer activity against 9L cells,,CHEMBL620107,,1,1,N,80653,Intermediate,,392.0,BAO_0000219,
5712,Rattus norvegicus,,F,Anti proliferation activity determined; Weak effect,,CHEMBL620283,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5713,Rattus norvegicus,,F,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,CHEMBL875176,10116.0,0,1,U,22226,Autocuration,,,BAO_0000219,
5714,Rattus norvegicus,,F,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,CHEMBL620284,10116.0,0,1,U,22226,Autocuration,,,BAO_0000219,
5715,Rattus norvegicus,,F,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,CHEMBL623515,10116.0,0,1,U,22226,Autocuration,,,BAO_0000219,
5716,Mus musculus,,F,The cytotoxic activity was in vitro tested by 9PS assay method,,CHEMBL623516,10090.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5717,Mus musculus,,F,The cytotoxic activity was in vitro tested by 9PS assay method.,,CHEMBL623517,10090.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5718,,,A,Partition coefficient (logD6.5),,CHEMBL857878,,0,1,U,22224,Autocuration,,,BAO_0000019,
5719,Homo sapiens,,F,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,CHEMBL623518,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
5720,Homo sapiens,,F,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,CHEMBL624195,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
5721,Homo sapiens,,F,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,CHEMBL624196,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
5722,Homo sapiens,,F,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,CHEMBL624197,9606.0,9,1,D,9,Expert,,500.0,BAO_0000219,
5723,Homo sapiens,,F,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,CHEMBL624198,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5724,Homo sapiens,,F,in vitro cytotoxicity against A 498 cancer cell line,,CHEMBL621287,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5725,Homo sapiens,,F,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,CHEMBL621288,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5726,Homo sapiens,,F,Cytotoxic activity against A 498 renal cancer cell lines.,,CHEMBL876496,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5727,Homo sapiens,,F,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,CHEMBL621289,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5728,Staphylococcus aureus,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,CHEMBL621290,1280.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5729,Staphylococcus aureus,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,CHEMBL621291,1280.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5730,Staphylococcus aureus,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,CHEMBL621292,1280.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5731,Staphylococcus aureus,,F,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,CHEMBL621293,1280.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5732,Homo sapiens,,F,Inhibitory concentration required against A 549 lung cancer cell line,,CHEMBL621294,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5733,Homo sapiens,,F,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,CHEMBL621295,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5734,Homo sapiens,,F,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,CHEMBL884007,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5735,Homo sapiens,,F,In vitro cytotoxicity against lung cancer A 549 cell lines,,CHEMBL621296,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5736,Homo sapiens,,F,Compound was tested for its cytotoxicity against A 549 cell line,,CHEMBL621297,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5737,Homo sapiens,,F,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,CHEMBL839828,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5738,Homo sapiens,,F,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,CHEMBL620397,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5739,Homo sapiens,,F,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,CHEMBL620398,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5740,Homo sapiens,,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,CHEMBL620399,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5741,Homo sapiens,,F,In vitro inhibition of A549 (human lung cancer) cell growth.,,CHEMBL620400,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5742,Homo sapiens,,F,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,CHEMBL620401,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5743,Homo sapiens,,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,CHEMBL620402,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5744,Homo sapiens,,F,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,CHEMBL620403,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5745,,,F,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,CHEMBL620404,,0,1,U,22226,Autocuration,,,BAO_0000218,
5746,,,F,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,CHEMBL620405,,4,1,H,104694,Autocuration,,,BAO_0000218,
5747,,,F,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,CHEMBL620406,,4,1,H,104694,Autocuration,,,BAO_0000218,
5748,,,F,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,CHEMBL620407,,4,1,H,104694,Autocuration,,,BAO_0000218,
5749,,,F,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,CHEMBL620408,,4,1,H,104694,Autocuration,,,BAO_0000218,
5750,,,F,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,CHEMBL620409,,4,1,H,104694,Autocuration,,,BAO_0000218,
5751,Homo sapiens,,F,Inhibition of A-498 human Renal cell proliferation,,CHEMBL620410,9606.0,1,1,N,80021,Expert,,624.0,BAO_0000219,
5752,Rattus norvegicus,,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,CHEMBL620411,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5753,Rattus norvegicus,,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,CHEMBL620412,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5754,Rattus norvegicus,,F,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,CHEMBL876596,10116.0,0,1,U,22226,Autocuration,,,BAO_0000019,
5755,Homo sapiens,,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,CHEMBL620413,9606.0,1,1,N,80012,Expert,,622.0,BAO_0000219,
5756,Homo sapiens,,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL620414,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
5757,Homo sapiens,,F,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL620415,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
5758,Homo sapiens,,F,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,CHEMBL620416,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5759,Homo sapiens,,F,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,CHEMBL620417,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5760,Homo sapiens,,F,Cytotoxic activity evaluated against A549 tumor cells,,CHEMBL620418,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5761,Homo sapiens,,F,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,CHEMBL620419,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5762,Homo sapiens,,F,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,CHEMBL620420,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5763,Homo sapiens,,F,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,CHEMBL620421,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5764,Homo sapiens,,F,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,CHEMBL620422,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5765,Homo sapiens,,F,Cytotoxicity of compound against A549 cell line,,CHEMBL620423,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5766,Homo sapiens,,F,Cytotoxicity against human lung cell carcinoma A549 cell line,,CHEMBL620424,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5767,Homo sapiens,,F,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,CHEMBL620425,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5768,Homo sapiens,,F,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,CHEMBL620426,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5769,Homo sapiens,,F,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,CHEMBL620427,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5770,Homo sapiens,,F,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,CHEMBL620428,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5771,Homo sapiens,,F,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,CHEMBL620429,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5772,Homo sapiens,,F,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,CHEMBL620430,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5773,Homo sapiens,,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,CHEMBL839887,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5774,Homo sapiens,,F,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,CHEMBL620431,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5775,Homo sapiens,,F,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,CHEMBL884010,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5776,Homo sapiens,,F,In vitro cytotoxicity against A549 (human lung cancer),,CHEMBL620538,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5777,Homo sapiens,,F,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,CHEMBL620539,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5778,Homo sapiens,,F,In vivo antiproliferative activity against A549 cell line,,CHEMBL623373,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5779,Homo sapiens,,F,Inhibition of non-small-cell lung adenocarcinoma (A549),,CHEMBL623374,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5780,Homo sapiens,,F,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,CHEMBL623375,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5781,Homo sapiens,,F,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,CHEMBL623376,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5782,Homo sapiens,,F,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,CHEMBL623377,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5783,Homo sapiens,,F,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,CHEMBL623378,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5784,Homo sapiens,,F,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,CHEMBL623379,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5785,Homo sapiens,,F,Inhibitory activity against A549 lung cancer cell line,,CHEMBL623380,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5786,Homo sapiens,,F,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,CHEMBL623381,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5787,Homo sapiens,,F,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,CHEMBL623382,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5788,Homo sapiens,,F,Inhibitory concentration against A549 (lung cancer) cell line,,CHEMBL623383,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5789,Homo sapiens,,F,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,CHEMBL623384,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5790,Homo sapiens,,F,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,CHEMBL623385,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5791,Homo sapiens,,F,Activity against A549 cancer cell line.,,CHEMBL623386,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5792,Homo sapiens,,F,The compound was evaluated for cytotoxicity against A549 cell line,,CHEMBL884105,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5793,Homo sapiens,,F,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,CHEMBL623387,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5794,Homo sapiens,,F,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,CHEMBL621568,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5795,Homo sapiens,,F,Growth inhibitory activity was measured for human A549 tumor cell line.,,CHEMBL621569,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5796,Homo sapiens,,F,Inhibitory activity against A549 lung cancer cell line,,CHEMBL621570,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5797,Homo sapiens,,F,Inhibitory activity against A549 cell line; inactive,,CHEMBL621571,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5798,Homo sapiens,,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,CHEMBL621572,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5799,Homo sapiens,,F,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,CHEMBL621573,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5800,Homo sapiens,,F,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,CHEMBL621574,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5801,Homo sapiens,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,CHEMBL621575,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5802,Homo sapiens,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,CHEMBL621576,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5803,Homo sapiens,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,CHEMBL621577,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5804,Homo sapiens,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,CHEMBL621578,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5805,Homo sapiens,,F,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,CHEMBL621579,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5806,Homo sapiens,,F,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,CHEMBL621580,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5807,Canis lupus familiaris,,A,Plasma clearance (in vivo) in mongrel dogs was determined,,CHEMBL621581,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5808,Canis lupus familiaris,,A,Plasma clearance was measured in dog,,CHEMBL621582,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5809,Canis lupus familiaris,,A,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,CHEMBL621583,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5810,Canis lupus familiaris,,A,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,CHEMBL621584,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5811,Canis lupus familiaris,,A,Tested for plasma clearance in dog,,CHEMBL621585,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5812,Canis lupus familiaris,,A,The compound was tested for clearance in dog plasma.,,CHEMBL621586,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5813,Canis lupus familiaris,,A,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,CHEMBL875835,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5814,Canis lupus familiaris,,A,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,CHEMBL621587,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5815,Canis lupus familiaris,,A,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,CHEMBL621588,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5816,Canis lupus familiaris,,A,In vitro clearance in dog liver microsomes,,CHEMBL621589,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
5817,Canis lupus familiaris,,A,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,CHEMBL621590,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5818,Canis lupus familiaris,,A,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,CHEMBL621591,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5819,Canis lupus familiaris,,A,Plasma clearance in dog,,CHEMBL621592,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5820,Canis lupus familiaris,,A,Clearance rate in dog,,CHEMBL621593,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5821,Canis lupus familiaris,,A,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,CHEMBL621594,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5822,Canis lupus familiaris,,A,Clearance in dogs,,CHEMBL621595,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5823,Canis lupus familiaris,,A,Plasma clearance in dogs,,CHEMBL621596,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5824,Canis lupus familiaris,,A,Plasma clearance was determined,,CHEMBL621597,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5825,Canis lupus familiaris,,A,Lower clearance in dog (i.v.) at 0.5 mpk,,CHEMBL621598,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5826,Canis lupus familiaris,,A,Plasma clearance in Beagle dogs,,CHEMBL621599,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5827,Canis lupus familiaris,,A,Plasma clearance (Clp) in dog,,CHEMBL875836,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5828,Canis lupus familiaris,,A,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,CHEMBL621600,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5829,Canis lupus familiaris,,A,Plasma clearance (pharmacokinetic parameter) in dog was determined,,CHEMBL621601,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5830,Canis lupus familiaris,,A,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,CHEMBL618474,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5831,Canis lupus familiaris,,A,Plasma clearance of compound was determined in dog,,CHEMBL618475,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5832,Canis lupus familiaris,,A,Plasma clearance after intravenous administration of 1 mg/kg in dog,,CHEMBL624524,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5833,Canis lupus familiaris,,A,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,CHEMBL624525,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5834,Canis lupus familiaris,,A,Plasma clearance in dog was determined,,CHEMBL624526,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5835,Canis lupus familiaris,,A,Plasma clearance was calculated in dog,,CHEMBL624527,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5836,Canis lupus familiaris,,A,Plasma clearance at the dose of 2 mg/kg in dog,,CHEMBL624528,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5837,Canis lupus familiaris,,A,Plasma clearance in dog,,CHEMBL624529,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5838,Canis lupus familiaris,,A,Plasma clearance in dog,,CHEMBL624530,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5839,Canis lupus familiaris,,A,Plasma clearance in dog; Unable to calculate,,CHEMBL624531,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5840,Canis lupus familiaris,,A,Plasma clearance in rhesus monkey,,CHEMBL624532,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5841,Canis lupus familiaris,,A,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL624533,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5842,Canis lupus familiaris,,A,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624534,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5843,Canis lupus familiaris,,A,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624535,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5844,Canis lupus familiaris,,A,Plasma clearance was evaluated in dog,,CHEMBL624536,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5845,Canis lupus familiaris,,A,Plasma clearance was evaluated in dog; Not tested,,CHEMBL624537,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5846,Canis lupus familiaris,,A,Plasma clearance was evaluated in rhesus,,CHEMBL624538,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5847,Canis lupus familiaris,,A,Plasma clearance was evaluated in rhesus; Not tested,,CHEMBL624539,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5848,Canis lupus familiaris,,A,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,CHEMBL624540,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5849,Canis lupus familiaris,,A,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL624541,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5850,Canis lupus familiaris,,A,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,CHEMBL624542,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5851,Canis lupus familiaris,,A,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL624543,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5852,Canis lupus familiaris,,A,Clearance value at a dose of 0.2 mg/kg i.v.,,CHEMBL624544,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5853,Canis lupus familiaris,,A,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,CHEMBL624545,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5854,Canis lupus familiaris,,A,Cmax after oral dose of compound at 3 mg/kg in dogs,,CHEMBL624546,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5855,Canis lupus familiaris,,A,Cmax after single intravenous bolus of 1 mg/kg in dogs,,CHEMBL875957,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5856,Canis lupus familiaris,,A,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL624547,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5857,Canis lupus familiaris,,A,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,CHEMBL624548,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5858,Canis lupus familiaris,,A,Cmax in dog after administration of 1 mg/kg iv,,CHEMBL624549,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5859,Canis lupus familiaris,,A,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,CHEMBL624550,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
5860,Canis lupus familiaris,,A,Cmax on p.o. administration of 10 mg/kg was measured in dog,,CHEMBL621613,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5861,Canis lupus familiaris,,A,Cmax was determine after peroral administration at 10 mpk in dog,,CHEMBL621614,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5862,Canis lupus familiaris,,A,Cmax was determine after peroral administration at 5 mpk in dog,,CHEMBL623431,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5863,Canis lupus familiaris,,A,Cmax was determine after peroral administration at 5 mg/kg in dog,,CHEMBL623432,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5864,Canis lupus familiaris,,A,Cmax after 0.3 mg/kg po administration in dog,,CHEMBL623433,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5865,Canis lupus familiaris,,A,Cmax after peroral administration in dogs at 2.4 uM/kg,,CHEMBL623434,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5866,Canis lupus familiaris,,A,Cmax in dog after oral administration at 1 mg/kg,,CHEMBL623435,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5867,Canis lupus familiaris,,A,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,CHEMBL623436,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5868,Canis lupus familiaris,,A,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,CHEMBL875958,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5869,Canis lupus familiaris,,A,Cmax value after 15 mg/kg iv dose in Dogs,,CHEMBL623437,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5870,Mus musculus,,A,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623438,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5871,Mus musculus,,A,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623439,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
5872,Mus musculus,,A,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623440,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
5873,Mus musculus,,A,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623441,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
5874,Mus musculus,,A,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623442,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
5875,Mus musculus,,A,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623469,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5876,Mus musculus,,A,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623470,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5877,Mus musculus,,A,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623471,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5878,Mus musculus,,A,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623472,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5879,Mus musculus,,A,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623473,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5880,Mus musculus,,A,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623474,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
5881,Mus musculus,,A,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623475,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5882,Mus musculus,,A,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623476,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5883,Mus musculus,,A,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623477,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
5884,Mus musculus,,A,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL621896,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
5885,Mus musculus,,A,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL621897,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
5886,Mus musculus,,A,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL621898,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
5887,Mus musculus,,A,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL621899,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5888,Mus musculus,,A,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL621900,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5889,Mus musculus,,A,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL621901,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
5890,Mus musculus,,A,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL621902,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
5891,Mus musculus,,A,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL621903,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
5892,Mus musculus,,A,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL622587,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
5893,Mus musculus,,A,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620285,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
5894,Mus musculus,,A,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL875285,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
5895,Mus musculus,,A,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL620286,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
5896,Mus musculus,,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620287,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5897,Mus musculus,,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL620288,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5898,Mus musculus,,A,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL620289,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
5899,Mus musculus,,A,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620290,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
5900,Mus musculus,,A,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL620291,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
5901,Mus musculus,,A,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL620292,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
5902,Mus musculus,,A,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620293,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
5903,Mus musculus,,A,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL620294,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
5904,Mus musculus,,A,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL618614,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
5905,Mus musculus,,A,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL618615,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
5906,Mus musculus,,A,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL618616,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
5907,Homo sapiens,,F,Cytotoxicity against A-172 human tumor cell lines,,CHEMBL618617,9606.0,1,1,N,80012,Expert,,622.0,BAO_0000219,
5908,Homo sapiens,,F,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,CHEMBL618618,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
5909,Homo sapiens,,F,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,CHEMBL618619,9606.0,1,1,N,80014,Intermediate,,623.0,BAO_0000219,
5910,Homo sapiens,,F,Tested for antiproliferative activity against A-2780 tumoral cell line,,CHEMBL618620,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
5911,Homo sapiens,,F,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,CHEMBL618621,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
5912,Homo sapiens,,F,Tested in vitro against A-375 cell line human melanoma,,CHEMBL618622,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
5913,Homo sapiens,,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,CHEMBL618623,9606.0,1,1,N,80019,Expert,,797.0,BAO_0000219,
5914,Homo sapiens,,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL618624,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
5915,Homo sapiens,,F,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,CHEMBL618625,9606.0,1,1,N,80019,Expert,,797.0,BAO_0000219,
5916,Homo sapiens,,F,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL618626,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
5917,Homo sapiens,,F,Antitumor activity on A-427 lung carcinoma cell lines,,CHEMBL618627,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
5918,Homo sapiens,,F,Cytotoxic activity against human A-427 lung tumor cell line,,CHEMBL618628,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
5919,Homo sapiens,,F,In vitro antitumor effects against human A-427 cell lines.,,CHEMBL618629,9606.0,1,1,N,80019,Expert,,797.0,BAO_0000219,
5920,Homo sapiens,,F,In vitro inhibition of A-427 (human lung cancer) cell growth.,,CHEMBL618630,9606.0,1,1,N,80019,Expert,,797.0,BAO_0000219,
5921,Homo sapiens,,F,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,CHEMBL618631,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
5922,Homo sapiens,,F,Cytotoxic activity of compound against A-427 lung human tumor cell line,,CHEMBL618632,9606.0,1,1,N,80019,Intermediate,,797.0,BAO_0000219,
5923,Homo sapiens,,F,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,CHEMBL618633,9606.0,1,1,N,80852,Expert,,500.0,BAO_0000219,
5924,Homo sapiens,,F,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,CHEMBL619315,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5925,Homo sapiens,,F,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,CHEMBL619316,9606.0,1,1,N,80021,Expert,,624.0,BAO_0000219,
5926,Homo sapiens,,F,Cytotoxicity against human kidney carcinoma A-498cell lines,,CHEMBL619317,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5927,Homo sapiens,,F,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,CHEMBL619318,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5928,Homo sapiens,,F,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,CHEMBL619319,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5929,Homo sapiens,,F,Antitumor cytotoxic activity against A-498 cell line was determined,,CHEMBL619739,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5930,Homo sapiens,,F,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,CHEMBL619740,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5931,Homo sapiens,,F,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,CHEMBL883158,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5932,Homo sapiens,,F,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,CHEMBL884012,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5933,Homo sapiens,,F,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,CHEMBL619741,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5934,Homo sapiens,,F,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,CHEMBL619742,9606.0,1,1,N,80021,Intermediate,,624.0,BAO_0000219,
5935,Homo sapiens,,F,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,CHEMBL876610,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5936,Homo sapiens,,F,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,CHEMBL619743,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5937,Homo sapiens,,F,In vitro antiproliferative activity against human A-549 NSCL cell line,,CHEMBL619744,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5938,Homo sapiens,,F,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,CHEMBL619745,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5939,Homo sapiens,,F,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,CHEMBL619746,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5940,Homo sapiens,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,CHEMBL619747,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5941,Homo sapiens,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,CHEMBL619748,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5942,Homo sapiens,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,CHEMBL619749,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5943,Homo sapiens,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,CHEMBL619750,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5944,Homo sapiens,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,CHEMBL624014,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5945,Homo sapiens,,F,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,CHEMBL624015,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5946,Homo sapiens,,F,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,CHEMBL885344,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5947,Homo sapiens,,F,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,CHEMBL623224,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5948,Homo sapiens,,F,Cytotoxic activity against A-549 cell line,,CHEMBL623225,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5949,Homo sapiens,,F,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,CHEMBL622698,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5950,Homo sapiens,,F,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,CHEMBL622699,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5951,Homo sapiens,,F,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,CHEMBL622700,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5952,Homo sapiens,,F,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,CHEMBL622701,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5953,Homo sapiens,,F,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,CHEMBL622702,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5954,Homo sapiens,,F,Cytotoxic activity against human lung carcinoma (A-549) cell line,,CHEMBL622703,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5955,Homo sapiens,,F,Cytotoxic activity towards A-549 cells,,CHEMBL622704,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5956,Homo sapiens,,F,"In vitro percent inhibition of A549, lung carcinoma.",,CHEMBL622705,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5957,Homo sapiens,,F,"In vitro percent inhibition of A549, lung carcinoma",,CHEMBL622706,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5958,Homo sapiens,,F,"In vitro percent inhibition of A549, lung carcinoma.",,CHEMBL622707,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5959,Homo sapiens,,F,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,CHEMBL622708,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5960,Homo sapiens,,F,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,CHEMBL622709,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5961,Homo sapiens,,F,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,CHEMBL622710,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5962,Homo sapiens,,F,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,CHEMBL622711,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5963,Homo sapiens,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622712,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5964,Homo sapiens,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622713,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5965,Homo sapiens,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622714,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5966,Homo sapiens,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622715,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5967,Homo sapiens,,F,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622716,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5968,Homo sapiens,,F,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,CHEMBL622717,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5969,Homo sapiens,,F,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,CHEMBL622718,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
5970,Homo sapiens,,F,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,CHEMBL622719,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5971,Homo sapiens,,F,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,CHEMBL622720,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5972,Homo sapiens,,F,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,CHEMBL622721,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5973,Homo sapiens,,F,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,CHEMBL622722,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5974,Homo sapiens,,F,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,CHEMBL876030,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5975,Homo sapiens,,F,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,CHEMBL620206,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5976,Homo sapiens,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,CHEMBL620207,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5977,Homo sapiens,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,CHEMBL620208,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5978,Homo sapiens,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,CHEMBL620209,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5979,Homo sapiens,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,CHEMBL620210,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5980,Homo sapiens,,F,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,CHEMBL621639,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5981,Homo sapiens,,F,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,CHEMBL621640,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5982,Homo sapiens,,F,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,CHEMBL621641,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5983,Homo sapiens,,F,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,CHEMBL621642,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
5984,Homo sapiens,,F,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,CHEMBL621643,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5985,Homo sapiens,,F,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,CHEMBL621644,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5986,Homo sapiens,,F,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,CHEMBL621645,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5987,Mus musculus,,F,In vitro antiproliferative activity against A549 cell line,,CHEMBL621646,10090.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5988,,,F,Synergism with indomethacin in A549 cells,,CHEMBL621647,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5989,,,F,Synergism with tolmetin in A549 cells,,CHEMBL621648,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5990,,,F,Synergism with sulindac in A549 cells,,CHEMBL621649,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5991,,,F,Antagonism of indomethacin in A549 cells,,CHEMBL621650,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5992,,,F,Antagonism of sulindac in A549 cells,,CHEMBL621651,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5993,,,F,Antagonism of tolmetin in A549 cells,,CHEMBL621652,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5994,,,F,Synergism with indomethacin in A549 cells,,CHEMBL621653,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5995,,,F,Synergism with sulindac in A549 cells,,CHEMBL621654,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5996,,,F,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,CHEMBL621655,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
5997,Canis lupus familiaris,,A,Cmax value after 30 mg/kg po dose in Dogs,,CHEMBL621656,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5998,Canis lupus familiaris,,A,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL621657,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
5999,Canis lupus familiaris,,A,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,CHEMBL621658,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6000,Canis lupus familiaris,,A,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL621659,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6001,Canis lupus familiaris,,A,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,CHEMBL621660,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6002,Canis lupus familiaris,,A,Cmax value after administration of 4 mg/Kg oral dose in dog,,CHEMBL621661,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6003,Canis lupus familiaris,,A,Cmax value in dog,,CHEMBL621662,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6004,Canis lupus familiaris,,A,Cmax value in dogs after oral administration at 1 mg/kg,,CHEMBL621663,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6005,Canis lupus familiaris,,A,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,CHEMBL621664,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6006,Canis lupus familiaris,,A,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,CHEMBL621665,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6007,Canis lupus familiaris,,A,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,CHEMBL621666,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6008,Canis lupus familiaris,,A,Concentration maxima after oral dosing in dogs,,CHEMBL621667,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6009,Canis lupus familiaris,,A,Concentration maxima after oral dosing in dogs; not available,,CHEMBL876738,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6010,Canis lupus familiaris,,A,Concentration maxima after oral dosing in dogs; not available,,CHEMBL621668,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6011,Canis lupus familiaris,,A,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,CHEMBL621669,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6012,Canis lupus familiaris,,A,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,CHEMBL621670,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6013,Canis lupus familiaris,,A,In vivo maximal concentration was calculated at 1 mg/kg in dog,,CHEMBL621671,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6014,Canis lupus familiaris,,A,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,CHEMBL622360,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6015,Canis lupus familiaris,,A,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,CHEMBL622361,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6016,Canis lupus familiaris,,A,Cmax in dog plasma after oral dose (1 mg/kg),,CHEMBL622362,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6017,Canis lupus familiaris,,A,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,CHEMBL622363,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6018,Canis lupus familiaris,,A,Maximal plasma concentration at a dose of 1 mg/kg,,CHEMBL622364,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6019,Canis lupus familiaris,,A,Maximal plasma concentration at a dose of 1 mg/kg (oral),,CHEMBL622365,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6020,Canis lupus familiaris,,A,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,CHEMBL622533,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6021,Canis lupus familiaris,,A,Maximum concentration of compound in dog was evaluated.,,CHEMBL622534,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6022,Canis lupus familiaris,,A,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL622535,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6023,Canis lupus familiaris,,A,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,CHEMBL876739,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6024,Canis lupus familiaris,,A,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL622536,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6025,Canis lupus familiaris,,A,Maximum concentration obtained in dog plasma was determined,,CHEMBL622537,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6026,Canis lupus familiaris,,A,Maximum concentration was determined,,CHEMBL622538,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6027,Canis lupus familiaris,,A,Maximum concentration at the dose of 2 mg/kg in dog,,CHEMBL627867,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6028,Canis lupus familiaris,,A,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL627868,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6029,Canis lupus familiaris,,A,Maximum concentration was evaluated in dog plasma,,CHEMBL627869,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6030,Canis lupus familiaris,,A,Maximum concentration was evaluated after 75 min after administration in dog,,CHEMBL627870,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6031,Canis lupus familiaris,,A,Maximum plasma concentration determined in dog after oral administration of 17b,,CHEMBL627871,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6032,Canis lupus familiaris,,A,Maximum plasma concentration determined in dog after oral administration of 2b,,CHEMBL627872,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6033,Canis lupus familiaris,,A,Maximum plasma concentration in dog,,CHEMBL627873,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6034,Canis lupus familiaris,,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,CHEMBL627874,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6035,Canis lupus familiaris,,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,CHEMBL627875,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6036,Canis lupus familiaris,,A,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,CHEMBL627876,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6037,Canis lupus familiaris,,A,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,CHEMBL627877,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6038,Canis lupus familiaris,,A,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL627878,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6039,Canis lupus familiaris,,A,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,CHEMBL627879,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6040,Canis lupus familiaris,,A,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL875355,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6041,Canis lupus familiaris,,A,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL627880,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6042,Canis lupus familiaris,,A,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,CHEMBL627881,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6043,Canis lupus familiaris,,A,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL627882,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6044,Canis lupus familiaris,,A,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,CHEMBL627883,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6045,Canis lupus familiaris,,A,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,CHEMBL628526,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6046,Canis lupus familiaris,,A,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,CHEMBL628527,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6047,Canis lupus familiaris,,A,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,CHEMBL628528,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6048,Canis lupus familiaris,,A,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,CHEMBL628529,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6049,Canis lupus familiaris,,A,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,CHEMBL628530,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6050,Canis lupus familiaris,,A,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,CHEMBL625243,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6051,Canis lupus familiaris,,A,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL625244,9615.0,1,1,N,50588,Expert,,,BAO_0000218,1969.0
6052,Canis lupus familiaris,,A,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,CHEMBL625245,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6053,Canis lupus familiaris,,A,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,CHEMBL625246,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6054,Mus musculus,,A,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL625247,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
6055,Mus musculus,,A,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL625248,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
6056,Mus musculus,,A,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,CHEMBL625249,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
6057,Mus musculus,,A,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,CHEMBL625250,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
6058,Mus musculus,,A,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,CHEMBL625251,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6059,Mus musculus,,A,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,CHEMBL875356,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6060,Mus musculus,,A,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,CHEMBL625252,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6061,Mus musculus,,A,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,CHEMBL625253,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
6062,Mus musculus,,A,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,CHEMBL625254,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6063,Mus musculus,,A,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,CHEMBL625255,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6064,Mus musculus,,A,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,CHEMBL625256,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6065,Mus musculus,,A,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,CHEMBL625257,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
6066,Mus musculus,,A,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,CHEMBL625258,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
6067,Mus musculus,,A,Compound was evaluated for washout rate in mice (Radiolabeled compound),,CHEMBL625259,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6068,Mus musculus,,A,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,CHEMBL625260,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6069,Mus musculus,,A,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,CHEMBL625261,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6070,Mus musculus,,A,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,CHEMBL625262,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6071,Mus musculus,,A,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,CHEMBL622639,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6072,Mus musculus,,A,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,CHEMBL622640,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6073,Mus musculus,,A,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,CHEMBL622812,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6074,Mus musculus,,A,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,CHEMBL622813,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6075,Mus musculus,,A,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,CHEMBL622814,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6076,Mus musculus,,A,Time at maximum activity in mice (Radiolabeled compound),,CHEMBL622815,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6077,Mus musculus,,A,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,CHEMBL625342,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6078,Mus musculus,,A,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,CHEMBL625343,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6079,Mus musculus,,A,Binding towards mouse plasma protein at 10 uM,,CHEMBL877591,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6080,Mus musculus,,A,Binding towards mouse plasma protein at 100 uM,,CHEMBL625344,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6081,Mus musculus,,A,Bioavailability was evaluated in mice after intravenous administration,,CHEMBL625345,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6082,Mus musculus,,A,Bioavailability was evaluated in mice after oral administration,,CHEMBL625346,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6083,Mus musculus,,A,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,CHEMBL625347,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6084,Mus musculus,,A,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,CHEMBL625348,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6085,Mus musculus,,A,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL625349,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6086,Mus musculus,,A,Oral bioavailability in mouse,,CHEMBL625350,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6087,Mus musculus,,A,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,CHEMBL882952,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6088,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625351,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6089,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625352,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6090,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL877592,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6091,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625353,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6092,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625354,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6093,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626019,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6094,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626020,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
6095,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626021,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
6096,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626022,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
6097,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626192,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
6098,Homo sapiens,,F,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,CHEMBL626193,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6099,Homo sapiens,,F,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,CHEMBL626194,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6100,Homo sapiens,,F,Cytotoxicity against human lung carcinoma A-549 cell lines,,CHEMBL626195,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6101,Homo sapiens,,F,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,CHEMBL626196,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6102,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549,,CHEMBL626197,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6103,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,CHEMBL626198,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6104,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,CHEMBL626199,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6105,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,CHEMBL626200,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6106,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,CHEMBL626201,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6107,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,CHEMBL626202,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6108,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,CHEMBL626203,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6109,Homo sapiens,,F,In vitro cytotoxicity against A-549 human lung cancer cells,,CHEMBL626204,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6110,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,CHEMBL624701,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6111,Homo sapiens,,F,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,CHEMBL624702,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6112,Homo sapiens,,F,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,CHEMBL624703,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6113,Homo sapiens,,F,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,CHEMBL624704,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6114,Homo sapiens,,F,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,CHEMBL624705,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6115,Homo sapiens,,F,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,CHEMBL624706,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6116,Homo sapiens,,F,Antitumor cytotoxic activity against A-549 cell line was determined,,CHEMBL624707,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6117,Homo sapiens,,F,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,CHEMBL624708,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6118,Homo sapiens,,F,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,CHEMBL624709,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6119,Homo sapiens,,F,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,CHEMBL884107,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6120,Homo sapiens,,F,Antitumoral activity was assayed against A-549 cell line,,CHEMBL624710,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6121,Homo sapiens,,F,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,CHEMBL624711,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6122,Homo sapiens,,F,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,CHEMBL624712,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6123,Homo sapiens,,F,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,CHEMBL624713,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6124,Homo sapiens,,F,Compound was tested for inhibition of cell growth of A-549 cells,,CHEMBL624714,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6125,Homo sapiens,,F,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,CHEMBL624715,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6126,Homo sapiens,,F,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,CHEMBL624716,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6127,Homo sapiens,,F,In vitro cytotoxicity against A549-human lung carcinoma cells.,,CHEMBL619505,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6128,Homo sapiens,,F,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,CHEMBL619506,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6129,Homo sapiens,,F,Cytotoxic activity against A-549 cell lines.,,CHEMBL619507,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6130,Homo sapiens,,F,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,CHEMBL619508,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6131,Homo sapiens,,F,Cytotoxicity against human A549 non small cell lung cell lines,,CHEMBL619509,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6132,Homo sapiens,,F,Inhibition of cell growth in (A-549) lung cell line,,CHEMBL619510,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6133,Homo sapiens,,F,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,CHEMBL619511,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6134,Homo sapiens,,F,In vitro antitumor activity against A-549 tumor cells.,,CHEMBL619512,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6135,Homo sapiens,,F,In vitro antitumor effects against human A-549 cell lines.,,CHEMBL619513,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6136,Homo sapiens,,F,In vitro cytotoxic activity of compound against A-549 cell line,,CHEMBL619514,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6137,Homo sapiens,,F,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,CHEMBL619515,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6138,Homo sapiens,,F,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,CHEMBL619516,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6139,Homo sapiens,,F,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,CHEMBL884005,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6140,Homo sapiens,,F,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,CHEMBL619517,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6141,Homo sapiens,,F,Inhibitory concentration of compound against A-549 cell line,,CHEMBL619518,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6142,Homo sapiens,,F,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,CHEMBL619519,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6143,Homo sapiens,,F,cytotoxic activity against leukemia (A-549) cancer cell line,,CHEMBL876489,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6144,Homo sapiens,,F,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,CHEMBL619520,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6145,Homo sapiens,,F,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,CHEMBL619521,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6146,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,CHEMBL619522,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6147,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,CHEMBL619523,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6148,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,CHEMBL619524,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6149,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,CHEMBL619525,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6150,,,F,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,CHEMBL619526,,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6151,Homo sapiens,,F,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,CHEMBL619527,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6152,Homo sapiens,,F,Cytotoxicity against A549 cells; No cytotoxicity,,CHEMBL619528,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6153,Homo sapiens,,F,Cytotoxicity against human lung carcinoma (A549) cell lines,,CHEMBL619529,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6154,Homo sapiens,,F,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,CHEMBL619530,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6155,Homo sapiens,,F,In vitro anticancer activity against human lung (A549) cell line,,CHEMBL876490,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6156,Homo sapiens,,F,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,CHEMBL619531,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6157,Homo sapiens,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,CHEMBL619532,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6158,Homo sapiens,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,CHEMBL619533,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6159,Homo sapiens,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,CHEMBL619534,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6160,Homo sapiens,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,CHEMBL620164,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6161,Homo sapiens,,F,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,CHEMBL620165,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6162,Homo sapiens,,F,Inhibition of A549 human lung tumor cell proliferation,,CHEMBL620166,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6163,Homo sapiens,,F,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,CHEMBL620167,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6164,Homo sapiens,,F,In vitro cytotoxicity against human tumor cell line A549,,CHEMBL620168,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6165,Homo sapiens,,F,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,CHEMBL620338,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6166,Homo sapiens,,F,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,CHEMBL620339,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6167,Homo sapiens,,F,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,CHEMBL620340,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6168,Homo sapiens,,F,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,CHEMBL620341,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6169,Homo sapiens,,F,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,CHEMBL876491,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6170,Homo sapiens,,F,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,CHEMBL620342,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6171,Homo sapiens,,F,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,CHEMBL620343,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6172,Homo sapiens,,F,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,CHEMBL620344,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6173,Homo sapiens,,F,In vitro anticancer activity against human lung (A549) cell line,,CHEMBL620345,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6174,Homo sapiens,,F,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,CHEMBL620346,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6175,Homo sapiens,,F,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,CHEMBL620347,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6176,Homo sapiens,,F,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,CHEMBL620348,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6177,Homo sapiens,,F,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,CHEMBL620349,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6178,Homo sapiens,,F,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,CHEMBL618667,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6179,Homo sapiens,,F,Percentage inhibition of human lung carcinoma (A549) cell lines,,CHEMBL618668,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6180,Homo sapiens,,F,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,CHEMBL876031,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6181,Homo sapiens,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,CHEMBL618759,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6182,Homo sapiens,,F,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,CHEMBL618760,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6183,Homo sapiens,,F,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,CHEMBL619000,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6184,Homo sapiens,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,CHEMBL619001,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6185,Homo sapiens,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,CHEMBL619002,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6186,Homo sapiens,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,CHEMBL619003,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6187,Homo sapiens,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,CHEMBL619597,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6188,Homo sapiens,,F,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,CHEMBL619598,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6189,Homo sapiens,,F,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,CHEMBL619599,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6190,Homo sapiens,,F,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,CHEMBL619600,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6191,Homo sapiens,,F,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,CHEMBL619601,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6192,Homo sapiens,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,CHEMBL619602,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6193,Homo sapiens,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,CHEMBL619603,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6194,Homo sapiens,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,CHEMBL619604,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6195,Homo sapiens,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,CHEMBL619605,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6196,Canis lupus familiaris,,A,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,CHEMBL619606,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6197,Canis lupus familiaris,,A,Pharmacokinetic activity (Cmax) in dog,,CHEMBL876032,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6198,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,CHEMBL619607,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6199,Canis lupus familiaris,,A,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,CHEMBL619608,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6200,Canis lupus familiaris,,A,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,CHEMBL619609,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6201,Canis lupus familiaris,,A,Cmax in dog plasma after 30mg/kg oral dose,,CHEMBL619610,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6202,Canis lupus familiaris,,A,Tested for the peak blood level in dog,,CHEMBL619611,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
6203,Canis lupus familiaris,,A,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,CHEMBL619612,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6204,Canis lupus familiaris,,A,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,CHEMBL619613,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6205,Canis lupus familiaris,,A,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,CHEMBL619614,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
6206,Canis lupus familiaris,,A,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,CHEMBL619615,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6207,Canis lupus familiaris,,A,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,CHEMBL619616,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6208,Canis lupus familiaris,,A,Final plasma concentration in dogs after oral administration at 1 mg/kg,,CHEMBL619617,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6209,Canis lupus familiaris,,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,CHEMBL619618,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6210,Canis lupus familiaris,,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,CHEMBL876033,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6211,Canis lupus familiaris,,A,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,CHEMBL619619,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6212,Canis lupus familiaris,,A,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,CHEMBL619620,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6213,Canis lupus familiaris,,A,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,CHEMBL619621,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
6214,Canis lupus familiaris,,A,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,CHEMBL619622,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
6215,Canis lupus familiaris,,A,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,CHEMBL618874,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
6216,Canis lupus familiaris,,A,Absolute bioavailability was evaluated in dog,,CHEMBL618875,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6217,Canis lupus familiaris,,A,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,CHEMBL618876,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6218,Canis lupus familiaris,,A,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,CHEMBL618877,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6219,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL618878,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6220,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL618879,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6221,Canis lupus familiaris,,A,Bioavailability after intravenous administration in dogs,,CHEMBL618880,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6222,Canis lupus familiaris,,A,Bioavailability after peroral administration in dogs,,CHEMBL618881,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6223,Canis lupus familiaris,,A,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,CHEMBL618882,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6224,Canis lupus familiaris,,A,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,CHEMBL624226,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6225,Canis lupus familiaris,,A,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,CHEMBL624227,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6226,Canis lupus familiaris,,A,Bioavailability,,CHEMBL624228,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6227,Canis lupus familiaris,,A,Bioavailability,,CHEMBL624229,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6228,Canis lupus familiaris,,A,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,CHEMBL624230,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6229,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL624231,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6230,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL624232,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6231,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL625127,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6232,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL625128,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6233,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL621675,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6234,Canis lupus familiaris,,A,Bioavailability in dog (p.o.) at 2.0 mpk,,CHEMBL621676,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6235,Canis lupus familiaris,,A,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,CHEMBL621677,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6236,Canis lupus familiaris,,A,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL621678,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6237,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL621679,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6238,Canis lupus familiaris,,A,Bioavailability was evaluated after oral administration in dog,,CHEMBL621680,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6239,Canis lupus familiaris,,A,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL621681,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6240,Canis lupus familiaris,,A,Bioavailability was evaluated in dog,,CHEMBL876740,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6241,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL621682,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6242,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL621683,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6243,Canis lupus familiaris,,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,CHEMBL621684,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6244,Canis lupus familiaris,,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,CHEMBL621685,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6245,Canis lupus familiaris,,A,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,CHEMBL621686,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6246,Canis lupus familiaris,,A,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL621687,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6247,Canis lupus familiaris,,A,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,CHEMBL621688,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6248,Canis lupus familiaris,,A,Bioavailability of compound in dog was determined after peroral administration,,CHEMBL621689,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6249,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621690,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6250,Canis lupus familiaris,,A,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,CHEMBL621691,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6251,Canis lupus familiaris,,A,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,CHEMBL875941,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6252,Canis lupus familiaris,,A,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,CHEMBL621692,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6253,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL621693,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6254,Canis lupus familiaris,,A,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,CHEMBL621694,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6255,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621695,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
6256,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621696,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
6257,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621697,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6258,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621698,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6259,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623420,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6260,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623421,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6261,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623422,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6262,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623423,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6263,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623424,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6264,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623425,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6265,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623426,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6266,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623427,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6267,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623428,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6268,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL875947,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6269,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623429,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6270,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623430,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6271,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622588,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6272,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622589,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6273,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622751,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6274,Mus musculus,,A,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622752,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6275,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,CHEMBL622753,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6276,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,CHEMBL622647,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6277,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,CHEMBL875163,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6278,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,CHEMBL622648,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6279,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,CHEMBL622649,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6280,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,CHEMBL622650,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,955.0
6281,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,CHEMBL622651,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,955.0
6282,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,CHEMBL622652,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,955.0
6283,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,CHEMBL622653,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,955.0
6284,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,CHEMBL622654,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,955.0
6285,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,CHEMBL622655,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6286,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,CHEMBL622656,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6287,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,CHEMBL622657,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6288,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,CHEMBL622658,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6289,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,CHEMBL622659,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6290,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,CHEMBL624630,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2113.0
6291,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,CHEMBL624631,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2113.0
6292,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,CHEMBL624632,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2113.0
6293,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,CHEMBL624633,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6294,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,CHEMBL624634,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6295,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,CHEMBL624635,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6296,Homo sapiens,,F,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,CHEMBL624636,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6297,Homo sapiens,,F,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,CHEMBL857055,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6298,Homo sapiens,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,CHEMBL624637,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6299,Homo sapiens,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,CHEMBL624638,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6300,Homo sapiens,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,CHEMBL874366,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6301,Homo sapiens,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,CHEMBL624639,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6302,Homo sapiens,,F,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,CHEMBL624640,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6303,Homo sapiens,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,CHEMBL624641,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6304,Homo sapiens,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,CHEMBL624642,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6305,Homo sapiens,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,CHEMBL624643,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6306,Homo sapiens,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,CHEMBL624644,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6307,Homo sapiens,,F,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,CHEMBL624645,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6308,Homo sapiens,,F,The compound was evaluated for its cytotoxic potency against A-549 cell line,,CHEMBL619445,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6309,Homo sapiens,,F,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,CHEMBL839886,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6310,Homo sapiens,,F,Cytotoxic activity of compound against A-549 tumor cell line.,,CHEMBL619446,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6311,Homo sapiens,,F,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,CHEMBL619447,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6312,Homo sapiens,,F,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,CHEMBL619448,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6313,Homo sapiens,,F,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,CHEMBL619449,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6314,Homo sapiens,,F,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,CHEMBL619450,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6315,Homo sapiens,,F,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,CHEMBL619451,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6316,Homo sapiens,,F,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,CHEMBL619452,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6317,Homo sapiens,,F,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,CHEMBL619453,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6318,Homo sapiens,,F,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,CHEMBL874367,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6319,Homo sapiens,,F,Cytotoxic concentration against A-549 tumor cells.,,CHEMBL619454,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6320,Homo sapiens,,F,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,CHEMBL619455,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6321,Homo sapiens,,F,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,CHEMBL619456,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6322,Acinetobacter baumannii,,F,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,CHEMBL619457,470.0,1,1,N,50191,Expert,,,BAO_0000218,
6323,Acinetobacter calcoaceticus,,F,Activity against Acinetobacter calcoaceticus (AC54),,CHEMBL619458,471.0,1,1,N,50192,Intermediate,,,BAO_0000218,
6324,Aspergillus flavus,,F,In vitro antifungal activity against Aspergillus flavus CM74,,CHEMBL619459,5059.0,1,1,N,50274,Expert,,,BAO_0000218,
6325,Aspergillus flavus,,F,In vitro antifungal activity against Aspergillus flavus CM74,,CHEMBL619460,5059.0,1,1,N,50274,Expert,,,BAO_0000218,
6326,Aspergillus fumigatus,,F,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,CHEMBL619461,746128.0,1,1,N,50416,Intermediate,,,BAO_0000218,
6327,Aspergillus fumigatus,,F,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,CHEMBL619462,746128.0,1,1,N,50416,Intermediate,,,BAO_0000218,
6328,Aspergillus fumigatus,,F,Antimicrobial activity against Aspergillus fumigatus (MIC),,CHEMBL620388,746128.0,1,1,N,50416,Intermediate,,,BAO_0000218,
6329,Aspergillus fumigatus,,F,Antimicrobial activity against Aspergillus fumigatus (MIC),,CHEMBL620389,746128.0,1,1,N,50416,Intermediate,,,BAO_0000218,
6330,Aspergillus fumigatus,,F,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,CHEMBL620390,746128.0,1,1,N,50416,Intermediate,,,BAO_0000218,
6331,Aspergillus fumigatus,,F,In vitro antifungal activity against Aspergillus fumigatus 48238E,,CHEMBL620391,746128.0,1,1,N,50416,Expert,,,BAO_0000218,
6332,Aspergillus fumigatus,,F,In vitro antifungal activity against Aspergillus fumigatus 48238E,,CHEMBL621073,746128.0,1,1,N,50416,Expert,,,BAO_0000218,
6333,Actinomyces naeslundii,,F,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,CHEMBL621074,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6334,Actinomyces viscosus,,F,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,CHEMBL621075,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6335,Acanthocheilonema viteae,,F,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,CHEMBL619554,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6336,Acanthocheilonema viteae,,F,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,CHEMBL619555,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6337,Aggregatibacter actinomycetemcomitans,,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,CHEMBL619556,714.0,1,1,N,50169,Intermediate,,,BAO_0000218,
6338,Aggregatibacter actinomycetemcomitans,,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,CHEMBL619557,714.0,1,1,N,50169,Intermediate,,,BAO_0000218,
6339,Aggregatibacter actinomycetemcomitans,,F,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,CHEMBL619558,714.0,1,1,N,50169,Intermediate,,,BAO_0000218,
6340,Homo sapiens,,F,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,CHEMBL619559,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6341,Homo sapiens,,F,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,CHEMBL619560,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6342,Homo sapiens,,F,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,CHEMBL619561,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6343,Homo sapiens,,F,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,CHEMBL619562,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6344,Homo sapiens,,F,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,CHEMBL619563,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6345,Homo sapiens,,F,GI values against A549 cells (lung cancer),,CHEMBL857457,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6346,Homo sapiens,,F,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,CHEMBL619564,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6347,Homo sapiens,,F,Inhibitory activity against A549 human adenocarcinoma,,CHEMBL619565,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6348,Homo sapiens,,F,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,CHEMBL619566,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
6349,Homo sapiens,,F,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,CHEMBL619567,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
6350,Homo sapiens,,F,Inhibitory activity against A549 lung adenocarcinoma cell line,,CHEMBL619568,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6351,Homo sapiens,,F,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,CHEMBL619569,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6352,Homo sapiens,,F,Cytotoxicity against human A549 lung cells,,CHEMBL619570,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6353,Homo sapiens,,F,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,CHEMBL619571,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000218,
6354,Homo sapiens,,F,Growth inhibition of A549 (human lung carcinoma) cell line.,,CHEMBL619572,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6355,Homo sapiens,,F,Effective dose required for inhibitory activity against A549 human tumor cell line.,,CHEMBL619573,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6356,Homo sapiens,,F,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,CHEMBL619574,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6357,Homo sapiens,,F,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,CHEMBL619575,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6358,Homo sapiens,,F,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,CHEMBL619576,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6359,Homo sapiens,,F,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,CHEMBL619577,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6360,Homo sapiens,,F,In vitro inhibitory activity against A549 tumor cell culture,,CHEMBL619578,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6361,Homo sapiens,,F,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,CHEMBL884009,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6362,Homo sapiens,,F,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,CHEMBL619579,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6363,Homo sapiens,,F,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,CHEMBL619580,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6364,Homo sapiens,,F,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,CHEMBL619581,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6365,Homo sapiens,,F,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,CHEMBL619582,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6366,Homo sapiens,,F,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,CHEMBL619583,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6367,Homo sapiens,,F,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,CHEMBL876502,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6368,Homo sapiens,,F,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,CHEMBL619584,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6369,Homo sapiens,,F,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,CHEMBL619585,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6370,Homo sapiens,,F,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,CHEMBL619586,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6371,Homo sapiens,,F,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,CHEMBL619587,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6372,Homo sapiens,,F,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,CHEMBL619588,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6373,Homo sapiens,,F,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,CHEMBL619589,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6374,Homo sapiens,,F,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,CHEMBL619590,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6375,Homo sapiens,,F,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,CHEMBL619591,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6376,Homo sapiens,,F,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,CHEMBL619592,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6377,Homo sapiens,,F,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,CHEMBL619593,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6378,Homo sapiens,,F,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,CHEMBL620217,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6379,Homo sapiens,,F,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,CHEMBL620218,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6380,Homo sapiens,,F,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,CHEMBL620219,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6381,Homo sapiens,,F,Antitumor activity against A549/ATCC cell line,,CHEMBL620220,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6382,Homo sapiens,,F,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,CHEMBL625141,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6383,Homo sapiens,,F,In vitro cytotoxicity against A549/ATCC cell line.,,CHEMBL625142,9606.0,1,1,N,80682,Expert,,646.0,BAO_0000219,
6384,Homo sapiens,,F,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,CHEMBL625143,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6385,Homo sapiens,,F,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,CHEMBL625144,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6386,Homo sapiens,,F,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,CHEMBL622474,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6387,Homo sapiens,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,CHEMBL884104,9606.0,1,1,N,80682,Intermediate,,646.0,BAO_0000219,
6388,Homo sapiens,,F,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,CHEMBL622475,9606.0,0,1,U,22226,Autocuration,,,BAO_0000219,
6389,Canis lupus familiaris,,A,Compound was tested for oral bioavailability in dogs,,CHEMBL622476,9615.0,0,1,U,22224,Intermediate,,,BAO_0000218,
6390,Canis lupus familiaris,,A,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,CHEMBL875831,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6391,Canis lupus familiaris,,A,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,CHEMBL622477,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6392,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL622478,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6393,Canis lupus familiaris,,A,Compound was tested for the oral bioavailability in dog; No availability,,CHEMBL623172,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6394,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 mg/kg),,CHEMBL623173,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6395,Canis lupus familiaris,,A,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,CHEMBL623174,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6396,Canis lupus familiaris,,A,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,CHEMBL623175,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6397,Canis lupus familiaris,,A,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,CHEMBL623340,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6398,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 mg/kg),,CHEMBL623341,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6399,Canis lupus familiaris,,A,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,CHEMBL623342,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6400,Canis lupus familiaris,,A,Oral bioavailability of active FTIs in dogs,,CHEMBL623343,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6401,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,CHEMBL623344,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6402,Canis lupus familiaris,,A,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL623345,9615.0,1,1,N,50588,Expert,,,BAO_0000218,
6403,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL875832,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6404,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623346,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6405,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623347,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6406,Canis lupus familiaris,,A,Oral bioavailability of compound was determined in dog; Not tested,,CHEMBL623348,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6407,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623349,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6408,Canis lupus familiaris,,A,Oral bioavailability (10 mg/kg) was determined in dog,,CHEMBL623350,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6409,Canis lupus familiaris,,A,Oral bioavailability,,CHEMBL623351,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6410,Canis lupus familiaris,,A,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,CHEMBL623352,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6411,Canis lupus familiaris,,A,Oral bioavailability administered in solution in rats,,CHEMBL623353,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6412,Canis lupus familiaris,,A,Oral bioavailability after 30 mg/kg po dose in Dogs,,CHEMBL875833,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6413,Canis lupus familiaris,,A,Oral bioavailability at a dose of 1 mg/kg in dogs,,CHEMBL623354,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6414,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 1 mg/kg p.o.),,CHEMBL623355,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6415,Canis lupus familiaris,,A,Oral bioavailability in Dog; ND = not determined,,CHEMBL623356,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6416,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623357,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6417,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623358,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6418,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623359,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6419,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623360,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6420,Canis lupus familiaris,,A,Oral bioavailability in dogs; No data,,CHEMBL623361,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6421,Canis lupus familiaris,,A,Oral bioavailability measured in dogs,,CHEMBL623362,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6422,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623363,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6423,Canis lupus familiaris,,A,Oral bioavailability was calculated in dog,,CHEMBL623364,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6424,Canis lupus familiaris,,A,Oral bioavailability after 0.3 mg/kg po administration in dog,,CHEMBL875834,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6425,Canis lupus familiaris,,A,Oral bioavailability in dog (i.v. dosing),,CHEMBL623365,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6426,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623366,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6427,Canis lupus familiaris,,A,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,CHEMBL623367,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6428,Canis lupus familiaris,,A,Oral bioavailability in Beagle dogs,,CHEMBL623368,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6429,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623369,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6430,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623370,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6431,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623371,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6432,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL623372,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6433,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621351,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6434,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621352,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6435,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621353,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6436,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621354,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6437,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621355,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6438,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621356,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6439,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621357,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6440,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621358,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6441,Canis lupus familiaris,,A,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,CHEMBL621359,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6442,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,CHEMBL621360,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6443,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,CHEMBL621361,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6444,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621362,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6445,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621363,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6446,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621364,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6447,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,CHEMBL621166,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6448,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL621167,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6449,Canis lupus familiaris,,A,Oral bioavailability (F) in dogs,,CHEMBL621168,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6450,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL621169,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6451,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL875950,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6452,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621170,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6453,Canis lupus familiaris,,A,Oral bioavailability after peroral administration at 5 mpk in Dog,,CHEMBL621171,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6454,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 mg/kg),,CHEMBL621172,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6455,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621173,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6456,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,CHEMBL621174,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2113.0
6457,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,CHEMBL621175,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2113.0
6458,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,CHEMBL621176,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6459,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,CHEMBL621177,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6460,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,CHEMBL621178,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6461,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,CHEMBL621179,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6462,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,CHEMBL621180,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6463,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,CHEMBL875951,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6464,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,CHEMBL621181,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6465,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,CHEMBL621182,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6466,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,CHEMBL621183,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6467,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,CHEMBL621184,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6468,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,CHEMBL621185,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6469,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,CHEMBL621186,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6470,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,CHEMBL621187,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6471,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,CHEMBL621188,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6472,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,CHEMBL621189,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6473,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,CHEMBL621190,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2106.0
6474,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,CHEMBL618520,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2106.0
6475,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,CHEMBL621739,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2106.0
6476,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,CHEMBL621740,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2106.0
6477,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,CHEMBL621741,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2106.0
6478,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,CHEMBL621742,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6479,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,CHEMBL621743,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6480,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,CHEMBL621744,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6481,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,CHEMBL621745,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6482,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,CHEMBL621746,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6483,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,CHEMBL621747,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6484,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,CHEMBL621748,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6485,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,CHEMBL621749,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6486,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,CHEMBL621750,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6487,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,CHEMBL621751,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6488,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,CHEMBL621752,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6489,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,CHEMBL621753,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6490,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,CHEMBL875955,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6491,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,CHEMBL621754,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6492,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,CHEMBL621755,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,948.0
6493,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,CHEMBL621756,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6494,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,CHEMBL624199,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6495,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,CHEMBL624200,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6496,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,CHEMBL624375,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6497,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,CHEMBL624376,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2107.0
6498,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,CHEMBL624377,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6499,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,CHEMBL624378,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6500,aeinetobacter anitrotap,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL857901,107673.0,1,1,N,50067,Intermediate,,,BAO_0000218,
6501,Acinetobacter calcoaceticus subsp. anitratus,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL875274,107673.0,1,1,N,50067,Intermediate,,,BAO_0000218,
6502,Acinetobacter calcoaceticus subsp. anitratus,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL624379,107673.0,1,1,N,50067,Intermediate,,,BAO_0000218,
6503,aeinetobacter anitrotap,,F,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL624380,107673.0,1,1,N,50067,Intermediate,,,BAO_0000218,
6504,Acinetobacter calcoaceticus,,F,Activity against Acinetobacter calcoaceticus (AC54),,CHEMBL624381,471.0,1,1,N,50192,Intermediate,,,BAO_0000218,
6505,Anolis carolinensis,,F,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,CHEMBL624382,28377.0,1,1,N,50714,Intermediate,,,BAO_0000218,
6506,Anolis carolinensis,,F,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,CHEMBL624383,28377.0,1,1,N,50714,Intermediate,,,BAO_0000218,
6507,Actinomyces naeslundii,,F,Chlorohexidine coefficient for Actinomyces naeslundii 631,,CHEMBL624384,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6508,Actinomyces naeslundii,,F,Chlorohexidine coefficient for Actinomyces naeslundii B74,,CHEMBL624385,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6509,Actinomyces naeslundii,,F,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,CHEMBL624386,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6510,Actinomyces naeslundii,,F,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,CHEMBL624387,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6511,Actinomyces naeslundii,,F,Plaque bactericidal index against Actinomyces naeslundii 631,,CHEMBL624388,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6512,Actinomyces naeslundii,,F,Plaque bactericidal index against Actinomyces naeslundii N/9,,CHEMBL624389,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6513,Actinomyces naeslundii,,F,Plaque bactericidal index against Actinomyces naeslundii B74,,CHEMBL624390,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6514,Actinomyces naeslundii,,F,Plaque bactericidal index against Actinomyces naeslundii N/3,,CHEMBL875275,1655.0,1,1,N,50296,Intermediate,,,BAO_0000218,
6515,Artemia salina,,F,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,CHEMBL624391,85549.0,1,1,N,50056,Intermediate,,,BAO_0000218,
6516,Artemia salina,,F,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,CHEMBL623636,85549.0,1,1,N,50056,Intermediate,,,BAO_0000218,
6517,Ascaris suum,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,CHEMBL623637,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6518,Ascaris suum,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,CHEMBL623638,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6519,Ascaris suum,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,CHEMBL623639,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6520,Ascaris suum,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,CHEMBL623640,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6521,Ascaris suum,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,CHEMBL623641,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6522,Ascaris suum,,F,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,CHEMBL623642,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6523,Ascaris suum,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,CHEMBL623643,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6524,Ascaris suum,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,CHEMBL623644,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6525,Ascaris suum,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,CHEMBL623645,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6526,Ascaris suum,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,CHEMBL623646,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6527,Ascaris suum,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,CHEMBL623647,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6528,Ascaris suum,,F,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,CHEMBL623648,6253.0,1,1,N,50532,Intermediate,,,BAO_0000218,
6529,Actinomyces viscosus,,F,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,CHEMBL623649,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6530,Actinomyces viscosus,,F,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,CHEMBL623650,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6531,Actinomyces viscosus,,F,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,CHEMBL623651,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6532,Actinomyces viscosus,,F,Chlorohexidine coefficient for Actinomyces viscosus M-100,,CHEMBL623652,1656.0,1,1,N,50366,Expert,,,BAO_0000218,
6533,Actinomyces viscosus,,F,Chlorohexidine coefficient for Actinomyces viscosus M-626,,CHEMBL623653,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6534,Actinomyces viscosus,,F,Chlorohexidine coefficient for Actinomyces viscosus T14V,,CHEMBL623654,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6535,Actinomyces viscosus,,F,Plaque bactericidal index against Actinomyces viscosus 8A06,,CHEMBL623655,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6536,Actinomyces viscosus,,F,Plaque bactericidal index against Actinomyces viscosus M-100,,CHEMBL623656,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6537,Actinomyces viscosus,,F,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,CHEMBL623657,1656.0,1,1,N,50366,Expert,,,BAO_0000218,
6538,Actinomyces viscosus,,F,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,CHEMBL623658,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6539,Actinomyces viscosus,,F,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,CHEMBL623659,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6540,Actinomyces viscosus,,F,Plaque bactericidal index against Actinomyces viscosus 626,,CHEMBL623660,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6541,Actinomyces viscosus,,F,Plaque bactericidal index against Actinomyces viscosus T14V,,CHEMBL623661,1656.0,1,1,N,50366,Intermediate,,,BAO_0000218,
6542,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,CHEMBL875281,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6543,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,CHEMBL623662,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6544,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,CHEMBL623663,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6545,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,CHEMBL623664,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6546,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,CHEMBL623665,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6547,Homo sapiens,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,CHEMBL621856,9606.0,1,1,N,80023,Intermediate,,165.0,BAO_0000219,
6548,Homo sapiens,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,CHEMBL620432,9606.0,1,1,N,80661,Intermediate,,645.0,BAO_0000219,
6549,Rattus norvegicus,,F,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,CHEMBL620433,10116.0,0,1,U,22226,Autocuration,,,BAO_0000219,
6550,Mus musculus,,F,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,CHEMBL620434,10090.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6551,Mus musculus,,F,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,CHEMBL620435,10090.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6552,Homo sapiens,,F,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,CHEMBL620436,9606.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6553,Homo sapiens,,F,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,CHEMBL876597,9606.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6554,Homo sapiens,,F,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,CHEMBL620437,9606.0,1,1,N,81037,Expert,,874.0,BAO_0000219,
6555,Mus musculus,,F,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,CHEMBL620438,10090.0,1,1,N,80024,Expert,,625.0,BAO_0000219,
6556,Mus musculus,,F,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,CHEMBL620439,10090.0,1,1,N,80024,Expert,,625.0,BAO_0000219,
6557,Mus musculus,,F,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,CHEMBL619657,10090.0,1,1,N,80024,Expert,,625.0,BAO_0000219,
6558,Mus musculus,,F,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,CHEMBL619658,10090.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6559,Mus musculus,,F,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,CHEMBL619659,10090.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6560,,,F,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,CHEMBL619660,,8,1,H,10649,Expert,,,BAO_0000019,
6561,Mus musculus,,F,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,CHEMBL619661,10090.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6562,Mus musculus,,F,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,CHEMBL619662,10090.0,1,1,N,80024,Intermediate,,625.0,BAO_0000219,
6563,Cricetulus griseus,,F,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,CHEMBL619663,10029.0,1,1,N,80663,Intermediate,,975.0,BAO_0000219,
6564,Homo sapiens,,F,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,CHEMBL619664,9606.0,0,1,U,22226,Autocuration,,,BAO_0000219,
6565,Homo sapiens,,F,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,CHEMBL619665,9606.0,0,1,U,22226,Autocuration,,,BAO_0000219,
6566,Homo sapiens,,F,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,CHEMBL883244,9606.0,1,1,N,80662,Intermediate,,974.0,BAO_0000219,
6567,Homo sapiens,,F,Cytotoxicity was measured against AA5/HIV-1(IIIB),,CHEMBL884011,9606.0,1,1,N,80662,Intermediate,,974.0,BAO_0000219,
6568,Homo sapiens,,F,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,CHEMBL619666,9606.0,1,1,N,80662,Intermediate,,974.0,BAO_0000219,
6569,Homo sapiens,,F,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,CHEMBL619667,9606.0,1,1,N,80566,Intermediate,,379.0,BAO_0000219,
6570,Cricetulus griseus,,F,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,CHEMBL619668,10029.0,1,1,N,80578,Intermediate,,274.0,BAO_0000219,
6571,Cricetulus griseus,,F,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,CHEMBL619669,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6572,Cricetulus griseus,,F,Average intracellular compound concentration when the hypoxic SER=1.6,,CHEMBL876608,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6573,Cricetulus griseus,,F,Average intracellular compound concentration when the hypoxic SER=1.6.,,CHEMBL619670,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6574,Cricetulus griseus,,F,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,CHEMBL619671,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6575,Cricetulus griseus,,F,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,CHEMBL619672,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6576,Cricetulus griseus,,F,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,CHEMBL619673,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6577,Cricetulus griseus,,F,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,CHEMBL619674,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6578,Cricetulus griseus,,F,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,CHEMBL619675,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6579,Cricetulus griseus,,F,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,CHEMBL619676,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6580,Cricetulus griseus,,F,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHEMBL619677,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6581,Cricetulus griseus,,A,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHEMBL619678,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6582,Cricetulus griseus,,A,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,CHEMBL619679,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6583,Cricetulus griseus,,A,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,CHEMBL619680,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6584,Cricetulus griseus,,A,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,CHEMBL621457,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6585,Cricetulus griseus,,F,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,CHEMBL876609,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6586,Cricetulus griseus,,F,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,CHEMBL621458,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6587,hampster,,F,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,CHEMBL621459,36483.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6588,Cricetulus griseus,,F,Aerobic growth inhibition in Chinese hamster cell line AA8,,CHEMBL621460,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6589,Cricetulus griseus,,F,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,CHEMBL621461,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6590,Cricetulus griseus,,F,Inhibition of growth under aerobic conditions in AA8 cells,,CHEMBL621462,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6591,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621463,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6592,Canis lupus familiaris,,A,Oral bioavailability in dog at 10 mg/kg of the compound,,CHEMBL621464,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6593,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 uM/kg),,CHEMBL621465,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6594,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 uM/kg),,CHEMBL621466,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6595,Canis lupus familiaris,,A,Oral bioavailability in dog (mongrel),,CHEMBL621467,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6596,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621468,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6597,Canis lupus familiaris,,F,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL876734,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6598,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL618476,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6599,Canis lupus familiaris,,A,Bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL618477,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6600,Canis lupus familiaris,,A,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,CHEMBL618478,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6601,Canis lupus familiaris,,A,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,CHEMBL618479,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6602,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL618480,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6603,Canis lupus familiaris,,A,Bioavailability in dog (dose 3-10 mg/kg),,CHEMBL618481,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6604,Canis lupus familiaris,,A,The compound was tested for bioavailability of compound in plasma of dog; Complete,,CHEMBL618482,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6605,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL618483,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6606,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL618484,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6607,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL618485,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6608,Canis lupus familiaris,,A,oral bioavailability was measured in dogs,,CHEMBL618486,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6609,Canis lupus familiaris,,A,Compound was tested for plasma protein binding in dog; Not determined,,CHEMBL618487,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6610,Canis lupus familiaris,,A,Compound was tested for plasma protein binding of dog,,CHEMBL618488,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6611,Canis lupus familiaris,,A,Compound was tested for plasma protein binding of dog; Not determined,,CHEMBL876735,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6612,Canis lupus familiaris,,A,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,CHEMBL618489,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6613,Canis lupus familiaris,,A,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,CHEMBL618490,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6614,Canis lupus familiaris,,A,Half life was determined,,CHEMBL618491,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6615,Canis lupus familiaris,,A,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,CHEMBL618492,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6616,Canis lupus familiaris,,A,Half life was evaluated in dog,,CHEMBL873354,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6617,Canis lupus familiaris,,A,Half life was determined,,CHEMBL618493,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6618,Canis lupus familiaris,,A,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618494,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6619,Canis lupus familiaris,,A,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618495,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,948.0
6620,Canis lupus familiaris,,A,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618496,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2113.0
6621,Canis lupus familiaris,,A,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618497,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
6622,Canis lupus familiaris,,A,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618498,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2048.0
6623,Canis lupus familiaris,,A,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618499,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2106.0
6624,Canis lupus familiaris,,A,LogP in dog,,CHEMBL876736,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6625,Canis lupus familiaris,,A,Partition coefficient (logP),,CHEMBL618500,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6626,Canis lupus familiaris,,A,Partition coefficient in dog,,CHEMBL857831,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6627,Canis lupus familiaris,,A,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL618501,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6628,Canis lupus familiaris,,A,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,CHEMBL618502,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6629,Canis lupus familiaris,,A,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,CHEMBL618503,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6630,Canis lupus familiaris,,A,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,CHEMBL618504,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6631,Canis lupus familiaris,,A,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,CHEMBL618505,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6632,Canis lupus familiaris,,A,Metabolism of compound in dog S9 microsomes; Trace,,CHEMBL618506,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6633,Canis lupus familiaris,,A,In vitro metabolic potential in dog liver microsomes,,CHEMBL618507,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
6634,Canis lupus familiaris,,A,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,CHEMBL876737,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6635,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL618508,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6636,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL618509,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6637,Canis lupus familiaris,,A,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL618510,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6638,Canis lupus familiaris,,A,The compound was tested for bioavailability in dogs,,CHEMBL618511,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6639,Canis lupus familiaris,,A,The compound was tested for oral bioavailability in dogs,,CHEMBL618512,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6640,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL618513,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6641,Canis lupus familiaris,,A,Compound was tested for percent protein binding (PB) in dog,,CHEMBL618514,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6642,Canis lupus familiaris,,A,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,CHEMBL620052,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6643,Canis lupus familiaris,,A,Compound was evaluated for plasma clearance.,,CHEMBL620053,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6644,Canis lupus familiaris,,A,The compound was tested for plasma clearance in dog,,CHEMBL620054,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6645,Canis lupus familiaris,,A,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,CHEMBL620055,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6646,Canis lupus familiaris,,A,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,CHEMBL620056,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6647,Canis lupus familiaris,,A,In vitro relative rate of metabolism was determined in dog liver microsomes,,CHEMBL620057,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
6648,Canis lupus familiaris,,A,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,CHEMBL618939,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6649,Canis lupus familiaris,,A,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,CHEMBL618940,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6650,Canis lupus familiaris,,A,Half life after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL618941,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6651,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,CHEMBL624473,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6652,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,CHEMBL624474,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6653,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,CHEMBL624475,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,2048.0
6654,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,CHEMBL624476,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6655,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,CHEMBL623478,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6656,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,CHEMBL623479,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6657,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,CHEMBL623480,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6658,Mus musculus,,A,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,CHEMBL623481,10090.0,1,1,N,50594,Intermediate,,42.0,BAO_0000218,
6659,Mus musculus,,A,C2 in brain of mice at the oral dose of 50 mg/kg,,CHEMBL623482,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6660,Mus musculus,,A,C2 in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL623483,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6661,Mus musculus,,A,C2 in liver of mice at the oral dose of 50 mg/kg,,CHEMBL623484,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6662,Mus musculus,,A,C2 in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL623485,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6663,Mus musculus,,A,C2 in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL623486,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
6664,Mus musculus,,A,Plasma clearance in mouse,,CHEMBL623487,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6665,Mus musculus,,A,Clearance of compound after intravenous administration in mice at 24 uM/kg,,CHEMBL623488,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6666,Mus musculus,,A,Clearance from mouse blood following i.v. administration of 10 mg/kg,,CHEMBL623489,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6667,Mus musculus,,A,Clearance was evaluated in mice after intravenous administration,,CHEMBL875157,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6668,Mus musculus,,A,Clearance was evaluated in mice after oral administration,,CHEMBL623490,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6669,Mus musculus,,A,Pharmacokinetic property (Plasma clearance) was measured in mouse,,CHEMBL623491,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6670,Mus musculus,,A,Plasma clearance of compound was determined at 40 mg/Kg,,CHEMBL623492,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6671,Mus musculus,,A,Plasma clearance of at 24 mg/Kg,,CHEMBL623493,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6672,Mus musculus,,A,Plasma clearance at 24 mg/Kg,,CHEMBL623494,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6673,Mus musculus,,A,Plasma clearance at 5 mg/Kg,,CHEMBL623495,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6674,Mus musculus,,A,Plasma clearance in mice,,CHEMBL623496,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6675,Mus musculus,,A,Plasma clearance value upon iv administration in mouse,,CHEMBL623497,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6676,Mus musculus,,A,Total plasma clearance in mice,,CHEMBL623498,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6677,Mus musculus,,A,Clearance in mouse,,CHEMBL623499,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6678,Mus musculus,,A,Clearance value was determined,,CHEMBL623500,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6679,Mus musculus,,A,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL623501,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6680,,,P,Calculated partition coefficient (clogP),,CHEMBL875158,,0,1,U,22229,Intermediate,,,BAO_0000100,
6681,Mus musculus,,A,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL623502,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6682,Mus musculus,,A,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL623503,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6683,Mus musculus,,A,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL623504,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6684,Mus musculus,,A,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL623505,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6685,Mus musculus,,A,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL623506,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6686,Mus musculus,,A,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,CHEMBL623507,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6687,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,CHEMBL623508,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6688,Mus musculus,,A,Cmax after oral administration at 30 mg/kg in ICR mouse,,CHEMBL623509,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6689,Mus musculus,,A,Cmax after peroral administration in mice at 2.4 uM/kg,,CHEMBL875159,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6690,Mus musculus,,A,Cmax in brain of mice at the oral dose of 50 mg/kg,,CHEMBL623510,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
6691,Mus musculus,,A,Cmax in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL623511,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
6692,Mus musculus,,A,Cmax in liver of mice at the oral dose of 50 mg/kg,,CHEMBL623512,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
6693,Mus musculus,,A,Cmax in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL623513,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
6694,Mus musculus,,F,Cmax in mice at 18 uM/kg i.p. administration,,CHEMBL623514,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6695,Mus musculus,,F,Cmax in mice at 23 uM/kg i.v. administration,,CHEMBL622609,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6696,Mus musculus,,F,Cmax in mice at 24 uM/kg i.p. administration,,CHEMBL622610,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6697,Mus musculus,,F,Cmax in mice at 25 uM/kg i.p. administration,,CHEMBL621823,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6698,Mus musculus,,F,Cmax in mice at 26 uM/kg i.p. administration,,CHEMBL621824,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6699,Mus musculus,,A,Cmax in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL621825,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
6700,Mus musculus,,A,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL621826,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6701,Mus musculus,,A,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL621827,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6702,Mus musculus,,A,Cmax value was determined,,CHEMBL621828,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6703,Mus musculus,,A,Cmax value in IRC mice,,CHEMBL621829,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6704,Mus musculus,,A,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,CHEMBL621830,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6705,Mus musculus,,A,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,CHEMBL621831,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6706,Mus musculus,,A,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,CHEMBL621832,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6707,Mus musculus,,A,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,CHEMBL624579,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6708,Mus musculus,,A,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,CHEMBL624580,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6709,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,CHEMBL624581,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6710,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,CHEMBL624582,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6711,Acanthocheilonema viteae,,F,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,CHEMBL624583,6277.0,1,1,N,50535,Intermediate,,,BAO_0000218,
6712,Homo sapiens,,F,Inhibitory activity against human tumor cell line A0375 melanoma.,,CHEMBL624584,9606.0,1,1,N,80018,Intermediate,,455.0,BAO_0000219,
6713,Rattus norvegicus,,B,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,CHEMBL624585,10116.0,9,1,D,12512,Expert,,,BAO_0000249,
6714,Homo sapiens,,F,Forskolin-induced cAMP production at human A1 adenosine receptor,,CHEMBL875165,9606.0,9,1,D,114,Expert,,,BAO_0000019,
6715,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,CHEMBL619490,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6716,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHEMBL619491,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6717,,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,CHEMBL619492,,8,1,H,114,Expert,,449.0,BAO_0000219,
6718,,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,CHEMBL619493,,8,1,H,114,Expert,,449.0,BAO_0000219,
6719,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,CHEMBL619494,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6720,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,CHEMBL619495,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6721,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,CHEMBL619496,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6722,Homo sapiens,,F,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHEMBL619497,9606.0,9,1,D,114,Expert,,449.0,BAO_0000219,
6723,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,CHEMBL619498,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6724,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,CHEMBL619499,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6725,,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,CHEMBL619500,,8,1,H,114,Expert,,449.0,BAO_0000219,
6726,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,CHEMBL619501,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6727,,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,CHEMBL619502,,8,1,H,114,Expert,,449.0,BAO_0000219,
6728,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,CHEMBL619503,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6729,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHEMBL619504,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6730,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,CHEMBL621298,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6731,,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,CHEMBL621299,,8,1,H,114,Expert,,449.0,BAO_0000219,
6732,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,CHEMBL621300,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6733,,,F,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,CHEMBL621301,,8,1,H,114,Autocuration,,449.0,BAO_0000219,
6734,,,F,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHEMBL621302,,8,1,H,114,Expert,,449.0,BAO_0000219,
6735,Oryctolagus cuniculus,,F,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,CHEMBL621303,9986.0,1,1,N,80013,Intermediate,,164.0,BAO_0000219,
6736,Rattus norvegicus,,F,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,CHEMBL621304,10116.0,0,1,U,22226,Autocuration,,164.0,BAO_0000219,
6737,Rattus norvegicus,,F,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,CHEMBL621305,10116.0,0,1,U,22226,Autocuration,,164.0,BAO_0000219,
6738,Rattus norvegicus,,F,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,CHEMBL621306,10116.0,1,1,N,80013,Intermediate,,164.0,BAO_0000219,
6739,Rattus norvegicus,,F,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,CHEMBL618444,10116.0,1,1,N,80013,Intermediate,,164.0,BAO_0000219,
6740,Rattus norvegicus,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,CHEMBL618445,10116.0,1,1,N,80013,Intermediate,,164.0,BAO_0000219,
6741,Cricetulus griseus,,F,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,CHEMBL618446,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6742,Cricetulus griseus,,F,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,CHEMBL618447,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6743,Cricetulus griseus,,F,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,CHEMBL618448,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6744,Cricetulus griseus,,F,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,CHEMBL618449,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6745,Cricetulus griseus,,F,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,CHEMBL618637,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6746,Cricetulus griseus,,F,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,CHEMBL618638,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6747,Cricetulus griseus,,F,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,CHEMBL618639,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6748,Cricetulus griseus,,F,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,CHEMBL618640,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6749,Cricetulus griseus,,F,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,CHEMBL618641,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6750,Cricetulus griseus,,F,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,CHEMBL618642,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6751,Cricetulus griseus,,F,Inhibitory activity against aerobic growth of AA8 cells.,,CHEMBL618643,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6752,Cricetulus griseus,,A,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHEMBL884013,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6753,Cricetulus griseus,,F,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHEMBL622723,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6754,Cricetulus griseus,,F,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHEMBL622724,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6755,Cricetulus griseus,,F,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,CHEMBL622725,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6756,Cricetulus griseus,,F,Cytotoxicity against AA8 cell line,,CHEMBL622726,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6757,Cricetulus griseus,,F,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,CHEMBL622727,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6758,Cricetulus griseus,,A,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHEMBL622728,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6759,Cricetulus griseus,,F,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHEMBL622729,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6760,Cricetulus griseus,,A,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHEMBL622730,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6761,Cricetulus griseus,,F,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,CHEMBL622731,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6762,Cricetulus griseus,,F,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHEMBL622732,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6763,Cricetulus griseus,,F,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHEMBL622733,10029.0,1,1,N,80089,Intermediate,,185.0,BAO_0000219,
6764,Cricetulus griseus,,F,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,CHEMBL622734,10029.0,0,1,U,22224,Autocuration,,,BAO_0000218,
6765,Cricetulus griseus,,F,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,CHEMBL622735,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6766,Cricetulus griseus,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,CHEMBL618746,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6767,Cricetulus griseus,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,CHEMBL618747,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6768,Cricetulus griseus,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,CHEMBL620540,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6769,Cricetulus griseus,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,CHEMBL620541,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6770,Cricetulus griseus,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,CHEMBL620542,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6771,Cricetulus griseus,,F,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,CHEMBL620543,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6772,Cricetulus griseus,,F,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,CHEMBL618832,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6773,Cricetulus griseus,,F,Concentration required to reduce AA8 cell survival by 10%,,CHEMBL618833,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6774,Cricetulus griseus,,F,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,CHEMBL618834,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6775,Cricetulus griseus,,F,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHEMBL618835,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6776,Cricetulus griseus,,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHEMBL618836,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6777,Cricetulus griseus,,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,CHEMBL618837,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6778,Cricetulus griseus,,F,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,CHEMBL618838,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6779,Cricetulus griseus,,F,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,CHEMBL618839,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6780,Cricetulus griseus,,F,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,CHEMBL618840,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6781,Cricetulus griseus,,F,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,CHEMBL618841,10029.0,0,1,U,22224,Autocuration,,,BAO_0000019,
6782,Cricetulus griseus,,F,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,CHEMBL618842,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6783,Cricetulus griseus,,F,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,CHEMBL618843,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6784,Canis lupus familiaris,,A,Half life period after 15 mg/kg iv dose in Dogs,,CHEMBL618844,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6785,Canis lupus familiaris,,A,Half life period after 30 mg/kg po dose in Dogs,,CHEMBL618845,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6786,Canis lupus familiaris,,A,Half life was measured after oral 2b administration (tested in 6 dogs),,CHEMBL618846,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6787,Canis lupus familiaris,,A,Half life was measured in dog after oral 17b administration,,CHEMBL618847,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6788,Canis lupus familiaris,,A,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,CHEMBL618848,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6789,Canis lupus familiaris,,A,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,CHEMBL618849,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6790,Canis lupus familiaris,,A,Tmax value after 15 mg/kg iv dose in Dogs,,CHEMBL618850,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6791,Canis lupus familiaris,,A,Tmax value after 30 mg/kg po dose in Dogs,,CHEMBL618851,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6792,Canis lupus familiaris,,A,Compound was evaluated for its half life when administered intravenously in dog,,CHEMBL873815,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6793,Canis lupus familiaris,,A,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,CHEMBL618852,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6794,Canis lupus familiaris,,A,Elimination Half-life of compound was determined in dog,,CHEMBL618853,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6795,Canis lupus familiaris,,A,Half life of compound in dog following oral administration,,CHEMBL618854,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6796,Canis lupus familiaris,,A,Half life of compound was determined in dog,,CHEMBL618855,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6797,Canis lupus familiaris,,A,Half life of compound was determined in dog blood,,CHEMBL618856,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
6798,Canis lupus familiaris,,A,Half life after oral and iv dosing in dogs,,CHEMBL875827,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6799,Canis lupus familiaris,,A,Half life in dogs in hours,,CHEMBL618857,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6800,Canis lupus familiaris,,A,Half life on i.v. administration of 2 mg/kg was measured in dog,,CHEMBL618858,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6801,Canis lupus familiaris,,A,t1/2 in dog after oral dose (1 mg/kg),,CHEMBL618859,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6802,Canis lupus familiaris,,A,Half life was evaluated in dog,,CHEMBL618860,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6803,Canis lupus familiaris,,A,Half life period of compound was determined after intravenous administration at 2 mg/kg,,CHEMBL618861,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6804,Canis lupus familiaris,,A,Half life period of compound was determined after peroral administration at 2 mg/kg,,CHEMBL622539,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6805,Canis lupus familiaris,,A,Half life period (10 mg/kg) was determined in dog,,CHEMBL622540,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6806,Canis lupus familiaris,,A,Half life period (10 mg/kg) was determined in dog,,CHEMBL873803,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6807,Canis lupus familiaris,,A,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,CHEMBL873804,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6808,Canis lupus familiaris,,A,Half life period by po administration in dog at a dose of 0.3 mg/kg,,CHEMBL624311,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6809,Canis lupus familiaris,,A,Half life period in dog,,CHEMBL624312,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6810,Canis lupus familiaris,,A,Half life period in dogs after oral administration at 1 mg/kg,,CHEMBL624313,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6811,Canis lupus familiaris,,A,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL624314,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6812,Canis lupus familiaris,,A,Half-life of compound was determined in dogs,,CHEMBL624315,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6813,Canis lupus familiaris,,A,Half-life in dog plasma,,CHEMBL624316,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6814,Canis lupus familiaris,,A,Half-life in mongrel dogs was determined,,CHEMBL624317,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6815,Canis lupus familiaris,,A,Half-life in dog upon oral administration,,CHEMBL624318,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6816,Canis lupus familiaris,,A,Half-life in dog upon oral administration; Unable to calculate,,CHEMBL624319,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6817,Canis lupus familiaris,,A,Half-life was measured in dog,,CHEMBL624496,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6818,Canis lupus familiaris,,A,Half-life was measured in dog,,CHEMBL624497,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6819,Canis lupus familiaris,,A,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,CHEMBL624498,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6820,Canis lupus familiaris,,A,Oral half life was determined,,CHEMBL624499,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6821,Canis lupus familiaris,,A,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,CHEMBL624500,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6822,Canis lupus familiaris,,A,Plasma half life was evaluated,,CHEMBL624501,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6823,Canis lupus familiaris,,A,Plasma half life was evaluated in Dog,,CHEMBL623666,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6824,Canis lupus familiaris,,A,Plasma half life was evaluated in dog,,CHEMBL623667,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6825,Canis lupus familiaris,,A,T1/2 (Half-life) was after oral administration at 5 mg/kg,,CHEMBL623668,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6826,Canis lupus familiaris,,A,Tested for the half life value in dog,,CHEMBL623669,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6827,Canis lupus familiaris,,A,Maximum time at the dose of 2 mg/kg in dog,,CHEMBL623670,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6828,Canis lupus familiaris,,A,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL623671,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6829,Canis lupus familiaris,,A,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL875945,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
6830,Canis lupus familiaris,,A,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL623672,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
6831,Canis lupus familiaris,,A,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,CHEMBL623673,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6832,Canis lupus familiaris,,A,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,CHEMBL623674,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6833,Canis lupus familiaris,,A,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,CHEMBL623675,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6834,Canis lupus familiaris,,A,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,CHEMBL872526,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6835,Canis lupus familiaris,,A,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,CHEMBL623676,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6836,Canis lupus familiaris,,A,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL623677,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6837,Canis lupus familiaris,,A,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,CHEMBL623678,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6838,Canis lupus familiaris,,A,Time taken for maximum plasma concentration in dog,,CHEMBL623679,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6839,Canis lupus familiaris,,A,Time to reach Cmax after oral administration to dogs,,CHEMBL623680,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6840,Canis lupus familiaris,,A,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL623681,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
6841,Canis lupus familiaris,,A,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,CHEMBL623682,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6842,Canis lupus familiaris,,A,Tmax after peroral administration (1 mg/kg) was determined in dog,,CHEMBL623683,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6843,Canis lupus familiaris,,A,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL623684,9615.0,1,1,N,50588,Expert,,,BAO_0000218,
6844,Canis lupus familiaris,,A,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL622745,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6845,Canis lupus familiaris,,A,Tmax after peroral administration in dogs at 2.4 uM/kg,,CHEMBL622746,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6846,Mus musculus,,A,In vivo Cmax in mice at dose of 100 mg/kg,,CHEMBL622747,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6847,Mus musculus,,A,In vivo Cmax in mice at dose of 50 mg/kg,,CHEMBL622748,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6848,Mus musculus,,A,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,CHEMBL622749,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6849,Mus musculus,,A,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL622750,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6850,Mus musculus,,A,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL623411,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6851,Mus musculus,,A,Maximum concentration obtained in mouse plasma was determined,,CHEMBL875946,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6852,Mus musculus,,A,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,CHEMBL623412,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6853,Mus musculus,,A,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL623413,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6854,Mus musculus,,A,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,CHEMBL623414,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6855,Mus musculus,,A,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,CHEMBL623415,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6856,Mus musculus,,A,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,CHEMBL623416,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6857,Mus musculus,,A,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,CHEMBL623417,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6858,Mus musculus,,A,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,CHEMBL623418,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6859,Mus musculus,,A,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,CHEMBL623419,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6860,Mus musculus,,A,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL622816,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6861,Mus musculus,,A,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,CHEMBL623313,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6862,Mus musculus,,A,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,CHEMBL623314,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6863,Mus musculus,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,CHEMBL876788,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6864,Mus musculus,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,CHEMBL623315,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6865,Mus musculus,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,CHEMBL623316,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6866,Mus musculus,,A,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,CHEMBL623317,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6868,Mus musculus,,A,Cmax in male mice after 2 mg/kg oral dose,,CHEMBL623319,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6869,Mus musculus,,A,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,CHEMBL623320,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6870,Mus musculus,,A,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,CHEMBL623321,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6871,Mus musculus,,A,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,CHEMBL623322,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6872,Mus musculus,,A,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,CHEMBL623323,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6873,Mus musculus,,A,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,CHEMBL623324,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6874,Mus musculus,,A,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,CHEMBL623325,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6875,Mus musculus,,A,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,CHEMBL623326,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6876,Mus musculus,,A,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,CHEMBL623327,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6877,Mus musculus,,A,Maximum concentration in plasma upon oral administration in mouse,,CHEMBL623328,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6878,Mus musculus,,A,Maximum plasma concentration was evaluated in mice after oral administration,,CHEMBL623329,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6879,Mus musculus,,A,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,CHEMBL623330,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
6880,Mus musculus,,A,Dose at which the compound induced fecal excretion in mice,,CHEMBL876789,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
6893,Rattus norvegicus,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,CHEMBL623333,10116.0,1,1,N,80013,Expert,,164.0,BAO_0000219,
6894,Rattus norvegicus,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,CHEMBL623334,10116.0,1,1,N,80013,Expert,,164.0,BAO_0000219,
6895,Rattus norvegicus,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,CHEMBL627536,10116.0,1,1,N,80013,Expert,,164.0,BAO_0000219,
6896,Rattus norvegicus,,F,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,CHEMBL627537,10116.0,1,1,N,80013,Expert,,164.0,BAO_0000219,
6897,Rattus norvegicus,,F,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,CHEMBL627538,10116.0,1,1,N,80013,Intermediate,,164.0,BAO_0000219,
6898,Homo sapiens,,F,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,CHEMBL884106,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6899,Homo sapiens,,F,Anticancer activity against human ovarian carcinoma A121 cells,,CHEMBL625294,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6900,Homo sapiens,,F,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,CHEMBL625295,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6901,Homo sapiens,,F,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,CHEMBL625296,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6902,Homo sapiens,,F,Growth inhibition of human ovarian carcinoma (A121) cell line,,CHEMBL625297,9606.0,1,1,N,80655,Expert,,393.0,BAO_0000219,
6903,Homo sapiens,,F,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,CHEMBL625298,9606.0,1,1,N,80655,Expert,,393.0,BAO_0000219,
6904,Homo sapiens,,F,Cytotoxicity against human A121 ovarian cells,,CHEMBL625960,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6905,Homo sapiens,,F,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,CHEMBL625961,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6906,Homo sapiens,,F,In vitro cytotoxicity against human ovarian carcinoma A21,,CHEMBL625962,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6907,Homo sapiens,,F,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,CHEMBL624717,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6908,Homo sapiens,,F,Inhibitory activity of compound against human A121 ovarian cell line.,,CHEMBL624718,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6909,Homo sapiens,,F,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,CHEMBL624719,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6910,Homo sapiens,,F,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,CHEMBL624720,9606.0,1,1,N,80655,Intermediate,,393.0,BAO_0000219,
6911,Homo sapiens,,F,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,CHEMBL624721,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
6912,Homo sapiens,,F,In vitro cytotoxicity against A172 human tumor cell lines.,,CHEMBL624722,9606.0,1,1,N,80012,Expert,,622.0,BAO_0000219,
6913,Homo sapiens,,F,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,CHEMBL877597,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
6914,Homo sapiens,,F,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,CHEMBL624723,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
6915,Homo sapiens,,F,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,CHEMBL624724,9606.0,1,1,N,80012,Intermediate,,622.0,BAO_0000219,
6916,Canis lupus familiaris,,B,Association constant against A2 adenosine receptor,,CHEMBL624725,9615.0,4,1,H,104729,Autocuration,,,BAO_0000224,
6917,fish,,F,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,CHEMBL624726,,1,1,N,80656,Intermediate,,1085.0,BAO_0000219,
6918,Rattus norvegicus,,B,Ratio of Ki for adenosine A2 and A1 receptor binding,,CHEMBL857535,10116.0,5,1,D,104713,Autocuration,,,BAO_0000224,
6919,Homo sapiens,,F,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,CHEMBL624727,9606.0,1,1,N,80014,Expert,,623.0,BAO_0000219,
6920,Homo sapiens,,F,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,CHEMBL624728,9606.0,1,1,N,80014,Expert,,623.0,BAO_0000219,
6921,Homo sapiens,,F,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,CHEMBL624729,9606.0,1,1,N,80015,Intermediate,,404.0,BAO_0000219,
6922,Homo sapiens,,F,Growth inhibition against Human squamous cell line(A 253),,CHEMBL624730,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6923,Homo sapiens,,F,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,CHEMBL624731,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6924,Homo sapiens,,F,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,CHEMBL624732,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6925,Homo sapiens,,F,Growth inhibition of A253 cell lines.,,CHEMBL883245,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6926,Homo sapiens,,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,CHEMBL624733,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6927,Homo sapiens,,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,CHEMBL624734,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6928,Homo sapiens,,F,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,CHEMBL624735,9606.0,1,1,N,80657,Intermediate,,973.0,BAO_0000219,
6929,Homo sapiens,,F,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,CHEMBL621780,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6930,Homo sapiens,,F,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,CHEMBL877598,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6931,Homo sapiens,,F,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,CHEMBL621781,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
6932,Homo sapiens,,F,Cytotoxicity against human cancer cell lines A2780 (ovarian),,CHEMBL621782,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6933,Homo sapiens,,F,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,CHEMBL621783,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
6934,Homo sapiens,,F,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,CHEMBL621784,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6935,Homo sapiens,,F,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,CHEMBL621785,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6936,Homo sapiens,,F,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,CHEMBL621968,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
6937,Homo sapiens,,F,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,CHEMBL621969,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
6938,Homo sapiens,,F,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,CHEMBL621970,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
6939,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,CHEMBL621971,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6940,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,CHEMBL621972,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6941,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,CHEMBL884108,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
6942,Cricetulus griseus,,F,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,CHEMBL623826,10029.0,0,1,U,22224,Autocuration,,,BAO_0000019,
6943,Cricetulus griseus,,A,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,CHEMBL623827,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6944,Cricetulus griseus,,F,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,CHEMBL623828,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6945,Cricetulus griseus,,F,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,CHEMBL623829,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6946,Cricetulus griseus,,F,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,CHEMBL623830,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6947,Cricetulus griseus,,F,Growth inhibition against CHO-derived cell line AA8,,CHEMBL623831,10029.0,0,1,U,22224,Autocuration,,,BAO_0000019,
6948,Cricetulus griseus,,F,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,CHEMBL623832,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6949,hampster,,F,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,CHEMBL623833,36483.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6950,Cricetulus griseus,,F,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,CHEMBL623834,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6951,Cricetulus griseus,,F,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,CHEMBL623835,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6952,Cricetulus griseus,,F,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,CHEMBL623836,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6953,Cricetulus griseus,,F,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,CHEMBL623837,10029.0,0,1,U,22224,Autocuration,,185.0,BAO_0000219,
6954,Cricetulus griseus,,F,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,CHEMBL623838,10029.0,1,1,N,80089,Expert,,185.0,BAO_0000219,
6955,,,F,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,CHEMBL623839,,8,1,H,12675,Autocuration,,,BAO_0000019,
6956,,,F,Number of binding sites (n) of isolated serum protein AAG,,CHEMBL623840,,8,1,H,12675,Autocuration,,,BAO_0000019,
6957,,,B,Association constant for binding to AATT duplex,,CHEMBL623841,,3,1,M,22222,Intermediate,,,BAO_0000225,
6958,Homo sapiens,,F,Inhibition of ABAE human fibroblast cell proliferation,,CHEMBL623842,9606.0,1,1,N,100090,Expert,,416.0,BAO_0000219,
6959,Mus musculus,,F,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,CHEMBL623843,10090.0,1,1,N,80668,Intermediate,,1064.0,BAO_0000218,
6960,Oryctolagus cuniculus,,F,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,CHEMBL618669,9986.0,9,1,D,102444,Expert,,,BAO_0000218,
6961,Oryctolagus cuniculus,,F,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,CHEMBL618670,9986.0,9,1,D,102444,Expert,,,BAO_0000218,
6962,,,B,Inhibitory activity against angiotensin-converting enzyme (ACE).,,CHEMBL618671,,8,1,H,69,Autocuration,,,BAO_0000357,
6963,,,B,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,CHEMBL618672,,8,1,H,69,Autocuration,,,BAO_0000357,
6964,Homo sapiens,,F,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,CHEMBL618673,9606.0,1,1,N,80669,Intermediate,,978.0,BAO_0000219,
6965,Homo sapiens,,F,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,CHEMBL618674,9606.0,1,1,N,80669,Intermediate,,978.0,BAO_0000219,
6966,Human immunodeficiency virus 1,,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,CHEMBL618675,11676.0,0,1,U,22224,Autocuration,,998.0,BAO_0000219,
6967,Human immunodeficiency virus 1,,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,CHEMBL618676,11676.0,0,1,U,22224,Autocuration,,998.0,BAO_0000219,
6968,Human immunodeficiency virus 1,,F,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,CHEMBL618677,11676.0,0,1,U,22224,Autocuration,,998.0,BAO_0000219,
6969,Homo sapiens,,F,Inhibition of growth of renal cancer ACHN cell line,,CHEMBL618678,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6970,Homo sapiens,,F,Inhibition of growth of ACHN renal cancer cell line,,CHEMBL618679,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6971,Homo sapiens,,F,Inhibitory concentration required against ACHN renal cancer cell line,,CHEMBL618680,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6972,Homo sapiens,,F,Concentration required to inhibit growth of human renal (ACHN) cell line,,CHEMBL618681,9606.0,1,1,N,80025,Expert,,626.0,BAO_0000219,
6973,Homo sapiens,,F,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,CHEMBL618682,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6974,Homo sapiens,,F,Cytotoxic activity against ACHN Renal cancer cell line,,CHEMBL618683,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6975,Homo sapiens,,F,Cytotoxicity evaluation against ACHN renal cancer cells,,CHEMBL618684,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6976,Homo sapiens,,F,In vitro antitumor activity against human renal ACHN cell line,,CHEMBL618685,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6977,Homo sapiens,,F,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,CHEMBL876499,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6978,Homo sapiens,,F,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,CHEMBL618686,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6979,Homo sapiens,,F,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,CHEMBL618687,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6980,Homo sapiens,,F,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,CHEMBL618688,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6981,Homo sapiens,,F,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,CHEMBL618689,9606.0,1,1,N,80025,Expert,,626.0,BAO_0000219,
6982,Homo sapiens,,F,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,CHEMBL618690,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6983,Homo sapiens,,F,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,CHEMBL618691,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6984,Homo sapiens,,F,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,CHEMBL619373,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6985,Homo sapiens,,F,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,CHEMBL884008,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6986,Homo sapiens,,F,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,CHEMBL619374,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6987,Homo sapiens,,F,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,CHEMBL619375,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6988,Homo sapiens,,F,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,CHEMBL619376,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6989,Homo sapiens,,F,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,CHEMBL619377,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6990,Homo sapiens,,F,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,CHEMBL619378,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
6991,Canis lupus familiaris,,A,Tmax value after administration of 4 mg/Kg oral dose in dog,,CHEMBL872527,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6992,Canis lupus familiaris,,A,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,CHEMBL876500,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6993,Canis lupus familiaris,,A,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,CHEMBL619379,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6994,Canis lupus familiaris,,A,Volume distribution after 15 mg/kg iv dose in Dogs,,CHEMBL619538,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6995,Canis lupus familiaris,,A,Volume distribution after 30 mg/kg po dose in Dogs,,CHEMBL619539,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6996,Canis lupus familiaris,,A,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,CHEMBL619540,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6997,Canis lupus familiaris,,A,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,CHEMBL619541,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6998,Canis lupus familiaris,,A,Volume of distribution was evaluated in dog,,CHEMBL619542,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
6999,Canis lupus familiaris,,A,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,CHEMBL619543,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7000,Canis lupus familiaris,,A,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL619544,9615.0,1,1,N,50588,Expert,,,BAO_0000218,
7001,Canis lupus familiaris,,A,The compound was tested for volume of distribution in dog,,CHEMBL619545,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7002,Canis lupus familiaris,,A,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,CHEMBL619546,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7003,Canis lupus familiaris,,A,Vd (1 mg/kg) was determined in dog (in vivo),,CHEMBL619547,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7004,Canis lupus familiaris,,A,Vd in dog,,CHEMBL619548,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7005,Canis lupus familiaris,,A,Volume distribution was determined,,CHEMBL619549,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7006,Canis lupus familiaris,,A,Volume of distribution in dog,,CHEMBL619550,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7007,Canis lupus familiaris,,A,Volume of distribution by as 4 fold increase by iv administration in dogs,,CHEMBL876501,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7008,Canis lupus familiaris,,A,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL619551,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7009,Canis lupus familiaris,,A,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL619552,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7010,Canis lupus familiaris,,A,Volume distribution at the dose of 2 mg/kg in dog,,CHEMBL619553,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7011,Canis lupus familiaris,,A,Steady state volume of distribution was determined,,CHEMBL618722,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7012,Canis lupus familiaris,,A,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,CHEMBL618723,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7013,Canis lupus familiaris,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL618724,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7014,Canis lupus familiaris,,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,CHEMBL618725,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7015,Canis lupus familiaris,,A,Bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL618726,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7016,Canis lupus familiaris,,A,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,CHEMBL618727,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7017,Canis lupus familiaris,,A,Pharmacokinetic property (vdss) was measured in dog,,CHEMBL624233,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7018,Canis lupus familiaris,,A,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,CHEMBL624234,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7019,Canis lupus familiaris,,A,Vdss was determined after iv 0.1 mg/kg administration in dog,,CHEMBL624235,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7020,Canis lupus familiaris,,A,Volume displacement was calculated in dog,,CHEMBL624236,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7021,Canis lupus familiaris,,A,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,CHEMBL624237,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7022,Canis lupus familiaris,,A,Volume distribution constant was determined,,CHEMBL624238,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7023,Canis lupus familiaris,,A,Volume distribution at a dose of 1 uM/kg in dog was determined,,CHEMBL624239,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7024,Canis lupus familiaris,,A,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,CHEMBL875829,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7025,Canis lupus familiaris,,A,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL624240,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7026,Canis lupus familiaris,,A,Volume distribution (Vdss) was measured in dog,,CHEMBL624241,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7027,Canis lupus familiaris,,A,Volume distribution (Vdss) was measured in dog,,CHEMBL624242,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7028,Canis lupus familiaris,,A,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL624243,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7029,Canis lupus familiaris,,A,Volume of distribution in steady state was determined in dog,,CHEMBL624244,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7030,Canis lupus familiaris,,A,Volume of distribution of compound was determined in dog,,CHEMBL624245,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7031,Canis lupus familiaris,,A,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,CHEMBL624246,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7032,Canis lupus familiaris,,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,CHEMBL624247,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7033,Canis lupus familiaris,,A,Volume of distribution (Vdss) was measured in dog,,CHEMBL624248,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7034,Canis lupus familiaris,,A,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL624249,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7035,Canis lupus familiaris,,A,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624250,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7036,Canis lupus familiaris,,A,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624251,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7037,Canis lupus familiaris,,A,Maximum rate of depolarization of the upstroke of the action potential,,CHEMBL624252,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7038,Canis lupus familiaris,,A,Steady state volume distribution in dog,,CHEMBL624253,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7039,Canis lupus familiaris,,A,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,CHEMBL624950,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7040,Canis lupus familiaris,,A,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,CHEMBL624951,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7041,Canis lupus familiaris,,A,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,CHEMBL875830,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7042,Canis lupus familiaris,,A,Volume distribution in dog after administration of 1 mg/kg iv,,CHEMBL624952,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7043,Canis lupus familiaris,,A,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL624953,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7044,Canis lupus familiaris,,A,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,CHEMBL624954,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7045,Canis lupus familiaris,,A,Vss on i.v. administration of 2 mg/kg was measured in dog,,CHEMBL624955,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7046,Canis lupus familiaris,,A,Vss was determined,,CHEMBL624956,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7047,Canis lupus familiaris,,A,Vss in dog,,CHEMBL625129,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7048,Canis lupus familiaris,,A,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,CHEMBL625130,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7049,Canis lupus familiaris,,A,Volume distribution in dogs,,CHEMBL625131,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7050,Canis lupus familiaris,,A,Volume of distribution in dog,,CHEMBL625132,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7051,Canis lupus familiaris,,A,Tested for the oral bioavailability in dog,,CHEMBL872263,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7060,Mus musculus,,A,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,CHEMBL624336,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7061,Mus musculus,,A,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,CHEMBL624337,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7062,Mus musculus,,A,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,CHEMBL624338,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7063,Mus musculus,,A,Bioavailability was measured in mouse,,CHEMBL624339,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7064,Mus musculus,,A,Bioavailability in mouse,,CHEMBL624340,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7065,Mus musculus,,A,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL624341,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7066,Mus musculus,,A,Bioavailability in mouse,,CHEMBL624342,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7067,Mus musculus,,A,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,CHEMBL624343,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7068,Mus musculus,,A,Oral bioavailability in mouse,,CHEMBL624344,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7069,Mus musculus,,A,Oral availability at 50 mg/kg po in male mice,,CHEMBL624345,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7070,Mus musculus,,A,Oral bioavailability in mouse (dose 10 mg/kg),,CHEMBL624346,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7071,Mus musculus,,A,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,CHEMBL624347,10090.0,1,1,N,50594,Expert,,,BAO_0000218,
7072,Mus musculus,,A,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,CHEMBL624348,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7074,Mus musculus,,A,Oral bioavailability in mouse,,CHEMBL622754,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7075,Mus musculus,,A,Oral bioavailability in vivo in mice;ND=Not determined,,CHEMBL622755,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7076,Mus musculus,,A,Oral bioavailability in mouse at 10 mg/kg of the compound,,CHEMBL622756,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7077,Mus musculus,,A,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,CHEMBL622757,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7078,Mus musculus,,A,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,CHEMBL622758,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7079,Mus musculus,,A,Tested for bioavailability of the compound,,CHEMBL622759,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7080,Mus musculus,,A,Tested for half life at the dose of 10 mg/kg when administered intravenously,,CHEMBL622760,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7081,Mus musculus,,A,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,CHEMBL622761,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
7082,Mus musculus,,A,The plasma half life of compound was determined on heparin prepared by human plasma. ,,CHEMBL622762,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
7083,Mus musculus,,A,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,CHEMBL622763,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
7084,Mus musculus,,A,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,CHEMBL622764,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
7085,Mus musculus,,A,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,CHEMBL622765,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
7086,Mus musculus,,F,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,CHEMBL622766,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7087,Mus musculus,,A,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,CHEMBL622767,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7088,Mus musculus,,A,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,CHEMBL622768,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7089,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL875948,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7090,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL622769,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7091,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL622770,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7092,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL622771,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7093,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL622772,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7094,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL622773,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7095,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL622774,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
7096,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL621725,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7097,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL621726,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7098,Homo sapiens,,F,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,CHEMBL621727,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7099,Homo sapiens,,F,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,CHEMBL622413,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7100,Homo sapiens,,F,Compound was evaluated for cytotoxicity against A2780 cell line,,CHEMBL622414,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7101,Homo sapiens,,F,Inhibition of A2780 cell clonogenic assay,,CHEMBL622415,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7102,Homo sapiens,,F,Cytotoxic effect on ovarian cancer cell line (A2780),,CHEMBL884001,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7103,Homo sapiens,,F,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,CHEMBL622416,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7104,Homo sapiens,,F,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,CHEMBL622417,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7105,Homo sapiens,,F,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,CHEMBL622590,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7106,Homo sapiens,,F,Antiproliferative activity against human A2780 cells,,CHEMBL622591,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7107,Homo sapiens,,F,Inhibition of human A2780 cell proliferation,,CHEMBL622592,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7108,Homo sapiens,,F,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,CHEMBL622593,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7109,Homo sapiens,,F,Inhibition of human A2780 cell proliferation (No data),,CHEMBL622594,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7110,Homo sapiens,,F,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,CHEMBL622595,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7111,Homo sapiens,,F,Compound was evaluated against human Ovarian carcinoma cell line A2780,,CHEMBL622596,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7112,Homo sapiens,,F,Growth inhibition against A2780 wild-type ovarian cell lines,,CHEMBL622597,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7113,Homo sapiens,,F,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,CHEMBL622598,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7114,Homo sapiens,,F,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,CHEMBL622599,9606.0,5,1,D,104766,Autocuration,,,BAO_0000019,
7115,Homo sapiens,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,CHEMBL622600,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7116,Homo sapiens,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,CHEMBL622601,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7117,Homo sapiens,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,CHEMBL622602,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7118,Homo sapiens,,F,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,CHEMBL622603,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7119,Homo sapiens,,F,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,CHEMBL622604,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7120,Homo sapiens,,F,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,CHEMBL622605,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7121,Homo sapiens,,F,In vitro inhibition of human ovarian cell line A2780,,CHEMBL622606,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7122,Homo sapiens,,F,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,CHEMBL619463,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7123,Homo sapiens,,F,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,CHEMBL619464,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7124,Homo sapiens,,F,Concentration required to inhibit A2780-cell growth by 50%,,CHEMBL619465,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7125,Homo sapiens,,F,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,CHEMBL619466,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7126,Homo sapiens,,F,Cytotoxic effect on human ovarian (A2780) cancer cell line,,CHEMBL619467,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7127,Homo sapiens,,F,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,CHEMBL619468,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7128,Homo sapiens,,F,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,CHEMBL619469,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7129,Homo sapiens,,F,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,CHEMBL619470,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7130,Homo sapiens,,F,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,CHEMBL619471,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7131,Homo sapiens,,F,Cytotoxicity against human ovarian carcinoma A2780 cell line,,CHEMBL619472,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7132,Homo sapiens,,F,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,CHEMBL619473,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7133,Homo sapiens,,F,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,CHEMBL874368,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7134,Homo sapiens,,F,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,CHEMBL884003,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7135,Homo sapiens,,F,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,CHEMBL622690,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7136,Homo sapiens,,F,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,CHEMBL622691,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7137,Homo sapiens,,F,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,CHEMBL622692,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7138,Homo sapiens,,F,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,CHEMBL623406,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7139,Homo sapiens,,F,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,CHEMBL884004,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7140,Homo sapiens,,F,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,CHEMBL623407,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7141,Homo sapiens,,F,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,CHEMBL623408,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7142,Homo sapiens,,F,In vitro antitumor activity against A2780 cell line.,,CHEMBL623409,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7143,Homo sapiens,,F,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,CHEMBL623410,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7144,Homo sapiens,,F,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,CHEMBL623576,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7145,Homo sapiens,,F,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,CHEMBL623577,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7146,Homo sapiens,,F,The IC50 value was measured on ACHN cell line in renal tumor type.,,CHEMBL623578,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7147,Homo sapiens,,F,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,CHEMBL623579,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7148,Homo sapiens,,F,In vitro lethal concentration against most sensitive ACHN cell line,,CHEMBL623580,9606.0,1,1,N,80025,Expert,,626.0,BAO_0000219,
7149,Homo sapiens,,F,Tested for cytotoxic activity against renal cancer ACHN cell line,,CHEMBL623581,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7150,Homo sapiens,,F,Compound tested for growth inhibition of renal cancer cell line ACHN,,CHEMBL857456,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7151,Homo sapiens,,F,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,CHEMBL623582,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7152,Homo sapiens,,F,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,CHEMBL623583,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7153,Homo sapiens,,F,In vitro anticancer activity against ACHN renal cancer cell line,,CHEMBL623584,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7154,Homo sapiens,,F,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,CHEMBL623585,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7155,Homo sapiens,,F,Percent selectivity was evaluated in renal ACHN cell lines,,CHEMBL623586,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7156,Homo sapiens,,F,In vitro inhibitory activity against renal ACHN cancer cell line,,CHEMBL623587,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7157,Homo sapiens,,F,Tested for cytotoxicity against ACHN cell lines in renal cancer,,CHEMBL875279,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7158,Homo sapiens,,F,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,CHEMBL623588,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7159,Homo sapiens,,F,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,CHEMBL623589,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7160,Homo sapiens,,F,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,CHEMBL623590,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7161,Homo sapiens,,F,Cytotoxic effect on renal cancer line ACHN,,CHEMBL623591,9606.0,1,1,N,80025,Expert,,626.0,BAO_0000219,
7162,Homo sapiens,,F,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,CHEMBL623592,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7163,Homo sapiens,,F,In vitro inhibition of Renal Cancer ACHN cell lines,,CHEMBL623593,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7164,Homo sapiens,,F,Antitumor activity against human renal adenocarcinoma ACHN cells,,CHEMBL623594,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7165,Homo sapiens,,F,Antitumor activity against human renal adenocarcinoma ACHN cells.,,CHEMBL621833,9606.0,1,1,N,80025,Expert,,626.0,BAO_0000219,
7166,Homo sapiens,,F,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,CHEMBL621834,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7167,Homo sapiens,,F,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,CHEMBL621835,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7168,Homo sapiens,,F,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,CHEMBL621836,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7169,Homo sapiens,,F,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,CHEMBL621837,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7170,Homo sapiens,,F,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,CHEMBL875280,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7171,Homo sapiens,,F,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,CHEMBL621838,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7172,Homo sapiens,,F,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,CHEMBL621839,9606.0,1,1,N,80025,Intermediate,,626.0,BAO_0000219,
7173,,,A,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL621840,,0,1,U,22224,Autocuration,,,BAO_0000019,
7174,,,F,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,CHEMBL621841,,8,1,H,10647,Autocuration,,,BAO_0000019,
7175,Cytomegalovirus,,F,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,CHEMBL622979,10358.0,1,1,N,50529,Expert,,468.0,BAO_0000218,
7176,Cytomegalovirus,,F,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,CHEMBL876595,10358.0,1,1,N,50529,Intermediate,,,BAO_0000218,
7177,,,B,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,CHEMBL620221,,8,1,H,12159,Autocuration,,,BAO_0000357,
7178,,,B,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,CHEMBL620222,,8,1,H,12159,Autocuration,,,BAO_0000357,
7179,Bos taurus,,F,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,CHEMBL620506,9913.0,1,1,N,80670,Intermediate,,979.0,BAO_0000219,
7180,Mus musculus,,F,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,CHEMBL620507,10090.0,1,1,N,80671,Intermediate,,980.0,BAO_0000219,
7181,Mus musculus,,F,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,CHEMBL620508,10090.0,1,1,N,80671,Intermediate,,980.0,BAO_0000219,
7182,Mus musculus,,F,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,CHEMBL620509,10090.0,1,1,N,80671,Intermediate,,980.0,BAO_0000219,
7183,Mus musculus,,F,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,CHEMBL620510,10090.0,1,1,N,80671,Intermediate,,980.0,BAO_0000219,
7184,Mus musculus,,A,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,CHEMBL620511,10090.0,1,1,N,80671,Intermediate,,980.0,BAO_0000219,
7185,Mus musculus,,F,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,CHEMBL620512,10090.0,1,1,N,80671,Intermediate,,980.0,BAO_0000219,
7186,Mus musculus,,F,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,CHEMBL620513,10090.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7187,Mus musculus,,F,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,CHEMBL620514,10090.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7188,Mus musculus,,F,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,CHEMBL620515,10090.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7189,Bacillus subtilis,,A,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,CHEMBL620516,1423.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7190,Canis lupus familiaris,,A,AUC value in dog after IV administration at a dose of 5 mg/kg,,CHEMBL620517,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7191,Canis lupus familiaris,,A,AUC value in dog after oral administration at a dose of 5 mg/kg,,CHEMBL620518,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7192,Canis lupus familiaris,,A,Cmax value in dog after oral administration at a dose of 5 mg/kg,,CHEMBL620519,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7193,Canis lupus familiaris,,A,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,CHEMBL621386,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7194,Canis lupus familiaris,,A,Tmax value in dog after oral administration at a dose of 5 mg/kg,,CHEMBL621387,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7195,Canis lupus familiaris,,A,Compound was evaluated for its clearance when administered intravenously in dog,,CHEMBL621388,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7196,Canis lupus familiaris,,A,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL621389,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7197,Canis lupus familiaris,,A,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,CHEMBL621390,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7198,,,P,Calculated partition coefficient (clogP),,CHEMBL621391,,0,1,U,22229,Intermediate,,,BAO_0000100,
7199,Canis lupus familiaris,,A,Half life in dog,,CHEMBL621392,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7200,Canis lupus familiaris,,A,Time taken for EC90 was determined when tested in dog,,CHEMBL621393,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7201,Canis lupus familiaris,,A,Half life (iv) was determined,,CHEMBL621394,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7202,Canis lupus familiaris,,A,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,CHEMBL621395,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
7203,Canis lupus familiaris,,A,Area under the curve was calculated in dog after iv administration,,CHEMBL621396,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7204,Canis lupus familiaris,,A,Area under the curve was calculated in dog after peroral administration,,CHEMBL621397,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7205,Canis lupus familiaris,,A,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,CHEMBL621398,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7206,Canis lupus familiaris,,A,pKa was evaluated in dog,,CHEMBL618818,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7207,Canis lupus familiaris,,A,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,CHEMBL618819,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7208,Canis lupus familiaris,,A,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL618820,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7209,Canis lupus familiaris,,A,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL873810,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7210,Canis lupus familiaris,,A,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,CHEMBL876606,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7211,Canis lupus familiaris,,A,Compound was evaluated for the half-life (t 1/2) in hours,,CHEMBL618821,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7212,Canis lupus familiaris,,A,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL618822,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
7213,Canis lupus familiaris,,A,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL618823,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
7214,Canis lupus familiaris,,A,Half life after intravenous administration of 1 mg/kg in dog,,CHEMBL618824,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7215,Canis lupus familiaris,,A,Half life was measured in dog,,CHEMBL618825,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7216,Canis lupus familiaris,,A,Half life period in dog after 5 mg/kg dose,,CHEMBL618826,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7217,Canis lupus familiaris,,A,Half life period was evaluated in dog; 4-4.8,,CHEMBL618827,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7218,Canis lupus familiaris,,A,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL618828,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7219,Canis lupus familiaris,,A,Half-life was determined in dog after a3 mg/kg of iv dose,,CHEMBL618829,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7220,Canis lupus familiaris,,A,Half-life was determined,,CHEMBL618830,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7221,Canis lupus familiaris,,A,Half life in dogs,,CHEMBL618831,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7222,Canis lupus familiaris,,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,CHEMBL619489,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7223,Canis lupus familiaris,,A,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,CHEMBL619649,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7224,Canis lupus familiaris,,A,Compound was evaluated for the half life period after iv administration in Beagle dog.,,CHEMBL876607,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7225,Canis lupus familiaris,,A,Compound was evaluated for the half life period after oral administration in conscious dog.,,CHEMBL619650,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7226,Canis lupus familiaris,,A,Compound was tested for half life in dog,,CHEMBL619651,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7227,Canis lupus familiaris,,A,Compound was tested for its half life in dog,,CHEMBL619652,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7228,Canis lupus familiaris,,A,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL619653,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7229,Canis lupus familiaris,,A,Half life of compound in dog was determined,,CHEMBL619654,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7230,Canis lupus familiaris,,A,Half life (iv) was determined,,CHEMBL619655,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7231,Canis lupus familiaris,,A,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,CHEMBL619656,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
7232,Canis lupus familiaris,,A,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,CHEMBL873812,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7233,Canis lupus familiaris,,F,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,CHEMBL621365,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7234,Canis lupus familiaris,,A,Half life in dog,,CHEMBL621366,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7235,Canis lupus familiaris,,A,Half life in dog plasma,,CHEMBL621367,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7236,Canis lupus familiaris,,A,Half life in dog plasma after administration of 0.25 mg/kg iv,,CHEMBL621368,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7237,Canis lupus familiaris,,A,Half life in dog plasma after administration of 1 mg/kg iv,,CHEMBL621369,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7238,Canis lupus familiaris,,A,Half life in dog plasma was determined at dose 10 mg/kg,,CHEMBL621370,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7239,Canis lupus familiaris,,A,Half life in dog was determined,,CHEMBL621371,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7240,Canis lupus familiaris,,A,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL621372,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7241,Canis lupus familiaris,,A,Half life upon exposure to human plasma,,CHEMBL621373,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7242,Canis lupus familiaris,,A,Half life was calculated in dog,,CHEMBL621374,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7243,Canis lupus familiaris,,A,Half life was determined,,CHEMBL621375,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7244,Canis lupus familiaris,,A,Half life was determined,,CHEMBL621376,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7245,Canis lupus familiaris,,A,Half life by intravenous administration of 1.2 mg/kg in dog,,CHEMBL619624,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7246,Canis lupus familiaris,,A,Half life in dog,,CHEMBL875840,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7247,Canis lupus familiaris,,A,Half life in dog after intra venous administration of the compound,,CHEMBL619625,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7248,Canis lupus familiaris,,A,Half life in dog after intra venous administration of the compound; ND means Not determined,,CHEMBL619626,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7249,Canis lupus familiaris,,A,Half life in dog after po administration of the compound,,CHEMBL619627,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7250,Canis lupus familiaris,,A,Half life in dog after po administration of the compound; ND means Not determined,,CHEMBL873817,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7251,Canis lupus familiaris,,A,Half life in dog at the single oral dose of 1 mg/kg,,CHEMBL619628,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7252,Canis lupus familiaris,,A,Half life in dogs,,CHEMBL619629,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7253,Canis lupus familiaris,,A,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,CHEMBL619630,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7254,Canis lupus familiaris,,A,Half life in rat,,CHEMBL619631,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7255,Canis lupus familiaris,,A,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL619632,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7256,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL619633,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7257,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL875841,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7258,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL619634,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7259,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL619635,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7260,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL619636,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
7261,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL619637,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7262,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL619638,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7263,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL619639,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7264,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL619640,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7265,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL619641,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7266,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL619642,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7267,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL619643,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000004.0
7268,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL619644,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7269,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL621112,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7270,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL621113,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7271,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL621114,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7272,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL621115,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7273,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL621116,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7274,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL621117,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
7275,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL621118,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7276,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL621119,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7277,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL621120,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7278,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL621757,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7279,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL621758,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7280,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL621759,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7281,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL621760,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
7282,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL621761,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7283,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL621762,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7284,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL621763,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7285,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL624502,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7286,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL624503,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7287,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL624504,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7288,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL624505,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
7289,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL624506,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7290,Homo sapiens,,F,In vitro cytotoxicity against A2780 (human ovarian cancer),,CHEMBL624507,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7291,Homo sapiens,,F,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,CHEMBL624508,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7292,Homo sapiens,,F,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,CHEMBL624509,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7293,Homo sapiens,,F,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,CHEMBL624510,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7294,Homo sapiens,,F,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,CHEMBL875956,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7295,Homo sapiens,,F,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,CHEMBL839885,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7296,Homo sapiens,,F,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,CHEMBL624511,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7297,Homo sapiens,,F,In vitro cytotoxicity against A2780 cell line,,CHEMBL624512,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7298,Homo sapiens,,F,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,CHEMBL624513,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7299,Homo sapiens,,F,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,CHEMBL624514,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7300,Homo sapiens,,F,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,CHEMBL618547,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000218,
7301,Homo sapiens,,F,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,CHEMBL618548,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7302,Homo sapiens,,F,Inhibition of tubulin polymerization in analogy of ca.,,CHEMBL618549,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7303,Homo sapiens,,F,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,CHEMBL618550,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7304,Homo sapiens,,F,Cytotoxic effect in ovarian cancer cell line (A2780),,CHEMBL618551,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7305,Homo sapiens,,F,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,CHEMBL618552,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7306,Homo sapiens,,F,Tested for the cytotoxicity in A2780 ovarian cell line,,CHEMBL618553,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7307,Homo sapiens,,F,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,CHEMBL618554,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7308,Homo sapiens,,F,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,CHEMBL618555,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7309,,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,CHEMBL618556,,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
7310,,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,CHEMBL618557,,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
7311,,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,CHEMBL618558,,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
7312,,,F,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,CHEMBL618559,,1,1,N,80017,Intermediate,,481.0,BAO_0000219,
7313,Homo sapiens,,F,In vivo log of cells killed after administration of compound in A2780 cell line,,CHEMBL618560,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000218,
7314,Homo sapiens,,F,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,CHEMBL618561,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000218,
7315,Homo sapiens,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,CHEMBL618562,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7316,Homo sapiens,,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,CHEMBL618563,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7317,Homo sapiens,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,CHEMBL618564,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7318,Homo sapiens,,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,CHEMBL618565,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7319,Homo sapiens,,F,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,CHEMBL618566,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000218,
7320,Homo sapiens,,F,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,CHEMBL618567,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7321,Homo sapiens,,F,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,CHEMBL618568,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7322,Homo sapiens,,F,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,CHEMBL618569,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7323,Homo sapiens,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,CHEMBL621857,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7324,Homo sapiens,,F,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,CHEMBL621858,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7325,Homo sapiens,,F,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,CHEMBL621859,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7326,Homo sapiens,,F,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,CHEMBL621860,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7327,Homo sapiens,,F,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,CHEMBL621861,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7328,Homo sapiens,,F,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,CHEMBL621862,9606.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7329,Homo sapiens,,F,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,CHEMBL621863,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7330,Homo sapiens,,F,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,CHEMBL621864,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7331,Homo sapiens,,F,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,CHEMBL621865,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7332,Mus musculus,,F,In vitro antiproliferative activity against A2780 cell line,,CHEMBL621866,10090.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7333,Mus musculus,,F,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,CHEMBL621867,10090.0,1,1,N,81034,Expert,,478.0,BAO_0000219,
7334,Homo sapiens,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,CHEMBL621868,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7335,Homo sapiens,,F,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,CHEMBL875282,9606.0,1,1,N,81034,Intermediate,,478.0,BAO_0000219,
7336,Canis lupus familiaris,,A,Vc value in dog after IV administration at a dose of 5 mg/kg,,CHEMBL621869,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7337,Canis lupus familiaris,,A,Half life period in dog after IV administration at a dose of 5 mg/kg,,CHEMBL621870,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7338,Cercopithecidae,,A,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL621871,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7339,Cercopithecidae,,A,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL621243,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
7340,Cercopithecidae,,A,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL621244,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
7341,Macaca fascicularis,,A,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,CHEMBL621245,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7342,Macaca fascicularis,,A,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,CHEMBL621246,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7343,Macaca fascicularis,,A,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,CHEMBL621247,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7344,Rattus norvegicus,,A,Oral Bioavailability in rat,,CHEMBL618386,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7345,Cercopithecidae,,A,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL618387,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7346,Cercopithecidae,,A,Area under curve value in monkey at a dose of 5 mg/kg,,CHEMBL618388,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7347,Cercopithecidae,,A,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,CHEMBL618389,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7348,Cercopithecidae,,A,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,CHEMBL618574,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7349,Cercopithecidae,,A,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,CHEMBL618575,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7350,Cercopithecidae,,A,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,CHEMBL618576,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7351,Cercopithecidae,,A,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,CHEMBL618577,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7352,Cercopithecidae,,A,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,CHEMBL876487,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7353,Cercopithecidae,,A,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL618578,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7354,Cercopithecidae,,A,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL618579,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7355,Cercopithecidae,,A,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL618580,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7356,Cercopithecidae,,A,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,CHEMBL618581,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7357,Cercopithecidae,,A,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,CHEMBL618582,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7358,Cercopithecidae,,A,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,CHEMBL618583,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7359,Cercopithecidae,,A,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,CHEMBL618584,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7360,Cercopithecidae,,A,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,CHEMBL618585,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7361,Cercopithecidae,,A,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,CHEMBL618586,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7362,Cercopithecidae,,A,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL618587,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7363,Cercopithecidae,,A,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL618588,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7364,Cercopithecidae,,A,Binding towards monkey plasma protein at 10 uM,,CHEMBL618589,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7365,Cercopithecidae,,A,Binding towards monkey plasma protein at 100 uM,,CHEMBL618590,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7366,Cercopithecidae,,A,Apparent bioavailability in squirrel monkey was determined,,CHEMBL872262,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7367,Cercopithecidae,,A,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,CHEMBL618591,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7368,monkey,,A,Bioavailability in monkey (dose 2 mg/kg),,CHEMBL618592,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7369,Cercopithecidae,,A,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,CHEMBL876488,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7370,Cercopithecidae,,A,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL618593,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7371,monkey,,A,Bioavailability in monkey (i.d. dosing),,CHEMBL618594,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7372,Cercopithecidae,,A,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,CHEMBL618595,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7373,Cercopithecidae,,A,Clearance of the drug was measured in cynomolgus,,CHEMBL621469,9527.0,0,1,U,22224,Autocuration,,,BAO_0000019,
7374,Cercopithecidae,,A,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,CHEMBL621470,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7375,Cercopithecidae,,A,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL621471,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7376,Macaca mulatta,,A,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL621472,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
7377,Cercopithecidae,,A,Plasma clearance in rhesus monkey was determined,,CHEMBL621473,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7378,Cercopithecidae,,A,Plasma clearance in monkey after administration of 1 mg/kg iv,,CHEMBL621474,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7379,Cercopithecidae,,A,Plasma clearance in cynomolgus monkey,,CHEMBL621475,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7380,Cercopithecidae,,A,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL621476,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7381,Cercopithecidae,,A,Plasma clearance after peroral administration at 10 mpk in Rhesus,,CHEMBL624290,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7382,Cercopithecidae,,A,The total clearance was determined after intravenous administration in cynomolgus monkeys,,CHEMBL624291,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7383,Cercopithecidae,,A,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL624292,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7384,Cercopithecidae,,A,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,CHEMBL624293,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7385,Cercopithecidae,,A,Tested for Clearance upon iv administration to african green monkey,,CHEMBL624294,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7386,Cercopithecidae,,A,Clearance in monkey,,CHEMBL624295,9527.0,0,1,U,22224,Autocuration,,,BAO_0000218,
7387,Canis lupus familiaris,,A,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624296,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7388,Canis lupus familiaris,,A,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624297,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7389,Canis lupus familiaris,,A,Half life was evaluated after intravenous administration to dogs,,CHEMBL624298,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7390,Canis lupus familiaris,,A,Half life was evaluated in dog,,CHEMBL624299,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7391,Canis lupus familiaris,,A,Half life was evaluated in dog,,CHEMBL624300,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7392,Canis lupus familiaris,,A,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,CHEMBL624301,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7393,Canis lupus familiaris,,A,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,CHEMBL624302,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7394,Canis lupus familiaris,,A,Half life period after intravenous administration in dog,,CHEMBL876026,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7395,Canis lupus familiaris,,A,Half life period after oral administration (2.5 mg/kg) in dog was determined,,CHEMBL624303,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7396,Canis lupus familiaris,,A,Half life period at a dose of 1 uM/kg in dog was determined,,CHEMBL624304,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7397,Canis lupus familiaris,,A,Half life period was determine after peroral administration at 10 mpk in dog,,CHEMBL624305,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7398,Canis lupus familiaris,,A,Half life period was determine after peroral administration at 5 mpk in dog,,CHEMBL624306,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7399,Canis lupus familiaris,,A,Half life period was determined,,CHEMBL624307,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7400,Canis lupus familiaris,,A,Half life period was determined,,CHEMBL624308,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7401,Canis lupus familiaris,,A,Half life period by iv administration in dog at a dose of 6 mg/kg,,CHEMBL624309,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7402,Canis lupus familiaris,,A,Half life period was evaluated in dog,,CHEMBL624310,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7403,Canis lupus familiaris,,A,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,CHEMBL625003,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7404,Canis lupus familiaris,,A,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,CHEMBL625004,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7405,Canis lupus familiaris,,A,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,CHEMBL625005,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7406,Canis lupus familiaris,,A,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL873813,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7407,Canis lupus familiaris,,A,Half-life after oral dose of compound at 3 mg/kg in dogs,,CHEMBL625006,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7408,Canis lupus familiaris,,A,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,CHEMBL625007,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7409,Canis lupus familiaris,,A,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,CHEMBL876027,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7410,Canis lupus familiaris,,A,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,CHEMBL625008,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7411,Canis lupus familiaris,,A,Half-life of compound in dog following p.o. administration of 1 mg/kg,,CHEMBL625009,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7412,Canis lupus familiaris,,A,Half-life of compound in plasma of dog was determined,,CHEMBL625010,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7413,Canis lupus familiaris,,A,Half-life of compound was determined in dogs,,CHEMBL625011,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7414,Canis lupus familiaris,,A,Half-life after administration of 4 mg/Kg oral dose in dog,,CHEMBL621553,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7415,Canis lupus familiaris,,A,Half-life after intravenous administration of 1 mg/kg/h in dog,,CHEMBL621554,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7416,Canis lupus familiaris,,A,Half-life in Dog,,CHEMBL621555,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7417,Canis lupus familiaris,,A,Half-life in Dog,,CHEMBL621556,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7418,Canis lupus familiaris,,A,Half-life in dog,,CHEMBL621557,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7419,Canis lupus familiaris,,A,Half-life in dog after oral administration at 1 mg/kg,,CHEMBL621558,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7420,Canis lupus familiaris,,A,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,CHEMBL621559,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7421,Canis lupus familiaris,,A,Half-life in dogs,,CHEMBL621560,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7422,Canis lupus familiaris,,A,Half-life in dogs; ND indicates not determined,,CHEMBL876028,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7423,Canis lupus familiaris,,A,Half-life in plasma of dog,,CHEMBL621561,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7424,Canis lupus familiaris,,A,Half-life in plasma of dog at dose of 3-10 mgkg,,CHEMBL621562,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7425,Canis lupus familiaris,,A,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,CHEMBL621563,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7426,Canis lupus familiaris,,A,Half-life was measured in dog after an iv dose of 1 mg/kg,,CHEMBL621564,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7427,Canis lupus familiaris,,A,Half-life was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL621565,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7428,Canis lupus familiaris,,A,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,CHEMBL621566,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7429,Canis lupus familiaris,,A,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,CHEMBL621567,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7430,Canis lupus familiaris,,A,Half-life of the compound after 0.3 mg/kg po administration in dog,,CHEMBL622978,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7431,Canis lupus familiaris,,A,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,CHEMBL873814,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7432,Canis lupus familiaris,,A,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,CHEMBL623219,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7433,Canis lupus familiaris,,A,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,CHEMBL624477,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7434,Canis lupus familiaris,,A,t1/2 in dog,,CHEMBL624478,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7435,Canis lupus familiaris,,A,Half-life period measured in dogs,,CHEMBL624479,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7436,Canis lupus familiaris,,A,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,CHEMBL624480,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7437,Canis lupus familiaris,,A,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL623595,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7438,Canis lupus familiaris,,A,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL623596,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7439,Canis lupus familiaris,,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,CHEMBL623597,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7440,Canis lupus familiaris,,A,In vivo half life period was calculated at 1 mg/kg in dog,,CHEMBL623598,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7441,Canis lupus familiaris,,A,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,CHEMBL623599,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7442,Canis lupus familiaris,,A,Longer half-life in dog (i.v.) at 0.5 mpk,,CHEMBL623600,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7443,Canis lupus familiaris,,A,Oral bioavailability in dog (dose 5 uM/kg),,CHEMBL623601,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7444,Canis lupus familiaris,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL623602,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7445,Canis lupus familiaris,,A,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,CHEMBL623603,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7446,Canis lupus familiaris,,A,Bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL623604,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7447,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL623605,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7448,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL623606,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7449,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL623607,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7450,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL623608,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7451,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL623609,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7452,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL623610,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
7453,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL623611,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7454,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL623612,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7455,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL623613,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7456,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL623614,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7457,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL623615,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7458,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL623616,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7459,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL623617,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
7460,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL875944,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7461,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL623618,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7462,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL623619,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7463,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL623620,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7464,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL623621,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7465,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL623622,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7466,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL623623,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
7467,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL623624,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7468,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL618521,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7469,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL618522,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7470,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL618523,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7471,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL618524,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7472,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL618525,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7473,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL624586,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
7474,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL624587,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7475,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL624588,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7476,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL624589,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7477,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL624590,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7478,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL624591,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7479,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL624592,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7480,Mus musculus,,A,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL624593,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
7481,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL624594,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7482,Rattus norvegicus,,A,Tested for the bioavailability in rat,,CHEMBL624595,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7483,Rattus norvegicus,,A,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL624596,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7484,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL624597,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7485,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL624598,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7486,Rattus norvegicus,,A,Bioavailability in rat (dose 3-10 mg/kg),,CHEMBL624599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7487,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL875166,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7488,Rattus norvegicus,,A,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL624600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7489,Rattus norvegicus,,A,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,CHEMBL624601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7490,Rattus norvegicus,,A,Half life after oral administration was determined in rats at 6 mg/kg,,CHEMBL624602,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7491,Rattus norvegicus,,A,Half life was determined,,CHEMBL624603,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7492,Rattus norvegicus,,A,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,CHEMBL624604,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7493,Rattus norvegicus,,A,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,CHEMBL624605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7494,Rattus norvegicus,,A,Half life in rats,,CHEMBL624606,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7495,Rattus norvegicus,,A,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,CHEMBL624607,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7496,Rattus norvegicus,,A,Hill coefficient of the compound,,CHEMBL624608,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7497,Rattus norvegicus,,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,CHEMBL624609,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7498,Rattus norvegicus,,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,CHEMBL624610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7499,Rattus norvegicus,,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,CHEMBL624611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7500,Rattus norvegicus,,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,CHEMBL624612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7501,Rattus norvegicus,,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,CHEMBL875167,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7502,Rattus norvegicus,,A,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,CHEMBL624613,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7503,Rattus norvegicus,,A,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,CHEMBL624614,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7504,Rattus norvegicus,,A,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,CHEMBL624392,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7505,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,CHEMBL624393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7506,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,CHEMBL624394,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7507,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,CHEMBL624395,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7508,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,CHEMBL624396,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7509,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,CHEMBL624397,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7510,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,CHEMBL624398,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7511,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,CHEMBL624399,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7512,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,CHEMBL624400,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7513,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,CHEMBL624401,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7514,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,CHEMBL624402,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7515,Rattus norvegicus,,A,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL624403,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7516,Rattus norvegicus,,A,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL624404,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7517,Rattus norvegicus,,A,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL624405,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7518,Rattus norvegicus,,A,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL624406,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7519,Rattus norvegicus,,A,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL624407,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7520,Rattus norvegicus,,A,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL624408,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7521,Rattus norvegicus,,A,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618644,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7522,Rattus norvegicus,,A,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618645,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7523,Rattus norvegicus,,A,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL618646,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7524,Rattus norvegicus,,A,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618647,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7525,Rattus norvegicus,,A,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618648,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7526,Rattus norvegicus,,A,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL618649,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7527,Rattus norvegicus,,A,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618650,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7528,Rattus norvegicus,,A,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618651,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7529,Rattus norvegicus,,A,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL876497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7530,Rattus norvegicus,,A,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618652,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
7531,Rattus norvegicus,,A,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618653,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
7532,Rattus norvegicus,,A,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL618654,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
7533,Rattus norvegicus,,A,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,CHEMBL618655,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7534,Rattus norvegicus,,A,Compound was tested for solubility in water,,CHEMBL618656,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7535,,,P,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,CHEMBL618657,,0,1,U,22229,Intermediate,,,BAO_0000100,
7536,Rattus norvegicus,,A,Solubility was determined,,CHEMBL618658,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7537,Rattus norvegicus,,A,solubility in water (ug/mL) at 37 degree C.,,CHEMBL618659,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7538,Rattus norvegicus,,A,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,CHEMBL618660,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7539,Rattus norvegicus,,A,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,CHEMBL618661,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7540,Rattus norvegicus,,A,Half life in rats,,CHEMBL873807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7541,Rattus norvegicus,,A,Half life in Dawley rat,,CHEMBL618662,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7542,Rattus norvegicus,,A,Half life period after 3 mg/kg iv administration,,CHEMBL618663,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7543,Rattus norvegicus,,A,Half life period after 3 mg/kg iv administration in rat,,CHEMBL618664,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7544,Rattus norvegicus,,A,Half life period after 3 mg/kg iv administration in the rat,,CHEMBL618665,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7545,Rattus norvegicus,,A,Half life period in female Sprague-Dawley rats,,CHEMBL876498,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7546,Rattus norvegicus,,A,Half life period in rat,,CHEMBL618666,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7547,Rattus norvegicus,,A,Half-life in rats was determined,,CHEMBL620440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7548,Rattus norvegicus,,A,Half-life in rats with metabolic oxidation,,CHEMBL620441,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7549,Rattus norvegicus,,A,Half-life in rats,,CHEMBL620442,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7550,Rattus norvegicus,,A,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL620443,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7551,Rattus norvegicus,,A,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL620444,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7552,Rattus norvegicus,,A,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL620445,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7553,Rattus norvegicus,,A,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL620446,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7554,Rattus norvegicus,,A,Biological half-life measured in plasma of rat,,CHEMBL620447,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7555,Rattus norvegicus,,A,Biological half-life measured in plasma of rat; 22-25,,CHEMBL621129,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7556,Rattus norvegicus,,A,Biological half-life measured in plasma of rat; 9-16,,CHEMBL621130,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7557,Rattus norvegicus,,A,Compound was evaluated for its half life when administered intravenously in rat,,CHEMBL873808,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7558,Rattus norvegicus,,A,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,CHEMBL876598,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7559,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,CHEMBL621131,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7560,Rattus norvegicus,,A,Half life (T1/2) after oral administration in rat,,CHEMBL621132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7561,Rattus norvegicus,,A,Half life of compound after iv administration of 20 mg/kg dose in rat,,CHEMBL621133,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7562,Rattus norvegicus,,A,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL621312,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
7563,Rattus norvegicus,,A,Half life of compound was determined in rat,,CHEMBL621313,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7564,Rattus norvegicus,,A,Half life of compound was determined in rat blood,,CHEMBL621314,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7565,Rattus norvegicus,,A,Half life at 1 mg/kg was determined in rat,,CHEMBL621315,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7566,Rattus norvegicus,,A,Half life at 10 mg/kg was determined in rat,,CHEMBL621316,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7567,Rattus norvegicus,,A,Half life in rats,,CHEMBL621317,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7568,Rattus norvegicus,,A,Half life in rats in hours,,CHEMBL621318,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7569,Rattus norvegicus,,A,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,CHEMBL621319,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7570,Rattus norvegicus,,A,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,CHEMBL621377,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7571,Rattus norvegicus,,A,Half life was determined,,CHEMBL621378,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7572,Rattus norvegicus,,A,Half life after i.v. administration,,CHEMBL876599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7573,Rattus norvegicus,,A,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,CHEMBL621379,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7574,Rattus norvegicus,,A,Half life in rat plasma,,CHEMBL621380,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7575,Rattus norvegicus,,A,Half life in rat plasma; Not detected,,CHEMBL621381,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7576,Rattus norvegicus,,A,Half life in rats,,CHEMBL618515,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7577,Rattus norvegicus,,A,Half life period of compound was determined after peroral administration,,CHEMBL618516,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7578,Rattus norvegicus,,A,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,CHEMBL618517,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7579,Rattus norvegicus,,A,Half life period in rat,,CHEMBL618518,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7580,Rattus norvegicus,,A,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,CHEMBL618519,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7581,Rattus norvegicus,,A,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,CHEMBL618698,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7582,Rattus norvegicus,,A,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,CHEMBL618862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7583,Rattus norvegicus,,A,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL618863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7584,Rattus norvegicus,,A,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,CHEMBL618864,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7585,Rattus norvegicus,,A,Half life time in rat the dose of 2 mg/kg,,CHEMBL618865,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7586,Rattus norvegicus,,A,Half-life 24 hr after 10 mg/kg iv administration in rats,,CHEMBL618866,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7587,Rattus norvegicus,,A,Half-life 24 hr after 2 mg/kg iv administration in rats,,CHEMBL618867,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7588,Rattus norvegicus,,A,Half-life consistent with the observed metabolic steady state in rats,,CHEMBL875828,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7589,Rattus norvegicus,,A,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,CHEMBL618868,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7590,Rattus norvegicus,,A,Half-life for oxidative metabolic stability was determined using male human,,CHEMBL618869,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7591,Rattus norvegicus,,A,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL618870,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7592,Rattus norvegicus,,A,Half-life in rat plasma,,CHEMBL618871,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7593,Rattus norvegicus,,A,Half-life in rat plasma was determined,,CHEMBL618872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7594,Rattus norvegicus,,A,Half-life in rats was determined,,CHEMBL873816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7595,,,A,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,CHEMBL618873,,0,1,U,22224,Autocuration,,,BAO_0000218,
7596,,,A,Area under curve after oral dose of 0.1 mg//kg,,CHEMBL621602,,0,1,U,22224,Autocuration,,,BAO_0000019,
7597,,,A,Area under curve after oral dose of 0.3 mg/kg,,CHEMBL621603,,0,1,U,22224,Autocuration,,,BAO_0000218,
7598,,,A,Area under curve after oral dose of 1 mg/kg,,CHEMBL621604,,0,1,U,22224,Autocuration,,,BAO_0000218,
7599,,,A,Area under curve after oral dose of 10 mg/kg,,CHEMBL621605,,0,1,U,22224,Autocuration,,,BAO_0000218,
7600,,,A,Area under curve after oral dose of 23.4 mg/kg,,CHEMBL621606,,0,1,U,22224,Autocuration,,,BAO_0000218,
7601,,,A,Area under curve after oral dose of 3 mg/kg,,CHEMBL621607,,0,1,U,22224,Autocuration,,,BAO_0000218,
7602,,,A,Area under curve after oral dose of 3.87 mg/kg,,CHEMBL621608,,0,1,U,22224,Autocuration,,,BAO_0000218,
7603,,,A,Area under curve was determined,,CHEMBL621609,,0,1,U,22224,Autocuration,,,BAO_0000019,
7604,,,A,Area under curve at a dose of 10 mg/kg,,CHEMBL621610,,0,1,U,22224,Autocuration,,,BAO_0000218,
7605,Rattus norvegicus,,A,Area under curve was determined; ND=No data,,CHEMBL621611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7606,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL621612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7607,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,CHEMBL622308,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7608,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7609,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,CHEMBL622310,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7610,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,CHEMBL622311,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7611,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,CHEMBL622312,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7612,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7613,Rattus norvegicus,,A,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,CHEMBL622932,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7614,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7615,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,CHEMBL622737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7616,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622738,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7617,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,CHEMBL622739,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7618,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,CHEMBL622740,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7619,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,CHEMBL622741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7620,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7621,Rattus norvegicus,,A,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,CHEMBL622743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7622,Mus musculus,,A,AUC in mice,,CHEMBL622744,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
7623,,,A,Area under curve was measured from the graph obtained from concentration Vs time,,CHEMBL624134,,0,1,U,22224,Autocuration,,,BAO_0000019,
7624,,,A,Area under curve value of compound per hour after oral administration,,CHEMBL624135,,0,1,U,22224,Autocuration,,,BAO_0000019,
7625,Rattus norvegicus,,A,Area under curve was determined after oral administration in rats,,CHEMBL624136,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7626,Rattus norvegicus,,A,Area under curve was determined after oral administration in rats; No data,,CHEMBL624137,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7627,Rattus norvegicus,,A,Area under curve was determined after oral administration in rats;No data,,CHEMBL624320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7628,Canis lupus familiaris,,A,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,CHEMBL624321,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7629,Rattus norvegicus,,A,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,CHEMBL624322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7630,Rattus norvegicus,,A,Area under curve was determined for the compound after iv dose of 5.06 in rats,,CHEMBL624323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7631,Rattus norvegicus,,A,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,CHEMBL624324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7632,Rattus norvegicus,,A,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,CHEMBL624325,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7633,Rattus norvegicus,,A,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,CHEMBL624326,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7634,Rattus norvegicus,,A,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,CHEMBL624327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7635,Rattus norvegicus,,A,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,CHEMBL624328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7636,Canis lupus familiaris,,A,Area under curve was determined in Dogs after peroral administration,,CHEMBL627848,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7637,Rattus norvegicus,,A,Area under curve was determined in Rats after peroral administration,,CHEMBL627849,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7638,Rattus norvegicus,,A,Area under curve was determined in carotid blood of rat when administered intradermally,,CHEMBL627850,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7639,Rattus norvegicus,,A,Area under curve was determined in portal blood of rat when administered intradermally,,CHEMBL627851,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7640,Mus musculus,,A,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627852,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7641,Mus musculus,,A,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL627853,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7642,Mus musculus,,A,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,CHEMBL627854,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7643,Mus musculus,,A,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627855,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7644,Mus musculus,,A,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,CHEMBL627856,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7645,Mus musculus,,A,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL875339,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7646,Mus musculus,,A,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,CHEMBL627857,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7647,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,CHEMBL627858,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7648,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,CHEMBL627859,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7649,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,CHEMBL627860,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7650,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,CHEMBL627019,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7651,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,CHEMBL627020,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7652,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,CHEMBL627021,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
7653,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,CHEMBL627022,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
7654,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,CHEMBL627023,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7655,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,CHEMBL627024,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7656,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,CHEMBL627025,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7657,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,CHEMBL627026,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7658,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,CHEMBL627027,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7659,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,CHEMBL627028,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7660,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,CHEMBL627029,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7661,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,CHEMBL627030,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7662,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,CHEMBL627031,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7663,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,CHEMBL627032,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
7664,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,CHEMBL627033,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
7665,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,CHEMBL627034,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7666,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,CHEMBL627035,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7667,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,CHEMBL627036,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7668,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,CHEMBL875340,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7669,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,CHEMBL627037,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7670,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,CHEMBL627038,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7671,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,CHEMBL627039,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7672,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,CHEMBL627040,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
7673,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,CHEMBL624663,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7674,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,CHEMBL625963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
7675,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,CHEMBL876799,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7676,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,CHEMBL626133,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
7677,Rattus norvegicus,,A,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,CHEMBL626134,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7678,Rattus norvegicus,,A,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,CHEMBL626135,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7679,Rattus norvegicus,,A,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,CHEMBL626136,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7680,Rattus norvegicus,,A,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,CHEMBL626137,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7681,Rattus norvegicus,,A,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,CHEMBL626138,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7682,Rattus norvegicus,,A,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,CHEMBL626139,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7683,Rattus norvegicus,,A,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL626140,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7684,Rattus norvegicus,,A,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL626141,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7685,Rattus norvegicus,,A,C24h in rat p.o. at 20 mg/kg concentration,,CHEMBL626142,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7686,Rattus norvegicus,,A,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL627930,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
7687,Rattus norvegicus,,A,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL627931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
7688,Rattus norvegicus,,A,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL627932,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
7689,Rattus norvegicus,,A,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL627933,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7690,Rattus norvegicus,,A,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL627934,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7691,Rattus norvegicus,,A,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL627935,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
7692,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,CHEMBL627936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7693,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,CHEMBL627937,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7694,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL627938,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7695,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL627939,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7696,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,CHEMBL627940,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7697,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL627941,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7698,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL876800,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7699,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,CHEMBL627942,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7700,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,CHEMBL627943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7701,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,CHEMBL627944,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7702,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,CHEMBL627945,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7703,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,CHEMBL628584,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7704,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,CHEMBL628585,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7705,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,CHEMBL628586,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7706,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,CHEMBL628587,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7707,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,CHEMBL628588,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7708,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,CHEMBL628589,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7709,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,CHEMBL625304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7710,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,CHEMBL625305,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7711,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,CHEMBL625306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7712,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,CHEMBL625307,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7713,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,CHEMBL625308,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7714,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL627740,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7715,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,CHEMBL627741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7716,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL627742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7717,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,CHEMBL627743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7718,Rattus norvegicus,,A,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,CHEMBL627744,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
7719,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,CHEMBL627745,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7720,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL627746,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7721,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,CHEMBL627747,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7722,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL876810,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7723,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,CHEMBL627748,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7724,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL627749,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7725,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL627750,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7726,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,CHEMBL618728,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7727,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,CHEMBL618729,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7728,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,CHEMBL618730,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7729,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,CHEMBL618731,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7730,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,CHEMBL618732,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7731,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,CHEMBL618733,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7732,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,CHEMBL618734,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7733,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,CHEMBL618735,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7734,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,CHEMBL876602,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7735,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,CHEMBL618736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7736,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,CHEMBL618737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7737,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL618738,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7738,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,CHEMBL618739,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7739,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL618740,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7740,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL618741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7741,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,CHEMBL618742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7742,Rattus norvegicus,,A,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,CHEMBL618743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
7743,Rattus norvegicus,,A,Half-life from rat plasma at a single oral dose of 25 mg/kg,,CHEMBL618744,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7744,Rattus norvegicus,,A,Half-life in male rat,,CHEMBL618745,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7745,Rattus norvegicus,,A,Half-life in rat after peroral administration at 10 mg/kg concentration,,CHEMBL620479,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7746,Rattus norvegicus,,A,Half-life in rat after peroral administration at 5 mg/kg concentration,,CHEMBL620480,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7747,Rattus norvegicus,,A,Half-life in rat at a dose of 3 mg/kg,,CHEMBL620481,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7748,Rattus norvegicus,,A,Half-life was evaluated in rats,,CHEMBL620482,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7749,Rattus norvegicus,,A,Half-life was measured in rat,,CHEMBL876603,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7750,Rattus norvegicus,,A,Half-life period for the compound was determined in rats at 50 mg/kg dose,,CHEMBL620483,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7751,Rattus norvegicus,,A,Half-life period in rats after intravenous administration at 5 mg/kg,,CHEMBL620484,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7752,Rattus norvegicus,,A,Half-life period in rat at 10 mg/kg,,CHEMBL620485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7753,Rattus norvegicus,,A,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL620486,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7754,Rattus norvegicus,,A,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,CHEMBL620487,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7755,Rattus norvegicus,,A,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL620488,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7756,Rattus norvegicus,,A,Half-life time in rat the dose of 2 mg/kg,,CHEMBL620489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7757,Rattus norvegicus,,A,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,CHEMBL620490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7758,Rattus norvegicus,,A,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,CHEMBL620491,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7759,Rattus norvegicus,,A,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,CHEMBL876604,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7760,Rattus norvegicus,,A,Oral half life was determined,,CHEMBL620492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7761,Rattus norvegicus,,A,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL620493,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7762,Rattus norvegicus,,A,Pharmacokinetic property (t1/2) in rat,,CHEMBL620494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7763,Rattus norvegicus,,A,Plasma elimination half-life was determined,,CHEMBL620495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7764,Rattus norvegicus,,A,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL620496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7765,Rattus norvegicus,,A,Plasma half life was observed after intravenous administration in rat,,CHEMBL620497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7766,Rattus norvegicus,,A,Plasma half-life was determined,,CHEMBL620498,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7767,Rattus norvegicus,,A,Plasma half-life following oral administration in Fisher rats,,CHEMBL620499,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7768,Rattus norvegicus,,A,Plasma half-life in rat,,CHEMBL620500,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7769,Rattus norvegicus,,A,Plasmatic Half-life after intravenous administration to rat,,CHEMBL873809,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7770,Rattus norvegicus,,A,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,CHEMBL620501,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7771,Rattus norvegicus,,A,Terminal half life after intravenous administration (1 mg/kg) in rat,,CHEMBL620502,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7772,Rattus norvegicus,,A,Terminal half life in Rat at a oral dose of 5 mg/kg,,CHEMBL620503,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7773,Rattus norvegicus,,A,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,CHEMBL620504,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7774,Rattus norvegicus,,A,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,CHEMBL876605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7775,Rattus norvegicus,,A,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,CHEMBL620505,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7776,Rattus norvegicus,,A,plasma half life was observed after intravenous administration in rat,,CHEMBL873811,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7777,Rattus norvegicus,,A,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL624016,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
7778,Rattus norvegicus,,A,Half life of compound determined in rat,,CHEMBL624017,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7779,Rattus norvegicus,,A,Mean residence time determined in rat,,CHEMBL624018,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7780,Rattus norvegicus,,A,Plasma half life determined in rat,,CHEMBL624019,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7781,Rattus norvegicus,,A,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,CHEMBL624020,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
7782,Rattus norvegicus,,A,Compound was evaluated for pharmacokinetic parameter maximum time period,,CHEMBL624201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7783,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,CHEMBL872528,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7784,Rattus norvegicus,,A,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL624202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7785,Rattus norvegicus,,A,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL624203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7786,Rattus norvegicus,,A,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL624350,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7787,Rattus norvegicus,,A,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL621320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7788,Rattus norvegicus,,A,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,CHEMBL621321,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7789,Rattus norvegicus,,A,Maximum time (Tmax) required to reach Cmax in rats,,CHEMBL621322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7790,Rattus norvegicus,,A,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,CHEMBL621323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7791,Rattus norvegicus,,A,Maximum time of clearance of compound in rats after peroral administration,,CHEMBL621324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7792,Rattus norvegicus,,A,Maximum time at the dose of 2 mg/kg in rat,,CHEMBL621325,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7793,Rattus norvegicus,,A,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,CHEMBL875837,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7794,Rattus norvegicus,,A,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,CHEMBL621326,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7795,Rattus norvegicus,,A,Tmax in Guinea pig (PO dose),,CHEMBL621327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7796,Rattus norvegicus,,A,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL621328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7797,Rattus norvegicus,,A,Pharmacokinetic parameter (Tmax) in rat,,CHEMBL621329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7798,Rattus norvegicus,,A,Pharmacokinetic parameter (Tmax) was estimated,,CHEMBL621330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7799,Rattus norvegicus,,A,Pharmacokinetic property (Tmax) in rat,,CHEMBL621331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7800,Rattus norvegicus,,A,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,CHEMBL621332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7801,Rattus norvegicus,,A,T max in Rat at a oral dose of 5 mg/kg,,CHEMBL621333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7802,Rattus norvegicus,,A,T max was determined at 10 mg/kg po dose in rats,,CHEMBL621334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7803,Mus musculus,,A,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,CHEMBL621335,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7804,Canis lupus familiaris,,A,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,CHEMBL621336,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7805,Rattus norvegicus,,A,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,CHEMBL621337,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7806,Canis lupus familiaris,,A,Area under curve was measured after i.v. administration into Beagle dog.,,CHEMBL621338,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7807,Canis lupus familiaris,,A,Area under curve was measured after iv administration into Beagle dog,,CHEMBL875838,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7808,Canis lupus familiaris,,A,Area under curve was measured after po administration into Beagle dog,,CHEMBL621339,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7809,Canis lupus familiaris,,A,Area under curve was measured after po administration into Beagle dog.,,CHEMBL621340,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7810,,,A,Area under curve was measured at peroral dose of 3 mg/kg,,CHEMBL621341,,0,1,U,22224,Autocuration,,,BAO_0000218,
7811,,,A,Area under curve was measured by using concentration Vs time,,CHEMBL621342,,0,1,U,22224,Autocuration,,,BAO_0000019,
7812,,,A,Area under curve was measured by using concentration Vs time; not tested,,CHEMBL621343,,0,1,U,22224,Autocuration,,,BAO_0000019,
7813,Mus musculus,,A,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,CHEMBL621344,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7814,Mus musculus,,A,Area under curve(AUC) was measured in mice after oral administration.,,CHEMBL621345,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7815,,,A,Area under curve(AUC) value of the compound,,CHEMBL621346,,0,1,U,22224,Autocuration,,,BAO_0000019,
7816,,,A,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,CHEMBL621347,,0,1,U,22224,Autocuration,,,BAO_0000218,
7817,Canis lupus familiaris,,A,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,CHEMBL621348,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7818,,,A,Area under curve(carotid artery) was determined by the availability in blood,,CHEMBL621349,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
7819,,,A,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,CHEMBL621350,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
7820,,,A,Area under curve(carotid artery) was determined by the availability in blood; No data,,CHEMBL875839,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
7821,,,A,Area under curve(portal vein) was determined by the availability in blood,,CHEMBL620211,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
7822,,,A,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,CHEMBL620212,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
7823,,,A,Area under curve(portal vein) was determined by the availability in blood; No data,,CHEMBL620213,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
7824,Macaca mulatta,,A,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,CHEMBL620214,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,1969.0
7825,Macaca mulatta,,A,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,CHEMBL620215,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,1969.0
7826,Macaca mulatta,,A,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,CHEMBL620216,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,1969.0
7827,Canis lupus familiaris,,A,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,CHEMBL620888,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7828,Canis lupus familiaris,,A,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,CHEMBL620889,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
7829,,,A,Area under plasma concentration vs time curve observed in rats for 0-3 h,,CHEMBL620890,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
7830,Rattus norvegicus,,A,Area under plasma time curve determined in male rat,,CHEMBL620891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7831,,,A,Area under the MAP curve measured over 5 min.,,CHEMBL620892,,0,1,U,22224,Autocuration,,,BAO_0000019,
7832,Mus musculus,,A,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,CHEMBL621079,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7833,Mus musculus,,A,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,CHEMBL621080,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
7834,Canis lupus familiaris,,A,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,CHEMBL621081,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7835,Cricetinae,,A,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,CHEMBL621082,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
7836,Rattus norvegicus,,A,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,CHEMBL621083,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7837,Canis lupus familiaris,,A,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,CHEMBL621084,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7838,Canis lupus familiaris,,A,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,CHEMBL621085,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7839,Canis lupus familiaris,,A,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,CHEMBL621086,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7840,Canis lupus familiaris,,A,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,CHEMBL621087,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7841,Canis lupus familiaris,,A,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,CHEMBL622607,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7842,Canis lupus familiaris,,A,Serum AUC in marmosets (IV dose),,CHEMBL622608,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7843,,,A,Area under the curve after intravenous administration at a dose of 10 umol/kg,,CHEMBL624481,,0,1,U,22224,Autocuration,,,BAO_0000019,
7844,,,A,Area under the curve after intravenous administration at a dose of 2 umol/kg,,CHEMBL624482,,0,1,U,22224,Autocuration,,,BAO_0000019,
7845,,,A,Area under the curve after intravenous administration at a dose of 4 umol/kg,,CHEMBL624483,,0,1,U,22224,Autocuration,,,BAO_0000019,
7846,,,A,Area under the curve after intravenous administration at a dose of 40 umol/kg,,CHEMBL624484,,0,1,U,22224,Autocuration,,,BAO_0000019,
7847,,,A,Area under the curve after intravenous administration at a dose of 5 umol/kg,,CHEMBL624485,,0,1,U,22224,Autocuration,,,BAO_0000019,
7848,Rattus norvegicus,,A,Area under the curve for fumarate salt was evaluated in F344 Rats.,,CHEMBL624486,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7849,,,A,Area under the curve for the compound was calculated.,,CHEMBL624487,,0,1,U,22224,Autocuration,,,BAO_0000019,
7850,,,A,Area under the curve in concentration/ time,,CHEMBL624488,,0,1,U,22224,Autocuration,,,BAO_0000019,
7851,Rattus norvegicus,,A,Area under the curve administered intraintestinal in rats.,,CHEMBL624489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7852,Rattus norvegicus,,A,Area under the curve administered intravenously in rats.,,CHEMBL625184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7853,,,A,Area under the curve during intravenous administration,,CHEMBL625185,,0,1,U,22224,Autocuration,,,BAO_0000019,
7854,,,A,Area under the curve during intravenous administration; Not determined,,CHEMBL875954,,0,1,U,22224,Autocuration,,,BAO_0000019,
7855,,,A,Area under the curve during systemic administration,,CHEMBL625186,,0,1,U,22224,Autocuration,,,BAO_0000019,
7856,,,A,Area under the curve during systemic administration; Not determined,,CHEMBL625187,,0,1,U,22224,Autocuration,,,BAO_0000019,
7857,,,A,Area under the curve was calculated for the compound.,,CHEMBL625188,,0,1,U,22224,Autocuration,,,BAO_0000019,
7858,Canis lupus familiaris,,A,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,CHEMBL625189,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7859,Canis lupus familiaris,,A,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,CHEMBL625190,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
7860,Rattus norvegicus,,A,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,CHEMBL621733,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7861,Rattus norvegicus,,A,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,CHEMBL621734,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7862,Rattus norvegicus,,A,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,CHEMBL621735,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7863,Rattus norvegicus,,A,Clearance of the drug was measured in the plasma of rat; No data,,CHEMBL621736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7864,Rattus norvegicus,,A,The pharmacokinetic parameter plasma clearance in vivo in rats,,CHEMBL621737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7865,Rattus norvegicus,,A,Plasma clearance at the dose of 2 mg/kg in rat,,CHEMBL621738,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7866,Rattus norvegicus,,A,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL622806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7867,Rattus norvegicus,,A,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL623519,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7868,Rattus norvegicus,,A,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL623520,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7869,Rattus norvegicus,,A,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL623521,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7870,Rattus norvegicus,,A,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL623522,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7871,Rattus norvegicus,,A,Clearance rate in rat,,CHEMBL623523,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7872,Rattus norvegicus,,A,Clearance rate in rat,,CHEMBL623690,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7873,Rattus norvegicus,,A,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623691,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7874,Rattus norvegicus,,A,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623692,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7875,Rattus norvegicus,,A,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623693,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7876,Rattus norvegicus,,A,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623694,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7877,Rattus norvegicus,,A,Clearance of compound after iv administration of 20 mg/kg dose in rat,,CHEMBL623695,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7878,Rattus norvegicus,,A,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL623696,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7879,Rattus norvegicus,,A,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL623697,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7880,Macaca mulatta,,A,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL623698,9544.0,0,1,U,22224,Intermediate,,,BAO_0000218,1969.0
7881,Rattus norvegicus,,A,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,CHEMBL623699,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,1969.0
7882,Rattus norvegicus,,A,Mean (%CV) PK parameters for CL(mL/min/kg).,,CHEMBL623700,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7883,Rattus norvegicus,,A,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,CHEMBL623701,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7884,Rattus norvegicus,,A,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,CHEMBL623702,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7885,Rattus norvegicus,,A,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,CHEMBL623703,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7886,Rattus norvegicus,,A,Plasma clearance in rat was determined,,CHEMBL623704,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7887,Rattus norvegicus,,A,Plasma clearance in rat after administration of 2 mg/kg iv,,CHEMBL623705,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7888,Rattus norvegicus,,A,Plasma clearance in rat after administration of 2 mg/kg iv,,CHEMBL623706,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7889,Rattus norvegicus,,A,Plasma clearance was determined,,CHEMBL623707,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7890,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL623708,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7891,Rattus norvegicus,,A,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,CHEMBL623709,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7892,Rattus norvegicus,,A,Plasma clearance in rat by iv administration,,CHEMBL623710,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7893,Rattus norvegicus,,A,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,CHEMBL623711,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7894,Rattus norvegicus,,A,Plasma clearance in rat p.o.,,CHEMBL623712,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7895,Rattus norvegicus,,A,Plasma clearance in rats,,CHEMBL623713,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7896,Rattus norvegicus,,A,Plasma clearance was determined; ND denotes no data,,CHEMBL623714,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7897,Rattus norvegicus,,A,Plasma clearance was determined; ND denotes not determined,,CHEMBL623715,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7898,Rattus norvegicus,,A,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,CHEMBL623716,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7899,Rattus norvegicus,,A,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL622980,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7900,Rattus norvegicus,,A,Plasma administration to rats,,CHEMBL622981,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7901,Rattus norvegicus,,A,Plasma clearance of the compound in female Sprague-Dawley rats,,CHEMBL622982,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7902,Rattus norvegicus,,A,Plasma clearance was observed after intravenous administration in rat,,CHEMBL622983,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7903,Rattus norvegicus,,A,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,CHEMBL622984,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7904,Rattus norvegicus,,A,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,CHEMBL622985,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7905,Rattus norvegicus,,A,plasma clearance was observed after intravenous administration in rat,,CHEMBL623631,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7906,Rattus norvegicus,,A,In vivo CL/F determined,,CHEMBL623632,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7907,Rattus norvegicus,,A,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,CHEMBL623633,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7908,Rattus norvegicus,,A,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,CHEMBL623634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7909,Rattus norvegicus,,A,Compound was tested for the lower blood clearance in rat,,CHEMBL623635,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7910,Rattus norvegicus,,A,Evaluated for the low clearance in rat (in vivo),,CHEMBL621195,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7911,Rattus norvegicus,,A,Pharmacokinetic property (CLb)of the compound was determined in rat,,CHEMBL621196,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7912,Rattus norvegicus,,A,Rapid clearance after intravenous administration in rat was determined,,CHEMBL875287,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7913,Rattus norvegicus,,A,Clearance measured in rat,,CHEMBL621197,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7914,Rattus norvegicus,,A,Compound was evaluated for plasma clearance in rat,,CHEMBL621198,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7915,Rattus norvegicus,,A,Low plasma clearance was calculated in rat,,CHEMBL621199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7916,Rattus norvegicus,,A,Pharmacokinetic property (Clp) in rat,,CHEMBL621200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7917,Rattus norvegicus,,A,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,CHEMBL621201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7918,Rattus norvegicus,,A,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,CHEMBL621202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7919,Rattus norvegicus,,A,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,CHEMBL621203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7920,Rattus norvegicus,,A,Plasma clearance after IV dosing at 1 mg/kg in rat,,CHEMBL621204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7921,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,CHEMBL621205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7922,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7923,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,CHEMBL621207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7924,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,CHEMBL621208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7925,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL621209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7926,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,CHEMBL876484,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7927,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL621210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7928,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7929,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,CHEMBL621212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7930,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,CHEMBL621213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7931,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,CHEMBL621214,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7932,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,CHEMBL621215,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7933,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,CHEMBL621216,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7934,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,CHEMBL621217,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7935,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,CHEMBL621218,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7936,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,CHEMBL621219,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7937,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,CHEMBL621220,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7938,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL621221,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7939,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,CHEMBL621222,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7940,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL621223,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7941,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,CHEMBL876485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7942,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL621224,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7943,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,CHEMBL621225,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7944,Rattus norvegicus,,A,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,CHEMBL621226,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
7945,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7946,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL621228,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7947,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,CHEMBL621229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7948,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL621230,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7949,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,CHEMBL621231,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7950,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL621232,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7951,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL621233,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7952,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621234,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7953,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,CHEMBL621235,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7954,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL621236,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7955,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,CHEMBL621237,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7956,Rattus norvegicus,,A,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,CHEMBL876486,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
7957,Rattus norvegicus,,A,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,CHEMBL622436,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
7958,Rattus norvegicus,,A,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,CHEMBL622437,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
7959,Rattus norvegicus,,A,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,CHEMBL622438,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
7960,Rattus norvegicus,,A,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,CHEMBL622439,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7961,Rattus norvegicus,,A,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL622440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7962,Rattus norvegicus,,A,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,CHEMBL622441,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7963,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,CHEMBL622442,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7964,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,CHEMBL622443,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7965,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL622444,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7966,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,CHEMBL622445,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7967,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL622446,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7968,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL622447,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7969,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,CHEMBL622448,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7970,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,CHEMBL622449,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7971,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,CHEMBL622450,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7972,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,CHEMBL622451,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7973,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,CHEMBL622452,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7974,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,CHEMBL622453,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7975,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,CHEMBL622454,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7976,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,CHEMBL622455,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7977,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,CHEMBL876024,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
7978,Rattus norvegicus,,A,T max was determined at 3 mg/kg po dose in rats,,CHEMBL622456,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7979,Rattus norvegicus,,A,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622457,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7980,Rattus norvegicus,,A,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7981,Rattus norvegicus,,A,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,CHEMBL622459,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7982,Rattus norvegicus,,A,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,CHEMBL873343,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7983,Rattus norvegicus,,A,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,CHEMBL622460,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7984,Rattus norvegicus,,A,Time for maximum plasma concentration determined in rat,,CHEMBL622461,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7985,Rattus norvegicus,,A,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,CHEMBL622462,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7986,Rattus norvegicus,,A,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,CHEMBL622463,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7987,Rattus norvegicus,,A,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,CHEMBL622464,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7988,Rattus norvegicus,,A,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,CHEMBL622465,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7989,Rattus norvegicus,,A,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,CHEMBL622466,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7990,Rattus norvegicus,,A,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,CHEMBL622467,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7991,Rattus norvegicus,,A,Time of maximum plasma concentration in rat,,CHEMBL622468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7992,Rattus norvegicus,,A,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL876025,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7993,Rattus norvegicus,,A,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,CHEMBL622469,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7994,Rattus norvegicus,,A,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,CHEMBL622470,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7995,Rattus norvegicus,,A,Time required to reach maximum concentration (Cmax) after oral administration in rat,,CHEMBL622471,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
7996,Rattus norvegicus,,A,Time required to reach maximum concentration in rat plasma,,CHEMBL622472,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7997,Rattus norvegicus,,A,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,CHEMBL622473,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7998,Rattus norvegicus,,A,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,CHEMBL624282,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
7999,Rattus norvegicus,,A,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL624283,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8000,Rattus norvegicus,,A,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL624284,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8001,Rattus norvegicus,,A,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,CHEMBL624285,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8002,Rattus norvegicus,,A,Time to reach Cmax after oral administration to rats,,CHEMBL624286,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8003,Rattus norvegicus,,A,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,CHEMBL624287,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8004,Rattus norvegicus,,A,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,CHEMBL624288,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8005,Rattus norvegicus,,A,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,CHEMBL624289,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8006,Rattus norvegicus,,A,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,CHEMBL873344,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8007,Rattus norvegicus,,A,Tmax after peroral administration (10 mg/kg) was determined in rat,,CHEMBL619623,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8008,Rattus norvegicus,,A,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL621399,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
8009,Rattus norvegicus,,A,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL621400,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8010,Rattus norvegicus,,A,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL621401,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8011,Rattus norvegicus,,A,Tmax was determined,,CHEMBL621402,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8012,Rattus norvegicus,,A,Tmax was determined,,CHEMBL621403,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8013,Rattus norvegicus,,A,Tmax after oral administration in rat,,CHEMBL621121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8014,Rattus norvegicus,,A,Tmax after peroral administration in rats at 2.4 uM/kg,,CHEMBL872525,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8015,Rattus norvegicus,,A,Tmax in male rat,,CHEMBL621122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8016,Rattus norvegicus,,A,Tmax in rat at 10 mg/kg,,CHEMBL621123,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8017,Rattus norvegicus,,A,Tmax in rat by po administration at a dose of 40 mg/kg,,CHEMBL621124,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8018,Rattus norvegicus,,A,Tmax in rats,,CHEMBL621125,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8019,Rattus norvegicus,,A,Tmax was measured in rats after peroral administration at 5 mg/kg,,CHEMBL621126,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8020,Rattus norvegicus,,A,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,CHEMBL621127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8021,Rattus norvegicus,,A,Tmax value after administration of 20 mg/Kg oral dose in rat,,CHEMBL621128,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8022,Rattus norvegicus,,A,Tmax value at a dose of 10 mg/kg in male SD rats,,CHEMBL618263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8023,Rattus norvegicus,,A,Tmax value at a dose of 100 mg/kg in male SD rats,,CHEMBL618264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8024,Rattus norvegicus,,A,Tmax value at a dose of 50 mg/kg in male SD rats,,CHEMBL618265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8025,Rattus norvegicus,,A,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL618266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8026,Rattus norvegicus,,A,time required to reach maximum concentration (Cmax) after oral administration in rat,,CHEMBL618267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8027,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,CHEMBL618450,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
8028,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,CHEMBL618451,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
8029,Rattus norvegicus,,A,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,CHEMBL618452,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8030,Rattus norvegicus,,A,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,CHEMBL618453,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
8031,Rattus norvegicus,,A,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,CHEMBL618454,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
8032,Rattus norvegicus,,A,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,CHEMBL618455,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
8033,Rattus norvegicus,,A,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,CHEMBL618456,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8034,Rattus norvegicus,,A,Compound distribution in rat tissues was determined,,CHEMBL618457,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8035,Rattus norvegicus,,A,Volume of distribution was evaluated in rat,,CHEMBL618458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8036,Rattus norvegicus,,A,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,CHEMBL618459,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8037,Rattus norvegicus,,A,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,CHEMBL876733,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8038,Canis lupus familiaris,,A,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,CHEMBL618460,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
8039,Rattus norvegicus,,A,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,CHEMBL618461,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8040,,,A,Area under the curve was determined after oral administration (300 uM/Kg),,CHEMBL618462,,0,1,U,22224,Autocuration,,,BAO_0000019,
8041,Rattus norvegicus,,A,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,CHEMBL618463,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8042,Rattus norvegicus,,A,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,CHEMBL618464,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8043,Rattus norvegicus,,A,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,CHEMBL618465,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8044,Rattus norvegicus,,A,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,CHEMBL618466,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8045,Rattus norvegicus,,A,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,CHEMBL618467,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8046,Rattus norvegicus,,A,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,CHEMBL618468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8047,Canis lupus familiaris,,A,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,CHEMBL618469,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
8048,Canis lupus familiaris,,A,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,CHEMBL618470,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
8049,,,A,Plasma drug AUC in rat (PO dose),,CHEMBL618471,,0,1,U,22224,Autocuration,,,BAO_0000218,
8050,Mus musculus,,A,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,CHEMBL618472,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8051,,,A,Area under was determined at a dose of 30 mg/kg,,CHEMBL618473,,0,1,U,22224,Autocuration,,,BAO_0000218,
8052,Mustela putorius furo,,A,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,CHEMBL621699,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
8053,Rattus norvegicus,,A,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,CHEMBL621700,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8054,Rattus norvegicus,,A,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,CHEMBL621701,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8055,Mustela putorius furo,,A,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,CHEMBL621702,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
8056,Canis lupus familiaris,,A,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,CHEMBL621703,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
8057,Canis lupus familiaris,,A,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,CHEMBL621704,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
8058,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,CHEMBL624259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8059,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,CHEMBL624260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8060,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,CHEMBL624430,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8061,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,CHEMBL624431,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8062,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,CHEMBL624432,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8063,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,CHEMBL624433,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8064,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,CHEMBL624434,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8065,Rattus norvegicus,,A,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,CHEMBL624435,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8066,Mus musculus,,A,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,CHEMBL618570,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8067,Mus musculus,,A,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL618571,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8068,Mus musculus,,A,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,CHEMBL618572,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8069,Mus musculus,,A,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL618573,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8070,Mus musculus,,A,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,CHEMBL619267,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8071,Mus musculus,,A,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL619431,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8072,Mus musculus,,A,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,CHEMBL619432,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8073,Mus musculus,,A,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL619433,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8074,,,A,AUC in mice after oral dose (50 mg/kg),,CHEMBL619434,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
8075,Mus musculus,,A,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,CHEMBL619435,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1977.0
8076,,,A,AUC (0-4 hr) ug/ml/h,,CHEMBL619436,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
8077,Rattus norvegicus,,A,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,CHEMBL619437,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8078,,,A,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,CHEMBL619438,,0,1,U,22224,Autocuration,,,BAO_0000218,
8079,Mus musculus,,A,Compound was evaluated for Area under curve in mice,,CHEMBL619439,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8080,Rattus norvegicus,,A,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,CHEMBL619440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8081,,,F,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,CHEMBL619441,,0,1,U,22224,Autocuration,,,BAO_0000218,
8082,Rattus norvegicus,,A,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,CHEMBL619442,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8083,,,A,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,CHEMBL875156,,0,1,U,22224,Autocuration,,,BAO_0000019,
8084,,,A,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,CHEMBL619443,,0,1,U,22224,Autocuration,,,BAO_0000019,
8085,,,A,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,CHEMBL619444,,0,1,U,22224,Autocuration,,,BAO_0000019,
8086,,,A,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,CHEMBL623464,,0,1,U,22224,Autocuration,,,BAO_0000019,
8087,Mus musculus,,A,Compound was evaluated for area under curve when administered through oral route in mouse,,CHEMBL623465,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8088,Rattus norvegicus,,A,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,CHEMBL623466,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8089,Rattus norvegicus,,A,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,CHEMBL623467,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8090,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL623468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8091,Rattus norvegicus,,A,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,CHEMBL622660,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8092,Rattus norvegicus,,A,Plasma clearance rate in Sprague-Dawley rats,,CHEMBL622661,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8093,Rattus norvegicus,,F,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL622662,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8094,Rattus norvegicus,,A,Pharmacokinetic property (total body clearance) in rat,,CHEMBL622663,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8095,Rattus norvegicus,,A,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,CHEMBL622664,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8096,Rattus norvegicus,,A,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,CHEMBL622665,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8097,Rattus norvegicus,,A,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,CHEMBL622666,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8098,Rattus norvegicus,,A,Cl in rat i.v. at 2 mg/kg concentration,,CHEMBL621615,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8099,Rattus norvegicus,,A,Clearance of compound after intravenous administration in rats at 24 uM/kg,,CHEMBL621616,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8100,Rattus norvegicus,,A,Clearance was determined,,CHEMBL621617,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8101,Rattus norvegicus,,A,Clearance by intravenous administration of 3.4 mg/kg in rat,,CHEMBL621618,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8102,Rattus norvegicus,,A,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,CHEMBL621619,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8103,Rattus norvegicus,,A,Clearance rate after i.v. administration in rats,,CHEMBL621620,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8104,Rattus norvegicus,,A,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL621786,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8105,Rattus norvegicus,,A,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,CHEMBL621787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8106,Rattus norvegicus,,A,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,CHEMBL621788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8107,Rattus norvegicus,,A,Clearance (Cl) after oral administration in rat,,CHEMBL621789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8108,Rattus norvegicus,,A,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,CHEMBL621790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8109,Rattus norvegicus,,A,Compound was tested for plasma clearance in rat,,CHEMBL621791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8110,Rattus norvegicus,,A,In vitro microsome metabolism clearance in rat was determined,,CHEMBL621792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8111,Rattus norvegicus,,A,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,CHEMBL621793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8112,Rattus norvegicus,,A,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL621794,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8113,Rattus norvegicus,,A,In vivo plasma clearance was determined,,CHEMBL621795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8114,Rattus norvegicus,,A,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,CHEMBL621796,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8115,Rattus norvegicus,,A,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,CHEMBL621797,10116.0,1,1,N,50597,Intermediate,,401.0,BAO_0000218,2107.0
8116,Rattus norvegicus,,A,Pharmacokinetic property (Plasma clearance) was measured in rat,,CHEMBL621798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8117,Rattus norvegicus,,A,Pharmacokinetic property (clearance) in rat i.v.,,CHEMBL621799,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8118,Rattus norvegicus,,A,"Plasma Clearance was evaluated in rats, iv",,CHEMBL621800,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8119,Rattus norvegicus,,A,Plasma clearance (in vivo) in rats was determined,,CHEMBL621801,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8120,Rattus norvegicus,,A,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,CHEMBL621802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8121,Rattus norvegicus,,A,Plasma clearance was determined,,CHEMBL618596,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8122,Rattus norvegicus,,A,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,CHEMBL618597,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8123,Rattus norvegicus,,A,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,CHEMBL618598,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8124,Rattus norvegicus,,A,Plasma clearance in rats,,CHEMBL618599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8125,Rattus norvegicus,,A,Plasma clearance rate determined in rat,,CHEMBL618600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8126,Rattus norvegicus,,A,Plasma clearance was determined in rat,,CHEMBL618601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8127,Rattus norvegicus,,A,Plasma clearance was determined,,CHEMBL618602,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8128,Rattus norvegicus,,A,Plasma clearance value in rat,,CHEMBL618603,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8129,Rattus norvegicus,,A,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,CHEMBL618604,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8130,Rattus norvegicus,,A,Clearance in rat,,CHEMBL618605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8131,Rattus norvegicus,,A,Total body clearance in rat i.v. at 2 mg/kg concentration,,CHEMBL618606,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8132,Rattus norvegicus,,A,Clearance of compound in rats after intravenous administration,,CHEMBL618607,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8133,Rattus norvegicus,,A,Clearance after iv administration to rats,,CHEMBL618608,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8134,Rattus norvegicus,,A,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,CHEMBL618609,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8135,Rattus norvegicus,,A,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,CHEMBL618610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8136,Rattus norvegicus,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,CHEMBL618611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8137,Rattus norvegicus,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,CHEMBL618612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8138,Rattus norvegicus,,A,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,CHEMBL618613,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8139,Rattus norvegicus,,A,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,CHEMBL621076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8140,Rattus norvegicus,,A,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,CHEMBL621077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8141,Rattus norvegicus,,A,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL621078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8142,Rattus norvegicus,,A,Clearance in rat,,CHEMBL621251,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8143,Rattus norvegicus,,A,Clearance in rat after oral administration at 10 mg/kg,,CHEMBL621252,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8144,Rattus norvegicus,,A,Clearance in rat.,,CHEMBL621253,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8145,Rattus norvegicus,,A,Clearance rate following an oral dose of 20 mg/kg in rats,,CHEMBL621254,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8146,Rattus norvegicus,,A,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,CHEMBL621255,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8147,Rattus norvegicus,,A,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,CHEMBL621256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8148,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,CHEMBL621257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8149,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,CHEMBL621258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8150,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,CHEMBL621259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8151,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,CHEMBL621260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8152,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL876494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8153,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,CHEMBL621261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8154,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL621262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8155,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL621263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8156,Rattus norvegicus,,A,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,CHEMBL621264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8157,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8158,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL621266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8159,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,CHEMBL621267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8160,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8161,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,CHEMBL621269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8162,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,CHEMBL621270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8163,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,CHEMBL621271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8164,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,CHEMBL621272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8165,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL621273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8166,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL621274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8167,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,CHEMBL876495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8168,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,CHEMBL621275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8169,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,CHEMBL621276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8170,Rattus norvegicus,,A,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,CHEMBL621277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8171,Rattus norvegicus,,A,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,CHEMBL621278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8172,Rattus norvegicus,,A,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,CHEMBL621279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8173,Rattus norvegicus,,A,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,CHEMBL621280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8174,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621281,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8175,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,CHEMBL621282,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8176,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,CHEMBL621283,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8177,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621284,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8178,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,CHEMBL621285,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8179,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,CHEMBL621286,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8180,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,CHEMBL623220,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8181,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,CHEMBL623221,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8182,Rattus norvegicus,,A,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,CHEMBL876029,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8183,Rattus norvegicus,,A,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,CHEMBL623222,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8184,Rattus norvegicus,,A,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,CHEMBL623223,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8185,Rattus norvegicus,,A,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,CHEMBL621445,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8186,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621446,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8187,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621447,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8188,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619681,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8189,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619682,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8190,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619683,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8191,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619684,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8192,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619685,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8193,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619686,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8194,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619687,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8195,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619688,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8196,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619689,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8197,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619690,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8198,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619691,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8199,Rattus norvegicus,,A,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,CHEMBL619692,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8200,Rattus norvegicus,,A,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL619693,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
8201,Rattus norvegicus,,A,Vc value after IV dose at a dose of 5 mg/kg in rats.,,CHEMBL619694,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8202,Rattus norvegicus,,A,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,CHEMBL619695,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8203,Rattus norvegicus,,A,Compound was evaluated for pharmacokinetic parameter volume of distribution,,CHEMBL619696,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8204,Rattus norvegicus,,A,Compound was evaluated for volume of distribution in rat,,CHEMBL619697,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8205,Rattus norvegicus,,A,Steady state volume distribution was determined; steady state(ss),,CHEMBL619698,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8206,Rattus norvegicus,,A,Steady state volume of distribution after iv administration to rats,,CHEMBL619699,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8207,Rattus norvegicus,,A,Steady state volume of distribution dosing at 3 mg/kg iv,,CHEMBL619700,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8208,Rattus norvegicus,,A,The compound was evaluated for volume of distribution in rat,,CHEMBL619701,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8209,Rattus norvegicus,,A,The compound was tested for volume of distribution in rat,,CHEMBL619702,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8210,Rattus norvegicus,,A,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,CHEMBL620335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8211,Rattus norvegicus,,A,Volume distribution (VD) after oral administration in rat,,CHEMBL620336,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8212,Rattus norvegicus,,A,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL620337,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8213,Rattus norvegicus,,A,Volume distribution in rat,,CHEMBL620520,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8214,Rattus norvegicus,,A,Volume distribution in rat,,CHEMBL620521,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8215,Rattus norvegicus,,A,Volume distribution in rat after peroral administration at 10 mg/kg,,CHEMBL875825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8216,Rattus norvegicus,,A,Volume distribution in rat after peroral administration at 5 mg/kg,,CHEMBL620522,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8217,Rattus norvegicus,,A,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,CHEMBL620523,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8218,Rattus norvegicus,,A,Volume of distribution in rat.,,CHEMBL620524,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8219,Rattus norvegicus,,A,Volume of distribution in rat,,CHEMBL620525,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8220,Rattus norvegicus,,A,Volume of distribution in rat,,CHEMBL620526,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8221,Rattus norvegicus,,A,Volume of distribution in rat by iv administration,,CHEMBL620527,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8222,Rattus norvegicus,,A,Volume of distribution in rats,,CHEMBL620528,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8223,Rattus norvegicus,,A,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL620529,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8224,Rattus norvegicus,,A,Volume distribution at the dose of 2 mg/kg in rat,,CHEMBL620530,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8225,Rattus norvegicus,,A,Steady state volume of distribution was determined,,CHEMBL620531,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8226,Macaca mulatta,,A,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL620532,9544.0,0,1,U,22224,Intermediate,,,BAO_0000218,
8227,Rattus norvegicus,,A,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,CHEMBL620533,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
8228,Rattus norvegicus,,A,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,CHEMBL620534,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
8229,Rattus norvegicus,,A,Mean (%CV) PK parameters for Vdss(mL/kg).,,CHEMBL620535,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8230,Rattus norvegicus,,A,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,CHEMBL875826,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8231,Rattus norvegicus,,A,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,CHEMBL620536,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8232,Rattus norvegicus,,A,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,CHEMBL620537,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8233,Rattus norvegicus,,A,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,CHEMBL618526,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8234,Rattus norvegicus,,A,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,CHEMBL618527,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8235,Rattus norvegicus,,A,Pharmacokinetic property (Vdss) in rat,,CHEMBL618528,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8236,Rattus norvegicus,,A,Pharmacokinetic property (vdss) was measured in rat,,CHEMBL618529,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8237,Rattus norvegicus,,A,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,CHEMBL618530,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8238,Rattus norvegicus,,A,Volume of distribution in rat,,CHEMBL618531,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8239,Rattus norvegicus,,A,The pharmacokinetic parameter volume of distribution in vivo in rats,,CHEMBL618532,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8240,Rattus norvegicus,,F,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL618533,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8241,Rattus norvegicus,,A,Vdss in rat i.v. at 2 mg/kg concentration,,CHEMBL618534,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8242,Rattus norvegicus,,A,Volume distribution after intravenous administration (1 mg/kg) in rat,,CHEMBL618535,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8243,Rattus norvegicus,,A,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL618536,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8244,Rattus norvegicus,,A,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL618537,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8245,Rattus norvegicus,,A,Volume distribution at a dose of 10 uM/kg in rat was determined,,CHEMBL618538,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8246,Rattus norvegicus,,A,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL618539,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8247,Rattus norvegicus,,A,Volume distribution was calculated in rat,,CHEMBL618540,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8248,Rattus norvegicus,,A,Volume distribution was determined,,CHEMBL618541,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8249,Rattus norvegicus,,A,Volume of distribution after intravenous administration was evaluated in rat,,CHEMBL618542,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8250,Rattus norvegicus,,A,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL622544,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8251,Rattus norvegicus,,A,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,CHEMBL622545,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8252,Rattus norvegicus,,A,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,CHEMBL622546,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8253,Rattus norvegicus,,A,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL622547,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8254,Rattus norvegicus,,A,Volume of distribution in steady state was determined in rat,,CHEMBL622548,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8255,Rattus norvegicus,,A,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,CHEMBL622549,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8256,Rattus norvegicus,,A,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,CHEMBL622550,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8257,Mus musculus,,A,Compound was evaluated for area under curve when administered through oral route to mouse,,CHEMBL622551,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8258,Rattus norvegicus,,A,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,CHEMBL622552,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8259,Rattus norvegicus,,A,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,CHEMBL622553,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8260,,,F,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,CHEMBL622554,,0,1,U,22224,Autocuration,,,BAO_0000218,
8261,Canis lupus familiaris,,A,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,CHEMBL622555,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
8262,Mus musculus,,A,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,CHEMBL622556,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8263,Mus musculus,,A,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,CHEMBL622557,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8264,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,CHEMBL622558,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8265,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,CHEMBL622559,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8266,Canis lupus familiaris,,A,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,CHEMBL622560,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
8267,Rattus norvegicus,,A,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,CHEMBL622561,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8268,Rattus norvegicus,,A,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,CHEMBL622562,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8269,Rattus norvegicus,,A,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,CHEMBL622563,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8270,,,A,Concentration of compound in Central nervous system,,CHEMBL622564,,0,1,U,22224,Autocuration,,,BAO_0000019,
8271,,,A,Concentration of compound in Central nervous system; Not detectable,,CHEMBL622565,,0,1,U,22224,Autocuration,,,BAO_0000019,
8272,Mus musculus,,A,"Concentration of diester in the blood, following oral administration in mice",,CHEMBL622566,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8273,Mus musculus,,A,"Concentration of monoester in the blood, following oral administration in mice",,CHEMBL624515,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8274,Mus musculus,,A,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,CHEMBL624516,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8275,,,A,Evaluated for Pharmacokinetic property: Area under the curve,,CHEMBL624517,,0,1,U,22224,Autocuration,,,BAO_0000019,
8276,Mus musculus,,A,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,CHEMBL624518,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8277,Macaca fascicularis,,A,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,CHEMBL624519,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8278,Macaca fascicularis,,A,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,CHEMBL624520,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8279,Macaca fascicularis,,A,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,CHEMBL624521,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8280,Macaca fascicularis,,A,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,CHEMBL624522,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8281,Macaca fascicularis,,A,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL624523,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8282,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL624409,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8283,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,CHEMBL624410,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8284,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL624411,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8285,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,CHEMBL623531,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8286,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL623532,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8287,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,CHEMBL623533,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8288,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL623534,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
8289,Mus musculus,,A,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623535,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8290,Mus musculus,,A,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623536,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8291,Mus musculus,,A,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623537,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8292,Mus musculus,,A,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623538,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8293,Mus musculus,,A,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,CHEMBL623539,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8294,Mus musculus,,A,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623540,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8295,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,CHEMBL623541,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8296,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,CHEMBL623542,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8297,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,CHEMBL623543,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8298,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,CHEMBL623544,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8299,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,CHEMBL623545,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8300,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,CHEMBL623546,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8301,Rattus norvegicus,,A,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,CHEMBL623547,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8302,Rattus norvegicus,,A,High i.v. clearance in Dawley rats,,CHEMBL623548,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8303,Rattus norvegicus,,A,In vitro clearance in rat liver microsomes,,CHEMBL623549,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8304,Rattus norvegicus,,A,Intrinsic clearance in rat liver microsomes was determined,,CHEMBL623550,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8305,Rattus norvegicus,,A,Intrinsic clearance in rat hepatocytes was determined,,CHEMBL875276,10116.0,1,1,N,50597,Intermediate,,401.0,BAO_0000218,2107.0
8306,Rattus norvegicus,,A,Plasma Clearance was determined,,CHEMBL621872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8307,Rattus norvegicus,,A,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,CHEMBL621873,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8308,Rattus norvegicus,,A,Plasma clearance in rat.,,CHEMBL621874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8309,Rattus norvegicus,,A,Plasma clearance in rats,,CHEMBL621875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8310,Rattus norvegicus,,A,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,CHEMBL621876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8311,Rattus norvegicus,,A,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL621877,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8312,Rattus norvegicus,,A,Plasma clearance was measured in rat,,CHEMBL621878,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8313,Rattus norvegicus,,A,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,CHEMBL621879,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8314,Rattus norvegicus,,A,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,CHEMBL621880,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8315,Rattus norvegicus,,A,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,CHEMBL621881,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8316,Rattus norvegicus,,A,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL621882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8317,Rattus norvegicus,,A,Total clearance at 1 mg/kg was determined in rat,,CHEMBL875283,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8318,Rattus norvegicus,,A,Total clearance at 10 mg/kg was determined in rat,,CHEMBL621883,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8319,Rattus norvegicus,,A,Clearance in rat,,CHEMBL621884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8320,Rattus norvegicus,,A,Plasma clearance rate determined in rats,,CHEMBL621885,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8321,Rattus norvegicus,,A,Clearance of compound in rat was evaluated,,CHEMBL621886,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8322,Rattus norvegicus,,A,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,CHEMBL621887,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8323,Rattus norvegicus,,A,Pharmacokinetic property (blood clearance) in rat,,CHEMBL621888,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8324,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL621889,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8325,Rattus norvegicus,,A,Plasma clearance in rats,,CHEMBL621890,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8326,Rattus norvegicus,,A,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,CHEMBL621891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8327,Rattus norvegicus,,A,Clearance in Dawley rat,,CHEMBL621892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8328,Rattus norvegicus,,A,Clearance rat,,CHEMBL621893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8329,Rattus norvegicus,,A,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,CHEMBL621894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8330,Rattus norvegicus,,A,Clearance rat; Not determined,,CHEMBL621895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8331,Rattus norvegicus,,A,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,CHEMBL875284,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8332,Rattus norvegicus,,A,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,CHEMBL618699,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8333,Rattus norvegicus,,A,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,CHEMBL618700,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8334,Rattus norvegicus,,A,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL618701,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8335,Rattus norvegicus,,A,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,CHEMBL876600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8336,Rattus norvegicus,,A,Clearance of compound in rat after 1 mg/kg i.v. administration,,CHEMBL618702,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8337,Rattus norvegicus,,A,Compound was evaluated for Hepatic clearance in rat,,CHEMBL618703,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8338,Rattus norvegicus,,A,In vivo clearance after 5 mg/kg dose,,CHEMBL618704,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8339,Rattus norvegicus,,A,Compound was tested for plasma clearance in rats,,CHEMBL618705,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8340,Rattus norvegicus,,A,Hepatic clearance after intravenous administration was evaluated in rat,,CHEMBL618706,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8341,Rattus norvegicus,,A,Lower clearance in rat (i.v.) at 0.5 mpk,,CHEMBL618707,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8342,Rattus norvegicus,,A,Pharmacokinetic parameter expressed as plasma clearance in rat,,CHEMBL618708,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8343,Rattus norvegicus,,A,Pharmacokinetic property (Clp) in rat,,CHEMBL618709,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8344,Rattus norvegicus,,A,Plasma clearance in Sprague-Dawley rats,,CHEMBL618710,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8345,Rattus norvegicus,,A,Plasma clearance (Clp) in rat,,CHEMBL618711,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8346,Rattus norvegicus,,A,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,CHEMBL618712,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8347,Rattus norvegicus,,A,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,CHEMBL618713,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8348,Rattus norvegicus,,A,Plasma clearance after intravenous administration of 1 mg/kg in rat,,CHEMBL618714,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8349,Rattus norvegicus,,A,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL618715,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8350,Rattus norvegicus,,A,Plasma clearance in rat was determined,,CHEMBL618716,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8351,Rattus norvegicus,,A,Plasma clearance measured in rat,,CHEMBL876601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8352,Rattus norvegicus,,A,Plasma clearance was calculated in rat,,CHEMBL618717,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8353,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL618718,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8354,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL618719,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8355,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL618720,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8356,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL618721,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8357,Rattus norvegicus,,A,Plasma clearance in rats,,CHEMBL621477,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8358,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL621478,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8359,Rattus norvegicus,,A,Plasma clearance was evaluated in rat,,CHEMBL621479,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8360,Rattus norvegicus,,A,Plasma clearance was evaluated in rat; Not tested,,CHEMBL621480,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8361,Rattus norvegicus,,A,Plasma clearance rate was determined for the compound in rat,,CHEMBL621481,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8362,Rattus norvegicus,,A,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,CHEMBL621482,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8363,Rattus norvegicus,,A,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,CHEMBL621483,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8364,Rattus norvegicus,,A,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL621484,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8365,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8366,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621486,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8367,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621487,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8368,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621488,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8369,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8370,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8371,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621491,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
8372,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8373,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,CHEMBL621493,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8374,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8375,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8376,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8377,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8378,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621498,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8379,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621499,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8380,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,CHEMBL618634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8381,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL618635,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8382,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL618636,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8383,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8384,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619738,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8385,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8386,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8387,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8388,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8389,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8390,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8391,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8392,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620016,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8393,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620169,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8394,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620170,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8395,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,CHEMBL620171,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8396,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620172,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
8397,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620173,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8398,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,CHEMBL620174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8399,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620175,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8400,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620176,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8401,Rattus norvegicus,,A,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620177,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
8402,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620178,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8403,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620179,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8404,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620180,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8405,Rattus norvegicus,,A,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,CHEMBL620181,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8406,Rattus norvegicus,,A,Volume of distribution of compound in rats after intravenous administration,,CHEMBL620182,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8407,Rattus norvegicus,,A,Volume of distribution in rat,,CHEMBL620183,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8408,Rattus norvegicus,,A,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,CHEMBL620184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8409,Rattus norvegicus,,A,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,CHEMBL620185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8410,Rattus norvegicus,,A,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,CHEMBL620186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8411,Rattus norvegicus,,A,Volume of distribution was determined in Dawley rat,,CHEMBL620187,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8412,Rattus norvegicus,,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,CHEMBL620188,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8413,Rattus norvegicus,,A,Volume of distribution was reported in Sprague-Dawley rat,,CHEMBL620189,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8414,Rattus norvegicus,,A,Volumes of distribution in rat after peroral administration,,CHEMBL620190,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8415,Rattus norvegicus,,A,Volumes of distribution in rat after po administration,,CHEMBL620191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8416,Rattus norvegicus,,A,Volumes of distribution in rat after po administration; Not determined,,CHEMBL620192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8417,Rattus norvegicus,,A,Pharmacokinetic property (Volume) in rat i.v.,,CHEMBL620193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8418,Rattus norvegicus,,A,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,CHEMBL620194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8419,Rattus norvegicus,,A,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL876730,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8420,Rattus norvegicus,,A,Volume distribution in rat after oral administration at 10 mg/kg,,CHEMBL620195,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8421,Rattus norvegicus,,A,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,CHEMBL620196,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8422,Rattus norvegicus,,A,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,CHEMBL620197,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8423,Rattus norvegicus,,A,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,CHEMBL620198,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8424,Rattus norvegicus,,A,Volume of distribution in rats,,CHEMBL620199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8425,Rattus norvegicus,,A,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL620200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8426,Rattus norvegicus,,A,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL620201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8427,Rattus norvegicus,,A,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL620202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8428,Rattus norvegicus,,A,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL620203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8429,Rattus norvegicus,,A,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,CHEMBL620204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8430,Rattus norvegicus,,A,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL620205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8431,Rattus norvegicus,,A,Pharmacokinetic parameter (Vss) in rat,,CHEMBL624664,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8432,Rattus norvegicus,,A,Pharmacokinetic property (Volume) in rat i.v.,,CHEMBL624665,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8433,Rattus norvegicus,,A,Pharmacokinetic property (Vss) in rat,,CHEMBL624666,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8434,Rattus norvegicus,,A,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,CHEMBL624667,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8435,Rattus norvegicus,,A,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,CHEMBL624668,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8436,Rattus norvegicus,,A,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL624669,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8437,Rattus norvegicus,,A,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL624670,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8438,Rattus norvegicus,,A,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL624671,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8439,Rattus norvegicus,,A,Steady state volume distribution in rat,,CHEMBL624672,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8440,Rattus norvegicus,,A,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,CHEMBL624673,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8441,Rattus norvegicus,,A,Steady state volume of distribution determined in rat,,CHEMBL624674,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8442,Rattus norvegicus,,A,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL624675,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8443,Rattus norvegicus,,A,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,CHEMBL621728,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8444,Rattus norvegicus,,A,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,CHEMBL621729,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8445,Rattus norvegicus,,A,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,CHEMBL621730,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8446,Rattus norvegicus,,A,Volume distribution in rat after administration of 2 mg/kg iv,,CHEMBL621731,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8447,Rattus norvegicus,,A,Volume distribution in rat after administration of 2 mg/kg iv,,CHEMBL621732,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8448,Rattus norvegicus,,A,Volume in steady state distribution value was determined,,CHEMBL621908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8449,Rattus norvegicus,,A,Volume in steady state distribution value was determined; ND denotes no data,,CHEMBL875347,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8450,Rattus norvegicus,,A,Volume in steady state distribution value was determined; ND denotes not determined,,CHEMBL621909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8451,Rattus norvegicus,,A,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL621910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8452,Rattus norvegicus,,A,Volume of distribution at steady state was evaluated in rats,,CHEMBL621911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8453,Rattus norvegicus,,A,Volume of distribution at steady state was observed after intravenous administration in rat,,CHEMBL621912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8454,Rattus norvegicus,,A,Volume of distribution in steady state was determined in rat,,CHEMBL621913,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8455,Rattus norvegicus,,A,Volume of distribution in steady state was determined in rat,,CHEMBL621914,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8456,Rattus norvegicus,,A,Volume of distribution after i.v. administration,,CHEMBL621915,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8457,Rattus norvegicus,,A,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,CHEMBL621916,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8458,Mus musculus,,A,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL621917,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8459,Mus musculus,,A,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL621918,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8460,Mus musculus,,A,Biodistribution of compound (oxidized form) in spleen tissue,,CHEMBL621919,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8461,Mus musculus,,A,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL621920,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8462,Mus musculus,,A,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL621921,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8463,Mus musculus,,A,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622401,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8464,Mus musculus,,A,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL875348,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8465,Mus musculus,,A,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL622402,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8466,Mus musculus,,A,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,CHEMBL622403,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8467,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622404,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8468,Mus musculus,,A,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,CHEMBL622405,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8469,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,CHEMBL622406,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8470,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622407,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8471,Mus musculus,,A,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,CHEMBL622408,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8472,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,CHEMBL622409,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8473,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622410,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8474,Mus musculus,,A,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,CHEMBL622411,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8475,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,CHEMBL627864,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8476,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL627865,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8477,Mus musculus,,A,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,CHEMBL627866,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8478,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL627751,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8479,Mus musculus,,A,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,CHEMBL627752,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8480,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,CHEMBL627753,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8481,Mus musculus,,A,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL627754,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8482,Mus musculus,,A,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,CHEMBL627755,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8483,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL627756,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8484,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627757,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8485,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627758,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8486,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627759,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8487,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627760,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8488,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627761,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8489,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL876811,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8490,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627762,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8491,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627763,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8492,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627764,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8493,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627765,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8494,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627766,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
8495,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL627767,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8496,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627768,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8497,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL628422,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8498,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL628423,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8499,Rattus norvegicus,,A,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,CHEMBL628424,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8500,Rattus norvegicus,,A,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,CHEMBL628425,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8501,Rattus norvegicus,,A,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,CHEMBL628426,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8502,Rattus norvegicus,,A,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL628427,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8503,Rattus norvegicus,,A,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,CHEMBL626938,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8504,Rattus norvegicus,,A,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,CHEMBL626939,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8505,Rattus norvegicus,,A,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,CHEMBL626940,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8506,Rattus norvegicus,,A,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,CHEMBL626941,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8507,Rattus norvegicus,,A,Plasma clearance was reported in Sprague-Dawley rat,,CHEMBL626942,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8508,Rattus norvegicus,,A,Plasma clearance after intravenous administration (1 mg/kg) in rat,,CHEMBL876812,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8509,Rattus norvegicus,,A,Plasma clearance of compound in rats was evaluated,,CHEMBL626943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8510,Rattus norvegicus,,A,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,CHEMBL626944,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8511,Rattus norvegicus,,A,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,CHEMBL626945,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8512,Rattus norvegicus,,A,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,CHEMBL626946,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8513,Rattus norvegicus,,A,Plasma clearance rate in Sprague-Dawley rats,,CHEMBL626856,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8514,Rattus norvegicus,,A,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,CHEMBL626857,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8515,Rattus norvegicus,,A,The compound was evaluated for plasma clearance in rat,,CHEMBL626858,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8516,Rattus norvegicus,,A,Total plasma clearance in rat,,CHEMBL627018,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8517,Rattus norvegicus,,A,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,CHEMBL625331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8518,Rattus norvegicus,,A,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,CHEMBL625332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8519,Rattus norvegicus,,A,C max was determined at 10 mg/kg po dose in rats,,CHEMBL877590,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8520,Rattus norvegicus,,A,C max was determined at 3 mg/kg po dose in rats,,CHEMBL625333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8521,Rattus norvegicus,,A,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,CHEMBL625334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8522,Rattus norvegicus,,A,Cmax after single intravenous bolus of 1 mg/kg in rats,,CHEMBL625335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8523,Rattus norvegicus,,A,Cmax of compound at 5 mg/kg after po administration was determined in rat,,CHEMBL625336,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8524,Rattus norvegicus,,A,Cmax 24 hr after 10 mg/kg oral administration in rats,,CHEMBL625337,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8525,Rattus norvegicus,,A,Cmax 24 hr after 2 mg/kg oral administration in rats,,CHEMBL625338,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8526,Rattus norvegicus,,A,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL625339,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8527,Rattus norvegicus,,A,Cmax in rat after administration of 2 mg/kg iv,,CHEMBL625340,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8528,Rattus norvegicus,,A,Cmax in rat after administration of 2 mg/kg iv,,CHEMBL625341,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8529,Rattus norvegicus,,A,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,CHEMBL622687,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8530,Rattus norvegicus,,A,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,CHEMBL622688,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8531,Rattus norvegicus,,A,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,CHEMBL622689,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8532,Rattus norvegicus,,A,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,CHEMBL620295,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8533,Rattus norvegicus,,A,Cmax after 10 mg/kg oral administration in rat,,CHEMBL620296,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8534,Rattus norvegicus,,A,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,CHEMBL620297,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8535,Rattus norvegicus,,A,Cmax after IV dosing at 1 mg/kg in rat; no data,,CHEMBL620298,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8536,Rattus norvegicus,,A,Cmax after oral administration at 20 mpk in rats,,CHEMBL620299,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8537,Rattus norvegicus,,A,Cmax after oral administration at 20 mpk in rats; Not performed.,,CHEMBL620300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8538,Rattus norvegicus,,A,Cmax after oral administration at 20 mpk in rats d; Not performed.,,CHEMBL620301,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8539,Rattus norvegicus,,A,Cmax after oral administration in rat,,CHEMBL620302,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8540,Rattus norvegicus,,A,Cmax after oral administration at a dose of 2 mg/kg in rat,,CHEMBL620303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8541,Rattus norvegicus,,A,Cmax after oral administration at a dose of 4 mg/kg in rat,,CHEMBL620304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8542,Rattus norvegicus,,A,Cmax in rats after 20 mg/kg oral dose,,CHEMBL620305,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8543,Rattus norvegicus,,A,Cmax after peroral administration in rats at 2.4 uM/kg,,CHEMBL620306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8544,Rattus norvegicus,,A,Cmax at the dose of 2 mg/Kg administered perorally in rats,,CHEMBL620307,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8545,Rattus norvegicus,,A,Cmax at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL620308,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8546,Rattus norvegicus,,A,Cmax by administering at 20 mg/kg p.o. in rats,,CHEMBL620309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8547,Rattus norvegicus,,A,Cmax in male rat,,CHEMBL620310,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8548,Rattus norvegicus,,A,Cmax in rat,,CHEMBL620311,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8549,Rattus norvegicus,,A,Cmax in rat,,CHEMBL620312,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8550,Rattus norvegicus,,A,Cmax in rat,,CHEMBL620313,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8551,Rattus norvegicus,,A,Cmax in rat at 10 mg/kg,,CHEMBL620314,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8552,Rattus norvegicus,,A,Cmax in rat at the dose of 1 mg/kg i.v.,,CHEMBL620315,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8553,Rattus norvegicus,,A,Cmax in rat by po administration at a dose of 40 mg/kg,,CHEMBL620316,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8554,Rattus norvegicus,,A,Cmax in rat p.o. at 20 mg/kg concentration,,CHEMBL620317,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8555,Rattus norvegicus,,A,Cmax in rats,,CHEMBL620318,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8556,Rattus norvegicus,,A,Cmax in rats,,CHEMBL620319,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8557,Rattus norvegicus,,A,Cmax was evaluated after 20 uM/kg of peroral administration,,CHEMBL620320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8558,Rattus norvegicus,,A,Cmax was measured in rats after peroral administration at 3 mg/kg,,CHEMBL620321,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8559,Rattus norvegicus,,A,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,CHEMBL620322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8560,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8561,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1870.0
8562,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620325,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1870.0
8563,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620326,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
8564,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
8565,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8566,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8567,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1891.0
8568,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL875286,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1891.0
8569,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8570,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8571,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8572,Rattus norvegicus,,A,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8573,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL621015,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8574,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL621016,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8575,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL621191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8576,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL621192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8577,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL621193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8578,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL621194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8579,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL624204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8580,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL624205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8581,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL624206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8582,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL624207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8583,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL624208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8584,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL624209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8585,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL624210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8586,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL624211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8587,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL624212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8588,Rattus norvegicus,,A,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL624213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8589,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL876611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8590,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL624214,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8591,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL624215,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8592,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL624216,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8593,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL624217,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8594,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL624218,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8595,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL624219,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8596,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL624220,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8597,Rattus norvegicus,,A,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL624221,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8598,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL624222,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8599,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL624223,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8600,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL624224,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8601,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL624225,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8602,Rattus norvegicus,,A,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,CHEMBL622420,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8603,Rattus norvegicus,,A,Volume of steady state distribution after i.v. administration in rats,,CHEMBL622421,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8604,Rattus norvegicus,,A,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,CHEMBL622422,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8605,Rattus norvegicus,,A,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL622423,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8606,Rattus norvegicus,,A,Vss was determined,,CHEMBL622424,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8607,Rattus norvegicus,,A,Vss in rat,,CHEMBL622425,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8608,Rattus norvegicus,,A,Vss was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL876612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8609,Rattus norvegicus,,A,volume of distribution at steady state was observed after intravenous administration in rat,,CHEMBL622426,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8610,Rattus norvegicus,,A,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,CHEMBL622427,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8611,Rattus norvegicus,,A,Pharmacokinetic (PK) parameter Vz in rat,,CHEMBL622428,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8612,Rattus norvegicus,,A,Volume distribution in rats,,CHEMBL622429,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8613,Rattus norvegicus,,A,Volume of distribution in rat; No data,,CHEMBL622430,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8614,Rattus norvegicus,,A,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL622431,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8615,Rattus norvegicus,,A,% absorption predicted from in vitro rat ileum transport studies,,CHEMBL622432,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2116.0
8616,Rattus norvegicus,,A,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,CHEMBL622433,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8617,Rattus norvegicus,,A,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,CHEMBL622434,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8618,Rattus norvegicus,,A,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,CHEMBL622435,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8619,Rattus norvegicus,,A,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,CHEMBL618748,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8620,Rattus norvegicus,,A,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,CHEMBL618749,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8621,Rattus norvegicus,,A,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,CHEMBL618750,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8622,Rattus norvegicus,,A,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,CHEMBL618751,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8623,Rattus norvegicus,,A,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,CHEMBL618752,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8624,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618753,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8625,Rattus norvegicus,,A,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,CHEMBL618754,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8626,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618755,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8627,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618756,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8628,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618757,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8629,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL618758,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8630,Rattus norvegicus,,A,Oral bioavailability in rat (dose 30 mg/kg),,CHEMBL621088,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8631,Rattus norvegicus,,A,Pharmacokinetic property (cLogP) in rat,,CHEMBL621089,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8632,Rattus norvegicus,,F,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,CHEMBL621090,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8633,Rattus norvegicus,,F,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,CHEMBL621091,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8634,Rattus norvegicus,,A,Clearance in rat.,,CHEMBL876731,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8635,Rattus norvegicus,,A,Compound was evaluated for its clearance when administered intravenously in rat,,CHEMBL621092,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8636,Rattus norvegicus,,A,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL621093,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8637,Rattus norvegicus,,A,Blood: Brain distribution ratio is determined in rat,,CHEMBL621094,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8638,Rattus norvegicus,,A,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,CHEMBL621095,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8639,Rattus norvegicus,,A,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,CHEMBL621096,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8640,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL621097,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8641,Rattus norvegicus,,F,Percent dose excreted in 0-48 hours administered ip to male rat,,CHEMBL621098,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8642,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621099,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8643,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621100,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8644,Rattus norvegicus,,A,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL621101,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8645,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621102,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8646,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL876732,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
8647,Rattus norvegicus,,A,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621103,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8648,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621104,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8649,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL621105,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8650,Rattus norvegicus,,A,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621106,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8651,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621107,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8652,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621108,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8653,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621109,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8654,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL621110,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8655,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL621111,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
8656,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL622541,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8657,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL622542,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8658,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL622543,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8659,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624412,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8660,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624413,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8661,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624414,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
8662,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL624415,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
8663,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624416,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
8664,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624417,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
8665,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624418,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
8666,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624419,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
8667,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624420,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
8668,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,CHEMBL624421,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
8669,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624422,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
8670,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624423,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
8671,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL625123,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
8672,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL625124,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
8673,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL625125,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
8674,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL625126,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
8675,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626947,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
8676,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626948,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
8677,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626949,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
8678,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626950,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
8679,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626951,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
8680,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL626952,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8681,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626953,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8682,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626954,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8683,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626955,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8684,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626956,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8685,Mus musculus,,A,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626957,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
8686,Mus musculus,,A,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL626958,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8687,Mus musculus,,A,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626959,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8688,Mus musculus,,A,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626960,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8689,Mus musculus,,A,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626961,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8690,Mus musculus,,A,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627589,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8691,Mus musculus,,A,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627590,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8692,Mus musculus,,A,Time taken for EC90 was determined when tested in mouse,,CHEMBL627591,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8693,Mus musculus,,A,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,CHEMBL627592,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8694,Mus musculus,,A,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,CHEMBL627593,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8695,Mus musculus,,A,Half life in mice,,CHEMBL627594,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8696,Mus musculus,,A,Half life period in mouse after 10 mg/Kg dose,,CHEMBL876813,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8697,Mus musculus,,A,Half life period in mouse after 10 mg/kg dose,,CHEMBL627595,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8698,Mus musculus,,A,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL627596,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8699,Rattus norvegicus,,A,Cmax value at 5 mg/kg po was determined in rat,,CHEMBL627597,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8700,Rattus norvegicus,,A,Cmax value evaluated in rat,,CHEMBL627598,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8701,Rattus norvegicus,,A,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,CHEMBL627599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8702,Rattus norvegicus,,A,Cmax value after administration of 20 mg/Kg oral dose in rat,,CHEMBL627600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8703,Rattus norvegicus,,A,Cmax value at 1 mg/kg po in rat,,CHEMBL627601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8704,Rattus norvegicus,,A,Cmax value at 5 mg/kg po in rat,,CHEMBL627776,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8705,Rattus norvegicus,,A,Cmax value at a dose of 10 mg/kg in male SD rats,,CHEMBL627777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8706,Rattus norvegicus,,A,Cmax value at a dose of 100 mg/kg in male SD rats,,CHEMBL627778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8707,Rattus norvegicus,,A,Cmax value at a dose of 50 mg/kg in male SD rats,,CHEMBL627779,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8708,Rattus norvegicus,,A,Cmax value in rats at 10 mg/kg,,CHEMBL876814,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8709,Rattus norvegicus,,A,Cmax value was evaluated in rats at a dose of 20 mg/kg,,CHEMBL627780,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8710,Rattus norvegicus,,A,Cmax value was determined after peroral administration of 20 mg/kg in rat,,CHEMBL627781,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8711,Rattus norvegicus,,A,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,CHEMBL627782,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8712,Rattus norvegicus,,A,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,CHEMBL627783,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8713,Rattus norvegicus,,A,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,CHEMBL627784,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8714,Rattus norvegicus,,A,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL627785,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8715,Rattus norvegicus,,A,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL627786,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8716,Rattus norvegicus,,A,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,CHEMBL627787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8717,Rattus norvegicus,,A,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,CHEMBL627788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8718,Rattus norvegicus,,A,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,CHEMBL626579,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8719,Rattus norvegicus,,A,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,CHEMBL626580,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8720,Rattus norvegicus,,A,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,CHEMBL876815,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8721,Rattus norvegicus,,A,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,CHEMBL626581,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8722,Rattus norvegicus,,A,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,CHEMBL626582,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8723,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,CHEMBL626583,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8724,Rattus norvegicus,,A,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL626205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8725,Rattus norvegicus,,A,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL626206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8726,Rattus norvegicus,,A,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL626207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8727,Rattus norvegicus,,A,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL623882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8728,Rattus norvegicus,,A,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,CHEMBL623883,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8729,Rattus norvegicus,,A,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,CHEMBL623884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8730,Rattus norvegicus,,A,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,CHEMBL623885,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8731,Rattus norvegicus,,A,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,CHEMBL623886,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8732,Rattus norvegicus,,A,Maximal concentration in rat was determined,,CHEMBL623887,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8733,Rattus norvegicus,,A,Maximal concentration after i.v. administration,,CHEMBL623888,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8734,Rattus norvegicus,,A,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,CHEMBL623889,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8735,Rattus norvegicus,,A,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,CHEMBL623890,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8736,Rattus norvegicus,,A,Cmax in rat plasma after oral dose (50 mg/Kg),,CHEMBL623891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8737,Rattus norvegicus,,A,Maximal plasma concentration was determined.,,CHEMBL623892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8738,Rattus norvegicus,,A,Maximal plasma drug concentration was determined,,CHEMBL623893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8739,Rattus norvegicus,,A,Maximal concentration in rats after peroral administration,,CHEMBL877616,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8740,Rattus norvegicus,,A,Maximum concentration in rat after 2 mg/kg peroral administration,,CHEMBL623894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8741,Rattus norvegicus,,A,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,CHEMBL623895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8742,Rattus norvegicus,,A,Maximum concentration of compound in rat was evaluated.,,CHEMBL623896,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8743,Rattus norvegicus,,A,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,CHEMBL623897,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8744,Rattus norvegicus,,A,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,CHEMBL623898,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8745,Rattus norvegicus,,A,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,CHEMBL623899,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8746,Rattus norvegicus,,A,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,CHEMBL623900,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8747,Rattus norvegicus,,A,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL623901,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8748,Rattus norvegicus,,A,Maximum concentration was evaluated in rats,,CHEMBL623902,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8749,Rattus norvegicus,,A,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,CHEMBL623903,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1359.0
8750,Rattus norvegicus,,A,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,CHEMBL623904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8751,Rattus norvegicus,,A,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,CHEMBL877617,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8752,Rattus norvegicus,,A,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,CHEMBL623905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8753,Rattus norvegicus,,A,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,CHEMBL623906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8754,Rattus norvegicus,,A,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL623907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8755,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL623908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8756,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL623909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8757,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL623910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8758,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL623911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8759,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL623912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8760,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL624616,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8761,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL624617,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8762,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL624618,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8763,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL624619,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8764,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL624794,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8765,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL624795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8766,Rattus norvegicus,,A,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL623921,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8767,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL623922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8768,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL623923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8769,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL623924,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8770,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL623925,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8771,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL623926,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8772,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL623927,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8773,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL623928,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8774,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL623929,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8775,Rattus norvegicus,,A,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL623930,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8776,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL623931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8777,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622165,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8778,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL621249,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8779,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL621250,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8780,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL621448,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8781,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL621449,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8782,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL621450,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8783,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL621451,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8784,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL621452,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8785,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL621453,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8786,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL621454,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8787,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL621455,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8788,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL621456,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8789,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL625145,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8790,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL875847,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8791,Rattus norvegicus,,A,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL625146,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8792,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL625147,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8793,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL625148,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8794,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL625149,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8795,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL625150,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8796,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL625151,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8797,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL625152,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8798,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL625153,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8799,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL625154,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8800,Rattus norvegicus,,A,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL625155,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8801,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL625156,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8802,Rattus norvegicus,,A,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624354,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8803,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624355,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
8804,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624356,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
8805,Rattus norvegicus,,A,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624357,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
8806,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624358,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
8807,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624359,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8808,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624360,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8809,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL624361,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8810,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624362,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8811,Rattus norvegicus,,A,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624363,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
8812,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624364,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8813,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624365,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8814,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624366,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8815,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624367,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8816,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624368,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8817,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624369,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8818,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL624370,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8819,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625069,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8820,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625070,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8821,Rattus norvegicus,,A,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626051,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8822,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626052,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8823,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL626053,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8824,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626054,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8825,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626055,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8826,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626056,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8827,Rattus norvegicus,,A,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626057,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8828,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8829,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8830,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625195,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8831,Rattus norvegicus,,A,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625196,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8832,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL625197,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8833,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625198,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8834,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627929,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
8835,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627074,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8836,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627075,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8837,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL627076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8838,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8839,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
8840,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL627079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8841,Mus musculus,,A,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,CHEMBL873824,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8842,Mus musculus,,A,Half life in mouse plasma was determined at dose 25 mg/kg,,CHEMBL627080,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
8843,Mus musculus,,A,Half life was determined,,CHEMBL627081,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8844,Mus musculus,,A,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,CHEMBL627082,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8845,Mus musculus,,A,Half-life in male mice after 1 mg/kg intravenous dose,,CHEMBL627083,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8847,Mus musculus,,A,Half life in mice plasma,,CHEMBL627085,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
8848,Mus musculus,,A,Half life in mouse,,CHEMBL627086,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8849,Mus musculus,,A,Half life in mouse plasma at dose 25 mg/kg,,CHEMBL627087,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
8850,Mus musculus,,A,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,CHEMBL627088,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8851,Mus musculus,,A,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,CHEMBL627089,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8852,Mus musculus,,A,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,CHEMBL627090,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8853,Mus musculus,,A,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL627091,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8854,Mus musculus,,A,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,CHEMBL627092,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8855,Mus musculus,,A,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,CHEMBL876785,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8856,Mus musculus,,A,Half-life by iv administration in mouse,,CHEMBL627093,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8857,Mus musculus,,A,Half-life by oral administration in mouse,,CHEMBL627094,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8858,Mus musculus,,A,Half-life in mice,,CHEMBL627095,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8859,Mus musculus,,A,Half-life using mouse brain homogenate,,CHEMBL627096,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8860,Mus musculus,,A,Half-life was measured in mice,,CHEMBL627097,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8861,Mus musculus,,A,Half-life was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL627098,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8862,Mus musculus,,A,Half-life period was determined in mouse blood,,CHEMBL627099,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
8863,Mus musculus,,A,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,CHEMBL627100,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
8864,Mus musculus,,A,Plasma half life in mouse,,CHEMBL627101,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
8865,Mus musculus,,A,Stability of the peptide in the presence of mouse serum,,CHEMBL627102,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8866,Mus musculus,,A,Terminal half life of compound was determined in mouse,,CHEMBL627103,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8867,Mus musculus,,A,Terminal half life was evaluated in mice after intravenous administration,,CHEMBL627104,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8868,Mus musculus,,A,Terminal half life was evaluated in mice after oral administration,,CHEMBL627105,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8869,Mus musculus,,A,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,CHEMBL876786,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8870,Mus musculus,,A,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,CHEMBL873825,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8871,Mus musculus,,A,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,CHEMBL627106,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8872,Mus musculus,,A,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,CHEMBL626336,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8873,Mus musculus,,A,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,CHEMBL877462,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8874,Mus musculus,,A,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,CHEMBL626337,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8875,Mus musculus,,A,Half life after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL626338,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8876,Mus musculus,,A,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,CHEMBL626339,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8877,Mus musculus,,A,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,CHEMBL626340,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8878,Mus musculus,,A,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,CHEMBL625377,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8879,Mus musculus,,A,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,CHEMBL625378,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8880,Mus musculus,,A,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,CHEMBL625379,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
8881,Sus scrofa,,A,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL625380,9823.0,0,1,U,22224,Autocuration,,,BAO_0000251,
8882,Sus scrofa,,A,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,CHEMBL625381,9823.0,0,1,U,22224,Autocuration,,,BAO_0000251,
8883,Sus scrofa,,A,Stability to porcine renal DHP-I,,CHEMBL625382,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
8884,Sus scrofa,,A,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,CHEMBL873828,9823.0,0,1,U,22224,Autocuration,,,BAO_0000218,
8885,Sus scrofa,,A,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,CHEMBL625383,9823.0,0,1,U,22224,Autocuration,,,BAO_0000218,
8886,Sus scrofa,,A,Half-life of the parent prodrug in porcine esterase solution,,CHEMBL625384,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
8887,Sus scrofa,,A,"First order rate constant, k was determined in in pig liver Esterase",,CHEMBL625385,9823.0,0,1,U,22224,Autocuration,,,BAO_0000019,
8888,Sus scrofa,,A,Half life of the in pig liver Esterase,,CHEMBL625386,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8889,Sus scrofa,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,CHEMBL623571,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8890,Sus scrofa,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,CHEMBL623572,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8891,Sus scrofa,,A,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,CHEMBL623573,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8892,Sus scrofa,,A,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,CHEMBL623574,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8893,Sus scrofa,,A,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,CHEMBL623575,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8894,Sus scrofa,,A,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,CHEMBL623749,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8895,Sus scrofa,,A,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,CHEMBL623750,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8896,Sus scrofa,,A,Half-life in vitro in pig liver,,CHEMBL623751,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8897,Sus scrofa,,A,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,CHEMBL623752,9823.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
8898,Rattus norvegicus,,A,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,CHEMBL623753,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8899,Rattus norvegicus,,A,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,CHEMBL623754,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8900,Rattus norvegicus,,A,Maximum concentration in rat plasma was determined,,CHEMBL623755,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8901,Rattus norvegicus,,A,Maximum concentration in rats,,CHEMBL623756,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8902,Rattus norvegicus,,A,Maximum concentration in rats at 1-2 hours,,CHEMBL623757,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8903,Rattus norvegicus,,A,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,CHEMBL623758,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8904,Rattus norvegicus,,A,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,CHEMBL623759,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
8905,Rattus norvegicus,,A,Maximum concentration at the dose of 2 mg/kg in rat,,CHEMBL623760,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8906,Rattus norvegicus,,A,Maximum concentration was evaluated in rats,,CHEMBL623761,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8907,Rattus norvegicus,,A,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,CHEMBL623762,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8908,Rattus norvegicus,,A,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,CHEMBL877594,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8909,Rattus norvegicus,,A,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,CHEMBL623763,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8910,Rattus norvegicus,,A,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,CHEMBL623764,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8911,Rattus norvegicus,,A,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,CHEMBL623765,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8912,Rattus norvegicus,,A,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,CHEMBL623766,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8913,Rattus norvegicus,,A,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,CHEMBL623767,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8914,Rattus norvegicus,,A,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,CHEMBL623768,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
8915,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623769,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8916,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623770,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8917,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623771,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8918,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623772,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8919,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,CHEMBL623773,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8920,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,CHEMBL623774,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8921,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,CHEMBL623775,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8922,Rattus norvegicus,,A,Cmax in rat (PO dose),,CHEMBL623776,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
8923,Rattus norvegicus,,A,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL622191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8924,Rattus norvegicus,,A,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL622192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8925,Rattus norvegicus,,A,Maximum plasma concentration determined in rat,,CHEMBL622193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8926,Rattus norvegicus,,A,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL622194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8927,Rattus norvegicus,,A,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL622195,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8928,Rattus norvegicus,,A,Maximum plasma concentration in rat,,CHEMBL622196,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8929,Rattus norvegicus,,A,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL622197,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8930,Rattus norvegicus,,A,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,CHEMBL622198,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8931,Rattus norvegicus,,A,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,CHEMBL622199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8932,Rattus norvegicus,,A,Maximum plasma concentration of compound was measured in rat,,CHEMBL622200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8933,Rattus norvegicus,,A,Maximum plasma concentration after 20 mg/kg oral administration in rat,,CHEMBL622201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8934,Rattus norvegicus,,A,Maximum plasma concentration after oral administration to rats,,CHEMBL623990,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8935,Rattus norvegicus,,A,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623991,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8936,Rattus norvegicus,,A,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,CHEMBL623992,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8937,Rattus norvegicus,,A,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623993,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8938,Rattus norvegicus,,A,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,CHEMBL623994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8939,Rattus norvegicus,,F,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,CHEMBL623995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8940,Rattus norvegicus,,F,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL623996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8941,Rattus norvegicus,,F,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,CHEMBL623997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8942,Rattus norvegicus,,A,Maximum plasma concentration dosed orally in rats,,CHEMBL623998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8943,Rattus norvegicus,,A,Maximum plasma concentration dosed orally in rats after 6 hours,,CHEMBL623999,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8944,Rattus norvegicus,,A,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,CHEMBL624000,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8945,Rattus norvegicus,,A,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,CHEMBL624001,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8946,Rattus norvegicus,,A,Maximum plasma concentration in rat after po administration,,CHEMBL624002,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8947,Rattus norvegicus,,A,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,CHEMBL624003,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8948,Rattus norvegicus,,A,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,CHEMBL624004,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
8949,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL624005,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8950,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL624006,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8951,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL624007,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8952,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL624008,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8953,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL624009,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8954,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL874387,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8955,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL624010,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8956,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL624011,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8957,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL624012,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8958,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL624013,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8959,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL624736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8960,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL624737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8961,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL624738,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8962,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL624739,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8963,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL624740,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8964,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL624896,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8965,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL624897,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8966,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL624108,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8967,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL624109,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8968,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL624110,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8969,Rattus norvegicus,,A,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL624111,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8970,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL624112,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8971,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL624113,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8972,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL619709,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8973,Rattus norvegicus,,A,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL619710,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
8974,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL619711,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8975,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL619712,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8976,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL619713,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8977,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL619714,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8978,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL619715,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8979,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL619716,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8980,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL619717,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8981,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL619718,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8982,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL619719,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8983,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL875329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8984,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL619720,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8985,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL619721,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8986,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL619722,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8987,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL619723,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8988,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL619724,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8989,Rattus norvegicus,,A,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL619725,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8990,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL619726,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8991,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL619727,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8992,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL619728,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8993,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL619729,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
8994,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619730,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8995,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619731,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8996,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL619732,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8997,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619733,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8998,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619734,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
8999,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619735,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9000,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL875330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9001,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL628465,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9002,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628466,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9003,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628467,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9004,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9005,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628469,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9006,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL628470,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9007,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628471,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9008,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628472,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9009,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9010,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9011,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL875337,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9012,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626341,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9013,Rattus norvegicus,,A,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626342,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9014,Rattus norvegicus,,A,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9015,Rattus norvegicus,,A,Half life in rats,,CHEMBL621944,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9016,Rattus norvegicus,,A,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,CHEMBL621945,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9017,Rattus norvegicus,,A,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,CHEMBL621946,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9018,Rattus norvegicus,,A,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,CHEMBL621947,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9019,Rattus norvegicus,,A,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,CHEMBL621948,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9020,Rattus norvegicus,,A,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,CHEMBL621949,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9021,Rattus norvegicus,,A,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,CHEMBL621950,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9022,Rattus norvegicus,,A,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,CHEMBL621951,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9023,Rattus norvegicus,,A,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,CHEMBL621952,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9024,Rattus norvegicus,,A,Stability (%) in rat liver microsomes,,CHEMBL621953,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9025,Rattus norvegicus,,A,Area under curve was calculated after intravenous administration,,CHEMBL621954,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9026,Rattus norvegicus,,A,Area under the curve was calculated after iv administration in rat,,CHEMBL621955,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9027,Rattus norvegicus,,A,Area under the curve was calculated in rat after peroral administration,,CHEMBL621956,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9028,Rattus norvegicus,,A,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL621957,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9029,Rattus norvegicus,,A,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,CHEMBL621958,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9030,Rattus norvegicus,,A,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,CHEMBL621959,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9031,Rattus norvegicus,,A,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,CHEMBL621960,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9032,Rattus norvegicus,,A,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,CHEMBL621961,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9033,Rattus norvegicus,,A,p value of the compound,,CHEMBL621962,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9034,Rattus norvegicus,,F,p value of the compound,,CHEMBL876787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9035,Rattus norvegicus,,A,p value of the compound,,CHEMBL621963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9036,Rattus norvegicus,,A,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622637,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9037,Rattus norvegicus,,A,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622638,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9038,Rattus norvegicus,,A,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL626561,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9039,Oryctolagus cuniculus,,F,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,CHEMBL626562,9986.0,0,1,U,22224,Autocuration,,,BAO_0000019,
9040,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,CHEMBL626563,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9041,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,CHEMBL626564,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9042,Oryctolagus cuniculus,,A,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,CHEMBL626565,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9043,Oryctolagus cuniculus,,A,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,CHEMBL626566,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9044,Oryctolagus cuniculus,,A,Clearance rate in rabbits,,CHEMBL626567,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9045,Oryctolagus cuniculus,,A,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,CHEMBL626568,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9046,Oryctolagus cuniculus,,A,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,CHEMBL626569,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9047,Oryctolagus cuniculus,,A,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,CHEMBL626570,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9048,Oryctolagus cuniculus,,A,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,CHEMBL626571,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9049,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,CHEMBL626572,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9050,Oryctolagus cuniculus,,A,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,CHEMBL626573,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
9051,Oryctolagus cuniculus,,A,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,CHEMBL626574,9986.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
9052,Oryctolagus cuniculus,,A,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,CHEMBL626575,9986.0,0,1,U,22224,Autocuration,,,BAO_0000251,2107.0
9053,Oryctolagus cuniculus,,A,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,CHEMBL626576,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9054,Oryctolagus cuniculus,,A,Dose at which bioavailability of perorally administered compound was tested in rabbit,,CHEMBL626577,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9055,Oryctolagus cuniculus,,A,The compound was tested for its bioavailability in rabbit (by oral dosage).,,CHEMBL626578,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9056,Oryctolagus cuniculus,,A,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,CHEMBL625263,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9057,Oryctolagus cuniculus,,A,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,CHEMBL625264,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9058,Oryctolagus cuniculus,,A,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,CHEMBL625265,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9059,Oryctolagus cuniculus,,A,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL625266,9986.0,0,1,U,22224,Autocuration,,,BAO_0000251,
9060,Oryctolagus cuniculus,,A,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,CHEMBL876796,9986.0,0,1,U,22224,Autocuration,,,BAO_0000251,
9061,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,CHEMBL625267,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9062,Oryctolagus cuniculus,,A,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,CHEMBL625268,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
9063,Oryctolagus cuniculus,,A,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,CHEMBL625269,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
9064,Oryctolagus cuniculus,,A,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,CHEMBL624689,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
9065,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,CHEMBL624690,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9066,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,CHEMBL624691,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
9067,Oryctolagus cuniculus,,A,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,CHEMBL624692,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
9068,Oryctolagus cuniculus,,A,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,CHEMBL624693,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9069,Oryctolagus cuniculus,,A,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,CHEMBL624694,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9070,Oryctolagus cuniculus,,A,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,CHEMBL877596,9986.0,0,1,U,22224,Autocuration,,,BAO_0000221,
9071,Oryctolagus cuniculus,,A,Time within which only 10% of the drug was degraded,,CHEMBL624695,9986.0,0,1,U,22224,Autocuration,,,BAO_0000019,
9072,Oryctolagus cuniculus,,A,Half life period in rabbit liver homogenate,,CHEMBL624696,9986.0,0,1,U,22224,Autocuration,,,BAO_0000221,2107.0
9073,Oryctolagus cuniculus,,A,Half life value in rabbits,,CHEMBL624697,9986.0,0,1,U,22224,Autocuration,,,BAO_0000019,
9074,Oryctolagus cuniculus,,A,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,CHEMBL624698,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
9075,Oryctolagus cuniculus,,A,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,CHEMBL624699,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
9076,Oryctolagus cuniculus,,A,Half-life period in rabbits following intravenous administration at 2 mg/kg,,CHEMBL624700,9986.0,0,1,U,22224,Autocuration,,,BAO_0000218,
9077,Rattus norvegicus,,A,AUC 0-8 hr value in rats at 10 mg/kg,,CHEMBL622903,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9078,Rattus norvegicus,,A,AUC after administration at 2000 mg/kg/day in rats,,CHEMBL622904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9079,Rattus norvegicus,,A,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,CHEMBL622905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9080,Rattus norvegicus,,A,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL622906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9081,Rattus norvegicus,,A,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL622907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9082,Rattus norvegicus,,A,AUC in rat after oral administration at 10.5 mg/kg dose,,CHEMBL622908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9083,Rattus norvegicus,,A,AUC in rat after oral administration at 11.2 mg/kg dose,,CHEMBL622909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9084,Rattus norvegicus,,A,AUC in rat after oral administration at 9.7 mg/kg dose,,CHEMBL622910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9085,Rattus norvegicus,,A,AUC in rat brain after oral administration at 10 mg/kg,,CHEMBL622911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9086,Rattus norvegicus,,A,AUC in rat p.o.,,CHEMBL622912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9087,Rattus norvegicus,,A,AUC in rat p.o. at 20 mg/kg concentration,,CHEMBL622913,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9088,Rattus norvegicus,,A,AUC in rat plasma after oral administration at 10 mg/kg,,CHEMBL622914,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9089,Rattus norvegicus,,A,AUC in rats,,CHEMBL622915,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9090,Rattus norvegicus,,A,AUC value after IV dose at a dose of 5 mg/kg in rats.,,CHEMBL622916,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9091,Rattus norvegicus,,A,AUC value after oral dose at a dose of 10 mg/kg in rats.,,CHEMBL622917,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9092,Rattus norvegicus,,A,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,CHEMBL622918,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9093,Rattus norvegicus,,A,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,CHEMBL622919,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9094,Rattus norvegicus,,A,Maximum plasma concentration was evaluated in rat,,CHEMBL622920,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9095,Rattus norvegicus,,A,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,CHEMBL622921,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9096,Rattus norvegicus,,A,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,CHEMBL622922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9097,Rattus norvegicus,,A,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,CHEMBL622923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9098,Rattus norvegicus,,A,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,CHEMBL877604,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9099,Rattus norvegicus,,A,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,CHEMBL622924,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9100,Rattus norvegicus,,A,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL622925,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9101,Rattus norvegicus,,A,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,CHEMBL622926,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9102,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,CHEMBL623625,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9103,Rattus norvegicus,,A,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL623626,10116.0,1,1,N,50597,Expert,,,BAO_0000218,1969.0
9104,Rattus norvegicus,,A,Maximum plasma drug concentration was determined,,CHEMBL623627,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9105,Rattus norvegicus,,A,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,CHEMBL623628,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9106,Rattus norvegicus,,A,Mean peak plasma concentration was observed after intravenous administration in rat,,CHEMBL623629,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9107,Rattus norvegicus,,A,Mean peak plasma concentration was observed after oral administration in rat,,CHEMBL623630,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9108,Rattus norvegicus,,A,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,CHEMBL623804,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9109,Rattus norvegicus,,A,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,CHEMBL623805,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9110,Rattus norvegicus,,A,Peak oral plasma concentration was determined in rats by oral administration,,CHEMBL623806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9111,Rattus norvegicus,,A,Peak plasma concentration (Cmax) was determined,,CHEMBL623807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9112,Rattus norvegicus,,A,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,CHEMBL623808,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9113,Rattus norvegicus,,A,Peak plasma concentration (Cmax) in rats,,CHEMBL623809,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9114,Rattus norvegicus,,A,Peak plasma concentration at 1 mg/kg peroral administration,,CHEMBL623810,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9115,Rattus norvegicus,,A,Peak plasma concentration in rat,,CHEMBL623811,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9116,Rattus norvegicus,,A,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL623812,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9117,Rattus norvegicus,,A,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,CHEMBL877605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9118,Rattus norvegicus,,A,Pharmacokinetic property (Cmax) in rat,,CHEMBL623813,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9119,Rattus norvegicus,,A,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,CHEMBL623814,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9120,Rattus norvegicus,,A,Cmax in rat after 3mg/kg oral dose,,CHEMBL623815,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9121,Rattus norvegicus,,A,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Sprague-Dawley,CHEMBL623816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9122,Rattus norvegicus,,A,Cmax in rats after 20 mg/kg oral dose,,CHEMBL623145,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9123,Rattus norvegicus,,A,Cmax in rat plasma after 30mg/kg oral dose,,CHEMBL623146,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9124,Rattus norvegicus,,A,Plasma concentration after oral administration of 100 mg/kg to rats,,CHEMBL623147,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9125,Rattus norvegicus,,A,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL623042,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9126,Rattus norvegicus,,A,Tested for the Cmax in rat at 10 mg/kg per orally,,CHEMBL623043,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9127,Rattus norvegicus,,A,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL623044,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9128,Rattus norvegicus,,A,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL623045,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9129,Rattus norvegicus,,A,Bioavailability as oral Cmax in rats at 30 mins,,CHEMBL623046,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9130,Rattus norvegicus,,A,Bioavailability as oral Cmax in rats at 6hr,,CHEMBL623226,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9131,Rattus norvegicus,,A,The maximum concentration of compound was measured at the dose of 100 umol/kg,,CHEMBL623227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9132,Rattus norvegicus,,A,The maximum concentration of compound was measured at the dose of 300 umol/kg,,CHEMBL623228,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9133,Rattus norvegicus,,A,The maximum concentration of compound was measured at the dose of 30 umol/kg,,CHEMBL623229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9134,Rattus norvegicus,,A,The maximum plasma levels for the compounds were determined by LC-MS.,,CHEMBL623230,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9135,Rattus norvegicus,,A,mean peak plasma concentration was observed after intravenous administration in rat,,CHEMBL623231,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9136,Rattus norvegicus,,A,mean peak plasma concentration was observed after oral administration in rat,,CHEMBL623232,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9137,Rattus norvegicus,,A,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,CHEMBL623233,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9138,Rattus norvegicus,,A,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,CHEMBL623234,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9139,Rattus norvegicus,,A,Concentration in plasma (portal) following oral dose in rats at 1 hr,,CHEMBL623235,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9140,Rattus norvegicus,,A,Concentration in plasma (portal) following oral dose in rats at 2 hr,,CHEMBL623236,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9141,Rattus norvegicus,,A,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,CHEMBL623237,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9142,Rattus norvegicus,,A,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,CHEMBL623238,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9143,Rattus norvegicus,,A,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,CHEMBL623239,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9144,Rattus norvegicus,,A,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,CHEMBL623240,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,1969.0
9145,Rattus norvegicus,,A,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,CHEMBL623241,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
9146,Rattus norvegicus,,A,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,CHEMBL623242,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
9147,Rattus norvegicus,,A,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,CHEMBL874394,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9148,Rattus norvegicus,,A,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,CHEMBL623243,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9149,Rattus norvegicus,,A,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL623244,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9150,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL623245,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9151,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL623246,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9152,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL623247,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9153,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL623248,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9154,Rattus norvegicus,,A,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL623249,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9155,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL625072,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9156,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL625073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9157,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL625074,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9158,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL625075,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9159,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL625076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9160,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL625077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9161,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL625078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9162,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL874395,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9163,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL625079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9164,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL625080,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9165,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL625081,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9166,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL625082,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9167,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL625083,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9168,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL625084,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9169,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL625085,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9170,Rattus norvegicus,,A,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL625086,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9171,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL625087,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9172,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL625088,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9173,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL622205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9174,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL622206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9175,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL622207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9176,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL622366,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9177,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL622367,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9178,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL875331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9179,Rattus norvegicus,,A,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL622368,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9180,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL622369,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9181,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622370,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9182,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL622371,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9183,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL622372,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9184,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL622373,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9185,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL622374,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9186,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL622375,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9187,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL622376,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9188,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL622377,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9189,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL622378,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9190,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL622379,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9191,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL622380,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9192,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL622381,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9193,Rattus norvegicus,,A,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL622382,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9194,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,CHEMBL622383,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9195,Rattus norvegicus,,A,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL875332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9196,Rattus norvegicus,,A,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622384,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9197,Rattus norvegicus,,A,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622385,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9198,Rattus norvegicus,,A,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622386,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9199,Rattus norvegicus,,A,The compound was tested for the plasma binding in rat,,CHEMBL622387,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9200,Rattus norvegicus,,A,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,CHEMBL622388,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9201,Rattus norvegicus,,A,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,CHEMBL622389,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9202,Rattus norvegicus,,A,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,CHEMBL622390,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9203,Rattus norvegicus,,A,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,CHEMBL622391,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9204,Rattus norvegicus,,A,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,CHEMBL622392,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9205,Rattus norvegicus,,A,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,CHEMBL622393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9206,Rattus norvegicus,,A,Plasma level at 2 hr after administration of the compound,,CHEMBL622394,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9207,Rattus norvegicus,,A,plasma level at 2 hr after administration of the compound,,CHEMBL622395,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9208,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 1 min,,CHEMBL622396,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9209,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 10 min,,CHEMBL624894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9210,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 10 mins,,CHEMBL624895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9211,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 2 hr,,CHEMBL624058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9212,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 3 min,,CHEMBL624059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9213,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 3 mins,,CHEMBL624060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9214,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 5 min,,CHEMBL624061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9215,Rattus norvegicus,,A,Stability in rat serum measured as % recovery at 5 mins,,CHEMBL624062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9216,Rattus norvegicus,,A,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL624063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9217,Rattus norvegicus,,A,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL624064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9218,Rattus norvegicus,,A,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,CHEMBL624065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9219,Rattus norvegicus,,A,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,CHEMBL624066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9220,Rattus norvegicus,,A,Half life tested in mature male rat at a dose of 30 mg/kg,,CHEMBL877490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9221,Rattus norvegicus,,A,Half life after intravenous administration of 1 mg/kg in rat,,CHEMBL874442,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9222,Rattus norvegicus,,A,Half life period after administration (30 mg/kg) in rat,,CHEMBL626890,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9223,Rattus norvegicus,,A,Half life period in rat after 5 mg/Kg dose,,CHEMBL626891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9224,Rattus norvegicus,,A,Half life period in rat after 5 mg/kg dose,,CHEMBL626892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9225,Rattus norvegicus,,A,Half life period was determined,,CHEMBL626893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9226,Rattus norvegicus,,A,Half life period was evaluated in rat,,CHEMBL626894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9227,Rattus norvegicus,,A,Half life period was evaluated in rat; 0.5-1.0,,CHEMBL626895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9228,Rattus norvegicus,,A,Half life period was evaluated in rat; 5.9-7.5,,CHEMBL626896,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9229,Rattus norvegicus,,A,Half-life in rat plasma,,CHEMBL626897,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9230,Rattus norvegicus,,A,Half-life time in rat was determined,,CHEMBL626898,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9231,Rattus norvegicus,,A,Terminal half-life after iv administration to rats,,CHEMBL626899,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9232,Rattus norvegicus,,A,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,CHEMBL626900,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9233,Rattus norvegicus,,A,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,CHEMBL626901,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9234,Rattus norvegicus,,A,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,CHEMBL626902,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9235,Rattus norvegicus,,A,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,CHEMBL626903,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9236,Rattus norvegicus,,A,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,CHEMBL874443,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9237,Rattus norvegicus,,A,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,CHEMBL626904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9238,Rattus norvegicus,,A,Half life in rats,,CHEMBL626905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9239,Rattus norvegicus,,A,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,CHEMBL873830,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9240,Rattus norvegicus,,A,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,CHEMBL626906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9241,Rattus norvegicus,,A,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL631076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9242,Rattus norvegicus,,A,Biological half-life was measured in plasma of rats,,CHEMBL631077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9243,Rattus norvegicus,,A,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL631078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9244,Rattus norvegicus,,A,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,CHEMBL631079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9245,Rattus norvegicus,,A,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,CHEMBL631080,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9246,Rattus norvegicus,,A,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL631081,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9247,Rattus norvegicus,,A,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL631239,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9248,Rattus norvegicus,,A,Compound was evaluated for plasma half life in rat,,CHEMBL631240,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9249,Rattus norvegicus,,A,AUC value at a dose of 5 mg/kg (p.o.) in rats,,CHEMBL631241,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9250,Rattus norvegicus,,A,AUC value after administration of 20 mg/Kg oral dose in rat,,CHEMBL631242,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9251,Rattus norvegicus,,A,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,CHEMBL631243,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9252,Rattus norvegicus,,A,AUC0-96 after administration at 50 mg/kg,,CHEMBL874444,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9253,Rattus norvegicus,,A,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,CHEMBL631244,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9254,Rattus norvegicus,,A,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,CHEMBL631245,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9255,Rattus norvegicus,,A,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,CHEMBL627162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9256,Rattus norvegicus,,A,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,CHEMBL627163,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9257,Rattus norvegicus,,A,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,CHEMBL627164,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9258,Rattus norvegicus,,A,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,CHEMBL627165,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9259,Rattus norvegicus,,A,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,CHEMBL627166,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9260,Rattus norvegicus,,A,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,CHEMBL627167,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9261,Rattus norvegicus,,A,Area under curve (AUC) at a dose of 30 mg/kg in rats,,CHEMBL627822,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9262,Rattus norvegicus,,A,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,CHEMBL627823,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9263,Rattus norvegicus,,A,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,CHEMBL627824,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9264,Rattus norvegicus,,A,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,CHEMBL627825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9265,Rattus norvegicus,,A,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,CHEMBL627826,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9266,Rattus norvegicus,,A,Area under curve (Pharmacokinetic property) was determined,,CHEMBL627827,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9267,Rattus norvegicus,,A,Area under curve (Pharmacokinetic property) of the compound; Not determined,,CHEMBL627828,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9268,Rattus norvegicus,,A,Area under curve after intravenous administration (1 mg/kg) in rat,,CHEMBL627829,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9269,Rattus norvegicus,,A,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,CHEMBL627830,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9270,Rattus norvegicus,,A,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL627831,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9271,Rattus norvegicus,,A,Area under curve in male SD rats was observed after oral administration in rat,,CHEMBL627832,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9272,Rattus norvegicus,,A,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,CHEMBL627833,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9273,Rattus norvegicus,,A,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL627834,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
9274,Rattus norvegicus,,A,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL628004,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
9275,Rattus norvegicus,,A,Area under curve at 5 mg/kg po was determined in rat,,CHEMBL628005,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9276,Rattus norvegicus,,A,Area under curve in Rat at a oral dose of 5 mg/kg,,CHEMBL628006,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9277,Rattus norvegicus,,A,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL628007,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9278,Rattus norvegicus,,A,Area under curve was determined,,CHEMBL625676,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9279,Rattus norvegicus,,A,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,CHEMBL631309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9280,Rattus norvegicus,,A,Area under curve after intravenous administration at 3 mg/kg,,CHEMBL631310,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9281,Rattus norvegicus,,A,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,CHEMBL631311,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9282,Rattus norvegicus,,A,Area under curve at 4 hr in rat,,CHEMBL631312,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9283,Rattus norvegicus,,A,Area under curve at a dose of 30 mg/kg,,CHEMBL631313,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9284,Rattus norvegicus,,A,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,CHEMBL631314,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9285,Rattus norvegicus,,A,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL631315,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9286,Rattus norvegicus,,A,Area under curve for a 2-mpk po dose in SD rats,,CHEMBL631316,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9287,Rattus norvegicus,,A,Area under curve in SD rats,,CHEMBL631317,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9288,Rattus norvegicus,,A,Area under curve in rat after oral administration at 13 mg/kg dose,,CHEMBL874471,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9289,Rattus norvegicus,,A,Area under curve in rat by po administration at 0-24 hr,,CHEMBL631318,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9290,Rattus norvegicus,,A,Area under curve in rat plasma,,CHEMBL631319,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9291,Rattus norvegicus,,A,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,CHEMBL631320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9292,Rattus norvegicus,,A,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,CHEMBL631321,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9293,Rattus norvegicus,,A,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,CHEMBL631322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9294,Rattus norvegicus,,A,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,CHEMBL631323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9295,Rattus norvegicus,,A,Area under curve value in rat at a dose of 5 mg/kg,,CHEMBL631324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9296,Rattus norvegicus,,A,Area under curve was determined after oral administration in rats,,CHEMBL631325,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9297,Rattus norvegicus,,A,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,CHEMBL631326,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9298,Rattus norvegicus,,A,Area under curve was determined after peroral administration in rat,,CHEMBL631327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9299,Rattus norvegicus,,A,Area under curve was determined at a dose 30 mpk administered orally.,,CHEMBL631328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9300,Rattus norvegicus,,A,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,CHEMBL631329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9301,Rattus norvegicus,,A,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,CHEMBL627217,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9302,Rattus norvegicus,,A,Area under curve was determined in male rat,,CHEMBL626352,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9303,Rattus norvegicus,,A,Area under curve was determined in rat after PO administration,,CHEMBL626353,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9304,Rattus norvegicus,,A,Area under curve was determined in rat after a 3 mg/kg of oral dose,,CHEMBL626354,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9305,Rattus norvegicus,,A,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,CHEMBL626355,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9306,Rattus norvegicus,,A,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,CHEMBL626356,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9307,Rattus norvegicus,,A,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,CHEMBL626357,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9308,Rattus norvegicus,,A,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL626358,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9309,Rattus norvegicus,,A,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL626359,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9310,Rattus norvegicus,,A,Peak plasma concentration in rat at a dose of 3 mg/kg,,CHEMBL626360,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9311,Rattus norvegicus,,A,Plasma concentration at 2 hr in rats was evaluated.,,CHEMBL626361,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9312,Rattus norvegicus,,A,Plasma concentration at 2 hr in rats was evaluated; Not available,,CHEMBL626362,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9313,Rattus norvegicus,,A,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL626363,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9314,Rattus norvegicus,,A,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626970,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9315,Rattus norvegicus,,A,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626971,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9316,Rattus norvegicus,,A,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626972,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9317,Rattus norvegicus,,A,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626973,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9318,Rattus norvegicus,,A,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626974,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9319,Rattus norvegicus,,A,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL874592,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9320,Rattus norvegicus,,A,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,CHEMBL626975,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9321,Rattus norvegicus,,A,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,CHEMBL626976,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9322,Rattus norvegicus,,A,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,CHEMBL626977,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9323,Rattus norvegicus,,A,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,CHEMBL626978,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9324,Rattus norvegicus,,A,PK study was carried to determine the relative absorption ranking in rat.,,CHEMBL626979,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9325,Rattus norvegicus,,A,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,CHEMBL626980,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9326,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,CHEMBL626981,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9327,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,CHEMBL626982,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9328,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,CHEMBL626983,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9329,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,CHEMBL622522,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9330,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,CHEMBL622523,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9331,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,CHEMBL622524,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9332,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,CHEMBL622525,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9333,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,CHEMBL622526,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9334,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,CHEMBL619849,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9335,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,CHEMBL619850,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9336,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,CHEMBL623864,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9337,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,CHEMBL623865,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9338,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,CHEMBL623866,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9339,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,CHEMBL623867,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9340,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,CHEMBL877615,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9341,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,CHEMBL623868,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9342,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,CHEMBL623869,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9343,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,CHEMBL623870,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9344,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,CHEMBL623871,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9345,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL623872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9346,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL622129,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9347,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL622130,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9348,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL622131,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9349,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL622132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9350,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL622133,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9351,Rattus norvegicus,,A,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL622134,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9352,Rattus norvegicus,,A,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL622135,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9353,Rattus norvegicus,,A,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL622136,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9354,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL622137,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9355,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622138,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9356,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL623017,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9357,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL623018,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9358,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL623019,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9359,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL623020,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9360,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL623021,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9361,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL623022,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9362,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL623023,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9363,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL623024,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9364,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL623025,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9365,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL620545,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9366,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL620546,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9367,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL620547,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9368,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL620548,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9369,Rattus norvegicus,,A,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL620549,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9370,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL620550,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9371,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,CHEMBL620551,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9372,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL620552,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9373,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL620553,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9374,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL620554,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9375,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL875845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9376,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL620555,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9377,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL620556,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9378,Rattus norvegicus,,A,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL620557,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9379,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL620558,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9380,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL620559,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9381,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL622939,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9382,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL622940,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9383,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL622941,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9384,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL622942,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9385,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL622943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9386,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL622944,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9387,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL622945,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9388,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL622946,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9389,Rattus norvegicus,,A,Compound was evaluated for terminal half life in rat,,CHEMBL622947,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9390,Rattus norvegicus,,A,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,CHEMBL622948,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9391,Rattus norvegicus,,A,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,CHEMBL622949,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9392,Rattus norvegicus,,A,Compound was tested for its half life in rat,,CHEMBL622950,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9393,Macaca mulatta,,A,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,CHEMBL622951,9544.0,0,1,U,22224,Intermediate,,,BAO_0000218,1969.0
9394,Rattus norvegicus,,A,Compound was tested for its plasma half life in Sprague Dawley rats,,CHEMBL622952,10116.0,0,1,U,22224,Intermediate,,,BAO_0000366,1969.0
9395,Rattus norvegicus,,A,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,CHEMBL622953,10116.0,0,1,U,22224,Intermediate,,,BAO_0000366,1969.0
9396,Rattus norvegicus,,A,Compound was tested for plasma half-life period in rat,,CHEMBL873818,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9397,Rattus norvegicus,,A,Elimination half life after i.v. administration of compound in rats,,CHEMBL622954,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9398,Rattus norvegicus,,A,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,CHEMBL622955,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9399,Rattus norvegicus,,A,Elimination half-life after IV dosing at 1 mg/kg in rat,,CHEMBL875229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9400,Rattus norvegicus,,A,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,CHEMBL622956,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9401,Rattus norvegicus,,A,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,CHEMBL622957,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9402,Rattus norvegicus,,A,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,CHEMBL622958,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9403,Rattus norvegicus,,A,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL622959,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9404,Rattus norvegicus,,A,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,CHEMBL622960,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9405,Rattus norvegicus,,A,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL622961,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9406,Rattus norvegicus,,A,Evaluated for the half life in rat (in vivo),,CHEMBL622962,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9407,Rattus norvegicus,,A,Hafl life in rat,,CHEMBL622963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9408,Rattus norvegicus,,A,Hafl life rat,,CHEMBL622964,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9409,Rattus norvegicus,,A,Hafl life rat,,CHEMBL622965,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9410,Rattus norvegicus,,A,Hafl life rat; Not determined,,CHEMBL622966,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9411,Rattus norvegicus,,A,Hafl life rat; Not determined,,CHEMBL622967,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9412,Rattus norvegicus,,A,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622968,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9413,Rattus norvegicus,,A,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9414,Rattus norvegicus,,A,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL875327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9415,Rattus norvegicus,,A,Half life in rat after 1 mg/kg i.v. administration,,CHEMBL628638,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9416,Rattus norvegicus,,A,Half life in rat after 2 mg/kg peroral administration,,CHEMBL628639,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9417,Rattus norvegicus,,A,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL625840,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9418,Rattus norvegicus,,A,Half life of 10 mg/kg oral dose determined in rats,,CHEMBL625841,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9419,Rattus norvegicus,,A,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL625842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9420,Rattus norvegicus,,A,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL625843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9421,Rattus norvegicus,,A,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL625844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9422,Rattus norvegicus,,A,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL873822,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9423,Rattus norvegicus,,A,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL625845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9424,Rattus norvegicus,,A,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL627059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9425,Rattus norvegicus,,A,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL627060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9426,Rattus norvegicus,,A,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL627061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9427,Rattus norvegicus,,A,Half life of compound at 5 mg/kg after po administration was determined in rat,,CHEMBL627709,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9428,Rattus norvegicus,,A,Half life of compound determined after intravenous administration to rat,,CHEMBL627710,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9429,Rattus norvegicus,,A,Half life of compound was determined in rat,,CHEMBL627711,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9430,Rattus norvegicus,,A,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL627712,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9431,Rattus norvegicus,,A,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627713,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9432,Rattus norvegicus,,A,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627714,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9433,Macaca fascicularis,,A,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,CHEMBL627889,9541.0,0,1,U,22224,Intermediate,,,BAO_0000218,
9434,Rattus norvegicus,,A,Half life determined in rat by intravenous administration,,CHEMBL627890,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
9435,Rattus norvegicus,,A,Half life determined in rats after iv administration,,CHEMBL627891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9436,Rattus norvegicus,,A,Half life in rat plasma after administration of 2 mg/kg iv,,CHEMBL627892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9437,Rattus norvegicus,,A,Half life in rat plasma after administration of 2 mg/kg iv,,CHEMBL627893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9438,Rattus norvegicus,,A,Half life in rat plasma was determined,,CHEMBL627894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9439,Rattus norvegicus,,A,Half life in rat plasma was determined; NA means not applicable,,CHEMBL627895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9440,Rattus norvegicus,,A,Half life in rat was tested,,CHEMBL627896,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9441,Rattus norvegicus,,A,Half life measured in rat plasma,,CHEMBL627897,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9442,Rattus norvegicus,,A,Half life recorded in rats,,CHEMBL627898,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9443,Rattus norvegicus,,A,Half life was calculated,,CHEMBL627899,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9444,Rattus norvegicus,,A,Half life was calculated in rat,,CHEMBL873823,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9445,Rattus norvegicus,,A,Half life was determined,,CHEMBL627900,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9446,Rattus norvegicus,,A,Half life after 10 mg/kg oral administration in rat,,CHEMBL627901,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9447,Rattus norvegicus,,A,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,CHEMBL627902,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9448,Rattus norvegicus,,A,Half life after administering orally a dose of 30 mg/kg,,CHEMBL627903,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9449,Rattus norvegicus,,A,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,CHEMBL627904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9450,Rattus norvegicus,,A,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,CHEMBL627905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9451,Rattus norvegicus,,A,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,CHEMBL627906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9452,Rattus norvegicus,,A,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,CHEMBL627907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9453,Rattus norvegicus,,A,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,CHEMBL876783,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9454,Rattus norvegicus,,A,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,CHEMBL627908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9455,Rattus norvegicus,,A,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL627909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9456,Rattus norvegicus,,A,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,CHEMBL627910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9457,Rattus norvegicus,,A,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,CHEMBL627911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9458,Rattus norvegicus,,A,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,CHEMBL627912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9459,Rattus norvegicus,,A,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,CHEMBL627913,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9460,Rattus norvegicus,,A,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,CHEMBL627914,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9461,Rattus norvegicus,,A,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL627915,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9462,Rattus norvegicus,,A,Area under the curve was evaluated after 20 uM/kg of peroral administration,,CHEMBL627916,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9463,Rattus norvegicus,,A,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,CHEMBL627917,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9464,Rattus norvegicus,,A,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,CHEMBL627918,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9465,Rattus norvegicus,,A,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,CHEMBL627919,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9466,Rattus norvegicus,,A,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,CHEMBL627920,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9467,Rattus norvegicus,,A,Area under the curve was evaluated at an oral dose of 30 mg/kg,,CHEMBL627921,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9468,Rattus norvegicus,,A,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9469,Rattus norvegicus,,A,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL876784,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9470,Rattus norvegicus,,A,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9471,Rattus norvegicus,,A,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9472,Rattus norvegicus,,A,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9473,Rattus norvegicus,,A,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9474,Rattus norvegicus,,A,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,CHEMBL627994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9475,Rattus norvegicus,,A,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,CHEMBL627995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9476,Rattus norvegicus,,A,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,CHEMBL627996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9477,Rattus norvegicus,,A,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,CHEMBL627997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9478,Rattus norvegicus,,A,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL627998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9479,Rattus norvegicus,,A,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL628640,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9480,Rattus norvegicus,,A,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL628641,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9481,Rattus norvegicus,,A,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL628642,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9482,Rattus norvegicus,,A,Compound was evaluated for area under the curve expressed as (h*ug/ml),,CHEMBL628643,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9483,Rattus norvegicus,,A,Compound was tested for area under curve in rat,,CHEMBL628644,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9484,Rattus norvegicus,,A,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,CHEMBL628645,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9485,Rattus norvegicus,,A,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL628646,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9486,Rattus norvegicus,,A,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,CHEMBL628647,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9487,Rattus norvegicus,,A,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,CHEMBL628648,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9488,Rattus norvegicus,,A,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL625358,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9489,Rattus norvegicus,,A,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,CHEMBL625359,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9490,Rattus norvegicus,,A,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL625360,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9491,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,CHEMBL625361,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9492,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,CHEMBL625362,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9493,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,CHEMBL625363,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9494,Rattus norvegicus,,A,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,CHEMBL625364,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9495,Rattus norvegicus,,A,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL625365,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9496,Rattus norvegicus,,A,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL625366,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9497,Rattus norvegicus,,A,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL625367,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9498,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,CHEMBL625368,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9499,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,CHEMBL625369,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9500,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,CHEMBL625370,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9501,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,CHEMBL625371,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9502,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,CHEMBL625372,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9503,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,CHEMBL625373,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9504,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,CHEMBL625374,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9505,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,CHEMBL877593,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9506,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,CHEMBL625375,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9507,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,CHEMBL625376,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9508,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,CHEMBL621973,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9509,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,CHEMBL621974,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9510,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,CHEMBL621975,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9511,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,CHEMBL622166,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9512,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,CHEMBL622167,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9513,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,CHEMBL622168,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9514,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,CHEMBL622169,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9515,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,CHEMBL622170,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9516,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,CHEMBL622171,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9517,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,CHEMBL622172,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9518,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,CHEMBL622173,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9519,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,CHEMBL622174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9520,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,CHEMBL622175,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9521,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,CHEMBL622176,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9522,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,CHEMBL622177,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9523,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,CHEMBL622178,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9524,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,CHEMBL622179,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9525,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,CHEMBL622180,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9526,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL622181,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9527,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL622182,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9528,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL622183,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9529,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL622184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9530,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL622185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9531,Rattus norvegicus,,A,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL622186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9532,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL622187,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9533,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,CHEMBL625002,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9534,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,CHEMBL622090,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9535,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL622091,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9536,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL622092,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9537,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL622093,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9538,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL622094,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9539,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL622095,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9540,Rattus norvegicus,,A,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL622264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9541,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL622265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9542,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9543,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL622267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9544,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL622268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9545,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL622269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9546,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL625071,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9547,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL621621,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9548,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL621622,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9549,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL621623,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9550,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL621624,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9551,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL621625,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9552,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL621626,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9553,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL621627,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9554,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL621628,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9555,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL875328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9556,Rattus norvegicus,,A,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL621629,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9557,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL621630,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9558,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL621631,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9559,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL621632,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9560,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL621633,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9561,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL621634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9562,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL621635,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9563,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL621636,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9564,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL621637,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9565,Rattus norvegicus,,A,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL621638,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9566,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL618883,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9567,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL618884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9568,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL628627,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9569,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL628628,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9570,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL628629,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9571,Rattus norvegicus,,A,Half life after administering orally a dose of 3 mg/kg,,CHEMBL628630,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9572,Rattus norvegicus,,A,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,CHEMBL628631,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9573,Rattus norvegicus,,A,Half life after administering intravenously a dose of 1 mg/kg,,CHEMBL628632,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9574,Rattus norvegicus,,A,Half life after oral dosing in rats,,CHEMBL628633,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9575,Rattus norvegicus,,A,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,CHEMBL628634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9576,Rattus norvegicus,,A,Half life by intravenous administration of 3.4 mg/kg in rat,,CHEMBL627789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9577,Rattus norvegicus,,A,Half life in rat,,CHEMBL627790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9578,Rattus norvegicus,,A,Half life in rat,,CHEMBL627791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9579,Rattus norvegicus,,A,Half life in rat,,CHEMBL627792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9580,Rattus norvegicus,,A,Half life in rat after intravenous administration of the compound,,CHEMBL627793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9581,Rattus norvegicus,,A,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,CHEMBL627794,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9582,Rattus norvegicus,,A,Half life in rat after po administration of the compound,,CHEMBL627795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9583,Rattus norvegicus,,A,Half life in rat after po administration of the compound; ND means Not determined,,CHEMBL627796,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9584,Rattus norvegicus,,A,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,CHEMBL875335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9585,Rattus norvegicus,,A,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,CHEMBL627797,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9586,Rattus norvegicus,,A,Half life in rat i.v.,,CHEMBL627798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9587,Rattus norvegicus,,A,Half life in rat i.v. at 2 mg/kg concentration,,CHEMBL627799,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9588,Rattus norvegicus,,A,Half life in rats,,CHEMBL627800,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9589,Rattus norvegicus,,A,Half life in rats after intravenous administration,,CHEMBL627801,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9590,Rattus norvegicus,,A,Half life in rats at the dose of 1.0 mpk by i.v. administration,,CHEMBL627802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9591,Rattus norvegicus,,A,Half life in rat,,CHEMBL627803,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
9592,Rattus norvegicus,,A,Half life was evaluated after intravenous administration to rats,,CHEMBL873820,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9593,Rattus norvegicus,,A,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,CHEMBL627804,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9594,Rattus norvegicus,,A,Half life was evaluated in rat,,CHEMBL627805,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9595,Rattus norvegicus,,A,Half life was evaluated in rat,,CHEMBL627806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9596,Rattus norvegicus,,A,Half life was evaluated in rat; Not tested,,CHEMBL627107,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9597,Rattus norvegicus,,A,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,CHEMBL627108,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9598,Rattus norvegicus,,A,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,CHEMBL627109,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9599,Rattus norvegicus,,A,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,CHEMBL627110,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9600,Primates,,A,Half life was measured in monkey at dose of 10 mg/kg by po administration,,CHEMBL627111,9443.0,0,1,U,22224,Intermediate,,,BAO_0000218,
9601,Primates,,A,Half life was measured in monkey at dose of 10 mg/kg by po administration,,CHEMBL627112,9443.0,0,1,U,22224,Intermediate,,,BAO_0000218,
9602,Rattus norvegicus,,A,Half life was measured in rat at dose of 30 mg/kg by iv administration,,CHEMBL627113,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
9603,Rattus norvegicus,,A,Half life was measured in rat at dose of 30 mg/kg by po administration,,CHEMBL627114,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
9604,Rattus norvegicus,,A,Half life (t1/2) was determined,,CHEMBL627115,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9605,Rattus norvegicus,,A,Half life period at a dose of 10 uM/kg in rat was determined,,CHEMBL627116,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9606,Rattus norvegicus,,A,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,CHEMBL627117,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9607,Rattus norvegicus,,A,Half life period was determined,,CHEMBL627118,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9608,Rattus norvegicus,,A,Half life period after intravenous administration at 20 mpk in rats,,CHEMBL627119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9609,Rattus norvegicus,,A,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,CHEMBL627120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9610,Rattus norvegicus,,A,Half life period after intravenous administration in rat,,CHEMBL626922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9611,Rattus norvegicus,,A,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL626923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9612,Rattus norvegicus,,A,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL626924,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9613,Rattus norvegicus,,A,Half life period in 80% rat plasma at 37 degree Centigrade,,CHEMBL626925,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9614,Rattus norvegicus,,A,Half life period in SD rats,,CHEMBL626926,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9615,Rattus norvegicus,,A,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,CHEMBL626927,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9616,Rattus norvegicus,,A,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,CHEMBL626928,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9617,Rattus norvegicus,,A,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626929,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9618,Rattus norvegicus,,A,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626930,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9619,Rattus norvegicus,,A,Half life period in rat,,CHEMBL626931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9620,Rattus norvegicus,,A,Half life period in rat,,CHEMBL626932,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9621,Rattus norvegicus,,A,Half life period in rat,,CHEMBL626933,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9622,Rattus norvegicus,,A,Half life period in rat after oral administration at 10.5 mg/kg dose,,CHEMBL873826,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9623,Rattus norvegicus,,A,Half life period in rat after oral administration at 11.2 mg/kg dose,,CHEMBL626934,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9624,Rattus norvegicus,,A,Half life period in rat after oral administration at 13 mg/kg dose,,CHEMBL626935,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9625,Rattus norvegicus,,A,Half life period in rat after oral administration at 9.7 mg/kg dose,,CHEMBL626936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9626,Rattus norvegicus,,A,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL626937,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9627,Rattus norvegicus,,A,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,CHEMBL625906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9628,Rattus norvegicus,,A,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,CHEMBL625907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9629,Rattus norvegicus,,A,PK study was carried to determine AUC (area under curve) value in rat,,CHEMBL625908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9630,Rattus norvegicus,,A,Pharmacokinetic parameter AUC after intravenous administration to rats,,CHEMBL625909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9631,Rattus norvegicus,,A,Pharmacokinetic parameter AUC after oral administration to rats,,CHEMBL625910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9632,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,CHEMBL625911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9633,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,CHEMBL625912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9634,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,CHEMBL626538,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9635,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,CHEMBL876794,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9636,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,CHEMBL626539,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9637,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,CHEMBL626540,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9638,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,CHEMBL626541,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9639,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,CHEMBL626542,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9640,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,CHEMBL626543,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9641,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,CHEMBL626544,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9642,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,CHEMBL626545,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9643,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,CHEMBL626546,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9644,Rattus norvegicus,,A,Pharmacokinetic parameter area under curve was reported,,CHEMBL626547,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9645,Rattus norvegicus,,A,Pharmacokinetic property (AUC) in rat,,CHEMBL626548,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9646,Rattus norvegicus,,A,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,CHEMBL626549,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9647,Rattus norvegicus,,A,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,CHEMBL626550,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9648,Rattus norvegicus,,A,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,CHEMBL626551,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9649,Rattus norvegicus,,A,Pharmacokinetic property was determined,,CHEMBL623777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9650,Rattus norvegicus,,A,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,CHEMBL623778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9651,Rattus norvegicus,,A,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,CHEMBL623779,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9652,Rattus norvegicus,,A,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL623780,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9653,Rattus norvegicus,,A,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL622015,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9654,Rattus norvegicus,,A,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL622016,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9655,Rattus norvegicus,,A,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,CHEMBL622017,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9656,Rattus norvegicus,,A,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,CHEMBL622018,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9657,Rattus norvegicus,,A,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,CHEMBL622019,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9658,Rattus norvegicus,,A,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,CHEMBL622020,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9659,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,CHEMBL622021,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9660,Rattus norvegicus,,A,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,CHEMBL622022,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9661,Rattus norvegicus,,A,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,CHEMBL622023,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9662,Rattus norvegicus,,A,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,CHEMBL622024,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9663,Rattus norvegicus,,A,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,CHEMBL622693,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9664,Rattus norvegicus,,A,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,CHEMBL622694,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9665,Rattus norvegicus,,A,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL622695,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9666,Rattus norvegicus,,A,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,CHEMBL622696,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9667,Rattus norvegicus,,A,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL622697,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9668,Rattus norvegicus,,A,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,CHEMBL622874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9669,Rattus norvegicus,,A,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,CHEMBL622875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9670,Rattus norvegicus,,A,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,CHEMBL622876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9671,Rattus norvegicus,,A,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,CHEMBL622877,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9672,Rattus norvegicus,,A,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL622878,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9673,Rattus norvegicus,,A,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL622879,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9674,Rattus norvegicus,,A,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,CHEMBL877602,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9675,Rattus norvegicus,,A,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622880,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9676,Rattus norvegicus,,A,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622881,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9677,Rattus norvegicus,,A,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9678,Rattus norvegicus,,A,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622883,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9679,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,CHEMBL622884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9680,Rattus norvegicus,,A,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,CHEMBL622885,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9681,Rattus norvegicus,,A,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,CHEMBL622886,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9682,Rattus norvegicus,,A,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL622887,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9683,Rattus norvegicus,,A,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,CHEMBL622888,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9684,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622889,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9685,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622890,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9686,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9687,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL877603,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9688,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9689,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9690,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9691,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9692,Rattus norvegicus,,A,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,CHEMBL622896,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9693,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622897,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9694,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622898,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9695,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622899,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9696,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622900,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9697,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624114,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9698,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624115,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9699,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624116,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9700,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624117,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9701,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624118,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9702,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9703,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9704,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9705,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9706,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624123,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9707,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624124,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9708,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624125,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9709,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624126,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9710,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9711,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624128,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9712,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624129,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9713,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624130,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9714,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622340,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9715,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622341,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
9716,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622342,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
9717,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622343,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
9718,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622344,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
9719,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622345,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
9720,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622346,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9721,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622347,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9722,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622348,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9723,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622349,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9724,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL622350,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9725,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL622351,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9726,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL622352,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9727,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL622353,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9728,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL622354,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9729,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL622355,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9730,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL622356,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9731,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL622357,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9732,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL622358,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9733,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL622359,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9734,Rattus norvegicus,,A,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL874393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9735,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL622872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9736,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL622873,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9737,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL623047,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9738,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL623048,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9739,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL623049,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9740,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL623050,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9741,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL623051,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9742,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL623052,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9743,Rattus norvegicus,,A,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL626343,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9744,Rattus norvegicus,,A,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL626344,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9745,Rattus norvegicus,,A,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL626345,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9746,Rattus norvegicus,,A,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL626346,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9747,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL626347,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9748,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL626348,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9749,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL626349,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9750,Rattus norvegicus,,F,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL626350,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9751,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL626351,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9752,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL627650,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9753,Rattus norvegicus,,F,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL627651,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9754,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL627652,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9755,Rattus norvegicus,,A,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL627653,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9756,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,CHEMBL627654,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9757,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,CHEMBL627835,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9758,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,CHEMBL627836,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9759,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,CHEMBL627837,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9760,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,CHEMBL627838,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9761,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,CHEMBL875338,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9762,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,CHEMBL627839,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9763,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,CHEMBL627840,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9764,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,CHEMBL627841,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9765,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,CHEMBL627842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9766,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,CHEMBL627843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9767,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,CHEMBL627844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9768,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,CHEMBL627845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9769,Rattus norvegicus,,A,Half life period in rat by iv administration at a dose of 3 mg/kg,,CHEMBL627846,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9770,Rattus norvegicus,,A,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,CHEMBL627847,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9771,Rattus norvegicus,,A,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,CHEMBL873821,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9772,Rattus norvegicus,,A,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9773,Rattus norvegicus,,A,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626080,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9774,Rattus norvegicus,,A,Half life period was evaluated in rat plasma,,CHEMBL626081,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9775,Rattus norvegicus,,A,Half life period was evaluated in rat plasma; Not tested,,CHEMBL875344,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9776,Rattus norvegicus,,A,Half life period was evaluated in rats,,CHEMBL626082,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9777,Rattus norvegicus,,A,"Half life period was evaluated in rats, iv",,CHEMBL626250,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9778,Rattus norvegicus,,A,Half life period after intravenous administration at 5 mg/kg in rat,,CHEMBL626251,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9779,Rattus norvegicus,,A,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,CHEMBL626252,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9780,Rattus norvegicus,,A,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,CHEMBL626253,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9781,Rattus norvegicus,,A,Half life stability of compound was evaluated in rat plasma,,CHEMBL626254,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9782,Rattus norvegicus,,A,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,CHEMBL626255,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9783,Rattus norvegicus,,A,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,CHEMBL626256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9784,Rattus norvegicus,,A,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,CHEMBL626257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9785,Rattus norvegicus,,A,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,CHEMBL626258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9786,Rattus norvegicus,,A,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,CHEMBL626259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9787,Rattus norvegicus,,A,Half in rat i.v.,,CHEMBL626260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9788,Rattus norvegicus,,A,Half period in rat after intravenous administration,,CHEMBL875345,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9789,Rattus norvegicus,,A,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,CHEMBL626261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9790,Rattus norvegicus,,A,Half-life measured in in vitro Cathepsin B assay in rat liver,,CHEMBL626262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9791,Rattus norvegicus,,A,Half-life of compound was determined in rats,,CHEMBL626263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9792,Rattus norvegicus,,A,Half-life at 10 mg/kg in rat upon intravenous administration,,CHEMBL625270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9793,Rattus norvegicus,,A,Half-life determined in rat,,CHEMBL625271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9794,Rattus norvegicus,,A,Half-life determined in rat,,CHEMBL625272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9795,Rattus norvegicus,,A,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL625273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9796,Rattus norvegicus,,A,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,CHEMBL625274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9797,Rattus norvegicus,,A,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL625275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9798,Rattus norvegicus,,A,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL625276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9799,Rattus norvegicus,,A,Half-life in rat plasma,,CHEMBL625277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9800,Rattus norvegicus,,A,Half-life in rat plasma was determined,,CHEMBL625278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9801,Rattus norvegicus,,A,Half-life in rat plasma; Not tested,,CHEMBL625279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9802,Rattus norvegicus,,A,Half-life in rat serum,,CHEMBL625280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9803,Rattus norvegicus,,A,Half-life in rat serum; na is not available,,CHEMBL876797,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
9804,Rattus norvegicus,,A,Half-life was calculated in rat,,CHEMBL625281,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9805,Rattus norvegicus,,A,Half-life was calculated in rat plasma,,CHEMBL873827,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9806,Rattus norvegicus,,A,Half-life was determined,,CHEMBL625282,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9807,Rattus norvegicus,,A,Half-life was determined,,CHEMBL625283,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9808,Rattus norvegicus,,A,Half-life after administration of 20 mg/Kg oral dose in rat,,CHEMBL625284,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9809,Rattus norvegicus,,A,Half-life after administration of 3.2 mg/kg intravenously in male rat,,CHEMBL625285,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9810,Rattus norvegicus,,A,Half-life after intravenous administration in female rat,,CHEMBL625286,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9811,Rattus norvegicus,,A,Half-life after intravenous administration in male rat,,CHEMBL625287,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9812,Rattus norvegicus,,A,Half-life after intravenous dose in rat,,CHEMBL625288,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9813,Rattus norvegicus,,A,Half-life in a rat liver homogenate preparation,,CHEMBL625289,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9814,Rattus norvegicus,,A,Half-life in plasma of rat,,CHEMBL625290,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9815,Rattus norvegicus,,A,Half-life in plasma of rat at dose of 3-10 mgkg,,CHEMBL876798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9816,Rattus norvegicus,,A,Half-life in rat,,CHEMBL625291,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9817,Rattus norvegicus,,A,Half-life in rat,,CHEMBL625292,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9818,Rattus norvegicus,,A,Half-life in rat,,CHEMBL625293,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9819,Rattus norvegicus,,A,Half-life in rat,,CHEMBL622832,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9820,Rattus norvegicus,,A,Half-life in rat,,CHEMBL622833,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9821,Rattus norvegicus,,A,Half-life in rat,,CHEMBL622834,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9822,Rattus norvegicus,,A,Half-life in rat after oral administration at 10 mg/kg,,CHEMBL622835,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9823,Rattus norvegicus,,A,Half-life in rat after po administration at a dose of 10 mg/kg,,CHEMBL622836,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9824,Rattus norvegicus,,A,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,CHEMBL622837,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9825,Rattus norvegicus,,A,Half-life in rat at 3 mg/kg dose administered intravenously,,CHEMBL622838,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9826,Rattus norvegicus,,A,Half-life in rat brain homogenate,,CHEMBL622839,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9827,Rattus norvegicus,,A,Half-life in rat plasma,,CHEMBL622840,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9828,Rattus norvegicus,,A,Half-life in rats,,CHEMBL622841,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9829,Rattus norvegicus,,A,Half-life in Dawley rats,,CHEMBL622842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9830,Rattus norvegicus,,A,Half-life in vitro in rat plasma,,CHEMBL622843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9831,Rattus norvegicus,,A,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,CHEMBL622844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9832,Rattus norvegicus,,A,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,CHEMBL622845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9833,Rattus norvegicus,,A,The area under the curve of compound was measured at the dose of 100 umol/kg,,CHEMBL622846,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9834,Rattus norvegicus,,A,The area under the curve of compound was measured at the dose of 300 umol/kg,,CHEMBL622847,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9835,Rattus norvegicus,,A,The area under the curve of compound was measured at the dose of 30 umol/kg,,CHEMBL622848,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9836,Rattus norvegicus,,A,Bioavailability as oral AUC in rats,,CHEMBL622849,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9837,Rattus norvegicus,,A,The plasma concentration versus time curve (AUC) was determined,,CHEMBL622850,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9838,Rattus norvegicus,,A,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL876807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9839,Rattus norvegicus,,A,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622851,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9840,Rattus norvegicus,,A,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622852,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9841,Rattus norvegicus,,A,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,CHEMBL622853,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9842,Rattus norvegicus,,A,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,CHEMBL622854,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9843,Rattus norvegicus,,A,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622855,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9844,Rattus norvegicus,,A,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL622856,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9845,Rattus norvegicus,,A,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL622857,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9846,Rattus norvegicus,,A,AUC in rat after po administration at a dose of 10 mg/kg,,CHEMBL622858,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9847,Rattus norvegicus,,A,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,CHEMBL622859,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9848,Rattus norvegicus,,A,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,CHEMBL622860,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9849,Rattus norvegicus,,A,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,CHEMBL622861,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9850,Rattus norvegicus,,A,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,CHEMBL622862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9851,Rattus norvegicus,,A,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,CHEMBL622863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9852,Rattus norvegicus,,A,Area under curve value 6 hr after po administration in rat,,CHEMBL623817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9853,Rattus norvegicus,,A,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623818,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9854,Rattus norvegicus,,A,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,CHEMBL623819,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9855,Rattus norvegicus,,A,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623820,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9856,Rattus norvegicus,,A,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,CHEMBL623821,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9857,Rattus norvegicus,,A,AUC normalized for dose (AUCN) in rat,,CHEMBL623822,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9858,Rattus norvegicus,,A,Area under curve in rat after p.o. administration,,CHEMBL623823,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9859,Rattus norvegicus,,A,Area under curve in rat after p.o. administration,,CHEMBL623824,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9860,Rattus norvegicus,,A,Area under curve in rat after p.o. administration; Not determined,,CHEMBL623825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9861,Rattus norvegicus,,A,Area under curve in rat after peroral administration,,CHEMBL622070,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9862,Rattus norvegicus,,A,Area under curve (carotid artery) value of the compound,,CHEMBL622071,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9863,Rattus norvegicus,,A,Bioavailability expressed as the area under curve of rat carotid artery,,CHEMBL622072,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9864,Rattus norvegicus,,A,Area under curve in male SD rats was observed after intravenous administration in rat,,CHEMBL622073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9865,Rattus norvegicus,,A,Area under curve of the compound was determined,,CHEMBL622074,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9866,Rattus norvegicus,,A,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,CHEMBL622075,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9867,Rattus norvegicus,,A,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,CHEMBL622076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9868,Rattus norvegicus,,A,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,CHEMBL622077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9869,Rattus norvegicus,,A,Area under curve (portal vein) value of the compound,,CHEMBL622078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9870,Rattus norvegicus,,A,Bioavailability expressed as the area under curve of rat portal vein,,CHEMBL622079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9871,Rattus norvegicus,,A,Area Under plasma concentration time curve in rat upon peroral administration,,CHEMBL622080,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9872,Rattus norvegicus,,A,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,CHEMBL877612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9873,Rattus norvegicus,,A,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,CHEMBL622081,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9874,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats,,CHEMBL622082,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9875,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats after iv administration,,CHEMBL622083,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9876,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats; 30-80,,CHEMBL622084,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9877,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats; 50-60,,CHEMBL622085,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9878,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats; no data,,CHEMBL622086,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9879,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats; peptide,,CHEMBL622087,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9880,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,CHEMBL622088,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9881,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,CHEMBL622089,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9882,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,CHEMBL623685,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9883,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,CHEMBL623686,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9884,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL623687,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9885,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL623688,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9886,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL623689,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9887,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,945.0
9888,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622486,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9889,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL877613,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9890,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622487,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9891,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622488,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
9892,Rattus norvegicus,,A,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9893,Rattus norvegicus,,A,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,CHEMBL622490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9894,Rattus norvegicus,,A,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,CHEMBL622491,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9895,Rattus norvegicus,,A,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,CHEMBL622492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9896,Rattus norvegicus,,A,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,CHEMBL622493,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9897,Rattus norvegicus,,A,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,CHEMBL622494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9898,Rattus norvegicus,,A,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9899,Rattus norvegicus,,A,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,CHEMBL622496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9900,Rattus norvegicus,,A,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,CHEMBL622497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9901,Rattus norvegicus,,A,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,CHEMBL622498,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9902,Rattus norvegicus,,A,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,CHEMBL624918,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9903,Rattus norvegicus,,A,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,CHEMBL624919,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9904,Rattus norvegicus,,A,Biodistribution of compound in rat blood after 5 min of administration,,CHEMBL624920,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9905,Rattus norvegicus,,A,Biodistribution of compound in rat blood after 5 min of administration.,,CHEMBL624921,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
9906,Rattus norvegicus,,A,Biodistribution of compound in rat brain after 5 min of administration,,CHEMBL624922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
9907,Rattus norvegicus,,A,Biodistribution of compound in rat heart after 5 min of administration,,CHEMBL624923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9908,Rattus norvegicus,,A,Biodistribution of compound in rat heart after 5 min of administration.,,CHEMBL624924,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9909,Rattus norvegicus,,A,Biodistribution of compound in rat kidney after 5 min of administration,,CHEMBL624925,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9910,Rattus norvegicus,,A,Biodistribution of compound in rat kidney after 5 min of administration.,,CHEMBL624926,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9911,Rattus norvegicus,,A,Biodistribution of compound in rat liver after 5 min of administration,,CHEMBL624927,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9912,Rattus norvegicus,,A,Biodistribution of compound in rat liver after 5 min of administration.,,CHEMBL874402,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9913,Rattus norvegicus,,A,Biodistribution of compound in rat lung after 5 min of administration,,CHEMBL624928,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9914,Rattus norvegicus,,A,Biodistribution of compound in rat lung after 5 min of administration.,,CHEMBL624929,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
9915,Rattus norvegicus,,A,Biodistribution of compound in rat muscle after 5 min of administration,,CHEMBL624930,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9916,Rattus norvegicus,,A,Biodistribution of compound in rat muscle after 5 min of administration.,,CHEMBL624931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9917,Rattus norvegicus,,A,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624932,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9918,Rattus norvegicus,,A,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624933,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
9919,Rattus norvegicus,,A,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624934,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9920,Rattus norvegicus,,A,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624935,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9921,Rattus norvegicus,,A,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9922,Rattus norvegicus,,A,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624937,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9923,Rattus norvegicus,,A,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624938,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9924,Rattus norvegicus,,A,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624939,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
9925,Rattus norvegicus,,A,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624940,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9926,Rattus norvegicus,,A,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL874403,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9927,Rattus norvegicus,,A,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,CHEMBL624941,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9928,Rattus norvegicus,,A,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,CHEMBL624942,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9929,Rattus norvegicus,,A,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,CHEMBL624943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
9930,Rattus norvegicus,,A,% Bioavailability after 1 day of the drug administration in rats,,CHEMBL624944,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9931,Rattus norvegicus,,A,% Bioavailability after 4 day of the drug administration in rats,,CHEMBL624945,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9932,Rattus norvegicus,,A,Absolute bioavailability was evaluated in rat,,CHEMBL624946,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9933,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,CHEMBL624947,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9934,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,CHEMBL624948,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9935,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,CHEMBL624949,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9936,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,CHEMBL622025,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9937,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,CHEMBL622026,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9938,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,CHEMBL622027,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9939,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,CHEMBL622028,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
9940,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,CHEMBL622029,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9941,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,CHEMBL622208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9942,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,CHEMBL622209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9943,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,CHEMBL622210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
9944,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,CHEMBL622211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9945,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,CHEMBL622212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9946,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,CHEMBL622213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9947,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,CHEMBL874404,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9948,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,CHEMBL620452,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9949,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,CHEMBL620453,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9950,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,CHEMBL620454,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9951,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,CHEMBL624067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9952,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,CHEMBL624068,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9953,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,CHEMBL624069,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
9954,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,CHEMBL624070,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
9955,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,CHEMBL624071,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
9956,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,CHEMBL624072,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
9957,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,CHEMBL624073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
9958,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,CHEMBL624788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
9959,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,CHEMBL624789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
9960,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,CHEMBL624790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9961,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,CHEMBL624791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9962,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,CHEMBL624792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9963,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,CHEMBL624793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9964,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,CHEMBL877491,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9965,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,CHEMBL624957,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9966,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,CHEMBL624958,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9967,Rattus norvegicus,,A,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,CHEMBL624959,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
9968,Rattus norvegicus,,A,Dissociation constant was determined,,CHEMBL624960,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9969,Rattus norvegicus,,A,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL624961,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9970,Rattus norvegicus,,A,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624962,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9971,Rattus norvegicus,,A,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9972,Rattus norvegicus,,A,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,CHEMBL624964,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9973,Rattus norvegicus,,A,LogP value was evaluated in the in situ rat gut perfusion assay,,CHEMBL624965,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9974,Rattus norvegicus,,A,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL624966,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9975,Rattus norvegicus,,A,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,CHEMBL624967,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9976,Rattus norvegicus,,A,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,CHEMBL624968,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9977,Rattus norvegicus,,A,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL624969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9978,Rattus norvegicus,,F,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,CHEMBL624970,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
9979,Rattus norvegicus,,A,Half-life was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL624971,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9980,Rattus norvegicus,,A,Half-life was evaluated after 20 uM/kg of peroral administration,,CHEMBL624972,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9981,Rattus norvegicus,,A,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,CHEMBL624973,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9982,Rattus norvegicus,,A,Half-life was evaluated in plasma of rat,,CHEMBL624974,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9983,Rattus norvegicus,,A,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,CHEMBL624975,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9984,Rattus norvegicus,,A,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL877492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9985,Rattus norvegicus,,A,Half-life was measured in rat after an iv dose of 1 mg/kg,,CHEMBL624976,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9986,Rattus norvegicus,,A,Half-life period of compound in rats after peroral administration,,CHEMBL624977,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9987,Rattus norvegicus,,A,Half-life period of compound was measured in rat plasma.,,CHEMBL626848,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9988,Rattus norvegicus,,A,Half-life period of compound was measured in rat plasma; ND is not determined,,CHEMBL626849,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9989,Rattus norvegicus,,A,Half-life period of compound was measured in rat plasma; not determined,,CHEMBL626850,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
9990,Rattus norvegicus,,A,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL626851,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9991,Rattus norvegicus,,A,Half-life period in rat by iv administration,,CHEMBL626852,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9992,Rattus norvegicus,,A,Half-life period in rats following intravenous administration at 2 mg/kg,,CHEMBL626853,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9993,Rattus norvegicus,,A,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL626854,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9994,Rattus norvegicus,,A,Half-life period was determined for the compound in rat,,CHEMBL627486,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9995,Rattus norvegicus,,A,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,CHEMBL627487,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9996,Rattus norvegicus,,A,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,CHEMBL627488,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9997,Rattus norvegicus,,A,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,CHEMBL627489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9998,Rattus norvegicus,,A,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL627490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
9999,Rattus norvegicus,,A,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,CHEMBL873829,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10000,Rattus norvegicus,,A,Half-life was determined in rat at a dose of 1 mpk i.v.,,CHEMBL627655,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10001,Rattus norvegicus,,A,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,CHEMBL625994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10002,Rattus norvegicus,,A,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,CHEMBL625995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10003,Rattus norvegicus,,A,Half-life in rat,,CHEMBL625996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10004,Rattus norvegicus,,A,In vitro half life in rat plasma,,CHEMBL625850,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10005,Rattus norvegicus,,A,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,CHEMBL625851,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10006,Rattus norvegicus,,A,In vitro half life in rat,,CHEMBL625852,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10007,Rattus norvegicus,,A,In vivo half life period after intravenous administration in rat,,CHEMBL625853,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10008,Rattus norvegicus,,A,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL625854,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10009,Rattus norvegicus,,A,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,CHEMBL874450,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10010,Rattus norvegicus,,A,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL625855,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10011,Rattus norvegicus,,A,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL625856,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10012,Rattus norvegicus,,A,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL625857,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10013,Rattus norvegicus,,A,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL873831,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10014,Rattus norvegicus,,A,Longer half-life in rat (i.v.) at 0.5 mpk,,CHEMBL625858,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10015,Rattus norvegicus,,A,Longer half-life in rat (p.o.) at 2.0 mpk,,CHEMBL625859,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10016,Rattus norvegicus,,A,Pharmacokinetic property (half life) in rat,,CHEMBL625860,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10017,Rattus norvegicus,,A,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,CHEMBL625861,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10018,Rattus norvegicus,,A,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,CHEMBL625862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10019,Rattus norvegicus,,A,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,CHEMBL625863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10020,Rattus norvegicus,,A,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,CHEMBL625864,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10021,Rattus norvegicus,,A,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,CHEMBL625865,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10022,Rattus norvegicus,,A,Pharmacokinetic half time was determined intravenously in rats.,,CHEMBL625866,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10023,Rattus norvegicus,,A,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,CHEMBL625867,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10024,Rattus norvegicus,,A,Plasma half life of hydrolysis of the compound,,CHEMBL625868,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10025,Rattus norvegicus,,A,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,CHEMBL625869,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10026,Rattus norvegicus,,A,Plasma half life period was calculated in rat,,CHEMBL874451,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10027,Rattus norvegicus,,A,Plasma half-life in Sprague-Dawley rats,,CHEMBL625870,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10028,Rattus norvegicus,,A,Plasma half-life in Sprague-Dawley rats; Not determined,,CHEMBL625871,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10029,Rattus norvegicus,,A,Plasma half-life in rats,,CHEMBL625872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10030,Rattus norvegicus,,A,Plasma half-life in rats; <MQL,,CHEMBL625873,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10031,Rattus norvegicus,,A,Plasma half-life period (0-8 h) was determined,,CHEMBL625874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10032,Rattus norvegicus,,A,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,CHEMBL625875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10033,Rattus norvegicus,,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,CHEMBL625876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10034,Rattus norvegicus,,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,CHEMBL631258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10035,Rattus norvegicus,,A,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,CHEMBL631259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10036,Rattus norvegicus,,A,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,CHEMBL631260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10037,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,CHEMBL631261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10038,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,CHEMBL631262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10039,Rattus norvegicus,,A,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,CHEMBL631263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10040,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,CHEMBL631264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10041,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,CHEMBL631265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10042,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,CHEMBL631266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10043,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,CHEMBL631267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10044,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,CHEMBL631268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10045,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,CHEMBL631269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10046,Rattus norvegicus,,A,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,CHEMBL631270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10047,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,CHEMBL631271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10048,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,CHEMBL631272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10049,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,CHEMBL631273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10050,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,CHEMBL631274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10051,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,CHEMBL631275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10052,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,CHEMBL626984,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10053,Rattus norvegicus,,A,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,CHEMBL626985,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10054,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,CHEMBL626986,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10055,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,CHEMBL626987,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10056,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,CHEMBL626988,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10057,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,CHEMBL626989,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10058,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,CHEMBL626990,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10059,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,CHEMBL626991,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10060,Rattus norvegicus,,A,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,CHEMBL626992,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10061,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,CHEMBL626993,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10062,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,CHEMBL874593,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10063,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,CHEMBL626994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10064,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,CHEMBL626995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10065,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,CHEMBL626190,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10066,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,CHEMBL626191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10067,Rattus norvegicus,,A,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,CHEMBL626364,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10068,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,CHEMBL626365,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10069,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,CHEMBL626366,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10070,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,CHEMBL626367,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10071,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,CHEMBL626368,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10072,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,CHEMBL626369,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10073,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,CHEMBL626370,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10074,Rattus norvegicus,,A,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,CHEMBL626371,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10075,Rattus norvegicus,,A,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,CHEMBL626372,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10076,Rattus norvegicus,,A,Bioavailability after a dose of 10 mg/kg p.o.,,CHEMBL626373,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10077,Rattus norvegicus,,A,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,CHEMBL626374,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10078,Rattus norvegicus,,A,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,CHEMBL626375,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10079,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,CHEMBL626376,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10080,Rattus norvegicus,,A,Bioavailability in rat po was determined,,CHEMBL626377,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10081,Rattus norvegicus,,A,Bioavailability of compound at 10 mg/kg in rat after oral administration,,CHEMBL626378,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10082,Rattus norvegicus,,A,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,CHEMBL626379,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10083,Rattus norvegicus,,A,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL626380,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10084,Rattus norvegicus,,A,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL626381,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10085,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL626382,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10086,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley) (female),,CHEMBL626383,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10087,Rattus norvegicus,,A,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL874652,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10088,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,CHEMBL626384,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10089,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,CHEMBL626385,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10090,Rattus norvegicus,,A,Bioavailability in rat at an oral dose of 2 mg/kg,,CHEMBL626386,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10091,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL626387,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10092,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL626388,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10093,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL626389,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10094,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL626390,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10095,Rattus norvegicus,,A,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,CHEMBL626391,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10096,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL626392,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10097,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL626393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10098,Rattus norvegicus,,A,Bioavailability was determined in rat,,CHEMBL623026,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10099,Rattus norvegicus,,A,Bioavailability,,CHEMBL623027,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10100,Rattus norvegicus,,A,Bioavailability,,CHEMBL623028,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10101,Rattus norvegicus,,A,Bioavailability in rat after 1 day dosing,,CHEMBL623029,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10102,Rattus norvegicus,,A,Bioavailability in rat after 4 day dosing,,CHEMBL623030,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10103,Rattus norvegicus,,A,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,CHEMBL623031,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10104,Rattus norvegicus,,A,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,CHEMBL623032,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10105,Rattus norvegicus,,A,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,CHEMBL623033,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10106,Rattus norvegicus,,A,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,CHEMBL623034,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10107,Rattus norvegicus,,A,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,CHEMBL623035,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10108,Rattus norvegicus,,A,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL623036,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10109,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL623037,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10110,Rattus norvegicus,,A,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,CHEMBL623038,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10111,Rattus norvegicus,,A,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,CHEMBL874385,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10112,Rattus norvegicus,,A,Bioavailability in rat (Fisher) (fasted),,CHEMBL623039,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10113,Primates,,A,Bioavailability in monkey after po administration of 10 mg/kg dose,,CHEMBL623040,9443.0,0,1,U,22224,Intermediate,,,BAO_0000218,
10114,Primates,,A,Oral bioavailability in monkey (dose 10 mg/kg),,CHEMBL623041,9443.0,0,1,U,22224,Intermediate,,,BAO_0000218,
10115,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL623741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10116,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL623742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10117,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL623743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10118,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL623744,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10119,Rattus norvegicus,,A,Bioavailability in rat (dose 2.0 mg/kg p.o.),,CHEMBL623745,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10120,Rattus norvegicus,,A,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,CHEMBL623746,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10121,Rattus norvegicus,,A,Oral bioavailability in rat (dose 5 mg/kg p.o.),,CHEMBL623747,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10122,Rattus norvegicus,,A,Bioavailability in rat after po administration of 30 mg/kg dose,,CHEMBL623748,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
10123,Rattus norvegicus,,A,Bioavailability in rat after po administration of 30 mg/kg dose,,CHEMBL623916,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
10124,Rattus norvegicus,,A,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL623917,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10125,Rattus norvegicus,,A,Bioavailability in rat (dose 2 mg/kg i.v.),,CHEMBL623918,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10126,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL874386,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10127,Rattus norvegicus,,A,Bioavailability in rat; Only traces detected in rat plasma,,CHEMBL623919,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10128,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL623920,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10129,Rattus norvegicus,,A,Bioavailability upon oral administration of compound,,CHEMBL623148,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10130,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,CHEMBL623149,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10131,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL623150,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10132,Rattus norvegicus,,A,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,CHEMBL623151,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10133,Rattus norvegicus,,A,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,CHEMBL623152,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10134,Rattus norvegicus,,F,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,CHEMBL623153,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
10135,Rattus norvegicus,,F,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,CHEMBL623154,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
10136,Rattus norvegicus,,A,In vitro and metabolic stability was determined,,CHEMBL623155,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10137,Rattus norvegicus,,A,In vitro metabolic stability in rat hepatocytes,,CHEMBL623156,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10138,Rattus norvegicus,,A,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,CHEMBL623157,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10139,Rattus norvegicus,,A,Metabolic rate for compound was observed in rat hepatocytes,,CHEMBL623158,10116.0,1,1,N,50597,Intermediate,,401.0,BAO_0000218,2107.0
10140,Rattus norvegicus,,A,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,CHEMBL623159,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10141,Rattus norvegicus,,A,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL874390,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10142,Rattus norvegicus,,A,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,CHEMBL623160,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10143,Rattus norvegicus,,A,Metabolism of compound in rat S9 microsomes; Trace,,CHEMBL623161,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10144,Rattus norvegicus,,A,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,CHEMBL623162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10145,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,CHEMBL623163,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10146,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,CHEMBL623164,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10147,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,CHEMBL623165,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10148,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,CHEMBL623166,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10149,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,CHEMBL624983,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10150,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,CHEMBL624984,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10151,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,CHEMBL624985,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10152,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,CHEMBL622970,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10153,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,CHEMBL622971,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10154,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,CHEMBL622972,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10155,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,CHEMBL622973,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10156,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,CHEMBL622974,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10157,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,CHEMBL622975,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10158,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,CHEMBL622976,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10159,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,CHEMBL622977,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10160,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,CHEMBL624351,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10161,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,CHEMBL624352,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10162,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,CHEMBL624353,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10163,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,CHEMBL622397,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10164,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,CHEMBL622398,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10165,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,CHEMBL622399,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10166,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,CHEMBL622400,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10167,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,CHEMBL628428,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10168,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,CHEMBL628590,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10169,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,CHEMBL628591,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10170,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,CHEMBL628592,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10171,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,CHEMBL628593,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10172,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,CHEMBL875333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10173,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,CHEMBL628594,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10174,Rattus norvegicus,,A,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,CHEMBL628595,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10175,Rattus norvegicus,,A,Stability in rat plasma was determined,,CHEMBL628596,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10176,Rattus norvegicus,,A,Stability in rat plasma was determined; ND= no data,,CHEMBL628597,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10177,Rattus norvegicus,,A,Tested for plasma half life period in rat (0-8 hr),,CHEMBL628598,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10178,Rattus norvegicus,,A,Tested for plasma half life period in rat (0-8 hr); Not determined,,CHEMBL628599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10179,Rattus norvegicus,,A,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,CHEMBL628600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10180,Rattus norvegicus,,A,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL628601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10181,Rattus norvegicus,,A,Tested for the half life in rat,,CHEMBL628602,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10182,Rattus norvegicus,,A,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,CHEMBL628603,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10183,Rattus norvegicus,,A,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,CHEMBL628604,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10184,Rattus norvegicus,,A,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,CHEMBL628605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10185,Rattus norvegicus,,A,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,CHEMBL628606,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10186,Rattus norvegicus,,A,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,CHEMBL628607,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10187,Rattus norvegicus,,A,The biological half life the compound was measured at the dose of 100 umol/kg,,CHEMBL628608,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10188,Rattus norvegicus,,A,The biological half life the compound was measured at the dose of 30 umol/kg,,CHEMBL628609,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10189,Rattus norvegicus,,A,The compound was evaluated for plasma half life period in rat,,CHEMBL628610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10190,Rattus norvegicus,,A,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL873819,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10191,Rattus norvegicus,,A,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL628611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10192,Rattus norvegicus,,A,The pharmacokinetic parameter half-life period in vivo in rats,,CHEMBL628612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10193,Rattus norvegicus,,A,"The pharmacokinetic property, Half-life was determined",,CHEMBL628613,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10194,Rattus norvegicus,,A,"The pharmacokinetic property, Half-life in rat in vivo",,CHEMBL628614,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10195,Rattus norvegicus,,A,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,CHEMBL628615,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10196,Rattus norvegicus,,A,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,CHEMBL628616,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10197,Rattus norvegicus,,A,The plasma half life period in rats,,CHEMBL627924,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10198,Rattus norvegicus,,A,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,CHEMBL627925,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10199,Rattus norvegicus,,A,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,CHEMBL627926,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10200,Rattus norvegicus,,A,t1/2 (apparent elimination)of the compound was determined,,CHEMBL627927,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10201,Rattus norvegicus,,A,t1/2 value in rat,,CHEMBL627928,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10202,Rattus norvegicus,,A,Half life in rat,,CHEMBL627539,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10203,Rattus norvegicus,,A,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,CHEMBL876790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10204,Rattus norvegicus,,A,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,CHEMBL858186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10205,Rattus norvegicus,,A,Half-life period in fasted rats,,CHEMBL627540,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10206,Rattus norvegicus,,A,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL627541,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10207,Rattus norvegicus,,A,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL627715,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10208,Rattus norvegicus,,A,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,CHEMBL627716,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10209,Rattus norvegicus,,A,Maximum time required to achieve Cmax was determined in rat,,CHEMBL627717,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10210,Rattus norvegicus,,A,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL627718,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10211,Rattus norvegicus,,A,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL627719,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10212,Rattus norvegicus,,A,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,CHEMBL627720,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10213,Rattus norvegicus,,A,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,CHEMBL627721,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10214,Rattus norvegicus,,A,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,CHEMBL627722,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10215,Rattus norvegicus,,A,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL627723,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10216,Rattus norvegicus,,A,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL626058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10217,Rattus norvegicus,,A,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL626059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10218,Rattus norvegicus,,A,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL626060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10219,Rattus norvegicus,,A,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL626061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10220,Rattus norvegicus,,A,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL876791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10221,Rattus norvegicus,,A,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10222,Rattus norvegicus,,A,Tmax at the dose of 2 mg/Kg administered perorally in rats,,CHEMBL626063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10223,Rattus norvegicus,,A,Tmax at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL626064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10224,Rattus norvegicus,,A,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,CHEMBL626065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10225,Rattus norvegicus,,A,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,CHEMBL626066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10226,Rattus norvegicus,,A,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL626067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10227,Rattus norvegicus,,F,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,CHEMBL626068,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10228,Rattus norvegicus,,F,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,CHEMBL626069,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10229,Rattus norvegicus,,F,Percent total excretion of 3-methoxyacetaminophen glucuronide,,CHEMBL626070,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10230,Rattus norvegicus,,F,Percent total excretion of N-methoxyacetaminophen glucuronide,,CHEMBL626071,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10231,Rattus norvegicus,,F,Percent total excretion of N-methoxyacetaminophen sulfate,,CHEMBL626072,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10232,Rattus norvegicus,,F,Percent total excretion of acetaminophen,,CHEMBL626073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10233,Rattus norvegicus,,A,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,CHEMBL626741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
10234,Rattus norvegicus,,A,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,CHEMBL626742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10235,Rattus norvegicus,,A,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,CHEMBL626743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10236,Rattus norvegicus,,A,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,CHEMBL876792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10237,Rattus norvegicus,,A,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,CHEMBL626744,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10238,Rattus norvegicus,,A,Compound was tested for antidiuretic activity in rats,,CHEMBL626745,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10239,Rattus norvegicus,,A,AUC in rat after 3mg/kg oral dose,,CHEMBL626746,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10240,Rattus norvegicus,,A,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,CHEMBL626747,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10241,Rattus norvegicus,,A,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,CHEMBL626748,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10242,Rattus norvegicus,,A,Bioavailability administered orally at a dose of 10 mg/kg to rats,,CHEMBL626749,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10243,Rattus norvegicus,,A,Oral Bioavailability was determined,,CHEMBL626750,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10244,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL626751,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10245,Rattus norvegicus,,A,Oral bioavailability in rat; Not performed.,,CHEMBL626913,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10246,Rattus norvegicus,,A,Bioavailability,,CHEMBL626914,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10247,Rattus norvegicus,,A,Bioavailability was determined; ND denotes no data,,CHEMBL626915,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10248,Rattus norvegicus,,A,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,CHEMBL626916,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10249,Rattus norvegicus,,A,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,CHEMBL626917,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10250,Rattus norvegicus,,A,Binding towards rat plasma protein at 10 uM,,CHEMBL626918,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10251,Rattus norvegicus,,A,Binding towards rat plasma protein at 100 uM,,CHEMBL626919,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10252,Rattus norvegicus,,A,Bioavailability in rat (dose 20 mg/kg p.o.),,CHEMBL626920,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10253,Rattus norvegicus,,A,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,CHEMBL621976,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10254,Rattus norvegicus,,A,Bioavailability in rat after 5 mg/kg oral gavage,,CHEMBL877599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10255,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL621977,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10256,Rattus norvegicus,,A,Bioavailability in rat (dose 1 mg/kg i.v.),,CHEMBL621978,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10257,Rattus norvegicus,,A,Bioavailability in rat (dose 3 mg/kg p.o.),,CHEMBL621979,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10258,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL621980,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10259,Rattus norvegicus,,A,Bioavailability of the compound in rats after administration of 30 mg/kg,,CHEMBL621981,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10260,Rattus norvegicus,,A,Bioavailability after administration of 10 mg/kg in rats,,CHEMBL621982,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10261,Rattus norvegicus,,A,Bioavailability after administration of 2 mg/kg in rats,,CHEMBL882953,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10262,Rattus norvegicus,,A,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL621983,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10263,Rattus norvegicus,,A,Bioavailability in dogs was determined; high,,CHEMBL621984,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10264,Rattus norvegicus,,A,Bioavailability in monkey after intravenous administration at 1 mpk,,CHEMBL621985,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10265,Rattus norvegicus,,A,Bioavailability in monkey after peroral administration at 10 mpk,,CHEMBL621986,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10266,Rattus norvegicus,,A,Bioavailability in rat after intravenous administration at 1 mpk,,CHEMBL621987,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10267,Rattus norvegicus,,F,Bioavailability in rat after intravenous administration at 2 mpk,,CHEMBL877600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10268,Rattus norvegicus,,A,Bioavailability in rat after peroral administration at 30 mpk,,CHEMBL621988,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10269,Rattus norvegicus,,F,Bioavailability in rat after peroral administration at at 100 mpk,,CHEMBL621989,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10270,Rattus norvegicus,,A,Bioavailability in rats was evaluated,,CHEMBL621990,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10271,Rattus norvegicus,,A,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,CHEMBL621991,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10272,Rattus norvegicus,,A,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,CHEMBL621992,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10273,Rattus norvegicus,,A,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,CHEMBL621993,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10274,Rattus norvegicus,,A,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,CHEMBL621994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10275,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL621995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10276,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL621996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10277,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL621997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10278,Rattus norvegicus,,A,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,CHEMBL621998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10279,Rattus norvegicus,,A,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL621999,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10280,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622000,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10281,Rattus norvegicus,,A,Bioavailability was measured in rat after oral administration; 2-4,,CHEMBL622001,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10282,Rattus norvegicus,,A,Bioavailability was measured in rat after oral administration; 3-7,,CHEMBL622002,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10283,Rattus norvegicus,,A,Bioavailability in rat (intraduodenal administration),,CHEMBL622003,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10284,Rattus norvegicus,,A,Bioavailability in rat (intraduodenal administration),,CHEMBL877601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10285,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL624871,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10286,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622004,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10287,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,CHEMBL882954,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10288,Rattus norvegicus,,A,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,CHEMBL622005,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10289,Rattus norvegicus,,A,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,CHEMBL622006,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10290,Rattus norvegicus,,A,Bioavailability was measured in rat,,CHEMBL622007,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10291,Rattus norvegicus,,A,Bioavailability was reported,,CHEMBL622008,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10292,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL622009,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10293,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL622010,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10294,Rattus norvegicus,,A,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL622011,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10295,Rattus norvegicus,,A,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,CHEMBL622012,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10296,Rattus norvegicus,,A,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,CHEMBL622013,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10297,Rattus norvegicus,,A,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL622014,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10298,Rattus norvegicus,,A,Bioavailability was determined at 3 mg/kg po dose in rats,,CHEMBL624749,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10299,Rattus norvegicus,,A,Oral bioavailability in rat (dose 2 mg/kg),,CHEMBL624750,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10300,Rattus norvegicus,,A,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL624751,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10301,Rattus norvegicus,,A,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,CHEMBL624752,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10302,Rattus norvegicus,,A,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,CHEMBL624753,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10303,Rattus norvegicus,,A,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,CHEMBL624754,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10304,Rattus norvegicus,,A,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,CHEMBL624755,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10305,Rattus norvegicus,,A,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL624756,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10306,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL624757,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10307,Rattus norvegicus,,A,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,CHEMBL624758,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10308,Rattus norvegicus,,A,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL622270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10309,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley),,CHEMBL622271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10310,Rattus norvegicus,,A,Bioavailability in rat at the dose of 2 mg/kg,,CHEMBL622272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10311,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10312,Rattus norvegicus,,A,Bioavailability in rat (cannulated) (dose 2 mg/kg),,CHEMBL622274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10313,Rattus norvegicus,,A,Bioavailability value of compound in rats was determined after peroral administration,,CHEMBL622275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10314,Rattus norvegicus,,A,Oral bioavailability in rat (dose 20 mg/kg),,CHEMBL622276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10315,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10316,Rattus norvegicus,,A,Oral bioavailability in rat (dose 5 mg/kg),,CHEMBL622278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10317,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10318,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10319,Rattus norvegicus,,A,Compound was evaluated for oral bioavailability in rats; 15-27 %,,CHEMBL624083,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10320,Rattus norvegicus,,A,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,CHEMBL624084,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10321,Rattus norvegicus,,A,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,CHEMBL624085,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10322,Rattus norvegicus,,A,Compound was tested for bioavailability in rats,,CHEMBL624086,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10323,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL624087,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10324,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL624088,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10325,Macaca mulatta,,A,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,CHEMBL624089,9544.0,0,1,U,22224,Intermediate,,,BAO_0000218,
10326,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL624090,10116.0,0,1,U,22224,Intermediate,,,BAO_0000218,
10327,Rattus norvegicus,,A,Evaluated for the bioavailability in rat (in vivo),,CHEMBL624091,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10328,Rattus norvegicus,,A,F value of compound in rats was determined after peroral administration,,CHEMBL624092,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10329,Rattus norvegicus,,A,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL624093,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10330,Rattus norvegicus,,A,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL624094,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10331,Rattus norvegicus,,A,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL624095,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10332,Rattus norvegicus,,A,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL624096,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10333,Rattus norvegicus,,A,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,CHEMBL624097,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10334,Rattus norvegicus,,A,Maximum fall in carotid flow in rat,,CHEMBL624098,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10335,Rattus norvegicus,,A,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,CHEMBL874392,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10336,Rattus norvegicus,,A,Oral bioavailability in rat (dose 5 mg/kg),,CHEMBL624099,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10337,Rattus norvegicus,,A,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL624100,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10338,Rattus norvegicus,,A,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL624101,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10339,Rattus norvegicus,,A,Oral bioavailability in rat (male Wistar),,CHEMBL624102,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10340,Rattus norvegicus,,A,Oral bioavailability after administration (30 mg/kg) in rat; good,,CHEMBL624103,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10341,Rattus norvegicus,,A,Oral bioavailability at the dose of 2 mg/kg in rat,,CHEMBL624104,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10342,Rattus norvegicus,,A,Oral bioavailability determined in rats,,CHEMBL624105,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10343,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,CHEMBL624106,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10344,Rattus norvegicus,,A,Oral bioavailability in rat (dose single 10 mg/kg),,CHEMBL624107,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10345,Rattus norvegicus,,A,Oral bioavailability in rat (dose single 10 mg/kg),,CHEMBL623943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10346,Rattus norvegicus,,A,Oral bioavailability in rat (dose 5 mg/kg,,CHEMBL623944,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10347,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,CHEMBL623945,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10348,Rattus norvegicus,,A,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,CHEMBL623946,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10349,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,CHEMBL623947,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10350,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,CHEMBL623948,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10351,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,CHEMBL623949,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10352,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,CHEMBL623950,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10353,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,CHEMBL874398,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10354,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,CHEMBL623951,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10355,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,CHEMBL623952,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10356,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,CHEMBL623953,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10357,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,CHEMBL623954,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10358,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,CHEMBL623955,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10359,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,CHEMBL623956,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10360,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,CHEMBL627807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10361,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,CHEMBL627808,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10362,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,CHEMBL627809,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10363,Rattus norvegicus,,A,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,CHEMBL627810,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10364,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,CHEMBL627811,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10365,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,CHEMBL627812,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10366,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,CHEMBL627813,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10367,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,CHEMBL627814,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10368,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,CHEMBL875336,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10369,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,CHEMBL627815,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10370,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,CHEMBL627816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10371,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,CHEMBL627817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10372,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,CHEMBL627818,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10373,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,CHEMBL627819,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10374,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,CHEMBL627820,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10375,Rattus norvegicus,,A,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,CHEMBL627821,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10376,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,CHEMBL628464,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10377,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,CHEMBL626239,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10378,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,CHEMBL626240,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10379,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,CHEMBL626241,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10380,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,CHEMBL626242,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10381,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,CHEMBL626243,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10382,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,CHEMBL626244,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10383,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,CHEMBL626907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10384,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,CHEMBL626908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10385,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,CHEMBL626909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10386,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,CHEMBL626910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10387,Rattus norvegicus,,F,Percent total excretion of acetaminophen cysteine conjugate,,CHEMBL875342,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10388,Rattus norvegicus,,F,Percent total excretion of acetaminophen glucuronide,,CHEMBL626911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10389,Rattus norvegicus,,F,Percent total excretion of acetaminophen sulfate,,CHEMBL626912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10390,Rattus norvegicus,,F,Percent total excretion of acetaminophen-mercapturic acid,,CHEMBL627065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10391,Rattus norvegicus,,A,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,CHEMBL627066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
10392,Rattus norvegicus,,A,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL627067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10393,ratrat,,A,Biodistribution of compound in rat muscle after 5 min of administration,,CHEMBL627068,8656.0,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
10394,ratrat,,A,Biodistribution of compound in rat muscle after 5 min of administration.,,CHEMBL627069,8656.0,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
10395,Ovis aries,,A,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL627070,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10396,Ovis aries,,A,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL627071,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10397,Ovis aries,,A,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL627072,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10398,Ovis aries,,A,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL627073,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10399,Ovis aries,,A,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL625387,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10400,Ovis aries,,A,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL625388,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10401,Ovis aries,,A,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL625389,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
10402,Ovis aries,,A,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL875343,9940.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
10403,Serpentes,,A,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,CHEMBL876795,8570.0,1,1,N,50497,Intermediate,,,BAO_0000218,
10404,Serpentes,,A,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,CHEMBL626552,8570.0,1,1,N,50497,Intermediate,,,BAO_0000218,
10405,Serpentes,,A,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,CHEMBL626553,8570.0,1,1,N,50497,Intermediate,,,BAO_0000218,
10406,Homo sapiens,,A,The human biological plasma half life of the compound,,CHEMBL626554,9606.0,0,1,U,22224,Autocuration,,,BAO_0000366,1969.0
10407,Rattus norvegicus,,A,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,CHEMBL626555,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
10408,Rattus norvegicus,,A,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,CHEMBL626556,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10409,Rattus norvegicus,,A,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,CHEMBL626557,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10410,Rattus norvegicus,,A,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,CHEMBL626558,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10411,Rattus norvegicus,,A,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,CHEMBL626559,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10412,Rattus norvegicus,,A,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,CHEMBL626560,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10413,Rattus norvegicus,,A,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,CHEMBL876803,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10414,Rattus norvegicus,,A,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,CHEMBL627964,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10415,Rattus norvegicus,,A,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,CHEMBL627965,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10416,Rattus norvegicus,,A,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,CHEMBL627966,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10417,Rattus norvegicus,,A,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,CHEMBL627967,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10418,Rattus norvegicus,,A,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,CHEMBL627968,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10419,Rattus norvegicus,,A,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,CHEMBL627969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10420,Rattus norvegicus,,A,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,CHEMBL627970,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10421,Rattus norvegicus,,A,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,CHEMBL627971,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10422,Rattus norvegicus,,A,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,CHEMBL627972,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10423,Homo sapiens,,B,Dissociation constant against binding to human cyclophilin A,,CHEMBL856029,9606.0,9,1,D,180,Expert,,,BAO_0000357,
10424,Bos taurus,,B,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,CHEMBL627973,9913.0,8,1,H,11591,Expert,,,BAO_0000019,
10425,,,A,-Log C was determined by performing the electroshock minimum test,,CHEMBL627974,,0,1,U,22224,Autocuration,,,BAO_0000019,
10426,,,A,-Log C was determined by performing the foot shock test,,CHEMBL627975,,0,1,U,22224,Autocuration,,,BAO_0000019,
10427,,,A,-Log C was determined by performing the incl screen test,,CHEMBL627976,,0,1,U,22224,Autocuration,,,BAO_0000019,
10428,,,A,-Log C was determined by performing the maximum electroshock test,,CHEMBL627977,,0,1,U,22224,Autocuration,,,BAO_0000019,
10429,,,A,-Log C was determined by performing the pentylenetetrazole test,,CHEMBL627978,,0,1,U,22224,Autocuration,,,BAO_0000019,
10430,,,A,Tested for experimental arotinoid inhibitory dose,,CHEMBL627979,,0,1,U,22224,Autocuration,,,BAO_0000019,
10431,,,A,Negative log transformed activity,,CHEMBL876804,,0,1,U,22224,Autocuration,,,BAO_0000019,
10432,,,A,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,CHEMBL627980,,0,1,U,22224,Autocuration,,,BAO_0000019,
10433,Cavia porcellus,,A,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,CHEMBL627981,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
10434,Cavia porcellus,,A,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,CHEMBL627982,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
10435,Cavia porcellus,,A,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,CHEMBL627983,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
10436,Cavia porcellus,,A,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,CHEMBL627984,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,2116.0
10437,,,P,Solubility in water was determined; values expressed as -log,,CHEMBL627985,,0,1,U,22229,Autocuration,,,BAO_0000100,
10438,,,A,Ratio of Kcat to that of Km was determined,,CHEMBL627986,,0,1,U,22224,Autocuration,,,BAO_0000019,
10439,,,A,Observed first order rate constant,,CHEMBL627987,,0,1,U,22224,Autocuration,,,BAO_0000019,
10440,,,A,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,CHEMBL627988,,0,1,U,22224,Autocuration,,,BAO_0000019,
10441,Rattus norvegicus,,A,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL627989,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10442,Rattus norvegicus,,A,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL627990,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10443,Rattus norvegicus,,A,Oral Bioavailability after administration of 10 mg/kg in male rat,,CHEMBL876805,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10444,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,CHEMBL627991,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10445,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL627992,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10446,Rattus norvegicus,,A,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,CHEMBL627993,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10447,Rattus norvegicus,,A,Oral bioavailability at 1 mg/kg was determined in rat,,CHEMBL622817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10448,Rattus norvegicus,,A,Oral bioavailability at 10 mg/kg was determined in rat,,CHEMBL622818,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10449,Rattus norvegicus,,A,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,CHEMBL622819,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10450,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL872267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10451,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622820,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10452,Rattus norvegicus,,A,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,CHEMBL622821,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10453,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622822,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10454,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622823,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10455,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622824,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10456,Rattus norvegicus,,A,Oral bioavailability in rat at a dose of 3 mg/kg,,CHEMBL622825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10457,Rattus norvegicus,,A,Oral bioavailability in rat after oral administration at 10 mg/kg,,CHEMBL622901,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10458,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622902,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10459,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL621844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10460,Rattus norvegicus,,A,Oral bioavailability in Dawley rats,,CHEMBL621845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10461,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL621846,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10462,Rattus norvegicus,,A,Oral bioavailability in rat (dose 30 mg/kg),,CHEMBL621847,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10463,Rattus norvegicus,,A,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL877609,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10464,Rattus norvegicus,,A,Bioavailability in rat (dose 3 mg/kg i.v.),,CHEMBL621848,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10465,Rattus norvegicus,,A,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL621849,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10466,Rattus norvegicus,,A,Oral bioavailability in rat (dose 60 mg/kg p.o.),,CHEMBL622030,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10467,Rattus norvegicus,,A,Percent oral bioavailability determined in rats,,CHEMBL622031,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10468,Rattus norvegicus,,A,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,CHEMBL622032,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10469,Rattus norvegicus,,A,The compound was evaluated for bioavailability in rats; 32-51,,CHEMBL622033,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10470,Rattus norvegicus,,A,Bioavailability in rat (dose 20 mg/kg p.o.),,CHEMBL622034,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10471,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622035,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10472,Rattus norvegicus,,A,Bioavailability percent in rat at the dose of 2 mg/kg,,CHEMBL882966,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10473,Rattus norvegicus,,A,Bioavailability was evaluated after 20 uM/kg of peroral administration,,CHEMBL622036,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10474,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622037,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10475,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622038,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10476,Rattus norvegicus,,A,Bioavailability in rats,,CHEMBL622039,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10477,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,CHEMBL622040,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10478,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,CHEMBL622041,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10479,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,CHEMBL622042,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10480,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,CHEMBL622043,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10481,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,CHEMBL622044,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10482,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,CHEMBL622045,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
10483,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,CHEMBL622046,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
10484,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,CHEMBL622047,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
10485,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,CHEMBL877610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
10486,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,CHEMBL622048,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10487,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,CHEMBL622049,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10488,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,CHEMBL622050,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10489,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,CHEMBL622051,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10490,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,CHEMBL622052,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10491,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,CHEMBL622053,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10492,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,CHEMBL622054,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10493,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,CHEMBL622055,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10494,Rattus norvegicus,,A,Oral bioavailability in rats was determined; High,,CHEMBL622056,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10495,Rattus norvegicus,,A,Oral bioavailability in the rat was determined,,CHEMBL622057,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10496,Rattus norvegicus,,A,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,CHEMBL628008,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10497,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,CHEMBL622058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10498,Rattus norvegicus,,A,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10499,Rattus norvegicus,,A,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10500,Rattus norvegicus,,A,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10501,Rattus norvegicus,,A,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10502,Rattus norvegicus,,A,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,CHEMBL622063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10503,Rattus norvegicus,,A,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL877611,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
10504,Rattus norvegicus,,A,Oral bioavailability of compound in Sprague Dawley rats,,CHEMBL622064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10505,Rattus norvegicus,,A,Oral bioavailability of compound in rat,,CHEMBL622065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10506,Rattus norvegicus,,A,Oral bioavailability in rat (dose 2 mg/kg),,CHEMBL622066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10507,Rattus norvegicus,,A,Oral bioavailability of compound in rat was determined,,CHEMBL622067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10508,Rattus norvegicus,,A,Oral bioavailability of compound in rats,,CHEMBL622068,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10509,Rattus norvegicus,,A,Oral bioavailability of compound was determined in rats,,CHEMBL622069,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10510,Rattus norvegicus,,A,Oral bioavailability at a dose of 30 mg/kg in rats,,CHEMBL624796,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10511,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL624797,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10512,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL623053,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10513,Rattus norvegicus,,A,Oral bioavailability evaluated in rat,,CHEMBL623054,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10514,Rattus norvegicus,,A,Oral bioavailability in fasted rat,,CHEMBL623055,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10515,Rattus norvegicus,,A,Oral bioavailability in fed rat,,CHEMBL623056,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10516,Rattus norvegicus,,A,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,CHEMBL623057,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10517,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10518,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg p.o.),,CHEMBL623059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10519,Rattus norvegicus,,A,Oral bioavailability in rat after administration of 10 mg/kg po,,CHEMBL623060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10520,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10521,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10522,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10523,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10524,Rattus norvegicus,,A,Oral bioavailability in ratrs,,CHEMBL623065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10525,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10526,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10527,Rattus norvegicus,,A,Oral bioavailability in rats was determined; High,,CHEMBL623068,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10528,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623069,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10529,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623070,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10530,Rattus norvegicus,,A,Oral bioavailability was calculated in rat,,CHEMBL623071,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10531,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL623072,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10532,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL623073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10533,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL623074,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10534,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL623075,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10535,Rattus norvegicus,,A,Oral bioavailability after i.v. administration,,CHEMBL623076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10536,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL623077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10537,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley),,CHEMBL623078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10538,Rattus norvegicus,,A,Oral bioavailability in Sprague-Dawley rats,,CHEMBL623079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10539,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL623080,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10540,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL623081,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10541,Rattus norvegicus,,A,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,CHEMBL623082,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10542,Rattus norvegicus,,A,Oral bioavailability in fasted rat,,CHEMBL874400,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10543,Rattus norvegicus,,A,Oral bioavailability in fed rat,,CHEMBL623083,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10544,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623084,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10545,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623085,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10546,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623086,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10547,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623087,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10548,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623088,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10549,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623089,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10550,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623090,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10551,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623091,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10552,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623092,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10553,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623093,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10554,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL874401,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10555,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623094,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10556,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL623095,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10557,Rattus norvegicus,,A,Oral bioavailability in rat after peroral administration at 10 mg/kg,,CHEMBL623096,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10558,Rattus norvegicus,,A,Oral bioavailability in rat after peroral administration at 5 mg/kg,,CHEMBL624913,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10559,Rattus norvegicus,,A,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,CHEMBL624914,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10560,Rattus norvegicus,,A,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,CHEMBL624915,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10561,Rattus norvegicus,,A,Oral bioavailability in rat; Not measured,,CHEMBL624916,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10562,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL624917,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10563,Rattus norvegicus,,A,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,CHEMBL625157,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10564,Rattus norvegicus,,A,In vitro metabolic potential in rat liver microsomes,,CHEMBL625158,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10565,Rattus norvegicus,,A,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,CHEMBL625159,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10566,Rattus norvegicus,,A,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,CHEMBL625160,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10567,Rattus norvegicus,,A,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,CHEMBL625161,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10568,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL625162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10569,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL625163,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10570,Rattus norvegicus,,A,Oral bioavailability in rats at 10 mg/kg,,CHEMBL625164,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10571,Rattus norvegicus,,A,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL625165,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10572,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL625166,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10573,Rattus norvegicus,,A,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,CHEMBL625167,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10574,Rattus norvegicus,,A,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,CHEMBL625168,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10575,Rattus norvegicus,,A,Plasma clearance of the compound,,CHEMBL625169,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10576,Rattus norvegicus,,A,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,CHEMBL626264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10577,Rattus norvegicus,,A,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,CHEMBL626265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10578,Rattus norvegicus,,A,The compound was tested for plasma clearance in rat,,CHEMBL626266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10579,Rattus norvegicus,,A,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,CHEMBL626267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10580,Rattus norvegicus,,A,Plasma concentration upon oral administration of 1 mg/Kg in rats,,CHEMBL626268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10581,Rattus norvegicus,,A,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,CHEMBL626269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10582,Rattus norvegicus,,A,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,CHEMBL626270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10583,Rattus norvegicus,,A,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,CHEMBL626271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10584,Rattus norvegicus,,A,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,CHEMBL626272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10585,Rattus norvegicus,,A,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,CHEMBL626273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10586,Rattus norvegicus,,A,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,CHEMBL875346,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10587,Rattus norvegicus,,A,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,CHEMBL626274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10588,Rattus norvegicus,,A,Compound was tested for protein binding in rat plasma,,CHEMBL626275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10589,Rattus norvegicus,,A,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,CHEMBL624646,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10590,Rattus norvegicus,,A,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,CHEMBL624647,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10591,Rattus norvegicus,,A,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,CHEMBL624648,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10592,Rattus norvegicus,,A,Area under curve ratio was determined (po/iv) in rat,,CHEMBL624649,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10593,Rattus norvegicus,,A,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,CHEMBL624650,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10594,Rattus norvegicus,,A,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,CHEMBL624651,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10595,Rattus norvegicus,,A,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,CHEMBL624652,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10596,Rattus norvegicus,,A,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,CHEMBL624653,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10597,Rattus norvegicus,,A,Ratio of AUCbrain to AUCplasma,,CHEMBL624654,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10598,Rattus norvegicus,,A,Ratio of brain to plasma,,CHEMBL624655,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10599,Rattus norvegicus,,A,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,CHEMBL624656,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10600,Rattus norvegicus,,A,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,CHEMBL624657,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10601,Rattus norvegicus,,A,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,CHEMBL624658,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10602,Rattus norvegicus,,A,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,CHEMBL624659,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10603,Rattus norvegicus,,A,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,CHEMBL624660,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10604,Rattus norvegicus,,A,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,CHEMBL624661,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10605,Rattus norvegicus,,A,Steady state brain :blood ratio was determined,,CHEMBL624662,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10606,Rattus norvegicus,,A,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL625199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10607,Rattus norvegicus,,A,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,CHEMBL625200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10608,Rattus norvegicus,,A,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL625201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10609,Rattus norvegicus,,A,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,CHEMBL625202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10610,Rattus norvegicus,,A,Percentage recovery after 3h incubation with rat hapatocytes was determined,,CHEMBL625203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10611,Rattus norvegicus,,A,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,CHEMBL625204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10612,Rattus norvegicus,,A,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,CHEMBL625205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10613,Rattus norvegicus,,A,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,CHEMBL625206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10614,,,A,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,CHEMBL625207,,0,1,U,22224,Autocuration,,,BAO_0000019,
10615,,,A,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,CHEMBL625208,,0,1,U,22224,Autocuration,,,BAO_0000019,
10616,Homo sapiens,,A,In vivo absorption in Caco-2 cell line monolayers was determined,,CHEMBL625209,9606.0,1,1,N,50587,Intermediate,,495.0,BAO_0000218,
10617,,,P,Calculated partition coefficient (clogP),,CHEMBL625210,,0,1,U,22229,Autocuration,,,BAO_0000100,
10618,Rattus norvegicus,,A,Area under curve was determine after peroral administration at 10 mpk in Rat,,CHEMBL625211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10619,Macaca mulatta,,A,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL625212,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
10620,Rattus norvegicus,,A,Area under curve was determine after peroral administration at 160 mpk in Rat,,CHEMBL625213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10621,Rattus norvegicus,,A,Area under curve was determine after peroral administration at 20 mpk in Rat,,CHEMBL625214,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10622,Rattus norvegicus,,A,Area under curve was determine after peroral administration at 50 mpk in Rat,,CHEMBL874542,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10623,,,P,Calculated partition coefficient (clogP) (AlogP),,CHEMBL625215,,0,1,U,22229,Autocuration,,,BAO_0000100,
10624,,,A,Activated partial thromboplastin time measured,,CHEMBL625216,,0,1,U,22224,Autocuration,,,BAO_0000019,
10625,,,P,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,CHEMBL625217,,0,1,U,22224,Autocuration,,,BAO_0000100,
10626,,,P,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,CHEMBL625218,,0,1,U,22224,Autocuration,,,BAO_0000100,
10627,Canis lupus familiaris,,A,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,CHEMBL622864,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
10628,Rattus norvegicus,,A,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,CHEMBL622865,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10629,Rattus norvegicus,,A,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,CHEMBL622866,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10630,Canis lupus familiaris,,A,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,CHEMBL622867,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
10631,Cavia porcellus,,A,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,CHEMBL876808,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,1969.0
10632,,,A,AUC in brain,,CHEMBL627725,,0,1,U,22224,Autocuration,,,BAO_0000019,955.0
10633,,,A,AUC in serum,,CHEMBL627726,,0,1,U,22224,Autocuration,,,BAO_0000019,1977.0
10634,,,A,AUC was determined,,CHEMBL627727,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10635,,,A,AUC of the compound.,,CHEMBL627728,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10636,,,A,AUC value (0-4 hr),,CHEMBL627729,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10637,,,A,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,CHEMBL627730,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10638,,,A,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,CHEMBL627731,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10639,,,A,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,CHEMBL627732,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10640,,,A,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,CHEMBL627733,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
10641,Rattus norvegicus,,A,AUC(area under curve) was determined after intravenous administration in rats,,CHEMBL627734,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10642,Rattus norvegicus,,A,AUC(area under curve) was determined after oral administration in rats,,CHEMBL627735,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10643,Cavia porcellus,,A,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,CHEMBL627736,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,1969.0
10644,Rattus norvegicus,,A,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,CHEMBL876809,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10645,,,A,Area Under Curve after oral dosing of 100 uM/Kg,,CHEMBL627737,,0,1,U,22224,Autocuration,,,BAO_0000019,
10646,,,A,Area Under Curve after oral dosing of 30 uM/Kg,,CHEMBL627738,,0,1,U,22224,Autocuration,,,BAO_0000019,
10647,,,A,Area Under Curve was measured by ploting the graph between concentration verses time,,CHEMBL627739,,0,1,U,22224,Autocuration,,,BAO_0000019,
10648,Canis lupus familiaris,,A,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,CHEMBL626143,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10649,Simiiformes,,A,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,CHEMBL626144,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10650,Oryctolagus cuniculus,,A,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,CHEMBL626145,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
10651,Rattus norvegicus,,A,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,CHEMBL626146,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10652,Rattus norvegicus,,A,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,CHEMBL626147,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10653,,,A,Area under curve (AUC) was determined,,CHEMBL626148,,0,1,U,22224,Autocuration,,,BAO_0000019,
10654,,,A,Area under curve (AUC) following ip administration at 1 mg/kg,,CHEMBL626149,,0,1,U,22224,Autocuration,,,BAO_0000218,
10655,,,A,Area under curve (AUC) was determined; ND is Not determined,,CHEMBL626150,,0,1,U,22224,Autocuration,,,BAO_0000019,
10656,Canis lupus familiaris,,A,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,CHEMBL626151,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10657,Canis lupus familiaris,,A,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,CHEMBL626152,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10658,Canis lupus familiaris,,A,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,CHEMBL626153,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10659,,,A,Area under curve (AUR) was determined,,CHEMBL626154,,0,1,U,22224,Autocuration,,,BAO_0000019,
10660,,,A,Area under curve at 1 uM/dg administered intravenously,,CHEMBL626155,,0,1,U,22224,Autocuration,,,BAO_0000019,
10661,,,A,Area under curve at 10 uM/dg administered perorally,,CHEMBL626156,,0,1,U,22224,Autocuration,,,BAO_0000019,
10662,,,A,Area under curve at 2 uM/dg administered intravenously,,CHEMBL626157,,0,1,U,22224,Autocuration,,,BAO_0000019,
10663,,,A,Area under curve at 20 uM/dg administered perorally,,CHEMBL626158,,0,1,U,22224,Autocuration,,,BAO_0000019,
10664,Canis lupus familiaris,,A,Area under curve at a peroral dose of 3 mg/kg in dog,,CHEMBL626159,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10665,Rattus norvegicus,,A,Area under curve at a peroral dose of 3 mg/kg in rat,,CHEMBL626160,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10666,Canis lupus familiaris,,A,Area under curve at an iv dose of 1 mg/kg in dog,,CHEMBL626161,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10667,Rattus norvegicus,,A,Area under curve at an iv dose of 1 mg/kg in rat,,CHEMBL626162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10668,,,A,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,CHEMBL626163,,0,1,U,22224,Autocuration,,,BAO_0000019,
10669,,,A,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,CHEMBL626164,,0,1,U,22224,Autocuration,,,BAO_0000019,
10670,Mus musculus,,A,Area under curve measured as conc vs time after intravenous administration to mice.,,CHEMBL626165,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10671,Mus musculus,,A,Area under curve measured as conc vs time after peroral administration to mice.,,CHEMBL626166,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10672,Canis lupus familiaris,,A,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,CHEMBL626167,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10673,Canis lupus familiaris,,A,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,CHEMBL626168,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10674,Canis lupus familiaris,,A,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,CHEMBL877463,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10675,Canis lupus familiaris,,A,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,CHEMBL626169,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10676,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,CHEMBL626170,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10677,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,CHEMBL626171,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10678,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,CHEMBL626172,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10679,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,CHEMBL626173,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10680,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,CHEMBL626174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10681,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,CHEMBL626175,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10682,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,CHEMBL626176,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10683,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,CHEMBL626177,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10684,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,CHEMBL622499,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10685,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,CHEMBL622500,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10686,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,CHEMBL622501,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10687,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,CHEMBL622502,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10688,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,CHEMBL622503,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10689,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,CHEMBL877614,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10690,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,CHEMBL624839,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10691,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,CHEMBL624840,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10692,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,CHEMBL624841,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10693,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,CHEMBL624842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10694,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,CHEMBL624843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10695,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,CHEMBL624844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10696,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,CHEMBL624845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10697,Rattus norvegicus,,A,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,CHEMBL621904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10698,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,CHEMBL621905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10699,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,CHEMBL874382,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10700,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,CHEMBL621906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
10701,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,CHEMBL621907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10702,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,CHEMBL622096,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10703,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,CHEMBL622097,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
10704,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,CHEMBL622098,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10705,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,CHEMBL622099,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10706,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,CHEMBL622100,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10707,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,CHEMBL622101,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10708,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,CHEMBL622102,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10709,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,CHEMBL622103,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10710,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,CHEMBL622104,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10711,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,CHEMBL622105,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10712,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,CHEMBL622106,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10713,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,CHEMBL622107,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10714,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,CHEMBL622108,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10715,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,CHEMBL622109,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
10716,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,CHEMBL622110,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10717,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,CHEMBL622111,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10718,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,CHEMBL874383,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
10719,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,CHEMBL622112,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
10720,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,CHEMBL622113,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
10721,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,CHEMBL622114,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
10722,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,CHEMBL622115,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
10723,Rattus norvegicus,,A,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,CHEMBL622116,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
10724,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622117,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10725,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622118,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10726,Rattus norvegicus,,A,Oral bioavailability in rats at 6 mg/kg,,CHEMBL622119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10727,Rattus norvegicus,,A,Oral bioavailability in rat (dose 6 mg/kg),,CHEMBL622120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10728,Rattus norvegicus,,A,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,CHEMBL622121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10729,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10730,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622123,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10731,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL622124,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10732,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL622125,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10733,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL622126,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10734,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL620455,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10735,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620456,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10736,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620457,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10737,Rattus norvegicus,,A,Oral bioavailability was evaluated; Not tested,,CHEMBL620458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10738,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL620459,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10739,Rattus norvegicus,,A,Oral bioavailability in rat by oral dosing,,CHEMBL620460,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10740,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg p.o.),,CHEMBL620461,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10741,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley),,CHEMBL620462,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10742,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL620463,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10743,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL620464,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10744,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL620465,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10745,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,CHEMBL620466,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10746,Rattus norvegicus,,A,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,CHEMBL620467,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10747,Rattus norvegicus,,A,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,CHEMBL620468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10748,Rattus norvegicus,,A,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,CHEMBL620469,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10749,Rattus norvegicus,,A,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,CHEMBL620470,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10750,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620471,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10751,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620472,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10752,Rattus norvegicus,,A,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,CHEMBL620473,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10753,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620474,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10754,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,CHEMBL620475,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10755,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620476,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10756,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620477,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10757,Rattus norvegicus,,A,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,CHEMBL620478,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10758,Rattus norvegicus,,A,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,CHEMBL618768,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10759,Rattus norvegicus,,A,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,CHEMBL618769,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10760,Rattus norvegicus,,A,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,CHEMBL618770,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10761,Rattus norvegicus,,A,Oral bioavailability (dose 20 mg/kg p.o.),,CHEMBL618771,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10762,Rattus norvegicus,,A,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,CHEMBL618772,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10763,Rattus norvegicus,,A,Oral bioavailability in rat at 10 mg/kg of the compound,,CHEMBL618773,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10764,Rattus norvegicus,,A,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL875842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10765,Rattus norvegicus,,A,Bioavailability in rat (dose 3 mg/kg i.v.),,CHEMBL618774,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10766,Rattus norvegicus,,A,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL618775,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10767,Rattus norvegicus,,A,Oral bioavailability in rat (dose 60 mg/kg p.o.),,CHEMBL618776,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10768,Rattus norvegicus,,A,Percent bioavailability (F) in rats after iv administration,,CHEMBL618777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10769,Rattus norvegicus,,A,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,CHEMBL618778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10770,Rattus norvegicus,,A,Bioavailability in rat (dose 5 uM/kg p.o.),,CHEMBL618779,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10771,Rattus norvegicus,,A,Oral bioavailability,,CHEMBL618780,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10772,Rattus norvegicus,,A,Bioavailability in rat (dose 2 mg/kg p.o.),,CHEMBL618781,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10773,Rattus norvegicus,,A,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL618782,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10774,Rattus norvegicus,,A,Oral bioavailability in rat (dose 20 mg/kg),,CHEMBL618783,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10775,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618784,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10776,Rattus norvegicus,,A,Percent oral bioavailability evaluated in rat,,CHEMBL618785,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10777,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618786,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10778,Rattus norvegicus,,A,Percent oral bioavailability in rat; Not determined,,CHEMBL618787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10779,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL618788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10780,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL618789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10781,Rattus norvegicus,,A,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,CHEMBL618790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10782,Rattus norvegicus,,A,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,CHEMBL618791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10783,Rattus norvegicus,,A,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,CHEMBL875843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10784,Rattus norvegicus,,A,Oral bioavailability in rat (dose 20 mg/kg p.o.),,CHEMBL618792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10785,Rattus norvegicus,,A,Cmax at a dose of 30 mg/kg in rat,,CHEMBL623395,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10786,Simiiformes,,A,Cmax in monkeys at a dose of 1 mg/kg,,CHEMBL623396,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10787,Rattus norvegicus,,A,Cmax in rat,,CHEMBL623397,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10788,Rattus norvegicus,,A,Cmax in rats at a dose of 1 mg/kg,,CHEMBL623398,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10789,Mus musculus,,A,Cmax was measured in mice after an oral dose of 50 mg/kg.,,CHEMBL623399,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10790,,,A,"Cmax value at a dose of 12.7 uM/kg, po",,CHEMBL623400,,0,1,U,22224,Autocuration,,,BAO_0000218,
10791,,,A,"Cmax value at a dose of 6.3 uM/kg, iv",,CHEMBL623401,,0,1,U,22224,Autocuration,,,BAO_0000218,
10792,,,A,"Cmax value at a dose of 7.1 uM/kg, iv",,CHEMBL623402,,0,1,U,22224,Autocuration,,,BAO_0000218,
10793,,,A,Cmax value of compound was determined after 1 hr,,CHEMBL623403,,0,1,U,22224,Autocuration,,,BAO_0000218,
10794,,,A,Cmax value of the compound,,CHEMBL623404,,0,1,U,22224,Autocuration,,,BAO_0000218,
10795,Rattus norvegicus,,A,Cmax value administered intraintestinal in rats.,,CHEMBL625997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10796,Rattus norvegicus,,A,Cmax value administered perorally was determined in rat; Not determined,,CHEMBL625998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10797,,,A,Cmax value at the dose of 2.3 mg/kg,,CHEMBL625999,,0,1,U,22224,Autocuration,,,BAO_0000218,
10798,,,A,Cmax value at the dose of 5 mg/kg,,CHEMBL626000,,0,1,U,22224,Autocuration,,,BAO_0000218,
10799,,,A,Cmax value in the period of 8 hr after dosing. ,,CHEMBL626001,,0,1,U,22224,Autocuration,,,BAO_0000218,
10800,,,A,Cmax value at a oral dose of 20 mg/kg; Not tested,,CHEMBL626002,,0,1,U,22224,Autocuration,,,BAO_0000218,
10801,,,A,Cmax value at a oral dose of 20 mg/kg,,CHEMBL626003,,0,1,U,22224,Autocuration,,,BAO_0000218,
10802,Rattus norvegicus,,A,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,CHEMBL626004,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10803,Cavia porcellus,,A,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,CHEMBL626005,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
10804,Rattus norvegicus,,A,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,CHEMBL626006,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10805,Rattus norvegicus,,A,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,CHEMBL626007,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10806,Mus musculus,,A,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,CHEMBL626008,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10807,Canis lupus familiaris,,A,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,CHEMBL626009,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
10808,Canis lupus familiaris,,A,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,CHEMBL626010,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10809,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,CHEMBL626011,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
10810,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,CHEMBL626012,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
10811,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,CHEMBL626013,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
10812,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,CHEMBL626014,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
10813,Mus musculus,,A,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,CHEMBL877496,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
10814,Canis lupus familiaris,,F,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,CHEMBL626015,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10815,Canis lupus familiaris,,F,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,CHEMBL626016,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10816,Canis lupus familiaris,,F,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,CHEMBL626017,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10817,Canis lupus familiaris,,A,Bioavailability as maximal plasma concentration in dogs,,CHEMBL626018,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
10818,Canis lupus familiaris,,A,Bioavailability as maximal plasma concentration in dogs,,CHEMBL626692,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
10819,Rattus norvegicus,,A,Bioavailability as maximal plasma concentration in rats,,CHEMBL626693,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10820,Rattus norvegicus,,A,Bioavailability as maximal plasma concentration in rats,,CHEMBL626694,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
10821,Canis lupus familiaris,,A,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626695,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
10822,Canis lupus familiaris,,A,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626696,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
10823,Canis lupus familiaris,,A,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626697,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
10824,Canis lupus familiaris,,A,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,CHEMBL626859,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
10825,Canis lupus familiaris,,A,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626860,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
10826,Canis lupus familiaris,,A,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626861,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
10827,Rattus norvegicus,,A,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,CHEMBL626296,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10828,,,A,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,CHEMBL626297,,0,1,U,22224,Autocuration,,,BAO_0000218,
10829,,,A,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,CHEMBL626298,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
10830,Rattus norvegicus,,A,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,CHEMBL626299,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10831,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,CHEMBL626300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10832,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,CHEMBL626301,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10833,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,CHEMBL626962,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10834,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,CHEMBL626963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10835,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,CHEMBL626964,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10836,Macaca fascicularis,,A,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,CHEMBL626965,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
10837,Mus musculus,,A,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL626966,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10838,Mus musculus,,A,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL626967,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10839,Macaca fascicularis,,A,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,CHEMBL626968,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
10840,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,CHEMBL626969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10841,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,CHEMBL627126,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10842,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,CHEMBL631276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10843,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,CHEMBL631277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10844,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,CHEMBL631278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10845,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,CHEMBL874457,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10846,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,CHEMBL631279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10847,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,CHEMBL631280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10848,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,CHEMBL631281,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10849,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,CHEMBL631968,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10850,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,CHEMBL631969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10851,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,CHEMBL631970,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10852,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,CHEMBL631971,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10853,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,CHEMBL631972,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10854,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,CHEMBL630435,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10855,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,CHEMBL630436,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10856,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,CHEMBL630437,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10857,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,CHEMBL630438,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10858,Rattus norvegicus,,A,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,CHEMBL630439,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
10859,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,CHEMBL630440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10860,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,CHEMBL630441,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10861,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,CHEMBL630442,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10862,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,CHEMBL625234,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10863,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,CHEMBL625235,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10864,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,CHEMBL625236,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10865,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,CHEMBL625237,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10866,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,CHEMBL626125,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10867,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,CHEMBL626126,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10868,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,CHEMBL626127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10869,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,CHEMBL626128,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10870,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,CHEMBL626129,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10871,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,CHEMBL626130,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10872,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,CHEMBL626131,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10873,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,CHEMBL626132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10874,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,CHEMBL626752,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10875,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,CHEMBL626753,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10876,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,CHEMBL626754,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10877,Rattus norvegicus,,A,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,CHEMBL626755,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
10878,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,CHEMBL626756,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10879,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,CHEMBL626757,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10880,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,CHEMBL626758,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10881,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,CHEMBL626759,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10882,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,CHEMBL626760,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
10883,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,CHEMBL626394,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10884,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,CHEMBL626395,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10885,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,CHEMBL626396,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10886,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL626397,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10887,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,CHEMBL626398,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10888,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,CHEMBL626399,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10889,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,CHEMBL874653,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10890,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL626400,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10891,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,CHEMBL626401,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10892,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL626402,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10893,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,CHEMBL626403,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10894,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL626404,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10895,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,CHEMBL626405,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10896,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL625529,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10897,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,CHEMBL625530,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10898,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL625531,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10899,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,CHEMBL625532,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10900,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL625533,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10901,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,CHEMBL875474,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10902,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL625534,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10903,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,CHEMBL625535,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10904,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL625536,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10905,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,CHEMBL625537,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10906,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL625538,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10907,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,CHEMBL625539,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10908,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL625540,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10909,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL625541,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10910,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL625542,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10911,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,CHEMBL625543,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10912,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL625544,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10913,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,CHEMBL625545,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10914,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,CHEMBL625546,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10915,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,CHEMBL625547,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10916,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,CHEMBL625548,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10917,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,CHEMBL625549,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10918,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,CHEMBL625550,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10919,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,CHEMBL625551,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10920,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,CHEMBL875475,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10921,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,CHEMBL625552,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10922,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,CHEMBL625553,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10923,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL625554,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10924,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,CHEMBL625555,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10925,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,CHEMBL625556,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10926,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,CHEMBL624986,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10927,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,CHEMBL624987,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10928,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624988,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10929,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,CHEMBL624989,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10930,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,CHEMBL624990,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10931,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,CHEMBL874391,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10932,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,CHEMBL624991,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10933,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,CHEMBL624992,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10934,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,CHEMBL624993,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10935,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,CHEMBL624994,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10936,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,CHEMBL624995,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10937,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,CHEMBL624996,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10938,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,CHEMBL624997,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10939,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,CHEMBL624998,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10940,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,CHEMBL624999,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10941,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,CHEMBL882955,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10942,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,CHEMBL625000,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10943,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,CHEMBL625001,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10944,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,CHEMBL625089,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10945,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,CHEMBL625090,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10946,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,CHEMBL625091,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10947,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,CHEMBL625092,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10948,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,CHEMBL625093,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10949,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,CHEMBL625094,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10950,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,CHEMBL625095,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
10951,Canis lupus familiaris,,A,Compound was evaluated for its bioavailability in the dogs,,CHEMBL625096,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10952,Rattus norvegicus,,A,Compound was evaluated for its bioavailability in the rats,,CHEMBL625097,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10953,,,A,Compound was evaluated for oral bioavailability,,CHEMBL882956,,0,1,U,22224,Autocuration,,,BAO_0000218,
10954,Rattus norvegicus,,A,Compound was evaluated for percentage of Oral bioavailability in rats,,CHEMBL625098,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10955,Cavia porcellus,,A,Bioavailability in guinea pig,,CHEMBL625099,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10956,Rattus norvegicus,,A,Compound was evaluated for the oral bioavailability in rat,,CHEMBL625100,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10957,Canis lupus familiaris,,A,Compound was evaluated for the oral bioavailability in dog,,CHEMBL625101,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10958,Rattus norvegicus,,A,Compound was evaluated for the oral bioavailability in rat,,CHEMBL874396,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10959,Canis lupus familiaris,,F,Bioavailability in dog (dosed i.v.),,CHEMBL625102,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10960,Canis lupus familiaris,,A,Compound was tested for in vivo bioavailability in dog,,CHEMBL625103,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
10961,Cricetinae,,A,Compound was tested for in vivo bioavailability in hamsters,,CHEMBL625104,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
10962,Simiiformes,,A,Compound was tested for in vivo bioavailability in monkey,,CHEMBL625105,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10963,Rattus norvegicus,,A,Compound was tested for in vivo bioavailability in rat,,CHEMBL625106,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10964,Mus musculus,,A,Oral bioavailability in mouse,,CHEMBL625107,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10965,Mus musculus,,A,Compound was tested for percent of oral bioavailability in mice; 56-74,,CHEMBL625108,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10966,Mus musculus,,A,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,CHEMBL625109,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10967,Macaca fascicularis,,A,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,CHEMBL625110,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10968,Macaca fascicularis,,A,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,CHEMBL625111,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10969,Mus musculus,,A,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,CHEMBL625112,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10970,Mus musculus,,A,Oral bioavailability in nude mice,,CHEMBL875334,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10971,Primates,,A,Bioavailability in monkey (i.d. dosing),,CHEMBL628617,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10972,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL628618,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
10973,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,CHEMBL628619,,0,1,U,22224,Autocuration,,,BAO_0000218,
10974,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,CHEMBL628620,,0,1,U,22224,Autocuration,,,BAO_0000218,
10975,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,CHEMBL628621,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
10976,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,CHEMBL628622,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
10977,Macaca fascicularis,,A,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,CHEMBL628623,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
10978,Macaca fascicularis,,A,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,CHEMBL628624,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
10979,Mus musculus,,A,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL628625,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10980,Macaca fascicularis,,A,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,CHEMBL628626,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
10981,Mus musculus,,A,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL627041,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10982,Mus musculus,,A,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL627042,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10983,Mus musculus,,A,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL627043,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10984,,,A,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,CHEMBL627044,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
10985,Mus musculus,,A,Cmax in mouse plasma,,CHEMBL627045,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
10986,,,A,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,CHEMBL627046,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
10987,Rattus norvegicus,,A,Maximal plasma concentration in rat,,CHEMBL627047,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10988,Rattus norvegicus,,A,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,CHEMBL627048,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
10989,Rattus norvegicus,,A,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,CHEMBL627049,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10990,Rattus norvegicus,,A,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,CHEMBL627050,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10991,Rattus norvegicus,,A,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,CHEMBL627051,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10992,Rattus norvegicus,,A,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,CHEMBL627052,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10993,Rattus norvegicus,,A,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,CHEMBL627053,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10994,Rattus norvegicus,,A,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,CHEMBL627054,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
10995,Mus musculus,,A,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627055,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10996,Mus musculus,,A,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL627056,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10997,Mus musculus,,A,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,CHEMBL627057,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10998,Mus musculus,,A,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627058,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
10999,Mus musculus,,A,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL626211,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11000,,,A,Maximum Concentration of the compound.,,CHEMBL626212,,0,1,U,22224,Autocuration,,,BAO_0000218,
11001,Canis lupus familiaris,,A,Maximum Concentration was measured after iv administration into Beagle dog,,CHEMBL626213,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11002,Canis lupus familiaris,,A,Maximum Concentration was measured after iv administration into Beagle dog.,,CHEMBL626214,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11003,Canis lupus familiaris,,A,Maximum Concentration was measured after po administration into Beagle dog,,CHEMBL626215,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11004,Canis lupus familiaris,,A,Maximum Concentration was measured after po administration into Beagle dog.,,CHEMBL626216,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11005,,,A,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,CHEMBL626217,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11006,,,A,Maximum blood level reached after an iv dose of 12.2 uM/kg,,CHEMBL626218,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11007,,,A,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,CHEMBL626219,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11008,,,A,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,CHEMBL626220,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11009,,,A,Maximum blood level reached after an oral dose of 5.0 mg/kg,,CHEMBL626221,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11010,,,A,Maximum blood level reached at dose of 10.6 uM/kg orally,,CHEMBL626222,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11011,Cavia porcellus,,A,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,CHEMBL626223,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
11012,Cavia porcellus,,A,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,CHEMBL626224,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
11013,Rattus norvegicus,,A,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL626225,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11014,Rattus norvegicus,,A,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,CHEMBL626226,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11015,Rattus norvegicus,,A,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,CHEMBL626227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11016,Rattus norvegicus,,A,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,CHEMBL626228,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11017,Rattus norvegicus,,A,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL626229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11018,Rattus norvegicus,,A,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,CHEMBL626921,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11019,Rattus norvegicus,,A,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,CHEMBL876793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11020,Rattus norvegicus,,A,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,CHEMBL625309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11021,Bacillus subtilis,,A,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,CHEMBL625310,1423.0,1,1,N,50278,Intermediate,,,BAO_0000218,
11022,Simiiformes,,A,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,CHEMBL625311,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11023,Rattus norvegicus,,A,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,CHEMBL625312,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11024,,,A,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,CHEMBL625313,,0,1,U,22224,Autocuration,,,BAO_0000218,
11025,Mus musculus,,A,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,CHEMBL625314,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11026,Rattus norvegicus,,A,Maximum concentration in male rats after iv administration of 20 mg/kg,,CHEMBL625315,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11027,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,CHEMBL625316,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11028,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,CHEMBL625317,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11029,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,CHEMBL625318,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11030,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,CHEMBL625319,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11031,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,CHEMBL625320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11032,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,CHEMBL625321,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11033,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,CHEMBL625322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11034,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,CHEMBL876801,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11035,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,CHEMBL625323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11036,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,CHEMBL625324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11037,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,CHEMBL625325,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11038,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,CHEMBL625326,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11039,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,CHEMBL625327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11040,Rattus norvegicus,,A,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,CHEMBL625328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11041,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,CHEMBL625329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11042,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,CHEMBL625330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11043,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,CHEMBL627774,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11044,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,CHEMBL627775,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11045,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,CHEMBL627949,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11046,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,CHEMBL627950,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11047,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,CHEMBL627951,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11048,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,CHEMBL627952,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11049,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,CHEMBL627953,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11050,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,CHEMBL627954,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11051,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,CHEMBL627955,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11052,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,CHEMBL627956,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11053,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,CHEMBL876802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11054,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,CHEMBL627957,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11055,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,CHEMBL627958,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11056,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,CHEMBL627959,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11057,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,CHEMBL627960,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11058,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,CHEMBL627961,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11059,Rattus norvegicus,,A,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,CHEMBL627962,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11060,Rattus norvegicus,,A,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL627963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11061,Rattus norvegicus,,A,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624759,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11062,Rattus norvegicus,,A,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL624760,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11063,Rattus norvegicus,,A,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624761,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11064,Rattus norvegicus,,A,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL877607,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11065,Rattus norvegicus,,A,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL624762,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11066,Rattus norvegicus,,A,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624763,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11067,Rattus norvegicus,,A,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL624764,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11068,Rattus norvegicus,,A,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624765,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11069,Rattus norvegicus,,A,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624766,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11070,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,CHEMBL624767,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11071,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,CHEMBL624768,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11072,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,CHEMBL624769,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11073,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624770,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11074,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,CHEMBL624771,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11075,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,CHEMBL624772,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11076,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,CHEMBL624773,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11077,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL624774,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11078,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,CHEMBL624775,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11079,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL624776,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11080,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,CHEMBL624777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11081,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL624778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11082,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,CHEMBL624779,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11083,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL624780,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11084,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,CHEMBL624781,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11085,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL877608,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11086,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,CHEMBL624782,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11087,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL624783,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11088,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,CHEMBL624784,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11089,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL624785,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11090,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,CHEMBL624786,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11091,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,CHEMBL624787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11092,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL628676,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11093,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,CHEMBL621842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11094,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL621843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11095,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL623873,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11096,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL623874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11097,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,CHEMBL623875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11098,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL623876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11099,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,CHEMBL623877,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11100,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,CHEMBL623878,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11101,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,CHEMBL623879,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11102,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,CHEMBL623880,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11103,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,CHEMBL623881,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11104,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,CHEMBL623957,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11105,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,CHEMBL623958,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11106,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,CHEMBL623959,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11107,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,CHEMBL623960,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11108,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,CHEMBL623961,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11109,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL623962,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11110,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,CHEMBL624676,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11111,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,CHEMBL624677,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11112,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,CHEMBL624678,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11113,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,CHEMBL624679,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11114,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624680,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11115,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,CHEMBL624849,,0,1,U,22224,Autocuration,,,BAO_0000218,
11116,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,CHEMBL624850,,0,1,U,22224,Autocuration,,,BAO_0000218,
11117,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,CHEMBL874399,,0,1,U,22224,Autocuration,,,BAO_0000218,
11118,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,CHEMBL624851,,0,1,U,22224,Autocuration,,,BAO_0000218,
11119,,,A,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,CHEMBL624852,,0,1,U,22224,Autocuration,,,BAO_0000218,
11120,Rattus norvegicus,,A,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL624853,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11121,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley),,CHEMBL624854,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11122,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL624855,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11123,Rattus norvegicus,,A,Oral bioavailability in rats was determined in vivo,,CHEMBL624856,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11124,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL882957,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11125,Simiiformes,,A,Oral bioavailability of compound in monkey,,CHEMBL624857,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11126,Rattus norvegicus,,A,Oral bioavailability of compound in rat,,CHEMBL622202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11127,Rattus norvegicus,,A,Bioavailability in rat of PMEA prodrug,,CHEMBL622203,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11128,Rattus norvegicus,,A,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,CHEMBL625522,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11129,Macaca mulatta,,A,Serum conc at 3 hours following 25 mg/kg dose,,CHEMBL622868,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11130,Macaca mulatta,,A,Urine conc 0-5 hours following 25 mg/kg dose,,CHEMBL622869,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
11131,Macaca mulatta,,A,Urine conc 0-24 hours following 25 mg/kg dose,,CHEMBL622870,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
11132,Chlorocebus aethiops,,A,Oral bioavailability in African green monkeys; 20-25,,CHEMBL622871,9534.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11133,Macaca fascicularis,,A,Oral bioavailability in cynomolgus monkey.,,CHEMBL620560,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11134,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL620561,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11135,Canis lupus familiaris,,A,Oral bioavailability in dog at 10 mg/kg oral dose,,CHEMBL620562,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11136,Cricetinae,,A,Oral bioavailability in hamster at 10 mg/kg oral dose,,CHEMBL620563,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
11137,Rattus norvegicus,,A,Oral bioavailability in rat at 10 mg/kg oral dose,,CHEMBL620564,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11138,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL872265,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11139,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620565,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11140,Eutheria,,A,Oral bioavailability,,CHEMBL620566,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11141,,,A,Oral bioavailability was determined; range 49-102%,,CHEMBL620567,,0,1,U,22224,Autocuration,,,BAO_0000218,
11142,Canis lupus familiaris,,A,Oral bioavailability was determined in dogs,,CHEMBL620568,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11143,Rattus norvegicus,,A,Oral bioavailability in rat,,CHEMBL620569,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11144,Eutheria,,A,Oral bioavailability,,CHEMBL620570,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11145,,,A,Oral bioavailability was determined; Not orally available,,CHEMBL620571,,0,1,U,22224,Autocuration,,,BAO_0000218,
11146,Mus musculus,,A,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,CHEMBL620572,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11147,Mus musculus,,A,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,CHEMBL620573,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11148,Mus musculus,,A,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,CHEMBL620574,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11149,Macaca mulatta,,A,Oral bioavailability in Rhesus monkey,,CHEMBL620575,9544.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11150,Canis lupus familiaris,,A,Oral bioavailability in dog (female mongrel),,CHEMBL620576,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11151,,,A,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,CHEMBL875846,,0,1,U,22224,Autocuration,,,BAO_0000218,
11152,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL620577,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11153,,,A,Percentage Bioavailability was evaluated.,,CHEMBL620578,,0,1,U,22224,Autocuration,,,BAO_0000218,
11154,Rattus norvegicus,,A,Bioavailability in rat administered i.d.,,CHEMBL620579,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11155,Eutheria,,A,Bioavailability,,CHEMBL621248,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11156,Canis lupus familiaris,,A,Bioavailability in dog (male Beagle) i.v. administration,,CHEMBL625390,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11157,Rattus norvegicus,,A,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,CHEMBL625391,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11158,Primates,,A,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,CHEMBL872266,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11159,Rattus norvegicus,,A,Oral bioavailability in rat (Sprague-Dawley) (male),,CHEMBL625392,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11160,Rattus norvegicus,,A,The oral bioavailability was measured on rats after oral administration,,CHEMBL625393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11161,Rattus norvegicus,,A,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,CHEMBL625394,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11162,Macaca mulatta,,A,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,CHEMBL625395,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
11163,Rattus norvegicus,,A,Bioavailability in rat (dose 10 mg/kg i.d.),,CHEMBL625396,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11164,Canis lupus familiaris,,A,Bioavailability in dog (male Beagle) i.v. administration,,CHEMBL625397,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11165,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625398,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11166,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625399,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
11167,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL626074,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2037.0
11168,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL626075,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11169,Rattus norvegicus,,A,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,CHEMBL626076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11170,Macaca mulatta,,A,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,CHEMBL626077,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,1969.0
11171,Rattus norvegicus,,A,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,CHEMBL626078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11172,,,A,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,CHEMBL625846,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11173,,,A,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,CHEMBL625847,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11174,Rattus norvegicus,,A,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,CHEMBL625848,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
11175,Rattus norvegicus,,A,Maximum concentration of compound in plasma administered orally to rats,,CHEMBL625849,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11176,Canis lupus familiaris,,A,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,CHEMBL626023,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11177,Canis lupus familiaris,,A,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,CHEMBL626024,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11178,Canis lupus familiaris,,A,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,CHEMBL626025,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11179,,,A,Maximum concentration after 10 mg/kg by oral administration,,CHEMBL626026,,0,1,U,22224,Autocuration,,,BAO_0000218,
11180,,,A,Maximum concentration at a dose of 1.5 mg/kg,,CHEMBL626027,,0,1,U,22224,Autocuration,,,BAO_0000218,
11181,,,A,Maximum concentration at a dose of 2.0 mg/kg,,CHEMBL626028,,0,1,U,22224,Autocuration,,,BAO_0000218,
11182,Canis lupus familiaris,,A,Maximum concentration in dog plasma,,CHEMBL626029,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11183,,,A,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,CHEMBL626030,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11184,,,A,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,CHEMBL626031,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11185,,,A,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,CHEMBL626032,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11186,,,A,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,CHEMBL626033,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11187,,,A,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,CHEMBL626034,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11188,Canis lupus familiaris,,A,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,CHEMBL626035,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11189,,,A,Maximum concentration in plasma at Tmax,,CHEMBL626036,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11190,Canis lupus familiaris,,A,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,CHEMBL626037,9615.0,1,1,N,50588,Expert,,,BAO_0000218,1969.0
11191,Cricetinae,,A,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,CHEMBL626038,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,1969.0
11192,Rattus norvegicus,,A,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,CHEMBL626039,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11193,Rattus norvegicus,,A,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,CHEMBL626040,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11194,Oryctolagus cuniculus,,A,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,CHEMBL626041,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1969.0
11195,,,A,Maximum concentration was calculated,,CHEMBL626042,,0,1,U,22224,Autocuration,,,BAO_0000218,
11196,,,A,Maximum concentration was calculated.,,CHEMBL626043,,0,1,U,22224,Autocuration,,,BAO_0000218,
11197,,,A,Maximum concentration at a peroral dose of 10 mg/kg,,CHEMBL626044,,0,1,U,22224,Autocuration,,,BAO_0000218,
11198,,,A,Maximum concentration of the drug at 10 uM/dg administered perorally,,CHEMBL626045,,0,1,U,22224,Autocuration,,,BAO_0000218,
11199,,,A,Maximum concentration of the drug at 2 uM/dg administered intravenously,,CHEMBL626046,,0,1,U,22224,Autocuration,,,BAO_0000218,
11200,Canis lupus familiaris,,A,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,CHEMBL626047,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11201,Cricetinae,,A,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,CHEMBL626048,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,1969.0
11202,Rattus norvegicus,,A,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,CHEMBL626049,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11203,Rattus norvegicus,,A,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,CHEMBL626050,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11204,Canis lupus familiaris,,A,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,CHEMBL874541,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11205,Cricetinae,,A,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,CHEMBL622826,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,1969.0
11206,Cricetinae,,A,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,CHEMBL622827,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,1969.0
11207,Rattus norvegicus,,A,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,CHEMBL622828,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11208,Rattus norvegicus,,A,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,CHEMBL622829,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11209,Rattus norvegicus,,A,Maximum concentration reached following intravenous administration in male rat,,CHEMBL876806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11210,Canis lupus familiaris,,A,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,CHEMBL622830,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11211,Rattus norvegicus,,A,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,CHEMBL622831,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11212,Canis lupus familiaris,,A,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,CHEMBL626794,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11213,Rattus norvegicus,,A,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,CHEMBL626795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11214,Rattus norvegicus,,A,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,CHEMBL626796,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11215,Rattus norvegicus,,A,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,CHEMBL626797,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11216,Rattus norvegicus,,A,Maximum drug concentration is determined after oral dosing in rats.,,CHEMBL626798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11217,Canis lupus familiaris,,A,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,CHEMBL626799,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11218,Canis lupus familiaris,,A,Maximum observed concentration in oral (5 mg/kg) fed dogs,,CHEMBL626800,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11219,,,A,Maximum plasma concentration,,CHEMBL626801,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11220,Rattus norvegicus,,A,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,CHEMBL876816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11221,Rattus norvegicus,,A,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,CHEMBL626802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11222,Canis lupus familiaris,,A,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,CHEMBL626803,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11223,,,A,Maximum plasma concentration following oral administration of 30 umol/kg,,CHEMBL626804,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11224,Rattus norvegicus,,A,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,CHEMBL626805,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11225,Rattus norvegicus,,A,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL626309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11226,Rattus norvegicus,,A,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL626310,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11227,Rattus norvegicus,,A,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626311,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11228,Rattus norvegicus,,A,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626312,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11229,Rattus norvegicus,,A,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626313,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11230,Rattus norvegicus,,A,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL626314,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11231,Rattus norvegicus,,A,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL626315,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11232,Rattus norvegicus,,A,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626316,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11233,Rattus norvegicus,,A,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626317,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11234,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626318,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11235,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626319,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11236,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11237,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL875053,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11238,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626321,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11239,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11240,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11241,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11242,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626325,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11243,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626326,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11244,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626327,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11245,Rattus norvegicus,,A,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626328,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11246,Rattus norvegicus,,A,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,CHEMBL626329,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11247,Rattus norvegicus,,A,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,CHEMBL626330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11248,Rattus norvegicus,,A,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,CHEMBL626331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11249,Rattus norvegicus,,A,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,CHEMBL626332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11250,Rattus norvegicus,,A,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,CHEMBL626333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11251,Rattus norvegicus,,A,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,CHEMBL626334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11252,Rattus norvegicus,,A,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,CHEMBL626335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11253,Rattus norvegicus,,A,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,CHEMBL624798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11254,Rattus norvegicus,,A,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,CHEMBL624799,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11255,Rattus norvegicus,,A,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,CHEMBL624800,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11256,Rattus norvegicus,,A,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,CHEMBL624801,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11257,Rattus norvegicus,,A,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,CHEMBL624802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11258,Rattus norvegicus,,A,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,CHEMBL624803,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11259,Rattus norvegicus,,A,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,CHEMBL624804,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11260,Rattus norvegicus,,A,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,CHEMBL624805,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11261,Rattus norvegicus,,A,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,CHEMBL624806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11262,Rattus norvegicus,,A,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,CHEMBL624807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11263,Rattus norvegicus,,A,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,CHEMBL624808,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11264,Rattus norvegicus,,A,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,CHEMBL624809,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11265,Rattus norvegicus,,A,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,CHEMBL624810,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11266,Rattus norvegicus,,A,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,CHEMBL877618,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11267,Rattus norvegicus,,A,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,CHEMBL624811,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11268,Rattus norvegicus,,A,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,CHEMBL624812,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11269,Rattus norvegicus,,A,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,CHEMBL624813,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11270,Rattus norvegicus,,A,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,CHEMBL624814,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11271,Rattus norvegicus,,A,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,CHEMBL624815,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11272,Rattus norvegicus,,A,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,CHEMBL624816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11273,Rattus norvegicus,,A,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,CHEMBL624817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11274,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,CHEMBL624818,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11275,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,CHEMBL624819,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11276,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,CHEMBL624820,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11277,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624821,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11278,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,CHEMBL624822,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11279,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,CHEMBL624823,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11280,Escherichia coli,,A,Observed diffusion coefficient in organic solvent for Escherichia coli,,CHEMBL624824,562.0,1,1,N,50212,Intermediate,,,BAO_0000218,
11281,Rattus norvegicus,,A,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11282,Rattus norvegicus,,A,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624826,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11283,Rattus norvegicus,,A,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL876817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2081.0
11284,Rattus norvegicus,,A,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624827,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2081.0
11285,Rattus norvegicus,,A,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624828,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11286,Rattus norvegicus,,A,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624829,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11287,Rattus norvegicus,,A,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624830,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11288,Rattus norvegicus,,A,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624831,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11289,Rattus norvegicus,,A,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624832,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2081.0
11290,Rattus norvegicus,,A,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624833,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2081.0
11291,Rattus norvegicus,,A,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624834,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11292,Rattus norvegicus,,A,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624835,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11293,Rattus norvegicus,,A,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624836,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11294,Rattus norvegicus,,A,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624837,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11295,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,CHEMBL624838,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11296,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,CHEMBL622188,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11297,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,CHEMBL622189,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11298,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,CHEMBL622190,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11299,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,CHEMBL625170,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11300,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,CHEMBL625171,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11301,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,CHEMBL625172,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11302,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,CHEMBL625173,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11303,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,CHEMBL625174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11304,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,CHEMBL625175,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11305,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,CHEMBL625176,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11306,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,CHEMBL625177,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11307,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,CHEMBL625178,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11308,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,CHEMBL625179,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11309,Rattus norvegicus,,A,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,CHEMBL625180,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11310,,,A,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,CHEMBL625181,,0,1,U,22224,Autocuration,,,BAO_0000218,
11311,Mus musculus,,A,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,CHEMBL625182,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
11312,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL625183,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11313,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL875848,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11314,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL622260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11315,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL622261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11316,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL622262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11317,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL622263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11318,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL622418,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11319,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL622419,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11320,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623388,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11321,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623389,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11322,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623390,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11323,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623391,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11324,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623392,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
11325,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623393,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2037.0
11326,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623394,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11327,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL618885,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11328,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL618886,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11329,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL618887,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11330,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619535,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11331,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619536,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
11332,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619537,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2037.0
11333,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619705,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11334,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619706,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11335,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619707,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11336,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619708,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11337,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625219,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11338,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625220,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
11339,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625221,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2037.0
11340,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625222,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11341,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625223,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11342,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625224,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11343,Mus musculus,,A,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625225,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11344,Rattus norvegicus,,A,Biodistribution in Rat blood after 24 hours of iv administration,,CHEMBL625226,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11345,Rattus norvegicus,,A,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,CHEMBL625227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11346,Rattus norvegicus,,A,Biodistribution in Rat blood after 30 minutes of iv administration,,CHEMBL625228,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11347,Rattus norvegicus,,A,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,CHEMBL875354,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11348,Rattus norvegicus,,A,Biodistribution in Rat blood after 5 minutes of iv administration,,CHEMBL625229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11349,Rattus norvegicus,,A,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,CHEMBL625230,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11350,Rattus norvegicus,,A,Biodistribution in Rat heart after 24 hours of iv administration,,CHEMBL625231,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11351,Rattus norvegicus,,A,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,CHEMBL625900,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11352,Rattus norvegicus,,A,Biodistribution in Rat heart after 30 minutes of iv administration,,CHEMBL625901,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11353,Rattus norvegicus,,A,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,CHEMBL625902,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11354,Rattus norvegicus,,A,Biodistribution in Rat heart after 5 minutes of iv administration,,CHEMBL625903,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11355,Rattus norvegicus,,A,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,CHEMBL625904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11356,Rattus norvegicus,,A,Biodistribution in Rat liver after 24 hours of iv administration,,CHEMBL625905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11357,Rattus norvegicus,,A,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,CHEMBL627861,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11358,Rattus norvegicus,,A,Biodistribution in Rat liver after 30 minutes of iv administration,,CHEMBL627862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11359,Rattus norvegicus,,A,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,CHEMBL627863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11360,Rattus norvegicus,,A,Biodistribution in Rat liver after 30 minutes of iv administration,,CHEMBL627769,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11361,Canis lupus familiaris,,A,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,CHEMBL627770,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11362,Macaca fascicularis,,A,Cmax in cynomolgus monkey (PO dose),,CHEMBL627771,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11363,Rattus norvegicus,,A,Cmax in rat (PO dose),,CHEMBL627772,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11364,Rattus norvegicus,,A,Cmax in rat (PO dose),,CHEMBL627773,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11365,Rattus norvegicus,,A,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,CHEMBL621922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11366,Rattus norvegicus,,A,Cmax in rat plasma after oral dose (10 mg/kg),,CHEMBL621923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11367,,,A,Cmax in plasma after oral dose (10 mg/kg),,CHEMBL621924,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11368,Canis lupus familiaris,,A,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,CHEMBL621925,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11369,Simiiformes,,A,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,CHEMBL621926,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11370,Oryctolagus cuniculus,,A,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,CHEMBL621927,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1969.0
11371,Rattus norvegicus,,A,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,CHEMBL621928,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11372,Rattus norvegicus,,A,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,CHEMBL621929,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11373,Mus musculus,,A,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,CHEMBL621930,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
11374,Rattus norvegicus,,A,Maximum plasma concentration after oral dosing in rat,,CHEMBL621931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11375,,,A,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,CHEMBL621932,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11376,,,A,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL621933,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11377,Canis lupus familiaris,,A,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,CHEMBL621934,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11378,Canis lupus familiaris,,A,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,CHEMBL621935,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11379,Rattus norvegicus,,A,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,CHEMBL621936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11380,,,A,Maximum plasma concentration was determined,,CHEMBL621937,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11381,,,A,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL621938,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11382,,,A,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL621939,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11383,,,A,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,CHEMBL621940,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11384,,,A,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,CHEMBL621941,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11385,,,A,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,CHEMBL621942,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11386,,,A,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL626178,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11387,,,A,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL626179,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11388,,,A,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,CHEMBL626180,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11389,Rattus norvegicus,,A,Plasma Cmax in rat (PO dose),,CHEMBL626181,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11390,Rattus norvegicus,,A,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,CHEMBL626182,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11391,Rattus norvegicus,,A,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,CHEMBL626183,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11392,Rattus norvegicus,,A,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,CHEMBL626184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11393,Rattus norvegicus,,A,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,CHEMBL626185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11394,Canis lupus familiaris,,A,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,CHEMBL626186,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11395,Canis lupus familiaris,,A,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,CHEMBL877589,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11396,,,A,Maximum concentration of the drug at 1 uM/dg administered intravenously,,CHEMBL626187,,0,1,U,22224,Autocuration,,,BAO_0000218,
11397,,,A,Maximum concentration of the drug at 20 uM/dg administered perorally,,CHEMBL626188,,0,1,U,22224,Autocuration,,,BAO_0000218,
11398,,,A,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,CHEMBL626189,,0,1,U,22224,Autocuration,,,BAO_0000218,
11399,,,A,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL626855,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11400,,,A,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL623781,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11401,,,A,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL623782,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11402,Rattus norvegicus,,A,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,CHEMBL623783,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11403,Canis lupus familiaris,,A,Cmax in dog plasma after 1mg/kg oral dose,,CHEMBL623784,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11404,Canis lupus familiaris,,A,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,CHEMBL623785,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11405,Rattus norvegicus,,A,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,CHEMBL623786,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11406,Rattus norvegicus,,A,Oral maximum concentration in rat,,CHEMBL623787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11407,Rattus norvegicus,,A,Oral maximum concentration in rat,,CHEMBL623788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11408,Mus musculus,,A,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,CHEMBL623789,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
11409,Mus musculus,,A,Peak concentration in blood after intravenous administration to mice,,CHEMBL623790,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
11410,Mus musculus,,A,Peak concentration in blood after peroral administration to mice,,CHEMBL623791,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
11411,Rattus norvegicus,,A,Peak concentration in rat plasma was determined,,CHEMBL623792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11412,Simiiformes,,A,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,CHEMBL623793,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11413,Mus musculus,,A,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,CHEMBL623794,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
11414,Rattus norvegicus,,A,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,CHEMBL623795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11415,Rattus norvegicus,,A,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,CHEMBL623796,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11416,Rattus norvegicus,,A,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,CHEMBL623797,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11417,Rattus norvegicus,,A,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,CHEMBL623798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11418,Rattus norvegicus,,A,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,CHEMBL623799,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11419,Rattus norvegicus,,A,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,CHEMBL624490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11420,Rattus norvegicus,,A,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,CHEMBL624491,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11421,Rattus norvegicus,,A,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,CHEMBL624492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11422,Rattus norvegicus,,A,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,CHEMBL624493,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11423,Rattus norvegicus,,A,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,CHEMBL877595,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11424,Rattus norvegicus,,A,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,CHEMBL624494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11425,Rattus norvegicus,,A,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,CHEMBL624495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11426,Rattus norvegicus,,A,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,CHEMBL624681,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
11427,Rattus norvegicus,,A,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,CHEMBL624682,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11428,Rattus norvegicus,,A,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,CHEMBL624683,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11429,Rattus norvegicus,,A,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,CHEMBL624684,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11430,Rattus norvegicus,,A,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,CHEMBL624685,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11431,Rattus norvegicus,,A,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,CHEMBL624686,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11432,Rattus norvegicus,,A,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,CHEMBL624687,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11433,Rattus norvegicus,,A,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,CHEMBL624688,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11434,Rattus norvegicus,,A,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,CHEMBL627161,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11435,Rattus norvegicus,,A,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,CHEMBL622127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11436,Rattus norvegicus,,A,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,CHEMBL622128,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11437,Rattus norvegicus,,A,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,CHEMBL874384,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11438,Rattus norvegicus,,A,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,CHEMBL624898,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11439,Rattus norvegicus,,A,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,CHEMBL624899,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11440,Rattus norvegicus,,A,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,CHEMBL624900,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11441,Rattus norvegicus,,A,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,CHEMBL624901,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11442,Rattus norvegicus,,A,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,CHEMBL624902,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11443,Rattus norvegicus,,A,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,CHEMBL624903,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11444,Rattus norvegicus,,A,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,CHEMBL624904,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11445,Rattus norvegicus,,A,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,CHEMBL624905,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11446,Rattus norvegicus,,A,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,CHEMBL624906,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11447,Rattus norvegicus,,A,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,CHEMBL624907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11448,Rattus norvegicus,,A,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,CHEMBL624908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11449,Rattus norvegicus,,A,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,CHEMBL624909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11450,Rattus norvegicus,,A,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,CHEMBL624910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11451,Rattus norvegicus,,A,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,CHEMBL624911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11452,Rattus norvegicus,,A,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,CHEMBL874388,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11453,Rattus norvegicus,,A,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,CHEMBL624912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11454,Rattus norvegicus,,A,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,CHEMBL622930,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11455,Rattus norvegicus,,A,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,CHEMBL623121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11456,Rattus norvegicus,,A,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,CHEMBL623122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11457,Rattus norvegicus,,A,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,CHEMBL623123,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11458,Rattus norvegicus,,A,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,CHEMBL623124,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11459,Rattus norvegicus,,A,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,CHEMBL623125,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11460,Rattus norvegicus,,A,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,CHEMBL623126,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11461,Rattus norvegicus,,A,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,CHEMBL623127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11462,Rattus norvegicus,,A,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,CHEMBL623128,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11463,Rattus norvegicus,,A,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,CHEMBL623129,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11464,Rattus norvegicus,,A,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,CHEMBL623130,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11465,Rattus norvegicus,,A,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,CHEMBL623131,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11466,Rattus norvegicus,,A,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,CHEMBL623132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11467,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL623133,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11468,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL623134,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11469,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL874389,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11470,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL623135,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11471,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL623136,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11472,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL623137,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11473,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL623138,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11474,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL623139,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11475,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL623140,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11476,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL623141,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11477,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL623142,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11478,Rattus norvegicus,,A,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL623143,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11479,Mus musculus,,A,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,CHEMBL623144,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
11480,Rattus norvegicus,,A,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,CHEMBL623405,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
11481,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL624074,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11482,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL624075,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11483,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL624076,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11484,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL624077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11485,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL624078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11486,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL624079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11487,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL624261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11488,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL624262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11489,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL624263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11490,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL624264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11491,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL624265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11492,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL624266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11493,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL624267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11494,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL624268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11495,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL875227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11496,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL624269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11497,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL624270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11498,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL624271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11499,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL624272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11500,Rattus norvegicus,,A,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL624273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11501,Rattus norvegicus,,A,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,CHEMBL624274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
11502,Rattus norvegicus,,A,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,CHEMBL624275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
11503,Rattus norvegicus,,A,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,CHEMBL624276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
11504,Rattus norvegicus,,A,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,CHEMBL624277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
11505,,,A,% dose converted to 2-amino-5-chlorophenyl sulfate,,CHEMBL624278,,0,1,U,22224,Autocuration,,,BAO_0000019,
11506,,,A,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,CHEMBL624279,,0,1,U,22224,Autocuration,,,BAO_0000019,
11507,Rattus norvegicus,,A,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL624280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
11508,Rattus norvegicus,,A,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL624281,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
11509,Rattus norvegicus,,A,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL622933,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
11510,Rattus norvegicus,,A,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL622934,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
11511,Rattus norvegicus,,A,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,CHEMBL622935,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11512,Rattus norvegicus,,A,Biodistribution in Rat liver after 5 minutes of iv administration,,CHEMBL622936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11513,Rattus norvegicus,,A,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,CHEMBL875228,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11514,Rattus norvegicus,,A,Biodistribution in Rat lung after 24 hours of iv administration,,CHEMBL622937,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11515,Rattus norvegicus,,A,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,CHEMBL622938,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11516,Rattus norvegicus,,A,Biodistribution in Rat lung after 30 minutes of iv administration,,CHEMBL619736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11517,Rattus norvegicus,,A,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,CHEMBL625117,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11518,Rattus norvegicus,,A,Biodistribution in Rat lung after 5 minutes of iv administration,,CHEMBL625118,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11519,Rattus norvegicus,,A,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,CHEMBL625119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11520,Rattus norvegicus,,A,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,CHEMBL625120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
11521,Rattus norvegicus,,A,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,CHEMBL625121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11522,Rattus norvegicus,,A,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,CHEMBL625122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000006.0
11523,Rattus norvegicus,,A,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL622204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11524,Rattus norvegicus,,A,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL877503,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11525,Rattus norvegicus,,A,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11526,,,A,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL627128,,0,1,U,22224,Autocuration,,,BAO_0000218,10000000.0
11527,,,A,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL627129,,0,1,U,22224,Autocuration,,,BAO_0000218,10000000.0
11528,,,A,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627130,,0,1,U,22224,Autocuration,,,BAO_0000218,10000000.0
11529,Rattus norvegicus,,A,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL627131,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11530,Rattus norvegicus,,A,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL627132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11531,Rattus norvegicus,,A,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627133,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11532,Rattus norvegicus,,A,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL627134,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
11533,Rattus norvegicus,,A,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL627135,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
11534,Rattus norvegicus,,A,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627136,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
11535,Rattus norvegicus,,A,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628435,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11536,Rattus norvegicus,,A,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628436,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11537,Rattus norvegicus,,A,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL628437,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11538,Rattus norvegicus,,A,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628438,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11539,Rattus norvegicus,,A,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628439,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11540,Rattus norvegicus,,A,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL628440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
11541,Rattus norvegicus,,A,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628441,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
11542,Rattus norvegicus,,A,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628442,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
11543,Rattus norvegicus,,A,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL628443,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
11544,Rattus norvegicus,,A,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628444,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11545,Rattus norvegicus,,A,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628445,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11546,Rattus norvegicus,,A,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL877504,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11547,Rattus norvegicus,,A,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628446,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11548,Rattus norvegicus,,A,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL626874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11549,Rattus norvegicus,,A,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL626875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11550,Rattus norvegicus,,A,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL626876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11551,Rattus norvegicus,,A,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL626877,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11552,Rattus norvegicus,,A,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL626878,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11553,Rattus norvegicus,,A,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL626879,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11554,Simiiformes,,A,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,CHEMBL626880,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11555,Mus musculus,,A,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,CHEMBL626881,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
11556,Rattus norvegicus,,A,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,CHEMBL626882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11557,Canis lupus familiaris,,A,Peak plasma concentration was measured in dogs,,CHEMBL626883,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11558,Rattus norvegicus,,A,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL626884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11559,Rattus norvegicus,,A,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,CHEMBL626885,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11560,Rattus norvegicus,,A,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,CHEMBL626886,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11561,Rattus norvegicus,,A,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,CHEMBL626887,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11562,Rattus norvegicus,,A,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL626888,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11563,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,CHEMBL626889,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11564,Simiiformes,,A,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,CHEMBL626761,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11565,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,CHEMBL626762,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11566,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,CHEMBL626763,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11567,Rattus norvegicus,,A,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,CHEMBL626764,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11568,Rattus norvegicus,,A,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,CHEMBL626765,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11569,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,CHEMBL626766,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11570,Rattus norvegicus,,A,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,CHEMBL626767,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11571,Rattus norvegicus,,A,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,CHEMBL626768,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11572,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,CHEMBL626769,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11573,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,CHEMBL874463,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11574,Simiiformes,,A,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,CHEMBL626770,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11575,Simiiformes,,A,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,CHEMBL626771,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11576,Rattus norvegicus,,A,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,CHEMBL626772,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11577,Macaca fascicularis,,A,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,CHEMBL626773,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11578,Mus musculus,,A,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,CHEMBL626774,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11579,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,CHEMBL626775,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11580,Canis lupus familiaris,,A,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,CHEMBL626776,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11581,Rattus norvegicus,,A,Maximum concentration (Cmax) in rat when administered orally,,CHEMBL626777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11582,Simiiformes,,A,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,CHEMBL626778,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11583,Rattus norvegicus,,A,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,CHEMBL626779,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11584,Rattus norvegicus,,A,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,CHEMBL626780,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11585,,,A,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,CHEMBL626781,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11586,Rattus norvegicus,,A,Pharmacokinetic profile Cmax was evaluated in rats,,CHEMBL632164,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11587,Canis lupus familiaris,,A,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,CHEMBL632165,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11588,Mus musculus,,A,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,CHEMBL632166,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11589,Canis lupus familiaris,,A,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,CHEMBL632167,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11590,Mus musculus,,A,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,CHEMBL632168,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11591,Rattus norvegicus,,A,Cmax in rat plasma,,CHEMBL632169,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11592,Canis lupus familiaris,,A,Cmax in dog plasma after 30mg/kg oral dose,,CHEMBL632170,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11593,Rattus norvegicus,,A,Cmax in rat plasma after 30mg/kg oral dose,,CHEMBL632171,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11594,Rattus norvegicus,,A,Plasma level in rats at 30 mg/kg,,CHEMBL632172,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11595,Mus musculus,,A,Tested for maximum plasma concentration in mice,,CHEMBL632173,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
11596,Rattus norvegicus,,A,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL632174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11597,Rattus norvegicus,,A,The Cmax values in female wistar rats.,,CHEMBL632175,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11598,Canis lupus familiaris,,A,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,CHEMBL632176,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11599,Rattus norvegicus,,A,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,CHEMBL632177,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11600,Rattus norvegicus,,A,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,CHEMBL632178,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11601,Rattus norvegicus,,A,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,CHEMBL632179,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11602,Rattus norvegicus,,A,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,CHEMBL632180,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11603,Rattus norvegicus,,A,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,CHEMBL632181,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11604,Rattus norvegicus,,A,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,CHEMBL632182,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11605,Mus musculus,,A,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,CHEMBL632183,10090.0,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11606,Canis lupus familiaris,,A,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,CHEMBL632184,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11607,Rattus norvegicus,,A,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,CHEMBL874470,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11608,Rattus norvegicus,,A,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,CHEMBL631302,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11609,Rattus norvegicus,,A,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,CHEMBL631303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11610,Rattus norvegicus,,A,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,CHEMBL631304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11611,Rattus norvegicus,,A,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,CHEMBL631305,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11612,Rattus norvegicus,,A,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,CHEMBL631306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11613,Rattus norvegicus,,A,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,CHEMBL631307,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11614,Rattus norvegicus,,A,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,CHEMBL631308,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11615,Rattus norvegicus,,A,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,CHEMBL625557,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11616,Rattus norvegicus,,A,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,CHEMBL625558,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11617,Rattus norvegicus,,A,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,CHEMBL625559,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11618,Rattus norvegicus,,A,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,CHEMBL625560,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11619,Rattus norvegicus,,A,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,CHEMBL625561,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11620,Rattus norvegicus,,A,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,CHEMBL625562,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11621,Rattus norvegicus,,A,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,CHEMBL875320,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11622,Rattus norvegicus,,A,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,CHEMBL625563,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11623,Rattus norvegicus,,A,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,CHEMBL625564,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11624,Rattus norvegicus,,A,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,CHEMBL625565,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11625,Rattus norvegicus,,A,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,CHEMBL625566,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11626,Rattus norvegicus,,A,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,CHEMBL625567,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11627,Rattus norvegicus,,A,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,CHEMBL625568,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11628,Rattus norvegicus,,A,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,CHEMBL628217,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11629,Rattus norvegicus,,A,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,CHEMBL628218,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11630,Rattus norvegicus,,A,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,CHEMBL628219,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11631,Rattus norvegicus,,A,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,CHEMBL628220,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
11632,,,A,Distribution in the blood after 120 min of intravenous administration,,CHEMBL628221,,0,1,U,22224,Autocuration,,,BAO_0000019,
11633,,,A,Distribution in the blood after 15 min of intravenous administration,,CHEMBL628222,,0,1,U,22224,Autocuration,,,BAO_0000019,
11634,,,A,Distribution in the blood after 30 min of intravenous administration,,CHEMBL628223,,0,1,U,22224,Autocuration,,,BAO_0000019,
11635,,,A,Distribution in the blood after 5 min of intravenous administration,,CHEMBL628224,,0,1,U,22224,Autocuration,,,BAO_0000019,
11636,,,A,Distribution in the blood after 60 min of intravenous administration,,CHEMBL628225,,0,1,U,22224,Autocuration,,,BAO_0000019,
11637,,,A,Distribution in the blood after 90 min of intravenous administration,,CHEMBL628226,,0,1,U,22224,Autocuration,,,BAO_0000019,
11638,,,A,Distribution in the bone after 120 min of intravenous administration,,CHEMBL628227,,0,1,U,22224,Autocuration,,,BAO_0000019,
11639,,,A,Distribution in the bone after 15 min of intravenous administration,,CHEMBL875481,,0,1,U,22224,Autocuration,,,BAO_0000019,
11640,,,A,Distribution in the bone after 30 min of intravenous administration,,CHEMBL628228,,0,1,U,22224,Autocuration,,,BAO_0000019,
11641,,,A,Distribution in the bone after 5 min of intravenous administration,,CHEMBL628229,,0,1,U,22224,Autocuration,,,BAO_0000019,
11642,,,A,Distribution in the bone after 60 min of intravenous administration,,CHEMBL628230,,0,1,U,22224,Autocuration,,,BAO_0000019,
11643,,,A,Distribution in the bone after 90 min of intravenous administration,,CHEMBL628231,,0,1,U,22224,Autocuration,,,BAO_0000019,
11644,,,A,Distribution in the heart after 120 min of intravenous administration,,CHEMBL628232,,0,1,U,22224,Autocuration,,,BAO_0000019,
11645,,,A,Distribution in the heart after 15 min of intravenous administration,,CHEMBL628233,,0,1,U,22224,Autocuration,,,BAO_0000019,
11646,,,A,Distribution in the heart after 30 min of intravenous administration,,CHEMBL628234,,0,1,U,22224,Autocuration,,,BAO_0000019,
11647,,,A,Distribution in the heart after 5 min of intravenous administration,,CHEMBL628235,,0,1,U,22224,Autocuration,,,BAO_0000019,
11648,,,A,Distribution in the heart after 60 min of intravenous administration,,CHEMBL628236,,0,1,U,22224,Autocuration,,,BAO_0000019,
11649,,,A,Distribution in the heart after 90 min of intravenous administration,,CHEMBL628237,,0,1,U,22224,Autocuration,,,BAO_0000019,
11650,,,A,Distribution in the kidneys after 120 min of intravenous administration,,CHEMBL628238,,0,1,U,22224,Autocuration,,,BAO_0000019,
11651,,,A,Distribution in the kidneys after 15 min of intravenous administration,,CHEMBL628239,,0,1,U,22224,Autocuration,,,BAO_0000019,
11652,,,A,Distribution in the kidneys after 30 min of intravenous administration,,CHEMBL628240,,0,1,U,22224,Autocuration,,,BAO_0000019,
11653,,,A,Distribution in the kidneys after 5 min of intravenous administration,,CHEMBL628241,,0,1,U,22224,Autocuration,,,BAO_0000019,
11654,,,A,Distribution in the kidneys after 60 min of intravenous administration,,CHEMBL628242,,0,1,U,22224,Autocuration,,,BAO_0000019,
11655,,,A,Distribution in the kidneys after 90 min of intravenous administration,,CHEMBL875482,,0,1,U,22224,Autocuration,,,BAO_0000019,
11656,,,A,Distribution in the liver after 120 min of intravenous administration,,CHEMBL628243,,0,1,U,22224,Autocuration,,,BAO_0000019,
11657,,,A,Distribution in the liver after 15 min of intravenous administration,,CHEMBL628244,,0,1,U,22224,Autocuration,,,BAO_0000019,
11658,,,A,Distribution in the liver after 30 min of intravenous administration,,CHEMBL628245,,0,1,U,22224,Autocuration,,,BAO_0000019,
11659,,,A,Distribution in the liver after 5 min of intravenous administration,,CHEMBL628246,,0,1,U,22224,Autocuration,,,BAO_0000019,
11660,,,A,Distribution in the liver after 60 min of intravenous administration,,CHEMBL628247,,0,1,U,22224,Autocuration,,,BAO_0000019,
11661,,,A,Distribution in the liver after 90 min of intravenous administration,,CHEMBL628248,,0,1,U,22224,Autocuration,,,BAO_0000019,
11662,,,A,Distribution in the lung after 120 min of intravenous administration,,CHEMBL628249,,0,1,U,22224,Autocuration,,,BAO_0000019,
11663,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,CHEMBL625452,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11664,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,CHEMBL625453,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11665,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,CHEMBL625454,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11666,Mus musculus,,A,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,CHEMBL623844,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11667,Rattus norvegicus,,A,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,CHEMBL623845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11668,Rattus norvegicus,,A,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,CHEMBL623846,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11669,,,A,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,CHEMBL623847,,0,1,U,22224,Autocuration,,,BAO_0000218,
11670,Macaca fascicularis,,A,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL623848,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11671,Macaca fascicularis,,A,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,CHEMBL623849,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11672,Macaca fascicularis,,A,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL623850,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11673,Macaca fascicularis,,A,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,CHEMBL623851,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11674,Simiiformes,,A,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL623852,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11675,Mustela putorius furo,,A,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,CHEMBL624551,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
11676,Mustela putorius furo,,A,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,CHEMBL624552,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
11677,Simiiformes,,A,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL624553,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11678,Simiiformes,,A,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,CHEMBL624554,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
11679,Rattus norvegicus,,A,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,CHEMBL624555,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11680,Rattus norvegicus,,A,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,CHEMBL624741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11681,Canis lupus familiaris,,A,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,CHEMBL624742,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11682,Cricetinae,,A,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,CHEMBL624743,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
11683,Rattus norvegicus,,A,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,CHEMBL877606,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11684,,,A,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,CHEMBL624744,,0,1,U,22224,Autocuration,,,BAO_0000218,
11685,,,A,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL624745,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11686,,,A,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL624746,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11687,,,A,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL624747,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
11688,,,A,Oral absorption expressed as Area under curve was determined,,CHEMBL624748,,0,1,U,22224,Autocuration,,,BAO_0000019,
11689,Canis lupus familiaris,,A,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,CHEMBL622504,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11690,Canis lupus familiaris,,A,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,CHEMBL622505,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11691,Cricetinae,,A,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,CHEMBL622506,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
11692,Cricetinae,,A,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,CHEMBL622507,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
11693,Rattus norvegicus,,A,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,CHEMBL622508,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11694,,,A,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,CHEMBL622509,,0,1,U,22224,Autocuration,,,BAO_0000019,
11695,Rattus norvegicus,,A,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL622510,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11696,Rattus norvegicus,,A,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,CHEMBL622511,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11697,Macaca fascicularis,,A,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,CHEMBL622512,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11698,Macaca fascicularis,,A,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,CHEMBL622513,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11699,Macaca fascicularis,,A,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,CHEMBL622514,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11700,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,CHEMBL622515,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11701,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,CHEMBL622516,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11702,Rattus norvegicus,,A,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,CHEMBL622517,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11703,Rattus norvegicus,,A,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,CHEMBL622518,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11704,Rattus norvegicus,,A,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,CHEMBL622519,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11705,Rattus norvegicus,,A,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL622520,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11706,Rattus norvegicus,,A,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL622521,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11707,Mus musculus,,A,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL625113,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
11708,Rattus norvegicus,,A,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL625114,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
11709,Rattus norvegicus,,A,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL874397,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
11710,Rattus norvegicus,,A,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL625115,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11711,Rattus norvegicus,,A,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL625116,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11712,Rattus norvegicus,,A,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL623932,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
11713,Rattus norvegicus,,A,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL623933,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
11714,Rattus norvegicus,,A,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL623934,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
11715,Rattus norvegicus,,A,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL623935,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
11716,Rattus norvegicus,,A,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL623936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
11717,Rattus norvegicus,,A,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL623937,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
11718,Rattus norvegicus,,A,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL623938,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
11719,Mus musculus,,A,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL623939,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11720,Mus musculus,,A,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL623940,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11721,Mus musculus,,A,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL623941,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11722,Mus musculus,,A,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL627216,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11723,Mus musculus,,A,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL623942,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11724,Mus musculus,,A,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618793,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
11725,Mus musculus,,A,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618794,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
11726,Mus musculus,,A,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618795,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
11727,Mus musculus,,A,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618796,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11728,Mus musculus,,A,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618797,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11729,Mus musculus,,A,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,CHEMBL618798,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
11730,Mus musculus,,A,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618799,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
11731,Mus musculus,,A,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL618800,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
11732,Mus musculus,,A,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL618801,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
11733,Mus musculus,,A,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618802,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
11734,Mus musculus,,A,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618803,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
11735,Mus musculus,,A,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,CHEMBL618804,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11736,Mus musculus,,A,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618805,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11737,Mus musculus,,A,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL618806,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11738,Mus musculus,,A,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL618807,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11739,Mus musculus,,A,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618808,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11740,Mus musculus,,A,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618809,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
11741,Mus musculus,,A,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618810,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
11742,Mus musculus,,A,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL618811,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
11743,Mus musculus,,A,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL875844,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
11744,Mus musculus,,A,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618812,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
11745,Mus musculus,,A,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618813,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
11746,Mus musculus,,A,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618814,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11747,Mus musculus,,A,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618815,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11748,Mus musculus,,A,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618816,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11749,Mus musculus,,A,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618817,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11750,Mus musculus,,A,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL620544,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11751,Rattus norvegicus,,A,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,CHEMBL626230,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11752,Rattus norvegicus,,A,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,CHEMBL626231,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11753,Rattus norvegicus,,A,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,CHEMBL626232,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11754,Canis lupus familiaris,,A,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,CHEMBL626233,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11755,Rattus norvegicus,,A,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,CHEMBL626234,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11756,Rattus norvegicus,,A,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,CHEMBL875341,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11757,Homo sapiens,,A,The maximum plasma concentration (100 mg/kg) administered orally in human,,CHEMBL626235,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
11758,Callithrix,,A,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,CHEMBL626236,9481.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11759,Simiiformes,,A,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,CHEMBL626237,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11760,Canis lupus familiaris,,A,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,CHEMBL626238,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11761,Homo sapiens,,A,The maximum plasma concentration (200 mg/kg) administered orally in human,,CHEMBL622412,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
11762,Rattus norvegicus,,A,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,CHEMBL623114,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11763,Callithrix,,A,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,CHEMBL623115,9481.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11764,Simiiformes,,A,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,CHEMBL623116,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11765,Canis lupus familiaris,,A,The maximum plasma concentration (30 mg/kg) administered orally in dog,,CHEMBL623117,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11766,Homo sapiens,,A,The maximum plasma concentration (400 mg/kg) administered orally in human,,CHEMBL623118,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
11767,Rattus norvegicus,,A,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,CHEMBL623119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11768,Rattus norvegicus,,A,The maximum plasma concentration (50 mg/kg) administered orally in rat,,CHEMBL623120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11769,Homo sapiens,,A,The maximum plasma concentration (800 mg/kg) administered orally in human,,CHEMBL623286,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
11770,Rattus norvegicus,,A,The maximum plasma concentration was measured on rats,,CHEMBL623287,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11771,Rattus norvegicus,,A,The maximum plasma concentration was measured on rats after oral administration,,CHEMBL623288,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11772,Rattus norvegicus,,A,Plasma drug Cmax in rat (PO dose),,CHEMBL623289,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11773,,,A,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,CHEMBL623290,,0,1,U,22224,Autocuration,,,BAO_0000218,
11774,Canis lupus familiaris,,A,maximum Plasma concentration in Dog was determined after Peroral administration,,CHEMBL623291,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11775,Rattus norvegicus,,A,maximum Plasma concentration in Rats was determined after Peroral administration,,CHEMBL623292,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11776,Canis lupus familiaris,,A,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,CHEMBL623293,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
11777,Simiiformes,,A,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,CHEMBL623294,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
11778,Rattus norvegicus,,A,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,CHEMBL623295,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11779,Mus musculus,,A,maximum concentration was measured when administered through oral route in mice,,CHEMBL623296,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11780,Mus musculus,,A,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,CHEMBL875349,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11781,Simiiformes,,A,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,CHEMBL623297,314293.0,0,1,U,22224,Autocuration,,,BAO_0000019,
11782,Simiiformes,,A,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,CHEMBL623298,314293.0,0,1,U,22224,Autocuration,,,BAO_0000019,
11783,Simiiformes,,A,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,CHEMBL623299,314293.0,0,1,U,22224,Autocuration,,,BAO_0000019,
11784,Rattus norvegicus,,A,Pharmacokinetic parameter was evaluated in rats,,CHEMBL623300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11785,Mus musculus,,A,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,CHEMBL623301,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11786,Mus musculus,,A,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,CHEMBL623302,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11787,Mus musculus,,A,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,CHEMBL623303,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11788,Mus musculus,,A,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,CHEMBL623304,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11789,Mus musculus,,A,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,CHEMBL623305,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11790,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11791,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623307,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11792,Rattus norvegicus,,A,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623308,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
11793,Mus musculus,,A,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623309,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
11794,Mus musculus,,A,Plasma Concentration after 120 min of oral administration to mice,,CHEMBL623310,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11795,Mus musculus,,A,Plasma Concentration after 30 min of oral administration to mice,,CHEMBL623311,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11796,Macaca fascicularis,,A,Plasma Concentration after 60 min of oral administration to mice,,CHEMBL623312,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11797,Mus musculus,,A,Plasma Concentration after 60 min of oral administration to mice; Not determined,,CHEMBL875350,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11798,Mus musculus,,A,Plasma Concentration after 90 min of oral administration to mice,,CHEMBL628635,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11799,Rattus norvegicus,,A,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,CHEMBL628636,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11800,Rattus norvegicus,,A,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,CHEMBL628637,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11801,Rattus norvegicus,,A,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,CHEMBL628058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11802,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,CHEMBL628059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11803,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,CHEMBL628060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11804,,,A,Distribution in the lung after 15 min of intravenous administration,,CHEMBL628061,,0,1,U,22224,Autocuration,,,BAO_0000019,
11805,,,A,Distribution in the lung after 30 min of intravenous administration,,CHEMBL628062,,0,1,U,22224,Autocuration,,,BAO_0000019,
11806,,,A,Distribution in the lung after 5 min of intravenous administration,,CHEMBL628063,,0,1,U,22224,Autocuration,,,BAO_0000019,
11807,,,A,Distribution in the lung after 60 min of intravenous administration,,CHEMBL628064,,0,1,U,22224,Autocuration,,,BAO_0000019,
11808,,,A,Distribution in the lung after 90 min of intravenous administration,,CHEMBL628065,,0,1,U,22224,Autocuration,,,BAO_0000019,
11809,,,A,Distribution in the muscle after 120 min of intravenous administration,,CHEMBL628066,,0,1,U,22224,Autocuration,,,BAO_0000019,2385.0
11810,,,A,Distribution in the muscle after 15 min of intravenous administration,,CHEMBL628067,,0,1,U,22224,Autocuration,,,BAO_0000019,2385.0
11811,Mus musculus,,A,Distribution in the muscle after 30 min of intravenous administration,,CHEMBL874646,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2385.0
11812,,,A,Distribution in the muscle after 5 min of intravenous administration,,CHEMBL628068,,0,1,U,22224,Autocuration,,,BAO_0000019,2385.0
11813,,,A,Distribution in the muscle after 60 min of intravenous administration,,CHEMBL628069,,0,1,U,22224,Autocuration,,,BAO_0000019,2385.0
11814,,,A,Distribution in the muscle after 90 min of intravenous administration,,CHEMBL628070,,0,1,U,22224,Autocuration,,,BAO_0000019,2385.0
11815,,,A,Distribution in the spleen after 120 min of intravenous administration,,CHEMBL628071,,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
11816,,,A,Distribution in the spleen after 15 min of intravenous administration,,CHEMBL628072,,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
11817,,,A,Distribution in the spleen after 30 min of intravenous administration,,CHEMBL628073,,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
11818,,,A,Distribution in the spleen after 5 min of intravenous administration,,CHEMBL628074,,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
11819,,,A,Distribution in the spleen after 60 min of intravenous administration,,CHEMBL628075,,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
11820,,,A,Distribution in the spleen after 90 min of intravenous administration,,CHEMBL628076,,0,1,U,22224,Autocuration,,,BAO_0000019,2106.0
11821,Rattus norvegicus,,A,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,CHEMBL628077,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1235.0
11822,Rattus norvegicus,,A,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,CHEMBL628078,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11823,Rattus norvegicus,,A,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,CHEMBL628079,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11824,Rattus norvegicus,,A,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,CHEMBL628080,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
11825,Rattus norvegicus,,A,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,CHEMBL628081,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
11826,Rattus norvegicus,,A,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,CHEMBL628082,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1235.0
11827,Rattus norvegicus,,A,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,CHEMBL874647,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11828,Rattus norvegicus,,A,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,CHEMBL626406,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11829,Rattus norvegicus,,A,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,CHEMBL626407,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
11830,Rattus norvegicus,,A,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,CHEMBL626408,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
11831,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,CHEMBL626409,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11832,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,CHEMBL626410,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11833,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,CHEMBL626411,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11834,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,CHEMBL626412,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11835,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,CHEMBL626413,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11836,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,CHEMBL626414,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11837,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,CHEMBL626415,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11838,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,CHEMBL626416,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11839,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,CHEMBL627062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11840,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,CHEMBL627063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11841,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,CHEMBL627064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11842,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,CHEMBL627227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11843,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,CHEMBL627228,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11844,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,CHEMBL627229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11845,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,CHEMBL625792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11846,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,CHEMBL625793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11847,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,CHEMBL625794,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11848,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,CHEMBL625795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11849,Mus musculus,,A,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,CHEMBL625796,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11850,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,CHEMBL625797,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11851,Canis lupus familiaris,,A,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,CHEMBL625798,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
11852,,,A,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL875613,,0,1,U,22224,Autocuration,,,BAO_0000218,
11853,,,A,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL625799,,0,1,U,22224,Autocuration,,,BAO_0000218,
11854,,,A,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,CHEMBL625800,,0,1,U,22224,Autocuration,,,BAO_0000218,
11855,,,A,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,CHEMBL625801,,0,1,U,22224,Autocuration,,,BAO_0000218,
11856,,,A,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,CHEMBL625802,,0,1,U,22224,Autocuration,,,BAO_0000218,
11857,,,A,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL625803,,0,1,U,22224,Autocuration,,,BAO_0000218,
11858,,,A,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,CHEMBL625804,,0,1,U,22224,Autocuration,,,BAO_0000019,
11859,,,A,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,CHEMBL622530,,0,1,U,22224,Autocuration,,,BAO_0000218,
11860,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,CHEMBL622531,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11861,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,CHEMBL622532,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11862,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,CHEMBL623176,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11863,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,CHEMBL623177,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11864,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,CHEMBL623178,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11865,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,CHEMBL623179,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11866,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,CHEMBL623180,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11867,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,CHEMBL623181,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11868,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,CHEMBL624131,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11869,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,CHEMBL624132,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11870,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,CHEMBL624133,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11871,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,CHEMBL624846,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11872,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,CHEMBL624847,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11873,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,CHEMBL624848,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11874,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,CHEMBL625012,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11875,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,CHEMBL625013,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11876,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,CHEMBL625014,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11877,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,CHEMBL625015,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11878,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,CHEMBL625016,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11879,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,CHEMBL625017,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11880,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,CHEMBL625018,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11881,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,CHEMBL625019,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11882,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,CHEMBL625020,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11883,Mus musculus,,A,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,CHEMBL625021,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11884,Rattus norvegicus,,A,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL625022,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11885,Mus musculus,,A,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,CHEMBL625023,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11886,Macaca fascicularis,,A,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,CHEMBL625024,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11887,Macaca fascicularis,,A,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,CHEMBL627626,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
11888,,,A,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,CHEMBL627627,,0,1,U,22224,Autocuration,,,BAO_0000218,955.0
11889,,,A,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,CHEMBL627628,,0,1,U,22224,Autocuration,,,BAO_0000218,1977.0
11890,,,A,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,CHEMBL627629,,0,1,U,22224,Autocuration,,,BAO_0000218,955.0
11891,,,A,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,CHEMBL627630,,0,1,U,22224,Autocuration,,,BAO_0000218,1977.0
11892,,,A,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,CHEMBL627631,,0,1,U,22224,Autocuration,,,BAO_0000019,
11893,,,A,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,CHEMBL629515,,0,1,U,22224,Autocuration,,,BAO_0000218,
11894,Mus musculus,,A,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL629516,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
11895,Mus musculus,,A,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL629517,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
11896,Mus musculus,,A,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL629518,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
11897,Mus musculus,,A,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL877499,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11898,Mus musculus,,A,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL629519,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11899,Mus musculus,,A,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL629520,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11900,Mus musculus,,A,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL629521,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11901,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,CHEMBL629522,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11902,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,CHEMBL629523,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11903,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,CHEMBL629524,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11904,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,CHEMBL629525,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11905,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,CHEMBL629526,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11906,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,CHEMBL629527,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11907,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,CHEMBL629528,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11908,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,CHEMBL629529,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11909,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,CHEMBL629530,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11910,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,CHEMBL629531,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11911,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,CHEMBL628656,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11912,Mus musculus,,A,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,CHEMBL628657,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
11913,Rattus norvegicus,,A,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL628658,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11914,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL628659,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11915,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL877500,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11916,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL628660,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11917,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL628661,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11918,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL628662,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11919,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL628663,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11920,Rattus norvegicus,,A,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL628664,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11921,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL628665,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11922,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL628666,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11923,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL628667,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11924,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL628668,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11925,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL628669,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11926,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL628670,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11927,Rattus norvegicus,,A,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL628671,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11928,Rattus norvegicus,,A,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL628672,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
11929,Rattus norvegicus,,A,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL630300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
11930,Rattus norvegicus,,A,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL629787,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
11931,Rattus norvegicus,,A,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
11932,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL629789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11933,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL629790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11934,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL629791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11935,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL629792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11936,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11937,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL629794,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11938,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,CHEMBL874459,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11939,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,CHEMBL629795,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11940,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,CHEMBL629796,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11941,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,CHEMBL629797,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11942,Rattus norvegicus,,A,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,CHEMBL629798,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11943,Rattus norvegicus,,A,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629799,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2369.0
11944,Rattus norvegicus,,A,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629800,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2369.0
11945,Rattus norvegicus,,A,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629801,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2369.0
11946,Rattus norvegicus,,A,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,CHEMBL629802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2369.0
11947,Rattus norvegicus,,A,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL629803,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2369.0
11948,Rattus norvegicus,,A,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629804,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11949,Rattus norvegicus,,A,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629805,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11950,Rattus norvegicus,,A,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,CHEMBL629806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11951,Rattus norvegicus,,A,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11952,Rattus norvegicus,,A,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL629808,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
11953,Rattus norvegicus,,A,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629809,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11954,Rattus norvegicus,,A,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629810,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11955,Rattus norvegicus,,A,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,CHEMBL629811,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11956,Rattus norvegicus,,A,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629812,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11957,Rattus norvegicus,,A,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,CHEMBL629813,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11958,Rattus norvegicus,,A,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL874460,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
11959,Rattus norvegicus,,A,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629814,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11960,Rattus norvegicus,,A,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629815,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11961,Rattus norvegicus,,A,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11962,Rattus norvegicus,,A,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL629817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11963,Rattus norvegicus,,A,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL626643,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11964,Rattus norvegicus,,A,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL626644,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11965,Rattus norvegicus,,A,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL626806,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11966,Rattus norvegicus,,A,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL626807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
11967,Rattus norvegicus,,A,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11968,Rattus norvegicus,,A,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11969,Rattus norvegicus,,A,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11970,Rattus norvegicus,,A,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
11971,Rattus norvegicus,,A,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11972,Rattus norvegicus,,A,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11973,Rattus norvegicus,,A,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11974,Rattus norvegicus,,A,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
11975,Rattus norvegicus,,A,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11976,Rattus norvegicus,,A,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
11977,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,CHEMBL627271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11978,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,CHEMBL627946,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11979,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,CHEMBL875472,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11980,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,CHEMBL627947,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11981,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,CHEMBL627948,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11982,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,CHEMBL628113,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11983,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,CHEMBL628114,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11984,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,CHEMBL628115,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11985,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,CHEMBL628116,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11986,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,CHEMBL628117,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11987,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,CHEMBL628118,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11988,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,CHEMBL628119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11989,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,CHEMBL628120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11990,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,CHEMBL628121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11991,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,CHEMBL628122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11992,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,CHEMBL627297,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11993,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,CHEMBL627298,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11994,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,CHEMBL627299,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11995,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,CHEMBL627300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11996,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,CHEMBL627301,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11997,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,CHEMBL627302,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11998,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,CHEMBL627303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
11999,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,CHEMBL627304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12000,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,CHEMBL627305,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12001,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,CHEMBL627306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12002,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,CHEMBL623982,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12003,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,CHEMBL623983,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12004,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,CHEMBL623984,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12005,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,CHEMBL623985,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12006,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,CHEMBL623986,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12007,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,CHEMBL623987,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12008,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,CHEMBL623988,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12009,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,CHEMBL623989,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12010,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,CHEMBL622215,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12011,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,CHEMBL622216,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12012,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,CHEMBL877481,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12013,,,A,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,CHEMBL622217,,0,1,U,22224,Autocuration,,,BAO_0000218,
12014,Mus musculus,,A,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,CHEMBL622218,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12015,Rattus norvegicus,,A,Pharmacokinetic profile AUC was evaluated in rats,,CHEMBL622219,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12016,,,A,Pharmacokinetic property (Area under curve),,CHEMBL622220,,0,1,U,22224,Autocuration,,,BAO_0000019,
12017,Canis lupus familiaris,,A,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,CHEMBL622221,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12018,Mus musculus,,A,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,CHEMBL622222,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12019,Canis lupus familiaris,,A,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,CHEMBL622223,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12020,Mus musculus,,A,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,CHEMBL622224,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12021,,,A,Plasma concentration (AUC) was determined,,CHEMBL622225,,0,1,U,22224,Autocuration,,,BAO_0000019,
12022,,,A,Plasma concentration (AUC) was determined; Not detectable,,CHEMBL622226,,0,1,U,22224,Autocuration,,,BAO_0000019,
12023,Cavia porcellus,,A,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,CHEMBL624154,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
12024,Rattus norvegicus,,A,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,CHEMBL624155,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12025,Rattus norvegicus,,A,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,CHEMBL624156,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12026,Rattus norvegicus,,A,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,CHEMBL624157,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12027,Rattus norvegicus,,A,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,CHEMBL624158,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12028,Rattus norvegicus,,A,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,CHEMBL624159,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12029,Rattus norvegicus,,A,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,CHEMBL624160,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12030,Rattus norvegicus,,A,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,CHEMBL624161,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12031,Rattus norvegicus,,A,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,CHEMBL624162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12032,Canis lupus familiaris,,A,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,CHEMBL624163,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12033,Rattus norvegicus,,A,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624164,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12034,Rattus norvegicus,,A,The AUC(0-infinity) values in female wistar rats.,,CHEMBL624165,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12035,Rattus norvegicus,,A,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624166,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12036,Rattus norvegicus,,A,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,CHEMBL624167,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12037,Rattus norvegicus,,A,The AUC(0-t)values in female wistar rats.,,CHEMBL624168,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12038,Rattus norvegicus,,A,The Area under the concentration time curve of compound was measured on rats,,CHEMBL624169,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12039,Homo sapiens,,A,The area under curve (100 mg/kg) administered orally in humans,,CHEMBL624170,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12040,Callithrix,,A,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,CHEMBL624171,9481.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12041,Simiiformes,,A,The area under curve (12.5 mg/kg) administered intravenously in monkey,,CHEMBL624172,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12042,Canis lupus familiaris,,A,The area under curve (15 mg/kg) administered intravenously in dog,,CHEMBL624173,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12043,Homo sapiens,,A,The area under curve (200 mg/kg) administered orally in humans,,CHEMBL877488,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12044,Rattus norvegicus,,A,The area under curve (25 mg/kg) administered intravenously in rat,,CHEMBL624174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12045,Callithrix,,A,The area under curve (25 mg/kg) administered orally in marmoset,,CHEMBL624175,9481.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12046,Simiiformes,,A,The area under curve (25 mg/kg) administered orally in monkey,,CHEMBL624176,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12047,Canis lupus familiaris,,A,The area under curve (30 mg/kg) administered orally in dog,,CHEMBL624177,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12048,Homo sapiens,,A,The area under curve (400 mg/kg) administered orally in humans,,CHEMBL624178,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12049,Rattus norvegicus,,A,The area under curve (50 mg/kg) administered orally in fasted rat,,CHEMBL624179,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12050,Rattus norvegicus,,A,The area under curve (50 mg/kg) administered orally in rat,,CHEMBL627689,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12051,Homo sapiens,,A,The area under curve (800 mg/kg) administered orally in humans,,CHEMBL627690,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12052,,,A,The compound was evaluated for area under the curve,,CHEMBL627691,,0,1,U,22224,Autocuration,,,BAO_0000019,
12053,Callithrix,,A,The compound was evaluated for area under the curve in marmosets,,CHEMBL627692,9481.0,0,1,U,22224,Autocuration,,,BAO_0000019,
12054,Callithrix,,A,The compound was evaluated for area under the curve in marmosets,,CHEMBL627693,9481.0,0,1,U,22224,Autocuration,,,BAO_0000019,
12055,Rattus norvegicus,,A,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627694,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12056,Rattus norvegicus,,A,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627695,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12057,,,A,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,CHEMBL627696,,0,1,U,22224,Autocuration,,,BAO_0000218,
12058,Rattus norvegicus,,A,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627697,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12059,Rattus norvegicus,,A,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627698,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12060,Rattus norvegicus,,A,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627699,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12061,Rattus norvegicus,,A,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,CHEMBL627700,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12062,Rattus norvegicus,,A,Total drug exposure is determined after oral dosing in rats.,,CHEMBL627701,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12063,,,A,Total drug exposure (5 mg/kg) when administered intravenously,,CHEMBL627702,,0,1,U,22224,Autocuration,,,BAO_0000218,
12064,,,A,Total drug exposure (5 mg/kg) when administered orally,,CHEMBL627703,,0,1,U,22224,Autocuration,,,BAO_0000218,
12065,Simiiformes,,A,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,CHEMBL626873,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12066,Rattus norvegicus,,A,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,CHEMBL629583,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12067,Canis lupus familiaris,,A,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,CHEMBL629584,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12068,Canis lupus familiaris,,A,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,CHEMBL629585,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12069,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL629586,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
12070,Rattus norvegicus,,A,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629587,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
12071,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL629588,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12072,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL629589,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12073,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL629590,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12074,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL629591,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12075,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629592,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12076,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL629593,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12077,Rattus norvegicus,,A,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL629594,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12078,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL629595,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12079,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL630290,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12080,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL627137,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12081,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627138,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12082,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627139,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12083,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL627140,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12084,Rattus norvegicus,,A,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627141,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12085,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627142,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12086,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL627143,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12087,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL874449,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12088,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627144,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12089,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627145,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12090,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL627146,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12091,Rattus norvegicus,,A,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627147,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12092,Rattus norvegicus,,A,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627148,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12093,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627149,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12094,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL632160,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12095,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL632161,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12096,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL632162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12097,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL632163,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12098,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL874469,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12099,Rattus norvegicus,,A,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627182,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12100,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627183,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12101,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL627184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12102,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL627185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12103,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12104,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627187,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12105,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL627188,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12106,Rattus norvegicus,,A,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627189,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12107,Rattus norvegicus,,A,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627190,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12108,Rattus norvegicus,,A,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL627191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12109,Rattus norvegicus,,A,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12110,Rattus norvegicus,,A,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12111,Rattus norvegicus,,A,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,CHEMBL874590,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12112,Rattus norvegicus,,A,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12113,Rattus norvegicus,,A,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627195,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12114,Rattus norvegicus,,A,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627196,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
12115,Rattus norvegicus,,A,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627197,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
12116,Rattus norvegicus,,A,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627198,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
12117,Rattus norvegicus,,A,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,CHEMBL627199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
12118,Rattus norvegicus,,A,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,992.0
12119,Rattus norvegicus,,A,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12120,Rattus norvegicus,,A,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12121,Rattus norvegicus,,A,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12122,Rattus norvegicus,,A,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12123,Rattus norvegicus,,A,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
12124,Rattus norvegicus,,A,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
12125,Rattus norvegicus,,A,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
12126,Rattus norvegicus,,A,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
12127,Rattus norvegicus,,A,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12128,Rattus norvegicus,,A,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12129,Rattus norvegicus,,A,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12130,Rattus norvegicus,,A,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12131,Rattus norvegicus,,A,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12132,Rattus norvegicus,,A,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL626599,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12133,Rattus norvegicus,,A,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL626600,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12134,Rattus norvegicus,,A,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL626601,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12135,,,A,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,CHEMBL627484,,0,1,U,22224,Autocuration,,,BAO_0000019,
12136,Macaca fascicularis,,A,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,CHEMBL627485,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
12137,Macaca fascicularis,,A,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,CHEMBL628147,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
12138,Macaca fascicularis,,A,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,CHEMBL628148,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
12139,Canis lupus familiaris,,A,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,CHEMBL628149,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12140,Canis lupus familiaris,,A,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,CHEMBL628150,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12141,Canis lupus familiaris,,A,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,CHEMBL628318,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12142,Canis lupus familiaris,,A,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,CHEMBL628319,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12143,Canis lupus familiaris,,A,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,CHEMBL875609,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12144,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,CHEMBL628320,,0,1,U,22224,Autocuration,,,BAO_0000019,
12145,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,CHEMBL628321,,0,1,U,22224,Autocuration,,,BAO_0000019,
12146,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,CHEMBL628322,,0,1,U,22224,Autocuration,,,BAO_0000019,
12147,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,CHEMBL628323,,0,1,U,22224,Autocuration,,,BAO_0000019,
12148,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,CHEMBL628324,,0,1,U,22224,Autocuration,,,BAO_0000019,
12149,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,CHEMBL628325,,0,1,U,22224,Autocuration,,,BAO_0000019,
12150,,,A,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,CHEMBL628326,,0,1,U,22224,Autocuration,,,BAO_0000019,
12151,Canis lupus familiaris,,A,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,CHEMBL628327,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1236.0
12152,Canis lupus familiaris,,A,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,CHEMBL628328,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1236.0
12153,Canis lupus familiaris,,A,"Concentration of compound in blood of dog 1, after administering intravenously",,CHEMBL628329,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
12154,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,CHEMBL628330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12155,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,CHEMBL628331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12156,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,CHEMBL628332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12157,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,CHEMBL628333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12158,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,CHEMBL628334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12159,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,CHEMBL628335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12160,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,CHEMBL628336,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12161,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,CHEMBL628337,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12162,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,CHEMBL628338,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12163,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,CHEMBL875610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12164,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,CHEMBL628339,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12165,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,CHEMBL628340,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12166,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,CHEMBL628341,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12167,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,CHEMBL622214,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12168,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,CHEMBL623167,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12169,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,CHEMBL623168,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12170,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,CHEMBL623169,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12171,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,CHEMBL623170,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12172,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,CHEMBL627224,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12173,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,CHEMBL875634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12174,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,CHEMBL627225,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12175,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,CHEMBL627226,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12176,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,CHEMBL626083,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12177,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,CHEMBL626084,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12178,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,CHEMBL626085,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12179,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,CHEMBL626086,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12180,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,CHEMBL626087,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12181,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,CHEMBL626088,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12182,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,CHEMBL626089,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12183,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,CHEMBL626090,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12184,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,CHEMBL626091,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12185,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,CHEMBL626092,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12186,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,CHEMBL626093,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12187,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,CHEMBL626094,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12188,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,CHEMBL626095,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12189,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,CHEMBL626096,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12190,Simiiformes,,A,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,CHEMBL626097,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12191,Rattus norvegicus,,A,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,CHEMBL626098,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12192,,,A,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,CHEMBL626099,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
12193,,,A,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,CHEMBL626100,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
12194,Canis lupus familiaris,,A,AUC 0-inf in dog,,CHEMBL626101,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12195,Cavia porcellus,,A,AUC 0-inf in guinea pig,,CHEMBL626102,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,1969.0
12196,Canis lupus familiaris,,A,AUC 0-t in dog,,CHEMBL626103,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12197,Cavia porcellus,,A,AUC 0-t in guinea pig,,CHEMBL628391,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,1969.0
12198,Rattus norvegicus,,A,The compound was tested for brain to plasma partition in rat,,CHEMBL628392,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12199,Rattus norvegicus,,A,The compound was tested for brain to plasma partition in rat.,,CHEMBL628393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12200,,,A,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,CHEMBL628394,,0,1,U,22224,Autocuration,,,BAO_0000019,178.0
12201,Canis lupus familiaris,,A,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,CHEMBL628395,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12202,Simiiformes,,A,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,CHEMBL628396,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12203,Oryctolagus cuniculus,,A,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,CHEMBL628397,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12204,Rattus norvegicus,,A,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,CHEMBL628398,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12205,Macaca mulatta,,A,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,CHEMBL628399,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
12206,Canis lupus familiaris,,A,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,CHEMBL628400,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12207,Rattus norvegicus,,A,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,CHEMBL874907,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12208,,,A,Area under curve of the compound was determined,,CHEMBL628401,,0,1,U,22224,Autocuration,,,BAO_0000019,
12209,Simiiformes,,A,AUC in monkeys at a dose of 1 mg/kg,,CHEMBL628402,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
12210,Rattus norvegicus,,A,AUC in rats at a dose of 1 mg/kg,,CHEMBL628403,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12211,,,A,Compound was evaluated for the overall absorbance loss at pH of 2,,CHEMBL628404,,0,1,U,22224,Autocuration,,,BAO_0000019,
12212,,,A,Compound was evaluated for the overall absorbance loss at pH of 4,,CHEMBL628405,,0,1,U,22224,Autocuration,,,BAO_0000019,
12213,,,A,Compound was evaluated for the overall absorbance loss at pH of 7,,CHEMBL628406,,0,1,U,22224,Autocuration,,,BAO_0000019,
12214,Rattus norvegicus,,A,Compound was evaluated for its absorption in the rats,,CHEMBL628407,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12215,Rattus norvegicus,,A,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,CHEMBL628408,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
12216,Rattus norvegicus,,A,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,CHEMBL629171,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
12217,Rattus norvegicus,,A,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,CHEMBL629172,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
12218,Rattus norvegicus,,A,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,CHEMBL629173,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
12219,Rattus norvegicus,,A,In vitro percent permeability into rat ileum,,CHEMBL629174,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12220,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 10-17,,CHEMBL629175,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12221,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 10-18,,CHEMBL629176,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12222,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 10-19,,CHEMBL629177,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12223,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 12-15,,CHEMBL629178,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12224,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 13-19,,CHEMBL631869,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12225,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 14-17,,CHEMBL631870,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12226,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 15-18,,CHEMBL631871,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12227,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 2-5,,CHEMBL631872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12228,,,A,In vitro percent permeability into rat ileum; Range is 23-42,,CHEMBL875775,,0,1,U,22224,Autocuration,,,BAO_0000221,2116.0
12229,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 28-36,,CHEMBL631873,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12230,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 29-35,,CHEMBL631874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12231,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 46-66,,CHEMBL631875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12232,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 50-68,,CHEMBL631876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12233,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; Range is 78-81,,CHEMBL631877,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12234,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,CHEMBL631878,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12235,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; nd indicates not detected,,CHEMBL631879,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12236,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; nt indicates not detected,,CHEMBL631880,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12237,Rattus norvegicus,,A,In vitro percent permeability into rat ileum; nt indicates not tested,,CHEMBL631881,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12238,Rattus norvegicus,,A,Compound was tested for oral absorption in bile-duct cannulated rats,,CHEMBL631882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12239,Rattus norvegicus,,A,Compound was tested for oral absorption in bile-duct cannulated rats.,,CHEMBL630749,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12240,Homo sapiens,,A,Oral absorption using Caco-2 cell monolayers.,,CHEMBL630750,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12241,Homo sapiens,,A,Percent of the drug absorbed after administration to humans was determined,,CHEMBL630253,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12242,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,CHEMBL630254,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12243,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,CHEMBL630255,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12244,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,CHEMBL630256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12245,Rattus norvegicus,,A,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL875781,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12246,Rattus norvegicus,,A,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL630257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12247,Rattus norvegicus,,A,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL630258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12248,Rattus norvegicus,,A,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,CHEMBL630259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12249,Rattus norvegicus,,A,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,CHEMBL630260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
12250,Rattus norvegicus,,A,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,CHEMBL630261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
12251,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,CHEMBL630262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12252,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,CHEMBL630263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12253,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,CHEMBL630264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12254,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,CHEMBL630265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12255,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,CHEMBL630266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12256,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,CHEMBL630267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12257,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,CHEMBL630268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12258,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,CHEMBL630269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12259,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,CHEMBL630270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12260,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,CHEMBL630141,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12261,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,CHEMBL630142,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12262,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,CHEMBL630143,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12263,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,CHEMBL630144,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12264,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,CHEMBL630145,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2367.0
12265,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,CHEMBL630146,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2367.0
12266,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,CHEMBL630147,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12267,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,CHEMBL630148,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12268,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,CHEMBL630149,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12269,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,CHEMBL630150,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
12270,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,CHEMBL630151,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
12271,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,CHEMBL632031,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12272,Rattus norvegicus,,A,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,CHEMBL632032,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12273,Rattus norvegicus,,A,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,CHEMBL632033,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12274,Rattus norvegicus,,A,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,CHEMBL632034,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12275,Rattus norvegicus,,A,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,CHEMBL632035,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12276,Rattus norvegicus,,A,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,CHEMBL632036,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12277,Rattus norvegicus,,A,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,CHEMBL632037,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12278,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,CHEMBL632038,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12279,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,CHEMBL632039,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12280,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,CHEMBL632040,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12281,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,CHEMBL632041,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12282,Canis lupus familiaris,,A,"Concentration of compound in blood of dog 2, after administering intravenously",,CHEMBL632042,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,178.0
12283,Canis lupus familiaris,,A,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,CHEMBL632043,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12284,Canis lupus familiaris,,A,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,CHEMBL632044,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12285,Canis lupus familiaris,,A,"Concentration of compound in liver of dog 1, after administering intravenously",,CHEMBL632045,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
12286,Canis lupus familiaris,,A,"Concentration of compound in liver of dog 2, after administering intravenously",,CHEMBL632046,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
12287,Canis lupus familiaris,,A,"Concentration of compound in lung of dog 1, after administering intravenously",,CHEMBL632047,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2048.0
12288,Canis lupus familiaris,,A,"Concentration of compound in lung of dog 2, after administering intravenously",,CHEMBL632048,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2048.0
12289,Canis lupus familiaris,,A,"Concentration of compound in muscle of dog 1, after administering intravenously",,CHEMBL632049,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2385.0
12290,Canis lupus familiaris,,A,"Concentration of compound in muscle of dog 2, after administering intravenously",,CHEMBL876418,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2385.0
12291,Canis lupus familiaris,,A,"Concentration of compound in spleen of dog 1,after administering intravenously",,CHEMBL632050,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2106.0
12292,Canis lupus familiaris,,A,"Concentration of compound in spleen of dog 2, after administering intravenously",,CHEMBL632051,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2106.0
12293,,,F,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,CHEMBL632052,,0,1,U,22224,Autocuration,,,BAO_0000218,
12294,,,F,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,CHEMBL632053,,0,1,U,22224,Autocuration,,,BAO_0000218,
12295,,,A,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,CHEMBL632054,,0,1,U,22224,Autocuration,,,BAO_0000218,
12296,,,F,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,CHEMBL632055,,0,1,U,22224,Autocuration,,,BAO_0000218,
12297,,,F,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,CHEMBL631181,,0,1,U,22224,Autocuration,,,BAO_0000218,
12298,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,CHEMBL631182,,0,1,U,22224,Autocuration,,,BAO_0000218,
12299,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,CHEMBL631183,,0,1,U,22224,Autocuration,,,BAO_0000218,
12300,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL631184,,0,1,U,22224,Autocuration,,,BAO_0000218,
12301,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL629774,,0,1,U,22224,Autocuration,,,BAO_0000218,
12302,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL629775,,0,1,U,22224,Autocuration,,,BAO_0000218,
12303,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL876549,,0,1,U,22224,Autocuration,,,BAO_0000218,
12304,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL628172,,0,1,U,22224,Autocuration,,,BAO_0000218,
12305,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,CHEMBL628173,,0,1,U,22224,Autocuration,,,BAO_0000218,
12306,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,CHEMBL628174,,0,1,U,22224,Autocuration,,,BAO_0000218,
12307,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,CHEMBL628175,,0,1,U,22224,Autocuration,,,BAO_0000218,
12308,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,CHEMBL628176,,0,1,U,22224,Autocuration,,,BAO_0000218,
12309,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628177,,0,1,U,22224,Autocuration,,,BAO_0000218,
12310,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL628178,,0,1,U,22224,Autocuration,,,BAO_0000218,
12311,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,CHEMBL628179,,0,1,U,22224,Autocuration,,,BAO_0000218,
12312,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,CHEMBL628180,,0,1,U,22224,Autocuration,,,BAO_0000218,
12313,,,A,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,CHEMBL628181,,0,1,U,22224,Autocuration,,,BAO_0000218,
12314,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL628182,,0,1,U,22224,Autocuration,,,BAO_0000218,
12315,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL628183,,0,1,U,22224,Autocuration,,,BAO_0000218,
12316,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,CHEMBL628184,,0,1,U,22224,Autocuration,,,BAO_0000218,
12317,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628185,,0,1,U,22224,Autocuration,,,BAO_0000218,
12318,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL875617,,0,1,U,22224,Autocuration,,,BAO_0000218,
12319,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,CHEMBL628186,,0,1,U,22224,Autocuration,,,BAO_0000218,
12320,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL628187,,0,1,U,22224,Autocuration,,,BAO_0000218,
12321,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,CHEMBL628188,,0,1,U,22224,Autocuration,,,BAO_0000218,
12322,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,CHEMBL628189,,0,1,U,22224,Autocuration,,,BAO_0000218,
12323,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,CHEMBL628190,,0,1,U,22224,Autocuration,,,BAO_0000218,
12324,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628191,,0,1,U,22224,Autocuration,,,BAO_0000218,
12325,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,CHEMBL626513,,0,1,U,22224,Autocuration,,,BAO_0000218,
12326,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,CHEMBL626514,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12327,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,CHEMBL626515,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12328,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,CHEMBL626516,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12329,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,CHEMBL626517,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12330,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,CHEMBL626518,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12331,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,CHEMBL626519,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12332,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,CHEMBL626520,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12333,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,CHEMBL626521,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12334,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,CHEMBL626522,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12335,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,CHEMBL626523,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12336,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,CHEMBL626524,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12337,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,CHEMBL626688,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12338,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,CHEMBL626689,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12339,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,CHEMBL626690,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12340,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,CHEMBL626691,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12341,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,CHEMBL627319,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12342,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,CHEMBL624052,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12343,Rattus norvegicus,,A,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,CHEMBL624053,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12344,Rattus norvegicus,,A,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624054,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12345,Rattus norvegicus,,A,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624055,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12346,Rattus norvegicus,,A,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624056,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12347,Rattus norvegicus,,A,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624057,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12348,Rattus norvegicus,,A,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622281,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12349,Rattus norvegicus,,A,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622282,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12350,Rattus norvegicus,,A,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622283,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12351,Rattus norvegicus,,A,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622284,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12352,Rattus norvegicus,,A,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622285,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12353,Rattus norvegicus,,A,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622286,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
12354,,,P,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,CHEMBL622287,,0,1,U,22224,Autocuration,,,BAO_0000100,
12355,Mus musculus,,A,Partition coefficient (logD7.4),,CHEMBL622288,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12356,Mus musculus,,A,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,CHEMBL622289,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12357,Mus musculus,,A,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,CHEMBL622290,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12358,Mus musculus,,A,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,CHEMBL622291,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12359,Mus musculus,,A,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,CHEMBL622292,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12360,Mus musculus,,A,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,CHEMBL622293,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12361,Mus musculus,,A,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,CHEMBL622294,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12362,Mus musculus,,A,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,CHEMBL622295,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12363,Rattus norvegicus,,A,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,CHEMBL622296,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
12364,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,CHEMBL874409,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12365,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,CHEMBL622297,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12366,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,CHEMBL622298,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12367,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,CHEMBL622299,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12368,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,CHEMBL622300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12369,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,CHEMBL622301,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12370,Rattus norvegicus,,A,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,CHEMBL622302,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12371,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,CHEMBL622303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12372,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,CHEMBL622304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12373,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,CHEMBL622305,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12374,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,CHEMBL622306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12375,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,CHEMBL626864,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12376,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,CHEMBL626865,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12377,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,CHEMBL626866,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12378,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,CHEMBL626867,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12379,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,CHEMBL626868,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12380,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,CHEMBL626869,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12381,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,CHEMBL626870,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12382,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,CHEMBL626871,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12383,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,CHEMBL626872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12384,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,CHEMBL632185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12385,Rattus norvegicus,,A,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,CHEMBL632186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12386,,,A,Amount of acetic acid produced by the compound,,CHEMBL629310,,0,1,U,22224,Autocuration,,,BAO_0000019,
12387,,,A,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,CHEMBL629311,,0,1,U,22224,Autocuration,,,BAO_0000019,
12388,Rattus norvegicus,,A,Log of (Cbrain/Cblood) in rats,,CHEMBL629312,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12389,,,A,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,CHEMBL629313,,0,1,U,22224,Autocuration,,,BAO_0000221,
12390,,,A,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,CHEMBL629314,,0,1,U,22224,Autocuration,,,BAO_0000221,
12391,,,A,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,CHEMBL629315,,0,1,U,22224,Autocuration,,,BAO_0000221,
12392,,,B,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,CHEMBL629316,,0,1,U,22224,Autocuration,,,BAO_0000219,
12393,,,A,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,CHEMBL629317,,0,1,U,22224,Autocuration,,,BAO_0000221,
12394,,,A,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,CHEMBL629318,,0,1,U,22224,Autocuration,,,BAO_0000019,
12395,,,A,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,CHEMBL877497,,0,1,U,22224,Autocuration,,,BAO_0000019,
12396,,,A,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,CHEMBL629319,,0,1,U,22224,Autocuration,,,BAO_0000019,
12397,,,A,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,CHEMBL629320,,0,1,U,22224,Autocuration,,,BAO_0000019,
12398,,,A,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,CHEMBL629496,,0,1,U,22224,Autocuration,,,BAO_0000019,
12399,,,A,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,CHEMBL629497,,0,1,U,22224,Autocuration,,,BAO_0000019,
12400,,,A,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,CHEMBL629498,,0,1,U,22224,Autocuration,,,BAO_0000019,
12401,,,A,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,CHEMBL629499,,0,1,U,22224,Autocuration,,,BAO_0000019,
12402,,,A,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,CHEMBL629500,,0,1,U,22224,Autocuration,,,BAO_0000019,
12403,,,A,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,CHEMBL629501,,0,1,U,22224,Autocuration,,,BAO_0000019,
12404,,,A,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,CHEMBL629502,,0,1,U,22224,Autocuration,,,BAO_0000019,
12405,,,F,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,CHEMBL629503,,0,1,U,22224,Autocuration,,,BAO_0000218,
12406,Canis lupus familiaris,,A,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,CHEMBL629504,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12407,,,A,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,CHEMBL629505,,0,1,U,22224,Autocuration,,,BAO_0000019,
12408,,,A,Compound was evaluated for total body clearance,,CHEMBL629506,,0,1,U,22224,Autocuration,,,BAO_0000019,
12409,,,A,Compound was evaluated for volume of distribution at steady state,,CHEMBL629507,,0,1,U,22224,Autocuration,,,BAO_0000019,
12410,,,A,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,CHEMBL877498,,0,1,U,22224,Autocuration,,,BAO_0000019,
12411,,,A,Percentage of the diamine which is monoprotonated at pH 7.4,,CHEMBL629508,,0,1,U,22224,Autocuration,,,BAO_0000019,
12412,,,A,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,CHEMBL629509,,0,1,U,22224,Autocuration,,,BAO_0000019,
12413,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,CHEMBL629510,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12414,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,CHEMBL629511,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12415,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL629512,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12416,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL629513,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12417,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,CHEMBL629514,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12418,Rattus norvegicus,,A,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL628447,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12419,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,CHEMBL628448,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12420,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,CHEMBL628449,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12421,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,CHEMBL631119,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12422,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,CHEMBL631120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12423,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,CHEMBL631121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12424,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,CHEMBL874458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12425,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL631122,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12426,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL631123,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12427,Rattus norvegicus,,A,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL631124,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12428,Rattus norvegicus,,A,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,CHEMBL631125,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12429,Rattus norvegicus,,A,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL631290,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12430,Rattus norvegicus,,A,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL631291,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12431,Rattus norvegicus,,A,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL631292,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12432,Rattus norvegicus,,A,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,CHEMBL631293,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12433,Rattus norvegicus,,A,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL631294,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12434,Rattus norvegicus,,A,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL631295,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12435,Rattus norvegicus,,A,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,CHEMBL631296,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12436,Rattus norvegicus,,A,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL631297,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12437,,,A,Maximum biodistribution (Bmax) was determined.,,CHEMBL631298,,0,1,U,22224,Autocuration,,,BAO_0000218,
12438,Mus musculus,,A,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,CHEMBL631299,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12439,Mus musculus,,A,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,CHEMBL631300,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12440,Mus musculus,,A,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,CHEMBL631301,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12441,Mus musculus,,A,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,CHEMBL630291,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12442,,,A,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL630292,,0,1,U,22224,Autocuration,,,BAO_0000218,
12443,,,A,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,CHEMBL630293,,0,1,U,22224,Autocuration,,,BAO_0000218,
12444,,,A,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,CHEMBL630294,,0,1,U,22224,Autocuration,,,BAO_0000218,
12445,,,A,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL630295,,0,1,U,22224,Autocuration,,,BAO_0000218,
12446,,,A,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL630296,,0,1,U,22224,Autocuration,,,BAO_0000218,
12447,,,A,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626782,,0,1,U,22224,Autocuration,,,BAO_0000218,
12448,,,A,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL626783,,0,1,U,22224,Autocuration,,,BAO_0000218,
12449,,,A,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL626784,,0,1,U,22224,Autocuration,,,BAO_0000218,
12450,,,A,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL626785,,0,1,U,22224,Autocuration,,,BAO_0000218,
12451,,,A,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626786,,0,1,U,22224,Autocuration,,,BAO_0000218,
12452,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL626787,,0,1,U,22224,Autocuration,,,BAO_0000218,
12453,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,CHEMBL626788,,0,1,U,22224,Autocuration,,,BAO_0000218,
12454,,,A,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,CHEMBL625927,,0,1,U,22224,Autocuration,,,BAO_0000218,
12455,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625928,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12456,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL625929,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12457,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,CHEMBL625930,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12458,Rattus norvegicus,,A,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,CHEMBL625931,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12459,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,CHEMBL627230,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12460,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627231,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12461,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL627232,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12462,Rattus norvegicus,,A,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,CHEMBL627233,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12463,Rattus norvegicus,,A,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL875470,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12464,Rattus norvegicus,,A,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627234,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12465,Rattus norvegicus,,A,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627235,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12466,Rattus norvegicus,,A,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627236,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12467,Rattus norvegicus,,A,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627237,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12468,Rattus norvegicus,,A,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627238,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12469,Rattus norvegicus,,A,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627239,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12470,Rattus norvegicus,,A,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627240,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12471,Rattus norvegicus,,A,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627241,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12472,Rattus norvegicus,,A,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627242,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12473,Rattus norvegicus,,A,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,CHEMBL627243,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12474,Rattus norvegicus,,A,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL627244,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12475,Rattus norvegicus,,A,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627245,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12476,Rattus norvegicus,,A,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627246,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12477,Rattus norvegicus,,A,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627247,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12478,Rattus norvegicus,,A,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627248,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12479,Rattus norvegicus,,A,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627249,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12480,Rattus norvegicus,,A,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625569,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12481,Rattus norvegicus,,A,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625570,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12482,Rattus norvegicus,,A,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625571,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12483,Rattus norvegicus,,A,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL625572,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12484,Rattus norvegicus,,A,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL625573,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12485,Rattus norvegicus,,A,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,CHEMBL625574,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12486,Rattus norvegicus,,A,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL626245,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12487,Rattus norvegicus,,A,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL626246,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12488,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL626247,,0,1,U,22224,Autocuration,,,BAO_0000218,
12489,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL626248,,0,1,U,22224,Autocuration,,,BAO_0000218,
12490,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,CHEMBL626249,,0,1,U,22224,Autocuration,,,BAO_0000218,
12491,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL626420,,0,1,U,22224,Autocuration,,,BAO_0000218,
12492,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,CHEMBL626421,,0,1,U,22224,Autocuration,,,BAO_0000218,
12493,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,CHEMBL626422,,0,1,U,22224,Autocuration,,,BAO_0000218,
12494,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL626423,,0,1,U,22224,Autocuration,,,BAO_0000218,
12495,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL626424,,0,1,U,22224,Autocuration,,,BAO_0000218,
12496,Canis lupus familiaris,,A,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,CHEMBL626425,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12497,Rattus norvegicus,,A,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,CHEMBL875476,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12498,Macaca fascicularis,,A,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,CHEMBL626426,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
12499,,,P,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,CHEMBL626427,,0,1,U,22224,Autocuration,,,BAO_0000100,
12500,,,P,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,CHEMBL626428,,0,1,U,22224,Autocuration,,,BAO_0000100,
12501,,,A,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,CHEMBL626429,,0,1,U,22224,Autocuration,,,BAO_0000019,
12502,,,A,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,CHEMBL625025,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
12503,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL625026,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12504,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL625027,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12505,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL874410,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12506,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL625028,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12507,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL625029,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12508,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL625030,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12509,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL625031,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12510,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL625032,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12511,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL625033,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12512,Rattus norvegicus,,A,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL625034,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12513,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL624872,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12514,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL624873,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12515,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL624874,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12516,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624875,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12517,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL624876,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12518,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624877,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12519,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624878,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12520,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL624879,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12521,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL624880,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12522,Rattus norvegicus,,A,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,CHEMBL624881,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12523,Rattus norvegicus,,A,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,CHEMBL624882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12524,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL624883,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12525,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL624884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12526,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL624885,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12527,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624886,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12528,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL624887,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12529,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624888,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12530,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624889,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12531,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL624890,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12532,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL621964,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12533,Rattus norvegicus,,A,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL621965,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12534,Rattus norvegicus,,A,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL621966,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12535,Rattus norvegicus,,A,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL621967,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12536,Rattus norvegicus,,A,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL622164,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12537,,,A,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,CHEMBL623097,,0,1,U,22224,Autocuration,,,BAO_0000019,
12538,,,A,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,CHEMBL623098,,0,1,U,22224,Autocuration,,,BAO_0000019,
12539,,,A,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,CHEMBL623099,,0,1,U,22224,Autocuration,,,BAO_0000019,
12540,,,A,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,CHEMBL623100,,0,1,U,22224,Autocuration,,,BAO_0000019,
12541,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,CHEMBL628673,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12542,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,CHEMBL628674,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12543,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,CHEMBL628675,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12544,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,CHEMBL627644,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12545,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,CHEMBL627645,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12546,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,CHEMBL627646,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12547,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,CHEMBL627647,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12548,Rattus norvegicus,,A,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,CHEMBL627648,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12549,Rattus norvegicus,,A,Free level in rat plasma,,CHEMBL627649,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12550,,,A,Level reaching in blood plasma of rat or human was determined,,CHEMBL628313,,0,1,U,22224,Autocuration,,,BAO_0000019,
12551,Rattus norvegicus,,A,Log (Cbrain/Cblood) in rats,,CHEMBL628314,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12552,,,A,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,CHEMBL628315,,0,1,U,22224,Autocuration,,,BAO_0000019,
12553,,,A,Mean percentage of compound transport through membrane; expressed as membrane transport,,CHEMBL628316,,0,1,U,22224,Autocuration,,,BAO_0000019,
12554,,,A,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,CHEMBL628317,,0,1,U,22224,Autocuration,,,BAO_0000218,
12555,,,A,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,CHEMBL628473,,0,1,U,22224,Autocuration,,,BAO_0000019,
12556,,,A,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,CHEMBL628474,,0,1,U,22224,Autocuration,,,BAO_0000019,
12557,,,A,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,CHEMBL628475,,0,1,U,22224,Autocuration,,,BAO_0000019,
12558,,,A,Net water uptake by a carrier mediated transport (%cm) mechanism,,CHEMBL628476,,0,1,U,22224,Autocuration,,,BAO_0000019,
12559,Simiiformes,,A,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL628477,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12560,Mustela putorius furo,,A,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,CHEMBL628478,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
12561,Mustela putorius furo,,A,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,CHEMBL628479,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
12562,Simiiformes,,A,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL628480,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12563,Simiiformes,,A,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,CHEMBL628481,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12564,Rattus norvegicus,,A,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,CHEMBL628482,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12565,Rattus norvegicus,,A,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,CHEMBL628483,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12566,Rattus norvegicus,,A,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,CHEMBL628484,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12567,Rattus norvegicus,,A,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,CHEMBL628485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12568,Macaca fascicularis,,A,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,CHEMBL628486,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
12569,Homo sapiens,,A,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,CHEMBL628487,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
12570,Rattus norvegicus,,A,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,CHEMBL628488,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12571,Rattus norvegicus,,A,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,CHEMBL628489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12572,Rattus norvegicus,,A,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,CHEMBL628490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12573,Macaca fascicularis,,A,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL628491,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
12574,Macaca fascicularis,,A,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL877507,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
12575,,,A,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,CHEMBL628492,,0,1,U,22224,Autocuration,,,BAO_0000218,
12576,Simiiformes,,A,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,CHEMBL628493,314293.0,0,1,U,22224,Autocuration,,,BAO_0000019,
12577,Simiiformes,,A,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,CHEMBL628494,314293.0,0,1,U,22224,Autocuration,,,BAO_0000019,
12578,Simiiformes,,A,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,CHEMBL628495,314293.0,0,1,U,22224,Autocuration,,,BAO_0000019,
12579,Homo sapiens,,A,Permeability in Caco-2 assay at 10E-6,,CHEMBL628496,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12580,,,A,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,CHEMBL628497,,0,1,U,22224,Autocuration,,,BAO_0000218,955.0
12581,,,A,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,CHEMBL628498,,0,1,U,22224,Autocuration,,,BAO_0000218,955.0
12582,,,A,Plasma protein binding was determined,,CHEMBL628499,,0,1,U,22224,Autocuration,,,BAO_0000019,
12583,,,A,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL627656,,0,1,U,22224,Autocuration,,,BAO_0000218,
12584,,,A,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL627657,,0,1,U,22224,Autocuration,,,BAO_0000218,
12585,,,A,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL626808,,0,1,U,22224,Autocuration,,,BAO_0000218,
12586,,,A,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626809,,0,1,U,22224,Autocuration,,,BAO_0000218,
12587,,,A,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL626810,,0,1,U,22224,Autocuration,,,BAO_0000218,
12588,,,A,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL626811,,0,1,U,22224,Autocuration,,,BAO_0000218,
12589,,,A,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL874465,,0,1,U,22224,Autocuration,,,BAO_0000218,
12590,,,A,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626812,,0,1,U,22224,Autocuration,,,BAO_0000218,
12591,,,A,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL626813,,0,1,U,22224,Autocuration,,,BAO_0000218,
12592,,,A,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626814,,0,1,U,22224,Autocuration,,,BAO_0000218,
12593,,,A,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,CHEMBL626815,,0,1,U,22224,Autocuration,,,BAO_0000019,
12594,,,A,Partition coefficient (logP),,CHEMBL628566,,0,1,U,22224,Autocuration,,,BAO_0000019,
12595,,,P,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,CHEMBL628567,,0,1,U,22229,Autocuration,,,BAO_0000100,
12596,,,P,Calculated partition coefficient (clogP),,CHEMBL628568,,0,1,U,22229,Autocuration,,,BAO_0000100,
12597,Canis lupus familiaris,,A,C max in dog,,CHEMBL628569,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12598,Cavia porcellus,,A,C max in guinea pig,,CHEMBL628570,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
12599,,,A,C max value was evaluated,,CHEMBL628571,,0,1,U,22224,Autocuration,,,BAO_0000218,
12600,,,A,Cmax value after oral dose of 0.1 mg//kg,,CHEMBL628572,,0,1,U,22224,Autocuration,,,BAO_0000218,
12601,,,A,Cmax value after oral dose of 0.3 mg/kg,,CHEMBL628573,,0,1,U,22224,Autocuration,,,BAO_0000218,
12602,,,A,Cmax value after oral dose of 1 mg/kg,,CHEMBL628574,,0,1,U,22224,Autocuration,,,BAO_0000218,
12603,,,A,Cmax value after oral dose of 10 mg/kg,,CHEMBL628575,,0,1,U,22224,Autocuration,,,BAO_0000218,
12604,,,A,Cmax value after oral dose of 23.4 mg/kg,,CHEMBL628576,,0,1,U,22224,Autocuration,,,BAO_0000218,
12605,,,A,Cmax value after oral dose of 3 mg/kg,,CHEMBL628577,,0,1,U,22224,Autocuration,,,BAO_0000218,
12606,,,A,Cmax value after oral dose of 3.87 mg/kg,,CHEMBL628578,,0,1,U,22224,Autocuration,,,BAO_0000218,
12607,Canis lupus familiaris,,A,Cmax value in female Beagle dogs,,CHEMBL874466,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12608,Rattus norvegicus,,A,Cmax value in male rats,,CHEMBL628579,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12609,Rattus norvegicus,,A,Cmax value in rat plasma when administered 20 mg/kg perorally,,CHEMBL628580,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12610,Canis lupus familiaris,,A,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,CHEMBL628581,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12611,Canis lupus familiaris,,A,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,CHEMBL628582,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12612,Canis lupus familiaris,,A,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,CHEMBL628583,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12613,Simiiformes,,A,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,CHEMBL625782,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12614,Oryctolagus cuniculus,,A,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,CHEMBL625783,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12615,Rattus norvegicus,,A,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,CHEMBL625784,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12616,Macaca mulatta,,A,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,CHEMBL625785,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,1969.0
12617,Rattus norvegicus,,A,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,CHEMBL625786,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12618,,,A,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,CHEMBL874467,,0,1,U,22224,Autocuration,,,BAO_0000019,
12619,Canis lupus familiaris,,A,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,CHEMBL625787,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12620,Human immunodeficiency virus,,A,cytotoxicity against HIV protease enzyme.,,CHEMBL625964,12721.0,1,1,N,50677,Intermediate,,,BAO_0000218,
12621,Mus musculus,,A,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,CHEMBL625965,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12622,Mus musculus,,A,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,CHEMBL625966,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12623,Canis lupus familiaris,,A,The plasma clearance in dog.,,CHEMBL625967,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12624,Rattus norvegicus,,A,The plasma clearance in rat.,,CHEMBL625968,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12625,Rattus norvegicus,,A,Clearance from plasma in male Sprague-Dawley rats,,CHEMBL625969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12626,Macaca fascicularis,,A,Clearance from plasma in male cynomolgus monkeys,,CHEMBL625970,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,1969.0
12627,Canis lupus familiaris,,A,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,CHEMBL625971,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12628,Canis lupus familiaris,,A,Clearance of compound in dog plasma,,CHEMBL625972,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12629,Homo sapiens,,A,Clearance of compound in human plasma,,CHEMBL625973,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
12630,Canis lupus familiaris,,A,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,CHEMBL625974,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12631,Canis lupus familiaris,,A,Clearance of compound when administered intravenously as an individual dose to a single dog.,,CHEMBL625975,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12632,Canis lupus familiaris,,A,"Clearance (10 mg/kg, intravenously) in dog plasma",,CHEMBL625976,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12633,Canis lupus familiaris,,A,Clearance value in dog,,CHEMBL625977,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12634,Cavia porcellus,,A,Clearance value in guinea pig,,CHEMBL625978,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
12635,Rattus norvegicus,,A,Clearance values in rats after iv administration.,,CHEMBL874468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12636,,,A,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,CHEMBL625421,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
12637,Oryctolagus cuniculus,,A,In vivo clearance (5 mg/kg) was determined in rabbits,,CHEMBL625422,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12638,Rattus norvegicus,,A,Plasma Clearance rate was determined for the compound in rats,,CHEMBL625423,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12639,Saimiri,,A,Plasma Clearance rate was determined for the compound in squirrel monkeys,,CHEMBL625424,9520.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12640,Rattus norvegicus,,A,Plasma clearance in rat,,CHEMBL625425,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12641,,,A,Plasma clearance of the compound,,CHEMBL625426,,0,1,U,22224,Autocuration,,,BAO_0000218,
12642,Cavia porcellus,,A,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,CHEMBL625427,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
12643,Cavia porcellus,,A,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,CHEMBL625428,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
12644,,,A,Plasma clearance was determined,,CHEMBL625429,,0,1,U,22224,Autocuration,,,BAO_0000218,
12645,Canis lupus familiaris,,A,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,CHEMBL625430,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12646,Rattus norvegicus,,A,Plasma clearance rate was determined for the compound in rats,,CHEMBL625431,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12647,Saimiri,,A,Plasma clearance rate was determined for the compound in squirrel monkeys,,CHEMBL627307,9520.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12648,,,A,Slow clearance (CL) was determined,,CHEMBL627308,,0,1,U,22224,Autocuration,,,BAO_0000218,
12649,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,CHEMBL627309,,0,1,U,22224,Autocuration,,,BAO_0000218,
12650,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,CHEMBL627310,,0,1,U,22224,Autocuration,,,BAO_0000218,
12651,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,CHEMBL627311,,0,1,U,22224,Autocuration,,,BAO_0000218,
12652,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,CHEMBL627312,,0,1,U,22224,Autocuration,,,BAO_0000218,
12653,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,CHEMBL627313,,0,1,U,22224,Autocuration,,,BAO_0000218,
12654,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,CHEMBL627314,,0,1,U,22224,Autocuration,,,BAO_0000218,
12655,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,CHEMBL627315,,0,1,U,22224,Autocuration,,,BAO_0000218,
12656,,,A,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL627316,,0,1,U,22224,Autocuration,,,BAO_0000218,
12657,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL627317,,0,1,U,22224,Autocuration,,,BAO_0000218,
12658,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL627318,,0,1,U,22224,Autocuration,,,BAO_0000218,
12659,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,CHEMBL627999,,0,1,U,22224,Autocuration,,,BAO_0000218,
12660,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628000,,0,1,U,22224,Autocuration,,,BAO_0000218,
12661,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,CHEMBL628001,,0,1,U,22224,Autocuration,,,BAO_0000218,
12662,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL628002,,0,1,U,22224,Autocuration,,,BAO_0000218,
12663,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,CHEMBL625610,,0,1,U,22224,Autocuration,,,BAO_0000218,
12664,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL625611,,0,1,U,22224,Autocuration,,,BAO_0000218,
12665,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,CHEMBL625612,,0,1,U,22224,Autocuration,,,BAO_0000218,
12666,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,CHEMBL625613,,0,1,U,22224,Autocuration,,,BAO_0000218,
12667,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL875479,,0,1,U,22224,Autocuration,,,BAO_0000218,
12668,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,CHEMBL625614,,0,1,U,22224,Autocuration,,,BAO_0000218,
12669,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,CHEMBL625615,,0,1,U,22224,Autocuration,,,BAO_0000218,
12670,,,A,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,CHEMBL626302,,0,1,U,22224,Autocuration,,,BAO_0000218,
12671,Rattus norvegicus,,A,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL626303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12672,Rattus norvegicus,,A,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627420,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12673,Rattus norvegicus,,A,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,CHEMBL627421,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12674,Rattus norvegicus,,A,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,CHEMBL625695,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12675,Rattus norvegicus,,A,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,CHEMBL625696,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12676,Mus musculus,,A,Distribution of compound in mice brain was measured after 1 hr,,CHEMBL875606,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12677,Mus musculus,,A,Distribution of compound in mice brain was measured after 24 hr r,,CHEMBL625697,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12678,Mus musculus,,A,Distribution of compound in mice brain was measured after 2 hr,,CHEMBL625698,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12679,Mus musculus,,A,Distribution of compound in mice brain was measured after 3 hr,,CHEMBL625699,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12680,Mus musculus,,A,Distribution of compound in mice brain was measured after 6 hr,,CHEMBL625700,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
12681,Mus musculus,,A,Distribution of compound in mice liver was measured after 1 hr,,CHEMBL625701,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12682,Mus musculus,,A,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,CHEMBL625702,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12683,Mus musculus,,A,Distribution of compound in mice liver was measured after 2 hr,,CHEMBL625703,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12684,Mus musculus,,A,Distribution of compound in mice liver was measured after 3 hr,,CHEMBL625704,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12685,Mus musculus,,A,Distribution of compound in mice liver was measured after 6 hr,,CHEMBL625705,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12686,Canis lupus familiaris,,A,Distribution in dog adrenal medulla 30 min after administration.,,CHEMBL625706,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1236.0
12687,Canis lupus familiaris,,A,Distribution in dog adrenal medulla 72 hours after administration.,,CHEMBL625707,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1236.0
12688,Canis lupus familiaris,,A,Distribution in female dog Ovary 24 hours after administration.,,CHEMBL625708,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12689,Canis lupus familiaris,,A,Distribution in female dog Ovary 72 hours after administration.,,CHEMBL625709,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12690,Canis lupus familiaris,,A,Distribution in female dog adipose 24 hours after administration.,,CHEMBL624180,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12691,Canis lupus familiaris,,A,Distribution in female dog adipose 72 hours after administration.,,CHEMBL624181,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12692,Canis lupus familiaris,,A,Distribution in female dog adrenal cortex 72 hours after administration.,,CHEMBL624182,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1235.0
12693,Canis lupus familiaris,,A,Distribution in female dog adrenal cortex 72 hours after administration.,,CHEMBL624183,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1235.0
12694,Rattus norvegicus,,A,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12695,Rattus norvegicus,,A,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL877489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12696,Rattus norvegicus,,A,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL624185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12697,Rattus norvegicus,,A,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL624186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12698,Rattus norvegicus,,A,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624187,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12699,Rattus norvegicus,,A,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624188,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12700,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL624189,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12701,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL624190,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12702,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL624191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12703,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL624192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12704,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12705,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL624194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12706,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12707,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12708,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL624893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12709,Rattus norvegicus,,A,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL627632,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12710,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL627633,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12711,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL627634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12712,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL627635,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12713,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL627636,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12714,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL626816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12715,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL626817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12716,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL626818,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12717,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL626819,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12718,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL626820,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12719,Rattus norvegicus,,A,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL626821,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12720,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL626822,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12721,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL626823,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12722,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL626824,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12723,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL626825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12724,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL626826,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12725,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL626827,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12726,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL626828,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12727,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL626829,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12728,Rattus norvegicus,,A,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL626830,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12729,Rattus norvegicus,,A,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL627150,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12730,Rattus norvegicus,,A,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL627151,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12731,Rattus norvegicus,,A,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL627152,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12732,Rattus norvegicus,,A,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL627153,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12733,,,A,Rate of acetate production by the compound was determined,,CHEMBL627154,,0,1,U,22224,Autocuration,,,BAO_0000019,
12734,,,A,Rate of acetate production by the compound was determined; Not determined,,CHEMBL627155,,0,1,U,22224,Autocuration,,,BAO_0000019,
12735,,,A,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,CHEMBL627156,,0,1,U,22224,Autocuration,,,BAO_0000019,
12736,,,A,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,CHEMBL627157,,0,1,U,22224,Autocuration,,,BAO_0000019,
12737,Oryctolagus cuniculus,,A,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,CHEMBL627158,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12738,Oryctolagus cuniculus,,A,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,CHEMBL627159,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1969.0
12739,Mus musculus,,A,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL627160,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12740,Rattus norvegicus,,A,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL628540,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12741,Rattus norvegicus,,A,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL628541,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12742,Rattus norvegicus,,A,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL628542,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12743,,,P,Solubility after at a pH 1.2,,CHEMBL628543,,0,1,U,22229,Autocuration,,,BAO_0000100,
12744,,,P,Solubility after at pH 1.2,,CHEMBL628544,,0,1,U,22229,Autocuration,,,BAO_0000100,
12745,,,P,Solubility after injection of water,,CHEMBL628545,,0,1,U,22229,Autocuration,,,BAO_0000100,
12746,,,A,Statistical significance of IC 50 values; Expressed as R value,,CHEMBL628546,,0,1,U,22224,Autocuration,,,BAO_0000019,
12747,,,A,Systemic availability with respect to methyldopa was determined,,CHEMBL874455,,0,1,U,22224,Autocuration,,,BAO_0000019,
12748,Rattus norvegicus,,A,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,CHEMBL628547,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12749,Rattus norvegicus,,A,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,CHEMBL628548,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12750,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,CHEMBL628549,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12751,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,CHEMBL628550,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12752,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,CHEMBL628551,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12753,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,CHEMBL628552,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12754,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,CHEMBL628553,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12755,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,CHEMBL628554,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12756,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL628555,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12757,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL628556,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12758,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,CHEMBL628557,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,2113.0
12759,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,CHEMBL628558,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12760,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,CHEMBL628559,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12761,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,CHEMBL628560,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12762,Oryctolagus cuniculus,,A,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,CHEMBL874456,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12763,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,CHEMBL628561,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12764,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,CHEMBL628562,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12765,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,CHEMBL628563,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12766,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,CHEMBL628564,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12767,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL628565,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12768,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL631248,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12769,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,CHEMBL631249,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
12770,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,CHEMBL627214,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,2113.0
12771,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,CHEMBL874591,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12772,Oryctolagus cuniculus,,A,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,CHEMBL627215,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12773,Oryctolagus cuniculus,,A,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,CHEMBL625471,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
12774,Oryctolagus cuniculus,,A,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,CHEMBL625472,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12775,Oryctolagus cuniculus,,A,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,CHEMBL625473,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12776,Canis lupus familiaris,,A,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,CHEMBL625474,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12777,Canis lupus familiaris,,A,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,CHEMBL625475,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12778,Rattus norvegicus,,A,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,CHEMBL625476,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12779,Rattus norvegicus,,A,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,CHEMBL625477,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12780,Rattus norvegicus,,A,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,CHEMBL625478,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12781,Rattus norvegicus,,A,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,CHEMBL625479,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12782,Rattus norvegicus,,A,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,CHEMBL625480,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12783,Rattus norvegicus,,A,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,CHEMBL625481,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12784,Rattus norvegicus,,A,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,CHEMBL625482,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12785,Rattus norvegicus,,A,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,CHEMBL625483,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12786,Rattus norvegicus,,A,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,CHEMBL625484,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12787,Rattus norvegicus,,A,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,CHEMBL625485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12788,Canis lupus familiaris,,A,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,CHEMBL625486,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12789,Rattus norvegicus,,A,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,CHEMBL625487,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12790,Rattus norvegicus,,A,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,CHEMBL625488,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12791,Rattus norvegicus,,A,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,CHEMBL625489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12792,Rattus norvegicus,,A,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,CHEMBL625490,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12793,Canis lupus familiaris,,A,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,CHEMBL625491,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
12794,Rattus norvegicus,,A,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,CHEMBL625492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
12795,Homo sapiens,,A,plasma clearance in human,,CHEMBL625493,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1969.0
12796,Rattus norvegicus,,A,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,CHEMBL625494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12797,Rattus norvegicus,,A,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,CHEMBL625495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12798,Rattus norvegicus,,A,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,CHEMBL625496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12799,,,P,1-Octanol/water partition coefficient measured at 7.4,,CHEMBL625497,,0,1,U,22229,Autocuration,,,BAO_0000100,
12800,,,P,Calculated partition coefficient (clogP),,CHEMBL625498,,0,1,U,22229,Autocuration,,,BAO_0000100,
12801,,,A,Partition coefficient (logP),,CHEMBL625499,,0,1,U,22224,Autocuration,,,BAO_0000019,
12802,,,P,Calculated partition coefficient (clogP),,CHEMBL625500,,0,1,U,22229,Autocuration,,,BAO_0000100,
12803,,,P,Calculated partition coefficient (clogP),,CHEMBL625501,,0,1,U,22229,Autocuration,,,BAO_0000100,
12804,,,P,Calculated partition coefficient (clogP),,CHEMBL625502,,0,1,U,22229,Autocuration,,,BAO_0000100,
12805,,,P,Calculated partition coefficient (clogP) (relative to BAY K 8644),,CHEMBL625503,,0,1,U,22229,Autocuration,,,BAO_0000100,
12806,,,P,Calculated partition coefficient (clogP),,CHEMBL625504,,0,1,U,22229,Autocuration,,,BAO_0000100,
12807,,,P,Calculated partition coefficient (clogP),,CHEMBL625505,,0,1,U,22229,Autocuration,,,BAO_0000100,
12808,,,P,Calculated partition coefficient of the compound,,CHEMBL625506,,0,1,U,22229,Autocuration,,,BAO_0000100,
12809,,,A,Partition coefficient (logP),,CHEMBL625507,,0,1,U,22224,Autocuration,,,BAO_0000019,
12810,,,P,Calculated partition coefficient (clogP),,CHEMBL625508,,0,1,U,22229,Autocuration,,,BAO_0000100,
12811,,,P,Calculated partition coefficient (clogP),,CHEMBL625509,,0,1,U,22229,Autocuration,,,BAO_0000100,
12812,,,P,Calculated partition coefficient (clogP),,CHEMBL625510,,0,1,U,22229,Autocuration,,,BAO_0000100,
12813,,,P,Calculated partition coefficient (clogP),,CHEMBL883125,,0,1,U,22229,Autocuration,,,BAO_0000100,
12814,,,P,Calculated partition coefficient (clogP),,CHEMBL625511,,0,1,U,22229,Autocuration,,,BAO_0000100,
12815,,,A,Partition coefficient of the compound,,CHEMBL874650,,0,1,U,22224,Autocuration,,,BAO_0000019,
12816,,,A,Partition coefficient of the compound,,CHEMBL625512,,0,1,U,22224,Autocuration,,,BAO_0000019,
12817,,,A,Partition coefficient of compound was determined,,CHEMBL625513,,0,1,U,22224,Autocuration,,,BAO_0000019,
12818,,,A,Partition coefficient was determined,,CHEMBL625514,,0,1,U,22224,Autocuration,,,BAO_0000019,
12819,,,P,Calculated partition coefficient (clogP),,CHEMBL625515,,0,1,U,22229,Autocuration,,,BAO_0000100,
12820,,,P,partition coefficient of compound was determined,,CHEMBL625516,,0,1,U,22229,Autocuration,,,BAO_0000100,
12821,Canis lupus familiaris,,A,The total body administered intravenously in dog,,CHEMBL625517,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12822,Rattus norvegicus,,A,The total body administered intravenously in rats,,CHEMBL625518,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12823,Mus musculus,,A,Time taken for the administration to female NIH mice weighing 25-30 g.,,CHEMBL625519,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
12824,,,A,Time taken for the administration,,CHEMBL625520,,0,1,U,22224,Autocuration,,,BAO_0000019,
12825,Canis lupus familiaris,,A,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,CHEMBL874651,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12826,Simiiformes,,A,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,CHEMBL625521,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
12827,Oryctolagus cuniculus,,A,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,CHEMBL623171,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12828,Rattus norvegicus,,A,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,CHEMBL623853,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12829,,,A,Plasma clearance for the compound was determined.,,CHEMBL623854,,0,1,U,22224,Autocuration,,,BAO_0000019,
12830,,,P,CLog P value of the compound,,CHEMBL874405,,0,1,U,22224,Autocuration,,,BAO_0000100,
12831,,,P,Calculated partition coefficient (clogP),,CHEMBL623855,,0,1,U,22229,Autocuration,,,BAO_0000100,
12832,,,P,Calculated partition coefficient (clogP),,CHEMBL623856,,0,1,U,22229,Autocuration,,,BAO_0000100,
12833,,,P,ClogP value of the compound; nd ='no data',,CHEMBL623857,,0,1,U,22224,Autocuration,,,BAO_0000100,
12834,,,P,ClogP value of the compound; nd ='not determined',,CHEMBL623858,,0,1,U,22224,Autocuration,,,BAO_0000100,
12835,,,P,CLog P was determined,,CHEMBL623859,,0,1,U,22224,Autocuration,,,BAO_0000100,
12836,,,P,Calculated partition coefficient (clogP),,CHEMBL839829,,0,1,U,22229,Autocuration,,,BAO_0000100,
12837,,,A,CLogP was calculated,,CHEMBL623860,,0,1,U,22224,Autocuration,,,BAO_0000019,
12838,,,A,CLogP value was determined,,CHEMBL623861,,0,1,U,22224,Autocuration,,,BAO_0000019,
12839,,,A,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,CHEMBL623862,,0,1,U,22224,Autocuration,,,BAO_0000019,
12840,,,P,Calculated partition coefficient (clogP),,CHEMBL874406,,0,1,U,22229,Autocuration,,,BAO_0000100,
12841,,,P,Calculated partition coefficient (clogP),,CHEMBL623863,,0,1,U,22229,Autocuration,,,BAO_0000100,
12842,,,P,Calculated partition coefficient (clogP),,CHEMBL624021,,0,1,U,22229,Autocuration,,,BAO_0000100,
12843,Canis lupus familiaris,,A,Distribution in female dog adrenal medulla 24 hours after administration.,,CHEMBL624022,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1236.0
12844,Canis lupus familiaris,,A,Distribution in female dog adrenal medulla 72 hours after administration.,,CHEMBL624023,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1236.0
12845,Canis lupus familiaris,,A,Distribution in female dog bile 24 hours after administration.,,CHEMBL624024,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12846,Canis lupus familiaris,,A,Distribution in female dog bile 72 hr after administration.,,CHEMBL624025,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12847,Canis lupus familiaris,,A,Distribution in female dog blood 24 hours after administration.,,CHEMBL624026,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12848,Canis lupus familiaris,,A,Distribution in female dog blood 72 hours after administration.,,CHEMBL624027,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12849,Canis lupus familiaris,,A,Distribution in female dog heart 24 hours after administration.,,CHEMBL624028,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12850,Canis lupus familiaris,,A,Distribution in female dog heart 72 hours after administration.,,CHEMBL624029,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12851,Canis lupus familiaris,,A,Distribution in female dog kidney 24 hours after administration.,,CHEMBL624030,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12852,Canis lupus familiaris,,A,Distribution in female dog kidney 72 hours after administration.,,CHEMBL624031,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12853,Canis lupus familiaris,,A,Distribution in female dog large intestine 24 hours after administration.,,CHEMBL624032,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,160.0
12854,Canis lupus familiaris,,A,Distribution in female dog large intestine 72 hours after administration.,,CHEMBL874407,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,160.0
12855,Canis lupus familiaris,,A,Distribution in female dog liver 24 hours after administration.,,CHEMBL624033,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12856,Canis lupus familiaris,,A,Distribution in female dog liver 72 hours after administration.,,CHEMBL624034,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12857,Canis lupus familiaris,,A,Distribution in female dog lung 24 hours after administration.,,CHEMBL624035,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12858,Canis lupus familiaris,,A,Distribution in female dog lung 72 hours after administration.,,CHEMBL624036,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12859,Canis lupus familiaris,,A,Distribution in female dog muscle 24 hours after administration.,,CHEMBL624037,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2385.0
12860,Canis lupus familiaris,,A,Distribution in female dog muscle 72 hours after administration.,,CHEMBL624038,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2385.0
12861,Canis lupus familiaris,,A,Distribution in female dog pancreas 24 hours after administration.,,CHEMBL624039,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12862,Canis lupus familiaris,,A,Distribution in female dog pancreas 72 hours after administration.,,CHEMBL624040,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12863,Canis lupus familiaris,,A,Distribution in female dog small intestine 24 hours after administration.,,CHEMBL624041,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,160.0
12864,Canis lupus familiaris,,A,Distribution in female dog small intestine 72 hours after administration.,,CHEMBL624042,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,160.0
12865,Canis lupus familiaris,,A,Distribution in female dog spleen 24 hours after administration.,,CHEMBL624043,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2106.0
12866,Canis lupus familiaris,,A,Distribution in female dog spleen 72 hours after administration.,,CHEMBL624044,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2106.0
12867,Canis lupus familiaris,,A,Distribution in female dog stomach 24 hours after administration.,,CHEMBL624045,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,945.0
12868,Canis lupus familiaris,,A,Distribution in female dog stomach 72 hours after administration.,,CHEMBL624046,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,945.0
12869,Canis lupus familiaris,,A,Distribution in female dog thyroid 24 hours after administration.,,CHEMBL624047,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2046.0
12870,Canis lupus familiaris,,A,Distribution in female dog thyroid 72 hours after administration.,,CHEMBL624048,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2046.0
12871,Canis lupus familiaris,,A,Distribution in female dog urine 24 hours after administration.,,CHEMBL874408,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
12872,Canis lupus familiaris,,A,Distribution in female dog urine 72 hr after administration.,,CHEMBL624049,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
12873,,,A,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,CHEMBL624050,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
12874,,,A,Plasma concentration at 7 hr after intravenous dosing,,CHEMBL624051,,0,1,U,22224,Autocuration,,,BAO_0000019,
12875,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,CHEMBL623278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12876,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,CHEMBL623279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12877,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,CHEMBL623280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12878,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,CHEMBL623963,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12879,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,CHEMBL623964,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12880,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,CHEMBL623965,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12881,Rattus norvegicus,,A,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,CHEMBL623966,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12882,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,CHEMBL874415,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12883,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,CHEMBL623967,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12884,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,CHEMBL623968,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12885,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,CHEMBL623969,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12886,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,CHEMBL628409,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12887,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,CHEMBL628410,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12888,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,CHEMBL628411,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12889,Rattus norvegicus,,A,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,CHEMBL628412,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12890,,,A,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,CHEMBL628413,,0,1,U,22224,Autocuration,,,BAO_0000019,
12891,,,A,The concentration in plasmat; Not determined,,CHEMBL628414,,0,1,U,22224,Autocuration,,,BAO_0000019,1969.0
12892,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in blood,,CHEMBL628415,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12893,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,CHEMBL628416,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12894,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in heart,,CHEMBL628417,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12895,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in liver,,CHEMBL874908,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12896,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in plasma,,CHEMBL628418,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12897,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,CHEMBL628419,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
12898,Rattus norvegicus,,A,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,CHEMBL628420,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12899,,,A,Water solubility at 37 degree C.,,CHEMBL628421,,0,1,U,22224,Autocuration,,,BAO_0000019,
12900,,,P,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,CHEMBL626726,,0,1,U,22229,Autocuration,,,BAO_0000100,
12901,,,P,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,CHEMBL626727,,0,1,U,22229,Autocuration,,,BAO_0000100,
12902,Rattus norvegicus,,A,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL626728,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12903,Rattus norvegicus,,A,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL626729,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12904,Rattus norvegicus,,A,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL626730,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12905,Rattus norvegicus,,A,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL626731,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12906,Rattus norvegicus,,A,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL626732,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
12907,Rattus norvegicus,,A,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL626733,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12908,Rattus norvegicus,,A,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL626734,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12909,Rattus norvegicus,,A,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL626735,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12910,Rattus norvegicus,,A,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL874909,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12911,Rattus norvegicus,,A,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL626736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
12912,Rattus norvegicus,,A,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL626737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12913,Rattus norvegicus,,A,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL630999,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12914,Rattus norvegicus,,A,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL631000,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12915,Rattus norvegicus,,A,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL631001,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12916,Rattus norvegicus,,A,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL631002,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
12917,Rattus norvegicus,,A,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL631003,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12918,Rattus norvegicus,,A,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL631004,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12919,Rattus norvegicus,,A,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL631005,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12920,Rattus norvegicus,,A,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL631006,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12921,Rattus norvegicus,,A,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL631007,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
12922,Rattus norvegicus,,A,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL631008,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12923,Rattus norvegicus,,A,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL631009,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12924,Rattus norvegicus,,A,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL631010,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12925,Rattus norvegicus,,A,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL631011,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12926,Rattus norvegicus,,A,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL631012,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
12927,Rattus norvegicus,,A,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL630271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12928,Rattus norvegicus,,A,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL630272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12929,Rattus norvegicus,,A,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL630273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12930,Rattus norvegicus,,A,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL630274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12931,Rattus norvegicus,,A,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL630275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
12932,Rattus norvegicus,,A,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,CHEMBL875782,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12933,Rattus norvegicus,,A,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,CHEMBL630276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12934,Rattus norvegicus,,A,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,CHEMBL630277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12935,Rattus norvegicus,,A,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,CHEMBL630278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12936,Rattus norvegicus,,A,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,CHEMBL630279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12937,,,A,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,CHEMBL630280,,0,1,U,22224,Autocuration,,,BAO_0000019,
12938,,,A,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL630281,,0,1,U,22224,Autocuration,,,BAO_0000019,
12939,Oryctolagus cuniculus,,A,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,CHEMBL630282,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12940,Oryctolagus cuniculus,,A,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,CHEMBL630283,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12941,,,A,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,CHEMBL630284,,0,1,U,22224,Autocuration,,,BAO_0000019,
12942,,,A,Alkylating activity was determined,,CHEMBL630285,,0,1,U,22224,Autocuration,,,BAO_0000019,
12943,,,A,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,CHEMBL630286,,0,1,U,22224,Autocuration,,,BAO_0000251,
12944,Oryctolagus cuniculus,,A,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,CHEMBL630069,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12945,Oryctolagus cuniculus,,A,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,CHEMBL630070,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12946,Oryctolagus cuniculus,,A,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,CHEMBL630071,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12947,Oryctolagus cuniculus,,A,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,CHEMBL630072,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12948,Oryctolagus cuniculus,,A,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,CHEMBL875110,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12949,Rattus norvegicus,,A,Compound was tested for antidiuretic activity in rats,,CHEMBL630073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12950,,,A,Compound was tested for inactivation kinetic values,,CHEMBL630074,,0,1,U,22224,Autocuration,,,BAO_0000019,
12951,,,A,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,CHEMBL630075,,0,1,U,22224,Autocuration,,,BAO_0000218,
12952,,,A,Dissociation rate calculated from the first-order equation using the t1/2 value,,CHEMBL630076,,0,1,U,22224,Autocuration,,,BAO_0000019,
12953,,,P,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,CHEMBL630077,,0,1,U,22229,Autocuration,,,BAO_0000100,
12954,,,P,Aqueous solubility was measured,,CHEMBL630078,,0,1,U,22229,Autocuration,,,BAO_0000100,
12955,,,P,Aqueous solubility was measured at a pH 4,,CHEMBL630079,,0,1,U,22229,Autocuration,,,BAO_0000100,
12956,,,P,Aqueous solubility (pH 7),,CHEMBL630080,,0,1,U,22229,Autocuration,,,BAO_0000100,
12957,,,P,Aqueous solubility was measured at a pH 9,,CHEMBL630081,,0,1,U,22229,Autocuration,,,BAO_0000100,
12958,,,A,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,CHEMBL630082,,0,1,U,22224,Autocuration,,,BAO_0000019,
12959,,,A,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,CHEMBL630083,,0,1,U,22224,Autocuration,,,BAO_0000019,
12960,,,A,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,CHEMBL630084,,0,1,U,22224,Autocuration,,,BAO_0000019,
12961,,,P,Aqueous solubility of the compound,,CHEMBL629198,,0,1,U,22229,Autocuration,,,BAO_0000100,
12962,,,P,Aqueous solubility at 37 degree Celsius at pH 7.38,,CHEMBL629199,,0,1,U,22229,Autocuration,,,BAO_0000100,
12963,,,P,Aqueous solubility in pH 7.4 phosphate buffer,,CHEMBL629200,,0,1,U,22229,Autocuration,,,BAO_0000100,
12964,Canis lupus familiaris,,A,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,CHEMBL629201,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12965,Canis lupus familiaris,,A,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,CHEMBL629202,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
12966,Homo sapiens,,A,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL875111,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12967,Homo sapiens,,A,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629203,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12968,Homo sapiens,,A,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629204,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12969,Homo sapiens,,A,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629205,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12970,Homo sapiens,,A,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629206,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
12971,,,A,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL631185,,0,1,U,22224,Autocuration,,,BAO_0000019,
12972,Rattus norvegicus,,A,Compound was evaluated for the average bile flow rat in rats,,CHEMBL631186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
12973,Oryctolagus cuniculus,,A,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,CHEMBL631187,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12974,Oryctolagus cuniculus,,A,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,CHEMBL631188,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
12975,,,A,Average half life period was determined,,CHEMBL876419,,0,1,U,22224,Autocuration,,,BAO_0000019,
12976,,,A,Average half life period was determined,,CHEMBL631189,,0,1,U,22224,Autocuration,,,BAO_0000019,
12977,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,CHEMBL631190,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12978,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,CHEMBL631191,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12979,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,CHEMBL631192,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12980,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,CHEMBL632400,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12981,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,CHEMBL630564,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12982,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,CHEMBL630565,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12983,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,CHEMBL630566,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12984,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,CHEMBL631229,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12985,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,CHEMBL631230,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
12986,,,P,Calculated partition coefficient (clogP),,CHEMBL876428,,0,1,U,22229,Autocuration,,,BAO_0000100,
12987,,,P,Calculated partition coefficient (clogP),,CHEMBL631231,,0,1,U,22229,Autocuration,,,BAO_0000100,
12988,,,P,Calculated partition coefficient (clogP) (MacLogP),,CHEMBL631232,,0,1,U,22229,Autocuration,,,BAO_0000100,
12989,,,A,Hydrophilicity was determined,,CHEMBL631233,,0,1,U,22224,Autocuration,,,BAO_0000019,
12990,,,P,Calculated partition coefficient (clogP),,CHEMBL631234,,0,1,U,22229,Autocuration,,,BAO_0000100,
12991,,,A,Increased absorption was determined,,CHEMBL883126,,0,1,U,22224,Autocuration,,,BAO_0000019,
12992,,,P,Lipophilicity value was evaluated,,CHEMBL631235,,0,1,U,22224,Autocuration,,,BAO_0000100,
12993,,,P,Log P value of the compound.,,CHEMBL631236,,0,1,U,22224,Autocuration,,,BAO_0000100,
12994,,,A,Partition coefficient of compound was determined,,CHEMBL631237,,0,1,U,22224,Autocuration,,,BAO_0000019,
12995,,,P,Calculated partition coefficient (clogP),,CHEMBL631238,,0,1,U,22229,Autocuration,,,BAO_0000100,
12996,,,P,Calculated partition coefficient (clogP),,CHEMBL876429,,0,1,U,22229,Autocuration,,,BAO_0000100,
12997,,,A,Partition coefficient was measured by medchem software; Not calculated,,CHEMBL631414,,0,1,U,22224,Autocuration,,,BAO_0000019,
12998,,,P,Partition coefficient was measured by octanol-water using standard shake-flask method,,CHEMBL631415,,0,1,U,22224,Autocuration,,,BAO_0000100,
12999,,,P,Calculated partition coefficient (clogP),,CHEMBL631416,,0,1,U,22229,Autocuration,,,BAO_0000100,
13000,,,A,Partition coefficient (logP),,CHEMBL631417,,0,1,U,22224,Autocuration,,,BAO_0000019,
13001,,,P,Calculated partition coefficient (clogP),,CHEMBL631418,,0,1,U,22229,Autocuration,,,BAO_0000100,
13002,,,P,The Octanol/Water partition coefficient CLogP,,CHEMBL631419,,0,1,U,22229,Autocuration,,,BAO_0000100,
13003,,,A,The pharmacokinetic parameter C Log p was reported,,CHEMBL631420,,0,1,U,22224,Autocuration,,,BAO_0000019,
13004,,,P,Calculated partition coefficient (clogP),,CHEMBL631421,,0,1,U,22229,Autocuration,,,BAO_0000100,
13005,,,P,Calculated partition coefficient (clogP),,CHEMBL631422,,0,1,U,22229,Autocuration,,,BAO_0000100,
13006,,,P,Calculated partition coefficient (clogP),,CHEMBL631423,,0,1,U,22229,Autocuration,,,BAO_0000100,
13007,Rattus norvegicus,,A,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL876430,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13008,Rattus norvegicus,,A,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,CHEMBL631424,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13009,Canis lupus familiaris,,A,Compound was administered intravenously in dog to evaluate plasma clearance values,,CHEMBL631425,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
13010,Simiiformes,,A,Compound was administered intravenously in monkey to evaluate plasma clearance values,,CHEMBL631426,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
13011,Mus musculus,,A,Compound was administered intravenously in mouse to evaluate plasma clearance values,,CHEMBL631427,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1969.0
13012,Canis lupus familiaris,,A,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,CHEMBL631428,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
13013,Macaca mulatta,,A,Intrinsic clearance in Rhesus liver microsome,,CHEMBL631429,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,2107.0
13014,Canis lupus familiaris,,A,Intrinsic clearance in dog liver microsome,,CHEMBL631430,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,2107.0
13015,Rattus norvegicus,,A,Intrinsic clearance in rat liver microsome,,CHEMBL631431,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13016,Macaca mulatta,,A,Low plasma clearance was calculated in rhesus monkey,,CHEMBL631432,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,1969.0
13017,Canis lupus familiaris,,A,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL631433,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13018,,,A,Plasma clearance after intravenous dose of 0.3 mg/kg,,CHEMBL631434,,0,1,U,22224,Autocuration,,,BAO_0000218,
13019,,,A,Plasma clearance after intravenous dose of 1 mg/kg,,CHEMBL631435,,0,1,U,22224,Autocuration,,,BAO_0000218,
13020,,,A,Plasma clearance after intravenous dose of 3 mg/kg,,CHEMBL631436,,0,1,U,22224,Autocuration,,,BAO_0000218,
13021,,,A,Plasma clearance after intravenous dose of 3.87 mg/kg,,CHEMBL631437,,0,1,U,22224,Autocuration,,,BAO_0000218,
13022,Rattus norvegicus,,A,Plasma clearance after peroral administration at 10 mpk in Rat,,CHEMBL631438,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13023,Macaca mulatta,,A,Plasma clearance after peroral administration at 10 mpk in Rhesus,,CHEMBL876431,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
13024,Canis lupus familiaris,,A,Plasma clearance after peroral administration at 10 mpk in dog,,CHEMBL631439,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13025,Rattus norvegicus,,A,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,CHEMBL631440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13026,,,A,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,CHEMBL631441,,0,1,U,22224,Autocuration,,,BAO_0000019,
13027,,,A,Critical Micellar concentration was determined,,CHEMBL631442,,0,1,U,22224,Autocuration,,,BAO_0000019,
13028,,,A,Critical Micellar concentration of the compound. was determined,,CHEMBL626525,,0,1,U,22224,Autocuration,,,BAO_0000019,
13029,,,A,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,CHEMBL627168,,0,1,U,22224,Autocuration,,,BAO_0000019,
13030,,,A,Critical micellar concentration was measured in water by the dye solubilization method,,CHEMBL875618,,0,1,U,22224,Autocuration,,,BAO_0000019,
13031,,,B,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,CHEMBL626612,,0,1,U,22224,Autocuration,,,BAO_0000019,
13032,,,A,CMR value (relative to BAY K 8644),,CHEMBL626613,,0,1,U,22224,Autocuration,,,BAO_0000019,
13033,,,A,Carbamoylating activity was determined,,CHEMBL626614,,0,1,U,22224,Autocuration,,,BAO_0000019,
13034,Simiiformes,,A,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL626615,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13035,,,A,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,CHEMBL626616,,0,1,U,22224,Autocuration,,,BAO_0000019,
13036,,,A,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,CHEMBL626617,,0,1,U,22224,Autocuration,,,BAO_0000019,
13037,Canis lupus familiaris,,A,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,CHEMBL626618,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
13038,Rattus norvegicus,,A,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,CHEMBL626619,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13039,Canis lupus familiaris,,A,"Clearance rate at 0.46 mg/kg, iv, in dogs",,CHEMBL626620,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13040,Rattus norvegicus,,A,"Clearance rate at 5.5 mg/kg, iv, in rat",,CHEMBL626621,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13041,Macaca fascicularis,,A,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,CHEMBL626622,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
13042,Macaca fascicularis,,A,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,CHEMBL626623,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
13043,Canis lupus familiaris,,A,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,CHEMBL626624,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13044,Rattus norvegicus,,A,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,CHEMBL626625,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13045,Rattus norvegicus,,A,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,CHEMBL626626,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13046,,,A,Tested for the total clearance of the compound,,CHEMBL626627,,0,1,U,22224,Autocuration,,,BAO_0000218,
13047,Canis lupus familiaris,,A,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,CHEMBL626628,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13048,,,A,Total body clearance was determined,,CHEMBL626629,,0,1,U,22224,Autocuration,,,BAO_0000218,
13049,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,CHEMBL626630,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13050,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,CHEMBL626631,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13051,,,P,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,CHEMBL626632,,0,1,U,22229,Autocuration,,,BAO_0000100,
13052,,,P,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,CHEMBL626633,,0,1,U,22229,Autocuration,,,BAO_0000100,
13053,,,P,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,CHEMBL626634,,0,1,U,22229,Autocuration,,,BAO_0000100,
13054,,,P,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,CHEMBL626635,,0,1,U,22229,Autocuration,,,BAO_0000100,
13055,,,P,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,CHEMBL626636,,0,1,U,22229,Autocuration,,,BAO_0000100,
13056,,,P,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,CHEMBL626637,,0,1,U,22229,Autocuration,,,BAO_0000100,
13057,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,CHEMBL626638,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13058,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,CHEMBL626639,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13059,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,CHEMBL626640,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13060,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,CHEMBL626641,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13061,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,CHEMBL627272,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13062,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,CHEMBL627273,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13063,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,CHEMBL627441,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13064,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,CHEMBL628355,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13065,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,CHEMBL628356,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13066,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,CHEMBL628357,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13067,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,CHEMBL628358,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13068,Pneumocystis carinii,,A,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,CHEMBL622307,4754.0,1,1,N,50339,Intermediate,,,BAO_0000218,
13069,,,A,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,CHEMBL622527,,0,1,U,22224,Autocuration,,,BAO_0000019,
13070,,,A,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,CHEMBL622528,,0,1,U,22224,Autocuration,,,BAO_0000019,
13071,,,A,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,CHEMBL622529,,0,1,U,22224,Autocuration,,,BAO_0000019,
13072,,,A,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,CHEMBL622992,,0,1,U,22224,Autocuration,,,BAO_0000019,
13073,,,A,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,CHEMBL622993,,0,1,U,22224,Autocuration,,,BAO_0000019,
13074,,,A,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,CHEMBL622994,,0,1,U,22224,Autocuration,,,BAO_0000019,
13075,Rattus norvegicus,,A,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,CHEMBL622995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13076,Rattus norvegicus,,A,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,CHEMBL622996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13077,Rattus norvegicus,,A,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,CHEMBL622997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13078,Rattus norvegicus,,A,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,CHEMBL622998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13079,,,A,Cp max following ip administration at 1 mg/kg,,CHEMBL622999,,0,1,U,22224,Autocuration,,,BAO_0000218,
13080,,,A,Maximum concentration in plasma was reported at 0.5 hour,,CHEMBL623000,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
13081,,,A,Maximum concentration in plasma was reported at 2 hour,,CHEMBL623001,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
13082,Mus musculus,,A,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,CHEMBL623002,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13083,,,P,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,CHEMBL623003,,0,1,U,22229,Autocuration,,,BAO_0000100,
13084,,,A,Steady state concentration was evaluated,,CHEMBL623004,,0,1,U,22224,Autocuration,,,BAO_0000019,
13085,,,A,Partition coefficient (logP),,CHEMBL623005,,0,1,U,22224,Autocuration,,,BAO_0000019,
13086,,,A,Partition coefficient (logD7.4),,CHEMBL623006,,0,1,U,22224,Autocuration,,,BAO_0000019,
13087,Rattus norvegicus,,A,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,CHEMBL623007,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13088,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,CHEMBL623008,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
13089,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,CHEMBL876654,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13090,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,CHEMBL623009,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13091,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,CHEMBL623010,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13092,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,CHEMBL623011,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13093,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,CHEMBL623012,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
13094,,,A,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,CHEMBL623013,,0,1,U,22224,Autocuration,,,BAO_0000019,
13095,,,A,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL623014,,0,1,U,22224,Autocuration,,,BAO_0000019,
13096,,,A,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,CHEMBL623015,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13097,,,A,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,CHEMBL623016,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13098,,,A,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,CHEMBL624858,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13099,Rattus norvegicus,,A,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,CHEMBL624859,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13100,Rattus norvegicus,,A,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL624860,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13101,Rattus norvegicus,,A,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,CHEMBL624861,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13102,Rattus norvegicus,,A,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,CHEMBL624862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13103,Rattus norvegicus,,A,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,CHEMBL624863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13104,Rattus norvegicus,,A,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,CHEMBL876655,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13105,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,CHEMBL624864,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13106,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,CHEMBL624865,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13107,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,CHEMBL624866,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13108,Canis lupus familiaris,,F,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,CHEMBL624867,9615.0,1,1,N,50588,Expert,,,BAO_0000218,
13109,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,CHEMBL624868,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13110,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,CHEMBL628450,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13111,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,CHEMBL628451,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13112,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,CHEMBL628452,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13113,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,CHEMBL628453,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13114,Canis lupus familiaris,,A,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,CHEMBL628454,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13115,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,CHEMBL628455,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13116,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,CHEMBL628456,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13117,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,CHEMBL628457,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13118,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,CHEMBL877505,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13119,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,CHEMBL628458,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13120,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,CHEMBL628459,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13121,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,CHEMBL628460,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13122,Canis lupus familiaris,,A,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,CHEMBL628461,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13123,,,B,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,CHEMBL628462,,0,1,U,22224,Autocuration,,,BAO_0000218,
13124,Canis lupus familiaris,,A,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL628463,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13125,Rattus norvegicus,,F,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,CHEMBL625666,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
13126,,,B,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL625667,,0,1,U,22224,Autocuration,,,BAO_0000218,
13127,Rattus norvegicus,,A,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL625668,10116.0,1,1,N,50597,Expert,,,BAO_0000218,
13128,Rattus norvegicus,,A,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL625669,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13129,,,A,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,CHEMBL625670,,0,1,U,22224,Autocuration,,,BAO_0000019,
13130,Rattus norvegicus,,A,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,CHEMBL625671,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13131,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,CHEMBL625672,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13132,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,CHEMBL625673,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13133,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,CHEMBL625674,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13134,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,CHEMBL625675,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13135,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,CHEMBL627637,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13136,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,CHEMBL627638,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13137,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,CHEMBL627639,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13138,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,CHEMBL627640,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13139,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,CHEMBL627641,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13140,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,CHEMBL627642,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13141,Human herpesvirus 1,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,CHEMBL877506,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
13142,Mus musculus,,A,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,CHEMBL627275,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13143,Mustela putorius furo,,A,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,CHEMBL627643,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13144,Mustela putorius furo,,A,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,CHEMBL631246,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13145,Mustela putorius furo,,A,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,CHEMBL631247,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13146,Mustela putorius furo,,A,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,CHEMBL629532,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13147,Mustela putorius furo,,A,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,CHEMBL629533,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13148,Mustela putorius furo,,A,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,CHEMBL629534,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13149,Mustela putorius furo,,A,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,CHEMBL629535,9669.0,1,1,N,50506,Intermediate,,,BAO_0000218,
13150,,,A,Pharmacokinetic parameter :drug bound to plasma was reported,,CHEMBL625932,,0,1,U,22224,Autocuration,,,BAO_0000019,
13151,,,A,compound was evaluated for drug bound in plasma,,CHEMBL625933,,0,1,U,22224,Autocuration,,,BAO_0000019,
13152,Rattus norvegicus,,A,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,CHEMBL625934,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13153,Eutheria,,A,Bioavailability,,CHEMBL625935,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13154,Rattus norvegicus,,A,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,CHEMBL625936,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13155,Rattus norvegicus,,A,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,CHEMBL625937,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13156,Canis lupus familiaris,,A,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,CHEMBL625938,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13157,Rattus norvegicus,,A,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,CHEMBL625939,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1970.0
13158,Rattus norvegicus,,A,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,CHEMBL625940,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1970.0
13159,Rattus norvegicus,,A,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,CHEMBL874464,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1970.0
13160,Rattus norvegicus,,A,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,CHEMBL625941,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1970.0
13161,Rattus norvegicus,,A,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,CHEMBL625942,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1970.0
13162,Rattus norvegicus,,A,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,CHEMBL625943,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1970.0
13163,Homo sapiens,,A,In vitro protein binding in human serum at 5 ug/ml,,CHEMBL625944,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1977.0
13164,,,A,Serum protein binding ability was measured,,CHEMBL625945,,0,1,U,22224,Autocuration,,,BAO_0000019,
13165,,,A,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,CHEMBL625946,,0,1,U,22224,Autocuration,,,BAO_0000019,
13166,Canis lupus familiaris,,A,Oral bioavailability in dog,,CHEMBL625947,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13167,Rattus norvegicus,,A,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,CHEMBL625948,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13168,,,A,Absolute oral bioavailability at an iv dose of 14 mg/kg,,CHEMBL625949,,0,1,U,22224,Autocuration,,,BAO_0000218,
13169,,,A,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,CHEMBL625950,,0,1,U,22224,Autocuration,,,BAO_0000218,
13170,Eutheria,,A,Oral bioavailability (dose 15 mg/kg i.v.),,CHEMBL625951,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13171,,,A,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,CHEMBL625952,,0,1,U,22224,Autocuration,,,BAO_0000218,
13172,,,A,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,CHEMBL625953,,0,1,U,22224,Autocuration,,,BAO_0000218,
13173,,,A,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,CHEMBL625954,,0,1,U,22224,Autocuration,,,BAO_0000218,
13174,,,A,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,CHEMBL882959,,0,1,U,22224,Autocuration,,,BAO_0000218,
13175,Canis lupus familiaris,,A,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,CHEMBL625955,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13176,Mustela putorius furo,,A,Bioavailability in ferret,,CHEMBL625956,9669.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13177,Macaca fascicularis,,A,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,CHEMBL625957,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
13178,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,CHEMBL625958,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13179,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,CHEMBL625959,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13180,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,CHEMBL626642,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13181,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,CHEMBL631330,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13182,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,CHEMBL631331,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13183,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,CHEMBL631332,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13184,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,CHEMBL631333,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13185,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,CHEMBL632018,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13186,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,CHEMBL632019,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13187,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,CHEMBL632020,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13188,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,CHEMBL632021,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13189,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,CHEMBL632022,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13190,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,CHEMBL632023,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13191,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,CHEMBL632024,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13192,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,CHEMBL874472,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13193,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,CHEMBL632025,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13194,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,CHEMBL632026,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13195,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,CHEMBL632027,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13196,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,CHEMBL632028,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13197,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,CHEMBL626430,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13198,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,CHEMBL626431,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13199,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,CHEMBL626432,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13200,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,CHEMBL626433,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13201,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,CHEMBL626434,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13202,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,CHEMBL627280,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13203,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,CHEMBL627281,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13204,Rattus norvegicus,,A,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,CHEMBL627282,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13205,,,A,Total body clearance was measured at given dose,,CHEMBL627283,,0,1,U,22224,Autocuration,,,BAO_0000019,
13206,,,A,Total body clearance was measured at given dose.,,CHEMBL627284,,0,1,U,22224,Autocuration,,,BAO_0000218,
13207,Rattus norvegicus,,A,Metabolic clearance from the body in rat,,CHEMBL627285,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13208,,,A,Renal clearance from the body,,CHEMBL627286,,0,1,U,22224,Autocuration,,,BAO_0000218,
13209,Rattus norvegicus,,A,Renal clearance from the body in rat,,CHEMBL875477,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13210,Rattus norvegicus,,A,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,CHEMBL627287,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13211,Canis lupus familiaris,,A,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,CHEMBL627288,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13212,Rattus norvegicus,,A,Total clearance from the body in rat,,CHEMBL627289,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13213,Rattus norvegicus,,A,Clearance into cortex from rat plasma or PBS,,CHEMBL627290,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13214,,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,CHEMBL627291,,0,1,U,22224,Autocuration,,,BAO_0000218,
13215,,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,CHEMBL627292,,0,1,U,22224,Autocuration,,,BAO_0000218,
13216,,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,CHEMBL627293,,0,1,U,22224,Autocuration,,,BAO_0000218,
13217,,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,CHEMBL627294,,0,1,U,22224,Autocuration,,,BAO_0000218,
13218,,,A,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,CHEMBL875478,,0,1,U,22224,Autocuration,,,BAO_0000218,
13219,,,A,Clearance was determined,,CHEMBL627295,,0,1,U,22224,Autocuration,,,BAO_0000218,
13220,Mus musculus,,A,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,CHEMBL627296,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13221,Oryctolagus cuniculus,,A,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,CHEMBL626119,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,
13222,Rattus norvegicus,,A,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,CHEMBL626120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13223,Rattus norvegicus,,A,Clearance in rat after iv dose (100 ug/kg),,CHEMBL626121,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13224,Cavia porcellus,,A,Clearance in guinea pig,,CHEMBL626122,10141.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13225,Rattus norvegicus,,A,Compound was evaluated for clearance in rat,,CHEMBL626123,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13226,Canis lupus familiaris,,A,Compound was evaluated for the clearance in dog,,CHEMBL623456,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13227,Rattus norvegicus,,A,Compound was evaluated for the clearance in rat,,CHEMBL623457,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13228,Rattus norvegicus,,A,Compound was tested in vivo for clearance after iv administration in the rat,,CHEMBL623458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13229,,,A,IV clearance determined at an iv dose of 14 mg/kg,,CHEMBL623459,,0,1,U,22224,Autocuration,,,BAO_0000218,
13230,,,A,IV clearance determined at an iv dose of 15.2 mg/kg,,CHEMBL875484,,0,1,U,22224,Autocuration,,,BAO_0000218,
13231,,,A,IV clearance determined at an iv dose of 15 mg/kg,,CHEMBL623460,,0,1,U,22224,Autocuration,,,BAO_0000218,
13232,,,A,IV clearance determined at an peroral dose of 30 mg/kg.,,CHEMBL623461,,0,1,U,22224,Autocuration,,,BAO_0000218,
13233,,,A,IV clearance determined at an peroral dose of 30.2 mg/kg.,,CHEMBL623462,,0,1,U,22224,Autocuration,,,BAO_0000218,
13234,,,A,IV clearance determined at an peroral dose of 30.3 mg/kg.,,CHEMBL627386,,0,1,U,22224,Autocuration,,,BAO_0000218,
13235,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,CHEMBL627387,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13236,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,CHEMBL627388,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13237,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,CHEMBL627389,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13238,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,CHEMBL627390,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13239,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,CHEMBL627391,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13240,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,CHEMBL627392,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13241,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,CHEMBL627393,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13242,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,CHEMBL627394,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,3126.0
13243,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,CHEMBL627395,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
13244,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,CHEMBL875485,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13245,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,CHEMBL627396,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13246,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,CHEMBL627397,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13247,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,CHEMBL627398,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13248,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,CHEMBL627399,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
13249,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,CHEMBL627400,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13250,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,CHEMBL627401,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13251,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,CHEMBL627402,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13252,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,CHEMBL627403,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13253,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,CHEMBL627404,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13254,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,CHEMBL623101,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13255,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,CHEMBL877480,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13256,Rattus norvegicus,,A,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,CHEMBL623102,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,3126.0
13257,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,CHEMBL623103,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
13258,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,CHEMBL623104,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13259,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,CHEMBL623105,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13260,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,CHEMBL623106,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13261,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,CHEMBL623107,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13262,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,CHEMBL623108,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
13263,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,CHEMBL623109,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13264,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,CHEMBL623110,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13265,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,CHEMBL623111,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13266,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,CHEMBL625060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13267,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,CHEMBL625061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13268,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,CHEMBL625062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13269,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,CHEMBL625063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13270,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,CHEMBL625064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,3126.0
13271,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,CHEMBL625065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000001.0
13272,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,CHEMBL625066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13273,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,CHEMBL625067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13274,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,CHEMBL625068,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13275,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,CHEMBL622159,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13276,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,CHEMBL622160,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,160.0
13277,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,CHEMBL622161,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13278,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,CHEMBL622162,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13279,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,CHEMBL622163,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13280,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,CHEMBL622313,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13281,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,CHEMBL622314,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13282,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,CHEMBL622315,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13283,Rattus norvegicus,,A,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,CHEMBL622316,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,3126.0
13284,Escherichia coli,,A,Normal diffusion coefficient in water for Escherichia coli,,CHEMBL877486,562.0,1,1,N,50212,Intermediate,,,BAO_0000218,
13285,,,A,Average max percent decrease in RVR (renal vascular resistance) was determined,,CHEMBL622317,,0,1,U,22224,Autocuration,,,BAO_0000019,
13286,,,A,Average max percent decrease in RVR (renal vascular resistance) was determined.,,CHEMBL622318,,0,1,U,22224,Autocuration,,,BAO_0000019,
13287,,,A,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,CHEMBL622319,,0,1,U,22224,Autocuration,,,BAO_0000019,
13288,,,A,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,CHEMBL622320,,0,1,U,22224,Autocuration,,,BAO_0000019,
13289,,,A,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,CHEMBL622321,,0,1,U,22224,Autocuration,,,BAO_0000019,
13290,,,A,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,CHEMBL622322,,0,1,U,22224,Autocuration,,,BAO_0000019,
13291,,,A,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,CHEMBL622323,,0,1,U,22224,Autocuration,,,BAO_0000019,
13292,Rattus norvegicus,,A,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,CHEMBL622324,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13293,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,CHEMBL622325,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13294,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,CHEMBL622326,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13295,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,CHEMBL877487,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13296,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,CHEMBL622327,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13297,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,CHEMBL622328,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13298,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,CHEMBL622329,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13299,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,CHEMBL622330,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13300,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,CHEMBL622331,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13301,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,CHEMBL622332,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13302,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,CHEMBL622333,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13303,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,CHEMBL627658,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13304,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,CHEMBL630428,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13305,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,CHEMBL630429,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13306,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,CHEMBL630430,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13307,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,CHEMBL630431,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13308,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,CHEMBL630432,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13309,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,CHEMBL630433,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13310,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,CHEMBL630434,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13311,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,CHEMBL629372,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13312,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,CHEMBL629553,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13313,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,CHEMBL629554,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13314,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,CHEMBL874447,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13315,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,CHEMBL629555,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13316,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,CHEMBL629556,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13317,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,CHEMBL629557,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13318,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,CHEMBL629558,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13319,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,CHEMBL629559,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13320,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,CHEMBL629560,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13321,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,CHEMBL629561,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13322,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,CHEMBL629562,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13323,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,CHEMBL629563,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13324,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,CHEMBL629564,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13325,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,CHEMBL629565,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13326,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,CHEMBL629566,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13327,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,CHEMBL629567,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13328,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,CHEMBL629568,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13329,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,CHEMBL629569,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13330,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,CHEMBL629570,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13331,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,CHEMBL629571,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13332,Rattus norvegicus,,A,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,CHEMBL629572,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13333,Rattus norvegicus,,A,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,CHEMBL629573,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13334,Eutheria,,A,Bioavailability (dose 20 mg/kg),,CHEMBL629574,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13335,Canis lupus familiaris,,A,Bioavailability in dog,,CHEMBL629575,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13336,Rattus norvegicus,,A,Bioavailability in rat (Sprague-Dawley) (male),,CHEMBL874448,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13337,Primates,,A,Bioavailability in monkey (dose 10 mg/kg i.d.),,CHEMBL629576,9443.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13338,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL629577,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13339,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL629578,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13340,Canis lupus familiaris,,A,Bioavailability in dog (dose 3.0 mg/kg p.o.),,CHEMBL629579,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13341,Canis lupus familiaris,,A,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,CHEMBL882958,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13342,Pan troglodytes,,A,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,CHEMBL629580,9598.0,1,1,N,50505,Intermediate,,,BAO_0000218,
13343,Eutheria,,A,Bioavailability,,CHEMBL629581,9347.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13344,Saimiri,,A,Bioavailability in squirrel monkey,,CHEMBL629582,9520.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13345,Canis lupus familiaris,,A,Bioavailability was evaluated in dog,,CHEMBL628522,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13346,Cricetinae,,A,Bioavailability was evaluated in hamster,,CHEMBL625432,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
13347,Rattus norvegicus,,A,Bioavailability in rat,,CHEMBL625433,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13348,Rattus norvegicus,,A,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL625434,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13349,Rattus norvegicus,,A,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,CHEMBL625435,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13350,Rattus norvegicus,,A,Bioavailability in rat (dose 10 mg/kg p.o.),,CHEMBL625436,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13351,Macaca fascicularis,,A,Bioavailability was measured in cynomolgus monkeys.,,CHEMBL874588,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
13352,Mus musculus,,A,Bioavailability was measured in nude mice.,,CHEMBL625437,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13353,Mustela putorius furo,,A,Bioavailability in ferret (dose 10 mg/kg i.d.),,CHEMBL625438,9669.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13354,Simiiformes,,A,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,CHEMBL625439,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13355,Simiiformes,,A,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,CHEMBL625440,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13356,Simiiformes,,A,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,CHEMBL625441,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13357,Rattus norvegicus,,A,Bioavailability in rat (dose 10 mg/kg i.d.),,CHEMBL625442,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13358,Rattus norvegicus,,A,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,CHEMBL625443,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13359,,,A,Bioavailability was determined; extremely poor,,CHEMBL625444,,0,1,U,22224,Autocuration,,,BAO_0000218,
13360,Mus musculus,,A,% bioavailability in mice after oral administration of prodrug,,CHEMBL625445,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13361,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,CHEMBL625446,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13362,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,CHEMBL882960,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13363,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,CHEMBL625447,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13364,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,CHEMBL625448,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13365,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,CHEMBL625449,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13366,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,CHEMBL874589,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13367,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,CHEMBL625450,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13368,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,CHEMBL625451,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13369,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,CHEMBL626584,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13370,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,CHEMBL626585,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13371,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,CHEMBL626586,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13372,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,CHEMBL626587,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13373,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,CHEMBL626588,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13374,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,CHEMBL626589,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13375,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,CHEMBL626590,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13376,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,CHEMBL626591,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13377,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,CHEMBL627181,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13378,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,CHEMBL628083,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13379,,,A,IV clearance determined at an peroral dose of 15 mg/kg.,,CHEMBL628084,,0,1,U,22224,Autocuration,,,BAO_0000218,
13380,Hymenolepis nana,,F,Mouse oral clearance was measured against Hymenolepiasis nana.,,CHEMBL628085,102285.0,1,1,N,50064,Expert,,,BAO_0000218,
13381,Heligmosomoides polygyrus,,F,Mouse oral clearance was measured against Nematospiroides dubius,,CHEMBL628086,6339.0,1,1,N,50545,Expert,,,BAO_0000218,
13382,,,F,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,CHEMBL628087,,0,1,U,22224,Autocuration,,,BAO_0000218,
13383,Mus musculus,,A,Mouse oral clearance was measured against N. nana; NT is Not Tested,,CHEMBL628088,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13384,,,B,Mouse oral clearance was measured against N. nana; NT is Not Tested,,CHEMBL628089,,0,1,U,22224,Autocuration,,,BAO_0000218,
13385,,,A,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,CHEMBL628090,,0,1,U,22224,Autocuration,,,BAO_0000218,
13386,,,A,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,CHEMBL628091,,0,1,U,22224,Autocuration,,,BAO_0000218,
13387,,,A,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,CHEMBL628092,,0,1,U,22224,Autocuration,,,BAO_0000218,
13388,,,A,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,CHEMBL628093,,0,1,U,22224,Autocuration,,,BAO_0000218,
13389,,,A,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,CHEMBL875607,,0,1,U,22224,Autocuration,,,BAO_0000218,
13390,,,A,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,CHEMBL625710,,0,1,U,22224,Autocuration,,,BAO_0000218,
13391,,,A,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,CHEMBL625711,,0,1,U,22224,Autocuration,,,BAO_0000218,
13392,,,A,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,CHEMBL625712,,0,1,U,22224,Autocuration,,,BAO_0000218,
13393,,,A,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,CHEMBL625713,,0,1,U,22224,Autocuration,,,BAO_0000218,
13394,Canis lupus familiaris,,A,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,CHEMBL625714,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13395,Macaca mulatta,,A,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,CHEMBL625715,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
13396,Rattus norvegicus,,A,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,CHEMBL625716,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13397,Rattus norvegicus,,A,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,CHEMBL625717,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13398,Rattus norvegicus,,A,Plasma clearance was determined for the compound in rats,,CHEMBL625718,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13399,Rattus norvegicus,,A,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,CHEMBL625719,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13400,Rattus norvegicus,,A,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,CHEMBL625720,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13401,Rattus norvegicus,,A,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,CHEMBL625721,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13402,Rattus norvegicus,,A,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,CHEMBL625722,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13403,Rattus norvegicus,,A,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,CHEMBL625723,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13404,Heligmosomoides polygyrus,,A,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,CHEMBL625724,6339.0,1,1,N,50545,Intermediate,,,BAO_0000218,
13405,Heligmosomoides polygyrus,,A,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,CHEMBL625725,6339.0,1,1,N,50545,Intermediate,,,BAO_0000218,
13406,Heligmosomoides polygyrus,,A,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,CHEMBL625726,6339.0,1,1,N,50545,Intermediate,,,BAO_0000218,
13407,Heligmosomoides polygyrus,,A,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,CHEMBL875608,6339.0,1,1,N,50545,Intermediate,,,BAO_0000218,
13408,Heligmosomoides polygyrus,,A,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,CHEMBL625727,6339.0,1,1,N,50545,Intermediate,,,BAO_0000218,
13409,Rattus norvegicus,,A,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,CHEMBL625728,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13410,Rattus norvegicus,,A,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,CHEMBL625729,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13411,Rattus norvegicus,,A,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,CHEMBL625730,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
13412,Rattus norvegicus,,A,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,CHEMBL625731,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13413,Rattus norvegicus,,A,Urinary clearance was determined in rat at 25 mg/kg os dosage,,CHEMBL626417,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13414,Homo sapiens,,A,Urinary clearance was determined at 100 mg/kg oral dosage in human,,CHEMBL626418,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,1088.0
13415,Canis lupus familiaris,,A,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,CHEMBL626419,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13416,Canis lupus familiaris,,A,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,CHEMBL626592,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
13417,Rattus norvegicus,,A,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,CHEMBL626593,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13418,Rattus norvegicus,,A,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,CHEMBL626594,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13419,Canis lupus familiaris,,A,Clearance rate in dogs,,CHEMBL625035,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13420,,,A,Compound was measured for intrinsic clearance,,CHEMBL625036,,0,1,U,22224,Autocuration,,,BAO_0000019,
13421,,,P,Calculated partition coefficient (clogP),,CHEMBL625037,,0,1,U,22229,Autocuration,,,BAO_0000100,
13422,,,P,Calculated partition coefficient (clogP),,CHEMBL625038,,0,1,U,22229,Autocuration,,,BAO_0000100,
13423,,,P,Calculated partition coefficient (clogP),,CHEMBL625039,,0,1,U,22229,Autocuration,,,BAO_0000100,
13424,,,P,Calculated partition coefficient (clogP),,CHEMBL625040,,0,1,U,22229,Autocuration,,,BAO_0000100,
13425,,,P,Calculated partition coefficient (clogP),,CHEMBL625041,,0,1,U,22229,Autocuration,,,BAO_0000100,
13426,,,P,Calculated partition coefficient (clogP),,CHEMBL625042,,0,1,U,22229,Autocuration,,,BAO_0000100,
13427,,,A,Partition coefficient of the compound,,CHEMBL874411,,0,1,U,22224,Autocuration,,,BAO_0000019,
13428,,,A,Permeability,,CHEMBL625043,,0,1,U,22224,Autocuration,,,BAO_0000019,
13429,,,P,Calculated partition coefficient (clogP),,CHEMBL625044,,0,1,U,22229,Autocuration,,,BAO_0000100,
13430,,,A,Partition coefficient (logD),,CHEMBL625045,,0,1,U,22224,Autocuration,,,BAO_0000019,
13431,,,P,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,CHEMBL625046,,0,1,U,22229,Autocuration,,,BAO_0000100,
13432,,,P,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,CHEMBL625047,,0,1,U,22229,Autocuration,,,BAO_0000100,
13433,,,P,Calculated partition coefficient (clogP),,CHEMBL625048,,0,1,U,22229,Autocuration,,,BAO_0000100,
13434,,,P,Calculated partition coefficient (clogP),,CHEMBL625049,,0,1,U,22229,Autocuration,,,BAO_0000100,
13435,,,P,Calculated logarithm of partition coefficient (P) was determined,,CHEMBL625050,,0,1,U,22229,Autocuration,,,BAO_0000100,
13436,,,P,Calculated partition coefficient (clogP),,CHEMBL625051,,0,1,U,22229,Autocuration,,,BAO_0000100,
13437,,,P,Calculated partition coefficient (clogP),,CHEMBL874412,,0,1,U,22229,Autocuration,,,BAO_0000100,
13438,,,P,Calculated partition coefficient (clogP),,CHEMBL625052,,0,1,U,22229,Autocuration,,,BAO_0000100,
13439,,,P,Calculated partition coefficient (clogP),,CHEMBL625053,,0,1,U,22229,Autocuration,,,BAO_0000100,
13440,,,A,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,CHEMBL623250,,0,1,U,22224,Autocuration,,,BAO_0000019,
13441,,,A,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,CHEMBL623251,,0,1,U,22224,Autocuration,,,BAO_0000019,
13442,,,A,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,CHEMBL623252,,0,1,U,22224,Autocuration,,,BAO_0000019,
13443,,,A,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,CHEMBL623253,,0,1,U,22224,Autocuration,,,BAO_0000019,
13444,,,A,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,CHEMBL623254,,0,1,U,22224,Autocuration,,,BAO_0000019,
13445,,,A,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,CHEMBL623255,,0,1,U,22224,Autocuration,,,BAO_0000019,
13446,,,A,Percent degradation of compound at a pH of 1 over a 18 hr period,,CHEMBL626831,,0,1,U,22224,Autocuration,,,BAO_0000019,
13447,,,A,Percent degradation of compound at pH of 1 over an 18 hr period,,CHEMBL877494,,0,1,U,22224,Autocuration,,,BAO_0000019,
13448,,,A,Delta Logarithm of Partition Coefficient value was determined.,,CHEMBL626832,,0,1,U,22224,Autocuration,,,BAO_0000019,
13449,,,A,Delta logPoct-cyc,,CHEMBL626833,,0,1,U,22224,Autocuration,,,BAO_0000019,
13450,,,P,Lipophilicity estimated on reversed phase TLC,,CHEMBL626834,,0,1,U,22224,Autocuration,,,BAO_0000100,
13451,,,A,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,CHEMBL626835,,0,1,U,22224,Autocuration,,,BAO_0000019,
13452,,,A,Delta logPoct-cyc,,CHEMBL626836,,0,1,U,22224,Autocuration,,,BAO_0000019,
13453,,,P,Change in logarithm of partition coefficient of the compound,,CHEMBL626837,,0,1,U,22229,Autocuration,,,BAO_0000100,
13454,,,A,Delta logD (pH 6.5),,CHEMBL626838,,0,1,U,22224,Autocuration,,,BAO_0000019,
13455,,,P,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,CHEMBL626839,,0,1,U,22224,Autocuration,,,BAO_0000100,
13456,,,A,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,CHEMBL626840,,0,1,U,22224,Autocuration,,,BAO_0000019,
13457,,,A,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,CHEMBL626841,,0,1,U,22224,Autocuration,,,BAO_0000019,
13458,,,A,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,CHEMBL626842,,0,1,U,22224,Autocuration,,,BAO_0000219,
13459,,,A,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,CHEMBL626843,,0,1,U,22224,Autocuration,,,BAO_0000219,
13460,Rattus norvegicus,,A,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,CHEMBL626844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13461,Rattus norvegicus,,A,Amount of deuterium retained was reported after normal workup in rats,,CHEMBL877495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13462,Rattus norvegicus,,A,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,CHEMBL626845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13463,Rattus norvegicus,,A,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,CHEMBL626846,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13464,Rattus norvegicus,,A,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,CHEMBL626847,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13465,Rattus norvegicus,,A,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,CHEMBL628677,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13466,Rattus norvegicus,,A,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,CHEMBL628678,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13467,,,A,Compound was subjected to electrochemical oxidation,,CHEMBL628679,,0,1,U,22224,Autocuration,,,BAO_0000019,
13468,,,A,Compound was subjected to photochemical oxidation,,CHEMBL628680,,0,1,U,22224,Autocuration,,,BAO_0000019,
13469,,,A,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,CHEMBL628681,,0,1,U,22224,Autocuration,,,BAO_0000019,
13470,,,A,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,CHEMBL628682,,0,1,U,22224,Autocuration,,,BAO_0000019,
13471,,,A,Oxidation of compound by methemoglobin in presence of hydroperoxide,,CHEMBL628683,,0,1,U,22224,Autocuration,,,BAO_0000019,
13472,Rattus norvegicus,,A,Percent diffusion through fuzzy rat skin after 48 h of incubation,,CHEMBL628684,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13473,,,P,Dissociation constant (pKa),,CHEMBL877501,,0,1,U,22229,Autocuration,,,BAO_0000100,
13474,,,P,Dissociation constant value of the compound; ND means not determined.,,CHEMBL628685,,0,1,U,22224,Autocuration,,,BAO_0000100,
13475,Rattus norvegicus,,A,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,CHEMBL628686,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13476,Rattus norvegicus,,A,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL628687,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13477,Rattus norvegicus,,A,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,CHEMBL628688,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13478,Rattus norvegicus,,A,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL628689,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13479,Rattus norvegicus,,A,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,CHEMBL628690,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13480,Rattus norvegicus,,A,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,CHEMBL629363,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13481,Rattus norvegicus,,A,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,CHEMBL629364,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13482,Rattus norvegicus,,A,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL629365,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13483,Rattus norvegicus,,A,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,CHEMBL629366,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13484,Rattus norvegicus,,A,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,CHEMBL629367,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13485,Rattus norvegicus,,A,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL629368,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
13486,Rattus norvegicus,,A,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,CHEMBL877502,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13487,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,CHEMBL629369,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2037.0
13488,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,CHEMBL629370,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
13489,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,CHEMBL629371,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13490,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,CHEMBL626276,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13491,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,CHEMBL626277,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13492,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,CHEMBL631250,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13493,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,CHEMBL631251,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13494,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,CHEMBL631252,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13495,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,CHEMBL631253,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13496,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,CHEMBL631254,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13497,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,CHEMBL631255,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13498,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,CHEMBL631256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13499,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,CHEMBL631257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13500,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,CHEMBL628009,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13501,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,CHEMBL628010,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13502,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,CHEMBL628011,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13503,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,CHEMBL628012,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13504,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,CHEMBL628013,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13505,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,CHEMBL628014,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13506,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,CHEMBL628015,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13507,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,CHEMBL628016,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13508,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,CHEMBL874461,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13509,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,CHEMBL628017,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13510,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,CHEMBL628018,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13511,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,CHEMBL628019,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13512,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,CHEMBL628020,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13513,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,CHEMBL628021,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13514,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,CHEMBL628022,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13515,Canis lupus familiaris,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,CHEMBL628023,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13516,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,CHEMBL628024,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13517,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,CHEMBL628025,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13518,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,CHEMBL628026,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13519,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,CHEMBL628027,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13520,Simiiformes,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,CHEMBL628028,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
13521,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,CHEMBL628029,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13522,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,CHEMBL628030,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13523,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,CHEMBL628031,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13524,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,CHEMBL628032,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13525,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,CHEMBL628033,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13526,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,CHEMBL628034,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13527,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,CHEMBL628035,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13528,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,CHEMBL628036,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13529,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,CHEMBL874462,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13530,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,CHEMBL628037,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13531,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,CHEMBL628123,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13532,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,CHEMBL628124,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13533,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,CHEMBL628125,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13534,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,CHEMBL628126,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13535,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,CHEMBL628127,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13536,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,CHEMBL628128,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13537,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,CHEMBL628129,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13538,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,CHEMBL628130,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13539,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,CHEMBL628131,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13540,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,CHEMBL628132,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13541,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,CHEMBL628133,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13542,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,CHEMBL628134,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13543,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,CHEMBL628135,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13544,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,CHEMBL628136,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13545,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,CHEMBL628137,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13546,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,CHEMBL628138,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13547,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,CHEMBL628139,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13548,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,CHEMBL628140,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13549,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,CHEMBL628141,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13550,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,CHEMBL628142,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13551,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,CHEMBL628143,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13552,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,CHEMBL628144,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13553,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,CHEMBL628145,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13554,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,CHEMBL628146,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13555,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,CHEMBL625355,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13556,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,CHEMBL625356,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13557,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,CHEMBL625357,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13558,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,CHEMBL625527,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13559,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,CHEMBL875473,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13560,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,CHEMBL625528,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13561,Rattus norvegicus,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,CHEMBL626304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13562,Canis lupus familiaris,,A,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,CHEMBL624138,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1637.0
13563,,,P,Calculated partition coefficient (clogP),,CHEMBL624139,,0,1,U,22229,Autocuration,,,BAO_0000100,
13564,,,P,Calculated partition coefficient (clogP),,CHEMBL624140,,0,1,U,22229,Autocuration,,,BAO_0000100,
13565,,,P,Calculated partition coefficient (clogP),,CHEMBL624141,,0,1,U,22229,Autocuration,,,BAO_0000100,
13566,,,P,Calculated partition coefficient (clogP),,CHEMBL624142,,0,1,U,22229,Autocuration,,,BAO_0000100,
13567,,,P,Calculated partition coefficient (clogP),,CHEMBL624143,,0,1,U,22229,Autocuration,,,BAO_0000100,
13568,,,P,Calculated partition coefficient (clogP),,CHEMBL624144,,0,1,U,22229,Autocuration,,,BAO_0000100,
13569,,,P,Calculated partition coefficient (clogP),,CHEMBL624145,,0,1,U,22229,Autocuration,,,BAO_0000100,
13570,,,P,Calculated partition coefficient (clogP),,CHEMBL624146,,0,1,U,22229,Autocuration,,,BAO_0000100,
13571,,,P,Calculated partition coefficient (clogP),,CHEMBL624147,,0,1,U,22229,Autocuration,,,BAO_0000100,
13572,,,P,Calculated partition coefficient (clogP) (MacLogP),,CHEMBL883123,,0,1,U,22229,Autocuration,,,BAO_0000100,
13573,,,A,Partition coefficient (logP),,CHEMBL624148,,0,1,U,22224,Autocuration,,,BAO_0000019,
13574,,,A,Kinetic parameter was determined,,CHEMBL874416,,0,1,U,22224,Autocuration,,,BAO_0000019,
13575,,,P,Calculated partition coefficient (clogP),,CHEMBL624149,,0,1,U,22229,Autocuration,,,BAO_0000100,
13576,,,P,Calculated partition coefficient (clogP),,CHEMBL624150,,0,1,U,22229,Autocuration,,,BAO_0000100,
13577,,,P,Lipophilicity was determined,,CHEMBL624151,,0,1,U,22224,Autocuration,,,BAO_0000100,
13578,,,P,Lipophilicity was determined,,CHEMBL624152,,0,1,U,22224,Autocuration,,,BAO_0000100,
13579,,,P,Lipophilicity was determined,,CHEMBL622139,,0,1,U,22224,Autocuration,,,BAO_0000100,
13580,,,P,Calculated partition coefficient (clogP),,CHEMBL622140,,0,1,U,22229,Autocuration,,,BAO_0000100,
13581,,,P,Lipophilicity was determined,,CHEMBL622141,,0,1,U,22224,Autocuration,,,BAO_0000100,
13582,,,P,Lipophilicity in octanol-water,,CHEMBL622142,,0,1,U,22224,Autocuration,,,BAO_0000100,
13583,,,P,Calculated partition coefficient (clogP),,CHEMBL622143,,0,1,U,22229,Autocuration,,,BAO_0000100,
13584,,,P,Octanol-water partition coefficient was determined,,CHEMBL622144,,0,1,U,22229,Autocuration,,,BAO_0000100,
13585,,,A,Partition coefficient (logP),,CHEMBL877473,,0,1,U,22224,Autocuration,,,BAO_0000019,
13586,,,P,Calculated partition coefficient (clogP),,CHEMBL622145,,0,1,U,22229,Autocuration,,,BAO_0000100,
13587,,,A,Partition coefficient was determined; ND means not determined,,CHEMBL622146,,0,1,U,22224,Autocuration,,,BAO_0000019,
13588,,,P,Calculated partition coefficient (clogP),,CHEMBL622147,,0,1,U,22229,Autocuration,,,BAO_0000100,
13589,,,A,Partition coefficient of the compound,,CHEMBL622148,,0,1,U,22224,Autocuration,,,BAO_0000019,
13590,,,A,Permeability was determined,,CHEMBL883124,,0,1,U,22224,Autocuration,,,BAO_0000019,
13591,,,P,The compound was evaluated for the partition coefficient,,CHEMBL622149,,0,1,U,22229,Autocuration,,,BAO_0000100,
13592,,,A,Partition coefficient (logP),,CHEMBL622150,,0,1,U,22224,Autocuration,,,BAO_0000019,
13593,,,P,The lipophilicity was reported,,CHEMBL622151,,0,1,U,22224,Autocuration,,,BAO_0000100,
13594,,,P,logarithm of the octanol-water partition coefficient for the compound,,CHEMBL622152,,0,1,U,22229,Autocuration,,,BAO_0000100,
13595,,,A,Clogp value was determined,,CHEMBL622153,,0,1,U,22224,Autocuration,,,BAO_0000019,
13596,,,A,Clp at a dose of 1.5 mg/kg,,CHEMBL877474,,0,1,U,22224,Autocuration,,,BAO_0000218,
13597,,,A,Clp at a dose of 2.0 mg/kg,,CHEMBL622154,,0,1,U,22224,Autocuration,,,BAO_0000218,
13598,,,A,"Clp, plasma clearance at a dose of 10 mg/kg",,CHEMBL622155,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
13599,,,A,"Clp, plasma clearance at a dose of 50 mg/kg",,CHEMBL622156,,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
13600,Rattus norvegicus,,A,Compound was tested for plasma clearance in rat,,CHEMBL622157,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13601,Rattus norvegicus,,A,Compound was tested for plasma clearance in rat; Not determined,,CHEMBL622158,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13602,Rattus norvegicus,,A,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,CHEMBL622807,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13603,Macaca mulatta,,A,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,CHEMBL622808,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
13604,,,A,Plasma clearance by iv administration at a dose 0.003 ug/mL,,CHEMBL622809,,0,1,U,22224,Autocuration,,,BAO_0000218,
13605,,,A,Plasma clearance determined,,CHEMBL622810,,0,1,U,22224,Autocuration,,,BAO_0000218,
13606,Cricetinae,,A,Plasma clearance after iv administration at 3 mg/kg in hamster,,CHEMBL876653,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
13607,Cricetinae,,A,Plasma clearance after iv administration at 4 mg/kg in hamster,,CHEMBL622811,10026.0,1,1,N,100712,Intermediate,,,BAO_0000218,
13608,Rattus norvegicus,,A,Rate of clearance in rat was determined,,CHEMBL622986,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13609,Rattus norvegicus,,A,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,CHEMBL622987,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13610,Rattus norvegicus,,A,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,CHEMBL622988,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13611,Rattus norvegicus,,A,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,CHEMBL622989,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13612,Rattus norvegicus,,A,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,CHEMBL622990,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13613,Simiiformes,,A,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,CHEMBL622991,314293.0,0,1,U,22224,Autocuration,,,BAO_0000218,1969.0
13614,Rattus norvegicus,,A,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,CHEMBL622227,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
13615,Canis lupus familiaris,,A,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,CHEMBL622228,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
13616,Rattus norvegicus,,A,Clpl value in rat,,CHEMBL622229,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13617,Cavia porcellus,,A,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,CHEMBL622230,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,
13618,Rattus norvegicus,,A,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,CHEMBL622231,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13619,Macaca fascicularis,,A,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,CHEMBL622232,9541.0,1,1,N,100710,Intermediate,,,BAO_0000218,
13620,,,A,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,CHEMBL622233,,0,1,U,22224,Autocuration,,,BAO_0000218,
13621,,,A,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,CHEMBL622234,,0,1,U,22224,Autocuration,,,BAO_0000218,
13622,,,A,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,CHEMBL622235,,0,1,U,22224,Autocuration,,,BAO_0000218,
13623,,,A,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,CHEMBL622236,,0,1,U,22224,Autocuration,,,BAO_0000218,
13624,,,A,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,CHEMBL622237,,0,1,U,22224,Autocuration,,,BAO_0000218,
13625,,,A,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,CHEMBL877482,,0,1,U,22224,Autocuration,,,BAO_0000218,
13626,,,A,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,CHEMBL622238,,0,1,U,22224,Autocuration,,,BAO_0000218,
13627,,,A,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,CHEMBL622239,,0,1,U,22224,Autocuration,,,BAO_0000218,
13628,,,A,Cmax was calculated as maximum concentration reached in the blood,,CHEMBL622240,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
13629,,,A,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,CHEMBL622241,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
13630,Rattus norvegicus,,A,Cmax was determine after peroral administration at 10 mpk in Rat,,CHEMBL631013,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13631,Macaca mulatta,,A,Cmax was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL631014,9544.0,1,1,N,50797,Intermediate,,,BAO_0000218,
13632,Canis lupus familiaris,,A,Cmax was determine after peroral administration at 10 mpk in dog,,CHEMBL631015,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13633,Rattus norvegicus,,A,Cmax was determine after peroral administration at 160 mpk in Rat,,CHEMBL631016,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13634,Rattus norvegicus,,A,Cmax was determine after peroral administration at 20 mpk in Rat,,CHEMBL631017,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13635,Rattus norvegicus,,A,Cmax was determine after peroral administration at 50 mpk in Rat,,CHEMBL631018,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13636,,,A,Cmax was determined,,CHEMBL631019,,0,1,U,22224,Autocuration,,,BAO_0000218,
13637,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,CHEMBL875761,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
13638,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,CHEMBL631020,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
13639,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,CHEMBL631669,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
13640,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,CHEMBL631670,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
13641,Mus musculus,,A,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,CHEMBL631671,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2435.0
13642,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,CHEMBL631672,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13643,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,CHEMBL631673,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13644,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,CHEMBL631856,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13645,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,CHEMBL631857,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13646,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,CHEMBL631858,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13647,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,CHEMBL631859,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13648,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,CHEMBL631860,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13649,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,CHEMBL631861,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13650,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,CHEMBL631862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13651,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,CHEMBL631863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13652,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,CHEMBL631864,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13653,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,CHEMBL631865,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13654,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,CHEMBL631866,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13655,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,CHEMBL629360,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13656,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,CHEMBL629361,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13657,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,CHEMBL629362,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13658,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,CHEMBL630740,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13659,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,CHEMBL630741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13660,Rattus norvegicus,,A,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,CHEMBL630742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13661,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,CHEMBL630743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13662,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,CHEMBL630744,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13663,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,CHEMBL630745,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13664,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,CHEMBL630746,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13665,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,CHEMBL630747,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13666,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,CHEMBL630748,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13667,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,CHEMBL632056,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13668,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,CHEMBL632057,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13669,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,CHEMBL632058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13670,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,CHEMBL632059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13671,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,CHEMBL632060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13672,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,CHEMBL632061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13673,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,CHEMBL629207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13674,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,CHEMBL629208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13675,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,CHEMBL629209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13676,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,CHEMBL629210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13677,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,CHEMBL629211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13678,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,CHEMBL629212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13679,Rattus norvegicus,,A,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,CHEMBL629213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13680,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,CHEMBL629214,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13681,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,CHEMBL629215,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13682,Rattus norvegicus,,A,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,CHEMBL635154,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13683,Rattus norvegicus,,A,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL629216,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13684,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,CHEMBL629217,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13685,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL629218,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13686,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,CHEMBL629219,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13687,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL629220,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13688,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,CHEMBL629221,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13689,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL631127,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13690,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,CHEMBL631128,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13691,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL631129,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13692,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,CHEMBL631130,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13693,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL631131,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13694,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,CHEMBL631132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13695,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL631133,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13696,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,CHEMBL631134,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13697,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL875120,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13698,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,CHEMBL631135,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13699,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL631136,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13700,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,CHEMBL631137,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13701,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL631138,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13702,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,CHEMBL631139,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13703,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL631140,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13704,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL631141,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13705,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL631142,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13706,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,CHEMBL631143,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13707,Rattus norvegicus,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL631144,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13708,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,CHEMBL631145,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13709,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,CHEMBL631146,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13710,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,CHEMBL631147,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13711,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,CHEMBL631148,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13712,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,CHEMBL631149,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13713,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,CHEMBL631150,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13714,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,CHEMBL631151,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13715,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,CHEMBL631152,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13716,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,CHEMBL631443,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13717,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,CHEMBL631444,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13718,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL631445,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13719,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,CHEMBL631446,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13720,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,CHEMBL631447,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13721,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,CHEMBL631448,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13722,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,CHEMBL631449,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13723,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,CHEMBL631450,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13724,Canis lupus familiaris,,A,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL629724,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
13725,Mus musculus,,A,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL629725,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
13726,Mus musculus,,A,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL629726,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,14.0
13727,Mus musculus,,A,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL629727,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
13728,Mus musculus,,A,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630404,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
13729,Mus musculus,,A,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630405,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
13730,Mus musculus,,A,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630406,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
13731,Mus musculus,,A,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630407,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
13732,Mus musculus,,A,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630573,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
13733,Mus musculus,,A,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630574,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
13734,Mus musculus,,A,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630575,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
13735,Mus musculus,,A,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630576,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13736,Mus musculus,,A,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630577,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13737,Mus musculus,,A,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630578,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13738,Mus musculus,,A,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630579,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13739,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,CHEMBL630580,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
13740,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,CHEMBL630581,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
13741,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,CHEMBL630582,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
13742,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,CHEMBL630583,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13743,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,CHEMBL630584,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13744,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,CHEMBL630585,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13745,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,CHEMBL630586,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13746,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,CHEMBL630587,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13747,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,CHEMBL630588,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13748,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,CHEMBL630589,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13749,Mus musculus,,A,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,CHEMBL630590,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13750,,,A,Removal of 238-Plutonium(IV) in feces at 24 h,,CHEMBL630591,,0,1,U,22224,Autocuration,,,BAO_0000019,1988.0
13751,,,A,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,CHEMBL630592,,0,1,U,22224,Autocuration,,,BAO_0000019,1988.0
13752,,,A,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,CHEMBL630593,,0,1,U,22224,Autocuration,,,BAO_0000019,
13753,,,A,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,CHEMBL630594,,0,1,U,22224,Autocuration,,,BAO_0000019,
13754,,,A,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,CHEMBL630595,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13755,,,A,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,CHEMBL630596,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13756,,,A,Removal of 238-Plutonium(IV) in urine after 0-24 h,,CHEMBL630597,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13757,,,A,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,CHEMBL630598,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13758,,,A,Removal of 238-Plutonium(IV) in urine after 0-4 h,,CHEMBL630599,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13759,,,A,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,CHEMBL630600,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13760,,,A,Removal of 238-Plutonium(IV) in urine after 4-24 h,,CHEMBL630601,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13761,,,A,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,CHEMBL630602,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13762,,,A,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,CHEMBL630603,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13763,,,A,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,CHEMBL630604,,0,1,U,22224,Autocuration,,,BAO_0000019,1088.0
13764,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL624869,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13765,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL624870,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13766,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL623189,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13767,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623190,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13768,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623191,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13769,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623192,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13770,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623193,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13771,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL623194,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13772,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623195,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13773,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623196,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13774,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,CHEMBL623197,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13775,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623198,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13776,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,CHEMBL623199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13777,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,CHEMBL623200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13778,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,CHEMBL623201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13779,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,CHEMBL623202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13780,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13781,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,CHEMBL623204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13782,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,CHEMBL623205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13783,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,CHEMBL623206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13784,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,CHEMBL623207,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13785,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,CHEMBL623208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13786,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13787,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,CHEMBL623210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13788,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13789,Rattus norvegicus,,A,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,CHEMBL623212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
13790,,,A,Tested in vitro for intrinsic activity relative to quinpirole,,CHEMBL623213,,0,1,U,22224,Autocuration,,,BAO_0000019,
13791,,,A,"Relative ion enhancement, determined in pulsed ultrafiltration",,CHEMBL623214,,0,1,U,22224,Autocuration,,,BAO_0000019,
13792,,,A,% ionization at the pH 7.4 at 37 degree Centigrade,,CHEMBL623215,,0,1,U,22224,Autocuration,,,BAO_0000019,
13793,,,A,Percentage ionization was measured,,CHEMBL623216,,0,1,U,22224,Autocuration,,,BAO_0000019,
13794,Bos taurus,,A,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,CHEMBL623217,9913.0,1,1,N,50591,Intermediate,,,BAO_0000218,
13795,,,A,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,CHEMBL623218,,0,1,U,22224,Autocuration,,,BAO_0000019,
13796,,,A,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,CHEMBL623913,,0,1,U,22224,Autocuration,,,BAO_0000019,
13797,,,A,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,CHEMBL623914,,0,1,U,22224,Autocuration,,,BAO_0000019,
13798,,,P,Compound was evaluated for the partition coefficient in octanol/water,,CHEMBL623915,,0,1,U,22229,Autocuration,,,BAO_0000100,
13799,,,P,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,CHEMBL624080,,0,1,U,22229,Autocuration,,,BAO_0000100,
13800,,,A,Equilibrium constant measured by the pulse radiolysis at pH 7,,CHEMBL624081,,0,1,U,22224,Autocuration,,,BAO_0000019,
13801,Homo sapiens,,A,In vitro hydrolytic rate constant determined in human blood,,CHEMBL624082,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
13802,Homo sapiens,,A,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,CHEMBL625054,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
13803,,,A,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,CHEMBL877485,,0,1,U,22224,Autocuration,,,BAO_0000019,
13804,Mus musculus,,A,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,CHEMBL625055,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13805,Mus musculus,,A,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,CHEMBL625056,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13806,Homo sapiens,,A,In vitro oxidation of compound in presence of human plasma,,CHEMBL625057,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
13807,,,A,In vitro oxidation of compound in presence of hydrogen peroxide,,CHEMBL625058,,0,1,U,22224,Autocuration,,,BAO_0000019,
13808,Mus musculus,,A,In vitro oxidation of compound in presence of mouse brain homogenate,,CHEMBL625059,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13809,Mus musculus,,A,In vitro oxidation of compound in presence of mouse liver homogenate,,CHEMBL629536,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13810,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,CHEMBL629537,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13811,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,CHEMBL629538,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13812,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,CHEMBL629539,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13813,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,CHEMBL874445,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13814,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,CHEMBL629540,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13815,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,CHEMBL629541,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13816,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,CHEMBL629542,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13817,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,CHEMBL630243,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13818,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,CHEMBL630244,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13819,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,CHEMBL630245,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13820,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,CHEMBL630246,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13821,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,CHEMBL630247,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13822,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,CHEMBL630248,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13823,Rattus norvegicus,,A,Biodistribution in rat blood at 240 minutes after dose administration.,,CHEMBL630249,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13824,Rattus norvegicus,,A,Biodistribution in rat blood at 30 minutes after dose administration.,,CHEMBL630250,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13825,Rattus norvegicus,,A,Biodistribution in rat blood at 360 minutes after dose administration.,,CHEMBL630251,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13826,Rattus norvegicus,,A,Biodistribution in rat blood at 3 hr after dose administration.,,CHEMBL630252,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13827,Rattus norvegicus,,A,Biodistribution in rat blood at 60 minutes after dose administration.,,CHEMBL630408,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
13828,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,CHEMBL630409,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13829,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,CHEMBL874446,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13830,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,CHEMBL630410,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13831,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,CHEMBL630411,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13832,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,CHEMBL630412,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13833,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,CHEMBL630413,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13834,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 3 hr after dose administration.,,CHEMBL630414,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13835,Rattus norvegicus,,A,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,CHEMBL630415,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
13836,Rattus norvegicus,,A,Biodistribution in rat cortex at 120 minutes after dose administration.,,CHEMBL630416,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13837,Rattus norvegicus,,A,Biodistribution in rat cortex at 1440 minutes after dose administration.,,CHEMBL630417,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13838,Rattus norvegicus,,A,Biodistribution in rat cortex at 15 minutes after dose administration.,,CHEMBL630418,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13839,Rattus norvegicus,,A,Biodistribution in rat cortex at 240 minutes after dose administration.,,CHEMBL630419,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13840,Rattus norvegicus,,A,Biodistribution in rat cortex at 30 minutes after dose administration.,,CHEMBL630420,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13841,Rattus norvegicus,,A,Biodistribution in rat cortex at 360 minutes after dose administration.,,CHEMBL630421,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13842,Rattus norvegicus,,A,Biodistribution in rat cortex at 3 hr after dose administration.,,CHEMBL630422,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13843,Rattus norvegicus,,A,Biodistribution in rat cortex at 60 minutes after dose administration.,,CHEMBL630423,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13844,Rattus norvegicus,,A,Biodistribution in rat heart at 120 minutes after dose administration.,,CHEMBL630424,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13845,Rattus norvegicus,,A,Biodistribution in rat heart at 15 minutes after dose administration.,,CHEMBL630425,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13846,Rattus norvegicus,,A,Biodistribution in rat heart at 240 minutes after dose administration.,,CHEMBL629462,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13847,Rattus norvegicus,,A,Biodistribution in rat heart at 30 minutes after dose administration.,,CHEMBL630426,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13848,Rattus norvegicus,,A,Biodistribution in rat heart at 360 minutes after dose administration.,,CHEMBL630427,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13849,Rattus norvegicus,,A,Biodistribution in rat heart at 3 hr after dose administration.,,CHEMBL625877,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13850,Rattus norvegicus,,A,Biodistribution in rat heart at 60 minutes after dose administration.,,CHEMBL625878,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
13851,Rattus norvegicus,,A,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,CHEMBL625879,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
13852,Rattus norvegicus,,A,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,CHEMBL625880,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
13853,Rattus norvegicus,,A,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,CHEMBL625881,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
13854,Rattus norvegicus,,A,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,CHEMBL625882,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
13855,Rattus norvegicus,,A,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,CHEMBL625883,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
13856,Rattus norvegicus,,A,Biodistribution in rat kidney at 120 minutes after dose administration.,,CHEMBL625884,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13857,Rattus norvegicus,,A,Biodistribution in rat kidney at 1440 minutes after dose administration.,,CHEMBL625885,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13858,Rattus norvegicus,,A,Biodistribution in rat kidney at 15 minutes after dose administration.,,CHEMBL628649,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13859,Rattus norvegicus,,A,Biodistribution in rat kidney at 240 minutes after dose administration.,,CHEMBL628650,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13860,Rattus norvegicus,,A,Biodistribution in rat kidney at 30 minutes after dose administration.,,CHEMBL628651,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13861,Rattus norvegicus,,A,Biodistribution in rat kidney at 360 minutes after dose administration.,,CHEMBL628652,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13862,Rattus norvegicus,,A,Biodistribution in rat kidney at 60 minutes after dose administration.,,CHEMBL628653,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13863,Rattus norvegicus,,A,Biodistribution in rat liver at 120 minutes after dose administration.,,CHEMBL628654,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13864,Rattus norvegicus,,A,Biodistribution in rat liver at 1440 minutes after dose administration.,,CHEMBL628655,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13865,Rattus norvegicus,,A,Biodistribution in rat liver at 15 minutes after dose administration.,,CHEMBL625238,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13866,Rattus norvegicus,,A,Biodistribution in rat liver at 240 minutes after dose administration.,,CHEMBL625239,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13867,Rattus norvegicus,,A,Biodistribution in rat liver at 30 minutes after dose administration.,,CHEMBL625240,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13868,Rattus norvegicus,,A,Biodistribution in rat liver at 360 minutes after dose administration.,,CHEMBL625241,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13869,Rattus norvegicus,,A,Biodistribution in rat liver at 60 minutes after dose administration.,,CHEMBL625242,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13870,Rattus norvegicus,,A,Biodistribution in rat lung at 120 minutes after dose administration.,,CHEMBL874587,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13871,Rattus norvegicus,,A,Biodistribution in rat lung at 1440 minutes after dose administration.,,CHEMBL625405,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13872,Rattus norvegicus,,A,Biodistribution in rat lung at 15 minutes after dose administration.,,CHEMBL625406,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13873,Rattus norvegicus,,A,Biodistribution in rat lung at 240 minutes after dose administration.,,CHEMBL625407,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13874,Rattus norvegicus,,A,Biodistribution in rat lung at 30 minutes after dose administration.,,CHEMBL625408,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13875,Rattus norvegicus,,A,Biodistribution in rat lung at 360 minutes after dose administration.,,CHEMBL625409,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13876,Rattus norvegicus,,A,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,CHEMBL625410,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13877,Rattus norvegicus,,A,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,CHEMBL625411,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13878,Rattus norvegicus,,A,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,CHEMBL625412,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13879,Rattus norvegicus,,A,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,CHEMBL625413,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13880,Rattus norvegicus,,A,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,CHEMBL625414,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13881,Rattus norvegicus,,A,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,CHEMBL625415,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13882,Rattus norvegicus,,A,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,CHEMBL625416,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1515.0
13883,Rattus norvegicus,,A,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,CHEMBL625417,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13884,Rattus norvegicus,,A,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,CHEMBL625418,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
13885,Rattus norvegicus,,A,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,CHEMBL625419,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13886,Rattus norvegicus,,A,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,CHEMBL625420,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13887,Rattus norvegicus,,A,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,CHEMBL626996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13888,Rattus norvegicus,,A,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,CHEMBL626997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
13889,Rattus norvegicus,,A,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,CHEMBL626998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
13890,Rattus norvegicus,,A,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,CHEMBL626999,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13891,Mus musculus,,A,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,CHEMBL627000,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13892,Mus musculus,,A,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,CHEMBL627001,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13893,Mus musculus,,A,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,CHEMBL627002,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13894,Mus musculus,,A,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,CHEMBL627003,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
13895,Mus musculus,,A,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,CHEMBL627004,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13896,Mus musculus,,A,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,CHEMBL627005,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13897,Mus musculus,,A,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,CHEMBL874594,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13898,Mus musculus,,A,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,CHEMBL627006,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13899,Mus musculus,,A,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,CHEMBL627007,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13900,Mus musculus,,A,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,CHEMBL627884,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13901,Mus musculus,,A,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,CHEMBL627885,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13902,Mus musculus,,A,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,CHEMBL627886,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13903,Mus musculus,,A,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,CHEMBL627887,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13904,Mus musculus,,A,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,CHEMBL627888,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13905,Mus musculus,,A,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,CHEMBL628057,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13906,Mus musculus,,A,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,CHEMBL627405,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
13907,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,CHEMBL627406,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13908,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,CHEMBL627407,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13909,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,CHEMBL627408,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13910,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,CHEMBL627409,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13911,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,CHEMBL875486,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13912,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,CHEMBL627410,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13913,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,CHEMBL627411,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13914,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,CHEMBL627412,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13915,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,CHEMBL627413,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13916,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,CHEMBL627414,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13917,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,CHEMBL627415,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13918,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,CHEMBL627416,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13919,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,CHEMBL627417,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13920,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,CHEMBL627418,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13921,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,CHEMBL627419,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13922,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,CHEMBL627320,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13923,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,CHEMBL627321,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
13924,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627322,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13925,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627323,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13926,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL627491,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13927,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627492,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13928,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627493,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
13929,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13930,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627495,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13931,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL627496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13932,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13933,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627498,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
13934,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627499,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13935,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627500,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13936,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL627501,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13937,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625616,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13938,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625617,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
13939,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625618,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13940,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625619,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13941,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL625620,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13942,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625621,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13943,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625622,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
13944,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625788,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13945,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13946,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL625790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13947,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13948,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622334,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13949,Rattus norvegicus,,A,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622335,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
13950,Rattus norvegicus,,A,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622336,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
13951,Rattus norvegicus,,A,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL622337,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
13952,Rattus norvegicus,,A,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622338,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
13953,Rattus norvegicus,,A,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622339,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
13954,Rattus norvegicus,,A,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL624153,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13955,Rattus norvegicus,,A,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL628430,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13956,Rattus norvegicus,,A,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL628431,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13957,Rattus norvegicus,,A,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL628432,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13958,Rattus norvegicus,,A,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL628433,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13959,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL628434,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13960,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626789,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13961,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,CHEMBL626790,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13962,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626791,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13963,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626792,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13964,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626793,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
13965,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,CHEMBL627436,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13966,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,CHEMBL627437,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13967,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,CHEMBL627438,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13968,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,CHEMBL627439,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13969,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,CHEMBL627440,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13970,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,CHEMBL627602,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13971,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,CHEMBL627603,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13972,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,CHEMBL627604,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13973,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,CHEMBL627605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13974,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,CHEMBL627606,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13975,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,CHEMBL627607,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13976,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,CHEMBL627608,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13977,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,CHEMBL627609,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13978,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,CHEMBL627610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13979,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,CHEMBL627611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13980,Rattus norvegicus,,A,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,CHEMBL627612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
13981,,,P,Octanol:water partition coefficient is evaluated,,CHEMBL627613,,0,1,U,22229,Autocuration,,,BAO_0000100,
13982,,,P,Partition coefficient in 1-octanol/water system,,CHEMBL627614,,0,1,U,22224,Autocuration,,,BAO_0000100,
13983,,,P,Partition coefficient in 1-octanol/water system measured using radio active compounds,,CHEMBL627615,,0,1,U,22224,Autocuration,,,BAO_0000100,
13984,,,P,Partition coefficient in octanol/water system was determined,,CHEMBL627616,,0,1,U,22224,Autocuration,,,BAO_0000100,
13985,,,P,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,CHEMBL627617,,0,1,U,22224,Autocuration,,,BAO_0000100,
13986,,,A,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,CHEMBL627618,,0,1,U,22224,Autocuration,,,BAO_0000019,
13987,,,A,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,CHEMBL627619,,0,1,U,22224,Autocuration,,,BAO_0000019,
13988,,,A,Pseudo-first-order rate constant of the compound,,CHEMBL627620,,0,1,U,22224,Autocuration,,,BAO_0000019,
13989,,,A,Pseudo-first-order rate constant with 1-min time point,,CHEMBL627621,,0,1,U,22224,Autocuration,,,BAO_0000019,
13990,,,A,Pseudo-first-order rate constant without 1-min time point,,CHEMBL627622,,0,1,U,22224,Autocuration,,,BAO_0000019,
13991,,,A,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,CHEMBL627623,,0,1,U,22224,Autocuration,,,BAO_0000019,
13992,,,A,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,CHEMBL627624,,0,1,U,22224,Autocuration,,,BAO_0000019,
13993,,,A,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,CHEMBL627625,,0,1,U,22224,Autocuration,,,BAO_0000019,
13994,,,A,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,CHEMBL628523,,0,1,U,22224,Autocuration,,,BAO_0000019,
13995,,,A,The alkaline hydrolysis second order rate constant(K OH) of the compound,,CHEMBL628524,,0,1,U,22224,Autocuration,,,BAO_0000019,
13996,,,A,The efflux rate constant of the compound,,CHEMBL628525,,0,1,U,22224,Autocuration,,,BAO_0000019,
13997,,,A,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,CHEMBL625732,,0,1,U,22224,Autocuration,,,BAO_0000019,
13998,,,A,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,CHEMBL625733,,0,1,U,22224,Autocuration,,,BAO_0000019,
13999,,,F,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,CHEMBL625734,,0,1,U,22224,Autocuration,,,BAO_0000019,
14000,,,A,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,CHEMBL625913,,0,1,U,22224,Autocuration,,,BAO_0000019,
14001,,,A,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,CHEMBL625914,,0,1,U,22224,Autocuration,,,BAO_0000019,
14002,,,A,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,CHEMBL625915,,0,1,U,22224,Autocuration,,,BAO_0000019,
14003,,,A,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,CHEMBL625916,,0,1,U,22224,Autocuration,,,BAO_0000019,
14004,,,A,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,CHEMBL625917,,0,1,U,22224,Autocuration,,,BAO_0000019,
14005,,,A,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625918,,0,1,U,22224,Autocuration,,,BAO_0000019,
14006,,,A,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625919,,0,1,U,22224,Autocuration,,,BAO_0000019,
14007,,,A,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625920,,0,1,U,22224,Autocuration,,,BAO_0000019,
14008,,,A,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL874453,,0,1,U,22224,Autocuration,,,BAO_0000019,
14009,,,A,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,CHEMBL625921,,0,1,U,22224,Autocuration,,,BAO_0000019,
14010,,,A,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,CHEMBL625922,,0,1,U,22224,Autocuration,,,BAO_0000019,
14011,,,A,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625923,,0,1,U,22224,Autocuration,,,BAO_0000019,
14012,,,A,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625924,,0,1,U,22224,Autocuration,,,BAO_0000019,
14013,,,A,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625925,,0,1,U,22224,Autocuration,,,BAO_0000019,
14014,,,A,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625926,,0,1,U,22224,Autocuration,,,BAO_0000019,
14015,Rattus norvegicus,,A,Biodistribution in rat lung at 60 minutes after dose administration.,,CHEMBL627704,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14016,Rattus norvegicus,,A,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,CHEMBL627705,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14017,Rattus norvegicus,,A,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,CHEMBL627706,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14018,Rattus norvegicus,,A,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,CHEMBL627707,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14019,Rattus norvegicus,,A,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,CHEMBL627708,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14020,Rattus norvegicus,,A,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,CHEMBL628361,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14021,Rattus norvegicus,,A,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,CHEMBL628362,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14022,Rattus norvegicus,,A,Biodistribution in rat striatum at 120 minutes after dose administration.,,CHEMBL628363,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14023,Rattus norvegicus,,A,Biodistribution in rat striatum at 1440 minutes after dose administration.,,CHEMBL628364,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14024,Rattus norvegicus,,A,Biodistribution in rat striatum at 15 minutes after dose administration.,,CHEMBL628365,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14025,Rattus norvegicus,,A,Biodistribution in rat striatum at 240 minutes after dose administration.,,CHEMBL874454,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14026,Rattus norvegicus,,A,Biodistribution in rat striatum at 30 minutes after dose administration.,,CHEMBL628531,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14027,Rattus norvegicus,,A,Biodistribution in rat striatum at 360 minutes after dose administration.,,CHEMBL628532,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14028,Rattus norvegicus,,A,Biodistribution in rat striatum at 3 hr after dose administration.,,CHEMBL628533,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14029,Rattus norvegicus,,A,Biodistribution in rat striatum at 60 minutes after dose administration.,,CHEMBL628534,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2435.0
14030,Rattus norvegicus,,A,Biodistribution in rat thyroid at 120 minutes after dose administration.,,CHEMBL628535,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14031,Rattus norvegicus,,A,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,CHEMBL628536,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14032,Rattus norvegicus,,A,Biodistribution in rat thyroid at 15 minutes after dose administration.,,CHEMBL628537,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14033,Rattus norvegicus,,A,Biodistribution in rat thyroid at 240 minutes after dose administration.,,CHEMBL628538,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14034,Rattus norvegicus,,A,Biodistribution in rat thyroid at 30 minutes after dose administration.,,CHEMBL628539,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14035,Rattus norvegicus,,A,Biodistribution in rat thyroid at 360 minutes after dose administration.,,CHEMBL630297,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14036,Rattus norvegicus,,A,Biodistribution in rat thyroid at 60 minutes after dose administration.,,CHEMBL630298,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14037,Rattus norvegicus,,A,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,CHEMBL630299,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14038,Rattus norvegicus,,A,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,CHEMBL628094,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14039,Rattus norvegicus,,A,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,CHEMBL628095,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14040,Rattus norvegicus,,A,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,CHEMBL874648,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14041,Rattus norvegicus,,A,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,CHEMBL628096,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14042,Rattus norvegicus,,A,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,CHEMBL628097,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14043,Rattus norvegicus,,A,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,CHEMBL628098,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14044,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,CHEMBL628099,,0,1,U,22224,Autocuration,,,BAO_0000019,
14045,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,CHEMBL628100,,0,1,U,22224,Autocuration,,,BAO_0000019,
14046,,,A,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,CHEMBL628101,,0,1,U,22224,Autocuration,,,BAO_0000019,
14047,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,CHEMBL628102,,0,1,U,22224,Autocuration,,,BAO_0000019,
14048,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,CHEMBL628103,,0,1,U,22224,Autocuration,,,BAO_0000019,
14049,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,CHEMBL628104,,0,1,U,22224,Autocuration,,,BAO_0000019,
14050,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,CHEMBL628105,,0,1,U,22224,Autocuration,,,BAO_0000019,
14051,,,A,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,CHEMBL628106,,0,1,U,22224,Autocuration,,,BAO_0000019,
14052,Rattus norvegicus,,A,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,CHEMBL628107,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14053,,,F,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,CHEMBL628108,,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
14054,Rattus norvegicus,,A,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,CHEMBL628109,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14055,,,F,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,CHEMBL625299,,0,1,U,22224,Autocuration,,,BAO_0000218,1088.0
14056,Rattus norvegicus,,A,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,CHEMBL625300,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14057,Rattus norvegicus,,A,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,CHEMBL625301,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14058,Rattus norvegicus,,A,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,CHEMBL625302,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14059,Rattus norvegicus,,A,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,CHEMBL874649,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14060,Rattus norvegicus,,A,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,CHEMBL625303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14061,Rattus norvegicus,,A,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,CHEMBL625463,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14062,Homo sapiens,,A,In vitro metabolism in human liver microsomes,,CHEMBL625464,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,2107.0
14063,Homo sapiens,,A,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,CHEMBL625465,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
14064,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,CHEMBL625466,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14065,Canis lupus familiaris,,A,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,CHEMBL625467,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14066,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,CHEMBL625468,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14067,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,CHEMBL625469,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14068,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,CHEMBL625470,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14069,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,CHEMBL632418,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14070,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,CHEMBL627250,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14071,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,CHEMBL627251,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14072,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,CHEMBL627252,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14073,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,CHEMBL627253,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14074,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,CHEMBL627254,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14075,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,CHEMBL875471,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14076,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,CHEMBL627255,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14077,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,CHEMBL627256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14078,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,CHEMBL627257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14079,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,CHEMBL627258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14080,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,CHEMBL627259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14081,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,CHEMBL627260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14082,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,CHEMBL623256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14083,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,CHEMBL874413,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14084,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,CHEMBL623257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14085,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,CHEMBL623258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14086,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,CHEMBL623259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14087,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,CHEMBL623260,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14088,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,CHEMBL623261,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14089,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,CHEMBL623262,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14090,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,CHEMBL623263,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14091,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,CHEMBL623264,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14092,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,CHEMBL623265,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14093,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,CHEMBL623266,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14094,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,CHEMBL623267,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14095,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,CHEMBL623268,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14096,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,CHEMBL623269,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14097,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,CHEMBL623270,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14098,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,CHEMBL623271,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14099,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,CHEMBL623272,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14100,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,CHEMBL623273,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14101,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,CHEMBL623274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14102,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,CHEMBL874414,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14103,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,CHEMBL623275,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14104,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,CHEMBL629150,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14105,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,CHEMBL623276,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14106,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,CHEMBL623277,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14107,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,CHEMBL623112,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14108,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,CHEMBL623113,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14109,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,CHEMBL623800,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14110,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,CHEMBL623801,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14111,Rattus norvegicus,,A,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL623802,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14112,Rattus norvegicus,,A,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623803,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
14113,Rattus norvegicus,,A,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623970,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
14114,Rattus norvegicus,,A,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623971,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,995.0
14115,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,CHEMBL623972,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14116,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,CHEMBL623973,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14117,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,CHEMBL623974,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14118,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,CHEMBL623975,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14119,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,CHEMBL623976,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14120,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,CHEMBL623977,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14121,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,CHEMBL623978,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14122,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,CHEMBL623979,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14123,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,CHEMBL623980,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14124,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,CHEMBL623981,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14125,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,CHEMBL626278,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14126,Rattus norvegicus,,A,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,CHEMBL626279,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14127,Mus musculus,,A,Biodistribution in mice bladder plus excreted urine was determined,,CHEMBL626280,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14128,Mus musculus,,A,"Percentage biodistribution in mouse blood, 10 minutes post injection",,CHEMBL626281,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14129,Mus musculus,,A,"Percentage biodistribution in mouse blood, 30 minutes post injection",,CHEMBL626282,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14130,Mus musculus,,A,"Percentage biodistribution in mouse blood, 5 minutes post injection",,CHEMBL626283,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14131,Mus musculus,,A,"Percentage biodistribution in mouse blood, 60 minutes post injection",,CHEMBL626284,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14132,Mus musculus,,A,"Percentage biodistribution in mouse brain, 10 minutes post injection",,CHEMBL626285,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
14133,Mus musculus,,A,"Percentage biodistribution in mouse brain, 30 minutes post injection",,CHEMBL626286,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
14134,Mus musculus,,A,"Percentage biodistribution in mouse brain, 5 minutes post injection",,CHEMBL626287,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
14135,Mus musculus,,A,"Percentage biodistribution in mouse brain, 60 minutes post injection",,CHEMBL626288,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,955.0
14136,Mus musculus,,A,"Percentage biodistribution in mouse heart, 10 minutes post injection",,CHEMBL626289,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14137,Mus musculus,,A,"Percentage biodistribution in mouse heart, 30 minutes post injection",,CHEMBL626290,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14138,Mus musculus,,A,"Percentage biodistribution in mouse heart, 5 minutes post injection",,CHEMBL626291,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14139,Mus musculus,,A,"Percentage biodistribution in mouse heart, 60 minutes post injection",,CHEMBL839888,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14140,Mus musculus,,A,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,CHEMBL626292,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
14141,Mus musculus,,A,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,CHEMBL626293,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
14142,Mus musculus,,A,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,CHEMBL626294,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
14143,Mus musculus,,A,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,CHEMBL626295,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,160.0
14144,Mus musculus,,A,"Percentage biodistribution in mouse liver, 10 minutes post injection",,CHEMBL627659,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14145,Mus musculus,,A,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,CHEMBL627660,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14146,Mus musculus,,A,"Percentage biodistribution in mouse liver, 5 minutes post injection",,CHEMBL627661,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14147,Mus musculus,,A,Biodistribution in mice liver at 60 minutes of post injection,,CHEMBL627662,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14148,Mus musculus,,A,Biodistribution in mice lungs at 10 min of post injection,,CHEMBL627663,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
14149,Mus musculus,,A,"Percentage biodistribution in mouse lung, 30 minutes post injection",,CHEMBL627664,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14150,Mus musculus,,A,"Percentage biodistribution in mousee lung, 5 minutes post injection",,CHEMBL627665,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14151,Mus musculus,,A,Biodistribution in mice lungs at 60 min of post injection,,CHEMBL627666,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2048.0
14152,Mus musculus,,A,Percentage biodistribution in mouse spleen,,CHEMBL627667,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
14153,Mus musculus,,A,Percentage biodistribution in mouse stomach,,CHEMBL627668,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,945.0
14154,Mus musculus,,A,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,CHEMBL627669,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,1088.0
14155,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,CHEMBL627670,,0,1,U,22224,Autocuration,,,BAO_0000218,1255.0
14156,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,CHEMBL627671,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
14157,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,CHEMBL627672,,0,1,U,22224,Autocuration,,,BAO_0000218,1474.0
14158,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,CHEMBL627673,,0,1,U,22224,Autocuration,,,BAO_0000218,
14159,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,CHEMBL627674,,0,1,U,22224,Autocuration,,,BAO_0000218,2113.0
14160,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,CHEMBL627675,,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
14161,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,CHEMBL627676,,0,1,U,22224,Autocuration,,,BAO_0000218,2048.0
14162,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,CHEMBL627677,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14163,,,A,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,CHEMBL627678,,0,1,U,22224,Autocuration,,,BAO_0000019,
14164,Rattus norvegicus,,A,Affinity for protein binding expressed as association constant in fresh rat serum,,CHEMBL627679,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
14165,,,A,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,CHEMBL627680,,0,1,U,22224,Autocuration,,,BAO_0000019,
14166,,,A,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,CHEMBL627681,,0,1,U,22224,Autocuration,,,BAO_0000019,
14167,,,A,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,CHEMBL627682,,0,1,U,22224,Autocuration,,,BAO_0000019,
14168,,,A,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,CHEMBL627683,,0,1,U,22224,Autocuration,,,BAO_0000019,
14169,,,A,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,CHEMBL627684,,0,1,U,22224,Autocuration,,,BAO_0000019,
14170,,,A,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,CHEMBL874441,,0,1,U,22224,Autocuration,,,BAO_0000019,
14171,,,A,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,CHEMBL627685,,0,1,U,22224,Autocuration,,,BAO_0000019,
14172,,,A,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,CHEMBL627686,,0,1,U,22224,Autocuration,,,BAO_0000019,
14173,,,A,Apparent rate constant Koff for inactivation of dTMP synthase.,,CHEMBL627687,,0,1,U,22224,Autocuration,,,BAO_0000019,
14174,,,A,The irreversible inhibitor activity by second order rate equation.,,CHEMBL627688,,0,1,U,22224,Autocuration,,,BAO_0000019,
14175,Rattus norvegicus,,A,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,CHEMBL628038,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14176,Rattus norvegicus,,A,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,CHEMBL628039,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14177,Rattus norvegicus,,A,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,CHEMBL628040,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14178,,,A,Dissociation rate calculated from the first-order equation using t1/2 value,,CHEMBL628041,,0,1,U,22224,Autocuration,,,BAO_0000019,
14179,,,A,The compound was tested for Binding constant against DNA,,CHEMBL630226,,0,1,U,22224,Autocuration,,,BAO_0000019,
14180,,,A,First order rate constant for cyclization of the compound,,CHEMBL628042,,0,1,U,22224,Autocuration,,,BAO_0000019,
14181,,,A,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,CHEMBL625232,,0,1,U,22224,Autocuration,,,BAO_0000019,
14182,,,A,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,CHEMBL625233,,0,1,U,22224,Autocuration,,,BAO_0000019,
14183,,,A,Hydrolysis rate constant was determined,,CHEMBL625979,,0,1,U,22224,Autocuration,,,BAO_0000019,
14184,,,A,Observed first order rate constant,,CHEMBL625980,,0,1,U,22224,Autocuration,,,BAO_0000019,
14185,,,A,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,CHEMBL625981,,0,1,U,22224,Autocuration,,,BAO_0000019,
14186,,,A,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,CHEMBL625982,,0,1,U,22224,Autocuration,,,BAO_0000019,
14187,,,A,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,CHEMBL625983,,0,1,U,22224,Autocuration,,,BAO_0000019,
14188,,,A,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625984,,0,1,U,22224,Autocuration,,,BAO_0000019,
14189,,,A,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625985,,0,1,U,22224,Autocuration,,,BAO_0000019,
14190,,,A,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625986,,0,1,U,22224,Autocuration,,,BAO_0000019,
14191,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625987,,0,1,U,22224,Autocuration,,,BAO_0000019,
14192,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625988,,0,1,U,22224,Autocuration,,,BAO_0000019,
14193,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625989,,0,1,U,22224,Autocuration,,,BAO_0000019,
14194,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625990,,0,1,U,22224,Autocuration,,,BAO_0000019,
14195,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625991,,0,1,U,22224,Autocuration,,,BAO_0000019,
14196,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625992,,0,1,U,22224,Autocuration,,,BAO_0000019,
14197,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625993,,0,1,U,22224,Autocuration,,,BAO_0000019,
14198,,,A,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL631973,,0,1,U,22224,Autocuration,,,BAO_0000019,
14199,,,A,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632143,,0,1,U,22224,Autocuration,,,BAO_0000019,
14200,,,A,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632144,,0,1,U,22224,Autocuration,,,BAO_0000019,
14201,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632145,,0,1,U,22224,Autocuration,,,BAO_0000019,
14202,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632146,,0,1,U,22224,Autocuration,,,BAO_0000019,
14203,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632147,,0,1,U,22224,Autocuration,,,BAO_0000019,
14204,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632148,,0,1,U,22224,Autocuration,,,BAO_0000019,
14205,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632149,,0,1,U,22224,Autocuration,,,BAO_0000019,
14206,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632150,,0,1,U,22224,Autocuration,,,BAO_0000019,
14207,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632151,,0,1,U,22224,Autocuration,,,BAO_0000019,
14208,Homo sapiens,,A,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,CHEMBL632152,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
14209,Homo sapiens,,A,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,CHEMBL632153,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
14210,Homo sapiens,,A,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,CHEMBL632154,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
14211,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,CHEMBL632155,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14212,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,CHEMBL632156,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14213,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,CHEMBL632157,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14214,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,CHEMBL632158,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14215,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,CHEMBL632159,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14216,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,CHEMBL626305,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14217,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,CHEMBL626306,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14218,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,CHEMBL626307,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14219,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,CHEMBL626308,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14220,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,CHEMBL626479,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14221,Human herpesvirus 1,,A,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,CHEMBL626480,10298.0,1,1,N,50602,Intermediate,,,BAO_0000218,
14222,,,P,Calculated partition coefficient (clogP) (MlogP),,CHEMBL626481,,0,1,U,22229,Autocuration,,,BAO_0000100,
14223,,,A,Equipotent potent ratio relative to carbachol (nicotinic activity),,CHEMBL626482,,0,1,U,22224,Autocuration,,,BAO_0000019,
14224,Canis lupus familiaris,,A,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,CHEMBL626483,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14225,Canis lupus familiaris,,A,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,CHEMBL626484,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14226,,,P,Solubility at pH 7.4 in micro g/mL;NA denotes available,,CHEMBL626485,,0,1,U,22229,Autocuration,,,BAO_0000100,
14227,,,P,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,CHEMBL626486,,0,1,U,22229,Autocuration,,,BAO_0000100,
14228,,,P,Solubility at pH 7.4 in ug/mL;NA denotes not available,,CHEMBL626487,,0,1,U,22229,Autocuration,,,BAO_0000100,
14229,Canis lupus familiaris,,A,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,CHEMBL626488,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1969.0
14230,Rattus norvegicus,,A,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,CHEMBL626489,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1977.0
14231,,,A,Area under the MAP curve measured over 5 min; ND means Not determined,,CHEMBL626490,,0,1,U,22224,Autocuration,,,BAO_0000019,
14232,,,P,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,CHEMBL626491,,0,1,U,22224,Autocuration,,,BAO_0000100,
14233,,,P,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,CHEMBL626492,,0,1,U,22229,Autocuration,,,BAO_0000100,
14234,,,A,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,CHEMBL626493,,0,1,U,22224,Autocuration,,,BAO_0000019,
14235,Rattus norvegicus,,A,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,CHEMBL626494,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14236,,,A,Half life after oral tested,,CHEMBL626495,,0,1,U,22224,Autocuration,,,BAO_0000218,
14237,Rattus norvegicus,,A,Half life was determined in plasma of rat; NT indicates not tested,,CHEMBL626496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
14238,Rattus norvegicus,,A,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,CHEMBL626497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14239,,,A,Oral bioavailability after oral tested,,CHEMBL626498,,0,1,U,22224,Autocuration,,,BAO_0000218,
14240,Rattus norvegicus,,A,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,CHEMBL626499,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14241,Rattus norvegicus,,A,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,CHEMBL626500,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14242,Rattus norvegicus,,A,half life was determined in plasma of rat; NT indicates not tested,,CHEMBL626501,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
14243,Rattus norvegicus,,A,half life was determined in plasma of rat; NT means not tested,,CHEMBL626502,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1969.0
14244,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,CHEMBL626503,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14245,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,CHEMBL626504,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14246,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,CHEMBL626505,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14247,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,CHEMBL626506,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14248,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,CHEMBL626507,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14249,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,CHEMBL626508,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14250,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,CHEMBL626509,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14251,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,CHEMBL875480,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14252,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,CHEMBL626510,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14253,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,CHEMBL626511,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14254,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,CHEMBL626512,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14255,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,CHEMBL628208,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14256,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,CHEMBL628209,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14257,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,CHEMBL628210,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14258,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,CHEMBL628211,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14259,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,CHEMBL628212,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14260,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,CHEMBL628213,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14261,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,CHEMBL628214,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14262,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,CHEMBL628215,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14263,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,CHEMBL628216,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14264,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,CHEMBL626595,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14265,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,CHEMBL626596,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14266,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,CHEMBL626597,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14267,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,CHEMBL626598,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14268,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,CHEMBL622242,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14269,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,CHEMBL622243,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14270,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,CHEMBL622244,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14271,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,CHEMBL622245,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14272,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,CHEMBL622246,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14273,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,CHEMBL622247,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14274,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,CHEMBL622248,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14275,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,CHEMBL877483,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14276,Rattus norvegicus,,A,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,CHEMBL622249,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14277,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,CHEMBL622250,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14278,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,CHEMBL622251,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14279,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,CHEMBL622252,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14280,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,CHEMBL622253,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14281,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,CHEMBL622254,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14282,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,CHEMBL622255,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14283,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,CHEMBL622256,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14284,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,CHEMBL622257,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14285,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,CHEMBL622258,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14286,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,CHEMBL622259,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14287,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,CHEMBL622927,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14288,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,CHEMBL622928,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14289,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,CHEMBL622929,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14290,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,CHEMBL623182,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14291,Canis lupus familiaris,,A,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,CHEMBL623183,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14292,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,CHEMBL623184,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14293,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,CHEMBL623185,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14294,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,CHEMBL877484,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14295,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,CHEMBL627274,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14296,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,CHEMBL623186,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14297,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,CHEMBL623187,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14298,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,CHEMBL623188,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14299,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,CHEMBL628055,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14300,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,CHEMBL628056,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14301,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,CHEMBL628200,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14302,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,CHEMBL628201,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14303,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,CHEMBL628202,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14304,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,CHEMBL628203,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14305,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,CHEMBL628204,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14306,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,CHEMBL628205,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14307,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,CHEMBL628206,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14308,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,CHEMBL628207,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14309,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,CHEMBL627220,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14310,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,CHEMBL627221,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14311,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,CHEMBL627222,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14312,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,CHEMBL627223,,0,1,U,22224,Autocuration,,,BAO_0000218,
14313,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,CHEMBL632062,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14314,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,CHEMBL632063,,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
14315,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,CHEMBL632064,,0,1,U,22224,Autocuration,,,BAO_0000218,1255.0
14316,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,CHEMBL632065,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
14317,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,CHEMBL632066,,0,1,U,22224,Autocuration,,,BAO_0000218,1474.0
14318,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,CHEMBL632067,,0,1,U,22224,Autocuration,,,BAO_0000218,
14319,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,CHEMBL629188,,0,1,U,22224,Autocuration,,,BAO_0000218,2113.0
14320,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,CHEMBL629189,,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
14321,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,CHEMBL629190,,0,1,U,22224,Autocuration,,,BAO_0000218,2048.0
14322,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,CHEMBL629191,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14323,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,CHEMBL629192,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14324,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,CHEMBL629193,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14325,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,CHEMBL629194,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14326,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,CHEMBL629195,,0,1,U,22224,Autocuration,,,BAO_0000218,
14327,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,CHEMBL629373,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14328,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,CHEMBL629374,,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
14329,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,CHEMBL629375,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14330,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,CHEMBL629376,,0,1,U,22224,Autocuration,,,BAO_0000218,1255.0
14331,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,CHEMBL629377,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
14332,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,CHEMBL629378,,0,1,U,22224,Autocuration,,,BAO_0000218,1474.0
14333,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,CHEMBL629379,,0,1,U,22224,Autocuration,,,BAO_0000218,
14334,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,CHEMBL629151,,0,1,U,22224,Autocuration,,,BAO_0000218,2113.0
14335,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,CHEMBL629152,,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
14336,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,CHEMBL629153,,0,1,U,22224,Autocuration,,,BAO_0000218,2048.0
14337,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,CHEMBL629154,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14338,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,CHEMBL629155,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14339,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,CHEMBL629156,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14340,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,CHEMBL629157,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14341,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,CHEMBL629158,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14342,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,CHEMBL629159,,0,1,U,22224,Autocuration,,,BAO_0000218,
14343,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,CHEMBL629160,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14344,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,CHEMBL629161,,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
14345,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,CHEMBL629162,,0,1,U,22224,Autocuration,,,BAO_0000218,1255.0
14346,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,CHEMBL629163,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
14347,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,CHEMBL629164,,0,1,U,22224,Autocuration,,,BAO_0000218,1474.0
14348,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,CHEMBL629165,,0,1,U,22224,Autocuration,,,BAO_0000218,
14349,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,CHEMBL629166,,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
14350,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,CHEMBL629167,,0,1,U,22224,Autocuration,,,BAO_0000218,2048.0
14351,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,CHEMBL629168,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14352,,,A,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,CHEMBL629169,,0,1,U,22224,Autocuration,,,BAO_0000019,
14353,,,A,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,CHEMBL629170,,0,1,U,22224,Autocuration,,,BAO_0000019,
14354,,,A,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,CHEMBL631153,,0,1,U,22224,Autocuration,,,BAO_0000019,
14355,,,A,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,CHEMBL875121,,0,1,U,22224,Autocuration,,,BAO_0000019,
14356,,,A,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,CHEMBL631154,,0,1,U,22224,Autocuration,,,BAO_0000019,
14357,,,A,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,CHEMBL631155,,0,1,U,22224,Autocuration,,,BAO_0000019,
14358,,,A,Hydrolysis rate constant was determined,,CHEMBL631156,,0,1,U,22224,Autocuration,,,BAO_0000019,
14359,,,A,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,CHEMBL631157,,0,1,U,22224,Autocuration,,,BAO_0000019,
14360,,,A,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,CHEMBL631158,,0,1,U,22224,Autocuration,,,BAO_0000019,
14361,,,A,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,CHEMBL631159,,0,1,U,22224,Autocuration,,,BAO_0000019,
14362,,,A,Observed second order rate constant,,CHEMBL631160,,0,1,U,22224,Autocuration,,,BAO_0000019,
14363,,,A,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,CHEMBL631161,,0,1,U,22224,Autocuration,,,BAO_0000019,
14364,,,A,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,CHEMBL631162,,0,1,U,22224,Autocuration,,,BAO_0000019,
14365,,,A,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,CHEMBL630313,,0,1,U,22224,Autocuration,,,BAO_0000019,
14366,,,A,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,CHEMBL630314,,0,1,U,22224,Autocuration,,,BAO_0000019,
14367,,,A,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,CHEMBL630315,,0,1,U,22224,Autocuration,,,BAO_0000019,
14368,,,A,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630316,,0,1,U,22224,Autocuration,,,BAO_0000019,
14369,,,A,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630986,,0,1,U,22224,Autocuration,,,BAO_0000019,
14370,,,A,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630987,,0,1,U,22224,Autocuration,,,BAO_0000019,
14371,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630988,,0,1,U,22224,Autocuration,,,BAO_0000019,
14372,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630989,,0,1,U,22224,Autocuration,,,BAO_0000019,
14373,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630990,,0,1,U,22224,Autocuration,,,BAO_0000019,
14374,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630991,,0,1,U,22224,Autocuration,,,BAO_0000019,
14375,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630992,,0,1,U,22224,Autocuration,,,BAO_0000019,
14376,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630993,,0,1,U,22224,Autocuration,,,BAO_0000019,
14377,,,A,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630994,,0,1,U,22224,Autocuration,,,BAO_0000019,
14378,Rattus norvegicus,,A,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,CHEMBL630995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14379,,,A,Association constant for compound at 31 degree C was determined,,CHEMBL629252,,0,1,U,22224,Autocuration,,,BAO_0000019,
14380,,,A,Calculated antagonist equilibrium dissociation constant of the compound,,CHEMBL629253,,0,1,U,22224,Autocuration,,,BAO_0000019,
14381,,,A,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,CHEMBL629944,,0,1,U,22224,Autocuration,,,BAO_0000019,
14382,Cavia porcellus,,A,Dissociation constants vs LTE4 on guinea pig trachea,,CHEMBL629945,10141.0,1,1,N,50512,Intermediate,,,BAO_0000218,3126.0
14383,,,A,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,CHEMBL629946,,0,1,U,22224,Autocuration,,,BAO_0000019,
14384,,,A,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,CHEMBL629947,,0,1,U,22224,Autocuration,,,BAO_0000019,
14385,,,A,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,CHEMBL629948,,0,1,U,22224,Autocuration,,,BAO_0000019,
14386,,,A,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,CHEMBL856024,,0,1,U,22224,Autocuration,,,BAO_0000019,
14387,,,A,Affinity constant KD value was derived from TMP,,CHEMBL629949,,0,1,U,22224,Autocuration,,,BAO_0000019,
14388,,,A,Apparent dissociation (binding) rate constant was evaluated,,CHEMBL629950,,0,1,U,22224,Autocuration,,,BAO_0000019,
14389,,,P,Dissociation constant (KD) of the compound,,CHEMBL630127,,0,1,U,22224,Autocuration,,,BAO_0000100,
14390,,,P,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,CHEMBL630128,,0,1,U,22224,Autocuration,,,BAO_0000100,
14391,,,P,Dissociation constant from ESR titration experiments,,CHEMBL630129,,0,1,U,22224,Autocuration,,,BAO_0000100,
14392,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,CHEMBL630130,,0,1,U,22224,Autocuration,,,BAO_0000019,
14393,,,P,Dissociation constant was evaluated.,,CHEMBL875234,,0,1,U,22224,Autocuration,,,BAO_0000100,
14394,,,P,Dissociation constant was reported,,CHEMBL630131,,0,1,U,22224,Autocuration,,,BAO_0000100,
14395,Rattus norvegicus,,A,Dissociation constant was determined in rat pituitary cells.,,CHEMBL630132,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14396,,,A,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,CHEMBL630133,,0,1,U,22224,Autocuration,,,BAO_0000019,
14397,,,A,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,CHEMBL630134,,0,1,U,22224,Autocuration,,,BAO_0000019,
14398,,,A,Equilibrium dissociation constant of the compound,,CHEMBL630135,,0,1,U,22224,Autocuration,,,BAO_0000019,
14399,,,A,Equilibrium dissociation constant was determined,,CHEMBL630136,,0,1,U,22224,Autocuration,,,BAO_0000019,
14400,,,A,Kinetic constant KD was evaluated,,CHEMBL630137,,0,1,U,22224,Autocuration,,,BAO_0000019,
14401,,,A,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,CHEMBL630138,,0,1,U,22224,Autocuration,,,BAO_0000019,
14402,,,A,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,CHEMBL630139,,0,1,U,22224,Autocuration,,,BAO_0000019,
14403,,,A,Rate constant for hydrolysis in aqueous acetone.,,CHEMBL630140,,0,1,U,22224,Autocuration,,,BAO_0000019,
14404,,,A,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,CHEMBL875235,,0,1,U,22224,Autocuration,,,BAO_0000019,
14405,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,CHEMBL876439,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14406,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,CHEMBL630605,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14407,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,CHEMBL630606,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14408,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,CHEMBL630607,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14409,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,CHEMBL630608,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14410,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,CHEMBL630609,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14411,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,CHEMBL630610,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14412,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,CHEMBL630611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14413,Rattus norvegicus,,A,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,CHEMBL629552,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14414,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,CHEMBL629733,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14415,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,CHEMBL629734,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14416,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,CHEMBL629735,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14417,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,CHEMBL629736,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14418,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,CHEMBL629737,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14419,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,CHEMBL629738,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14420,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,CHEMBL629739,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14421,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,CHEMBL629740,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14422,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,CHEMBL629741,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14423,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,CHEMBL629742,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14424,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,CHEMBL629743,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14425,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,CHEMBL629744,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14426,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,CHEMBL629745,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14427,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,CHEMBL629746,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14428,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,CHEMBL629747,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14429,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,CHEMBL629748,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14430,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,CHEMBL629749,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14431,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,CHEMBL629750,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14432,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,CHEMBL629751,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14433,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,CHEMBL629752,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14434,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,CHEMBL629753,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14435,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,CHEMBL629754,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14436,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,CHEMBL629755,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14437,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,CHEMBL629756,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14438,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,CHEMBL629757,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14439,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,CHEMBL629758,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14440,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,CHEMBL629759,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14441,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,CHEMBL629760,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14442,Rattus norvegicus,,A,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,CHEMBL876443,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14443,Canis lupus familiaris,,A,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,CHEMBL629761,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14444,Canis lupus familiaris,,A,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,CHEMBL629762,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14445,Mus musculus,,A,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629763,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14446,Mus musculus,,A,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,CHEMBL629764,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14447,Mus musculus,,A,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,CHEMBL629765,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14448,Mus musculus,,A,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,CHEMBL629766,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14449,Mus musculus,,A,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629767,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14450,Canis lupus familiaris,,A,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,CHEMBL629768,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14451,Mus musculus,,A,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,CHEMBL629769,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14452,Canis lupus familiaris,,A,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,CHEMBL629770,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14453,Canis lupus familiaris,,A,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,CHEMBL629771,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,
14454,Mus musculus,,A,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629772,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14455,Mus musculus,,A,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629773,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14456,Mus musculus,,A,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,CHEMBL625455,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14457,Mus musculus,,A,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,CHEMBL625456,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14458,Mus musculus,,A,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,CHEMBL625457,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14459,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,CHEMBL625458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14460,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,CHEMBL625459,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14461,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,CHEMBL875483,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14462,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,CHEMBL634779,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14463,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,CHEMBL625460,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14464,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,CHEMBL626117,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14465,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,CHEMBL626118,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14466,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,CHEMBL628342,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14467,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,CHEMBL628343,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14468,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,CHEMBL628344,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14469,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,CHEMBL628345,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14470,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,CHEMBL628346,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14471,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,CHEMBL628347,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14472,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,CHEMBL628348,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14473,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,CHEMBL628349,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14474,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,CHEMBL875611,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14475,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,CHEMBL628350,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14476,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,CHEMBL628351,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14477,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,CHEMBL628352,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14478,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,CHEMBL628353,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14479,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,CHEMBL628354,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14480,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,CHEMBL626667,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14481,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,CHEMBL626668,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14482,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,CHEMBL626669,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14483,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,CHEMBL626670,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14484,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,CHEMBL626671,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14485,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,CHEMBL626672,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14486,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,CHEMBL626673,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14487,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,CHEMBL626674,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14488,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,CHEMBL626675,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14489,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,CHEMBL626676,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14490,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,CHEMBL626677,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14491,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,CHEMBL626678,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14492,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,CHEMBL626679,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14493,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,CHEMBL875612,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14494,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,CHEMBL626680,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14495,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,CHEMBL626681,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14496,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,CHEMBL626682,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14497,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,CHEMBL626683,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14498,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,CHEMBL626684,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14499,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,CHEMBL626685,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14500,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,CHEMBL626686,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14501,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,CHEMBL626687,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14502,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,CHEMBL624978,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14503,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,CHEMBL624979,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14504,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,CHEMBL624980,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14505,Rattus norvegicus,,A,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,CHEMBL624981,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14506,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,CHEMBL624982,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14507,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,CHEMBL627564,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14508,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,CHEMBL627565,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14509,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,CHEMBL627566,,0,1,U,22224,Autocuration,,,BAO_0000218,
14510,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,CHEMBL627567,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14511,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,CHEMBL627568,,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
14512,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,CHEMBL627569,,0,1,U,22224,Autocuration,,,BAO_0000218,2113.0
14513,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,CHEMBL627570,,0,1,U,22224,Autocuration,,,BAO_0000218,1255.0
14514,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,CHEMBL627571,,0,1,U,22224,Autocuration,,,BAO_0000218,178.0
14515,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,CHEMBL627572,,0,1,U,22224,Autocuration,,,BAO_0000218,1474.0
14516,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,CHEMBL627573,,0,1,U,22224,Autocuration,,,BAO_0000218,
14517,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,CHEMBL627574,,0,1,U,22224,Autocuration,,,BAO_0000218,2113.0
14518,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,CHEMBL627575,,0,1,U,22224,Autocuration,,,BAO_0000218,2107.0
14519,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,CHEMBL627576,,0,1,U,22224,Autocuration,,,BAO_0000218,2048.0
14520,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,CHEMBL627577,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14521,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,CHEMBL627578,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14522,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,CHEMBL627579,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14523,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,CHEMBL627580,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14524,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,CHEMBL627581,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14525,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,CHEMBL627582,,0,1,U,22224,Autocuration,,,BAO_0000218,
14526,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,CHEMBL627583,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14527,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,CHEMBL627584,,0,1,U,22224,Autocuration,,,BAO_0000218,2106.0
14528,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,CHEMBL627585,,0,1,U,22224,Autocuration,,,BAO_0000218,2367.0
14529,,,A,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,CHEMBL627586,,0,1,U,22224,Autocuration,,,BAO_0000218,2385.0
14530,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL627587,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14531,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL627588,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14532,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL628250,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14533,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628251,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14534,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL628252,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14535,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628253,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14536,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL628254,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14537,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL877493,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14538,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628255,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14539,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628256,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14540,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628257,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14541,Rattus norvegicus,,A,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628258,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14542,Rattus norvegicus,,A,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628259,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14543,Rattus norvegicus,,A,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628429,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14544,Rattus norvegicus,,A,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL626862,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14545,Rattus norvegicus,,A,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,CHEMBL626863,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14546,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,CHEMBL625886,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
14547,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,CHEMBL625887,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
14548,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,CHEMBL625888,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14549,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,CHEMBL625889,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14550,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,CHEMBL625890,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14551,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,CHEMBL625891,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14552,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,CHEMBL625892,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14553,Rattus norvegicus,,A,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,CHEMBL625893,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14554,Rattus norvegicus,,A,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,CHEMBL625894,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2037.0
14555,Rattus norvegicus,,A,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,CHEMBL625895,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14556,,,A,Reaction rate parameter value for phosphate with transfer with respect to ATP,,CHEMBL625896,,0,1,U,22224,Autocuration,,,BAO_0000019,
14557,,,A,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,CHEMBL625897,,0,1,U,22224,Autocuration,,,BAO_0000019,
14558,,,A,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,CHEMBL625898,,0,1,U,22224,Autocuration,,,BAO_0000019,
14559,,,A,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,CHEMBL625899,,0,1,U,22224,Autocuration,,,BAO_0000019,
14560,,,A,Reaction rate parameter value for phosphate with transfer with respect to ATP,,CHEMBL626124,,0,1,U,22224,Autocuration,,,BAO_0000019,
14561,Escherichia coli,,A,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,CHEMBL628500,562.0,1,1,N,50212,Intermediate,,,BAO_0000218,
14562,Rattus norvegicus,,A,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,CHEMBL857856,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14563,Rattus norvegicus,,A,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,CHEMBL628501,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14564,,,A,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,CHEMBL628502,,0,1,U,22224,Autocuration,,,BAO_0000019,
14565,,,A,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,CHEMBL628503,,0,1,U,22224,Autocuration,,,BAO_0000019,
14566,,,A,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,CHEMBL628504,,0,1,U,22224,Autocuration,,,BAO_0000019,
14567,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,CHEMBL628505,,0,1,U,22224,Autocuration,,,BAO_0000019,
14568,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,CHEMBL874452,,0,1,U,22224,Autocuration,,,BAO_0000019,
14569,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,CHEMBL628506,,0,1,U,22224,Autocuration,,,BAO_0000019,
14570,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,CHEMBL628507,,0,1,U,22224,Autocuration,,,BAO_0000019,
14571,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,CHEMBL628508,,0,1,U,22224,Autocuration,,,BAO_0000019,
14572,,,A,Michaelis constant (KM) was evaluated,,CHEMBL628509,,0,1,U,22224,Autocuration,,,BAO_0000019,
14573,,,A,Reaction rate parameter value for phosphate with transfer with respect to ATP,,CHEMBL628510,,0,1,U,22224,Autocuration,,,BAO_0000019,
14574,,,B,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,CHEMBL628511,,0,1,U,22224,Autocuration,,,BAO_0000019,
14575,,,B,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,CHEMBL628512,,0,1,U,22224,Autocuration,,,BAO_0000019,
14576,,,B,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,CHEMBL628513,,0,1,U,22224,Autocuration,,,BAO_0000019,
14577,,,B,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,CHEMBL628514,,0,1,U,22224,Autocuration,,,BAO_0000019,
14578,,,A,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,CHEMBL628515,,0,1,U,22224,Autocuration,,,BAO_0000019,
14579,,,A,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,CHEMBL628516,,0,1,U,22224,Autocuration,,,BAO_0000019,
14580,,,A,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,CHEMBL628517,,0,1,U,22224,Autocuration,,,BAO_0000019,
14581,,,A,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,CHEMBL628518,,0,1,U,22224,Autocuration,,,BAO_0000019,
14582,,,A,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,CHEMBL628519,,0,1,U,22224,Autocuration,,,BAO_0000019,
14583,,,A,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,CHEMBL628520,,0,1,U,22224,Autocuration,,,BAO_0000019,
14584,,,A,Binding constant was determined,,CHEMBL628521,,0,1,U,22224,Autocuration,,,BAO_0000019,
14585,,,A,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,CHEMBL630443,,0,1,U,22224,Autocuration,,,BAO_0000019,
14586,,,A,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,CHEMBL630444,,0,1,U,22224,Autocuration,,,BAO_0000019,
14587,,,A,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,CHEMBL857732,,0,1,U,22224,Autocuration,,,BAO_0000019,
14588,,,P,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,CHEMBL630445,,0,1,U,22224,Autocuration,,,BAO_0000100,
14589,,,A,Catalytic rate constant of the compound,,CHEMBL630446,,0,1,U,22224,Autocuration,,,BAO_0000019,
14590,,,B,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,CHEMBL630447,,0,1,U,22224,Autocuration,,,BAO_0000019,
14591,,,A,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,CHEMBL630448,,0,1,U,22224,Autocuration,,,BAO_0000019,
14592,,,A,Catalytic rate constant against phospholipase A2 was determined,,CHEMBL630449,,0,1,U,22224,Autocuration,,,BAO_0000019,
14593,,,A,"Compound was evaluated for catalytic constant, Kcat",,CHEMBL630450,,0,1,U,22224,Autocuration,,,BAO_0000019,
14594,,,A,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,CHEMBL630451,,0,1,U,22224,Autocuration,,,BAO_0000019,
14595,,,A,Kcat calculated from 0.693/T1/2,,CHEMBL630452,,0,1,U,22224,Autocuration,,,BAO_0000019,
14596,,,A,Kcat was determined,,CHEMBL630453,,0,1,U,22224,Autocuration,,,BAO_0000019,
14597,,,A,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,CHEMBL630454,,0,1,U,22224,Autocuration,,,BAO_0000019,
14598,,,A,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,CHEMBL630455,,0,1,U,22224,Autocuration,,,BAO_0000019,
14599,,,A,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,CHEMBL631487,,0,1,U,22224,Autocuration,,,BAO_0000019,
14600,,,A,Kcat value was determined,,CHEMBL631488,,0,1,U,22224,Autocuration,,,BAO_0000019,
14601,,,A,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,CHEMBL876440,,0,1,U,22224,Autocuration,,,BAO_0000019,
14602,,,A,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,CHEMBL631489,,0,1,U,22224,Autocuration,,,BAO_0000019,
14603,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,CHEMBL857742,,0,1,U,22224,Autocuration,,,BAO_0000019,
14604,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,CHEMBL631490,,0,1,U,22224,Autocuration,,,BAO_0000019,
14605,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,CHEMBL631491,,0,1,U,22224,Autocuration,,,BAO_0000019,
14606,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,CHEMBL631492,,0,1,U,22224,Autocuration,,,BAO_0000019,
14607,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,CHEMBL631493,,0,1,U,22224,Autocuration,,,BAO_0000019,
14608,,,A,Kinetic parameter for rate of conversion to PABA was determined,,CHEMBL631494,,0,1,U,22224,Autocuration,,,BAO_0000019,
14609,,,A,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,CHEMBL631495,,0,1,U,22224,Autocuration,,,BAO_0000019,
14610,Rattus norvegicus,,A,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,CHEMBL631496,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1988.0
14611,Rattus norvegicus,,A,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL631497,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14612,Rattus norvegicus,,A,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL631498,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14613,Rattus norvegicus,,A,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL629776,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14614,Rattus norvegicus,,A,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL629777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14615,Rattus norvegicus,,A,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,CHEMBL629778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14616,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,CHEMBL630456,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14617,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,CHEMBL630457,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14618,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,CHEMBL630458,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14619,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,CHEMBL630459,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14620,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,CHEMBL630460,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14621,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,CHEMBL876550,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14622,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,CHEMBL630461,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14623,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,CHEMBL630462,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14624,Rattus norvegicus,,A,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,CHEMBL630463,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14625,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,CHEMBL630464,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14626,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,CHEMBL630465,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14627,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,CHEMBL630466,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14628,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,CHEMBL630467,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14629,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,CHEMBL630633,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14630,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,CHEMBL630634,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14631,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,CHEMBL630635,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14632,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,CHEMBL630636,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14633,Rattus norvegicus,,A,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,CHEMBL630637,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14634,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,CHEMBL630638,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14635,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,CHEMBL630639,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14636,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,CHEMBL630640,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14637,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,CHEMBL876551,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14638,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,CHEMBL630641,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14639,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,CHEMBL630642,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14640,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL630643,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14641,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL630644,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14642,Oryctolagus cuniculus,,A,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,CHEMBL630645,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14643,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,CHEMBL625599,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14644,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,CHEMBL625600,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14645,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,CHEMBL625601,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14646,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,CHEMBL625602,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1988.0
14647,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,CHEMBL627470,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14648,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,CHEMBL627471,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14649,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL627472,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14650,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL627473,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14651,Oryctolagus cuniculus,,A,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,CHEMBL627474,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,1088.0
14652,Rattus norvegicus,,A,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL627475,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14653,Rattus norvegicus,,A,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL627476,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14654,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,CHEMBL627477,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14655,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,CHEMBL627478,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14656,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,CHEMBL627479,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14657,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,CHEMBL627480,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14658,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,CHEMBL627481,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14659,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,CHEMBL627482,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14660,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,CHEMBL627483,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14661,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,CHEMBL875636,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14662,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,CHEMBL625764,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14663,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,CHEMBL625765,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14664,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,CHEMBL625766,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14665,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,CHEMBL625767,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14666,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,CHEMBL625768,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14667,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,CHEMBL625769,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14668,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,CHEMBL625770,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14669,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,CHEMBL625771,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14670,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,CHEMBL625772,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14671,Canis lupus familiaris,,A,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,CHEMBL625773,9615.0,1,1,N,50588,Intermediate,,,BAO_0000218,1088.0
14672,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,CHEMBL625774,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14673,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,CHEMBL625775,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14674,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,CHEMBL625776,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14675,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,CHEMBL625777,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14676,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,CHEMBL625778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14677,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,CHEMBL625779,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14678,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,CHEMBL625780,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14679,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,CHEMBL625781,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14680,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,CHEMBL875637,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14681,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,CHEMBL626473,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14682,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,CHEMBL626474,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14683,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,CHEMBL626475,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14684,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,CHEMBL626476,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14685,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,CHEMBL634397,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14686,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,CHEMBL626477,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14687,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,CHEMBL631069,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14688,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,CHEMBL631070,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14689,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,CHEMBL631071,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14690,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,CHEMBL631072,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14691,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,CHEMBL631073,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14692,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,CHEMBL631074,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14693,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,CHEMBL631075,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14694,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,CHEMBL631725,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14695,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,CHEMBL631726,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14696,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,CHEMBL631727,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14697,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,CHEMBL631728,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14698,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,CHEMBL631729,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14699,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,CHEMBL631730,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14700,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,CHEMBL631731,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14701,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,CHEMBL631910,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14702,Rattus norvegicus,,A,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,CHEMBL631911,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,10000000.0
14703,Rattus norvegicus,,A,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,CHEMBL631912,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14704,Rattus norvegicus,,A,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,CHEMBL631913,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1898.0
14705,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631914,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14706,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631915,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14707,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL875778,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14708,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631916,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14709,Rattus norvegicus,,A,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631917,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14710,Rattus norvegicus,,A,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631918,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14711,Rattus norvegicus,,A,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631919,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14712,Rattus norvegicus,,A,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631920,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14713,Rattus norvegicus,,A,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631921,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14714,Rattus norvegicus,,A,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631922,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14715,Rattus norvegicus,,A,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631923,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14716,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631924,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14717,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630234,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14718,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630235,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14719,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630236,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14720,Rattus norvegicus,,A,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630237,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14721,Rattus norvegicus,,A,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630238,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14722,Rattus norvegicus,,A,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630239,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14723,Rattus norvegicus,,A,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630303,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14724,Rattus norvegicus,,A,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630304,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14725,Rattus norvegicus,,A,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630305,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14726,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630306,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14727,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630307,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14728,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630308,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14729,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14730,Rattus norvegicus,,A,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL629309,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14731,Rattus norvegicus,,A,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL629993,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14732,Rattus norvegicus,,A,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL629994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14733,Rattus norvegicus,,A,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL629995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14734,Rattus norvegicus,,A,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631993,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14735,Rattus norvegicus,,A,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631994,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14736,Rattus norvegicus,,A,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631995,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14737,Rattus norvegicus,,A,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631996,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14738,Rattus norvegicus,,A,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631997,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14739,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631998,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14740,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631999,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14741,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL632000,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14742,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL632001,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14743,Rattus norvegicus,,A,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL874424,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14744,Rattus norvegicus,,A,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL632002,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14745,Rattus norvegicus,,A,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL632003,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14746,,,A,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,CHEMBL632004,,0,1,U,22224,Autocuration,,,BAO_0000019,
14747,,,A,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,CHEMBL632005,,0,1,U,22224,Autocuration,,,BAO_0000019,
14748,,,A,Compound was tested for amidase rate in the presence of N62C screen enzyme,,CHEMBL632006,,0,1,U,22224,Autocuration,,,BAO_0000019,
14749,,,A,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,CHEMBL632007,,0,1,U,22224,Autocuration,,,BAO_0000019,
14750,,,A,Compound was tested for amidase rate in the presence of S166C screen enzyme,,CHEMBL632008,,0,1,U,22224,Autocuration,,,BAO_0000019,
14751,,,A,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,CHEMBL632009,,0,1,U,22224,Autocuration,,,BAO_0000019,
14752,,,A,Compound was tested for esterase rate in the presence of N62C screen enzyme,,CHEMBL632010,,0,1,U,22224,Autocuration,,,BAO_0000019,
14753,,,A,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,CHEMBL857750,,0,1,U,22224,Autocuration,,,BAO_0000019,
14754,,,A,Compound was tested for esterase rate in the presence of S166C screen enzyme,,CHEMBL632011,,0,1,U,22224,Autocuration,,,BAO_0000019,
14755,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL632012,,0,1,U,22224,Autocuration,,,BAO_0000019,
14756,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL632013,,0,1,U,22224,Autocuration,,,BAO_0000019,
14757,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,CHEMBL632014,,0,1,U,22224,Autocuration,,,BAO_0000019,
14758,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL629622,,0,1,U,22224,Autocuration,,,BAO_0000019,
14759,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL629623,,0,1,U,22224,Autocuration,,,BAO_0000019,
14760,,,A,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,CHEMBL629624,,0,1,U,22224,Autocuration,,,BAO_0000019,
14761,,,A,Ratio of Kcat to that of Km was determined,,CHEMBL629625,,0,1,U,22224,Autocuration,,,BAO_0000019,
14762,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,CHEMBL629626,,0,1,U,22224,Autocuration,,,BAO_0000019,
14763,,,A,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,CHEMBL629627,,0,1,U,22224,Autocuration,,,BAO_0000019,
14764,,,A,"Compound was evaluated for constant, Kd",,CHEMBL629628,,0,1,U,22224,Autocuration,,,BAO_0000019,
14765,,,A,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,CHEMBL629629,,0,1,U,22224,Autocuration,,,BAO_0000019,
14766,,,A,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,CHEMBL629630,,0,1,U,22224,Autocuration,,,BAO_0000019,
14767,,,A,Dissociation Constant of compound determined,,CHEMBL856030,,0,1,U,22224,Autocuration,,,BAO_0000019,
14768,,,B,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,CHEMBL629631,,0,1,U,22224,Autocuration,,,BAO_0000019,
14769,,,B,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,CHEMBL629632,,0,1,U,22224,Autocuration,,,BAO_0000019,
14770,,,P,Dissociation constant of compound with Fructose was determined,,CHEMBL629633,,0,1,U,22224,Autocuration,,,BAO_0000100,
14771,,,P,Dissociation constant of compound with Fructose was determined; Not determined,,CHEMBL629634,,0,1,U,22224,Autocuration,,,BAO_0000100,
14772,,,P,Dissociation constant of compound with Lactulose was determined,,CHEMBL629635,,0,1,U,22224,Autocuration,,,BAO_0000100,
14773,,,P,Dissociation constant of compound with Lactulose was determined; Not determined,,CHEMBL629636,,0,1,U,22224,Autocuration,,,BAO_0000100,
14774,,,P,Dissociation constant of the Compound,,CHEMBL629637,,0,1,U,22224,Autocuration,,,BAO_0000100,
14775,,,P,Dissociation constant by non-linear regression analysis,,CHEMBL629638,,0,1,U,22224,Autocuration,,,BAO_0000100,
14776,,,P,Dissociation constant was determined,,CHEMBL629639,,0,1,U,22224,Autocuration,,,BAO_0000100,
14777,,,P,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,CHEMBL629640,,0,1,U,22224,Autocuration,,,BAO_0000100,
14778,,,P,Dissociation constant was determined,,CHEMBL629641,,0,1,U,22224,Autocuration,,,BAO_0000100,
14779,,,P,Dissociation constant was determined,,CHEMBL631344,,0,1,U,22224,Autocuration,,,BAO_0000100,
14780,Rattus norvegicus,,A,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,CHEMBL631345,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14781,,,A,The dissociation constant determined by fluorescence displacement assay,,CHEMBL631346,,0,1,U,22224,Autocuration,,,BAO_0000019,
14782,,,A,kd value surface plasmon resonance (SPR) method,,CHEMBL631524,,0,1,U,22224,Autocuration,,,BAO_0000019,
14783,Rattus norvegicus,,A,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,CHEMBL631525,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14784,,,F,First dissociation constant of the binding of compound to V30M TTR,,CHEMBL631526,,0,1,U,22224,Autocuration,,,BAO_0000019,
14785,,,F,Second dissociation constant of the binding of compound to V30M TTR,,CHEMBL631527,,0,1,U,22224,Autocuration,,,BAO_0000019,
14786,,,A,"Compound was evaluated for equilibrium constant, Ke",,CHEMBL631528,,0,1,U,22224,Autocuration,,,BAO_0000019,
14787,,,A,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,CHEMBL631529,,0,1,U,22224,Autocuration,,,BAO_0000019,1898.0
14788,,,A,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,CHEMBL631530,,0,1,U,22224,Autocuration,,,BAO_0000019,1898.0
14789,,,A,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL631531,,0,1,U,22224,Autocuration,,,BAO_0000019,
14790,,,A,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL631532,,0,1,U,22224,Autocuration,,,BAO_0000019,
14791,,,A,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL631533,,0,1,U,22224,Autocuration,,,BAO_0000019,
14792,Mus musculus,,A,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL876552,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14793,Mus musculus,,A,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,CHEMBL631534,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14794,Mus musculus,,A,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL631535,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14795,Mus musculus,,A,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL631536,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14796,Mus musculus,,A,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,CHEMBL631537,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14797,Mus musculus,,A,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,CHEMBL631538,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14798,Mus musculus,,A,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,CHEMBL631539,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14799,Mus musculus,,A,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL631540,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14800,Rattus norvegicus,,A,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL625637,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14801,Rattus norvegicus,,A,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL625638,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14802,Rattus norvegicus,,A,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL625639,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14803,Rattus norvegicus,,A,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625640,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14804,Rattus norvegicus,,A,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625641,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14805,Rattus norvegicus,,A,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625642,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
14806,Rattus norvegicus,,A,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625643,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
14807,Rattus norvegicus,,A,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625644,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14808,Rattus norvegicus,,A,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625645,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2113.0
14809,Rattus norvegicus,,A,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625646,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14810,Rattus norvegicus,,A,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625647,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14811,Rattus norvegicus,,A,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625648,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14812,Rattus norvegicus,,A,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,CHEMBL625649,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14813,Rattus norvegicus,,A,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625650,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14814,Rattus norvegicus,,A,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625651,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14815,Rattus norvegicus,,A,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625652,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
14816,Rattus norvegicus,,A,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625653,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,14.0
14817,Rattus norvegicus,,A,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625654,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14818,Rattus norvegicus,,A,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625655,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14819,Rattus norvegicus,,A,Biodistribution of Compound in rat blood after 15 minutes of administration,,CHEMBL625656,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14820,Rattus norvegicus,,A,Biodistribution of Compound in rat blood after 2 minutes of administration,,CHEMBL625657,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,178.0
14821,Rattus norvegicus,,A,Biodistribution of Compound in rat brain after 15 minutes of administration,,CHEMBL625658,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14822,Rattus norvegicus,,A,Biodistribution of Compound in rat brain after 2 minutes of administration,,CHEMBL625659,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,955.0
14823,Rattus norvegicus,,A,Biodistribution of Compound in rat heart after 15 minutes of administration,,CHEMBL625660,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
14824,Rattus norvegicus,,A,Biodistribution of Compound in rat heart after 2 minutes of administration,,CHEMBL625661,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,948.0
14825,Rattus norvegicus,,A,Biodistribution of Compound in rat liver after 15 minutes of administration,,CHEMBL625662,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14826,Rattus norvegicus,,A,Biodistribution of Compound in rat liver after 2 minutes of administration,,CHEMBL625663,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14827,Rattus norvegicus,,A,Biodistribution of Compound in rat lung after 15 minutes of administration,,CHEMBL875621,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14828,Rattus norvegicus,,A,Biodistribution of Compound in rat lung after 2 minutes of administration,,CHEMBL628382,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14829,Rattus norvegicus,,A,Biodistribution of Compound in rat muscle after 15 minutes of administration,,CHEMBL628383,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14830,Rattus norvegicus,,A,Biodistribution of Compound in rat muscle after 2 minutes of administration,,CHEMBL628384,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14831,Rattus norvegicus,,A,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,CHEMBL628385,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14832,Rattus norvegicus,,A,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,CHEMBL875753,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14833,Rattus norvegicus,,A,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,CHEMBL628386,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14834,Rattus norvegicus,,A,Organ distribution in rat blood 2 minutes after intravenous injection,,CHEMBL628387,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14835,Rattus norvegicus,,A,Organ distribution in rat blood 2 hr after intravenous injection,,CHEMBL628388,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14836,Rattus norvegicus,,A,Organ distribution in rat blood 30 minutes after intravenous injection,,CHEMBL628389,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14837,Rattus norvegicus,,A,Organ distribution in rat blood 30 min after intravenous injection,,CHEMBL632756,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14838,Rattus norvegicus,,A,Organ distribution in rat brain 2 minutes after intravenous injection,,CHEMBL628390,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14839,Rattus norvegicus,,A,Organ distribution in rat brain 2 hr after intravenous injection,,CHEMBL631811,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14840,Rattus norvegicus,,A,Organ distribution in rat brain 30 minutes after intravenous injection,,CHEMBL631812,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14841,Rattus norvegicus,,A,Organ distribution in rat heart 2 minutes after intravenous injection,,CHEMBL631813,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14842,Rattus norvegicus,,A,Organ distribution in rat heart 2 hr after intravenous injection,,CHEMBL631814,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14843,Rattus norvegicus,,A,Organ distribution in rat heart 30 minutes after intravenous injection,,CHEMBL631815,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14844,Rattus norvegicus,,A,Organ distribution in rat kidney 2 minutes after intravenous injection,,CHEMBL631816,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14845,Rattus norvegicus,,A,Organ distribution in rat kidney 2 hr after intravenous injection,,CHEMBL875758,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14846,Rattus norvegicus,,A,Organ distribution in rat kidney 30 minutes after intravenous injection,,CHEMBL631817,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14847,Rattus norvegicus,,A,Organ distribution in rat liver 2 minutes after intravenous injection,,CHEMBL631818,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14848,Rattus norvegicus,,A,Organ distribution in rat liver 2 hr after intravenous injection,,CHEMBL631819,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14849,Rattus norvegicus,,A,Organ distribution in rat liver 30 minutes after intravenous injection,,CHEMBL631820,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14850,Rattus norvegicus,,A,Organ distribution in rat lung 2 minutes after intravenous injection,,CHEMBL631821,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14851,Rattus norvegicus,,A,Organ distribution in rat lung 2 hr after intravenous injection,,CHEMBL631822,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14852,Rattus norvegicus,,A,Organ distribution in rat lung 30 minutes after intravenous injection,,CHEMBL631823,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14853,Rattus norvegicus,,A,Organ distribution in rat muscle 2 minutes after intravenous injection,,CHEMBL631824,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14854,Rattus norvegicus,,A,Organ distribution in rat muscle 2 hr after intravenous injection,,CHEMBL631825,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14855,Rattus norvegicus,,A,Organ distribution in rat muscle 30 minutes after intravenous injection,,CHEMBL631826,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14856,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,CHEMBL631827,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14857,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,CHEMBL631828,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14858,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,CHEMBL631829,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
14859,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,CHEMBL875759,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14860,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,CHEMBL631830,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14861,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,CHEMBL631831,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14862,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,CHEMBL631832,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14863,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,CHEMBL631833,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14864,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,CHEMBL631834,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14865,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,CHEMBL631835,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14866,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,CHEMBL631836,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14867,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,CHEMBL631837,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14868,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,CHEMBL631838,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14869,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,CHEMBL631839,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14870,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,CHEMBL631840,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14871,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,CHEMBL631841,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14872,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,CHEMBL631842,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14873,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,CHEMBL631843,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14874,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,CHEMBL631844,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14875,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,CHEMBL631845,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14876,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,CHEMBL631846,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14877,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,CHEMBL875760,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14878,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,CHEMBL632199,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14879,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,CHEMBL631847,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14880,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,CHEMBL631848,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14881,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,CHEMBL628707,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14882,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,CHEMBL628708,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14883,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,CHEMBL628709,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14884,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,CHEMBL628710,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14885,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,CHEMBL628711,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14886,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,CHEMBL628712,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14887,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,CHEMBL628713,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14888,Rattus norvegicus,,A,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,CHEMBL628714,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,1088.0
14889,Rattus norvegicus,,A,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,CHEMBL628715,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14890,,,A,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,CHEMBL629179,,0,1,U,22224,Autocuration,,,BAO_0000019,
14891,,,A,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,CHEMBL629180,,0,1,U,22224,Autocuration,,,BAO_0000019,
14892,,,A,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,CHEMBL875108,,0,1,U,22224,Autocuration,,,BAO_0000019,
14893,,,A,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,CHEMBL629181,,0,1,U,22224,Autocuration,,,BAO_0000019,1235.0
14894,,,A,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,CHEMBL629182,,0,1,U,22224,Autocuration,,,BAO_0000019,1235.0
14895,,,A,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,CHEMBL629183,,0,1,U,22224,Autocuration,,,BAO_0000019,
14896,,,A,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,CHEMBL629184,,0,1,U,22224,Autocuration,,,BAO_0000019,
14897,,,A,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,CHEMBL629185,,0,1,U,22224,Autocuration,,,BAO_0000019,1235.0
14898,,,A,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,CHEMBL629186,,0,1,U,22224,Autocuration,,,BAO_0000019,1235.0
14899,,,A,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,CHEMBL629187,,0,1,U,22224,Autocuration,,,BAO_0000019,
14900,,,A,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,CHEMBL629887,,0,1,U,22224,Autocuration,,,BAO_0000019,
14901,,,A,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,CHEMBL629888,,0,1,U,22224,Autocuration,,,BAO_0000019,
14902,,,A,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,CHEMBL629889,,0,1,U,22224,Autocuration,,,BAO_0000019,
14903,,,A,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,CHEMBL629890,,0,1,U,22224,Autocuration,,,BAO_0000019,1235.0
14904,,,A,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,CHEMBL629891,,0,1,U,22224,Autocuration,,,BAO_0000019,
14905,,,A,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,CHEMBL629892,,0,1,U,22224,Autocuration,,,BAO_0000019,
14906,,,A,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,CHEMBL629893,,0,1,U,22224,Autocuration,,,BAO_0000019,1235.0
14907,,,A,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,CHEMBL629894,,0,1,U,22224,Autocuration,,,BAO_0000019,
14908,,,A,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,CHEMBL629895,,0,1,U,22224,Autocuration,,,BAO_0000019,
14909,Canis lupus familiaris,,A,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,CHEMBL875109,9615.0,0,1,U,22224,Autocuration,,,BAO_0000218,
14910,Macaca fascicularis,,A,Absolute bioavailability in male cynomolgus monkeys,,CHEMBL629896,9541.0,0,1,U,22224,Autocuration,,,BAO_0000218,
14911,Rattus norvegicus,,A,Absolute bioavailability in maleSprague-Dawley rats,,CHEMBL629897,10116.0,0,1,U,22224,Autocuration,,,BAO_0000218,
14912,Rattus norvegicus,,A,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL629898,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14913,Rattus norvegicus,,A,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630057,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14914,Rattus norvegicus,,A,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630058,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2107.0
14915,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630059,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14916,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630060,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14917,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630061,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14918,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630062,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14919,Rattus norvegicus,,A,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630063,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14920,Rattus norvegicus,,A,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630064,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14921,Rattus norvegicus,,A,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630065,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14922,Rattus norvegicus,,A,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630066,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14923,Rattus norvegicus,,A,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630067,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14924,Rattus norvegicus,,A,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630068,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2048.0
14925,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631113,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14926,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631114,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14927,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631115,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14928,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631116,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14929,Rattus norvegicus,,A,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630528,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14930,Rattus norvegicus,,A,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630529,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14931,Rattus norvegicus,,A,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630530,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14932,Rattus norvegicus,,A,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630531,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14933,Rattus norvegicus,,A,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630532,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14934,Rattus norvegicus,,A,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630533,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2385.0
14935,Mus musculus,,A,Biodistribution in normal mice blood after 120 hr,,CHEMBL630534,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
14936,Mus musculus,,A,Biodistribution in normal mice blood after 24 hr,,CHEMBL630535,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
14937,Mus musculus,,A,Biodistribution in normal mice blood after 4 hr,,CHEMBL630536,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,178.0
14938,Mus musculus,,A,Biodistribution in normal mice bone after 120 hr,,CHEMBL630537,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
14939,Mus musculus,,A,Biodistribution in normal mice bone after 24 hr,,CHEMBL630538,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
14940,Mus musculus,,A,Biodistribution in normal mice bone after 4 hr,,CHEMBL630539,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,10000001.0
14941,Mus musculus,,A,Biodistribution in normal mice heart after 120 hr,,CHEMBL630540,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
14942,Mus musculus,,A,Biodistribution in normal mice heart after 24 hr,,CHEMBL630541,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
14943,Mus musculus,,A,Biodistribution in normal mice heart after 4 hr,,CHEMBL630542,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,948.0
14944,Mus musculus,,A,Biodistribution in normal mice kidney after 120 hr,,CHEMBL630543,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
14945,Mus musculus,,A,Biodistribution in normal mice kidney after 24 hr,,CHEMBL630544,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
14946,Mus musculus,,A,Biodistribution in normal mice kidney after 4 hr,,CHEMBL630545,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2113.0
14947,Mus musculus,,A,Biodistribution in normal mice liver after 120 hr,,CHEMBL630546,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14948,Mus musculus,,A,Biodistribution in normal mice liver after 24 hr,,CHEMBL630547,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14949,Mus musculus,,A,Biodistribution in normal mice liver after 4 hr,,CHEMBL630548,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2107.0
14950,Mus musculus,,A,Biodistribution in normal mice spleen after 120 hr,,CHEMBL630549,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
14951,Mus musculus,,A,Biodistribution in normal mice spleen after 24 hr,,CHEMBL630550,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
14952,Mus musculus,,A,Biodistribution in normal mice spleen after 4 hr,,CHEMBL876426,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,2106.0
14953,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630551,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14954,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630552,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14955,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630553,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14956,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630554,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14957,Rattus norvegicus,,A,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630555,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14958,Rattus norvegicus,,A,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630556,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14959,Rattus norvegicus,,A,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630557,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14960,Rattus norvegicus,,A,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630558,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14961,Rattus norvegicus,,A,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630559,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14962,Rattus norvegicus,,A,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630560,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2106.0
14963,Rattus norvegicus,,A,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL876427,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,2046.0
14964,Rattus norvegicus,,A,The Kel values in female wistar rats.,,CHEMBL630561,10116.0,1,1,N,50597,Intermediate,,,BAO_0000218,
14965,,,A,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,CHEMBL630562,,0,1,U,22224,Autocuration,,,BAO_0000019,
14966,,,A,Hydrolysis rate constant of the compound,,CHEMBL630563,,0,1,U,22224,Autocuration,,,BAO_0000019,
14967,,,P,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,CHEMBL629673,,0,1,U,22229,Autocuration,,,BAO_0000100,
14968,,,A,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,CHEMBL629674,,0,1,U,22224,Autocuration,,,BAO_0000019,
14969,,,A,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,CHEMBL629675,,0,1,U,22224,Autocuration,,,BAO_0000019,
14970,,,A,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,CHEMBL629676,,0,1,U,22224,Autocuration,,,BAO_0000019,
14971,,,A,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,CHEMBL629677,,0,1,U,22224,Autocuration,,,BAO_0000019,
14972,,,A,Apparent inactivation rate constant was evaluated,,CHEMBL629678,,0,1,U,22224,Autocuration,,,BAO_0000019,
14973,,,A,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,CHEMBL629679,,0,1,U,22224,Autocuration,,,BAO_0000019,
14974,,,A,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,CHEMBL629680,,0,1,U,22224,Autocuration,,,BAO_0000019,
14975,,,A,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,CHEMBL629681,,0,1,U,22224,Autocuration,,,BAO_0000019,
14976,,,A,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,CHEMBL629682,,0,1,U,22224,Autocuration,,,BAO_0000019,
14977,,,A,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,CHEMBL629683,,0,1,U,22224,Autocuration,,,BAO_0000019,
14978,,,F,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,CHEMBL629684,,0,1,U,22224,Autocuration,,,BAO_0000019,
14979,,,P,Dissociation constant was determined,,CHEMBL629685,,0,1,U,22224,Autocuration,,,BAO_0000100,
14980,,,P,Dissociation constant was determined,,CHEMBL629686,,0,1,U,22224,Autocuration,,,BAO_0000100,
14981,,,P,Dissociation constant at pH 7.4,,CHEMBL872932,,0,1,U,22224,Autocuration,,,BAO_0000100,
14982,,,P,Dissociation constant in presence of 1 mM dithiothreitol,,CHEMBL629687,,0,1,U,22224,Autocuration,,,BAO_0000100,
14983,,,A,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,CHEMBL872931,,0,1,U,22224,Autocuration,,,BAO_0000019,
14984,,,A,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,CHEMBL628151,,0,1,U,22224,Autocuration,,,BAO_0000019,
14985,,,A,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,CHEMBL628152,,0,1,U,22224,Autocuration,,,BAO_0000019,
14986,,,A,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,CHEMBL628153,,0,1,U,22224,Autocuration,,,BAO_0000019,
14987,,,A,Kinetic constant for aromatization of androstenedione,,CHEMBL628154,,0,1,U,22224,Autocuration,,,BAO_0000019,
14988,,,A,Kinetic constant for aromatization of testosterone,,CHEMBL628155,,0,1,U,22224,Autocuration,,,BAO_0000019,
14989,,,A,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,CHEMBL628156,,0,1,U,22224,Autocuration,,,BAO_0000019,
14990,,,A,Local inhibition constant was determined,,CHEMBL628157,,0,1,U,22224,Autocuration,,,BAO_0000019,
14991,Saccharomyces cerevisiae,,A,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,CHEMBL857533,4932.0,1,1,N,50347,Intermediate,,,BAO_0000218,
14992,,,P,Dissociation constant value of the compound,,CHEMBL628158,,0,1,U,22224,Autocuration,,,BAO_0000100,
14993,,,A,In vitro permeability through cornea without epithelium,,CHEMBL628159,,0,1,U,22224,Autocuration,,,BAO_0000019,964.0
14994,,,A,In vitro permeability through intact cornea,,CHEMBL875616,,0,1,U,22224,Autocuration,,,BAO_0000019,964.0
14995,Oryctolagus cuniculus,,A,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,CHEMBL628160,9986.0,1,1,N,50592,Intermediate,,,BAO_0000218,964.0
14996,,,A,Rate of enzyme inactivation for the compound was determined,,CHEMBL628161,,0,1,U,22224,Autocuration,,,BAO_0000019,
14997,,,A,In vitro permeability through cornea without epithelium,,CHEMBL628162,,0,1,U,22224,Autocuration,,,BAO_0000019,964.0
14998,,,A,In vitro permeability through intact cornea,,CHEMBL628163,,0,1,U,22224,Autocuration,,,BAO_0000019,964.0
14999,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628164,,0,1,U,22224,Autocuration,,,BAO_0000019,
15000,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628165,,0,1,U,22224,Autocuration,,,BAO_0000019,
15001,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628166,,0,1,U,22224,Autocuration,,,BAO_0000019,
15002,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628167,,0,1,U,22224,Autocuration,,,BAO_0000019,
15003,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628168,,0,1,U,22224,Autocuration,,,BAO_0000019,
15004,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628169,,0,1,U,22224,Autocuration,,,BAO_0000019,
15005,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628170,,0,1,U,22224,Autocuration,,,BAO_0000019,
15006,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628171,,0,1,U,22224,Autocuration,,,BAO_0000019,
15007,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL627434,,0,1,U,22224,Autocuration,,,BAO_0000019,
15008,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL627435,,0,1,U,22224,Autocuration,,,BAO_0000019,
15009,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628110,,0,1,U,22224,Autocuration,,,BAO_0000019,
15010,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628111,,0,1,U,22224,Autocuration,,,BAO_0000019,
15011,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628112,,0,1,U,22224,Autocuration,,,BAO_0000019,
15012,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628260,,0,1,U,22224,Autocuration,,,BAO_0000019,
15013,,,A,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628261,,0,1,U,22224,Autocuration,,,BAO_0000019,
15014,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,CHEMBL628262,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15015,Homo sapiens,,A,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,CHEMBL628263,9606.0,1,1,N,50587,Intermediate,,,BAO_0000218,
15016,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,CHEMBL628264,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15017,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,CHEMBL628265,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15018,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,CHEMBL628266,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15019,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,CHEMBL628267,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15020,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,CHEMBL628268,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15021,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,CHEMBL628269,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15022,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,CHEMBL628270,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15023,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,CHEMBL628271,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
15024,Mus musculus,,A,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,CHEMBL628272,10090.0,1,1,N,50594,Intermediate,,,BAO_0000218,
